<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23093306</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-822X</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current hematologic malignancy reports</Title><ISOAbbreviation>Curr Hematol Malig Rep</ISOAbbreviation></Journal><ArticleTitle>"Antivirals" in the treatment of adult T cell leukaemia- lymphoma (ATLL).</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>275</EndPage><MedlinePgn>267-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11899-012-0139-9</ELocationID><Abstract><AbstractText>Adult T cell leukaemia / lymphoma (ATLL) is a mature (post thymic) T cell lymphoma caused by the human T-lymphotropic virus type 1 (HTLV-1) infection. Overall survival in the aggressive subtypes (Acute Leukaemia and Lymphomatous) remains poor in part due to chemotherapy resistance. To improve treatment outcome for de novo disease, better induction therapies are required and since the pathogenic agent is known it would seem sensible to target the virus. In a recent meta-analysis the use of zidovudine and interferon alpha (ZDV/IFN) has been associated with improved response rates and prolonged overall survival in leukemic subtypes of ATLL (both acute and Chronic) confirmed in a multivariate analysis. In a more recent UK study the overall response rate for patients with aggressive ATLL treated with chemotherapy alone was 49&#160;% compared to 81&#160;% with combined first line therapy (chemotherapy with concurrent or sequential ZDV/IFN). Combined first line therapy prolonged median OS in acute (p&#8201;=&#8201;0.0081) and lymphomatous ATLL (p&#8201;=&#8201;0.001).These data support the use of low dose ZDV/IFN with chemotherapy as first line treatment for patients with newly diagnosed aggressive ATLL. Although the mechanisms of action are incompletely understood, some possible explanations for their efficacy will be discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Haematology, Guys and St Thomas', Kings College Hospitals, London, SE1 9RT, UK. paul.fields@gstt.nhs.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Graham P</ForeName><Initials>GP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Hematol Malig Rep</MedlineTA><NlmUniqueID>101262565</NlmUniqueID><ISSNLinking>1558-8211</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23093306</ArticleId><ArticleId IdType="doi">10.1007/s11899-012-0139-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2001 Feb 15;166(4):2602-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11160322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Mar 10;30(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 Jun;113(3):779-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2006 Aug 1;108(3):1021-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Nov 11;116(19):3802-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20587783</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20448111</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1990;14(10):841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2259221</ArticleId></ArticleIdList></Reference><Reference><Citation>IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424</Citation><ArticleIdList><ArticleId IdType="pubmed">9190379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2009 Jun 25;113(26):6528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19411628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2004 Nov;5(11):664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15522654</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2010 Sep 20;28(27):4177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2012 Jan 12;119(2):434-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22123848</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1744-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2010 Dec 20;207(13):2785-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21135137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1989 Dec 1;111(11):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2573306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol J. 2004;5(2):130-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Nov 04;6(11):e1001177</Citation><ArticleIdList><ArticleId IdType="pubmed">21079688</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Jun 3;115(22):4337-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinsho Byori. 2005 Sep;53(9):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16235837</ArticleId></ArticleIdList></Reference><Reference><Citation>Retrovirology. 2007 Apr 14;4:27</Citation><ArticleIdList><ArticleId IdType="pubmed">17433108</ArticleId></ArticleIdList></Reference><Reference><Citation>J Dermatol. 2008 May;35(5):270-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18477226</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2010 Dec;92(5):762-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21080125</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1983 Jan;80(1):26-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6185957</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2007 Apr;7(4):270-80</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2008 Feb 14;27(8):1135-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17704807</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2006 Mar 28;234(2):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15896902</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2005 Sep 5;24(39):6047-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16155611</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Apr 1;109(7):3060-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2000 Oct 12;19(43):4954-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11042682</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2011 Dec 10;29(35):4696-701</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1999 Dec;73(12):10289-95</Citation><ArticleIdList><ArticleId IdType="pubmed">10559346</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Clin Oncol. 1988 Dec;18(4):363-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3264588</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1989 Jun 15;43(6):1061-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2732000</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1989 Feb 15;43(2):250-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2917802</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2000 Oct;81(Pt 10):2341-2364</Citation><ArticleIdList><ArticleId IdType="pubmed">10993923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Cancer Res. 1989 Mar;80(3):191-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2498254</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Dec;77(24):13389-95</Citation><ArticleIdList><ArticleId IdType="pubmed">14645593</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2011 May;3(5):469-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21994743</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1749-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2010 Jul;51(7):1200-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20370541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol J. 2002;3(6):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2013 Mar;98(3):385-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22875625</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2012 Jul 09;3:247</Citation><ArticleIdList><ArticleId IdType="pubmed">22787458</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Oct;77(10):6134-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6969402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37191476</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1747-4094</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Season>Jul-Dec</Season></PubDate></JournalIssue><Title>Expert review of hematology</Title><ISOAbbreviation>Expert Rev Hematol</ISOAbbreviation></Journal><ArticleTitle>Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors.</ArticleTitle><Pagination><StartPage>535</StartPage><EndPage>541</EndPage><MedlinePgn>535-541</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/17474086.2023.2215424</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Immune checkpoint inhibitors (ICIs) are widely used for multiple types of malignancies and are considered the fourth pillar in cancer treatment. Anti-programmed death-1 (PD-1) antibodies pembrolizumab and nivolumab are approved for relapsed/refractory classical Hodgkin lymphoma. Nonetheless, two phase 2 trials for T-cell lymphoma were terminated because of hyperprogression after a single dose in some patients.</AbstractText><AbstractText Label="AREAS COVERED">In this review, we summarize available information on the rapid progression of peripheral T-cell lymphoma including adult T-cell leukemia/lymphoma (ATLL).</AbstractText><AbstractText Label="EXPERT OPINION">In the abovementioned two trials, disease subtypes in patients who experienced hyperprogression were mostly ATLL or angioimmunoblastic T-cell lymphoma. Possible hyperprogression mechanisms induced by PD-1 blockade are the compensatory upregulation of the expression of other checkpoints, altered expression of lymphoma-promoting growth factors, functional blockade of stromal PD-ligand 1 acting as a tumor suppressor, and unique immune environment in indolent ATLL. The differentiation between hyperprogression and pseudoprogression is practically essential. There are no established methods to predict hyperprogression before administration of an ICI. In the future, the progress of novel diagnostic modalities such as positron emission tomography with computed tomography and circulating tumor DNA is expected to facilitate early cancer detection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohmoto</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3642-2032</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Hematol</MedlineTA><NlmUniqueID>101485942</NlmUniqueID><ISSNLinking>1747-4094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000082082">Immune Checkpoint Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016411">Lymphoma, T-Cell, Peripheral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006689">Hodgkin Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016399">Lymphoma, T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">Anti-PD1 antibody</Keyword><Keyword MajorTopicYN="N">ICI</Keyword><Keyword MajorTopicYN="N">NTFHL-AI</Keyword><Keyword MajorTopicYN="N">hyperprogression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37191476</ArticleId><ArticleId IdType="doi">10.1080/17474086.2023.2215424</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34818414</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>1541</StartPage><EndPage>1556</EndPage><MedlinePgn>1541-1556</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2021012734</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3, JUNB, STAT3, and IL10RB as genes that are essential for the proliferation and/or survival of ATLL cells. As a single agent, the CDK6 inhibitor palbociclib induced cell cycle arrest and apoptosis in ATLL models with wild-type TP53. ATLL models that had inactivated TP53 genetically were relatively resistant to palbociclib owing to compensatory CDK2 activity, and this resistance could be reversed by APR-246, a small molecule activator of mutant TP53. The CRISPR-Cas9 screen further highlighted the dependence of ATLL cells on mTORC1 signaling. Treatment of ATLL cells with palbociclib in combination with mTORC1 inhibitors was synergistically toxic irrespective of the TP53 status. This work defines CDK6 as a novel therapeutic target for ATLL and supports the clinical evaluation of palbociclib in combination with mTORC1 inhibitors in this recalcitrant malignancy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishio</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sarvesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimono</LastName><ForeName>Joji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daenthanasanmak</LastName><ForeName>Anusara</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6404-7444</Identifier><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yuquan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Bonita</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrus</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachy</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2694-7510</Identifier><AffiliationInfo><Affiliation>Lymphoma Immuno-Biology (LIB) Research Unit, Claude Bernard Lyon 1 University-Hematology Department, Lyon Sud Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Da Wei</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yandan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Patrick L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Retrovirus Research, The Ohio State University, Columbus, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1822-5692</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Michiyuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Research and Medical Innovation Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatanaka</LastName><ForeName>Kanako C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Center for Development of Advanced Diagnostics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatanaka</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Division of Genome Companion Diagnostics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6470-3301</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Cancer Pathology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yibin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashino</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Health Care Center, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teshima</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0941-271X</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldmann</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staudt</LastName><ForeName>Louis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Masao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8602-6054</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 CA100730</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="C495911">CDK6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Blood. 2022 Mar 10;139(10):1435</RefSource><PMID Version="1">35267009</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051361">Cyclin-Dependent Kinase 6</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000076222">Mechanistic Target of Rapamycin Complex 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>24</Day><Hour>17</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34818414</ArticleId><ArticleId IdType="pmc">PMC8914179</ArticleId><ArticleId IdType="doi">10.1182/blood.2021012734</ArticleId><ArticleId IdType="pii">S0006-4971(21)01970-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-280.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci. 2015;106(4):344-351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409876</ArticleId><ArticleId IdType="pubmed">25613789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47(11):1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Schmitz R, Xiao W, et al. . Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med. 2014; 211(13):2497-2505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267233</ArticleId><ArticleId IdType="pubmed">25488980</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Shaffer AL III, Ceribelli M, et al. . Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma. Cancer Cell. 2018;34(2):286-297.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078141</ArticleId><ArticleId IdType="pubmed">30057145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo VN, Davis RE, Lamy L, et al. . A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441(7089):106-110.</Citation><ArticleIdList><ArticleId IdType="pubmed">16572121</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat J, Grueneberg DA, Yang X, et al. . A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124(6):1283-1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564017</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalem O, Sanjana NE, Hartenian E, et al. . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343(6166):84-87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089965</ArticleId><ArticleId IdType="pubmed">24336571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343(6166):80-84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972032</ArticleId><ArticleId IdType="pubmed">24336569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart T, Chandrashekhar M, Aregger M, et al. . High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163(6):1515-1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">26627737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Birsoy K, Hughes NW, et al. . Identification and characterization of essential genes in the human genome. Science. 2015;350(6264):1096-1101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662922</ArticleId><ArticleId IdType="pubmed">26472758</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomen VA, M&#225;jek P, Jae LT, et al. . Gene essentiality and synthetic lethality in haploid human cells. Science. 2015;350(6264):1092-1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">26472760</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Xu H, Xiao T, et al. . MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290824</ArticleId><ArticleId IdType="pubmed">25476604</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol. 2013;13(7): 499-509.</Citation><ArticleIdList><ArticleId IdType="pubmed">23787991</ArticleId></ArticleIdList></Reference><Reference><Citation>Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, Mesnard JM. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem. 2003;278(44):43620-43627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12937177</ArticleId></ArticleIdList></Reference><Reference><Citation>Song TL, Nairism&#228;gi ML, Laurensia Y, et al. . Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132(11): 1146-1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148343</ArticleId><ArticleId IdType="pubmed">30054295</ArticleId></ArticleIdList></Reference><Reference><Citation>Watatani Y, Sato Y, Miyoshi H, et al. . Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33(12):2867-2883.</Citation><ArticleIdList><ArticleId IdType="pubmed">31092896</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz R, Wright GW, Huang DW, et al. . Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6010183</ArticleId><ArticleId IdType="pubmed">29641966</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapuy B, Stewart C, Dunford AJ, et al. . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613387</ArticleId><ArticleId IdType="pubmed">29713087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennishi D, Jiang A, Boyle M, et al. . Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(3):190-201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6804880</ArticleId><ArticleId IdType="pubmed">30523716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy SE, Barrans SL, Beer PA, et al. . Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759-1771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259825</ArticleId><ArticleId IdType="pubmed">32187361</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#252;&#231;&#252;k C, Jiang B, Hu X, et al. . Activating mutations of STAT5B and STAT3 in lymphomas derived from &#947;&#948;-T or NK cells. Nat Commun. 2015;6(1):6025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7743911</ArticleId><ArticleId IdType="pubmed">25586472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13(1):21-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">24378801</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130-146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4480421</ArticleId><ArticleId IdType="pubmed">25633797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6(4):353-367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821753</ArticleId><ArticleId IdType="pubmed">26658964</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin P, Ruan J, Furman R, et al. . A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019; 60(12):2917-2921.</Citation><ArticleIdList><ArticleId IdType="pubmed">31120355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X, Litchfield LM, Webster Y, et al. . Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell. 2017;32(6):761-776.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29232554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Iwanaga M, Yasunaga JI, et al. . Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215-225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JM, Gorzov P, Veprintsev DB, et al. . PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15(5):376-388.</Citation><ArticleIdList><ArticleId IdType="pubmed">19411067</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400-414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722839</ArticleId><ArticleId IdType="pubmed">19440234</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28): 3943-3956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511239</ArticleId><ArticleId IdType="pubmed">28288132</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzig TE, Reeder C, Han JJ, et al. . The mTORC1 inhibitor everolimus has antitumor activity in&#160;vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3): 328-335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504947</ArticleId><ArticleId IdType="pubmed">25921059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T&#160;cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6): 323-342.</Citation><ArticleIdList><ArticleId IdType="pubmed">32249838</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Gravel SP, Ch&#233;nard V, et al. . mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18(5):698-711.</Citation><ArticleIdList><ArticleId IdType="pubmed">24206664</ArticleId></ArticleIdList></Reference><Reference><Citation>Malumbres M. CDK4/6 inhibitors: what is the best cocktail? Clin Cancer Res. 2019;25(1):6-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30115629</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem Biol. 2020;27(8): 998-1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9424844</ArticleId><ArticleId IdType="pubmed">32795419</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi Y, Yasunaga JI, Mitagami Y, et al. . HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proc Natl Acad Sci USA. 2020;117(24):13740-13749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7306771</ArticleId><ArticleId IdType="pubmed">32471947</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Petrus M, Bryant BR, et al. . Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 2010;116(26): 5948-5956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031384</ArticleId><ArticleId IdType="pubmed">20858854</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Petrus M, Bryant BR, et al. . Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood. 2008;111(10): 5163-5172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2384140</ArticleId><ArticleId IdType="pubmed">18339896</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Hatta Y, Murata K, et al. . Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15(5):1778-1785.</Citation><ArticleIdList><ArticleId IdType="pubmed">9164185</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30344845</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>HTLV-1, ATLL, severe hypercalcaemia and HIV-1 co-infection: an overview.</ArticleTitle><Pagination><StartPage>61</StartPage><MedlinePgn>61</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">61</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.2018.30.61.13238</ELocationID><Abstract><AbstractText>HIV and HTLV (Human T-ymphotropic Virus) are the only known retroviruses responsible for causing infection in humans. HTLV-1 and HIV-1 are frequent co-pathogens, however, despite its potential for accelerated progression of HIV disease and the risk of developing adult T-cell lymphoma/leukemia (ATLL), HTLV-1 is seldom considered for investigation in the HIV-1 positive individual. Severe/refractory hypercalcaemia, unresponsive to conventional calcium lowering therapy may complicate up to 70% of cases of ATLL. In addition, HTLV-1 and ATLL have both been associated with a rise in dysfunctional CD4 lymphocytes, thereby conveying a false sense of immune competence in the HIV-1 infected individual.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laher</LastName><ForeName>Abdullah Ebrahim</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine and Department of Critical Care, Faculty of Health Sciences, University of the Witwatersrand, 5 Jubilee Road, Parktown, Johannesburg, 2193, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebrahim</LastName><ForeName>Osman</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and HIV clinic, Life Brenthurst Hospital, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060085">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HIV-1</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">refractory hypercalcaemia</Keyword><Keyword MajorTopicYN="N">severe hypercalcaemia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30344845</ArticleId><ArticleId IdType="pmc">PMC6191272</ArticleId><ArticleId IdType="doi">10.11604/pamj.2018.30.61.13238</ArticleId><ArticleId IdType="pii">PAMJ-30-61</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verdonck K, Gonz&#225;lez E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007 Apr;7(4):266&#8211;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindo N, Alcantara LCJ, Van Dooren S, Salemi M, Costa MCR, Kashima S, et al. Human Retroviruses (HIV and HTLV) in Brazilian Indians: seroepidemiological study and molecular epidemiology of HTLV Type 2 isolates. AIDS Res Hum Retroviruses. 2002 Jan 5;18(1):71&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11804558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticona E, Huaman MA, Yanque O, Zunt JR. HIV and HTLV-1 coinfection: the need to initiate antiretroviral therapy. J Int Assoc Provid AIDS Care. 2013 Nov-Dec;12(6):373&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4170712</ArticleId><ArticleId IdType="pubmed">24222069</ArticleId></ArticleIdList></Reference><Reference><Citation>UNAIDS Accessed 2017 Jun 21.</Citation></Reference><Reference><Citation>Nicolas D, Ambrosioni J, Paredes R, Marcos M'ngeles, Manzardo C, Moreno A, et al. Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4. Expert Rev Anti Infect Ther. 2015 Aug 3;13(8):947&#8211;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26112187</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnaz S, Reich D, Ar&#233;valo-Valencia D, Kucinska S, Tulczynska J, Fleischman J. HTLV-1-associated adult T cell leukemia lymphoma presenting as granulomatous pneumocystis jiroveci pneumonia (PJP) and hypercalcemia. J Gen Intern Med. 2007 Mar;22(3):420&#8211;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1824742</ArticleId><ArticleId IdType="pubmed">17356979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyell V, Khatamzas E, Allain T. Severe hypercalcaemia and lymphoma in an HTLV-1 positive Jamaican woman: a case report. J Med Case Rep. 2007 Jul 25;1:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950877</ArticleId><ArticleId IdType="pubmed">17651486</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards CMB, Edwards SJE, Bhumbra RP, Chowdhury TA. Severe refractory hypercalcaemia in HTLV-1 infection. J R Soc Med. 2003 Mar;96(3):126&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539419</ArticleId><ArticleId IdType="pubmed">12612113</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik S, Kodali S, Agheli A, Dumlao T, Singh V, Plummer K, et al. HTLV-1 Adult T cell leukemia-lymphoma presenting with refractory hypercalcemia, cranial neuropathy and diagnosis by flow cytometry and cytogenetic findings. Blood. 2015;110:3864.</Citation></Reference><Reference><Citation>Nasir IA, Ahmad AE, Emeribe AU, Shehu MS, Medugu JT, Babayo A. Molecular detection and clinical implications of HTLV-1 infections among antiretroviral therapy-na&#239;ve HIV-1-infected Individuals in Abuja. Nigeria Virology (Auckl) 2015 Jan;6:17&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4678997</ArticleId><ArticleId IdType="pubmed">26688662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudo ES, Bhatt NB, Bila DR, Abreu CM, Tanuri A, Savino W, et al. Co-infection by human immunodeficiency virus type 1 (HIV-1) subtype C and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS. BMC Infect Dis. 2009 Jan;9:211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813852</ArticleId><ArticleId IdType="pubmed">20028500</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#231;alves DU, Proietti FA, Ribas JGR, Ara&#250;jo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010 Jul;23(3):577&#8211;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901658</ArticleId><ArticleId IdType="pubmed">20610824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazanderani AH, Ebrahim O. Progressive HIV infection in the presence of a raised CD4+ count: HIV/HTLV-1 co-infection. South African J HIV Med. 2013;14(2):92&#8211;4.</Citation></Reference><Reference><Citation>Pierik LT, Murphy EL. The clinical significance of HTLV-I and HTLV-II infection in the AIDS epidemic. AIDS Clin Rev. 1991 Jan;:39&#8211;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">1868010</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rossi A, Saggioro D, Calabr&#243; ML, Cenzato R, Chieco-Bianchi L. Reciprocal activation of human T-lymphotropic viruses in HTLV-I-transformed cells superinfected with HIV-1. J Acquir Immune Defic Syndr. 1991 Jan;4(4):380&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2007972</ArticleId></ArticleIdList></Reference><Reference><Citation>Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet (London, England) 1986 May 3;1(8488):1031&#8211;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">2871307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet (London, England) 1985 Aug 24;2(8452):407&#8211;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2863442</ArticleId></ArticleIdList></Reference><Reference><Citation>LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet (London, England) 1990 Dec 1;336(8727):1345&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1978165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ijichi S, Matsuda T, Maruyama I, Izumihara T, Kojima K, Niimura T, et al. Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier. Ann Rheum Dis. 1990 Sep;49(9):718&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1004211</ArticleId><ArticleId IdType="pubmed">2241290</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006 Sep 19;3:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1590049</ArticleId><ArticleId IdType="pubmed">16984654</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevino A, Parra P, Bar-Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother. 2012 Jan 1;67(1):218&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21965433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi M, Jaffes E, Ralfkiaer E. World Health Organization Classification of Tumours. In: Jaffes E, Harris N, Stein H, Vardiman J, editors. Tumours of Haemopoietic and lymphoid tissues. Lyon: IARC press; 2001. pp. 200&#8211;203.</Citation></Reference><Reference><Citation>Matutes E, Catovsky D. Adult T cell leukaemia lymphoma. 3rd ed. Oxford: blackwell scientific publications; 1998. pp. 416&#8211;433.</Citation></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the lymphoma study group (1984-87) Br J Haematol. 1991 Nov;79(3):428&#8211;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Aouba A, Lambotte O, Vasiliu V, Divine M, Valensi F, Varet B, et al. Hemophagocytic syndrome as a presenting sign of transformation of smoldering to acute adult T-cell leukemia/lymphoma: efficacy of anti-retroviral and interferon therapy. Am J Hematol. 2004 Jun;76(2):187&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15164389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29;332(26):1744&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995 Jun 29;332(26):1749&#8211;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801. J Clin Oncol. 2007 Dec 1;25(34):5458&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015 Jun;169(5):672&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessong PO, Mathomu LM. Seroprevalence of HTLV1/2, HSV1/2 and Toxoplasma gondii among chronic HIV-1 infected individuals in rural northeastern South Africa. African J Microbiol Res. 2010;4(23):2587&#8211;91.</Citation></Reference><Reference><Citation>Cortes E, Detels R, Aboulafia D, Li XL, Moudgil T, Alam M, et al. HIV-1, HIV-2 and HTLV-I infection in high-risk groups in Brazil. N Engl J Med. 1989 Apr 13;320(15):953&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2927478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori T, Koito A, Takatsuki K, Ikematsu S, Matsuda J, Mori H, et al. Frequent infection with human T-cell lymphotropic virus type I in patients with AIDS but not in carriers of human immunodeficiency virus type 1. J Acquir Immune Defic Syndr. 1989 Jan;2(3):272&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2724072</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhigjee AI, Vinsen C, Windsor IM, Gouws E, Bill PL, Tait D. Prevalence and transmission of HTLV-I infection in Natal/KwaZulu. S Afr Med J. 1993 Sep;83(9):665&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8123179</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ryst E, Joubert G, Smith MS, Terblanche M, Mollentze F, Pretorius AM. HTLV-I infection in the Free State region of South Africa: a sero-epidemiologic study. Cent Afr J Med. 1996 Mar;42(3):65&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8653770</ArticleId></ArticleIdList></Reference><Reference><Citation>Casoli C, Pilotti E, Bertazzoni U. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev. 2007 Jul-Sep;9(3):140&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleghorn FR, Blattner WA. Does human T-cell lymphotropic virus type I and human immunodeficiency virus type 1 coinfection accelerate acquired immunodeficiency syndrome? The jury is still out. Arch Intern Med. 1992 Jul;152(7):1372&#8211;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">1352674</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites C, Pedroso C, Netto E, Harrington W, Galv&#227;o-Castro B, Couto-Fernandez J, et al. Co-Infection by HTLV-I/II is Associated With Increased Viral Load in PBMC of HIV-1 Infected Patients in Bahia, Brazil. Braz J Infect Dis. 1998 Apr;2(2):70&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11101913</ArticleId></ArticleIdList></Reference><Reference><Citation>Demontis MA, Hilburn S, Taylor GP. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses. 2013 Feb;29(2):359&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">22894552</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedral-Sampaio D, Martins Netto E, Pedrosa C, Brites C, Duarte M, Harrington W. Co-infection of tuberculosis and HIV/HTLV retroviruses: frequency and prognosis among patients admitted in a Brazilian hospital. Braz J Infect Dis. 1997 Mar;1(1):31&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11107236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zane L, Sibon D, Mortreux F, Wattel E. Clonal expansion of HTLV-1 infected cells depends on the CD4 versus CD8 phenotype. Front Biosci (Landmark Ed) 2009 Jan 1;14:3935&#8211;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt NB, Gudo ES, Sem&#225; C, Bila D, Di Mattei P, Augusto O, et al. Loss of correlation between HIV viral load and CD4+ T-cell counts in HIV/HTLV-1 co-infection in treatment naive Mozambican patients. Int J STD AIDS. 2009 Dec;20(12):863&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19948902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginaldi L, De Martinis M, D'Ostilio A, Di Gennaro A, Marini L, Profeta V, et al. Activated naive and memory CD4+ and CD8+ subsets in different stages of HIV infection. Pathobiology. 1997 Jan;65(2):91&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9253033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, Kohno S, Morikawa N, Kadota J, Matsukura S, Hara K. Increase in T-cells bearing CD25 in bronchoalveolar lavage fluid from HAM/TSP patients and HTLV-I carriers. Microbiol Immunol. 1994 Jan;38(1):55&#8211;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8052162</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilke MA, Theall KP, O'Brien M, Clayton JL, Benjamin SM, Winsor EL, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis. 2004 Jul 15;39(2):256&#8211;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15307036</ArticleId></ArticleIdList></Reference><Reference><Citation>Regis C, Oliveira A, Brites C. Onset of opportunistic infections in patients co-infected by HTLV-1 and HIV-1, with high CD4+ cells count. Braz J Infect Dis. 2009 Aug;13(4):311&#8211;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">20231997</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites C, Sampalo J, Oliveira A. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev. 2009 Jan-Mar;11(1):8&#8211;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">19290030</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation Guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26598776</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullinan K. ARVs now for anyone with HIV-Motsoaledi. Johannesburg: 2016. Health24, HIV/AIDS. Accessed 2017 May 24.</Citation></Reference><Reference><Citation>Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002 Jan 15;99(2):634&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11781248</ArticleId></ArticleIdList></Reference><Reference><Citation>Canellos GP. Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci. 1974;230:240&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">4595945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagler KT, Lynch JW. Paraneoplastic manifestations of lymphoma. Clin Lymphoma. 2004 Jun;5(1):29&#8211;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15245605</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh HH, Mohd Noor N. The use of hemodialysis in refractory hypercalcemia secondary to parathyroid carcinoma. Case reports Crit care. 2014 Jan;2014:140906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010034</ArticleId><ArticleId IdType="pubmed">24829837</ArticleId></ArticleIdList></Reference><Reference><Citation>Camus C, Charasse C, Jouannic-Montier I, Seguin P, Tulzo YL, Bouget J, et al. Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia. Intensive Care Med. 1996 Feb;22(2):116&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8857118</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikaree J, Newby Y, Sundar S. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy. BMJ Case Rep. 2014 Jan;2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912364</ArticleId><ArticleId IdType="pubmed">24481018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18081707</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0609</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of haematology</Title><ISOAbbreviation>Eur J Haematol</ISOAbbreviation></Journal><ArticleTitle>Treatment of adult T-cell leukemia/lymphoma: past, present, and future.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>196</EndPage><MedlinePgn>185-96</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-cell lymphotrophic virus type I. Clinical manifestations of ATLL range from smoldering to chronic, lymphoma and acute. Patients with acute and lymphoma type ATLL require therapeutic intervention. Conventional chemotherapeutic regimens used against other malignant lymphoma have been administered to ATLL patients, but the therapeutic outcomes of acute and lymphoma type ATLL remain very poor. Promising results of allogeneic stem cell transplantation (SCT) for ATLL patients have recently been reported and the treatment outcome might be improved for some ATLL patients. Besides conventional chemotherapy and SCT, interferon, zidovudine, arsenic trioxide, targeted therapy against surface molecule on ATLL cells, retinoid derivatives, and bortezomib have been administered to ATLL patients in pilot or phase I/II studies. Further studies are required to confirm the clinical benefits of these novel therapeutics. This article reviews the current status and future directions of ATLL treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Internal Medicine, Division of Hematology and Oncology, Fukuoka University, Fukuoka, Japan. kenjiishitsuka@fukuoka-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Haematol</MedlineTA><NlmUniqueID>8703985</NlmUniqueID><ISSNLinking>0902-4441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005544">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005602">France</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>157</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18081707</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0609.2007.01016.x</ArticleId><ArticleId IdType="pii">EJH1016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27220263</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6536</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title><ISOAbbreviation>Biol Blood Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.</ArticleTitle><Pagination><StartPage>1608</StartPage><EndPage>1614</EndPage><MedlinePgn>1608-1614</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2016.05.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1083-8791(16)30089-1</ELocationID><Abstract><AbstractText>Mogamulizumab (MOG), a humanized anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, has recently played an important role in the treatment of adult T&#160;cell leukemia/lymphoma (ATLL). Because CCR4 is expressed on normal regulatory T&#160;cells as well as on ATLL cells, MOG may accelerate graft-versus-host disease (GVHD) by eradicating regulatory T&#160;cells in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is limited information about its safety and efficacy in patients treated with MOG before allo-HSCT. In the present study, 25 patients with ATLL were treated with MOG before allo-HSCT, after which 18 patients (72%) achieved remission. The overall survival and progression-free survival at 1&#160;year post-transplantation were 20.2% (95% CI, 6.0% to 40.3%) and 15.0% (95% CI, 4.3% to 32.0%), respectively. The cumulative incidence of acute GVHD was 64.0% (95% CI, 40.7% to 80.1%) for grade II-IV and 34.7% (95% CI, 15.8% to 54.4%) for grade III-IV. The cumulative incidence of transplantation-related mortality (TRM) was 49.0% (95% CI, 27.0% to 67.8%). Six of 7 patients with acute GVHD grade III-IV died from GVHD, which was the leading cause of death. In particular, a shorter interval from the last administration of MOG to allo-HSCT was associated with more severe GVHD. MOG use before allo-HSCT may decrease the ATLL burden; however, it is associated with an increase in TRM due to severe GVHD. Because MOG is a potent anti-ATLL agent, new treatment protocols should be developed to integrate MOG at suitable doses and timing of administration to minimize unwanted GVHD development.</AbstractText><CopyrightInformation>Copyright &#169; 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugio</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. Electronic address: kojikato@intmed1.med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Takatoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohta</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kitakyushu Municipal Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Noriyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shuro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henzan</LastName><ForeName>Hideho</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadowaki</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takase</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muta</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, JCHO Kyushu Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyawaki</LastName><ForeName>Kohta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamauchi</LastName><ForeName>Takuji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shima</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Shuichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimoto</LastName><ForeName>Goichi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamezaki</LastName><ForeName>Kenjiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takenaka</LastName><ForeName>Katsuto</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Cellular and Molecular Medicine, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Cellular and Molecular Medicine, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology, JCHO Kyushu Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>Yuju</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kitakyushu Municipal Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eto</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamimura</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Center for Cellular and Molecular Medicine, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Blood Marrow Transplant</MedlineTA><NlmUniqueID>9600628</NlmUniqueID><ISSNLinking>1083-8791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Graft-versus-host disease</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27220263</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2016.05.017</ArticleId><ArticleId IdType="pii">S1083-8791(16)30089-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34937829</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>4</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>Tumor microenvironment of adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>209</EndPage><MedlinePgn>202-209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3960/jslrt.21007</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a malignancy caused by the human T-cell leukemia virus type 1. Aggressive ATLL is refractory to conventional chemotherapy and has a poor prognosis. Better therapeutic approaches, including cancer immunotherapy, are required to improve survival and prognosis. The genetic landscape of ATLL reveals frequent genetic alterations in genes associated with immune surveillance, including major histocompatibility complex (MHC) class I, CD58 antigen, and programmed cell death ligand 1. Clinicopathological investigations also revealed tumor immunity mechanisms in ATLL, including immune checkpoint molecules, MHC molecules, tumor-associated macrophages, and chemokines. However, the tumor microenvironment of ATLL remains complex because ATLL itself originates from T-cells, usually expressing regulatory T-cell markers. In this review, we discuss the recent literature describing the tumor microenvironment of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University, Kurume, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University, Kurume, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University, Kurume, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hematolymphoid Tissues</Keyword><Keyword MajorTopicYN="N">Infectious</Keyword><Keyword MajorTopicYN="N">Lymphomas/Lymphoid Leukemias</Keyword><Keyword MajorTopicYN="N">Lymphoproliferative Disorders</Keyword><Keyword MajorTopicYN="N">Reactive</Keyword></KeywordList><CoiStatement>CONFLICT OF INTEREST. The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34937829</ArticleId><ArticleId IdType="pmc">PMC8808106</ArticleId><ArticleId IdType="doi">10.3960/jslrt.21007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874220</ArticleId><ArticleId IdType="pubmed">26980727</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87). Br J Haematol. 1991; 79: 428-437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010; 115: 4337-4343.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood. 1983; 61: 192-199.</Citation><ArticleIdList><ArticleId IdType="pubmed">6600211</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatsuki K, Yamaguchi K, Watanabe T. Adult T-cell leukemia and HTLV-I related diseases. Gann Mono Can Res. 1992; 39: 1-15.</Citation></Reference><Reference><Citation>Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4 + CD25 + regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004; 126: 81-84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15198736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicklin DJ, Wang Z, Arienti F, et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998; 101: 2720-2729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508863</ArticleId><ArticleId IdType="pubmed">9637706</ArticleId></ArticleIdList></Reference><Reference><Citation>Momburg F, M&#246;ller P, Moldenhauer G, H&#228;mmerling GJ. Loss of HLA-A,B,C in colorectal carcinoma is related to the degree of de-differentiation. J Immunogenet. 1986; 13: 195-199.</Citation><ArticleIdList><ArticleId IdType="pubmed">3469275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47: 1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano N, Miyoshi H, Kato T, et al. Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma. Histopathology. 2018; 72: 945-954.</Citation><ArticleIdList><ArticleId IdType="pubmed">29297942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sconocchia G, Eppenberger-Castori S, Zlobec I, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 2014; 16: 31-42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924546</ArticleId><ArticleId IdType="pubmed">24563618</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteban F, Ruiz-Cabello F, Concha A, et al. HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis. 1990; 8: 319-328.</Citation><ArticleIdList><ArticleId IdType="pubmed">2350918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004; 103: 4251-4258.</Citation><ArticleIdList><ArticleId IdType="pubmed">14976040</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer. Lung Cancer. 2017; 112: 75-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011; 186: 5173-5183.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441454</ArticleId></ArticleIdList></Reference><Reference><Citation>Holling TM, Schooten E, Langerak AW, van den Elsen PJ. Regulation of MHC class II expression in human T-cell malignancies. Blood. 2004; 103: 1438-1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">14563641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirono K, Hattori T, Hata H, Nishimura H, Takatsuki K. Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood. 1989; 73: 1664-1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">2713499</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi M, Miyoshi H, Asano N, et al. Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. Haematologica. 2019; 104: 1626-1632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6669171</ArticleId><ArticleId IdType="pubmed">30630986</ArticleId></ArticleIdList></Reference><Reference><Citation>Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of &#946;2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011; 20: 728-740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660995</ArticleId><ArticleId IdType="pubmed">22137796</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomero T, Couronn&#233; L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014; 46: 166-170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963408</ArticleId><ArticleId IdType="pubmed">24413734</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N, Karube K, Utsunomiya A, et al. Molecular characterization of chronic-type adult T-cell leukemia/lymphoma. Cancer Res. 2014; 74: 6129-6138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25320005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3&#8242;-UTR disruption in multiple cancers. Nature. 2016; 534: 402-406.</Citation><ArticleIdList><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016; 128: 1374-1381.</Citation><ArticleIdList><ArticleId IdType="pubmed">27418641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasinska IM, Sakhnevych SS, Pavlova L, et al. The Tim-3-Galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front Immunol. 2019; 10: 1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637653</ArticleId><ArticleId IdType="pubmed">31354733</ArticleId></ArticleIdList></Reference><Reference><Citation>Horlad H, Ohnishi K, Ma C, et al. TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma. Oncol Lett. 2016; 12: 1519-1524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4950894</ArticleId><ArticleId IdType="pubmed">27446463</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi M, Miyoshi H, Nakashima K, et al. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma. Ann Hematol. 2020; 99: 1093-1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157421</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020; 10: 414-433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7049610</ArticleId><ArticleId IdType="pubmed">32140389</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito M, Tanaka R, Arishima S, et al. Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology. 2013; 10: 51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659064</ArticleId><ArticleId IdType="pubmed">23651542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004; 21: 401-413.</Citation><ArticleIdList><ArticleId IdType="pubmed">15357951</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013; 13: 227-242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallois D, Dupuy A, Lemonnier F, et al. RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica. 2018; 103: e360-e363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068042</ArticleId><ArticleId IdType="pubmed">29545337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N, Shigemori K, Donaldson N, et al. Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. Blood. 2020; 135: 1467-1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180081</ArticleId><ArticleId IdType="pubmed">31961925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma. Br J Haematol. 2021; 192: 281-291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894310</ArticleId><ArticleId IdType="pubmed">33205842</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao NB, L&#252; MH, Fan YH, et al. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012; 2012: 948098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385963</ArticleId><ArticleId IdType="pubmed">22778768</ArticleId></ArticleIdList></Reference><Reference><Citation>Komohara Y, Niino D, Saito Y, et al. Clinical significance of CD 163 + tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 2013; 104: 945-951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657152</ArticleId><ArticleId IdType="pubmed">23557330</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lu S, Xu Y, et al. Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am J Transl Res. 2017; 9: 2901-2910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489890</ArticleId><ArticleId IdType="pubmed">28670378</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera L, Montes-Serv&#237;n E, Hernandez-Martinez JM, et al. CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer. 2017; 117: 385-397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537491</ArticleId><ArticleId IdType="pubmed">28632731</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagida E, Miyoshi H, Takeuchi M, et al. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRP&#945; in adult T-cell leukemia/lymphoma. Hematol Oncol. 2020; 38: 680-688.</Citation><ArticleIdList><ArticleId IdType="pubmed">32569413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa H, Nomura T, Kohno M, et al. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood. 2000; 95: 30-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607681</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Karube K, Arakawa F, et al. Upregulation of CC chemokine ligand 18 and downregulation of CX3C chemokine receptor 1 expression in human T-cell leukemia virus type 1-associated lymph node lesions: Results of chemokine and chemokine receptor DNA chip analysis. Cancer Sci. 2007; 98: 1875-1880.</Citation><ArticleIdList><ArticleId IdType="pubmed">17900259</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbecki J, Olbromski M, Dzi&#281;giel P. CCL18 in the progression of cancer. Int J Mol Sci. 2020; 21: 7955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7663205</ArticleId><ArticleId IdType="pubmed">33114763</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura M, Umehara H, Nakayama T, et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol. 2002; 168: 6173-6180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12055230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia&#8211;lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018; 378: 1947-1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">29768155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Utsunomiya A, Ishida T. PD-1 inhibitor therapy in adult T-cell leukemia&#8211;lymphoma. N Engl J Med. 2018; 379: 695-697.</Citation><ArticleIdList><ArticleId IdType="pubmed">30124278</ArticleId></ArticleIdList></Reference><Reference><Citation>Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018; 36: 942-950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5877802</ArticleId><ArticleId IdType="pubmed">29394125</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016; 7: 10582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740184</ArticleId><ArticleId IdType="pubmed">26822383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36593730</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-781X</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Critical reviews in clinical laboratory sciences</Title><ISOAbbreviation>Crit Rev Clin Lab Sci</ISOAbbreviation></Journal><ArticleTitle>Pathogenicity and virulence of human T lymphotropic virus type-1 (HTLV-1) in oncogenesis: adult T-cell leukemia/lymphoma (ATLL).</ArticleTitle><Pagination><StartPage>189</StartPage><EndPage>211</EndPage><MedlinePgn>189-211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10408363.2022.2157791</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy of CD4<sup>+</sup> T lymphocytes caused by human T lymphotropic virus type-1 (HTLV-1) infection. HTLV-1 was brought to the World Health Organization (WHO) and researchers to address its impact on global public health, oncogenicity, and deterioration of the host immune system toward autoimmunity. In a minority of the infected population (3-5%), it can induce inflammatory networks toward HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), or hijacking the infected CD4<sup>+</sup> T lymphocytes into T regulatory subpopulation, stimulating anti-inflammatory signaling networks, and prompting ATLL development. This review critically discusses the complex signaling networks in ATLL pathogenesis during virus-host interactions for better interpretation of oncogenicity and introduces the main candidates in the pathogenesis of ATLL. At least two viral factors, HTLV-1 trans-activator protein (TAX) and HTLV-1 basic leucine zipper factor (HBZ), are implicated in ATLL manifestation, interacting with host responses and deregulating cell signaling in favor of infected cell survival and virus dissemination. Such molecules can be used as potential novel biomarkers for ATLL prognosis or targets for therapy. Moreover, the challenging aspects of HTLV-1 oncogenesis introduced in this review could open new venues for further studies on acute leukemia pathogenesis. These features can aid in the discovery of effective immunotherapies when reversing the gene expression profile toward appropriate immune responses gradually becomes attainable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmadi Ghezeldasht</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9050-9016</Identifier><AffiliationInfo><Affiliation>Blood Borne Infections Research Center, Academic Center for Education, Culture, and Research (ACECR), Razavi Khorasan, Mashhad, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackbourn</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-6703-4497</Identifier><AffiliationInfo><Affiliation>Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosavat</LastName><ForeName>Arman</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8408-4664</Identifier><AffiliationInfo><Affiliation>Blood Borne Infections Research Center, Academic Center for Education, Culture, and Research (ACECR), Razavi Khorasan, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaee</LastName><ForeName>Seyed Abdolrahim</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-6814-5992</Identifier><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Rev Clin Lab Sci</MedlineTA><NlmUniqueID>8914816</NlmUniqueID><ISSNLinking>1040-8363</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014774">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015493">Paraparesis, Tropical Spastic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002471">Cell Transformation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma (ATLL)</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">oncogenesis</Keyword><Keyword MajorTopicYN="N">pathogenicity</Keyword><Keyword MajorTopicYN="N">virus&#8211;host molecular interactions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36593730</ArticleId><ArticleId IdType="doi">10.1080/10408363.2022.2157791</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36181532</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0851</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cancer immunology, immunotherapy : CII</Title><ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation></Journal><ArticleTitle>Live attenuated VZV vaccination induces antitumor immunity in ATLL patients.</ArticleTitle><Pagination><StartPage>929</StartPage><EndPage>944</EndPage><MedlinePgn>929-944</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-022-03301-6</ELocationID><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATLL) is a CD4-positive peripheral T cell lymphoma caused by human T cell lymphotropic virus type 1 (HTLV-1). Although ATLL is quite difficult to be cured, up-regulation of cellular immunity such as HTLV-1 Tax-specific cytotoxic T lymphocytes (CTLs) has been proved to be important to obtain long-term survival. At present, no efficacious method to activate ATLL-specific cellular immunity is available. This study aimed to investigate whether live attenuated varicella-zoster virus (VZV) vaccination to ATLL can activate HTLV-1 Tax-specific cellular immune response. A total of 3 indolent- and 3 aggressive-type ATLL patients were enrolled. All aggressive-type patients had the VZV vaccination after completing anti-ATLL treatment including mogamulizumab, which is a monoclonal antibody for C-C chemokine receptor 4 antigen, plus combination chemotherapy, whereas all indolent-type patients had the VZV vaccination without any antitumor treatment. Cellular immune responses including Tax-specific CTLs were analyzed at several time points of pre- and post-VZV vaccination. After the VZV vaccination, a moderate increase in 1 of 3 indolent-type patients and obvious increase in all 3 aggressive-type patients in Tax-specific CTLs percentage were observed. The increase in the cell-mediated immunity against VZV was observed in all indolent- and aggressive-type patients after VZV vaccination. To conclude, VZV vaccination to aggressive-type ATLL patients after mogamulizumab plus chemotherapy led to the up-regulation of HTLV-1 Tax-specific CTLs without any adverse event. Suppression of regulatory T lymphocytes by mogamulizumab may have contributed to increase tumor immunity in aggressive-type ATLL patients. Japan Registry of Clinical Trials number, jRCTs051180107.</AbstractText><CopyrightInformation>&#169; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5415-6228</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. tjmahamayurijnt@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubota-Koketsu</LastName><ForeName>Ritsuko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakai</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irie</LastName><ForeName>Sadaharu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuo</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Kuniko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shigematsu</LastName><ForeName>Kazuto</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AC00007-1605-00152</GrantID><Agency>BIKEN Foundation</Agency><Country /></Grant><Grant><GrantID>AC00007-1706-00220</GrantID><Agency>BIKEN Foundation</Agency><Country /></Grant><Grant><GrantID>AC00007-1808-00218</GrantID><Agency>BIKEN Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Cancer Immunol Immunother</MedlineTA><NlmUniqueID>8605732</NlmUniqueID><ISSNLinking>0340-7004</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014645">Herpesvirus 3, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014611">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">Adult T cell leukemia</Keyword><Keyword MajorTopicYN="N">HTLV-1 Tax</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">T cell receptor repertoire</Keyword><Keyword MajorTopicYN="N">VZV</Keyword><Keyword MajorTopicYN="N">Varicella-zoster virus vaccine</Keyword></KeywordList><CoiStatement>The authors have no relevant financial and non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>1</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36181532</ArticleId><ArticleId IdType="pmc">PMC10025209</ArticleId><ArticleId IdType="doi">10.1007/s00262-022-03301-6</ArticleId><ArticleId IdType="pii">10.1007/s00262-022-03301-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bangham CRM, Ratner L. How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)? Curr Opin Virol. 2015;14:93&#8211;100. doi: 10.1016/j.coviro.2015.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2015.09.004</ArticleId><ArticleId IdType="pmc">PMC4772697</ArticleId><ArticleId IdType="pubmed">26414684</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucin zipper factor gene mRNA supports proliferation of adult T-cell leukemia cells. Proc Natl Acad Sci U S A. 2006;103:720&#8211;725. doi: 10.1073/pnas.0507631103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0507631103</ArticleId><ArticleId IdType="pmc">PMC1334651</ArticleId><ArticleId IdType="pubmed">16407133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47:1304&#8211;1315. doi: 10.1038/ng.3415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3415</ArticleId><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan A, Dillon R, Witkover A, et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood. 2020;135:2023&#8211;2032. doi: 10.1182/blood.2019002665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019002665</ArticleId><ArticleId IdType="pmc">PMC7381760</ArticleId><ArticleId IdType="pubmed">32160278</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87) Br J Haematol. 1991;79:428&#8211;437. doi: 10.1111/j.1365-2141.1991.tb08051.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458&#8211;5464. doi: 10.1200/JCO.2007.11.9958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672&#8211;682. doi: 10.1111/bjh.13338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo T, Matsuzaka K, Shioya H, et al. Mogamulizumab plus EPOCH therapy for patients with newly diagnosed aggressive adult T-cell leukemia/lymphoma. Anticancer Res. 2020;40:5237&#8211;5243. doi: 10.21873/anticanres.14527.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.14527</ArticleId><ArticleId IdType="pubmed">32878812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Suarez F, Fields P, Hemine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118:1736&#8211;1745. doi: 10.1182/blood-2011-03-345702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-345702</ArticleId><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-Cell leukemia patients after hematopietic stem cell transplantaion. Cancer Res. 2004;64:391&#8211;399. doi: 10.1158/0008-5472.can-03-1452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.can-03-1452</ArticleId><ArticleId IdType="pubmed">14729650</ArticleId></ArticleIdList></Reference><Reference><Citation>Harashima N, Tanosaki R, Shimizu Y, et al. Identification of two HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopietic stem cell transplantation. J Virol. 2005;79:10088&#8211;10092. doi: 10.1128/JVI.79.15.10088-10092.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.15.10088-10092.2005</ArticleId><ArticleId IdType="pmc">PMC1181560</ArticleId><ArticleId IdType="pubmed">16014972</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo T, Noguchi K, Sakai T, et al. HTLV-1 Tax-specific memory cytotoxic T lymphocytes in long-term survivors of aggressive-type adult T-cell leukemia/lymphoma. Cancer Med. 2022;00:1&#8211;13. doi: 10.1002/cam4.4689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.4689</ArticleId><ArticleId IdType="pmc">PMC9468428</ArticleId><ArticleId IdType="pubmed">35315593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesnard JM, Barbeau B, C&#233;saire R, et al. Roles of HTLV-1 basic zip factor (HBZ) in viral chroniicity and leukemic transformation. Potential new therapeutic approaches to prevent and treat HTLV-1-related diseases. Viruses. 2015;7:6490&#8211;6505. doi: 10.3390/v7122952.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122952</ArticleId><ArticleId IdType="pmc">PMC4690875</ArticleId><ArticleId IdType="pubmed">26690203</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;304:1288&#8211;1290. doi: 10.1016/S0140-6736(74)900144-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(74)900144-5</ArticleId><ArticleId IdType="pubmed">4139526</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. Development of a live attenuated varicella vaccine. Biken J. 1975;18:25&#8211;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">167707</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga Y, Yamanishi K, Takahashi M. Experimental infection and immune response of guinea pigs with varicella-zoster virus. Infect Immun. 1982;37:407&#8211;412. doi: 10.1128/iai.37.2.407-412.1982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.37.2.407-412.1982</ArticleId><ArticleId IdType="pmc">PMC347548</ArticleId><ArticleId IdType="pubmed">6288560</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271&#8211;2284. doi: 10.1056/NEJMoa051016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051016</ArticleId><ArticleId IdType="pubmed">15930418</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano Y, Itakura N, Hiroishi Y, et al. Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J Infect Dis. 1985;152:863&#8211;868. doi: 10.1093/infdis/152.5.863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/152.5.863</ArticleId><ArticleId IdType="pubmed">2995510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis. 1990;162:1049&#8211;1054. doi: 10.1093/infdis/162.5.1049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/162.5.1049</ArticleId><ArticleId IdType="pubmed">2172393</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger R, Trannoy E, Holl&#228;nder G, et al. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis. 1998;178(Suppl 1):s99&#8211;103. doi: 10.1086/514265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/514265</ArticleId><ArticleId IdType="pubmed">9852985</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine AS, Sivulich M, Wiernik PH, Levy HB. Intitial clinical treials in cancer patients of polyriboinosinic-polybocytidylic acid stabilized with poly-L-lysin, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res. 1979;39:1645&#8211;1650.</Citation><ArticleIdList><ArticleId IdType="pubmed">371793</ArticleId></ArticleIdList></Reference><Reference><Citation>Coiffier B, Lapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235&#8211;422. doi: 10.1056/NEJMoa011795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011795</ArticleId><ArticleId IdType="pubmed">11807147</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Asano Y, Kamiya H, et al. Development of varicella vaccine. J Infect Dis. 2008;197:S41&#8211;44. doi: 10.1086/522132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/522132</ArticleId><ArticleId IdType="pubmed">18419406</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon AA, Gershon MD, Shapiro ED. Live attenuated varicella vaccine: prevention of varicella and of zoster. J Infect Dis. 2021;224:S387&#8211;397. doi: 10.1093/infdis/jiaa573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa573</ArticleId><ArticleId IdType="pmc">PMC8482020</ArticleId><ArticleId IdType="pubmed">34590140</ArticleId></ArticleIdList></Reference><Reference><Citation>Haredy AM, Takei M, Iwamoto SI, et al. Quantification of a cell-mediated immune response against varicella zoster virus by assessing responder CD4high memory cell proliferation in activated whole blood cultures. Vaccine. 2019;37:5225&#8211;5232. doi: 10.1016/j.vaccine.2019.07.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.068</ArticleId><ArticleId IdType="pubmed">31358406</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337&#8211;4343. doi: 10.1182/blood-2009-09-242347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-09-242347</ArticleId><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517&#8211;e526. doi: 10.1016/S1470-2045(14)70202-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother. 2004;53:249&#8211;255. doi: 10.1007/s00262-003-0473-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-003-0473-9</ArticleId><ArticleId IdType="pubmed">14704832</ArticleId></ArticleIdList></Reference><Reference><Citation>Suehiro Y, Hasegawa A, Iino T, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169:356&#8211;367. doi: 10.1111/bjh.13302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13302</ArticleId><ArticleId IdType="pubmed">25612920</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S, Masaki A, Ishida T, et al. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. Cancer Sci. 2012;103:1764&#8211;1763. doi: 10.1111/j.1349-7006.2012.02371.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2012.02371.x</ArticleId><ArticleId IdType="pmc">PMC7659279</ArticleId><ArticleId IdType="pubmed">22735080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Yamazaki R, Terasako-Saito K, et al. Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02+ patient with adult T-cell leukemia against a variety of HTV-1-infected T-cells. Immunol Lett. 2014;158:120&#8211;125. doi: 10.1016/j.imlet.2013.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2013.12.016</ArticleId><ArticleId IdType="pubmed">24389072</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109:559&#8211;567. doi: 10.1002/ijc.20007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.20007</ArticleId><ArticleId IdType="pubmed">14991578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogre Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood. 2022;139:967&#8211;982. doi: 10.1182/blood.2021013568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021013568</ArticleId><ArticleId IdType="pmc">PMC8854674</ArticleId><ArticleId IdType="pubmed">34695199</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani N, Yamanishi K, Sakaguchi Y, et al. Varicella-zoster virus-specific cell mediated immunity in subjects with herpes zoster. J Immunol Methods. 2012;377:53&#8211;55. doi: 10.1016/j.jim.2012.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2012.01.003</ArticleId><ArticleId IdType="pubmed">22261191</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200:1068&#8211;1077. doi: 10.1086/605611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/605611</ArticleId><ArticleId IdType="pmc">PMC4014851</ArticleId><ArticleId IdType="pubmed">19712037</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369:255&#8211;263. doi: 10.1056/NEJMMcp1302674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMMcp1302674</ArticleId><ArticleId IdType="pmc">PMC4789101</ArticleId><ArticleId IdType="pubmed">23863052</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuno Y, Takao Y, Miyazaki Y, et al. Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster. Epidemiol Infect. 2013;41:706&#8211;713. doi: 10.1017/S0950268812002671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268812002671</ArticleId><ArticleId IdType="pmc">PMC9151859</ArticleId><ArticleId IdType="pubmed">23218021</ArticleId></ArticleIdList></Reference><Reference><Citation>Asada H, Nagayama K, Okazaki A, et al. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. J Dematol Sci. 2013;69:243&#8211;249. doi: 10.1016/j.jdermsci.2012.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2012.10.015</ArticleId><ArticleId IdType="pubmed">23183011</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103&#8211;108. doi: 10.15585/mmwr.mm6703a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6703a5</ArticleId><ArticleId IdType="pmc">PMC5812314</ArticleId><ArticleId IdType="pubmed">29370152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37899180</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>9</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Adult T-cell leukemia/lymphoma].</ArticleTitle><Pagination><StartPage>1032</StartPage><EndPage>1040</EndPage><MedlinePgn>1032-1040</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.64.1032</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is an extremely refractory peripheral T-cell lymphoma that develops after persistent human T-lymphotropic virus type 1 (HTLV-1) infection. In recent years, the number of HTLV-1 carriers has decreased due to lifestyle changes and different measures. Rapid progression in comprehensive genetic analysis techniques has revealed the molecular basis of ATL. Therefore, in addition to conventional prognostic indices based on clinical parameters, prognostic indices incorporating genetic mutations have been proposed. The standard treatment for untreated aggressive ATL is combination chemotherapy such as VCAP-AMP-VECP or CHOP, followed by allogeneic hematopoietic stem cell transplantation, as appropriate. Combined mogamulizumab and chemotherapy is a promising first-line treatment option for patients not eligible for transplantation. Salvage treatment with lenalidomide, brentuximab vedotin, tucidinostat, and valemetostat, in addition to mogamulizumab, has been introduced over the last decade. Advancements in allogeneic transplantation therapy, including early induction and transplantation with post-transplant cyclophosphamide for GVHD prophylaxis, have also improved patient outcomes. This article highlights recent developments in the field of ATL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">HTLV-1 carrier</Keyword><Keyword MajorTopicYN="N">Valemetostat</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>30</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>29</Day><Hour>21</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37899180</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.64.1032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28592744</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>97</EndPage><MedlinePgn>87-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3960/jslrt.17008</ELocationID><Abstract><AbstractText>A classification for adult T-cell leukemia-lymphoma (ATL) based on clinical features was proposed in 1991: acute, lymphoma, chronic, and smoldering types, and their median survival times (MSTs) were reported to be 6.2, 10.2, 24.3 months, and not reached, respectively. Several new therapies for ATL have since been developed, i.e. dose-intensity multi-agent chemotherapies, allogeneic hematopoietic stem cell transplantation (allo-HSCT), monoclonal antibodies, and anti-viral therapy. The monoclonal antibody to CCR4, mogamulizumab, clearly improved response rates in patients with treatment-na&#239;ve and relapsed aggressive ATL, and has the potential to provide a survival advantage. The outcomes of allo-HSCT have been reported since the early 2000s. High treatment-related mortality was initially the crucial issue associated with this treatment approach; however, reduced intensity conditioning regimens have decreased the risk of treatment-related mortality. The introduction of allo- HSCT has had a positive impact on the prognosis of and potential curability with treatments for ATL. A meta-analysis of a treatment with interferon-&#945; and zidovudine (IFN/AZT) revealed a survival benefit in patients with the leukemic subtype. A phase 3 study comparing IFN/AZT with watchful waiting in patients with indolent ATL is ongoing in Japan. Several clinical trials on novel agents are currently being conducted, such as the histone deacetylase inhibitors, alemtuzumab, brentuximab vedotin, nivolumab, and an EZH1/2 dual inhibitor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsuya</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for AIDS Research, Kumamoto University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Imperial College London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology and Immunology, Center for Chronic Viral Diseases Graduate School of Medical and Dental Sciences, Kagoshima University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult T-cell leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">dose-intensity multi-agent chemotherapy</Keyword></KeywordList><CoiStatement><b>CONFLICT OF INTEREST:</b> H.K. has no conflicts of interest to declare. K.I. reports grants and personal fees from Kyowa Hakko Kirin, Chugai Pharmaceutical,
Takeda Pharmaceutical, Novartis, Eisai, and Taiho Pharmaceutical; personal fees from
Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical, and Pfizer; and grants from Yakult
Pharmaceutical, MSD, and Japan Blood Products Organization, outside the submitted
work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28592744</ArticleId><ArticleId IdType="pmc">PMC6144188</ArticleId><ArticleId IdType="doi">10.3960/jslrt.17008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de The G : Bomford R: An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 9: 381-386, 1993. 10.1089/aid.1993.9.381</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/aid.1993.9.381</ArticleId><ArticleId IdType="pubmed">8318266</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O: Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 3: 388, 2012. 10.3389/fmicb.2012.00388</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00388</ArticleId><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24: 6058-6068, 2005. 10.1038/sj.onc.1208968</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208968</ArticleId><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M, Watanabe T, Yamaguchi K: Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol 3: 322, 2012. 10.3389/fmicb.2012.00322</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00322</ArticleId><ArticleId IdType="pmc">PMC3437524</ArticleId><ArticleId IdType="pubmed">22973265</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991. 10.1111/j.1365-2141.1991.tb08051.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M: Chemotherapy of ATL, in Takatsuki K (ed): Adult T-Cell Leukemia. Oxford, United Kingdom, Oxford University Press, 1994, pp 221-237</Citation></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, et al. : Treatment and survival among 1594 patients with ATL. Blood 126: 2570-2577, 2015. 10.1182/blood-2015-03-632489</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, et al. : Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 115: 4337-4343, 2010. 10.1182/blood-2009-09-242347</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-09-242347</ArticleId><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, et al. : Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 30: 1635-1640, 2012. 10.1200/JCO.2011.38.2101</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.2101</ArticleId><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, et al. : Prognostic index for chronic and smoldering types adult T-cell leukemia/lymphoma. J Clin Oncol 33: 8522-8522, 2015. [abstract]</Citation></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, et al. : A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001. 10.1046/j.1365-2141.2001.02737.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2001.02737.x</ArticleId><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, et al. : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007. 10.1200/JCO.2007.11.9958</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, et al. : Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30: 837-842, 2012. 10.1200/JCO.2011.37.3472</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, et al. : Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 169: 672-682, 2015. 10.1111/bjh.13338</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, et al. : Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28: 4177-4183, 2010. 10.1200/JCO.2010.28.0669</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama MIM, Yunoki K, Oota K, Ogawa M: Final results of cooperative study of VEPA [vincristine, cyclophosphamide (endoxan), prednisolone and adriamycin] therapy in advanced adultnon-Hodgkin&#8217;s lymphoma: relation between T- or B-cell phenotype and response. Jpn J Clin Oncol 12, 1982</Citation></Reference><Reference><Citation>Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, et al. : Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin&#8217;s lymphoma treated with VEPA or VEPA-M. J Clin Oncol 6: 128-141, 1988. 10.1200/JCO.1988.6.1.128</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.1988.6.1.128</ArticleId><ArticleId IdType="pubmed">2891797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinai KSM, Minato K, Shirakawa S, Kobayashi T, Hotta T, et al. : Japan Clinical Oncology Group phase II trial of second-generation &#8219;LSG4 protocol&#8217; in aggressive T- and B-lymphoma: a new predictive model FOR T-and B-lymphoma. Proc Am Soc Clin Oncol, 1994. [abstract]</Citation></Reference><Reference><Citation>Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, et al. : Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 77: 164-170, 2003. 10.1007/BF02983215</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02983215</ArticleId><ArticleId IdType="pubmed">12627852</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, et al. : Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99: 1505-1511, 2002. 10.1182/blood.V99.5.1505</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.5.1505</ArticleId><ArticleId IdType="pubmed">11861261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, et al. : Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9: 3625-3634, 2003</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips A, Fields P, Hermine O, Ramos JC, Beltran BE, et al. : A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator&#8217;s Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival. Blood 128: 4159-4159, 2016. [abstract]</Citation></Reference><Reference><Citation>Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, et al. : A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk 17: 23-30.e2, 2017. 10.1016/j.clml.2016.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2016.09.009</ArticleId><ArticleId IdType="pubmed">27727135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, et al. : Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34: 3426-3433, 2016. 10.1200/JCO.2016.67.8250</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId><ArticleId IdType="pubmed">27507878</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, et al. : Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27: 15-20, 2001. 10.1038/sj.bmt.1702731</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1702731</ArticleId><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kami M, Hamaki T, Miyakoshi S, Murashige N, Kanda Y, et al. : Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol 120: 304-309, 2003. 10.1046/j.1365-2141.2003.04054.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2003.04054.x</ArticleId><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, et al. : Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19: 829-834, 2005. 10.1038/sj.leu.2403682</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.leu.2403682</ArticleId><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, et al. : Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105: 4143-4145, 2005. 10.1182/blood-2004-11-4193</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-11-4193</ArticleId><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Kanda Y, Eto T, Muta T, Gondo H, et al. : Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant 13: 90-99, 2007. 10.1016/j.bbmt.2006.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2006.09.002</ArticleId><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, et al. : A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant 14: 817-823, 2008. 10.1016/j.bbmt.2008.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2008.04.014</ArticleId><ArticleId IdType="pubmed">18541202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, et al. : Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 14: 702-708, 2008. 10.1016/j.bbmt.2008.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2008.03.010</ArticleId><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, et al. : Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant 46: 116-118, 2011. 10.1038/bmt.2010.92</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2010.92</ArticleId><ArticleId IdType="pubmed">20400987</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, Oku E, Nomura K, Morishige S, Takata Y, et al. : Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute. Int J Hematol 96: 657-663, 2012. 10.1007/s12185-012-1177-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-012-1177-8</ArticleId><ArticleId IdType="pubmed">22976114</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Itonaga H, Moriuchi Y, Yoshida S, Taguchi J, et al. : Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network. Int J Hematol 97: 485-490, 2013. 10.1007/s12185-013-1307-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-013-1307-y</ArticleId><ArticleId IdType="pubmed">23483425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, et al. : Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant 49: 1266-1268, 2014. 10.1038/bmt.2014.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2014.143</ArticleId><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Choi I, Wake A, Uike N, Taniguchi S, et al. : Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biol Blood Marrow Transplant 20: 1968-1974, 2014. 10.1016/j.bbmt.2014.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2014.08.012</ArticleId><ArticleId IdType="pubmed">25172635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, et al. : Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 120: 1734-1741, 2012. 10.1182/blood-2012-03-414490</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-414490</ArticleId><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, et al. : Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 119: 2141-2148, 2012. 10.1182/blood-2011-07-368233</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-07-368233</ArticleId><ArticleId IdType="pubmed">22234682</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigematsu A, Kobayashi N, Yasui H, Shindo M, Kakinoki Y, et al. : High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transplant 20: 801-805, 2014. 10.1016/j.bbmt.2014.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2014.02.014</ArticleId><ArticleId IdType="pubmed">24565990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawada H, Yoshimitsu M, Nakamura D, Arai A, Hayashida M, et al. : A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience. Biol Blood Marrow Transplant 21: 696-700, 2015. 10.1016/j.bbmt.2014.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2014.12.020</ArticleId><ArticleId IdType="pubmed">25542158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W, Jr, Kaplan MH, Ribeiro RC, Bennett JM, et al. : Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332: 1744-1748, 1995. 10.1056/NEJM199506293322603</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199506293322603</ArticleId><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, et al. : Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332: 1749-1751, 1995. 10.1056/NEJM199506293322604</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199506293322604</ArticleId><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, et al. : The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 40: 287-294, 2001. 10.3109/10428190109057927</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428190109057927</ArticleId><ArticleId IdType="pubmed">11426550</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, et al. : Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 113: 779-784, 2001. 10.1046/j.1365-2141.2001.02794.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2001.02794.x</ArticleId><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson A, Crichton S, Montoto S, Mir N, Matutes E, et al. : Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol 29: 4696-4701, 2011. 10.1200/JCO.2011.35.5578</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.35.5578</ArticleId><ArticleId IdType="pubmed">22042945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito T, Ando H, Suzuki T, Ogura T, Hotta K, et al. : Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350, 2010. 10.1126/science.1177319</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1177319</ArticleId><ArticleId IdType="pubmed">20223979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, et al. : Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26: 2326-2335, 2012. 10.1038/leu.2012.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2012.119</ArticleId><ArticleId IdType="pmc">PMC3496085</ArticleId><ArticleId IdType="pubmed">22552008</ArticleId></ArticleIdList></Reference><Reference><Citation>Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, et al. : A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 49: 2869-2876, 2013. 10.1016/j.ejca.2013.04.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2013.04.029</ArticleId><ArticleId IdType="pubmed">23731832</ArticleId></ArticleIdList></Reference><Reference><Citation>Toumishey E, Prasad A, Dueck G, Chua N, Finch D, et al. : Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121: 716-723, 2015. 10.1002/cncr.29103</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.29103</ArticleId><ArticleId IdType="pubmed">25355245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, et al. : Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. J Clin Oncol, 2016. 10.1200/JCO.2016.67.7732</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.7732</ArticleId><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006. 10.1038/nrc1779</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc1779</ArticleId><ArticleId IdType="pubmed">16397526</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K: Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res 20: 5217-5225, 2014. 10.1158/1078-0432.CCR-14-0572</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0572</ArticleId><ArticleId IdType="pubmed">25320371</ArticleId></ArticleIdList></Reference><Reference><Citation>Onizuka M, Ando K, Yoshimitsu M, Ishida T, Yoshida S, et al. : Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results. Blood 128: 1827-1827, 2016. [abstract]</Citation></Reference><Reference><Citation>Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, et al. : Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7: e39416, 2012. 10.1371/journal.pone.0039416</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039416</ArticleId><ArticleId IdType="pmc">PMC3382607</ArticleId><ArticleId IdType="pubmed">22761788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Janik JE, O&#8217;Mahony D, Stewart D, Pittaluga S, et al. : Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. Clin Cancer Res 23: 35-42, 2017. 10.1158/1078-0432.CCR-16-1022</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1022</ArticleId><ArticleId IdType="pmc">PMC5215752</ArticleId><ArticleId IdType="pubmed">27486175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen B, Zhang M, Dilillo D, Ravetch JV, Waldmann TA: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20. Cancer Res 75: 1332-1332, 2015. [abstract] 10.1158/1538-7445.AM2015-1332</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2015-1332</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al. : Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin&#8217;s lymphoma. J Clin Oncol 30: 2183-2189, 2012. 10.1200/JCO.2011.38.0410</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.0410</ArticleId><ArticleId IdType="pmc">PMC3646316</ArticleId><ArticleId IdType="pubmed">22454421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, et al. : Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30: 2190-2196, 2012. 10.1200/JCO.2011.38.0402</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.0402</ArticleId><ArticleId IdType="pubmed">22614995</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, et al. : Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123: 3095-3100, 2014. 10.1182/blood-2013-12-542142</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-12-542142</ArticleId><ArticleId IdType="pmc">PMC4425442</ArticleId><ArticleId IdType="pubmed">24652992</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, et al. : Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood 128: 2993-2993, 2016. [abstract]</Citation></Reference><Reference><Citation>Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, et al. : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014. 10.1200/JCO.2013.53.0105</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.53.0105</ArticleId><ArticleId IdType="pmc">PMC4811023</ArticleId><ArticleId IdType="pubmed">24590637</ArticleId></ArticleIdList></Reference><Reference><Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012. 10.1056/NEJMoa1200690</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId><ArticleId IdType="pmc">PMC3544539</ArticleId><ArticleId IdType="pubmed">22658127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, et al. : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#8217;s lymphoma. N Engl J Med 372: 311-319, 2015. 10.1056/NEJMoa1411087</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411087</ArticleId><ArticleId IdType="pmc">PMC4348009</ArticleId><ArticleId IdType="pubmed">25482239</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, et al. : PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 128: 1374-1381, 2016. 10.1182/blood-2016-02-698936</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-02-698936</ArticleId><ArticleId IdType="pubmed">27418641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, et al. : Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 96: 712-719, 2011. 10.3324/haematol.2010.028605</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2010.028605</ArticleId><ArticleId IdType="pmc">PMC3084918</ArticleId><ArticleId IdType="pubmed">21228036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, et al. : Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127: 1790-1802, 2016. 10.1182/blood-2015-08-662593</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-08-662593</ArticleId><ArticleId IdType="pubmed">26773042</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30981611</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2152-2669</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical lymphoma, myeloma &amp; leukemia</Title><ISOAbbreviation>Clin Lymphoma Myeloma Leuk</ISOAbbreviation></Journal><ArticleTitle>Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.</ArticleTitle><Pagination><StartPage>326</StartPage><EndPage>331</EndPage><MedlinePgn>326-331</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clml.2019.03.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2152-2650(19)30107-7</ELocationID><Abstract><AbstractText>Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in the allogenic stem cell transplant (allo-SCT) setting. It is possible that the efficacy of mogamulizumab could be established by the occurrence of skin rashes and/or CCR4 mutational status. Hence, this study reviews the current treatment strategies for patients with ATL and focuses on the safety and efficacy (single-agent and combined with chemotherapy or allo-SCT) of mogamulizumab.</AbstractText><CopyrightInformation>Copyright &#169; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ureshino</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University, Saga, Japan; Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine Saga University, Saga, Japan. Electronic address: m00010hu@jichi.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamachi</LastName><ForeName>Kazuharu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University, Saga, Japan; Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine Saga University, Saga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine Saga University, Saga, Japan; Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine Saga University, Saga, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lymphoma Myeloma Leuk</MedlineTA><NlmUniqueID>101525386</NlmUniqueID><ISSNLinking>2152-2669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000920">Antibody-Dependent Cell Cytotoxicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074322">Antineoplastic Agents, Immunological</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allogenic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">CCR4 mutaion</Keyword><Keyword MajorTopicYN="N">Conventional chemotherapy</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword><Keyword MajorTopicYN="N">T-cell repertoire</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30981611</ArticleId><ArticleId IdType="doi">10.1016/j.clml.2019.03.004</ArticleId><ArticleId IdType="pii">S2152-2650(19)30107-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37300656</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-6277</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current treatment options in oncology</Title><ISOAbbreviation>Curr Treat Options Oncol</ISOAbbreviation></Journal><ArticleTitle>Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions.</ArticleTitle><Pagination><StartPage>948</StartPage><EndPage>964</EndPage><MedlinePgn>948-964</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11864-023-01111-1</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a rare, aggressive subtype of peripheral T-cell lymphoma developing after many years of chronic, asymptomatic infection with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). HTLV-1 is endemic to certain geographic areas of the world, and primary infection generally occurs in infancy through mother-to-child transmission via breastfeeding. In less than 5% of infected individuals, a decades-long pathogenic process culminates in the development of ATL. Aggressive subtypes of ATL are life-threatening and challenging to treat, with median overall survival typically less than 1 year in the absence of allogeneic hematopoietic cell transplantation (alloHCT). Owing to the rarity of this illness, prospective large-scale clinical trials have been challenging to perform, and treatment recommendations are largely founded upon limited evidence. Herein, we review the current therapeutic options for ATL, providing a broad literature overview of the foremost clinical trials and reports of this disease. We emphasize our own treatment paradigm, which is broadly based upon disease subtype, patient fitness, and intent to perform alloHCT. Finally, we highlight recent advances in understanding ATL disease biology and important ongoing clinical trials that we foresee as informative and potentially practice-changing.</AbstractText><CopyrightInformation>&#169; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stuver</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0991-5170</Identifier><AffiliationInfo><Affiliation>Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E. 74th St, New York, NY, 10021, USA. stuverr@mskcc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horwitz</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E. 74th St, New York, NY, 10021, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein-Peterson</LastName><ForeName>Zachary D</ForeName><Initials>ZD</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E. 74th St, New York, NY, 10021, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Oncol</MedlineTA><NlmUniqueID>100900946</NlmUniqueID><ISSNLinking>1534-6277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018445">Infectious Disease Transmission, Vertical</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Human T-cell lymphotropic virus</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword><Keyword MajorTopicYN="N">Peripheral T-cell lymphoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37300656</ArticleId><ArticleId IdType="doi">10.1007/s11864-023-01111-1</ArticleId><ArticleId IdType="pii">10.1007/s11864-023-01111-1</ArticleId></ArticleIdList><ReferenceList><Title>References and Recommended Reading</Title><ReferenceList><Title>Papers of particular interest, published recently, have been highlighted as: &#8226; Of importance &#8226;&#8226; Of major importance</Title><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pubmed">23162541</ArticleId><ArticleId IdType="pmc">3498738</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2012.00388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#231;alves DU, Proietti FA, Ribas JGR, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23(3):577&#8211;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">20610824</ArticleId><ArticleId IdType="pmc">2901658</ArticleId><ArticleId IdType="doi">10.1128/CMR.00063-09</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Rowan AG, Melamed A, Taylor GP, Bangham CRM. HTLV-1&#8211;infected T cells contain a single integrated provirus in natural infection. Blood. 2012;120(17):3488&#8211;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">22955925</ArticleId><ArticleId IdType="pmc">3482858</ArticleId><ArticleId IdType="doi">10.1182/blood-2012-07-445593</ArticleId></ArticleIdList></Reference><Reference><Citation>Schierhout G, McGregor S, Gessain A, et al. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133&#8211;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31648940</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(19)30402-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448111</ArticleId><ArticleId IdType="doi">10.1182/blood-2009-12-257410</ArticleId></ArticleIdList></Reference><Reference><Citation>Demontis MA, Hilburn S, Taylor GP. Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses. 2013;29(2):359&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">22894552</ArticleId><ArticleId IdType="doi">10.1089/aid.2012.0132</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol. 2009;20(4):715&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150954</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdn696</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan: an update. Front Microbiol. 2020;11:1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">32547527</ArticleId><ArticleId IdType="pmc">7273189</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2020.01124</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Shah N, Qiao B, et al. Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States. Cancer. 2020;126(3):567&#8211;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">31769871</ArticleId><ArticleId IdType="doi">10.1002/cncr.32556</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan AG, Dillon R, Witkover A, et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood. 2020;135(23):2023&#8211;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32160278</ArticleId><ArticleId IdType="pmc">7381760</ArticleId><ArticleId IdType="doi">10.1182/blood.2019002665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Kubokawa M, Kuze Y, et al. Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun. 2021;12(1):1&#8211;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25101-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428&#8211;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittencourt AL, Vieira MDG, Brites CR, Farre L, Barbosa HS. Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol. 2007;128(5):875&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17951212</ArticleId><ArticleId IdType="doi">10.1309/2YGD1P0QCVCWBLDX</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.18.2428</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcarcel B, Sano H, Katsuya H, et al. Clinical features, treatment patterns, and outcomes among 837 patients with adult T-cell leukemia-lymphoma in the real-world setting: a comparison of endemic regions. Blood. 2022;140(Supplement 1):1072&#8211;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-168334</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164&#8211;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627852</ArticleId><ArticleId IdType="doi">10.1007/BF02983215</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113(2):375&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2141.2001.02737.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study JCOG9801. J Clin Oncol. 2007;25(34):5458&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId></ArticleIdList></Reference><Reference><Citation>Alduaij A, Butera JN, Treaba D, Castillo J. Complete remission in two cases of adult T-Cell Leukemia/Lymphoma treated with Hyper-CVAD: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10(6):480&#8211;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21156467</ArticleId><ArticleId IdType="doi">10.3816/CLML.2010.n.084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Rauch D, Abel H, et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6(3):e408.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015285</ArticleId><ArticleId IdType="pmc">4817103</ArticleId><ArticleId IdType="doi">10.1038/bcj.2016.21</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One. 2009;4(2):e4420.</Citation><ArticleIdList><ArticleId IdType="pubmed">19204798</ArticleId><ArticleId IdType="pmc">2636875</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0004420</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1&#8211;related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29545256</ArticleId><ArticleId IdType="pmc">5873228</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2017011106</ArticleId></ArticleIdList></Reference><Reference><Citation>Toriyama E, Imaizumi Y, Taniguchi H, et al. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma. Int J Hematol. 2018;108(2):167&#8211;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">29651666</ArticleId><ArticleId IdType="doi">10.1007/s12185-018-2455-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda Y, Nishimori H, Yoshida I, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102(12):2097&#8211;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28971899</ArticleId><ArticleId IdType="pmc">5709109</ArticleId><ArticleId IdType="doi">10.3324/haematol.2017.167742</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz N, Tr&#252;mper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660290</ArticleId><ArticleId IdType="doi">10.1182/blood-2010-02-270785</ArticleId></ArticleIdList></Reference><Reference><Citation>Escal&#243;n MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005;103(10):2091&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15816054</ArticleId><ArticleId IdType="doi">10.1002/cncr.20999</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116(14):3438&#8211;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId><ArticleId IdType="doi">10.1002/cncr.25147</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz S, O&#8217;Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30522922</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(18)32984-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittus C, Weinstock MJ, Barnes JA, et al. Interim results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia/lymphoma. Blood. 2021;138(Supplement 1):1395&#8211;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-144422</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera AF, Zain J, Savage KJ, et al. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood. 2021;138(Supplement 1):133&#8211;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-151105</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson A, Crichton S, Montoto S, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696&#8211;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId><ArticleId IdType="doi">10.1200/JCO.2011.35.5578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Phillips AA. How I treat adult T-cell leukemia/lymphoma. Blood. 2021;137(4):459&#8211;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">33075812</ArticleId><ArticleId IdType="doi">10.1182/blood.2019004045</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimoto K, Kato K, Aoki T, et al. CHOP plus sequential mogamulizumab as first-line therapy for untreated adult T-cell leukemia-lymphoma. Blood. 2021;138(Supplement 1):1393&#8211;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-151937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study. Br J Haematol. 2015;169(5):672&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">25733162</ArticleId><ArticleId IdType="pmc">5024033</ArticleId><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2019;184(3):479&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">29411857</ArticleId><ArticleId IdType="doi">10.1111/bjh.15123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo T, Matsuzaka K, Shioya H, et al. Mogamulizumab plus EPOCH therapy for patients with newly diagnosed aggressive adult T-cell leukemia/lymphoma. Anticancer Res. 2020;40(9):5237&#8211;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">32878812</ArticleId><ArticleId IdType="doi">10.21873/anticanres.14527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugio T, Kato K, Aoki T, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(9):1608&#8211;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">27220263</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2016.05.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426&#8211;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27507878</ArticleId><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant. 2016;51(5):725&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26691420</ArticleId><ArticleId IdType="doi">10.1038/bmt.2015.315</ArticleId></ArticleIdList></Reference><Reference><Citation>Haji S, Kiyasu J, Choi I, et al. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51(3):432&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26524267</ArticleId><ArticleId IdType="doi">10.1038/bmt.2015.254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Ramos JC, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma. Br J Haematol. 2021;195(4):571&#8211;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34405395</ArticleId><ArticleId IdType="pmc">9291095</ArticleId><ArticleId IdType="doi">10.1111/bjh.17749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma. Cancer Sci. 2022;113(1):349&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">34738707</ArticleId><ArticleId IdType="doi">10.1111/cas.15191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma. Br J Haematol. 2021;192(2):281&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">33205842</ArticleId><ArticleId IdType="doi">10.1111/bjh.17211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahata S, Morishita K. The role of CD28 in adult T-cell leukaemia/lymphoma. Br J Haematol. 2021;192(2):235&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33316073</ArticleId><ArticleId IdType="doi">10.1111/bjh.17214</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz SM, Ansell S, Ai WZ, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(3):285&#8211;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">35276674</ArticleId><ArticleId IdType="doi">10.6004/jnccn.2022.0015</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196(3):507&#8211;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">34811725</ArticleId><ArticleId IdType="doi">10.1111/bjh.17951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37(8):677&#8211;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">30657736</ArticleId><ArticleId IdType="pmc">6494249</ArticleId><ArticleId IdType="doi">10.1200/JCO.18.00501</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Fujiwara H, Nakano N, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51:2. 2015;51(2):205&#8211;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2015.265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49(10):1266&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId><ArticleId IdType="doi">10.1038/bmt.2014.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Yamaguchi T, Inoue Y, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1265.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.164996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369&#8211;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId><ArticleId IdType="doi">10.1182/blood-2009-10-247510</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19(5):829&#8211;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId><ArticleId IdType="doi">10.1038/sj.leu.2403682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol. 2003;120(2):304&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542491</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2141.2003.04054.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2001;27(1):15&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId><ArticleId IdType="doi">10.1038/sj.bmt.1702731</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein-Peterson ZD, Ganesan N, Barker JN, et al. Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. Leuk Lymphoma. 2021;62(9):2177&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">33779474</ArticleId><ArticleId IdType="pmc">9531547</ArticleId><ArticleId IdType="doi">10.1080/10428194.2021.1897806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito A, Nakano N, Tanaka T, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5(20):4156&#8211;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">34500464</ArticleId><ArticleId IdType="pmc">8945611</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021004932</ArticleId></ArticleIdList></Reference><Reference><Citation>&#8226; Iqbal M, Reljic T, Klocksieben F, et al. Efficacy of allogeneic hematopoietic cell transplantation in human T cell lymphotropic virus type 1-associated adult T cell leukemia/lymphoma: results of a systematic review/meta-analysis. Biol Blood Marrow Transplant. 2019;25(8):1695&#8211;700. Meta-Analysis of allogenetic transplant in ATL.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132453</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2019.05.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita K, Matsumoto T, Ohtsubo H, et al. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 1999;36(1&#8211;2):67&#8211;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10613451</ArticleId><ArticleId IdType="doi">10.3109/10428199909145950</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115(22):4337&#8211;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId><ArticleId IdType="doi">10.1182/blood-2009-09-242347</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId><ArticleId IdType="doi">10.1056/NEJM199506293322603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749&#8211;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId><ArticleId IdType="doi">10.1056/NEJM199506293322604</ArticleId></ArticleIdList></Reference><Reference><Citation>White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon aipha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;40(42067):287&#8211;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426550</ArticleId><ArticleId IdType="doi">10.3109/10428190109057927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Allard I, L&#233;vy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId><ArticleId IdType="doi">10.1038/sj.thj.6200195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinpara S, Kijiyama M, Takamori A, et al. Interferon-&#945; (IFN-&#945;) suppresses HTLV-1 gene expression and cell cycling, while IFN-&#945; combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 2013;10(1):52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23688327</ArticleId><ArticleId IdType="pmc">3698133</ArticleId><ArticleId IdType="doi">10.1186/1742-4690-10-52</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108(3):1021&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569765</ArticleId><ArticleId IdType="pmc">1895862</ArticleId><ArticleId IdType="doi">10.1182/blood-2006-01-0067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Imaizumi Y, Tokura Y, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol. 2014;41(1):26&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24438141</ArticleId><ArticleId IdType="doi">10.1111/1346-8138.12374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011;117(15):3961&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21325600</ArticleId><ArticleId IdType="doi">10.1182/blood-2010-11-316794</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21245435</ArticleId><ArticleId IdType="pmc">3083873</ArticleId><ArticleId IdType="doi">10.1200/JCO.2010.29.9024</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015;33(23):2492&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26101246</ArticleId><ArticleId IdType="pmc">5087312</ArticleId><ArticleId IdType="doi">10.1200/JCO.2014.59.2782</ArticleId></ArticleIdList></Reference><Reference><Citation>Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22271479</ArticleId><ArticleId IdType="doi">10.1200/JCO.2011.37.4223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20177026</ArticleId><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Yurimoto S, Tsuji Y, et al. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2019;102(5):407&#8211;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30740787</ArticleId><ArticleId IdType="pmc">6850465</ArticleId><ArticleId IdType="doi">10.1111/ejh.13220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28776876</ArticleId><ArticleId IdType="pmc">5623751</ArticleId><ArticleId IdType="doi">10.1111/cas.13343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu KE, Neal TM, Khodadoust MS, et al. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S&#233;zary Syndrome. JAMA Dermatol. 2021;157(6):700&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33881447</ArticleId><ArticleId IdType="doi">10.1001/jamadermatol.2021.0877</ArticleId></ArticleIdList></Reference><Reference><Citation>de Masson A, Darbord D, Dobos G, et al. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients. Blood. 2022;139(12):1820&#8211;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">34905599</ArticleId><ArticleId IdType="doi">10.1182/blood.2021013341</ArticleId></ArticleIdList></Reference><Reference><Citation>&#8226; Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator&#8217;s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2019;104(5):993&#8211;1003. Randomized trial of mogamulizumab versus investigator&#8217;s choice in R/R ATL outside of Asia.</Citation><ArticleIdList><ArticleId IdType="pubmed">30573506</ArticleId><ArticleId IdType="pmc">6518882</ArticleId><ArticleId IdType="doi">10.3324/haematol.2018.205096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">29930010</ArticleId><ArticleId IdType="doi">10.1182/blood-2018-02-835991</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Hematol Oncol. 2022;40(5):876&#8211;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">36043457</ArticleId><ArticleId IdType="pmc">10087024</ArticleId><ArticleId IdType="doi">10.1002/hon.3072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka N, Mori S, Kiyotani K, et al. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica. 2022;107(10):2418&#8211;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">35417939</ArticleId><ArticleId IdType="pmc">9521232</ArticleId><ArticleId IdType="doi">10.3324/haematol.2021.280352</ArticleId></ArticleIdList></Reference><Reference><Citation>Beygi S, Duran GE, Fernandez-Pol S, et al. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139(26):3732&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35436328</ArticleId><ArticleId IdType="pmc">9247360</ArticleId><ArticleId IdType="doi">10.1182/blood.2021014468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto H, Itonaga H, Sawayama Y, et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162&#8211;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31922287</ArticleId><ArticleId IdType="doi">10.1002/hon.2712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086&#8211;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">27621400</ArticleId><ArticleId IdType="doi">10.1200/JCO.2016.67.7732</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Giddings J, Lee SM, Horwitz SM. Lenalidomide in patients with Relapsed or Refractory HTLV-1 Related Adult T cell Leukemia/Lymphoma (ATLL). Int J Blood Res Disord. 2015;2:3.</Citation><ArticleIdList><ArticleId IdType="doi">10.23937/2469-5696/1410010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunning MA, Gonsky J, Ruan J, et al. Pralatrexate in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: a New York City Multi-Institutional Experience. Blood. 2012;120(21):2735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V120.21.2735.2735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhi N, Verma V, Ahmed A, et al. Romidepsin in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: a case series. Blood. 2015;126(23):5113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V126.23.5113.5113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. Cancer Sci. 2015;106(9):1219&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26179770</ArticleId><ArticleId IdType="pmc">4582992</ArticleId><ArticleId IdType="doi">10.1111/cas.12735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Suzumiya J, Aoki M, et al. Therapeutic potential of arsenic trioxide with or without interferon-&#945; for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2007;92(5):719&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17488707</ArticleId><ArticleId IdType="doi">10.3324/haematol.10703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5(2):130&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId><ArticleId IdType="doi">10.1038/sj.thj.6200374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Janik JE, O&#8217;Mahony D, et al. Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. Clin Cancer Res. 2017;23(1):35&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27486175</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1022</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Izutsu K, Jo T, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results. Cancer Sci. 2022;113(8):2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">35579212</ArticleId><ArticleId IdType="pmc">9357668</ArticleId><ArticleId IdType="doi">10.1111/cas.15431</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer SP, Sica RA, Ho PJ, et al. S262: The Cobalt-LYM Study of CTX130: a phase I dose escalation study of CD70-targeted allogeneic CRISPR-CAS9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. Hemasphere. 2022;6:163&#8211;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.HS9.0000843940.96598.e2</ArticleId></ArticleIdList></Reference><Reference><Citation>Pongas G, Toomey NL, Reis IM, et al. Safety and efficacy of belinostat trial with zidovudine plus interferon for HTLV-1 related adult T-cell leukemia-lymphoma: interim results. Blood. 2022;140(Supplement 1):9448&#8211;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-167888</ArticleId></ArticleIdList></Reference><Reference><Citation>Daenthanasanmak A, Bamford RN, Yoshioka M, et al. Triple combination of BET plus PI3K and NF-&#954;B inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. Blood Adv. 2022;6(7):2346&#8211;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">35030628</ArticleId><ArticleId IdType="pmc">9006306</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021005948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishio T, Kumar S, Shimono J, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood. 2022;139(10):1541&#8211;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">34818414</ArticleId><ArticleId IdType="pmc">8914179</ArticleId><ArticleId IdType="doi">10.1182/blood.2021012734</ArticleId></ArticleIdList></Reference><Reference><Citation>Daenthanasanmak A, Lin Y, Zhang M, et al. Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. Transl Oncol. 2021;14(1):100913.</Citation><ArticleIdList><ArticleId IdType="pubmed">33129109</ArticleId><ArticleId IdType="doi">10.1016/j.tranon.2020.100913</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Shahsafaei A, Liu C, Yu H, Dorfman DM. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leuk Lymphoma. 2015;56(7):2087&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">25263318</ArticleId><ArticleId IdType="doi">10.3109/10428194.2014.968780</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012;26(7):651&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22431509</ArticleId><ArticleId IdType="pmc">3323876</ArticleId><ArticleId IdType="doi">10.1101/gad.186411.111</ArticleId></ArticleIdList></Reference><Reference><Citation>&#8226; Izutsu K, Makita S, Nosaka K, et al. An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood. 2022;Sep 23(blood.2022016862.). Phase 2 trial of valemetostat in R/R ATL, leading to approval in Japan.</Citation></Reference><Reference><Citation>Ishitsuka K, Izutsu K, Maruyama D, et al. First inhuman study of the EZH1 and EZH2 dual inhibitor valemetostat (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphoma. Hematol Oncol. 2021;39(S2):Abstract S218.</Citation></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304&#8211;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId><ArticleId IdType="doi">10.1038/ng.3415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogure Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood. 2022;139(7):967&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">34695199</ArticleId><ArticleId IdType="pmc">8854674</ArticleId><ArticleId IdType="doi">10.1182/blood.2021013568</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20505272</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>Treatment of adult T-cell leukemia.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>25</EndPage><MedlinePgn>9-25</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell Leukemia (ATL) is an aggressive malignant disease of CD4+ T-cells associated with human T-cell leukemia virus type I (HTLV-I). Prognosis of ATL patients is directly correlated to the subtype of ATL. Treatment of the aggressive forms (acute and lymphoma types) of ATL remains inadequate, as most ATL patients receive conventional chemotherapy without stem cell rescue. At present, LSG15 is the standard chemotherapy for the treatment of aggressive ATL, but the efficacy of LSG15 in most patients is transient. To prolong median survival time, additional therapies for maintenance of complete response (CR) are needed after achieving CR by induction chemotherapy. Improved outcome after allogeneic stem cell transplantation (allo-SCT), despite a high incidence of graft-versus-host disease, has been reported. Thus, allogeneic bone marrow transplantation and allogeneic peripheral blood SCT may have great potential for eradication of HTLV-1 and cure of ATL. Recently, reduced-intensity conditioning stem cell transplantation was also reported to be effective for ATL. Although several issues, including selection criteria for patients and sources of stem cells remain to be resolved, allo-SCT may be considered as a treatment option for patients with aggressive ATL. To evaluate whether allo-SCT is more effective than the standard chemotherapy (LSG15) for aggressive ATL, an up front phase II clinical trial of JCOG-LSG is now being planned. Novel innovative targeted strategies, such as antiretroviral therapy, arsenic trioxide, nuclear factor-kappaB inhibitors, proteasome inhibitors, histone deacetylase inhibitors, several monoclonal antibodies including anti-CC chemokine receptor 4, anti-folate, purine nucleotide phosphorylase inhibitor, mTOR (mammalian target of rapamycin) inhibitor, bendamustine, small molecule Bcl-2 inhibitors and Tax-targeted immunotherapy, should be promptly studied in order to develop curative treatments for ATL in the near future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uozumi</LastName><ForeName>Kimiru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital. atl2002@me.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20505272</ArticleId><ArticleId IdType="doi">10.3960/jslrt.50.9</ArticleId><ArticleId IdType="pii">JST.JSTAGE/jslrt/50.9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31971149</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of tropical medicine and hygiene</Title><ISOAbbreviation>Am J Trop Med Hyg</ISOAbbreviation></Journal><ArticleTitle>Intraocular Infiltration.</ArticleTitle><Pagination><StartPage>7</StartPage><EndPage>8</EndPage><MedlinePgn>7-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.19-0539</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamoi</LastName><ForeName>Koju</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno-Matsui</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Trop Med Hyg</MedlineTA><NlmUniqueID>0370507</NlmUniqueID><ISSNLinking>0002-9637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005128">Eye Diseases</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011878">Radiotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055213">Retinal Pigment Epithelium</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D041623">Tomography, Optical Coherence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31971149</ArticleId><ArticleId IdType="pmc">PMC6947777</ArticleId><ArticleId IdType="doi">10.4269/ajtmh.19-0539</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kamoi K, Okayama A, Izumo S, Hamaguchi I, Uchimaru K, Tojo A, Ohno-Matsui K, 2018. Adult T-cell leukemia/lymphoma-related ocular manifestations: analysis of the first large-scale nationwide survey. Front Microbiol 9: 3240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331419</ArticleId><ArticleId IdType="pubmed">30671044</ArticleId></ArticleIdList></Reference><Reference><Citation>de-la-Torre A, et al. 2019. Coinfections and differential diagnosis in immunocompetent patients with uveitis of infectious origin. BMC Infect Dis 19: 91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347798</ArticleId><ArticleId IdType="pubmed">30683065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki M, Sugita S, Kamoi K, Takase H, 2017. A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases. Jpn J Ophthalmol 61: 1&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27787641</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin F, Tagaya Y, Gallo R, 2018. Time to eradicate HTLV-1: an open letter to WHO. Lancet 391: 1893&#8211;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">29781438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamoi K, Mochizuki M, 2012. HTLV infection and the eye. Curr Opin Ophthalmol 23: 557&#8211;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">23047174</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36794502</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Haematologica</Title><ISOAbbreviation>Haematologica</ISOAbbreviation></Journal><ArticleTitle>Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>2178</StartPage><EndPage>2191</EndPage><MedlinePgn>2178-2191</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2022.281510</ELocationID><Abstract><AbstractText>The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive chemotherapy, and who therefore might not require upfront allo-HSCT, we aimed to improve risk stratification of aggressive ATL patients aged &lt;70 years. The clinical risk factors and genetic mutations were incorporated into risk modeling for overall survival (OS). We generated the m7-ATLPI, a clinicogenetic risk model for OS, that included the ATL prognostic index (PI) (ATL-PI) risk category, and non-silent mutations in seven genes, namely TP53, IRF4, RHOA, PRKCB, CARD11, CCR7, and GATA3. In the training cohort of 99 patients, the m7-ATLPI identified a low-, intermediate-, and highrisk group with 2-year OS of 100%, 43%, and 19%, respectively (hazard ratio [HR] =5.46; P&lt;0.0001). The m7-ATLPI achieved superior risk stratification compared to the current ATL-PI (C-index 0.92 vs. 0.85, respectively). In the validation cohort of 84 patients, the m7-ATLPI defined low-, intermediate-, and high-risk groups with a 2-year OS of 81%, 30%, and 0%, respectively (HR=2.33; P=0.0094), and the model again outperformed the ATL-PI (C-index 0.72 vs. 0.70, respectively). The simplified m7-ATLPI, which is easier to use in clinical practice, achieved superior risk stratification compared to the ATLPI, as did the original m7-ATLPI; the simplified version was calculated by summing the following: high-risk ATL-PI category (+10), low-risk ATL-PI category (-4), and non-silent mutations in TP53 (+4), IRF4 (+3), RHOA (+1), PRKCB (+1), CARD11 (+0.5), CCR7 (-2), and GATA3 (-3).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kameda</LastName><ForeName>Takuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamiunten</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Michihiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Hospital Organization Kumamoto Medical Center, Kumamoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Nobuaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Kisato</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University of Medicine, Kumamoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasunaga</LastName><ForeName>Jun-Ichirou</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University of Medicine, Kumamoto, Japan; Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogure</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shide</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Karatsu Red Cross Hospital, Saga.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akizuki</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubuki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koya</LastName><ForeName>Junji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal medicine, Koga General Hospital, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyama</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal medicine, Miyazaki Prefectural Nobeoka Hospital, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Kouichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Hospital Organization Miyakonojo Medical center, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marutsuka</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anatomic Pathology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugio</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokunaga</LastName><ForeName>Masahito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Yukie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Imamura General Hospital, Kagoshima.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takaori-Kondo</LastName><ForeName>Akifumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University of Medicine, Kumamoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Practical Management of Medical Information, St Marianna University, Graduate School of Medicine, Tokyo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitanaka</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Seishi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki. kshimoda@med.miyazaki-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Haematologica</MedlineTA><NlmUniqueID>0417435</NlmUniqueID><ISSNLinking>0390-6078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054400">Receptors, CCR7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054400">Receptors, CCR7</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36794502</ArticleId><ArticleId IdType="pmc">PMC10388278</ArticleId><ArticleId IdType="doi">10.3324/haematol.2022.281510</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, et al. . Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428-437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Chemotherapy of ATL. K Takatsuki (Ed), Adult T-Cell Leukemia, Oxford University Press. Oxford. 1994:221-227.</Citation></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. . Revised Adult T-cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677-687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494249</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. . VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458-5464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine M, Kameda T, Shide K, et al. . Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma. Eur J Haematol. 2021;106(3):398-407.</Citation><ArticleIdList><ArticleId IdType="pubmed">33301622</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. . Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570-2577.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. . Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(1):15-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, et al. . Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369-1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Fujiwara H, Nakano N, et al. . Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51(2):205-211.</Citation><ArticleIdList><ArticleId IdType="pubmed">26524263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Nomura S, Shimoyama M, et al. . Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166(5):739-748.</Citation><ArticleIdList><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Yamanaka T, Ishitsuka K, et al. . Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30(14):1635-1640.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Yamaguchi T, Inoue Y, et al. . Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102(7):1258-1265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5566038</ArticleId><ArticleId IdType="pubmed">28341734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogure Y, Kameda T, Koya J, et al. . Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood. 2022;139(7):967-982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8854674</ArticleId><ArticleId IdType="pubmed">34695199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, et al. . Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature. 2016;534(7607):402-406.</Citation><ArticleIdList><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Iwanaga M, Yasunaga JI, et al. . Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215-225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy A, Zhang J, Davis NS, et al. . Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5659841</ArticleId><ArticleId IdType="pubmed">28985567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. . CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758-761.</Citation><ArticleIdList><ArticleId IdType="pubmed">29930010</ArticleId></ArticleIdList></Reference><Reference><Citation>Persky DO, Li H, Stephens DM, et al. . Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38(26):3003-3011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7479758</ArticleId><ArticleId IdType="pubmed">32658627</ArticleId></ArticleIdList></Reference><Reference><Citation>Relander T, Johnson NA, Farinha P, et al. . Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17):2902-2913.</Citation><ArticleIdList><ArticleId IdType="pubmed">20385990</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastore A, Jurinovic V, Kridel R, et al. . Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111-1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">26256760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakihama S, Morichika K, Saito R, et al. . Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: association with prognosis, ethnicity, and HTLV-1 strains. Cancer Sci. 2021;112(3):1300-1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7935801</ArticleId><ArticleId IdType="pubmed">33426772</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26381999</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6527</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current opinion in infectious diseases</Title><ISOAbbreviation>Curr Opin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Treatment of adult T-cell leukaemia/lymphoma: is the virus a target?</ArticleTitle><Pagination><StartPage>583</StartPage><EndPage>588</EndPage><MedlinePgn>583-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QCO.0000000000000207</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">To discuss current understanding of the mechanisms of human T-lymphotropic virus type-1 (HTLV-1) tumorigenesis and current and potential treatment strategies for adult T-cell leukaemia/lymphoma (ATL), an aggressive malignant disease of CD4 cells caused by HTLV-1.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Treatment of the aggressive subtypes of ATL remains inadequate, with little improvement in overall survival in the 30 years since HTLV-1 was discovered. Detailed analysis of the clonal expansion of HTLV-1 has provided new insight into pathogenesis. Most HTLV-1-infected cells, including ATL, express CCR4 which can be targeted. Reports of antitumour effects with allogeneic bone marrow transplantation provide a rationale for novel immunotherapy approaches. Progress has been made in the indolent subtypes of ATL with the use of 'antiviral' therapies.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">ATL has poor prognosis. There is a major, urgent, unmet clinical need to identify HTLV carriers who will develop ATL to develop biomarkers of transforming disease and disease progression and to provide novel treatment approaches within the context of clinical trials. Several strategies now include putative or actual antiviral therapy. Potentially, the risk of ATL would be reduced by eliminating some or all infected clones. HTLV-1 infection, and hence ATL, can be prevented by antenatal HTLV-1 screening.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Lucy B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>aSection of Virology, Department of Medicine, Imperial College London bDepartment of Medicine, National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Graham P</ForeName><Initials>GP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Infect Dis</MedlineTA><NlmUniqueID>8809878</NlmUniqueID><ISSNLinking>0951-7375</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26381999</ArticleId><ArticleId IdType="doi">10.1097/QCO.0000000000000207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37689806</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1559-131X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Medical oncology (Northwood, London, England)</Title><ISOAbbreviation>Med Oncol</ISOAbbreviation></Journal><ArticleTitle>Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review.</ArticleTitle><Pagination><StartPage>295</StartPage><MedlinePgn>295</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12032-023-02166-8</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL), an infrequent malignancy resultant from human T-cell lymphotropic virus type I (HTLV-1), exhibits a spectrum of phenotypes, encompassing acute, smoldering, lymphomatous, and chronic variants, each bearing distinct clinical presentations. The preponderant acute manifestation is characterized by hypercalcemia, systemic manifestations, organomegaly, and dermatological eruptions. Conversely, the chronic phenotype is typified by lymphocytosis and/or cutaneous eruptions, while smoldering ATLL assumes an asymptomatic course. Immunocompromise afflicts ATLL patients, heightening their vulnerability to opportunistic infections that frequently intricately intertwine with disease progression. Therefore, an early diagnosis is crucial to manage the disease appropriately. While conventional chemotherapeutic regimens have shown limited success, especially in acute and lymphoma types, recent studies suggest that allogeneic stem cell transplantation might enhance treatment results because it has shown promising outcomes in some patients. Novel therapeutics, such as interferon and monoclonal antibodies, have also shown promise, but more research is needed to confirm their efficacy. Moreover, the identification of biomarkers for ATLL and genetic changes in HTLV-1 infected cells has led to the development of targeted therapies that have shown remarkable success in clinical trials. These targeted therapies have the potential to offer a more personalized approach to the treatment of ATLL. The aim of our review is to elaborate on conventional and novel therapies and the efficiency of mentioned treatments.</AbstractText><CopyrightInformation>&#169; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Letafati</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soheili</LastName><ForeName>Roben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norouzi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soleimani</LastName><ForeName>Parastoo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Advanced Science Faculty, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozhgani</LastName><ForeName>Sayed-Hamidreza</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-4570-2252</Identifier><AffiliationInfo><Affiliation>Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran. hamidrezamozhgani@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Virology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. hamidrezamozhgani@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Oncol</MedlineTA><NlmUniqueID>9435512</NlmUniqueID><ISSNLinking>1357-0560</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Clinical features</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">Stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Targeting surface molecules</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37689806</ArticleId><ArticleId IdType="doi">10.1007/s12032-023-02166-8</ArticleId><ArticleId IdType="pii">10.1007/s12032-023-02166-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ishikawa C, Senba M, Mori N. Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. Eur J Pharmacol. 2020;872: 172953.</Citation><ArticleIdList><ArticleId IdType="pubmed">31996318</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2020.172953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno R, Masaoka T, Shirakawa S, Sakamoto S, Hirano M, Hanada S, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis (2, 6-dioxopiperazine). Cancer. 1993;71(7):2217&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8384067</ArticleId><ArticleId IdType="doi">10.1002/1097-0142(19930401)71:7&lt;2217::AID-CNCR2820710709&gt;3.0.CO;2-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop. 2010;50(1):9&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">20505272</ArticleId><ArticleId IdType="doi">10.3960/jslrt.50.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20177026</ArticleId><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, et al. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leuk Res. 2012;36(7):857&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22209076</ArticleId><ArticleId IdType="doi">10.1016/j.leukres.2011.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80(3):185&#8211;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">18081707</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0609.2007.01016.x</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hajj H, Tsukasaki K, Cheminant M, Bazarbachi A, Watanabe T, Hermine O. Novel treatments of adult T cell leukemia lymphoma. Front Microbiol. 2020;11:1062.</Citation><ArticleIdList><ArticleId IdType="pubmed">32547515</ArticleId><ArticleId IdType="pmc">7270167</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2020.01062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood J Am Soc Hematol. 2016;127(14):1790&#8211;802.</Citation></Reference><Reference><Citation>Dou F, Tian Z, Yang X, Li J, Wang R, Gao J. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. Drug Discoveries Therapeutics. 2022;16(6):297&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36310058</ArticleId><ArticleId IdType="doi">10.5582/ddt.2022.01085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanada S, Uematsu T, Iwahashi M, Nomura K, Utsunomiya A, Kodama M, et al. The prevalence of human T-cell leukemia virus type I infection in patients with hematologic and nonhematologic diseases in an adult T-cell leukemia-endemic area of Japan. Cancer. 1989;64(6):1290&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2766224</ArticleId><ArticleId IdType="doi">10.1002/1097-0142(19890915)64:6&lt;1290::AID-CNCR2820640620&gt;3.0.CO;2-Z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15(11):e517&#8211;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Phillips AA. How i treat adult t-cell leukemia/lymphoma. Blood. 2021;137(4):459&#8211;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">33075812</ArticleId><ArticleId IdType="doi">10.1182/blood.2019004045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano R, Utsunomiya A, Matsuoka H, Kawano F, Ikeda S, Izumi Y, et al. Registration of hematological disorders by the Kyushu Hematology Organization for Treatment (K-HOT) Study Group. Japanese J Clin Hematol. 2004;45(6):478&#8211;80.</Citation></Reference><Reference><Citation>Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058&#8211;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155612</ArticleId><ArticleId IdType="doi">10.1038/sj.onc.1208968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramezani S, Rezaee SA, Farjami Z, Ebrahimi N, Abdullabass HK, Jebur MII, et al. HTLV, a multi organ oncovirus. Microb Pathog. 2022. https://doi.org/10.1016/j.micpath.2022.105622 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2022.105622</ArticleId><ArticleId IdType="pubmed">35690233</ArticleId><ArticleId IdType="pmc">9176176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozhgani SH, Zarei-Ghobadi M, Teymoori-Rad M, Mokhtari-Azad T, Mirzaie M, Sheikhi M, et al. Human T-lymphotropic virus 1 (HTLV-1) pathogenesis: a systems virology study. J Cell Biochem. 2018;119(5):3968&#8211;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">29227540</ArticleId><ArticleId IdType="doi">10.1002/jcb.26546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki T, Karube K, Sakihama S, Tsuruta Y, Awazawa R, Hayashi M, et al. A Comprehensive study of the immunophenotype and its clinicopathologic significance in adult T-Cell leukemia/lymphoma. Mod Pathol. 2023;36(8): 100169.</Citation><ArticleIdList><ArticleId IdType="pubmed">36997002</ArticleId><ArticleId IdType="doi">10.1016/j.modpat.2023.100169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano R, Niino D, Ohshima K. Six cases of CD20-positive adult T-cell leukemia. J Clin Exp Hematop. 2016;56(2):119&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">27980301</ArticleId><ArticleId IdType="pmc">6144208</ArticleId><ArticleId IdType="doi">10.3960/jslrt.56.119</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1&#8211;transformed T cells. Blood. 2002;99(5):1505&#8211;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861261</ArticleId><ArticleId IdType="doi">10.1182/blood.V99.5.1505</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozuma S, Matsuura E, Tanaka M, Kodama D, Matsuzaki T, Yoshimura A, et al. Identification and tracking of HTLV-1-infected T cell clones in virus-associated neurologic disease. JCI Insight. 2023. https://doi.org/10.1172/jci.insight.167422 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.167422</ArticleId><ArticleId IdType="pubmed">37036006</ArticleId><ArticleId IdType="pmc">10132145</ArticleId></ArticleIdList></Reference><Reference><Citation>Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, et al. Expression of FoxP3, a key molecule in CD4+ CD25+ regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126(1):81&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15198736</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2141.2004.04999.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Araya N, Sato T, Ando H, Tomaru U, Yoshida M, Coler-Reilly A, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Investig. 2014;124(8):3431&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24960164</ArticleId><ArticleId IdType="pmc">4109535</ArticleId><ArticleId IdType="doi">10.1172/JCI75250</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson DP, Taylor BJ, La M, Sather H, Reaman GH, Ivy SP. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children&#8217;s Oncology Group. Leuk Lymphoma. 2005;46(5):681&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16019505</ArticleId><ArticleId IdType="doi">10.1080/10428190500032612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino H. Cellular factors involved in HTLV-1 entry and pathogenicit. Front Microbiol. 2012;3:222.</Citation><ArticleIdList><ArticleId IdType="pubmed">22737146</ArticleId><ArticleId IdType="pmc">3380293</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2012.00222</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+ T cells. Nat Med. 2008;14(4):429&#8211;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">18376405</ArticleId><ArticleId IdType="doi">10.1038/nm1745</ArticleId></ArticleIdList></Reference><Reference><Citation>Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Revista Espa&#241;ola Quimioterapia. 2019;32(6):485.</Citation></Reference><Reference><Citation>Pique C, Jones K. Pathways of cell-cell transmission of HTLV-1. Front Microbiol. 2012;3:378.</Citation><ArticleIdList><ArticleId IdType="pubmed">23109932</ArticleId><ArticleId IdType="pmc">3479854</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2012.00378</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpentier A, Barez PY, Hamaidia M, Gazon H, de Brogniez A, Perike S, et al. Modes of Human T Cell Leukemia Virus Type 1 Transmission. Replication Persistence Viruses. 2015;7(7):3603&#8211;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">26198240</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross C, Thoma-Kress AK. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8(3):74.</Citation><ArticleIdList><ArticleId IdType="pubmed">27005656</ArticleId><ArticleId IdType="pmc">4810264</ArticleId><ArticleId IdType="doi">10.3390/v8030074</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60(12):1373&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042693</ArticleId><ArticleId IdType="pmc">2095573</ArticleId><ArticleId IdType="doi">10.1136/jcp.2007.052456</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Matutes E, Catovsky D, Galton D, Nakada K, Takatsuki K. Strongyloides stercoralis as candidate co-factor for HTLV-I-induced leukaemogenesis. The Lancet. 1987;330(8550):94&#8211;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(87)92752-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart DM, Ramanathan R, Mahanty S, Fedorko DP, Janik JE, Morris JC. Disseminated strongyloides stercoralis infection in HTLV-1-associated adult t-cell leukemia/lymphoma. Acta Haematol. 2011;126(2):63&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21474923</ArticleId><ArticleId IdType="pmc">3080579</ArticleId><ArticleId IdType="doi">10.1159/000324799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunn PA Jr, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem. 1996;63(S24):12&#8211;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.240630503</ArticleId></ArticleIdList></Reference><Reference><Citation>Karthik U, Ganesan P, Sagar TG, Cyriac S, Majhi U. Adult T-cell leukemia in India: report of two cases and review of literature. J Cancer Res Ther. 2011;7(3):338&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22044818</ArticleId><ArticleId IdType="doi">10.4103/0973-1482.86999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao D-E, Chen C-P, Fang K-T, Hsu Y-H, Hung S-J. A rare presentation of adult T-cell leukemia/lymphoma with generalized cutaneous purpuric lesions. Dermatol Sin. 2015;33(4):234&#8211;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsi.2015.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima T, Mori M, Fujimoto M, Nunomura M, Sakurai Y, Okada Y, et al. Adult T-cell lymphoma involving the leptomeninges associated with a spinal cord schwannoma. Neuropathology. 2001;21(3):229&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11666021</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1789.2001.00391.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Merhi RA, Gessain A, Talhouk R, El-Khoury H, Nasr R, et al. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Can Res. 2004;64(6):2039&#8211;46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2390</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M, Group LS. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984&#8211;87). Br J Haematol. 1991;79(3):428&#8211;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi H, Kinoshita K-I, Takatsuki K, Tomonaga M, Araki K, Arima N, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquired Immune Deficiency Syndromes. 1996;12(2):182&#8211;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042560-199606010-00012</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita K, Matsumoto T, Ohtsubo H, Fujiwara H, Imamura N, Hidaka S, et al. Long-term maintenance combination chemotherapy with OPECMPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemialymphoma. Leuk Lymphoma. 1999;36(1&#8211;2):67&#8211;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10613451</ArticleId><ArticleId IdType="doi">10.3109/10428199909145950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, et al. Treatment of adult T-cell leukaemia&#8211;lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer. 1994;70(4):771&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7917938</ArticleId><ArticleId IdType="pmc">2033383</ArticleId><ArticleId IdType="doi">10.1038/bjc.1994.394</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimaru M, Kamihira S, Moriuchi Y, Kuraishi Y, Usui N, Toki H, et al. Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia. Gan to Kagaku ryoho Cancer and Chemotherapy. 1988;15(10):2975&#8211;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">3052302</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O. CCR4 as a therapeutic target for cancer immunotherapy. Cancers. 2021;13(21):5542.</Citation><ArticleIdList><ArticleId IdType="pubmed">34771703</ArticleId><ArticleId IdType="pmc">8583476</ArticleId><ArticleId IdType="doi">10.3390/cancers13215542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia&#8211;lymphoma. Int J Hematol. 2011;94:443&#8211;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21993874</ArticleId><ArticleId IdType="doi">10.1007/s12185-011-0941-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphomakw-0761 as a novel immunotherapeutic agent for ATLL. Clin Cancer Res. 2010;16(5):1520&#8211;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160057</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-09-2697</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27(1):11&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25087232</ArticleId><ArticleId IdType="doi">10.1093/intimm/dxu079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ureshino H, Kamachi K, Kimura S. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(6):326&#8211;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30981611</ArticleId><ArticleId IdType="doi">10.1016/j.clml.2019.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">30799938</ArticleId><ArticleId IdType="pmc">6369856</ArticleId><ArticleId IdType="doi">10.2147/OTT.S165615</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72:1293&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22686619</ArticleId><ArticleId IdType="doi">10.2165/11631090-000000000-00000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimitsu M, Arima N. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. 2014:17&#8211;23.</Citation></Reference><Reference><Citation>Duvic M, Pinter-Brown L, Foss FM, Sokol L, Jorgensen J, Spitalny GL, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood. 2010;116(21):962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V116.21.962.962</ArticleId></ArticleIdList></Reference><Reference><Citation>Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169(3):356&#8211;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">25612920</ArticleId><ArticleId IdType="doi">10.1111/bjh.13302</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac [see comments]. 1995.</Citation></Reference><Reference><Citation>Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol. 2014;155(2):176&#8211;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">25267440</ArticleId><ArticleId IdType="pmc">4306230</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2014.09.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19:S27&#8211;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12180489</ArticleId><ArticleId IdType="doi">10.1385/MO:19:2S:S27</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravandi F, Aribi A, O&#8217;Brien S, Faderl S, Jones D, Ferrajoli A, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009;27(32):5425.</Citation><ArticleIdList><ArticleId IdType="pubmed">19805674</ArticleId><ArticleId IdType="pmc">4881363</ArticleId><ArticleId IdType="doi">10.1200/JCO.2009.22.6688</ArticleId></ArticleIdList></Reference><Reference><Citation>Callens C, Moura I, Lepelletier Y, Coulon S, Renand A, Dussiot M, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia. 2008;22(1):42&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898788</ArticleId><ArticleId IdType="doi">10.1038/sj.leu.2404958</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda N, Muta H, Oflazoglu E, Yoshikai Y. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo. Cancer Sci. 2010;101(1):224&#8211;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">19799612</ArticleId><ArticleId IdType="doi">10.1111/j.1349-7006.2009.01354.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood. 2009;113(6):1287&#8211;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">18948574</ArticleId><ArticleId IdType="pmc">2637191</ArticleId><ArticleId IdType="doi">10.1182/blood-2008-04-149658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashiri SY, Nakamura H, Origuchi T, Aoyagi K, Kawakami A. Ultrasonography and magnetic resonance imaging findings of rheumatoid arthritis-like arthritis in a patient with adult T-cell leukemia. Mod Rheumatol. 2016;26(6):971&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25119259</ArticleId><ArticleId IdType="doi">10.3109/14397595.2014.948529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Maeda T, Arimura K, Taguchi J, Fukushima T, Miyazaki Y, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23(1):87&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037056</ArticleId><ArticleId IdType="doi">10.1038/sj.bmt.1701533</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(1):15&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId><ArticleId IdType="doi">10.1038/sj.bmt.1702731</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19(5):829&#8211;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId><ArticleId IdType="doi">10.1038/sj.leu.2403682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenji I, Kazuo T. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol. 2008;80(3):185&#8211;96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2007.01016.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Arima N, Akasaki Y, Ohtsubo H, Ozaki A, Kukita T, et al. Interferon-&#945; therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma. Acta Haematol. 2002;107(4):213&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12053149</ArticleId><ArticleId IdType="doi">10.1159/000058317</ArticleId></ArticleIdList></Reference><Reference><Citation>Makoto H, Midori G, Masahiko O, Ken-Ichi A, Noriaki K, Tsukasa N, et al. Mogamulizumab for post-transplant relapse of adult t-cell leukemia/lymphoma: a case study. Int J Hematol. 2022;117(1):143&#8211;8.</Citation></Reference><Reference><Citation>Shigeo F, Yoshitaka I, Atae U, Yukiyoshi M, Kaoru U, Ilseung C, et al. Pretransplantation anti-Ccr4 antibody mogamulizumab against adult t-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426&#8211;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihab N, El Hiba H, Youmna K, Olivier H, Ali B. Controversies in targeted therapy of adult t cell leukemia/lymphoma: ON Target or OFF target effects? Viruses. 2011;3(6):750&#8211;69.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3060750</ArticleId></ArticleIdList></Reference><Reference><Citation>Laribi K, Alani M, Truong C, Baugier de Materre A. Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist. 2018;23(9):1039&#8211;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">29674443</ArticleId><ArticleId IdType="pmc">6192612</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2017-0524</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegall CB. Seattle Genetics, Inc.</Citation></Reference><Reference><Citation>Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137.</Citation><ArticleIdList><ArticleId IdType="pubmed">25135998</ArticleId><ArticleId IdType="pmc">4171358</ArticleId><ArticleId IdType="doi">10.1200/JCO.2013.54.2456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Ramos JC, Tobinai K. A review of new findings in adult T-cell leukemia&#8211;lymphoma: a focus on current and emerging treatment strategies. Adv Ther. 2018;35:135&#8211;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">29411267</ArticleId><ArticleId IdType="pmc">5818559</ArticleId><ArticleId IdType="doi">10.1007/s12325-018-0658-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O&#8217;Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood J Am Soc Hematol. 2014;123(20):3095&#8211;100.</Citation></Reference><Reference><Citation>Oka S, Ono K, Nohgawa M. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. Anticancer Drugs. 2020;31(5):536&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31934889</ArticleId><ArticleId IdType="doi">10.1097/CAD.0000000000000895</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328&#8211;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24359243</ArticleId><ArticleId IdType="doi">10.3109/10428194.2013.876496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2(1):1&#8211;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-8722-2-36</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3(3):e107&#8211;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">26947199</ArticleId><ArticleId IdType="doi">10.1016/S2352-3026(15)00284-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Corporation. C. REVLIMID&#174;(Lenalidomide)[prescribing information]. 2006.</Citation></Reference><Reference><Citation>Ramos JC, Chapman JR, Komanduri KV, Barber GN. Trial in progress: a phase ii trial of belinostat as consolidation therapy with zidovudine for adult T-cell leukemia-lymphoma (ATLL). Blood. 2021;138:2477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-148650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields PA, Taylor GP. &#8220;Antivirals&#8221; in the treatment of adult T cell Leukaemia-Lymphoma (ATLL). Curr Hematol Malig Rep. 2012;7:267&#8211;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23093306</ArticleId><ArticleId IdType="doi">10.1007/s11899-012-0139-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata D, Brynes RK, Rabinowitz A, Hanson CA, Slovak ML, Spira TJ, et al. Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). Ann Intern Med. 1989;111(11):871&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2573306</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-111-11-871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696&#8211;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId><ArticleId IdType="doi">10.1200/JCO.2011.35.5578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Allard I, L&#233;vy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId><ArticleId IdType="doi">10.1038/sj.thj.6200195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T. Interferon-a (IFN-a) suppresses HTLV-1 gene expression and cell cycling, while IFN-a combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 2013;10(10):52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23688327</ArticleId><ArticleId IdType="pmc">3698133</ArticleId><ArticleId IdType="doi">10.1186/1742-4690-10-52</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Mar&#231;ais A, et al. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-&#945;. Blood Adv. 2017;1(12):748.</Citation><ArticleIdList><ArticleId IdType="pubmed">29296718</ArticleId><ArticleId IdType="pmc">5728049</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2016001370</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, et al. Epidemiology, clinical features, and outcome of HTLV-1&#8211;related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29545256</ArticleId><ArticleId IdType="pmc">5873228</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2017011106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-37.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31747604</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2019.10.083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Fujikawa D, Honma D, Adachi N, Nakagawa S, Hori M, et al. Polycomb-dependent epigenetic landscape in adult T cell leukemia (ATL); providing proof of concept for targeting EZH1/2 to selectively eliminate the HTLV-1 infected population. Am Soc Hematol Washington. 2015. https://doi.org/10.1182/blood.V126.23.572.572 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V126.23.572.572</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):1&#8211;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-020-00937-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood J Am Soc Hematol. 2023;141(10):1159&#8211;68.</Citation></Reference><Reference><Citation>Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int. 2016. https://doi.org/10.1155/2016/8797206 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/8797206</ArticleId><ArticleId IdType="pubmed">27556043</ArticleId><ArticleId IdType="pmc">4983322</ArticleId></ArticleIdList></Reference><Reference><Citation>San Jos&#233;-En&#233;riz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid Leukemia. Cancers. 2019;11(11):1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">31739588</ArticleId><ArticleId IdType="pmc">6896008</ArticleId><ArticleId IdType="doi">10.3390/cancers11111794</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant PA. A tale of histone modifications. Genome Biol. 2001;2:1&#8211;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2001-2-4-reviews0003</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">28671573</ArticleId><ArticleId IdType="pmc">5535906</ArticleId><ArticleId IdType="doi">10.3390/ijms18071414</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A, et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor &#954;B. Leuk Res. 2008;32(2):287&#8211;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644177</ArticleId><ArticleId IdType="doi">10.1016/j.leukres.2007.05.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sin C-f, P-hM M. The role of proteasome inhibitors in treating acute lymphoblastic Leukaemia. Front Oncol. 2021;11:5450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.802832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogli S, Galimberti S, Gori V, Del Re M, Danesi R. Pharmacology differences among proteasome inhibitors: implications for their use in clinical practice. Pharmacol Res. 2021;167: 105537.</Citation><ArticleIdList><ArticleId IdType="pubmed">33684510</ArticleId><ArticleId IdType="doi">10.1016/j.phrs.2021.105537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet. 2019;58:157&#8211;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">29802543</ArticleId><ArticleId IdType="doi">10.1007/s40262-018-0679-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton TM, Gannavarapu A, Blaney SM, D&#8217;Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16292537</ArticleId><ArticleId IdType="doi">10.1007/s00280-005-0135-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Xu J, Sun A, Shen Y, He G, Guo F. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-&#954;B activity. Leuk Lymphoma. 2011;52(12):2393&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745166</ArticleId><ArticleId IdType="doi">10.3109/10428194.2011.593271</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children&#8217;s Oncology Group study. Clin Cancer Res. 2007;13(5):1516&#8211;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17332297</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-06-2173</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(6):1216&#8211;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">24301524</ArticleId><ArticleId IdType="pmc">4051216</ArticleId><ArticleId IdType="doi">10.1038/leu.2013.366</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Hu X, Wang L, L&#252; S, Cheng H, Song X, et al. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemother Pharmacol. 2012;70:801&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22996635</ArticleId><ArticleId IdType="doi">10.1007/s00280-012-1953-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L-l, Wei J-y, Wang L, Huang S-l, Chen J-l. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin. 2017;38(8):1093&#8211;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28392570</ArticleId><ArticleId IdType="pmc">5547553</ArticleId><ArticleId IdType="doi">10.1038/aps.2017.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata S, Takahama Y, Kasahara M, Tanaka K. The immunoproteasome and thymoproteasome: functions, evolution and human disease. Nat Immunol. 2018;19(9):923&#8211;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30104634</ArticleId><ArticleId IdType="doi">10.1038/s41590-018-0186-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Rank CU, Schmiegelow K. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. Semin Hematol. 2020;57(3):102&#8211;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">33256899</ArticleId><ArticleId IdType="doi">10.1053/j.seminhematol.2020.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins TW, Downey-Kopyscinski SL, Fields JL, Rahme GJ, Colley WC, Israel MA, et al. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL&#8211;AF4 fusion protein. Sci Rep. 2021;11(1):10883.</Citation><ArticleIdList><ArticleId IdType="pubmed">34035431</ArticleId><ArticleId IdType="pmc">8149845</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-90451-9</ArticleId></ArticleIdList></Reference><Reference><Citation>da Mota THA, Camargo R, Biojone ER, Guimar&#227;es AFR, Pittella-Silva F, de Oliveira DM. The relevance of telomerase and telomere-associated proteins in B-acute lymphoblastic Leukemia. Genes. 2023;14(3):691.</Citation><ArticleIdList><ArticleId IdType="pubmed">36980962</ArticleId><ArticleId IdType="pmc">10048576</ArticleId><ArticleId IdType="doi">10.3390/genes14030691</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7(1):9&#8211;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11854543</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.7-1-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood J Am Soc Hematol. 2002;100(5):1715&#8211;20.</Citation></Reference><Reference><Citation>Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen C-S, Lairmore MD. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res. 2011;35(11):1491&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21802726</ArticleId><ArticleId IdType="pmc">3191315</ArticleId><ArticleId IdType="doi">10.1016/j.leukres.2011.07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M, Hasegawa A, Nagano Y, Kimpara S, Suehiro Y. Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology. 2019;16(1):23.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438973</ArticleId><ArticleId IdType="pmc">6704564</ArticleId><ArticleId IdType="doi">10.1186/s12977-019-0484-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: a hope for disease-preventive therapy. Cancer Sci. 2019;110(3):849&#8211;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30666755</ArticleId><ArticleId IdType="pmc">6398881</ArticleId><ArticleId IdType="doi">10.1111/cas.13948</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19064971</ArticleId><ArticleId IdType="pmc">2737379</ArticleId><ArticleId IdType="doi">10.1200/JCO.2008.18.2428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118(7):1736&#8211;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId><ArticleId IdType="doi">10.1182/blood-2011-03-345702</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari Maskouni E, Jamalvandi T, Tabatabaei F, Bourenjan Shirazi S, Saadati H, Letafati A, et al. Association between Epstein-Bar virus and colorectal cancer: a systematic review and meta-analysis. Microb Pathog. 2023;179: 106087.</Citation><ArticleIdList><ArticleId IdType="pubmed">37003501</ArticleId><ArticleId IdType="doi">10.1016/j.micpath.2023.106087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani S, Tambrchi V, Farzi R, Khatami A, Samiei RN, Saadati H, et al. Association between human Epstein-Barr virus and brain cancer: a systematic review and meta-analysis. Futur Virol. 2023;18(8):537&#8211;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2022-0219</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H. Current and emerging therapeutic strategies in adult T-cell leukemia&#8211;lymphoma. Int J Hematol. 2023;117(4):512&#8211;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">36862273</ArticleId><ArticleId IdType="doi">10.1007/s12185-023-03572-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar M-M, Shirdel A, Rastin M, et al. Zidovudine and interferon-&#945; treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma. 2007;48(2):330&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325893</ArticleId><ArticleId IdType="doi">10.1080/10428190601071717</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993. https://doi.org/10.1182/blood.V82.6.1701.bloodjournal8261701 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V82.6.1701.bloodjournal8261701</ArticleId><ArticleId IdType="pubmed">8400227</ArticleId></ArticleIdList></Reference><Reference><Citation>Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+ CD25+ regulatory T cells. J Exp Med. 2001;194(6):847&#8211;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11560999</ArticleId><ArticleId IdType="pmc">2195967</ArticleId><ArticleId IdType="doi">10.1084/jem.194.6.847</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Petrus MN, Ju W, Zhang M, Conlon KC, Nakagawa M, et al. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model. Leukemia. 2015;29(3):556&#8211;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25118879</ArticleId><ArticleId IdType="doi">10.1038/leu.2014.241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709797</ArticleId><ArticleId IdType="doi">10.1200/JCO.2007.11.4207</ArticleId></ArticleIdList></Reference><Reference><Citation>Krem MM, Press OW, Horwitz MS, Tidwell T. Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy. Br J Haematol. 2015;171(1):13&#8211;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">26018193</ArticleId><ArticleId IdType="doi">10.1111/bjh.13507</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihara K, Yoshida T, Ishida S, Takei Y, Kitanaka A, Shimoda K, et al. All-trans retinoic acid and interferon-&#945; increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors. Blood Cancer J. 2016;6(5): e421.</Citation><ArticleIdList><ArticleId IdType="pubmed">27176797</ArticleId><ArticleId IdType="pmc">4916299</ArticleId><ArticleId IdType="doi">10.1038/bcj.2016.30</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey MG, Minson KA, Earp HS, DeRyckere D, Graham DK. Targeting the TAM receptors in Leukemia. Cancers. 2016;8(11):101.</Citation><ArticleIdList><ArticleId IdType="pubmed">27834816</ArticleId><ArticleId IdType="pmc">5126761</ArticleId><ArticleId IdType="doi">10.3390/cancers8110101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21994759</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Targeting HTLV-1 activation of NF&#954;B in mouse models and ATLL patients.</ArticleTitle><Pagination><StartPage>886</StartPage><EndPage>900</EndPage><MedlinePgn>886-900</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/v3060886</ELocationID><Abstract><AbstractText>Of the millions of HTLV-1 infected carriers worldwide, 3-5% will develop an aggressive T-cell neoplasm that is highly refractory to conventional therapy. The virus carries the Tax oncogene which constitutively activates the NF&#954;B pathway. This co-option of signaling through NF&#954;B provides for the HTLV-1 infected cell an escape from cell cycle arrest and apoptosis, a steady source of growth factors, and a mechanism by which the virus can activate its own target cell. Therapies that target the NF&#954;B pathway sensitize adult T-cell leukemia/lymphoma (ATLL) cells to apoptosis. A focus on translational interrogation of NF&#954;B inhibitors in animal models and ATLL patients is needed to advance NF&#954;B-targeted ATLL therapies to the bedside.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA. drauch@dom.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 CA094056</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA63417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA 10073</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA063417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA94056</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514970">tax protein, Human T-lymphotrophic virus 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015533">Transcriptional Activation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL therapy</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">NF&#954;B</Keyword><Keyword MajorTopicYN="N">mouse models</Keyword><Keyword MajorTopicYN="N">tax</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21994759</ArticleId><ArticleId IdType="pmc">PMC3185776</ArticleId><ArticleId IdType="doi">10.3390/v3060886</ArticleId><ArticleId IdType="pii">v3060886</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peloponese J, Yeung M, Jeang K. Modulation of nuclear factor-kB by human T-cell leukemia virus type 1 tax protein: Implications for oncogenesis and inflammation. Immunol. Res. 2006;34:1&#8211;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720895</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie R. NF-kB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. Int. Rev. Immunol. 2007;26:269&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">18027201</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerenberg MI. An HTLV-I Transgenic Mouse Model: Role of the tax gene in pathogenesis in multiple organ systems. Curr. Top. Microbiol. Immunol. 1990;160:121&#8211;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">2191838</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakura Y, Tosu M, Yoshida E, Takiguchi M, Sato K, Kitajima I, Nishioka K, Yamamoto K, Takeda T, Hatanaka M, et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science. 1991;253:1026&#8211;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">1887217</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakura Y, Saijo S, Kioka Y, Nakayama-Yamada J, Itagaki K, Tosu M, Asano M, Kanai Y, Kakimoto K. Autoimmunity induction by human T-cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J. Immunol. 1995;155:1588&#8211;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">7636219</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto H, Sekiguchi T, Itagaki K, Saijo S, Iwakura Y. Inflammatory polyarthritis in mice transgenic for human T-cell leukemia virus type I. Arthritis Rheum. 1993;36:1612&#8211;1620.</Citation><ArticleIdList><ArticleId IdType="pubmed">8240438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisawa K, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T, Nishioka K. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J. Clin. Invest. 1996;98:271&#8211;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC507427</ArticleId><ArticleId IdType="pubmed">8755634</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman W, Kimata J, Wong F, Zutter M, Ley T, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. U. S. A. 1995;92:1057&#8211;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42636</ArticleId><ArticleId IdType="pubmed">7862633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa H, Sawa H, Lewis M, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Katano H, Takahashi H, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat. Med. 2006;12:466&#8211;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">16550188</ArticleId></ArticleIdList></Reference><Reference><Citation>Watters K, Dean J, Hasegawa H, Sawa H, Hall W, Sheehy N. Cytokine and growth factor expression by HTLV-1 Lck-tax transgenic cells in SCID mice. AIDS Res. Hum. Retroviruses. 2010;26:593&#8211;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">20438380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimata J, Wong F, Wang J, Ratner L. Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology. 1994;204:656&#8211;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">7941334</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek M, Ratner L. Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J. Virol. 1999;73:4856&#8211;4865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112529</ArticleId><ArticleId IdType="pubmed">10233947</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih V, Tsui R, Caldwell A, Hoffmann A. A single NF&#954;B system for both canonical and non-canonical signaling. Cell Res. 2011;21:86&#8211;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193412</ArticleId><ArticleId IdType="pubmed">21102550</ArticleId></ArticleIdList></Reference><Reference><Citation>Saggioro D, Silic-Benussi M, Biasiotto R, D'Agostino D, Ciminale V. Control of cell death pathways by HTLV-1 proteins. Front. Biosci. 2009;14:3338&#8211;3351.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Ballard D. Persistent activation of NF&#954;B by the tax transforming protein of HTLV-1; hijacking cellular IkappaB kinases. Oncogene. 1999;18:6948&#8211;6958.</Citation><ArticleIdList><ArticleId IdType="pubmed">10602469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S, Pise-Masison C, Radonovich M, Park H, Brady J. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 2005;24:6719&#8211;6728.</Citation><ArticleIdList><ArticleId IdType="pubmed">16007163</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Fujita N, Tsuruo T. 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. J. Biol. Chem. 2005;280:40965&#8211;40973.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207722</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahony A, Montano M, Van Beneden K, Chen L, Greene W. Human T-cell lymphotropic virus type 1 tax induction of biologically active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J. Biol. Chem. 2004;279:18137&#8211;18145.</Citation><ArticleIdList><ArticleId IdType="pubmed">14963024</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao G, Cvijic M, Fong A, Harhaj E, Uhlik M, Waterfield M, Sun S. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: Evidence for the involvement of IKKalpha. EMBO J. 2001;20:6805&#8211;6815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125766</ArticleId><ArticleId IdType="pubmed">11726516</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal-Mizrachi L, Lovly C, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U S A. 2006;103:9220&#8211;9225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482593</ArticleId><ArticleId IdType="pubmed">16751281</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji T, Higuchi M, Kondo R, Takahashi M, Oie M, Tanaka Y, Aoyagi Y, Fujii M. Identification of a novel motif responsible for the distinctive transforming activity of human T-cell leukemia virus (HTLV) type 1 Tax1 protein from HTLV-2 Tax2. Retrovirology. 2009;6:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754985</ArticleId><ArticleId IdType="pubmed">19761585</ArticleId></ArticleIdList></Reference><Reference><Citation>Portis T, Grossman W, Harding J, Hess J, Ratner L. Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model. J. Virol. 2001;75:2185&#8211;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114802</ArticleId><ArticleId IdType="pubmed">11160722</ArticleId></ArticleIdList></Reference><Reference><Citation>Pise-Masison C, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady J. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol. Cell. Biol. 2000;10:3377&#8211;3386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85630</ArticleId><ArticleId IdType="pubmed">10779327</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh U, McCormick M, Datta D, Turner R, Bobb K, Monie D, Sliskovic D, Tanaka Y, Zhang J, Meshulam J, et al. Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease. Blood. 2011;117:3363&#8211;3369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069676</ArticleId><ArticleId IdType="pubmed">21212284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436&#8211;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#228;fer M, Werner S. Cancer as an overhealing wound: An old hypothesis revisited. Nat. Rev. Mol. Cell. Biol. 2008;9:628&#8211;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">18628784</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood. 2005;106:4294&#8211;4302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895233</ArticleId><ArticleId IdType="pubmed">16118323</ArticleId></ArticleIdList></Reference><Reference><Citation>Portis T, Harding J, Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood. 2001;98:1200&#8211;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493471</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman W, Ratner L. Cytokine expression and tumorigenicity of large granular lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell leukemia virus type I. Blood. 1997;90:783&#8211;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">9226179</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross S, Gammon S, Moss B, Rauch D, Harding J, Heinecke J, Ratner L, Piwnica-Worms D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat. Med. 2009;15:455&#8211;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831476</ArticleId><ArticleId IdType="pubmed">19305414</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood. 2009;113:1493&#8211;1500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644076</ArticleId><ArticleId IdType="pubmed">18971418</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood. 2004;104:3305&#8211;3311.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292059</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Osame M, Kubota R, Tara M, Yoshida M. Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood. 1995;85:1865&#8211;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">7703492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham C, Osame M. Cellular immune response to HTLV-1. Oncogene. 2005;24:6035&#8211;6046.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155610</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch D, Gross S, Harding J, Bokhari S, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology. 2009;6:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806367</ArticleId><ArticleId IdType="pubmed">20017942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S, Harding J, Hess J, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood. 2004;104:802&#8211;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, Tomonaga M, Yamamoto N, Fujii M. Bay 11&#8211;7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100:1828&#8211;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176906</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie R. NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. Int. Rev. Immunol. 2007;26:269&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">18027201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler H, Taguchi H. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol. Cancer Ther. 2005;4:578&#8211;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">15827331</ArticleId></ArticleIdList></Reference><Reference><Citation>Okudaira T, Tomita M, Uchihara J, Matsuda T, Ishikawa C, Kawakami H, Masuda M, Tanaka Y, Ohshiro K, Takasu N, et al. NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol. Cancer Ther. 2006;5:704&#8211;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita M, Kawakami H, Uchihara J, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, et al. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int. J. Cancer. 2006;118:765&#8211;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">16106398</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneji K, Matsuda T, Tomita M, Kawakami H, Ohshiro K, Uchihara J, Masuda M, Takasu N, Tanaka Y, Ohta T, et al. Fucoidan extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Nutr. Cancer. 2005;52:189&#8211;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16201850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A, Kuwayama Y, Togitani K, Koeffler H, Taguchi H. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk. Res. 2008;32:287&#8211;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis. 2005;26:1382&#8211;1388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831528</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87) Br. J. Haematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos J, Harrington W, Jr, O'Mahony D, Janik J, Bittencourt A, Taylor G, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J. Clin. Oncol. 2009;27:453&#8211;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Seegulam M, Ratner L. Integrase Inhibitors Effective Against Human T-Cell Leukemia Virus Type 1. Antimicrob. Agents Chemother. 2011;55:2011&#8211;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088187</ArticleId><ArticleId IdType="pubmed">21343468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, et al. AIDS Malignancy Consortium. Human T-cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. Plos ONE. 2009;4:e4420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636875</ArticleId><ArticleId IdType="pubmed">19204798</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerenberg M, Hinrichs S, Reynolds R, Khoury G, Jay G. The tat Gene of Human T-Lymphotropic Virus Type 1 Induces Mesenchymal Tumors in Transgenic Mice. Science. 1987;237:1324&#8211;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">2888190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Winokur T, Lee H, Danielpour D, Kim K, Geiser A, Chen L, Sporn M, Roberts A, Jay G. Overexpression of transforming growth factor-beta in transgenic mice carrying the human T-cell lymphotropic virus type I tax gene. Mol. Cell. Biol. 1991;11:5222&#8211;5228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC361566</ArticleId><ArticleId IdType="pubmed">1922042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitajima I, Shinohara T, Bilakovics J, Brown D, Xu X, Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. Science. 1992;258:1792&#8211;1795.</Citation><ArticleIdList><ArticleId IdType="pubmed">1299224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs S, Nerenberg M, Reynolds R, Khoury G, Jay G. A transgenic mouse model for human neurofibromatosis. Science. 1987;237:1340&#8211;1343.</Citation><ArticleIdList><ArticleId IdType="pubmed">2888191</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Baird A, Hinrichs S, Klintworth G, Jay G. Adrenal medullary tumors and iris proliferation in a transgenic mouse model of neurofibromatosis. Am. J. Pathol. 1992;140:1401&#8211;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886554</ArticleId><ArticleId IdType="pubmed">1605307</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigenbaum L, Fujita K, Collins F, Jay G. Repression of the NF1 gene by Tax may explain the development of neurofibromas in human T-lymphotropic virus type 1 transgenic mice. J. Virol. 1996;70:3280&#8211;3285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190194</ArticleId><ArticleId IdType="pubmed">8627811</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J. Trans activation of nerve growth factor in transgenic mice containing the human T-cell lymphotropic virus type I tax gene. Mol. Cell. Biol. 1991;11:4635&#8211;4641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC361349</ArticleId><ArticleId IdType="pubmed">1875943</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerenberg M, Wiley C. Degeneration of oxidative muscle fibers in HTLV-1 tax transgenic mice. Am. J. Pathol. 1989;135:1025&#8211;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880495</ArticleId><ArticleId IdType="pubmed">2688429</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Hinrichs S, Vogel J, Jay G. Exocrinopathy resembling Sjogren's syndrome in HTLV-1 tax transgenic mice. Nature. 1989;341:72&#8211;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">2788824</ArticleId></ArticleIdList></Reference><Reference><Citation>Peebles R, Maliszewski C, Sato T, Hanley-Hyde J, Maroulakou I, Hunziker R, Schneck J, Green J. Abnormal B-cell function in HTLV-I-tax transgenic mice. Oncogene. 1995;10:1045&#8211;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">7700628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruddle N, Li C, Horne W, Santiago P, Troiano N, Jay G, Horowitz M, Baron R. Mice transgenic for HTLV-I LTR-tax exhibit tax expression in bone, skeletal alterations, and high bone turnover. Virology. 1993;197:196&#8211;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">8212554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieberich C, King C, Tinkle B, Jay G. A transgenic model of transactivation by the Tax protein of HTLV-I. Virology. 1993;196:309&#8211;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">8356801</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Brown D, Kitajima I, Bilakovics J, Fey L, Nerenberg M. Transcriptional suppression of the human T-cell leukemia virus type I long terminal repeat occurs by an unconventional interaction of a CREB factor with the R region. Mol. Cell. Biol. 1994;14:5371&#8211;5383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359056</ArticleId><ArticleId IdType="pubmed">8035815</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y, Aizawa S, Suda Y, Ikawa Y, Kishimoto H, Asano Y, Tada T, Hikikoshi A, Yoshida M, Seiki M. Thymic atrophy characteristic in transgenic mice that harbor pX genes of human T-cell leukemia virus type I. J. Virol. 1989;63:3185&#8211;3189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250880</ArticleId><ArticleId IdType="pubmed">2724422</ArticleId></ArticleIdList></Reference><Reference><Citation>Habu K, Nakayama-Yamada J, Asano M, Saijo S, Itagaki K, Horai R, Yamamoto H, Sekiguchi T, Nosaka T, Hatanaka M, et al. The human T cell leukemia virus type I-tax gene is responsible for the development of both inflammatory polyarthropathy resembling rheumatoid arthritis and noninflammatory ankylotic arthropathy in transgenic mice. J. Immunol. 1999;162:2956&#8211;2963.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi S, Saijo S, Arai M, Karasawa S, Ueda S, Kannagi M, Iwakura Y, Fujii M, Yonehara S. Resistance to fas-mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV-I) transgenic mice with autoimmune arthropathy. J. Exp. Med. 1997;186:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198961</ArticleId><ArticleId IdType="pubmed">9206997</ArticleId></ArticleIdList></Reference><Reference><Citation>Coscoy L, Gonzalez-Dunia D, Tangy F, Syan S, Brahic M, Ozden S. Molecular mechanism of tumorigenesis in mice transgenic for the human T cell leukemia virus Tax gene. Virology. 1998;248:332&#8211;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">9721242</ArticleId></ArticleIdList></Reference><Reference><Citation>Benvenisty N, Ornitz D, Bennett G, Sahagan B, Kuo A, Cardiff R, Leder P. Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR/c-myc and Ig/tax genes. Oncogene. 1992;7:2399&#8211;2405.</Citation><ArticleIdList><ArticleId IdType="pubmed">1461648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch D, Hurchla M, Harding J, Deng H, Shea L, Eagleton M, Niewiesk S, Lairmore M, Piwnica-Worms D, Rosol T, et al. The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS ONE. 2010;5:e15755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012707</ArticleId><ArticleId IdType="pubmed">21209895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon H, Ogle L, Benitez B, Bohuslav J, Montano M, Felsher D, Greene W. Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J. Biol. Chem. 2005;280:35713&#8211;35722.</Citation><ArticleIdList><ArticleId IdType="pubmed">16105841</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab S, Janin A, Mahfouz R, Nasr R, Kfoury Y, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J. Exp. Med. 2010;207:2785&#8211;2792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005222</ArticleId><ArticleId IdType="pubmed">21135137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi A, Orba Y, Kimura T, Iha H, Ogata M, Tsuji T, Ainai A, Sata T, Okamoto T, Hall W, et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood. 2009;114:2961&#8211;2968.</Citation><ArticleIdList><ArticleId IdType="pubmed">19657116</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, Masumi A, Ami Y, Hasegawa H, Hall W, Tsujimoto H, et al. Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood. 2009;114:2709&#8211;2720.</Citation><ArticleIdList><ArticleId IdType="pubmed">19584402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsugi T, Kumasaka T, Okada S, Urano T. The Tax protein of HTLV-1 promotes oncogenesis in not only immature T cells but also mature T cells. Nat. Med. 2007;13:527&#8211;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17479090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsugi T, Kumasaka T. Low CD4/CD8 T-cell ratio associated with inflammatory arthropathy in human T-cell leukemia virus type I Tax transgenic mice. PLoS ONE. 2011;6:e18518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069963</ArticleId><ArticleId IdType="pubmed">21483764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall A, Irvine J, Blyth K, Cameron E, Onions D, Campbell M. Tumours derived from HTLV-I tax transgenic mice are characterized by enhanced levels of apoptosis and oncogene expression. J. Pathol. 1998;186:209&#8211;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">9924438</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">30596217</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0927-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>176</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Cancer treatment and research</Title><ISOAbbreviation>Cancer Treat Res</ISOAbbreviation></Journal><ArticleTitle>Adult T-Cell Leukemia-Lymphoma.</ArticleTitle><Pagination><StartPage>145</StartPage><EndPage>161</EndPage><MedlinePgn>145-161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-319-99716-2_7</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-lymphocyte malignancy caused by an RNA retrovirus, human T-cell leukemia virus type 1. ATL is clinically classified into four disease subtypes. The acute, lymphoma type, and cases of the chronic type involving unfavorable prognostic factors are regarded as aggressive ATL subtypes that require immediate treatment. Dose-intensified chemotherapy, such as the VCAP-AMP-VECP regimen, is considered to be the most recommended treatment for aggressive ATL. However, ATL remains difficult to cure and has an extremely poor prognosis, even when such chemotherapy is employed. Allogeneic stem cell transplantation is the only known curative therapy and is recommended for younger patients with aggressive ATL. However, because of the increasing age at the onset of ATL, only a small fraction of patients with ATL can benefit from such transplants; therefore, there is an unmet medical need for novel drugs. Mogamulizumab, a defucosylated, humanized anti-C-C motif chemokine receptor 4 (CCR4) monoclonal antibody, was developed using a novel glycoengineering technique. Mogamulizumab monotherapy achieved clinically meaningful effects in patients with relapsed aggressive ATL and has exhibited acceptable toxicity profiles both inside and outside of Japan. In addition, lenalidomide has shown promising antitumor activity in patients with ATL. Furthermore, based on the results of translational research, several promising novel agents are currently being investigated and might contribute to improving the prognosis of ATL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munakata</LastName><ForeName>Wataru</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Cancer Center Hospital, 5-1-1Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. wmunakat@ncc.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobinai</LastName><ForeName>Kensei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Cancer Center Hospital, 5-1-1Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Treat Res</MedlineTA><NlmUniqueID>8008541</NlmUniqueID><ISSNLinking>0927-3042</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATL</Keyword><Keyword MajorTopicYN="N">Adult T-cell leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">CCR4</Keyword><Keyword MajorTopicYN="N">Lenalidomide</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30596217</ArticleId><ArticleId IdType="doi">10.1007/978-3-319-99716-2_7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32203145</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.</ArticleTitle><Pagination><StartPage>107</StartPage><EndPage>118</EndPage><MedlinePgn>107-118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41375-020-0788-y</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) patients have an extremely poor prognosis, partly due to their immunosuppressive state. The majority of ATLL patients have leukemic cells with phenotype similar to Tregs, prompting suggestions that ATLL cells themselves have immunosuppressive functions. In this study, we detected CD39 expression on ATLL cells, particularly frequent on aggressive subtypes. CD39 and CD73 convert extracellular adenosine triphosphate (ATP) into adenosine, a key player in Tregs' immunosuppression. In vitro culture, both CD39<sup>+</sup> ATLL cells and normal Tregs converted rapidly extracellular ATP to AMP, which was disturbed by CD39 inhibitors, and was negated in the CD39 knockout MJ cell line. The proliferation of cocultured CD4<sup>+</sup>/CD8<sup>+</sup> normal T cells was suppressed by CD39<sup>+</sup> MJ cells, but not by CD39 knockout MJ cells. Supplemented ATP was exhausted by an EG7-OVA T-cell line with stable CD39 induction, but not by mock. When these cell lines were subcutaneously transplanted into murine flanks, Poly(I:C) peritoneal administration reduced tumor size to 1/3 in mock-transplanted tumors, but not in CD39 induced tumors. Overall, we found that ATLL cells express CD39 at a high rate, and our results suggest that this helps ATLL cells escape antitumor immunity through the extracellular ATPDase-Adenosine cascade. These findings will guide future clinical strategies for ATLL treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagate</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezoe</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan. sezoe@bldon.med.osaka-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Environmental Space Infection Control, Osaka University Graduate School of Medicine, Suita, Japan. sezoe@bldon.med.osaka-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Jiro</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuzaki</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4552-783X</Identifier><AffiliationInfo><Affiliation>Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motooka</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishibashi</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichii</LastName><ForeName>Michiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanimura</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurashige</LastName><ForeName>Masako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Osaka University Graduate School of Medicine, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morii</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Osaka University Graduate School of Medicine, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Nishihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suehiro</LastName><ForeName>Youko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibayama</LastName><ForeName>Hirohiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oritani</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Graduate School of Medical Sciences, International University of Health and Welfare Hospital, Narita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanakura</LastName><ForeName>Yuzuru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.5</RegistryNumber><NameOfSubstance UI="D001081">Apyrase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.5</RegistryNumber><NameOfSubstance UI="C067869">CD39 antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000255">Adenosine Triphosphate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001081">Apyrase</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007108">Immune Tolerance</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056747">Immunomodulation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016176">T-Lymphocyte Subsets</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32203145</ArticleId><ArticleId IdType="pmc">PMC7787980</ArticleId><ArticleId IdType="doi">10.1038/s41375-020-0788-y</ArticleId><ArticleId IdType="pii">10.1038/s41375-020-0788-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481&#8211;92. doi: 10.1182/blood.V50.3.481.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V50.3.481.481</ArticleId><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatsuki K. Discovery of adult T-cell leukemia. Retrovirology. 2005;2:16. doi: 10.1186/1742-4690-2-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-2-16</ArticleId><ArticleId IdType="pmc">PMC555581</ArticleId><ArticleId IdType="pubmed">15743528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano N, Yoshida S, Kuriyama T, Tahara Y, Yamashita K, Nagahiro Y, et al. Clinical features and treatment outcomes of 81 patients with aggressive type adult T-cell leukemia-lymphoma at a single institution over a 7-year period (2006&#8211;12) Intern Med. 2015;54:1489&#8211;98. doi: 10.2169/internalmedicine.54.1953.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.54.1953</ArticleId><ArticleId IdType="pubmed">26073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T&#8208;cell leukaemia&#8208;lymphoma: a report from the Lymphoma Study Group (1984&#8211;87) Br J Haematol. 1991;79:428&#8211;37. doi: 10.1111/j.1365-2141.1991.tb08051.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R, Mar&#231;ais A, Hermine O, Bazarbachi A. Overview of targeted therapies for adult T-cell leukemia/lymphoma. Methods Mol Biol. 2017;1582:197&#8211;216. doi: 10.1007/978-1-4939-6872-5_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-6872-5_15</ArticleId><ArticleId IdType="pubmed">28357672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata M, Satou T, Kawano R, Yoshikawa T, Ikewaki J, Kohno K, et al. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for Adult T cell leukemia. J Med Virol. 2011;83:702&#8211;9. doi: 10.1002/jmv.22013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.22013</ArticleId><ArticleId IdType="pubmed">21328386</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M. HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals. Retrovirology. 2012;9:46. doi: 10.1186/1742-4690-9-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-9-46</ArticleId><ArticleId IdType="pmc">PMC3403885</ArticleId><ArticleId IdType="pubmed">22647666</ArticleId></ArticleIdList></Reference><Reference><Citation>Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, et al. Expression of FoxP3, a key molecule in CD4+CD25+ regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126:81&#8211;84. doi: 10.1111/j.1365-2141.2004.04999.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2004.04999.x</ArticleId><ArticleId IdType="pubmed">15198736</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Ishii N, Ine S, Ikeda S, Fujimura T, Ndhlovu LC, et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol. 2005;18:269&#8211;77. doi: 10.1093/intimm/dxh366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxh366</ArticleId><ArticleId IdType="pubmed">16361311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer. 2007;120:2052&#8211;7. doi: 10.1002/ijc.22536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.22536</ArticleId><ArticleId IdType="pubmed">17278106</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimauchi T, Kabashima K, Tokura Y. Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci. 2008;99:98&#8211;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">17970785</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulza F, Nosaka K, Takiguchi M, Pagliuca T, Mitsuya H, Tanaka Y, et al. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer. 2009;125:2375&#8211;82. doi: 10.1002/ijc.24664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.24664</ArticleId><ArticleId IdType="pubmed">19544530</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899&#8211;911. doi: 10.1016/j.immuni.2009.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.03.019</ArticleId><ArticleId IdType="pubmed">19464196</ArticleId></ArticleIdList></Reference><Reference><Citation>Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, et al. The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol. 2008;21:617&#8211;25. doi: 10.1038/modpathol.2008.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2008.25</ArticleId><ArticleId IdType="pubmed">18246047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezeldasht SA, Sadeghian H, Azarpazhooh MR, Shamsian SAA, Rafatpanah H, Mahmoodi M, et al. Evaluation of T regulatory lymphocytes transcription factors in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Appl Biochem Biotechnol. 2017;182:1403&#8211;14. doi: 10.1007/s12010-017-2406-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12010-017-2406-7</ArticleId><ArticleId IdType="pubmed">28101786</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulte D, Furman RR, Broekman MJ, Drosopoulos JHF, Ballard HS, Olson KE, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11:367&#8211;72. doi: 10.1016/j.clml.2011.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2011.06.005</ArticleId><ArticleId IdType="pmc">PMC3590911</ArticleId><ArticleId IdType="pubmed">21816376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li NP, et al. High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncol Lett. 2016;12:4080&#8211;6. doi: 10.3892/ol.2016.5189.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2016.5189</ArticleId><ArticleId IdType="pmc">PMC5104239</ArticleId><ArticleId IdType="pubmed">27895775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A. Adenosine A2A receptor antagonists: Blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol. 2008;153:S457&#8211;464. doi: 10.1038/bjp.2008.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjp.2008.23</ArticleId><ArticleId IdType="pmc">PMC2268051</ArticleId><ArticleId IdType="pubmed">18311159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+regulatory T Cells. J Biol Chem. 2010;285:7176&#8211;86. doi: 10.1074/jbc.M109.047423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.047423</ArticleId><ArticleId IdType="pmc">PMC2844167</ArticleId><ArticleId IdType="pubmed">19858205</ArticleId></ArticleIdList></Reference><Reference><Citation>Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257&#8211;65. doi: 10.1084/jem.20062512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062512</ArticleId><ArticleId IdType="pmc">PMC2118603</ArticleId><ArticleId IdType="pubmed">17502665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TRT. Regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5&#8217;-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780&#8211;6. doi: 10.4049/jimmunol.177.10.6780.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.10.6780</ArticleId><ArticleId IdType="pubmed">17082591</ArticleId></ArticleIdList></Reference><Reference><Citation>Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225&#8211;32. doi: 10.1182/blood-2006-12-064527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-12-064527</ArticleId><ArticleId IdType="pubmed">17449799</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi Y, Yokota T, Satoh Y, Okuzaki D, Tokunaga M, Ishibashi T, et al. Variable SATB1 levels regulate hematopoietic stem cell heterogeneity with distinct lineage fate. Cell Rep. 2018;23:3223&#8211;35. doi: 10.1016/j.celrep.2018.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.05.042</ArticleId><ArticleId IdType="pubmed">29898394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Nakano K, Watanabe E, Ishigaki T, Ohno N, Yuji K, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2014;20:2851&#8211;61. doi: 10.1158/1078-0432.CCR-13-3169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-13-3169</ArticleId><ArticleId IdType="pubmed">24727323</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonioli L, Blandizzi C, Pacher P, Hask&#243; G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13:842&#8211;57. doi: 10.1038/nrc3613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3613</ArticleId><ArticleId IdType="pubmed">24226193</ArticleId></ArticleIdList></Reference><Reference><Citation>Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942&#8211;9. doi: 10.1038/nm1093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1093</ArticleId><ArticleId IdType="pubmed">15322536</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27:145&#8211;59. doi: 10.1016/j.immuni.2007.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.04.017</ArticleId><ArticleId IdType="pubmed">17613255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci. 2013;110:17945&#8211;51790. doi: 10.1073/pnas.1316796110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1316796110</ArticleId><ArticleId IdType="pmc">PMC3816454</ArticleId><ArticleId IdType="pubmed">24127572</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759&#8211;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">20518016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasunaga JI, Sakai T, Nosaka K, Etoh KI, Tamiya S, Koga S, et al. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. Blood. 2001;97:3177&#8211;83. doi: 10.1182/blood.V97.10.3177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V97.10.3177</ArticleId><ArticleId IdType="pubmed">11342446</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama T. Human T cell leukemia virus type 1 (HTLV-1) and human diseases. Annu Rev Immunol. 1997;15:15&#8211;37. doi: 10.1146/annurev.immunol.15.1.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.15.1.15</ArticleId><ArticleId IdType="pubmed">9143680</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129:1071&#8211;81. doi: 10.1182/blood-2016-09-692574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-692574</ArticleId><ArticleId IdType="pmc">PMC5374731</ArticleId><ArticleId IdType="pubmed">28115366</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K. Genetic instability of adult T-cell leukemia/lymphoma by comparative genomic hybridization analysis. J Clin Immunol. 2002;22:57&#8211;63. doi: 10.1023/A:1014471500757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1014471500757</ArticleId><ArticleId IdType="pubmed">11998893</ArticleId></ArticleIdList></Reference><Reference><Citation>Airas L, Jalkanen S. CD73 mediates adhesion of B cells to follicular dendritic cells. Blood. 1996;88:1755&#8211;64. doi: 10.1182/blood.V88.5.1755.1755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V88.5.1755.1755</ArticleId><ArticleId IdType="pubmed">8781432</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler PJ, Saze Z, Hong CS, Muller L, Gillespie DG, Cheng D, et al. Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol. 2014;177:531&#8211;43. doi: 10.1111/cei.12354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12354</ArticleId><ArticleId IdType="pmc">PMC4226604</ArticleId><ArticleId IdType="pubmed">24749746</ArticleId></ArticleIdList></Reference><Reference><Citation>Abousamra NK, Salah El-Din M, Hamza Elzahaf E, Esmael ME. Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:113&#8211;9. doi: 10.3109/10428194.2014.907893.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2014.907893</ArticleId><ArticleId IdType="pubmed">24684231</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, et al. Expression of CD39 by human peripheral blood CD4+CD25+T cells denotes a regulatory memory phenotype. Am J Transpl. 2010;10:2410&#8211;20. doi: 10.1111/j.1600-6143.2010.03291.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2010.03291.x</ArticleId><ArticleId IdType="pmc">PMC2966025</ArticleId><ArticleId IdType="pubmed">20977632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li L, Wang L, Li J, Fan Z, Yang L, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78:1779&#8211;81. doi: 10.1158/0008-5472.CAN-17-2460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2460</ArticleId><ArticleId IdType="pmc">PMC5882589</ArticleId><ArticleId IdType="pubmed">29374065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura M, Ishida T, Taniwaki M, Ando K, Tobinai K, Fujimoto K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral and cutaneous T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157&#8211;63. doi: 10.1200/JCO.2013.52.0924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.52.0924</ArticleId><ArticleId IdType="pubmed">24616310</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591&#8211;8. doi: 10.1200/JCO.2009.25.3575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30104217</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>14</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.</ArticleTitle><Pagination><StartPage>1507</StartPage><EndPage>1518</EndPage><MedlinePgn>1507-1518</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2018-01-824607</ELocationID><Abstract><AbstractText>Adult T-cell leukemia lymphoma (ATLL) is a rare T cell neoplasm that is endemic in Japanese, Caribbean, and Latin American populations. Most North American ATLL patients are of Caribbean descent and are characterized by high rates of chemo-refractory disease and worse prognosis compared with Japanese ATLL. To determine genomic differences between these 2 cohorts, we performed targeted exon sequencing on 30 North American ATLL patients and compared the results with the Japanese ATLL cases. Although the frequency of TP53 mutations was comparable, the mutation frequency in epigenetic and histone modifying genes (57%) was significantly higher, whereas the mutation frequency in JAK/STAT and T-cell receptor/NF-&#954;B pathway genes was significantly lower. The most common type of epigenetic mutation is that affecting EP300 (20%). As a category, epigenetic mutations were associated with adverse prognosis. Dissimilarities with the Japanese cases were also revealed by RNA sequencing analysis of 9 primary patient samples. ATLL samples with a mutated EP300 gene have decreased total and acetyl p53 protein and a transcriptional signature reminiscent of p53-mutated cancers. Most importantly, decitabine has highly selective single-agent activity in the EP300-mutated ATLL samples, suggesting that decitabine treatment induces a synthetic lethal phenotype in EP300-mutated ATLL cells. In conclusion, we demonstrate that North American ATLL has a distinct genomic landscape that is characterized by frequent epigenetic mutations that are targetable preclinically with DNA methyltransferase inhibitors.</AbstractText><CopyrightInformation>&#169; 2018 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Urvi A</ForeName><Initials>UA</Initials><Identifier Source="ORCID">0000-0001-8419-1091</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Elaine Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giricz</LastName><ForeName>Orsi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Kith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon-Mitchell</LastName><ForeName>Shanisha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagat</LastName><ForeName>Tushar D</ForeName><Initials>TD</Initials><Identifier Source="ORCID">0000-0002-4527-5505</Identifier><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yongqiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Gaurav S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Ancy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7371-1696</Identifier><AffiliationInfo><Affiliation>Division of Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, Phelps Hospital, Northwell Health, Sleepy Hollow, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitego</LastName><ForeName>Nadege</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrish</LastName><ForeName>Crystall</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartenstein</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0908-770X</Identifier><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Swati</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantzaris</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shastri</LastName><ForeName>Aditi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derman</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gritsman</LastName><ForeName>Kira</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornblum</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunschweig</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagat</LastName><ForeName>Chirag</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genoptix, Carlsbad, CA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genoptix, Carlsbad, CA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graber</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genoptix, Carlsbad, CA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Oncology, Washington University School of Medicine, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanhua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Seishi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>B Hilda</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0000-0002-2281-422X</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janakiram</LastName><ForeName>Murali</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9323-8007</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 CA100730</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA013330</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA063417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 CA121947</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical><Chemical><RegistryNumber>776B62CQ27</RegistryNumber><NameOfSubstance UI="D000077209">Decitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D050881">E1A-Associated p300 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="C494360">EP300 protein, human</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077209">Decitabine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050881">E1A-Associated p300 Protein</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044127">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059645">Mutation Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict-of-interest disclosure: The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30104217</ArticleId><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="doi">10.1182/blood-2018-01-824607</ArticleId><ArticleId IdType="pii">S0006-4971(20)60709-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica Castillo LEPA, Reis IM, Gotuzzo E, et al. . Epidemiology, clinical features, and outcome of HTLV-1 related adult T-cell leukemia-lymphoma in a prevalent area in the United States. Blood. 2017;130(suppl 1):373.</Citation></Reference><Reference><Citation>Zell M, Assal A, Derman O, et al. . Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016;7(32):51981-51990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239529</ArticleId><ArticleId IdType="pubmed">27341021</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira PD, de Carvalho RF, Bittencourt AL. Adult T-cell leukemia/lymphoma in South and Central America and the Caribbean: systematic search and review. Int J STD AIDS. 2017;28(3):217-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">28178905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitar N, Hajj HE, Houmani Z, et al. . Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion. 2009;49(9):1859-1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453978</ArticleId></ArticleIdList></Reference><Reference><Citation>Licata MJ, Janakiram M, Tan S, et al. . Diagnostic challenges of adult T-cell leukemia/lymphoma in North America &#8211; a clinical, histological, and immunophenotypic correlation with a workflow proposal. Leuk Lymphoma. 2018;59(5):1188-1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">29504866</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al. . A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116(14):3438-3446.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. ; ATL-Prognostic Index Project. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570-2577.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34(9):963-971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070555</ArticleId><ArticleId IdType="pubmed">26962200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D, Ito H, Katanoda K, et al. . Increase in incidence of adult T-cell leukemia/lymphoma in non-endemic areas of Japan and the United States. Cancer Sci. 2012;103(10):1857-1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7659271</ArticleId><ArticleId IdType="pubmed">22738276</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428-437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874220</ArticleId><ArticleId IdType="pubmed">26980727</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris LG, Kaufman AM, Gong Y, et al. . Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013;45(3):253-261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729040</ArticleId><ArticleId IdType="pubmed">23354438</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Seehawer M, Schlee C, et al. . FAT1 expression and mutations in adult acute lymphoblastic leukemia. Blood Cancer J. 2014;4(6):e224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4080215</ArticleId><ArticleId IdType="pubmed">24972153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta R, Tiu B, Sakamoto KM. CBP/p300 acetyltransferase activity in hematologic malignancies. Mol Genet Metab. 2016;119(1-2):37-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">27380996</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman SR. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem. 2001;268(10):2773-2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">11358491</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008;133(4):612-626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914560</ArticleId><ArticleId IdType="pubmed">18485870</ArticleId></ArticleIdList></Reference><Reference><Citation>Migone TS, Lin JX, Cereseto A, et al. . Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269(5220):79-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7604283</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Kang SH, Heidenreich O, Okerholm M, O&#8217;Shea JJ, Nerenberg MI. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J Clin Invest. 1995;96(3):1548-1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC185780</ArticleId><ArticleId IdType="pubmed">7657825</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto S, Mulloy JC, Cereseto A, et al. . Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 1997;94(25):13897-13902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28404</ArticleId><ArticleId IdType="pubmed">9391124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Iwanaga M, Yasunaga JI, et al. . Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215-225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Lin X. Regulation of NF-&#954;B by the CARD proteins. Immunol Rev. 2012;246(1):141-153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339759</ArticleId><ArticleId IdType="pubmed">22435552</ArticleId></ArticleIdList></Reference><Reference><Citation>Couronn&#233; L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22216861</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomero T, Couronn&#233; L, Khiabanian H, et al. . Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166-170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963408</ArticleId><ArticleId IdType="pubmed">24413734</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh CH, Bai XT, Moles R, et al. . Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia [published correction appears in Mol Cancer. 2016;15:20]. Mol Cancer. 2016;15(1):15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754821</ArticleId><ArticleId IdType="pubmed">26880370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayther SA, Batley SJ, Linger L, et al. . Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24(3):300-303.</Citation><ArticleIdList><ArticleId IdType="pubmed">10700188</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CL, Asmar F, Klausen T, Hasselbalch H, Gr&#248;nb&#230;k K. Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. Leuk Res Rep. 2012;2(1):1-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850379</ArticleId><ArticleId IdType="pubmed">24371765</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin RD, Mendez-Lago M, Mungall AJ, et al. . Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3210554</ArticleId><ArticleId IdType="pubmed">21796119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunning MA, Green MR. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 2015;5(10):e361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635197</ArticleId><ArticleId IdType="pubmed">26473533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko M, Huang Y, Jankowska AM, et al. . Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003755</ArticleId><ArticleId IdType="pubmed">21057493</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Wang Z, Xie W, et al. . Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress. Mol Cell. 2017;65(2):323-335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260804</ArticleId><ArticleId IdType="pubmed">28107650</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. . Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189-195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3271441</ArticleId><ArticleId IdType="pubmed">21390126</ArticleId></ArticleIdList></Reference><Reference><Citation>Toomey NL RJ. Histone deacetylase inhibitors abolish HBZ protein expression and induce cell death in HTLV-1 related adult T-cell leukemia-lymphoma. Blood. 2017;130 (suppl 1):4012.</Citation></Reference><Reference><Citation>Fujikawa D, Nakagawa S, Hori M, et al. . Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790-1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">26773042</ArticleId></ArticleIdList></Reference><Reference><Citation>Clozel T, Yang S, Elstrom RL, et al. . Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013;3(9):1002-1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770813</ArticleId><ArticleId IdType="pubmed">23955273</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doorn R, Zoutman WH, Dijkman R, et al. . Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23(17):3886-3896.</Citation><ArticleIdList><ArticleId IdType="pubmed">15897551</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Fu J, Qu Z, et al. . PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood. 2009;113(18):4370-4380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676091</ArticleId><ArticleId IdType="pubmed">19131544</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res. 2000;60(4):1043-1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">10706122</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo M, Kobayashi C, Setsu N, et al. . Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17(11):3771-3782.</Citation><ArticleIdList><ArticleId IdType="pubmed">21262917</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi A, Nemoto Y, Yokoyama A, et al. . Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia. Int J Cancer. 2008;123(8):1824-1831.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato H, Oka T, Shinnou Y, et al. . Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol. 2010;176(1):402-415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797900</ArticleId><ArticleId IdType="pubmed">20019193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Takeuchi S, Tsukasaki K, et al. . Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res. 2005;29(1):47-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541474</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh DH, Kim MK, Kim HS, Chung HH, Song YS. Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer. J Cancer Prev. 2013;18(3):227-234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189470</ArticleId><ArticleId IdType="pubmed">25337550</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordian E, Ramachandran K, Singal R. Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity. Anticancer Res. 2009;29(8):3207-3210.</Citation><ArticleIdList><ArticleId IdType="pubmed">19661336</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29545256</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-9537</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>Blood advances</Title><ISOAbbreviation>Blood Adv</ISOAbbreviation></Journal><ArticleTitle>Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States.</ArticleTitle><Pagination><StartPage>607</StartPage><EndPage>620</EndPage><MedlinePgn>607-620</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2017011106</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a fatal disease caused by human T-cell leukemia virus type 1 (HTLV-1). We retrospectively analyzed 195 patients with ATLL (lymphomatous n = 96, acute n = 80, unfavorable chronic n = 7, chronic n = 5, smoldering n = 3, and unclassified n = 4) diagnosed between 1987 and 2016 (median age 52 years, 77% Afro-Caribbean). Hypercalcemia was associated with acute ATLL (65%, vs 23% lymphomatous) (<i>P</i> = .012). The median survival for patients treated with modern therapies between 2000 and 2016 was 4.1 months for acute, 10.2 months for lymphomatous, 72 months for chronic/smoldering, and not reached for unfavorable chronic type, with 4-year survival rates of 10%, 4%, 60%, and 83%, respectively. The overall response rate (ORR) after first-line multiagent chemotherapy was 78% (complete response [CR] 39%) for acute vs 67% (CR 33%) for lymphomatous ATLL. First-line zidovudine interferon-&#945; (AZT-IFN) resulted in ORR of 56% (CR 23%) for acute (n = 43), 33% (CR 16.5%) for lymphomatous (n = 6), and 86% (CR 29%) for unfavorable chronic ATLL. The median progression-free survival (PFS) in patients with aggressive ATLL who achieved CR after AZT-IFN was 48 months vs 11 months after chemotherapy (<i>P</i> = .003). Allogeneic hematopoietic stem cell transplant (allo-HSCT) resulted in a PFS of 24 and 28 months in 2 patients with lymphomatous ATLL. Our results suggest high-dose AZT-IFN is a reasonable up-front option for patients with aggressive leukemic ATLL followed by chemotherapy switch in nonresponders, whereas chemotherapy should be used in lymphomatous type followed by allo-HSCT when feasible.</AbstractText><CopyrightInformation>&#169; 2018 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malpica</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7082-1846</Identifier><AffiliationInfo><Affiliation>Internal Medicine Program, Jackson Memorial Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pimentel</LastName><ForeName>Agustin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Isildinha M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotuzzo</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alexander von Humboldt Institute of Tropical Medicine and Infectious Diseases, Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lekakis</LastName><ForeName>Lazaros</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Stem Cell Transplant Program.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komanduri</LastName><ForeName>Krishna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Stem Cell Transplant Program.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Glen N</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA223232</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Adv</MedlineTA><NlmUniqueID>101698425</NlmUniqueID><ISSNLinking>2473-9529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict-of-interest disclosure: The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29545256</ArticleId><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2017011106</ArticleId><ArticleId IdType="pii">bloodadvances.2017011106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S&#233;zary T-cell leukaemia. Nature. 1981;294(5838):268-271.</Citation><ArticleIdList><ArticleId IdType="pubmed">6272125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79(6):2031-2035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington WJ Jr, Ucar A, Gill P, et al. . Clinical spectrum of HTLV-I in south Florida. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):466-473.</Citation><ArticleIdList><ArticleId IdType="pubmed">7697443</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington WJ Jr, Miller GA, Kemper RR, Byrne GE Jr, Whitcomb CC, Rabin M. HTLV-I-associated leukemia/lymphoma in south Florida. J Acquir Immune Defic Syndr. 1991;4(3):284-289.</Citation><ArticleIdList><ArticleId IdType="pubmed">1992105</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake M, Yamada Y, Atogami S, Yamaguchi K. The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Japan. Leuk Lymphoma. 2015;56(6):1806-1812.</Citation><ArticleIdList><ArticleId IdType="pubmed">25219595</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al. . A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116(14):3438-3446.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428-437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Toma H, Sugahara K, et al. . Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis. Oncogene. 2002;21(16):2466-2475.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971181</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonck K, Gonz&#225;lez E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7(4):266-281.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumelle Y, Pascaline N, Nguyen D, et al. . Adult T-cell leukemia-lymphoma: a clinico-pathologic study of twenty-six patients from Martinique. Hematol Pathol. 1993;7(4):251-262.</Citation><ArticleIdList><ArticleId IdType="pubmed">8113152</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. ; ATL-Prognostic Index Project. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570-2577.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W Jr, Kaplan MH, et al. . Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744-1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, et al. . Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749-1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Taylor GP, Cavenagh J, et al. . Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113(3):779-784.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. . Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177-4183.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et al. . Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453-459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JC, Ruiz P Jr, Ratner L, et al. . IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood. 2007;109(7):3060-3068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852214</ArticleId><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Pfistner B, Juweid ME, et al. ; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.</Citation><ArticleIdList><ArticleId IdType="pubmed">17242396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell M, Assal A, Derman O, et al. . Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016;7(32):51981-51990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239529</ArticleId><ArticleId IdType="pubmed">27341021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. ; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458-5464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17325893</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1042-8194</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran.</ArticleTitle><Pagination><StartPage>330</StartPage><EndPage>336</EndPage><MedlinePgn>330-6</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell lymphotropic virus type I (HTLV-I) associated adult T-cell leukemia/lymphoma (ATLL) is endemic in southern Japan, the Caribbean, intertropical Africa, and Brazil. Recently north east Iran, particularly the region of Mashhad, has been recognized as a new endemic region. ATLL is an aggressive T-cell lymphoproliferative disorder. Patients with ATLL have high plasma levels of VEGF that induce angiogenesis. Prognosis of ATLL remains poor because of immunosuppression and intrinsic resistance to chemotherapy. Important advances in the treatment of ATLL were reported with the combination of zidovudine (AZT) and interferon-alpha. We investigated the effect of AZT/IFN treatment on vascular endothelium growth factor (VEGF) plasma levels and HTLV-I proviral load in ATLL patients from the region of Mashhad. We confirmed that AZT/IFN treatment induces a high response rate and prolonged survival with minimal side effects. We also confirmed that VEGF plasma levels and HTLV-I proviral load are higher in ATLL patients than in asymptomatic carriers. We finally showed that AZT/IFN treatment reduced both HTLV-I proviral load and importantly VEGF plasma levels, suggesting a potential antiangiogenic effect of this therapy. These results provide further evidence for the efficacy and the mechanism of action of AZT/IFN therapy for ATLL in a developing country.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kchour</LastName><ForeName>Ghada</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Immunology Research Centre, Bu-Ali Research institute, Mashhad University of Medical Sciences, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makhoul</LastName><ForeName>Nadine J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Mahmoudi</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kooshyar</LastName><ForeName>Mohamad-Mehdi</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Shirdel</LastName><ForeName>Abbas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rastin</LastName><ForeName>Maryam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rafatpanah</LastName><ForeName>Houshang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tarhini</LastName><ForeName>Mahdi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zalloua</LastName><ForeName>Pierre A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Farid</LastName><ForeName>Reza</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bazarbachi</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007492">Iran</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011533">Proviruses</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D042461">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17325893</ArticleId><ArticleId IdType="doi">10.1080/10428190601071717</ArticleId><ArticleId IdType="pii">770740115</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31288962</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0740-2570</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Seminars in diagnostic pathology</Title><ISOAbbreviation>Semin Diagn Pathol</ISOAbbreviation></Journal><ArticleTitle>Neoplastic hematological diseases associated with HTLV-1 infection.</ArticleTitle><Pagination><StartPage>98</StartPage><EndPage>103</EndPage><MedlinePgn>98-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.semdp.2019.06.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0740-2570(19)30066-8</ELocationID><Abstract><AbstractText>Adult cell lymphoma/leukemia (ATLL) is a type of lymphoma consisting of T-cells that are related to infection with the human T lymphotropic virus (HTLV-1). Four clinical forms have been described (leukemic, lymphomatous, chronic, smoldering) and the phenotype corresponds to regulatory CD4+ T cells. The histological characteristics are variable, with neoplastic cells showing a size ranging from small to large and atypical nuclei with irregular contours. A series of genetic and molecular alterations have been described, which partially explain the lymphomagenesis of the neoplasm, some of which are also factors related to the clinical course and overall survival. ATLL is a neoplasm with a poor prognosis, but in recent years new targeted therapies have been designed, with encouraging responses. This neoplasm should continue to be studied to improve treatment and evolution.</AbstractText><CopyrightInformation>Copyright &#169; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrionuevo-Cornejo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology. Instituto Nacional de Enfermedades Neopl&#225;sicas, Lima, Peru. Electronic address: cbarrionuevoc@unmsm.edu.pe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Due&#241;as-Hancco</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology. MD Anderson Cancer Center, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Diagn Pathol</MedlineTA><NlmUniqueID>8502262</NlmUniqueID><ISSNLinking>0740-2570</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">Clinical features</Keyword><Keyword MajorTopicYN="N">Histopathology</Keyword><Keyword MajorTopicYN="N">Immunophenotype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31288962</ArticleId><ArticleId IdType="doi">10.1053/j.semdp.2019.06.008</ArticleId><ArticleId IdType="pii">S0740-2570(19)30066-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28412288</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2399</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Experimental hematology</Title><ISOAbbreviation>Exp Hematol</ISOAbbreviation></Journal><ArticleTitle>Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators.</ArticleTitle><Pagination><StartPage>7</StartPage><EndPage>16</EndPage><MedlinePgn>7-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exphem.2017.04.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0301-472X(17)30134-0</ELocationID><Abstract><AbstractText>T-cell lymphoblastic lymphoma (T-LBL) is a rare, aggressive neoplasm of precursor T cells that occurs mostly in adolescents and young adults. In this review, we describe the treatment of adult T-LBL with a focus on recent advances using pediatric-inspired acute lymphoblastic leukemia regimens, which have greatly improved outcome. We also discuss the development of prognostic indicators for T-LBL, especially oncogenetic factors, that can identify patients at higher risk of relapse and may help further extend T-LBL patient survival. Pediatric-inspired acute lymphoblastic leukemia regimens have the potential to become the treatment of choice for adult T-LBL, and they might also reduce the need for other longstanding T-LBL interventions, particularly mediastinal irradiation and stem cell transplantation.</AbstractText><CopyrightInformation>Copyright &#169; 2017 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lepretre</LastName><ForeName>St&#233;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM) U1245, Department of Hematology, Centre Henri-Becquerel and Normandie Univ UNIROUEN, Rouen, France. Electronic address: stephane.lepretre@chb.unicancer.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graux</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Godinne University Hospital (UCL), Yvoir, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touzart</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Paris Descartes Sorbonne Cit&#233;, Institut Necker-Enfants Malades (INEM), INSERM U1151, Laboratoire d'Onco-Hematology, Assistance Publique-H&#244;pitaux de Paris (AP-HP), H&#244;pital Necker Enfants-Malades, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macintyre</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Paris Descartes Sorbonne Cit&#233;, Institut Necker-Enfants Malades (INEM), INSERM U1151, Laboratoire d'Onco-Hematology, Assistance Publique-H&#244;pitaux de Paris (AP-HP), H&#244;pital Necker Enfants-Malades, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boissel</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, H&#244;pital Saint-Louis, AP-HP, Universit&#233; Paris Diderot, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Exp Hematol</MedlineTA><NlmUniqueID>0402313</NlmUniqueID><ISSNLinking>0301-472X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28412288</ArticleId><ArticleId IdType="doi">10.1016/j.exphem.2017.04.002</ArticleId><ArticleId IdType="pii">S0301-472X(17)30134-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26694446</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma.</ArticleTitle><Pagination><StartPage>6604</StartPage><EndPage>6612</EndPage><MedlinePgn>6604-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/v7122960</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%-5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan. kojikato@intmed1.med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan. akashi@med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">J0101</Keyword><Keyword MajorTopicYN="N">adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">antiviral therapy</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">graft-versus-host disease</Keyword><Keyword MajorTopicYN="N">mogamulizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26694446</ArticleId><ArticleId IdType="pmc">PMC4690883</ArticleId><ArticleId IdType="doi">10.3390/v7122960</ArticleId><ArticleId IdType="pii">v7122960</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood. 1977;50:481&#8211;492. doi: 10.1016/0268-960X(88)90012-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0268-960X(88)90012-4</ArticleId><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA. 1980;77:7415&#8211;7419. doi: 10.1073/pnas.77.12.7415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.77.12.7415</ArticleId><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Osame M., Izumo S., Igata A., Matsumoto M., Matsumoto T., Sonoda S., Tara M., Shibata Y. Blood transfusion and HTLV-I associated myelopathy. Lancet. 1986;2:104&#8211;105. doi: 10.1016/S0140-6736(86)91636-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(86)91636-3</ArticleId><ArticleId IdType="pubmed">2873363</ArticleId></ArticleIdList></Reference><Reference><Citation>Laydon D.J., Melamed A., Sim A., Gillet N.A., Sim K., Darko S., Kroll J.S., Douek D.C., Price D.A., Bangham C.R., Asquith B. Quantification of HTLV-1 clonality and TCR diversity. PLoS Comput. Biol. 2014;10:e1003646. doi: 10.1371/journal.pcbi.1003646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003646</ArticleId><ArticleId IdType="pmc">PMC4063693</ArticleId><ArticleId IdType="pubmed">24945836</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87) Br. J. Haematol. 1991;79:428&#8211;437. doi: 10.1111/j.1365-2141.1991.tb08051.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y., Iwanaga M., Imaizumi Y., Tawara M., Joh T., Kohno T., Yamada Y., Kamihira S., Ikeda S., Miyazaki Y., et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337&#8211;4343. doi: 10.1182/blood-2009-09-242347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-09-242347</ArticleId><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H., Yamanaka T., Ishitsuka K., Utsunomiya A., Sasaki H., Hanada S., Eto T., Moriuchi Y., Saburi Y., Miyahara M., et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J. Clin. Oncol. 2012;30:1635&#8211;1640. doi: 10.1200/JCO.2011.38.2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.38.2101</ArticleId><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T., Nomura S., Shimoyama M., Shibata T., Imaizumi Y., Moriuchi Y., Tomoyose T., Uozumi K., Kobayashi Y., Fukushima N., et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A) Br. J. Haematol. 2014;166:739&#8211;748. doi: 10.1111/bjh.12962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12962</ArticleId><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K., Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517&#8211;e526. doi: 10.1016/S1470-2045(14)70202-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A., Choi I., Chihara D., Seto M. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci. 2015;106:344&#8211;351. doi: 10.1111/cas.12617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12617</ArticleId><ArticleId IdType="pmc">PMC4409876</ArticleId><ArticleId IdType="pubmed">25613789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A., Suarez F., Fields P., Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118:1736&#8211;1745. doi: 10.1182/blood-2011-03-345702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-345702</ArticleId><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O., Bouscary D., Gessain A., Turlure P., Leblond V., Franck N., Buzyn-Veil A., Rio B., Macintyre E., Dreyfus F., et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 1995;332:1749&#8211;1751. doi: 10.1056/NEJM199506293322604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199506293322604</ArticleId><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Hermine O., Bazarbachi A., Ratner L., Ramos J.C., Harrington W., Jr., O&#8217;Mahony D., Janik J.E., Bittencourt A.L., Taylor G.P., et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 2009;27:453&#8211;459. doi: 10.1200/JCO.2008.18.2428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.18.2428</ArticleId><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A., Plumelle Y., Carlos Ramos J., Tortevoye P., Otrock Z., Taylor G., Gessain A., Harrington W., Panelatti G., Hermine O. Meta-analysis on the use of zidovudine and interferon-&#945; in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 2010;28:4177&#8211;4183. doi: 10.1200/JCO.2010.28.0669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L., Harrington W., Feng X., Grant C., Jacobson S., Noy A., Sparano J., Lee J., Ambinder R., Campbell N., et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS ONE. 2009;4:e4420. doi: 10.1371/journal.pone.0004420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004420</ArticleId><ArticleId IdType="pmc">PMC2636875</ArticleId><ArticleId IdType="pubmed">19204798</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M., Sano M., Ikeda S., Takatsuki K., Kozuru M., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan CLINICAL ONCOLOGY GROUP STUDY 9303. Br. J. Haematol. 2001;113:375&#8211;382. doi: 10.1046/j.1365-2141.2001.02737.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2001.02737.x</ArticleId><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Utsunomiya A., Fukuda H., Shibata T., Fukushima T., Takatsuka Y., Ikeda S., Masuda M., Nagoshi H., Ueda R., et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J. Clin. Oncol. 2007;25:5458&#8211;5464. doi: 10.1200/JCO.2007.11.9958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Maeda T., Arimura K., Taguchi J., Fukushima T., Miyazaki Y., Moriuchi Y., Kuriyama K., Yamada Y., Tomonaga M. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: A case report and review of the literature. Bone Marrow Transpl. 1999;23:87&#8211;89. doi: 10.1038/sj.bmt.1701533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1701533</ArticleId><ArticleId IdType="pubmed">10037056</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A., Miyazaki Y., Takatsuka Y., Hanada S., Uozumi K., Yashiki S., Tara M., Kawano F., Saburi Y., Kikuchi H., et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;27:15&#8211;20. doi: 10.1038/sj.bmt.1702731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1702731</ArticleId><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kami M., Hamaki T., Miyakoshi S., Murashige N., Kanda Y., Tanosaki R., Takaue Y., Taniguchi S., Hirai H., Ozawa K., et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br. J. Haematol. 2003;120:304&#8211;309. doi: 10.1046/j.1365-2141.2003.04054.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2003.04054.x</ArticleId><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T., Miyazaki Y., Honda S., Kawano F., Moriuchi Y., Masuda M., Tanosaki R., Utsunomiya A., Uike N., Yoshida S., et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19:829&#8211;834. doi: 10.1038/sj.leu.2403682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.leu.2403682</ArticleId><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K., Kanda Y., Eto T., Muta T., Gondo H., Taniguchi S., Shibuya T., Utsunomiya A., Kawase T., Kato S., et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: Retrospective analysis of data from the Japan Marrow Donor Program. Biol. Blood Marrow Transpl. 2007;13:90&#8211;99. doi: 10.1016/j.bbmt.2006.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2006.09.002</ArticleId><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakase K., Hara M., Kozuka T., Tanimoto K., Nawa Y. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. Bone Marrow Transpl. 2006;37:41&#8211;44. doi: 10.1038/sj.bmt.1705197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1705197</ArticleId><ArticleId IdType="pubmed">16247419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiratori S., Yasumoto A., Tanaka J., Shigematsu A., Yamamoto S., Nishio M., Hashino S., Morita R., Takahata M., Onozawa M., et al. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): Clinical impact of graft-versus-leukemia/lymphoma effect. Biol. Blood Marrow Transpl. 2008;14:817&#8211;823. doi: 10.1016/j.bbmt.2008.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2008.04.014</ArticleId><ArticleId IdType="pubmed">18541202</ArticleId></ArticleIdList></Reference><Reference><Citation>Takizawa J., Aoki S., Kurasaki T., Higashimura M., Honma K., Kitajima T., Momoi A., Takahashi H., Nakamura N., Furukawa T., et al. Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am. J. Hematol. 2007;82:1113&#8211;1115. doi: 10.1002/ajh.21042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.21042</ArticleId><ArticleId IdType="pubmed">17696205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Hishizawa M., Kato K., Tanosaki R., Fukuda T., Taniguchi S., Eto T., Takatsuka Y., Miyazaki Y., Moriuchi Y., et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: A nationwide retrospective study. Blood. 2012;120:1734&#8211;1741. doi: 10.1182/blood-2012-03-414490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-414490</ArticleId><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M., Kanda J., Utsunomiya A., Taniguchi S., Eto T., Moriuchi Y., Tanosaki R., Kawano F., Miyazaki Y., Masuda M., et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood. 2010;116:1369&#8211;1376. doi: 10.1182/blood-2009-10-247510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-10-247510</ArticleId><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K., Choi I., Wake A., Uike N., Taniguchi S., Moriuchi Y., Miyazaki Y., Nakamae H., Oku E., Murata M., et al. Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: A Japanese nationwide retrospective survey. Biol. Blood Marrow Transpl. 2014;20:1968&#8211;1974. doi: 10.1016/j.bbmt.2014.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2014.08.012</ArticleId><ArticleId IdType="pubmed">25172635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T., Itonaga H., Moriuchi Y., Yoshida S., Taguchi J., Imaizumi Y., Imanishi D., Tsushima H., Sawayama Y., Matsuo E., et al. Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: A retrospective analysis of the Nagasaki Transplantation Network. Int J. Hematol. 2013;97:485&#8211;490. doi: 10.1007/s12185-013-1307-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-013-1307-y</ArticleId><ArticleId IdType="pubmed">23483425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T., Oku E., Nomura K., Morishige S., Takata Y., Seki R., Imamura R., Osaki K., Hashiguchi M., Yakushiji K., et al. Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute. Int. J. Hematol. 2012;96:657&#8211;663. doi: 10.1007/s12185-012-1177-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-012-1177-8</ArticleId><ArticleId IdType="pubmed">22976114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A., Cwynarski K., Boumendil A., Finel H., Fields P., Raj K., Nagler A., Mohty M., Sureda A., Dreger P., et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: A retrospective study by the EBMT LWP. Bone Marrow Transpl. 2014;49:1266&#8211;1268. doi: 10.1038/bmt.2014.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2014.143</ArticleId><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura J., Utsunomiya A., Tanosaki R., Uike N., Sonoda S., Kannagi M., Tomonaga M., Harada M., Kimura N., Masuda M., et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105:4143&#8211;4145. doi: 10.1182/blood-2004-11-4193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-11-4193</ArticleId><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I., Tanosaki R., Uike N., Utsunomiya A., Tomonaga M., Harada M., Yamanaka T., Kannagi M., Okamura J. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials. Bone Marrow Transpl. 2011;46:116&#8211;118. doi: 10.1038/bmt.2010.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2010.92</ArticleId><ArticleId IdType="pubmed">20400987</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K., Utsunomiya A., Tobinai K., Tsukasaki K., Uike N., Uozumi K., Yamaguchi K., Yamada Y., Hanada S., Tamura K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 2010;28:1591&#8211;1598. doi: 10.1200/JCO.2009.25.3575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Joh T., Uike N., Yamamoto K., Utsunomiya A., Yoshida S., Saburi Y., Miyamoto T., Takemoto S., Suzushima H., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J. Clin. Oncol. 2012;30:837&#8211;842. doi: 10.1200/JCO.2011.37.3472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Jo T., Takemoto S., Suzushima H., Uozumi K., Yamamoto K., Uike N., Saburi Y., Nosaka K., Utsunomiya A., et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study. Br. J. Haematol. 2015;169:672&#8211;682. doi: 10.1111/bjh.13338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Ito A., Sato F., Kusumoto S., Iida S., Inagaki H., Morita A., Akinaga S., Ueda R. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci. 2013;104:647&#8211;650. doi: 10.1111/cas.12116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12116</ArticleId><ArticleId IdType="pmc">PMC7657114</ArticleId><ArticleId IdType="pubmed">23360455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K., Miyamoto T., Numata A., Nakaike T., Oka H., Yurino A., Kuriyama T., Mori Y., Yamasaki S., Muta T., et al. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma. Int. J. Hematol. 2013;97:430&#8211;432. doi: 10.1007/s12185-013-1278-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-013-1278-z</ArticleId><ArticleId IdType="pubmed">23397210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K., Murahashi M., Katsuya H., Mogi A., Masaki M., Kawai C., Goto T., Ishizu M., Ikari Y., Takamatsu Y., et al. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. Int. J. Hematol. 2015;102:493&#8211;497. doi: 10.1007/s12185-015-1811-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-015-1811-3</ArticleId><ArticleId IdType="pubmed">25995001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y., Miyamoto T., Chong Y., Aoki T., Kato K., Akashi K., Kamimura T. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. Bone Marrow Transpl. 2013;48:998&#8211;999. doi: 10.1038/bmt.2012.268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.268</ArticleId><ArticleId IdType="pubmed">23292237</ArticleId></ArticleIdList></Reference><Reference><Citation>Motohashi K., Suzuki T., Kishimoto K., Numata A., Nakajima Y., Tachibana T., Ohshima R., Kuwabara H., Tanaka M., Tomita N., et al. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. Int. J. Hematol. 2013;98:258&#8211;260. doi: 10.1007/s12185-013-1387-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-013-1387-8</ArticleId><ArticleId IdType="pubmed">23801427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K., Utsunomiya A., Katsuya H., Takeuchi S., Takatsuka Y., Hidaka M., Sakai T., Yoshimitsu M., Ishida T., Tamura K. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. Cancer Sci. 2015;106:1219&#8211;1223. doi: 10.1111/cas.12735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12735</ArticleId><ArticleId IdType="pmc">PMC4582992</ArticleId><ArticleId IdType="pubmed">26179770</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K., Utsunomiya A., Takatsuka Y., Takeuchi S., Tashiro Y., Kanzaki T., Kanekura T. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2008;41:1029&#8211;1035. doi: 10.1038/bmt.2008.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2008.39</ArticleId><ArticleId IdType="pubmed">18332910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J., Hishizawa M., Utsunomiya A., Taniguchi S., Eto T., Moriuchi Y., Tanosaki R., Kawano F., Miyazaki Y., Masuda M., et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141&#8211;2148. doi: 10.1182/blood-2011-07-368233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-07-368233</ArticleId><ArticleId IdType="pubmed">22234682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamimura T., Miyamoto T., Kawano N., Numata A., Ito Y., Chong Y., Nagafuji K., Teshima T., Hayashi S., Akashi K. Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation. Int. J. Hematol. 2012;95:725&#8211;730. doi: 10.1007/s12185-012-1056-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-012-1056-3</ArticleId><ArticleId IdType="pubmed">22481502</ArticleId></ArticleIdList></Reference><Reference><Citation>Itonaga H., Tsushima H., Taguchi J., Fukushima T., Taniguchi H., Sato S., Ando K., Sawayama Y., Matsuo E., Yamasaki R., et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki Transplant Group experience. Blood. 2013;121:219&#8211;225. doi: 10.1182/blood-2012-07-444372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-07-444372</ArticleId><ArticleId IdType="pubmed">23100309</ArticleId></ArticleIdList></Reference><Reference><Citation>Harashima N., Kurihara K., Utsunomiya A., Tanosaki R., Hanabuchi S., Masuda M., Ohashi T., Fukui F., Hasegawa A., Masuda T., et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64:391&#8211;399. doi: 10.1158/0008-5472.CAN-03-1452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-03-1452</ArticleId><ArticleId IdType="pubmed">14729650</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai Y., Hasegawa A., Takamori A., Sasada A., Tanosaki R., Choi I., Utsunomiya A., Maeda Y., Yamano Y., Eto T., et al. Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation. J. Immunol. 2013;190:4382&#8211;4392. doi: 10.4049/jimmunol.1202971.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202971</ArticleId><ArticleId IdType="pubmed">23475215</ArticleId></ArticleIdList></Reference><Reference><Citation>Suehiro Y., Hasegawa A., Iino T., Sasada A., Watanabe N., Matsuoka M., Takamori A., Tanosaki R., Utsunomiya A., Choi I., et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br. J. Haematol. 2015;169:356&#8211;367. doi: 10.1111/bjh.13302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13302</ArticleId><ArticleId IdType="pubmed">25612920</ArticleId></ArticleIdList></Reference><Reference><Citation>Itonaga H., Taguchi J., Fukushima T., Tsushima H., Sato S., Ando K., Sawayama Y., Matsuo E., Yamasaki R., Onimaru Y., et al. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: A retrospective analysis in the Nagasaki transplant group. Biol. Blood Marrow Transpl. 2013;19:607&#8211;615. doi: 10.1016/j.bbmt.2013.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2013.01.011</ArticleId><ArticleId IdType="pubmed">23333533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29685460</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5778</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Actas dermo-sifiliograficas</Title><ISOAbbreviation>Actas Dermosifiliogr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Adult T-Cell Leukemia/Lymphoma. Review of the Literature.</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>407</EndPage><MedlinePgn>399-407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ad.2017.08.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0001-7310(17)30592-6</ELocationID><Abstract><AbstractText>Adult T-cell Leukemia/Lymphoma (ATLL) is an aggressive neoplasm of T lymphocytes associated with Human T-lymphotropic virus type1 (HTLV-1) infection. HTLV-1 is a public health problem because it is endemic in native groups in Latin America, and its infection leads to several chronic diseases as ATLL. We aimed to review current literature of ATLL in order to consider it as a differential diagnosis in front of patients with compatible symptoms. Prognosis is still poor in aggressive and indolent variants, with survival rates from months to few years. Treatment based on chemotherapy, antiretroviral, and allogenic stem cell transplantation are currently improving survival rates, but with limited results.</AbstractText><CopyrightInformation>Copyright &#169; 2017 AEDV. Publicado por Elsevier Espa&#241;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#237;guez-Z&#250;&#241;iga</LastName><ForeName>M J M</ForeName><Initials>MJM</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#237;a, Hospital Nacional Daniel Alcides Carri&#243;n, Callao, Per&#250;; Universidad Nacional Mayor de San Marcos, Lima, Per&#250;. Electronic address: Milton_rz@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortez-Franco</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#237;a, Hospital Nacional Daniel Alcides Carri&#243;n, Callao, Per&#250;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qujiano-Gomero</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Dermatolog&#237;a, Hospital Nacional Daniel Alcides Carri&#243;n, Callao, Per&#250;.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Leucemia/linfoma de c&#233;lulas T del adulto. Revisi&#243;n de la literatura cient&#237;fica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Dermosifiliogr (Engl Ed)</MedlineTA><NlmUniqueID>101777537</NlmUniqueID><ISSNLinking>2173-5778</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Am&#233;rica Latina</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Epidemiolog&#237;a</Keyword><Keyword MajorTopicYN="N">Human T lymphotropic virus type1</Keyword><Keyword MajorTopicYN="N">Informe de caso</Keyword><Keyword MajorTopicYN="N">Latin America</Keyword><Keyword MajorTopicYN="N">Leucemia/linfoma de c&#233;lulas T del adulto</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Pron&#243;stico</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Revisi&#243;n</Keyword><Keyword MajorTopicYN="N">Tratamiento</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword><Keyword MajorTopicYN="N">Virus humano T linfotr&#243;fico tipo1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29685460</ArticleId><ArticleId IdType="doi">10.1016/j.ad.2017.08.014</ArticleId><ArticleId IdType="pii">S0001-7310(17)30592-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31961925</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><Issue>17</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.</ArticleTitle><Pagination><StartPage>1467</StartPage><EndPage>1471</EndPage><MedlinePgn>1467-1471</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2019001815</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) in Japan presents at a median age of 70 years and only 5% of patients are &lt;50 years of age. We conducted RNA and targeted DNA sequencing of 8 ATLLs from Japanese patients &lt;50 years of age and identified 3 (37.5%) with both CTLA4-CD28 and inducible costimulator (ICOS)-CD28 fusions. Mutations of PLCG1, PRKCB, and STAT3, which were frequent in other ATLL-sequencing studies, were not identified. Differential expression analysis identified the negative checkpoint molecule LAG3 as the most downregulated gene among cases with the fusions. Immunohistochemistry demonstrated expression of CD80 and CD86, the ligands for CTLA4 and CD28, on ATLL cells and tumor-associated macrophages, respectively. Expression of CTLA4-CD28 in Ba/F3 cells conferred cytokine-independent growth when cocultured with Raji cells that express CD80 and CD86. Growth was associated with recruitment of the p85 subunit of phosphatidylinositol 3-kinase to CTLA4-CD28 and phosphorylation of AKT and extracellular signal-regulated kinase. A CTLA4-blocking antibody reduced cytokine-independent growth in a dose-dependent manner. Together, these results suggest that young Japanese ATLL cases have a unique biology dependent on cell-nonautonomous interactions that drive CD28 signaling. Assessment for CD28 fusions and treatment with CTLA4 blockade should be considered in younger patients with relapsed/refractory ATLL.</AbstractText><CopyrightInformation>&#169; 2020 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shigemori</LastName><ForeName>Kay</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donaldson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevisani</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordero</LastName><ForeName>Nicolas A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Kristen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arakawa</LastName><ForeName>Fumiko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, School of Medicine, Kurume University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoda</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Samuel Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstock</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 CA241089</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 CA231958</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018106">CD28 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Blood. 2020 Apr 23;135(17):1415-1416</RefSource><PMID Version="1">32324866</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018106">CD28 Antigens</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060908">CTLA-4 Antigen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015894">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015514">Oncogene Proteins, Fusion</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict-of-interest disclosure: D.M.W. receives research support from Verastem; AstraZeneca, Aileron, Abbvie, Daiichi Sankyo, Verastem and Surface Oncology, and consulting or Scientific Advisory Board Membership from Travera, Mundipharma EDO, Bantam, Ajax, Genentech/Roche, Dragonfly, Prescient, Ossium, and Myeloid Therapeutics. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31961925</ArticleId><ArticleId IdType="pmc">PMC7180081</ArticleId><ArticleId IdType="doi">10.1182/blood.2019001815</ArticleId><ArticleId IdType="pii">S0006-4971(20)62081-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yoshida N, Karube K, Utsunomiya A, et al. . Molecular characterization of chronic-type adult T-cell leukemia/lymphoma. Cancer Res. 2014;74(21):6129-6138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25320005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, et al. . Aberrant PD-L1 expression through 3&#8242;-UTR disruption in multiple cancers. Nature. 2016;534(7607):402-406.</Citation><ArticleIdList><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Iwanaga M, Yasunaga JI, et al. . Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215-225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N, Weinstock DM. Clinicogenetic risk modeling in ATL. Blood. 2018;131(2):159-160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757693</ArticleId><ArticleId IdType="pubmed">29326350</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T, Ohno Y, Tsugane S, et al. . Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res. 1989;80(3):191-195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917708</ArticleId><ArticleId IdType="pubmed">2498254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Iwanaga M, Imaizumi Y, et al. . Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: a nationwide survey. Cancer Sci. 2017;108(12):2478-2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715256</ArticleId><ArticleId IdType="pubmed">28905463</ArticleId></ArticleIdList></Reference><Reference><Citation>Muto R, Miyoshi H, Sato K, et al. . Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018;7(11):5843-5858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247037</ArticleId><ArticleId IdType="pubmed">30311404</ArticleId></ArticleIdList></Reference><Reference><Citation>Soda M, Choi YL, Enomoto M, et al. . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625570</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernt KM, Hunger SP. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol. 2014;4:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971203</ArticleId><ArticleId IdType="pubmed">24724051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SY, Yoshida N, Christie AL, et al. . Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964252</ArticleId><ArticleId IdType="pubmed">29789628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallois D, Dupuy A, Lemonnier F, et al. . RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica. 2018;103(8):e360-e363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068042</ArticleId><ArticleId IdType="pubmed">29545337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227-242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohr J, Guo S, Huo J, et al. . Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia. 2016;30(5):1062-1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688878</ArticleId><ArticleId IdType="pubmed">26719098</ArticleId></ArticleIdList></Reference><Reference><Citation>Shindoh N, Yoda A, Yoda Y, et al. . Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One. 2012;7(11):e49201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492311</ArticleId><ArticleId IdType="pubmed">23145123</ArticleId></ArticleIdList></Reference><Reference><Citation>Boomer JS, Deppong CM, Shah DD, Bricker TL, Green JM. Cutting edge: a double-mutant knockin of the CD28 YMNM and PYAP motifs reveals a critical role for the YMNM motif in regulation of T cell proliferation and Bcl-xL expression. J Immunol. 2014;192(8):3465-3469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994466</ArticleId><ArticleId IdType="pubmed">24639356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai YC, Cefai D, Schneider H, Raab M, Nabavi N, Rudd CE. Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity. 1995;3(4):417-426.</Citation><ArticleIdList><ArticleId IdType="pubmed">7584133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui E, Cheung J, Zhu J, et al. . T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286077</ArticleId><ArticleId IdType="pubmed">28280247</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo HY, Kim P, Kim WS, et al. . Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica. 2016;101(6):757-763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013939</ArticleId><ArticleId IdType="pubmed">26819049</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989-1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942846</ArticleId><ArticleId IdType="pubmed">27192565</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruhashi T, Okazaki IM, Sugiura D, et al. . LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol. 2018;19(12):1415-1426.</Citation><ArticleIdList><ArticleId IdType="pubmed">30349037</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncador G, Garcia JF, Garcia JF, et al. . FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia. 2005;19(12):2247-2253.</Citation><ArticleIdList><ArticleId IdType="pubmed">16193085</ArticleId></ArticleIdList></Reference><Reference><Citation>Karube K, Aoki R, Sugita Y, et al. . The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol. 2008;21(5):617-625.</Citation><ArticleIdList><ArticleId IdType="pubmed">18246047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen ED, Weinstock DM. Challenges and implications of genomics for T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2018;2018:63-68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6246015</ArticleId><ArticleId IdType="pubmed">30504292</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekulic A, Liang WS, Tembe W, et al. . Personalized treatment of S&#233;zary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med. 2015;3(2):130-136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367085</ArticleId><ArticleId IdType="pubmed">25802883</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz SM, Koch R, Porcu P, et al. . Activity of the PI3K-&#948;,&#947; inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888-898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824337</ArticleId><ArticleId IdType="pubmed">29233821</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Cook LBM, Rowan AG, Satou Y, Taylor GP, Bangham CRM. Phosphatidylinositol 3-kinase-&#948; (PI3K-&#948;) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomark Res. 2018;6:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052569</ArticleId><ArticleId IdType="pubmed">30034808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36828681</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1681</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Blood reviews</Title><ISOAbbreviation>Blood Rev</ISOAbbreviation></Journal><ArticleTitle>Prospects of early therapeutic interventions for indolent adult T-cell leukemia/lymphoma based on the chronic lymphocytic leukemia progression model.</ArticleTitle><Pagination><StartPage>101057</StartPage><MedlinePgn>101057</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.blre.2023.101057</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0268-960X(23)00018-8</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) has aggressive clinical behaviors, and improving its prognosis is a great challenge. A disease progression model from asymptomatic human T-cell leukemia virus type 1 carrier to aggressive-type ATLL has been proposed, and indolent ATLL comprising a smoldering or favorable chronic type is located at the midpoint. Even the most favorable smoldering type has a 4-year overall survival rate of &lt;60%. Although watchful waiting is pervasive in patients with indolent ATLL, early therapeutic intervention is discussed among hematologists. Indolent ATLL was once termed T-cell-derived chronic lymphocytic leukemia (CLL). Unlike indolent ATLL, several molecular-targeted agents at the initial treatment have dramatically improved CLL prognosis. Recent studies on CLL have revealed a similar progression model involving premalignant monoclonal B-cell lymphocytosis (MBL). In particular, individuals with high-count MBL have an increased lymphoma risk. Considering the unsatisfactory long-term prognosis of indolent ATLL, further treatment strategies, including precision medicine, are warranted.</AbstractText><CopyrightInformation>Copyright &#169; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohmoto</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 1358550, Japan; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Osaka International Cancer Institute, Osaka, 5418567, Japan. Electronic address: fujishige1231@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01712659</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Blood Rev</MedlineTA><NlmUniqueID>8708558</NlmUniqueID><ISSNLinking>0268-960X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015451">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D000970">Antineoplastic Agents</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CLL</Keyword><Keyword MajorTopicYN="N">Early therapeutic intervention</Keyword><Keyword MajorTopicYN="N">Indolent ATLL</Keyword><Keyword MajorTopicYN="N">Monoclonal B-cell lymphocytosis</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>22</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36828681</ArticleId><ArticleId IdType="doi">10.1016/j.blre.2023.101057</ArticleId><ArticleId IdType="pii">S0268-960X(23)00018-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20962495</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[ATL].</ArticleTitle><Pagination><StartPage>1595</StartPage><EndPage>1606</EndPage><MedlinePgn>1595-606</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20962495</ArticleId><ArticleId IdType="pii">JST.JSTAGE/rinketsu/51.1595</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25613789</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cancer science</Title><ISOAbbreviation>Cancer Sci</ISOAbbreviation></Journal><ArticleTitle>Recent advances in the treatment of adult T-cell leukemia-lymphomas.</ArticleTitle><Pagination><StartPage>344</StartPage><EndPage>351</EndPage><MedlinePgn>344-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.12617</ELocationID><Abstract><AbstractText>Recent advances in treatment for adult T-cell leukemia-lymphoma (ATL) are reviewed herein. It is currently possible to select a therapeutic strategy for ATL and predict prognosis by classification of patients by clinical subtypes and clinicopathological factors. Although the overall survival (OS) of patients with ATL has increased marginally because of advances in chemotherapy, further prolongation of survival might be difficult with conventional chemotherapy alone. Promising results have been reported for antiviral therapy using zidovudine and interferon-&#945;, and, indeed, antiviral therapy is currently the standard treatment for patients with ATL in western countries. Remarkably, the 5-year OS rates are 100% for both the smoldering-type and chronic-type ATL. Recently, treatments for ATL have included allogeneic hematopoietic stem cell transplantation and molecular targeted therapies. Furthermore, the anti-CCR4 monoclonal antibody mogamulizumab has been shown to have marked cytotoxic effects on ATL cells, especially in the leukemic type of ATL. In the lymphoma type of ATL, the response rate may be improved by combining mogamulizumab with chemotherapy. It should be recognized that prevention of infection from carriers of human T-cell leukemia virus type-I and transfer of the virus from mother to infant are crucial issues for the eradication of ATL.</AbstractText><CopyrightInformation>&#169; 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ilseung</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Chihara</LastName><ForeName>Dai</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Seto</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Sci</MedlineTA><NlmUniqueID>101168776</NlmUniqueID><ISSNLinking>1347-9032</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064987">Cell- and Tissue-Based Therapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018894">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">antiviral therapy</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">molecular targeted therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25613789</ArticleId><ArticleId IdType="pmc">PMC4409876</ArticleId><ArticleId IdType="doi">10.1111/cas.12617</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481&#8211;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Ann Rev Immunol. 2001;19:475&#8211;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244044</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T, Matsuoka M. HBZ and its roles in HTLV-1 oncogenesis. Front Microbilol. 2012;3:247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391691</ArticleId><ArticleId IdType="pubmed">22787458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87) Br J Haematol. 1991;79:428&#8211;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood. 2001;98:1160&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493465</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W, Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, et al. Treatment of adult T-cell leukemia lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749&#8211;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinpara S, Kijiyama M, Takamori A, et al. Interferon-&#945; (IFN-&#945;) suppresses HTLV-1 gene expression and cell cycling, while IFN-&#945; combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 2013;10:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698133</ArticleId><ArticleId IdType="pubmed">23688327</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058&#8211;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2012;84:327&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22170555</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D, Ito H, Matsuda T, et al. Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT) Blood Cancer J. 2013;3:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880440</ArticleId><ArticleId IdType="pubmed">24241399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D, Ito H, Katanoda K, et al. Increase in incidence of adult T-cell leukemia/lymphoma in non-endemic areas of Japan and the United States. Cancer Sci. 2012;103:1857&#8211;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7659271</ArticleId><ArticleId IdType="pubmed">22738276</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, editor. Adult T-Cell Leukemia. Oxford: Oxford University Press; 1994. pp. 221&#8211;37.</Citation></Reference><Reference><Citation>Lymphoma Study Group (1984&#8211;1987) Major prognostic factors of patients with adult T-cell leukemia lymphoma: a cooperative study. Leuk Res. 1991;15:81&#8211;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">2016910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K. Clinical trials and treatment of ATL. Leuk Res Treatment. 2012;2012:101754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3505932</ArticleId><ArticleId IdType="pubmed">23259064</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Ramos JC, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop. 2010;50:9&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">20505272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K, Hotta T, Shimoyama M. Lymphoma Study Group of JCOG. Jpn J Clin Oncol. 2012;42:85&#8211;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22147803</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23:87&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037056</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105:4143&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I, Tanosaki R, Uike N, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant. 2011;46:116&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20400987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2013. The Japanese Data Center for Hematopoietic Cell Transplantation/The Japan Society for Hematopoietic Cell Transplantation 2014, 15 March 2014.</Citation></Reference><Reference><Citation>Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536&#8211;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907701</ArticleId><ArticleId IdType="pubmed">24245986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2011;116:1369&#8211;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22234682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734&#8211;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49:1266&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64:391&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14729650</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Utsunomiya A, Takatsuka Y, et al. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1029&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">18332910</ArticleId></ArticleIdList></Reference><Reference><Citation>Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood. 2013;121:219&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M, Harashima N, Kurihara K, et al. Tumor immunity against adult T-cell leukemia. Cancer Sci. 2005;96:249&#8211;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15904464</ArticleId></ArticleIdList></Reference><Reference><Citation>Suehiro Y, Hasegawa A, Iino T, et al.  Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T-cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015 ; doi:  10.1111/bjh.13302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13302</ArticleId><ArticleId IdType="pubmed">25612920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517&#8211;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118:1736&#8211;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long- term study of indolent adult T-cell leukemia lymphoma. Blood. 2010;115:4337&#8211;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625&#8211;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520&#8211;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761 for relapsed adult T-cell leukemia lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive ATL: a randomized phase II study. Br J Haematol. 2015 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia. 2004;18:1357&#8211;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190257</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T, Ohno Y, Tsugane S, et al. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res. 1989;80:191&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917708</ArticleId><ArticleId IdType="pubmed">2498254</ArticleId></ArticleIdList></Reference><Reference><Citation>Umino A, Nakagawa M, Utsunomiya A, et al. Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes. Blood. 2011;117:5473&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21447829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham CR, Cook LB, Melamed A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. Semin Cancer Biol. 2014;26:89&#8211;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062949</ArticleId><ArticleId IdType="pubmed">24316494</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448111</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer. 1989;43:250&#8211;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka C, Ikezoe T, Yang J, et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor &#954;B. Leuk Res. 2008;32:287&#8211;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31769871</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0142</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.</ArticleTitle><Pagination><StartPage>567</StartPage><EndPage>574</EndPage><MedlinePgn>567-574</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.32556</ELocationID><Abstract><AbstractText Label="BACKGROUND">Globally, 5&#160;million to 10&#160;million people are infected with human T-cell leukemia virus type 1, which causes adult T-cell leukemia/lymphoma (ATLL) in 2% to 5% of the carriers. ATLL is a rare but extremely aggressive malignancy that can be challenging to diagnose. Very little data exist on the incidence patterns of ATLL in the United States.</AbstractText><AbstractText Label="METHODS">ATLL cases reported to the National Program of Cancer Registries, the Surveillance, Epidemiology, and End Results (SEER) program, and the New York State Cancer Registry were used for the study. Age-adjusted incidence rates were calculated by age, race/ethnicity, sex, and year of diagnosis. The 5-year survival rate was compared among race/ethnicity groups with the SEER data.</AbstractText><AbstractText Label="RESULTS">During 2001-2015, 2148 ATLL cases were diagnosed in the United States, 18% of which were in New York State. New York State had the highest incidence rate for ATLL, with a rising trend especially among non-Hispanic blacks (NHBs), whereas the incidence was stable across the remainder of the United States. NHBs were diagnosed at a younger median age (54&#160;years) and had a shorter overall survival (6&#160;months). In New York City, only 22.6% of the ATLL cases diagnosed were born in North America.</AbstractText><AbstractText Label="CONCLUSIONS">This is the largest epidemiological study of ATLL in the United States and shows a rising incidence in New York City. NHBs have a younger age at presentation and poor overall survival. The rising incidence is largely due to NHBs originating from the Caribbean.</AbstractText><CopyrightInformation>&#169; 2019 American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Urvi A</ForeName><Initials>UA</Initials><Identifier Source="ORCID">0000-0001-8419-1091</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nishi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Baozhen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>New York State Cancer Registry, New York State Department of Health, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acuna-Villaorduna</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Kith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adrianzen Herrera</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sica</LastName><ForeName>R Alejandro</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shastri</LastName><ForeName>Aditi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3650-0800</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantzaris</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derman</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornblum</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braunschweig</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>B Hilda</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janakiram</LastName><ForeName>Murali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008223">Lymphoma</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009519">New York City</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009656">North America</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018426">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044465">White People</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">National Program of Cancer Registries (NPCR)</Keyword><Keyword MajorTopicYN="N">New York</Keyword><Keyword MajorTopicYN="N">New York State Cancer Registry (NYSCR)</Keyword><Keyword MajorTopicYN="N">Surveillance</Keyword><Keyword MajorTopicYN="N">United States</Keyword><Keyword MajorTopicYN="N">adult T cell</Keyword><Keyword MajorTopicYN="N">and End Results (SEER)</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">human T-cell leukemia virus</Keyword><Keyword MajorTopicYN="N">leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">non-Hodgkin lymphoma</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement><b>Conflict of Interest Statement</b>: The authors have no relevant conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31769871</ArticleId><ArticleId IdType="mid">NIHMS1635639</ArticleId><ArticleId IdType="pmc">PMC7978489</ArticleId><ArticleId IdType="doi">10.1002/cncr.32556</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gallo RC, Willems L, Hasegawa H, Global Virus Network&#8217;s Task Force on H. Screening transplant donors for HTLV-1 and &#8722;2. Blood. 2016;128(26):3029&#8211;3031.</Citation><ArticleIdList><ArticleId IdType="pubmed">28034870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YB, Kaidarova Z, Hindes D, et al. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000&#8211;2009. J Infect Dis. 2014;209(4):523&#8211;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903373</ArticleId><ArticleId IdType="pubmed">24068702</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA. 2000;284(2):229&#8211;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">10889598</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AE, Fang CT, Slamon DJ, et al. Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science. 1988;240(4852):643&#8211;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">2896386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell M, Assal A, Derman O, et al. Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239529</ArticleId><ArticleId IdType="pubmed">27341021</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607&#8211;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="pubmed">29545256</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116(14):3438&#8211;3446.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Chung EY, Giricz O, et al. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018;132(14):1507&#8211;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="pubmed">30104217</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol. 2016;34(9):963&#8211;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070555</ArticleId><ArticleId IdType="pubmed">26962200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D, Ito H, Katanoda K, et al. Increase in incidence of adult T-cell leukemia/lymphoma in non-endemic areas of Japan and the United States. Cancer Sci. 2012;103(10):1857&#8211;1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7659271</ArticleId><ArticleId IdType="pubmed">22738276</ArticleId></ArticleIdList></Reference><Reference><Citation>KJA T. A Demographic Profile of Black Caribbean Immigrants In the United States. Washington DC: Migration Policy Institute. 2012.</Citation></Reference><Reference><Citation>Paiva A, Casseb J. Sexual transmission of human T-cell lymphotropic virus type 1. Rev Soc Bras Med Trop. 2014;47(3):265&#8211;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">25075475</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosadas C, Taylor GP. Mother-to-Child HTLV-1 Transmission: Unmet Research Needs. Front Microbiol. 2019;10:999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517543</ArticleId><ArticleId IdType="pubmed">31134031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Iwanaga M, Imaizumi Y, et al. Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010&#8211;2011: A nationwide survey. Cancer Sci. 2017;108(12):2478&#8211;2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715256</ArticleId><ArticleId IdType="pubmed">28905463</ArticleId></ArticleIdList></Reference><Reference><Citation>Blattner WA, Nomura A, Clark JW, et al. Modes of transmission and evidence for viral latency from studies of human T-cell lymphotrophic virus type I in Japanese migrant populations in Hawaii. Proc Natl Acad Sci U S A. 1986;83(13):4895&#8211;4898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323850</ArticleId><ArticleId IdType="pubmed">3014518</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997&#8211;2002. Cancer Causes Control. 2008;19(4):379&#8211;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064533</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87). Br J Haematol. 1991;79(3):428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo JN, Schoenbach VJ. The potential and limitations of data from population-based state cancer registries. Am J Public Health. 2000;90(5):695&#8211;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1446235</ArticleId><ArticleId IdType="pubmed">10800415</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez AD, Hirschman C. The Changing Racial and Ethnic Composition of the US Population: Emerging American Identities. Popul Dev Rev. 2009;35(1):1&#8211;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882688</ArticleId><ArticleId IdType="pubmed">20539823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22773213</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2012</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2078-2101</ISSN><JournalIssue CitedMedium="Print"><Issue>12</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Gulf journal of oncology</Title><ISOAbbreviation>Gulf J Oncolog</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>37</EndPage><MedlinePgn>27-37</MedlinePgn></Pagination><Abstract><AbstractText>The adult T-cell leukemia/lymphoma (ATLL) syndromes comprise neoplasms that arise in peripheral lymphoid tissues but a high frequency present with blood involvement mimicking T-cell leukemia. Clinically ATLL is sub-classified into four groups: acute, lymphomatous, chronic and smoldering. ATLL is etiologically linked to the human T-cell lymphotropic virus type I (HTLV-I). The diagnosis of ATLL is based upon a combination of characteristic clinical manifestations, morphological and immunophenotypic changes of the malignant cells, in addition to the confirmation of HTLV-I infection. ATLL is an aggressive malignancy with a median survival of less than 12 months and no successful treatment yet available. Patients are either refractory or only transiently respond to chemotherapy or purine analogues. Smoldering and chronic ATLL pursue an indolent course and survival for years until the disease progresses and becomes refractory to therapy. The major causes of death in ATLL are opportunistic pulmonary infections and progressive disease, often in association with hypercalcemia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rasul</LastName><ForeName>K I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Al-Amal Hospital, Hamad Medical Corporation, Doha, Qatar. kakil954@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barwari</LastName><ForeName>Z A</ForeName><Initials>ZA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Kuwait</Country><MedlineTA>Gulf J Oncolog</MedlineTA><NlmUniqueID>101500911</NlmUniqueID><ISSNLinking>2078-2101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22773213</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34349061</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>7</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Development of future treatment for ATL].</ArticleTitle><Pagination><StartPage>766</StartPage><EndPage>773</EndPage><MedlinePgn>766-773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.62.766</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by human T-cell leukemia virus type I. The clinical course of ATL is heterogeneous, and this condition has different types, which are as follows: acute, lymphoma, chronic, and smoldering. The chronic type is further subclassified into favorable and unfavorable subtypes. Acute, lymphoma, and unfavorable chronic type ATL and favorable chronic and smoldering-type ATL are defined as aggressive and indolent ATL, respectively. Newly identified prognostic indices based on clinical parameters and/or genetic predictors should be incorporated in the stratified treatment approach. The standard of care for aggressive ATL is multiagent chemotherapy, followed by allogeneic hematopoietic stem cell transplantation if applicable. Meanwhile, that for indolent ATL is watchful waiting until progression to the aggressive type. The combination of interferon-&#945; and zidovudine is a treatment option for indolent ATL in other countries, and a confirmatory phase 3 trial is ongoing in Japan. In addition to mogamulizumab, lenalidomide, and brentuximab vedotin, which have been recently utilized in clinical practice, the use of a novel histone deacetylase (HDAC) inhibitor has been filed for approval. Moreover, an EZH1/2 inhibitor has completed the enrollment of a phase 2 trial in Japan. The standard of care for elderly patients should be established because the median age of those with newly diagnosed ATL reaches up to 70 years old.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATL</Keyword><Keyword MajorTopicYN="N">Novel treatment</Keyword><Keyword MajorTopicYN="N">Prognostic index</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34349061</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.62.766</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2185999</PMID><DateCompleted><Year>1990</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0011-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>1990</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of dermatology</Title><ISOAbbreviation>Int J Dermatol</ISOAbbreviation></Journal><ArticleTitle>HTLV-I.</ArticleTitle><Pagination><StartPage>161</StartPage><EndPage>165</EndPage><MedlinePgn>161-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock 72205.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavanaugh</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Dermatol</MedlineTA><NlmUniqueID>0243704</NlmUniqueID><ISSNLinking>0011-9059</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000163">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001803">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>51</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2185999</ArticleId><ArticleId IdType="doi">10.1111/j.1365-4362.1990.tb03791.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">34735653</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1534-6269</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Current oncology reports</Title><ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation></Journal><ArticleTitle>Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.</ArticleTitle><Pagination><StartPage>141</StartPage><MedlinePgn>141</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11912-021-01138-3</ELocationID><Abstract><AbstractText Label="PURPOSE OF THE REVIEW">Adult T-cell leukemia (ATL) is an aggressive chemo-resistant malignancy secondary to HTLV-1 retrovirus. Prognosis of ATL remains dismal. Herein, we emphasized on the current ATL treatment modalities and their drawbacks, and opened up on promising targeted therapies with special focus on the HTLV-1 regulatory proteins Tax and HBZ.</AbstractText><AbstractText Label="RECENT FINDINGS">Indolent ATL and a fraction of acute ATL exhibit long-term survival following antiviral treatment with zidovudine and interferon-alpha. Monoclonal antibodies such as mogamulizumab improved response rates, but with little effect on survival. Allogeneic hematopoietic cell transplantation results in long-term survival in one third of transplanted patients, alas only few patients are transplanted. Salvage therapy with lenalidomide in relapsed/refractory patients leads to prolonged survival in some of them. ATL remains an unmet medical need. Targeted therapies focusing on the HTLV-1 viral replication and/or viral regulatory proteins, as well as on the host antiviral immunity, represent a promising approach for the treatment of ATL.</AbstractText><CopyrightInformation>&#169; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hleihel</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkouche</LastName><ForeName>Abdou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skayneh</LastName><ForeName>Hala</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institut Imagine-INSERM U1163, Necker Hospital, University of Paris, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazarbachi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. bazarbac@aub.edu.lb.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. bazarbac@aub.edu.lb.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Hajj</LastName><ForeName>Hiba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. he21@aub.edu.lb.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Oncol Rep</MedlineTA><NlmUniqueID>100888967</NlmUniqueID><ISSNLinking>1523-3790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074322">Antineoplastic Agents, Immunological</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HBZ</Keyword><Keyword MajorTopicYN="N">Human T lymphotropic virus type 1</Keyword><Keyword MajorTopicYN="N">Regulatory proteins</Keyword><Keyword MajorTopicYN="N">Tax</Keyword><Keyword MajorTopicYN="N">adult T-cell leukemia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>17</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34735653</ArticleId><ArticleId IdType="doi">10.1007/s11912-021-01138-3</ArticleId><ArticleId IdType="pii">10.1007/s11912-021-01138-3</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><ReferenceList><Title>Papers of particular interest, published recently, have been highlighted as: &#8226; Of importance &#8226;&#8226; Of major importance</Title><Reference><Citation>Afonso PV, Mekaouche M, Mortreux F, Toulza F, Moriceau A, Wattel E, Gessain A, Bangham CR, Dubreuil G, Plumelle Y, Hermine O, Estaquier J, Mahieux R. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. 2010;116(19):3802&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20587783</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonso PV, Cassar O, Gessain A. Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes. Retrovirology. 2019;16(1):39.</Citation><ArticleIdList><ArticleId IdType="pubmed">31842895</ArticleId><ArticleId IdType="pmc">6916231</ArticleId></ArticleIdList></Reference><Reference><Citation>Akagi T, Ono H, Shimotohno K. Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood. 1995;86(11):4243&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7492783</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkouche A, Moodad S, Hleihel R, Skayneh H, Chambeyron S, El Hajj H, Bazarbachi A. In vivo antagonistic role of the human T-cell leukemia virus type 1 regulatory proteins Tax and HBZ. PLoS Pathog.&#160;2021;17(1):e1009219.</Citation></Reference><Reference><Citation>Asquith B, Bangham CR. How does HTLV-I persist despite a strong cell-mediated immune response? Trends Immunol. 2008;29(1):4&#8211;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18042431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai XT, Nicot C. Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis. Front Microbiol. 2012;3:400.</Citation><ArticleIdList><ArticleId IdType="pubmed">23248621</ArticleId><ArticleId IdType="pmc">3518833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham CRM. Human T cell leukemia virus type 1: persistence and pathogenesis. Annu Rev Immunol. 2018;36:43&#8211;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29144838</ArticleId></ArticleIdList></Reference><Reference><Citation>Baratella M, Forlani G, Accolla RS. HTLV-1 HBZ viral protein: a key player in HTLV-1 mediated diseases. Front Microbiol. 2017;8:2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">29312275</ArticleId><ArticleId IdType="pmc">5744428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(Suppl 1):S186&#8211;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de Th&#233; H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93(1):278&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">9864171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Nasr R, El-Sabban ME, Mah&#233; A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix MK, de Th&#233; H, Hermine O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia. 2000;14(4):716&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Abou Merhi R, Gessain A, Talhouk R, El-Khoury H, Nasr R, Gout O, Sulahian R, Homaidan F, de Th&#233; H, Hermine O, El-Sabban ME. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res. 2004a;64(6):2039&#8211;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de Th&#233; H, El-Sabban ME, Hermine O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004b;5(11):664&#8211;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177&#8211;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118(7):1736&#8211;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, Nagler A, Mohty M, Sureda A, Dreger P, Hermine O. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49(10):1266&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Belrose G, Gross A, Olindo S, L&#233;zin A, Dueymes M, Komla-Soukha I, Smadja D, Tanaka Y, Willems L, Mesnard JM, Peloponese JM Jr, C&#233;saire R. Effects of valproate on Tax and HBZ expression in HTLV-1 and HAM/TSP T lymphocytes. Blood. 2011;118(9):2483&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">21505188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittencourt AL, da Gra&#231;as Vieira M, Brites CR, Farre L, Barbosa HS. Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol. 2007;128(5):875&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17951212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunn PA Jr, Schechter GP, Jaffe E, Blayney D, Young RC, Matthews MJ, Blattner W, Broder S, Robert-Guroff M, Gallo RC. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med. 1983;309(5):257&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6602943</ArticleId></ArticleIdList></Reference><Reference><Citation>Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, Bazarbachi A, Hermine O. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia. 2008;22(1):42&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898788</ArticleId></ArticleIdList></Reference><Reference><Citation>Catovsky D, Rose M, Goolden AWG, White JM, Bourikas G, Brownell AI, Blattner WA, Greaves MF, Galton DAG, McCluskey DR, Lampert I, Ireland R, Bridges JM, Gallo RC. Adult t-cell lymphoma-leukaemia in blacks from the west indies. The Lancet. 1982;319(8273):639&#8211;43.</Citation></Reference><Reference><Citation>Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood. 2009;113(6):1287&#8211;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">18948574</ArticleId><ArticleId IdType="pmc">2637191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677&#8211;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">30657736</ArticleId><ArticleId IdType="pmc">6494249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Th&#233; H, Bazarbachi A. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood. 2015;125(3):474&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">25395419</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108(3):1021&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16569765</ArticleId><ArticleId IdType="pmc">1895862</ArticleId></ArticleIdList></Reference><Reference><Citation>Dbaibo GS, Kfoury Y, Darwiche N, Panjarian S, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de The H, Bazarbachi A. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica. 2007;92(6):753&#8211;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17550847</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer. 1991;64(5):903&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1931613</ArticleId><ArticleId IdType="pmc">1977476</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y, Nicot C, Hermine O, Hall W, de Th&#233; H, Bazarbachi A. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. The Journal of experimental medicine. 2010a;207(13):2785&#8211;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21135137</ArticleId><ArticleId IdType="pmc">3005222</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y, Nicot C, Hermine O, Hall W, de Th&#233; H, Bazarbachi A. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010b;207(13):2785&#8211;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21135137</ArticleId><ArticleId IdType="pmc">3005222</ArticleId></ArticleIdList></Reference><Reference><Citation>El Hajj H, Tsukasaki K, Cheminant M, Bazarbachi A, Watanabe T, Hermine O. Novel Treatments of Adult T Cell Leukemia Lymphoma. Front Microbiol. 2020;11:1062.</Citation><ArticleIdList><ArticleId IdType="pubmed">32547515</ArticleId><ArticleId IdType="pmc">7270167</ArticleId></ArticleIdList></Reference><Reference><Citation>&#8226; El Hajj, H., R. Hleihel, M. El Sabban, J. Bruneau, G. Zaatari, M. Cheminant, A. Mar&#231;ais, A. Akkouche, H. Hasegawa, W. Hall, H. De Th&#233;, O. Hermine and A. Bazarbachi (2021). "Loss of interleukin-10 activates innate immunity to eradicate adult T cell leukemia initiating cells." Haematologica. This study highlights the importance of sequential targeting of malignant ATL cells and their immune microenvironment in leukemia initiating cell eradication to reach cure.</Citation></Reference><Reference><Citation>El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de Th&#233; H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96(8):2849&#8211;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11023521</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sabban ME, Merhi RA, Haidar HA, Arnulf B, Khoury H, Basbous J, Nijmeh J, de Th&#233; H, Hermine O, Bazarbachi A. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood. 2002;99(9):3383&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11964307</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, Yamochi T, Nakashima M, Kobayashi S, Tanaka Y, Iwanaga M, Utsunomiya A, Uchimaru K, Yamagishi M, Watanabe T. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790&#8211;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">26773042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, Tanosaki R, Utsunomiya A, Uike N, Yoshida S, Okamura J, Tomonaga M. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19(5):829&#8211;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002;76(24):12813&#8211;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12438606</ArticleId><ArticleId IdType="pmc">136662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A. Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases. Bull Soc Pathol Exot. 2011;104(3):167&#8211;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">21796326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Francis H, Sonan T, Giordano C, Akani F, Piquemal M, Caudie C, Malone G, Essex M, de-Th&#233; G (1986) HTLV-I and tropical spastic paraparesis in Africa. Lancet 2(8508):698</Citation></Reference><Reference><Citation>Giam CZ, Semmes OJ. HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ. Viruses. 2016;8(6).</Citation></Reference><Reference><Citation>Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92(4):1057&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">7862633</ArticleId><ArticleId IdType="pmc">42636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood. 2000;95(4):1386&#8211;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10666215</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington WJJ, Ucar A, Gill P, Snodgrass S, Sheremata W, Cabral L, Rabin M, Byrne GEJ, Berger J, Voight W, Kemper R, Miller G, Whitcomb CC, Greenberg A, Byrnes JJ, Poiesz B. Clinical Spectrum of HTLV-I in South Florida. JAIDS Journal of Acquired Immune Deficiency Syndromes. 1995;8(5):466&#8211;73.</Citation></Reference><Reference><Citation>Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Katano H, Takahashi H, Matsuda J, Sata T, Kurata T, Nagashima K, Hall WW. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12(4):466&#8211;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16550188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D, Usui T, Osaka A, Atogami S, Ishikawa C, Machijima Y, Sawada S, Hayashi T, Miyazaki Y, Kamihira S. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia. 2011;25(4):575&#8211;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">21242994</ArticleId><ArticleId IdType="pmc">3089964</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749&#8211;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A, A. T. L. t. g. French. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Dombret H, Poupon J, Arnulf B, Lefr&#232;re F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, Degos L, Varet B, de Th&#233; H, Bazarbachi A. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5(2):130&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369&#8211;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, Kumaran T, Ardeshna KM, Pagliuca A, Taylor GP, Fields PA. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29(35):4696&#8211;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30522922</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA. Corrigendum to &#8216;efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis&#8217; [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700]. Biol Blood Marrow Transplant. 2020;26(1):209&#8211;212. https://doi.org/10.1016/j.bbmt.2019.09.014 .</Citation></Reference><Reference><Citation>Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">25733162</ArticleId><ArticleId IdType="pmc">5024033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086&#8211;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature. 1990;348(6298):245&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2146511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagdi H, Demontis MA, Ramos JC, Taylor GP. Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infection. PLoS Pathog. 2018;14(2):e1006861.</Citation><ArticleIdList><ArticleId IdType="pubmed">29444188</ArticleId><ArticleId IdType="pmc">5828519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, et al. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol. 1991;3(8):761&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1911545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy. Cancer Sci. 2019;110(3):849&#8211;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30666755</ArticleId><ArticleId IdType="pmc">6398881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, Shibuya T, Utsunomiya A, Kawase T, Kato S, Morishima Y, Kodera Y, Harada M. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant. 2007;13(1):90&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Amano M, Hino R, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar MM, Shirdel A, Rastin M, Rafatpanah H, Tarhini M, Zalloua PA, Hermine O, Farid R, Bazarbachi A. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma. 2007;48(2):330&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rezaee SA, Yazdi MT, Shirdel A, de Th&#233; H, Hermine O, Farid R, Bazarbachi A. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113(26):6528&#8211;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">19411628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kchour G, Rezaee R, Farid R, Ghantous A, Rafatpanah H, Tarhini M, Kooshyar MM, El Hajj H, Berry F, Mortada M, Nasser R, Shirdel A, Dassouki Z, Ezzedine M, Rahimi H, Ghavamzadeh A, de The H, Hermine O, Mahmoudi M, Bazarbachi A. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology. 2013;10:91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23962110</ArticleId><ArticleId IdType="pmc">3751834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury Y, Nasr R, Favre-Bonvin A, El-Sabban M, Renault N, Giron ML, Setterblad N, Hajj HE, Chiari E, Mikati AG, Hermine O, Saib A, de Th&#233; H, Pique C, Bazarbachi A. Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome. Oncogene. 2008;27(12):1665&#8211;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17891179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury Y, Setterblad N, El-Sabban M, Zamborlini A, Dassouki Z, El Hajj H, Hermine O, Pique C, de Th&#233; H, Sa&#239;b A, Bazarbachi A. Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood. 2011;117(1):190&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury Y, Nasr R, Journo C, Mahieux R, Pique C, Bazarbachi A. The multifaceted oncoprotein Tax: subcellular localization, posttranslational modifications, and NF-&#954;B activation. Adv Cancer Res. 2012;113:85&#8211;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">22429853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T, Tanaka Y, Utsunomiya A, Kannagi M. Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 2013;10:52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23688327</ArticleId><ArticleId IdType="pmc">3698133</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marcais A, Marino-Merlo F, Turpin J, Bangham CR, Hermine O, Mastino A, Bazarbachi A. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-alpha. Blood Adv. 2017;1(12):748&#8211;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">29296718</ArticleId><ArticleId IdType="pmc">5728049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahgoub M, Yasunaga JI, Iwami S, Nakaoka S, Koizumi Y, Shimura K, Matsuoka M. Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc Natl Acad Sci USA. 2018;115(6):E1269&#8211;e1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">29358408</ArticleId><ArticleId IdType="pmc">5819419</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, Harrington T, Barber GN, Ramos JC. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29545256</ArticleId><ArticleId IdType="pmc">5873228</ArticleId></ArticleIdList></Reference><Reference><Citation>&#8226;&#8226; Marcais A, Cook L, Witkover A, Asnafi V, Avettand-Fenoel V, Delarue R, Cheminant M, Sibon D, Frenzel L, de The H, Bangham CRM, Bazarbachi A, Hermine O, Suarez F. Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma. Retrovirology. 2020;17(1):5.&#160;This study emphasizes that consolidation with Arsenic Trioxide&#160; can be a therapeutic option for patients with ATL in response after induction therapy and who are not eligible for allogeneic stem cell transplantation.</Citation></Reference><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270&#8211;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30(12):1379&#8211;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21119600</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113(3):779&#8211;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Moodad S, Akkouche A, Hleihel R, Darwiche N, El-Sabban M, Bazarbachi A, El Hajj H. Mouse Models That Enhanced Our Understanding of Adult T Cell Leukemia. Front Microbiol. 2018;9:558.</Citation><ArticleIdList><ArticleId IdType="pubmed">29643841</ArticleId><ArticleId IdType="pmc">5882783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N, Matsuda T, Tadano M, Kinjo T, Yamada Y, Tsukasaki K, Ikeda S, Yamasaki Y, Tanaka Y, Ohta T, Iwamasa T, Tomonaga M, Yamamoto N. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol. 2004;78(9):4582&#8211;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078940</ArticleId><ArticleId IdType="pmc">387669</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, Bazarbachi A, Benhamou M, Monteiro RC, Hermine O. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood. 2004;103(5):1838&#8211;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">14592824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, Staudt L, de Th&#233; H, Bazarbachi A. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101(11):4576&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12560223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R, Chiari E, El-Sabban M, Mahieux R, Kfoury Y, Abdulhay M, Yazbeck V, Hermine O, de Th&#233; H, Pique C, Bazarbachi A. Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. Blood. 2006;107(10):4021&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16424386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R, El Hajj H, Kfoury Y, de Th&#233; H, Hermine O, Bazarbachi A. Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects? Viruses. 2011;3(6):750&#8211;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">21994752</ArticleId><ArticleId IdType="pmc">3185778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G, Jay G. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science. 1987;237(4820):1324&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2888190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A, Kuwayama Y, Togitani K, Koeffler HP, Taguchi H. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res. 2008;32(2):287&#8211;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, Aoki T, Tsukasaki K, Taguchi J, Choi I, Maruyama D, Nosaka K, Chen N, Midorikawa S, Ohtsu T, Tobinai K. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3(3):e107&#8211;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">26947199</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka S, Ono K, Nohgawa M. Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy. Leuk Res Rep. 2019;11:21&#8211;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31016134</ArticleId><ArticleId IdType="pmc">6475659</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109&#8211;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17577020</ArticleId></ArticleIdList></Reference><Reference><Citation>Osame M, Igata A, Matsumoto M, Tara M. HTLV-I-associated myelopathy. Gan To Kagaku Ryoho. 1987;14(8):2411&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2887144</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, Wandroo F, Feldman T, Taylor GP, Sawas A, Humphrey J, Kurman M, Moriya J, Dwyer K, Leoni M, Conlon K, Cook L, Gonsky J, Horwitz SM. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2019;104(5):993&#8211;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">30573506</ArticleId><ArticleId IdType="pmc">6518882</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S&#233;zary T-cell leukaemia. Nature. 1981;294(5838):268&#8211;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">6272125</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, Sohgandi L, Azarpazhooh MR, Rezaee SA, Farid R, Bazarbachi A. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011;52(3):172&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JC, Lossos IS. Newly emerging therapies targeting viral-related lymphomas. Curr Oncol Rep. 2011;13(5):416&#8211;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">21792540</ArticleId><ArticleId IdType="pmc">4041592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L. PD-1 Inhibitor Therapy in Adult T-Cell Leukemia-Lymphoma. N Engl J Med. 2018;379(7):696&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30110590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M, Consortium AM. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One. 2009;4(2):e4420.</Citation><ArticleIdList><ArticleId IdType="pubmed">19204798</ArticleId><ArticleId IdType="pmc">2636875</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood. 2009;113(7):1493&#8211;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">18971418</ArticleId><ArticleId IdType="pmc">2644076</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek MD, Ratner L. Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J Virol. 1999;73(6):4856&#8211;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">10233947</ArticleId><ArticleId IdType="pmc">112529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Choi YL, Mano H, Marquez VE, Hayashi T, Yanagihara K, Moriwaki Y, Miyazaki Y, Kamihira S, Yamada Y. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica. 2011;96(5):712&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21228036</ArticleId><ArticleId IdType="pmc">3084918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada L, Nagano Y, Hasegawa A, Kanai H, Nogami K, Ito S, Sato T, Yamano Y, Tanaka Y, Masuda T, Kannagi M. IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13(9):e1006597.</Citation><ArticleIdList><ArticleId IdType="pubmed">28910419</ArticleId><ArticleId IdType="pmc">5614654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC. Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. Clin Cancer Res. 2017;23(1):35&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27486175</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Recent progress in non-Hodgkin's lymphoma study in Japan. Gan To Kagaku Ryoho. 1988;15(12):3169&#8211;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">2904243</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428&#8211;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirinian M, Kfoury Y, Dassouki Z, El-Hajj H, Bazarbachi A. Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-&#954;B activation. Front Microbiol. 2013;4:231.</Citation><ArticleIdList><ArticleId IdType="pubmed">23966989</ArticleId><ArticleId IdType="pmc">3744011</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirinian M, Kambris Z, Hamadeh L, Grabbe C, Journo C, Mahieux R, Bazarbachi A. A Transgenic Drosophila melanogaster Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1-Driven Transformation In Vivo. J Virol. 2015;89(15):8092&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25995252</ArticleId><ArticleId IdType="pmc">4505646</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma. 2020;61(2):309&#8211;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">31617432</ArticleId></ArticleIdList></Reference><Reference><Citation>Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, Takamori A, Tanosaki R, Utsunomiya A, Choi I, Fukuda T, Miura O, Takaishi S, Teshima T, Akashi K, Kannagi M, Uike N, Okamura J. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169(3):356&#8211;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">25612920</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugata K, Yasunaga J, Mitobe Y, Miura M, Miyazato P, Kohara M, Matsuoka M. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood. 2015;126(9):1095&#8211;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">26063164</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi H, Kinoshita K-I, Takatsuki K, Tomonaga M, Araki K, Arima N, Ikeda S, Uozumi K, Kohno H, Kawano F, Kikuchi H, Takahashi H, Tamura K, Chiyoda S, Tsuda H, Nishimura H, Hosokawa T, Matsuzaki H, Momita S, et al. An Intensive Chemotherapy of Adult T-Cell Leukemia/Lymphoma: CHOP Followed by Etoposide, Vindesine, Ranimustine, and Mitoxantrone with Granulocyte Colony-Stimulating Factor Support. JAIDS Journal of Acquired Immune Deficiency Syndromes. 1996a;12(2):182&#8211;6.</Citation></Reference><Reference><Citation>Taguchi H, Kinoshita KI, Takatsuki K, Tomonaga M, Araki K, Arima N, Ikeda S, Uozumi K, Kohno H, Kawano F, Kikuchi H, Takahashi H, Tamura K, Chiyoda S, Tsuda H, Nishimura H, Hosokawa T, Matsuzaki H, Momita S, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol. 1996b;12(2):182&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8680890</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, Tomonaga M, Tsukasaki K. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115(22):4337&#8211;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatsuki K, Uchiyama T, Sagawa K, Yodoi J. Surface markers of malignant lymphoid cells in the classification of lymphoproliferative disorders, with special reference to adult T-cell leukemia (author's transl). Rinsho Ketsueki. 1976;17(4):416&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">1085377</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 1991;51(18):4903&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654204</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M, Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci USA. 1990;87(3):1071&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2300570</ArticleId><ArticleId IdType="pmc">53412</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinai K. Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park). 2009;23(14):1250&#8211;6.</Citation></Reference><Reference><Citation>Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep. 2012;7(3):235&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22538464</ArticleId><ArticleId IdType="pmc">3425744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, Ohashi Y, Ota K. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer. 1994;70(4):771&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7917938</ArticleId><ArticleId IdType="pmc">2033383</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K. Clinical Trials and Treatment of ATL. Leuk Res Treatment. 2012;2012:101754.</Citation><ArticleIdList><ArticleId IdType="pubmed">23259064</ArticleId><ArticleId IdType="pmc">3505932</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, Tomonaga M, Araki K, Kasai M, Takatsuki K, Tara M, Mikuni C, Hotta T, G. Lymphoma Study Group of the Japan Clinical Oncology. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol. 2003;77(2):164&#8211;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19064971</ArticleId><ArticleId IdType="pmc">2737379</ArticleId></ArticleIdList></Reference><Reference><Citation>&#8226;&#8226; Tsukasaki K, Marcais A, Nasr R, Kato K, Fukuda T, Hermine O, Bazarbachi A. Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. Front Microbiol. 2020;11:1207.&#160;This review provides a detailed overview on diagnostic approaches and treatment strategies of ATL.</Citation></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, Tara M, Kawano F, Saburi Y, Kikuchi H, Hara M, Sao H, Morishima Y, Kodera Y, Sonoda S, Tomonaga M. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(1):15&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonck K, Gonz&#225;lez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7(4):266&#8211;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124&#8211;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">18626005</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, Roessler E, Horak ID, Zaknoen S, Kasten-Sportes C, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82(6):1701&#8211;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8400227</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69(5):2863&#8211;8. https://doi.org/10.1128/JVI.69.5.2863-2868.1995 .</Citation></Reference><Reference><Citation>White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, Derby M, Jackson-Booth PG, Marshall M, Lucy D, Jain A, Cranston B, Hanchard B, Lee CC, Top LE, Fleisher TA, Nelson DL, Waldmann TA. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;40(3-4):287&#8211;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426550</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">20697094</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T, Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113(2):375&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, Yamaguchi K, Uchimaru K, Ogawa S, Watanabe T. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-&#954;B pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">22264793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, Katano H, Hishima T, Kobayashi S, Nakano K, Nakashima M, Iwanaga M, Utsunomiya A, Tanaka Y, Okada S, Tsukasaki K, Tobinai K, Araki K, Watanabe T, Uchimaru K. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. Cell Rep. 2019;29(8):2321&#8211;37 e2327.</Citation><ArticleIdList><ArticleId IdType="pubmed">31747604</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, Nakagawa M, Suzuki Y, Matsuoka M. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathog. 2016;12(1):e1005372.</Citation><ArticleIdList><ArticleId IdType="pubmed">26735971</ArticleId><ArticleId IdType="pmc">4703212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Utsunomiya A, Takatsuka Y, Takeuchi S, Tashiro Y, Kanzaki T, Kanekura T. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(12):1029&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">18332910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Petrus MN, Ju W, Zhang M, Conlon KC, Nakagawa M, Maeda M, Bamford RN, Waldmann TA. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model. Leukemia. 2015;29(3):556&#8211;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25118879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci. 2019;16(3):424&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30911277</ArticleId><ArticleId IdType="pmc">6428980</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood. 2009;113(12):2755&#8211;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19064727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi H, Yang L, Kuo YL, Ho YK, Shih HM, Giam CZ. NF-&#954;B hyper-activation by HTLV-1 tax induces cellular senescence, but can be alleviated by the viral anti-sense protein HBZ. PLoS Pathog. 2011;7(4):e1002025.</Citation><ArticleIdList><ArticleId IdType="pubmed">21552325</ArticleId><ArticleId IdType="pmc">3084201</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen CS, Lairmore MD. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res. 2011;35(11):1491&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21802726</ArticleId><ArticleId IdType="pmc">3191315</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28756726</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1747-4094</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert review of hematology</Title><ISOAbbreviation>Expert Rev Hematol</ISOAbbreviation></Journal><ArticleTitle>Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.</ArticleTitle><Pagination><StartPage>757</StartPage><EndPage>760</EndPage><MedlinePgn>757-760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/17474086.2017.1361819</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL) is an aggressive variant of peripheral T-cell lymphoma of CD4+&#160;T-malignant cells caused by human T-lymphotropic virus type-1. Despite aggressive treatment with multidrug combination chemotherapies, ATL confers a poor prognosis and commonly develops resistance to conventional treatments. Areas covered: Mogamulizumab is a humanized, defucosylated monoclonal antibody that acts by targeting the CC chemokine receptor 4 (CCR4) on malignant cells of ATL. In phase I and II clinical trials, it has achieved overall response rates of 31-50% in CCR4+ malignancies. The most commonly observed hematologic and non-hematologic adverse events included lymphocytopenia, neutropenia, leukocytopenia, infusion reaction, rash, and pyrexia. Expert commentary: Mogamulizumab has shown significant efficacy in treating ATL with moderately high response rates and has been approved in Japan for use in ATL. It may serve as a bridge therapy to achieve disease control prior to allogeneic hematopoietic stem cell transplantation. It also offers potential for use in combination with conventional chemotherapy. Determining the optimal combination of mogamulizumab with conventional and novel therapies remains an important strategy to improve the prognosis of patients with ATL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winsett</LastName><ForeName>Frank T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>a University of Texas McGovern Medical School at Houston , Houston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-1610-5785</Identifier><AffiliationInfo><Affiliation>b School of Medicine , Baylor College of Medicine , Houston , TX , USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Department of Dermatology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duvic</LastName><ForeName>Madeleine</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8971-4565</Identifier><AffiliationInfo><Affiliation>c Department of Dermatology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Hematol</MedlineTA><NlmUniqueID>101485942</NlmUniqueID><ISSNLinking>1747-4094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000920">Antibody-Dependent Cell Cytotoxicity</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">CC Chemokine receptor 4</Keyword><Keyword MajorTopicYN="N">Cutaneous T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">Human T-lymphotropic virus type-1</Keyword><Keyword MajorTopicYN="N">Peripheral T-cell lymphoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28756726</ArticleId><ArticleId IdType="doi">10.1080/17474086.2017.1361819</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28340877</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-1977</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Hematology/oncology clinics of North America</Title><ISOAbbreviation>Hematol Oncol Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell Leukemia/Lymphoma: A Problem Abroad and at Home.</ArticleTitle><Pagination><StartPage>255</StartPage><EndPage>272</EndPage><MedlinePgn>255-272</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hoc.2016.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-8588(16)30173-3</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a rare T-cell disorder that is etiologically linked to chronic infection with human T-cell lymphotropic virus type 1. ATLL is divided into four subtypes: acute, lymphomatous, chronic, and smoldering. The acute and lymphomatous variants are often described clinically as the aggressive types of ATLL. Treatment strategies traditionally have focused on antiviral therapy with zidovudine and interferon-alpha and combination chemotherapy. Novel therapeutic approaches include the use of monoclonal antibodies, anti-CCR4 therapy, immunomodulatory therapy, and anti-TAX vaccines. Future research must focus on multi-institutional clinical trial participation because of the rarity of this deadly hematologic malignancy.</AbstractText><CopyrightInformation>Copyright &#169; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dittus</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, University of North Carolina at Chapel Hill, 170 Manning Drive, Campus Box 7305, Chapel Hill, NC 27599-7305, USA. Electronic address: cedittus@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>J Mark</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Boston University Medical Center, 820 Harrison Avenue, FGH Building, 1st Floor, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hematol Oncol Clin North Am</MedlineTA><NlmUniqueID>8709473</NlmUniqueID><ISSNLinking>0889-8588</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000912">Antibodies, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000912">Antibodies, Neoplasm</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014765">Viral Vaccines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggressive lymphoma</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Hypercalcemia</Keyword><Keyword MajorTopicYN="N">Leukemia</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">Rare cancer</Keyword><Keyword MajorTopicYN="N">T-cell lymphoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28340877</ArticleId><ArticleId IdType="doi">10.1016/j.hoc.2016.11.005</ArticleId><ArticleId IdType="pii">S0889-8588(16)30173-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">34153661</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.</ArticleTitle><Pagination><StartPage>107870</StartPage><MedlinePgn>107870</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2021.107870</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(21)00506-3</ELocationID><Abstract><AbstractText>Immunotherapy through immune checkpoints blockade and its subsequent clinical application has revolutionized the treatment of a spectrum of solid tumors. Blockade of Programmed cell death protein-1 and its ligand has shown promising results in clinical studies. The clinical trials that enrolled patients with different hematopoietic malignancies including non-Hodgkin lymphoma, Hodgkin lymphoma, and acute myeloid leukemia (AML) showed that anti-PD-1 agents could have potential therapeutic effects in the patients. Adult T-cell leukemia/lymphoma (ATLL) is a non-Hodgkin T-cell Lymphoma that is developed in a minority of HTLV-1-infected individuals after a long latency period. The inhibition of PD-1 as a treatment option is currently being investigated in ATLL patients. In this review, we present a summary of the biology of the PD-1/PD-L1 pathway, the evidence in the literature to support anti-PD-1/PDL-1 application in the treatment of different lymphoid, myeloid, and virus-related hematological malignancies, and controversies related to PD-1/PD-L1 blocking in the management of ATLL patients.</AbstractText><CopyrightInformation>Copyright &#169; 2021 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jalili-Nik</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltani</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mashkani</LastName><ForeName>Baratali</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafatpanah</LastName><ForeName>Houshang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: RafatPanahH@mums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemy</LastName><ForeName>Seyed Isaac</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: hashemyi@mums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020413">3' Untranslated Regions</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060890">B7-H1 Antigen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000082082">Immune Checkpoint Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Immune Checkpoint Blockade</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">PD-1</Keyword><Keyword MajorTopicYN="N">PD-L1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34153661</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2021.107870</ArticleId><ArticleId IdType="pii">S1567-5769(21)00506-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7760898</PMID><DateCompleted><Year>1995</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN><JournalIssue CitedMedium="Print"><Volume>332</Volume><Issue>26</Issue><PubDate><Year>1995</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>A surprising advance in the treatment of viral leukemia.</ArticleTitle><Pagination><StartPage>1783</StartPage><EndPage>1785</EndPage><MedlinePgn>1783-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 1995 Jun 29;332(26):1744-8</RefSource><PMID Version="1">7760890</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 1995 Jun 29;332(26):1749-51</RefSource><PMID Version="1">7760891</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>6</Month><Day>29</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>6</Month><Day>29</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7760898</ArticleId><ArticleId IdType="doi">10.1056/NEJM199506293322611</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31996318</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0712</ISSN><JournalIssue CitedMedium="Internet"><Volume>872</Volume><PubDate><Year>2020</Year><Month>Apr</Month><Day>05</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>172953</StartPage><MedlinePgn>172953</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2020.172953</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-2999(20)30045-5</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Successful treatment is limited by resistance to chemotherapies. Therefore, there is an urgent need to develop novel effective strategies. Artesunate (ART), a widely used antimalarial compound, has been shown to exert cytotoxicity. Here, we aimed to assess the anti-ATLL activities of ART and to elucidate the possible molecular mechanisms involved in this effect. Compared with uninfected T cells, HTLV-1-infected T-cell lines were sensitive to ART-induced cytotoxicity. ART caused cell cycle arrest at G<sub>1</sub> and/or G<sub>2</sub>/M phases, which was associated with decreased expression of cyclin dependent kinase 1/2/4/6, cyclin B1/D2/E and c-Myc, and increased expression of p21. ART-induced apoptosis corresponded to activation of caspase-8/9/3; decreased expression of Bcl-xL, Bcl-2, myeloid cell leukemia-1, survivin, X-linked inhibitor of apoptosis protein and cellular inhibitor of apoptosis 1/2; and increased expression of Bak. ART increased intracellular reactive oxygen species and activation of the DNA damage marker &#947;-H2AX. Moreover, ART-induced cytotoxicity was partly reversed by treatment with a reactive oxygen species scavenger, iron chelator, and necroptosis or ferroptosis inhibitor, suggesting the involvement of caspase-dependent and -independent lethal pathways. These effects were correlated with inhibition of nuclear factor-&#954;B and activator protein-1 signaling through dephosphorylation of I&#954;B&#945;, I&#954;B kinase (IKK) &#945; and IKK&#946;, and decreased expression of JunB and JunD. Importantly, intraperitoneal injection with ART lowered tumor burden in an ATLL murine model. These preclinical results provide a rationale for evaluating the efficacy of ART in patients with ATLL.</AbstractText><CopyrightInformation>Copyright &#169; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Chie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, 903-0215, Japan; Division of Health Sciences, Transdisciplinary Research Organization for Subtropics and Island Studies, University of the Ryukyus, Nishihara, Okinawa, 903-0213, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senba</LastName><ForeName>Masachika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, 852-8523, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, 903-0215, Japan. Electronic address: n-mori@med.u-ryukyu.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>60W3249T9M</RegistryNumber><NameOfSubstance UI="D000077332">Artesunate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077332">Artesunate</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007274">Injections, Intraperitoneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Activator protein-1</Keyword><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Artesunate</Keyword><Keyword MajorTopicYN="N">Human T-cell leukemia virus type 1</Keyword><Keyword MajorTopicYN="N">Nuclear factor-&#954;B</Keyword><Keyword MajorTopicYN="N">Reactive oxygen species</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31996318</ArticleId><ArticleId IdType="doi">10.1016/j.ejphar.2020.172953</ArticleId><ArticleId IdType="pii">S0014-2999(20)30045-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18042693</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1472-4146</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of clinical pathology</Title><ISOAbbreviation>J Clin Pathol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukaemia/lymphoma.</ArticleTitle><Pagination><StartPage>1373</StartPage><EndPage>1377</EndPage><MedlinePgn>1373-7</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution. The disease manifests with leukaemia in greater than two thirds of patients, while the remaining patients have a lymphomatous form. According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma. Organomegaly, skin involvement, circulating atypical lymphocytes ("flower" cells) with a CD4+ CD25+ phenotype and hypercalcaemia are the most common disease features. The diagnosis should be based on a constellation of clinical features and laboratory investigations. The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I. The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), S&#233;zary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease. The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms. Despite major advances in understanding the pathogenesis of the disease, management of these patients remains a challenge for clinicians as they do not respond or achieve only transient responses to therapies used in high-grade lymphomas. The use of antiretroviral agents such as zidovudine in combination with interferon-alpha, with or without concomitant chemotherapy, has shown activity in this disease with improvement in survival and response rate. Consolidation with high dose therapy and autologous or allogeneic stem-cell transplantation should be considered in young patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matutes</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Haemato-Oncology Unit, The Institute of Cancer Research/Royal Marsden NHS Trust, London, UK. Estella.Matutes@icr.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Pathol</MedlineTA><NlmUniqueID>0376601</NlmUniqueID><ISSNLinking>0021-9746</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18042693</ArticleId><ArticleId IdType="pmc">PMC2095573</ArticleId><ArticleId IdType="doi">10.1136/jcp.2007.052456</ArticleId><ArticleId IdType="pii">60/12/1373</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kikuchi M, Jaffe E S, Ralfkiaer E. Adult T&#8208;cell leukaemia/lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001200&#8211;203.</Citation></Reference><Reference><Citation>Matutes E, Catovsky D. Adult T cell leukaemia lymphoma. In: Whittaker JA, ed. Leukaemia, 3rd edn. Oxford: Blackwell Scientific Publications 1998416&#8211;433.</Citation></Reference><Reference><Citation>Shimomaya M. Diagnostic criteria and clinical subtypes of ATLL. A report from the Lymphoma Study Group (1984&#8211;87). Br J Haematol 199179428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori T, Asou N, Suzushima H.et al Leukaemia of novel gastrointestinal T&#8208;lymphocyte population infected with HTLV&#8208;I. Lancet 199133776&#8211;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">1670727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera M E, Labra S, Ford A.et al HTLV&#8208;I induced intestinal lymphoma. Leuk Lymphoma 199935637&#8211;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609805</ArticleId></ArticleIdList></Reference><Reference><Citation>Dungerwalla M, Osuji N, Waldman A D.et al Isolated central nervous system involvement in adult T&#8208;cell lymphoma/leukaemia. Br J Haematol 2005130511&#8211;515.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098064</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor G. Molecular aspects of TLV&#8208;I infection and ATLL. J Clin Pathol 2007601392&#8211;1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2095577</ArticleId><ArticleId IdType="pubmed">18042695</ArticleId></ArticleIdList></Reference><Reference><Citation>Pombo de Oliveira M S, Matutes E, Famadas L C.et al Adult T&#8208;cell leukaemia/lymphoma in Brazil and its relation to HTLV&#8208;I. Lancet 1990336987&#8211;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">1977015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Sung Yul L, Shimizu T.et al Concurrence of lymphoma type adult T&#8208;cell leukemia in three sisters. Cancer 1985561688&#8211;1690.</Citation><ArticleIdList><ArticleId IdType="pubmed">2992744</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Spittle M F, Smith N P.et al The first report of familial adult T&#8208;cell leukaemia lymphoma in the United Kingdom. Br J Haematol 199589615&#8211;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">7734362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartier L, Castillo J L, Cabrera M E.et al HTLV&#8208;I positive spastic paraparesis (TSP) associated with a lymphoid disorder in three Chilean patients. Leuk Lymphoma 199517459&#8211;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">7549838</ArticleId></ArticleIdList></Reference><Reference><Citation>Aouba A, Lambotte O, Vasiliu V.et al Hemophagocytic syndrome as a presenting sign of transformation of smouldering to acute adult T&#8208;cell leukemia/lymphoma: efficacy of anti&#8208;retroviral and interferon therapy. Am J Hematol 200476187&#8211;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">15164389</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Matutes E, Catovsky D.et al Strongyloides stercoralis as candidate cofactor for HTLV&#8208;I induced malignancies. Lancet 1987ii94&#8211;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">2885585</ArticleId></ArticleIdList></Reference><Reference><Citation>Duggan D, Ehrlich G, Davey F.et al HTLV&#8208;I induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV&#8208;I sequences in tumor DNA. Blood 1988711027&#8211;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">2895676</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima K, Kikuchi M, Yoshida T.et al Lymph nodes in incipient adult T&#8208;cell leukemia&#8208;lymphoma with Hodgkin's disease like histologic features. Cancer 1990671622&#8211;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">2001551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennert K, Kikuchi M, Sato E.et al HTLV&#8208;positive and &#8208;negative T&#8208;cell lymphomas. Morphological and immunohistochemical differences between European and HTLV&#8208;positive Japanese T&#8208;cell lymphomas. Int J Cancer 19853565&#8211;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K, Suzumiya J, Sato K.et al Nodal T&#8208;cell lymphoma in an HTLV&#8208;1 endemic area: proviral HTLV&#8208;1 DNA, histological classification and clinical evaluation. Br J Haematol 1998101703&#8211;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674744</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura K, Unoki T, Sagawa K.et al Clinical features of OKT4+/OKT8+ adult T&#8208;cell leukemia. Leuk Res 198591353&#8211;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">2867255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifth International Workshop on Chromosomes in Leukemia&#8211;lymphoma Correlation of chromosome abnormalities with histologic and immunologic characteristics in non&#8208;Hodgkin's lymphoma and adult T&#8208;cell leukemia lymphoma. Blood 1988701554&#8211;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">2889485</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K. Human T&#8208;lymphotropic virus type I in Japan. Lancet 1994343213&#8211;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">7904671</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Treatment of patients with adult T&#8208;cell leukemia&#8208;lymphoma: an overview. In: Takatsuki K, Hinuma Y, Yoshida M, eds. Advances in adult T&#8208;cell leukemia and HTLV&#8208;I research. Tokyo: Japan Scientific Societies Press, 19923943&#8211;56.</Citation></Reference><Reference><Citation>Sadamori N, Mine M, Hakariya S.et al Clinical significance of B2&#8208;microglobulin in serum of adult T cell leukemia. Leukemia 19959594&#8211;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">7723390</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura S, Asou N, Suzushima H.et al P53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. Leukemia 19959598&#8211;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">7723391</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirono K, Hattori T, Takatsuki K. A new classification of clinical stages of adult T&#8208;cell leukemia based on prognosis of the disease. Leukemia 199481834&#8211;1837.</Citation><ArticleIdList><ArticleId IdType="pubmed">7967729</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Ghez D, Lepelletier Y.et al New therapeutic approaches for adult T&#8208;cell leukaemia. Lancet Oncol 20045664&#8211;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522654</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor G P, Matsuoka M. Natural history of adult T&#8208;cell leukemia/lymphoma and approaches to therapy. Oncogene 2005246047&#8211;6057.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H.et al A new G&#8208;CSF&#8208;supported combination chemotherapy, LSG15, for adult T&#8208;cell leukaemia&#8208;lymphoma. Br J Haematol 2001113375&#8211;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercieca J, Matutes E, Dearden C.et al The role of pentostatin in the treatment of T&#8208;cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994122588&#8211;2593.</Citation><ArticleIdList><ArticleId IdType="pubmed">7989933</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann T A, White J D, Goldman C K.et al The interleukin&#8208;2 receptor: a target for monoclonal antibody treatment of human T&#8208;cell lymphotropic virus&#8208;I induced adult T&#8208;cell leukemia. Blood 1993821701&#8211;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">8400227</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann T A, White J D, Carrasquillo J A.et al Radio&#8208;immunotherapy of interleukin&#8208;2R alpha expressing adult T&#8208;cell leukemia with yttrium&#8208;90&#8208;labeled anti&#8208;Tac. Blood 1995864063&#8211;4075.</Citation><ArticleIdList><ArticleId IdType="pubmed">7492762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravandi F, Faderl S. Complete response in a patient with adult T&#8208;cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 200630103&#8211;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mone A, Puhalla S, Whitman S.et al Durable hematologic complete response and suppression of HTLV&#8208;1 viral load following alemtuzumab in zidovudine/IFN&#8208;a&#8208;refractory adult T&#8208;cell leukemia. Blood 20051063380&#8211;3382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895052</ArticleId><ArticleId IdType="pubmed">16076875</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill P S, Harrington W, Jr, Kaplan M H.et al Treatment of adult T&#8208;cell leukemia&#8208;lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 19953321744&#8211;1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Guessain A.et al Treatment of HTLV&#8208;1 associated adult T&#8208;cell leukemia&#8208;lymphoma with a combination of zidovudine and alpha&#8208;interferon. N Engl J Med 19953321749&#8211;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Taylor G P, Cavenagh J.et al Interferon alpha and zidovudine therapy in adult T&#8208;cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001113779&#8211;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Allard I, Levy V.et al A prospective phase II clinical trial with the use of zidovudine and interferon&#8208;alpha in the acute and lymphoma forms of adult T&#8208;cell leukemia/lymphoma. Haematology J 20023276&#8211;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahieux R. HTLV&#8208;I and AZT: die another day. Blood 2006108785&#8211;786.</Citation></Reference><Reference><Citation>Datta A, Bellon M, Sinha&#8208;Datta U.et al Persistent inhibition of telomerase reprograms adult T&#8208;cell leukemia to p53&#8208;dependent senescence. Blood 20061081021&#8211;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895862</ArticleId><ArticleId IdType="pubmed">16569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyakazi Y, Takatsuka Y.et al Improved outcome of adult T&#8208;cell leukemia/lymphoma by allogeneic stem cell transplantation. Bone Marrow Transplant 20012715&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kami M, Hamaki T, Miyakoshi S.et al Allogeneic haematopoietic stem cell transplantation for the treatment of adult T&#8208;cell leukaemia/lymphoma. Br J Haematol 2003120304&#8211;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakase K, Hara M, Kozuka T.et al Bone marrow transplantation from unrelated donors for patients with adult T&#8208;cell leukaemia/lymphoma. Bone Marrow Transplant 20063741&#8211;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247419</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura J, Utsunomiya A, Tanosaki R.et al Allogeneic stem&#8208;cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T&#8208;cell leukemia/lymphoma. Blood 20051054143&#8211;4145.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37832654</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>338</Volume><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Illuminating (HTLV-1)-induced adult T-cell leukemia/lymphoma transcriptomic signature: A systems virology approach.</ArticleTitle><Pagination><StartPage>199237</StartPage><MedlinePgn>199237</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">199237</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2023.199237</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(23)00199-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adult T-cell leukemia/lymphoma (ATLL) is a poor prognosis malignancy of peripheral T-cells caused by human T-cell leukemia virus type 1 (HTLV-1). The low survival rates observed in the patients are the result of the lack of sufficient knowledge about the disease pathogenesis.</AbstractText><AbstractText Label="METHODS">In the present study, we first identified differentially expressed genes in ATLL patients and the cellular signaling pathways affected by them. Then, genes of these pathways were subjected to more comprehensive evaluations, including WGCNA and module validation studies on five external datasets. Finally, potential biomarkers were selected for qRT-PCR validation.</AbstractText><AbstractText Label="RESULTS">Thirteen signaling pathways, including Apoptosis, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, and seven others were selected for deeper investigations. Results of our in-depth bioinformatics evaluations, highlighted pathways related to regulation of immune responses, T-cell receptor and activation, regulation of cell signaling receptors and messengers, Wnt signaling pathway, and apoptosis as key players in ATLL pathogenesis. MAPK3, PIK3CD, KRAS, NFKB1, TNF, PLCB3, PLCB2, PLCB1, MAPK11, JUN, ITPR1, ADCY1, GNAQ, ADCY3, ADCY4, CHEK1, CCND1, SOS2, BAX, FOS and GNA12 were identified as possible biomarkers. Upregulation of ADCY1 and ADCY3 genes was confirmed via qRT-PCR.</AbstractText><AbstractText Label="CONCLUSIONS">In this study, we performed a deep bioinformatic examination on a limited set of genes with high probabilities of involvement in the pathogenesis of ATLL. Our results highlighted signaling pathways and genes with potential key roles in disease formation and resistance against current treatment strategies. Further studies are required to test the possible benefits of highlighted genes as biomarkers and targets of treatment.</AbstractText><CopyrightInformation>Copyright &#169; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forghani-Ramandi</LastName><ForeName>Mohammad-Moien</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafavi</LastName><ForeName>Behnam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomedical Engineering Department, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Tehran, Iran; Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahavar</LastName><ForeName>Atefeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dehghankar</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siami</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department Infectious Disease and Tropical Medicine, Ziaeian Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozhgani</LastName><ForeName>Sayed-Hamidreza</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran; Non-Communicable Disease Research Center, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: hamidrezamozhgani@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059467">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell lymphoma/leukemia</Keyword><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Network analysis</Keyword><Keyword MajorTopicYN="N">RT-qPCR</Keyword><Keyword MajorTopicYN="N">WGCNA</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>13</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37832654</ArticleId><ArticleId IdType="pmc">PMC10618755</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2023.199237</ArticleId><ArticleId IdType="pii">S0168-1702(23)00199-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andre P., Song H., Kim W., Kispert A., Yang Y. Wnt5a and Wnt11 regulate mammalian anterior-posterior axis elongation. Development. 2015;142(8):1516&#8211;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4392599</ArticleId><ArticleId IdType="pubmed">25813538</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron L., Gombault A., Fanny M., Villeret B., Savigny F., Guillou N., et al. The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine. Cell Death Dis. 2015;6(2):e1629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4669808</ArticleId><ArticleId IdType="pubmed">25654762</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann K. Stem cells: a WNT switch to ageing. Nat. Rev. Mol. Cell Biol. 2013;14(12):752.</Citation><ArticleIdList><ArticleId IdType="pubmed">24201108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellon M., Ko N.L., Lee M.J., Yao Y., Waldmann T.A., Trepel J.B., et al. Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. Blood. 2013;121(25):5045&#8211;5054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689251</ArticleId><ArticleId IdType="pubmed">23660959</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellon M., Moles R., Chaib-Mezrag H., Pancewicz J., Nicot C. JAG1 overexpression contributes to Notch1 signaling and the migration of HTLV-1-transformed ATL cells. J. Hematol. Oncol. 2018;11(1):119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6146899</ArticleId><ArticleId IdType="pubmed">30231940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos J.L. Epac: a new cAMP target and new avenues in cAMP research. Nat. Rev. Mol. Cell Biol. 2003;4(9):733&#8211;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506476</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudny M., Trbusek M. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias. Cancer Treat. Rev. 2020;88</Citation><ArticleIdList><ArticleId IdType="pubmed">32592909</ArticleId></ArticleIdList></Reference><Reference><Citation>David L., Fernandez-Vidal A., Bertoli S., Grgurevic S., Lepage B., Deshaies D., et al. CHK1 as a therapeutic target to bypass chemoresistance in AML. Sci. Signal. 2016;9(445):ra90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27625304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernzen K.J., Panfil A.R. Regulation of HTLV-1 transformation. Biosci. Rep. 2022;42(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919135</ArticleId><ArticleId IdType="pubmed">35169839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghobadi M.Z., Emamzadeh R., Mozhgani S.H. Deciphering microRNA-mRNA regulatory network in adult T-cell leukemia/lymphoma; the battle between oncogenes and anti-oncogenes. PLoS ONE. 2021;16(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906381</ArticleId><ArticleId IdType="pubmed">33630973</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo R., Liu T., Shasaltaneh M.D., Wang X., Imani S., Wen Q. Targeting adenylate cyclase family: new concept of targeted cancer therapy. Front. Oncol. 2022:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9271773</ArticleId><ArticleId IdType="pubmed">35832555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashibara T., Yamada Y., Mori N., Harasawa H., Sugahara K., Miyanishi T., et al. Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem. Biophys. Res. Commun. 2003;300(1):128&#8211;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini P., Rahimi Foroushani A., Marjani A., Tavakoli M., Amiri A., Hosseini A., et al. Investigating the effect of MAP2K1 gene (MEK1) in MAPK pathway in the induction of adult T-cell leukemia/lymphoma (ATLL) Iran J. Microbiol. 2023;15(3):475&#8211;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10336286</ArticleId><ArticleId IdType="pubmed">37448673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K., Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15(11):e517&#8211;ee26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi M., Mohammadi H., Hemmatzadeh M., Mohammadi A., Rafatpanah H., Baradaran B. Role of the HTLV-1 viral factors in the induction of apoptosis. Biomed. Pharmacother. 2017;85:334&#8211;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">27887847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Kim D.W., Chang W., Choe J., Kim J., Park C.S., et al. Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt/Ca2+/NFAT/NF-&#954;B-B cell lymphoma 6 signaling. J. Immunol. 2012;188(1):182&#8211;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">22124122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozakai T., Takahashi M., Higuchi M., Hara T., Saito K., Tanaka Y., et al. MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia. Int. J. Hematol. 2018;107(3):337&#8211;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">29043551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress A.K., Schneider G., Pichler K., Kalmer M., Fleckenstein B., Grassmann R. Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1. J. Virol. 2010;84(17):8732&#8211;8742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918996</ArticleId><ArticleId IdType="pubmed">20573814</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P., Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P., Luo R., Oldham M.C., Horvath S. Is my network module preserved and reproducible? PLoS Comput. Biol. 2011;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei H., Jin J., Liu M., Li X., Luo H., Yang L., et al. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells. Leuk. Res. 2018;64:17&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29149649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig M.G., Seuwen K. Characterization of the human adenylyl cyclase gene family: cDNA, gene structure, and tissue distribution of the nine isoforms. J. Recept. Signal Transduct. Res. 2002;22(1&#8211;4):79&#8211;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">12503609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G., Yasunaga J., Fan J., Yanagawa S., Matsuoka M. HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene. 2013;32(36):4222&#8211;4230.</Citation><ArticleIdList><ArticleId IdType="pubmed">23045287</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado C.B., da Cunha L.S., Mau&#233;s J., Pessoa F., de Oliveira M.B., Ribeiro R.M., et al. Role of miRNAs in human T cell leukemia virus type 1 induced T cell leukemia: a literature review and bioinformatics approach. Int. J. Mol. Sci. 2022;23(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9141946</ArticleId><ArticleId IdType="pubmed">35628297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozhgani S.H., Zarei Ghobadi M., Norouzi M., Rahimi H., Valizadeh N., Teymoori-Rad M., et al. Signaling factors potentially associated to the pathogenesis of adult T-cell leukemia /lymphoma: a network-analysis and novel findings assessment. Virus Res. 2022;319</Citation><ArticleIdList><ArticleId IdType="pubmed">35868352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair A., Michael B., Hiraragi H., Fernandez S., Feuer G., Boris-Lawrie K., et al. Human T lymphotropic virus type 1 accessory protein p12I modulates calcium-mediated cellular gene expression and enhances p300 expression in T lymphocytes. AIDS Res. Hum. Retroviruses. 2005;21(4):273&#8211;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668121</ArticleId><ArticleId IdType="pubmed">15943569</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano K., Chihara Y., Kobayashi S., Iwanaga M., Utsunomiya A., Watanabe T., et al. Overexpression of aberrant Wnt5a and its effect on acquisition of malignant phenotypes in adult T-cell leukemia/lymphoma (ATL) cells. Sci. Rep. 2021;11(1):4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892546</ArticleId><ArticleId IdType="pubmed">33603066</ArticleId></ArticleIdList></Reference><Reference><Citation>Naskar D., Maiti G., Chakraborty A., Roy A., Chattopadhyay D., Sen M. Wnt5a-Rac1-NF-&#954;B homeostatic circuitry sustains innate immune functions in macrophages. J. Immunol. 2014;192(9):4386&#8211;4397.</Citation><ArticleIdList><ArticleId IdType="pubmed">24706725</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusse R., Clevers H. Wnt/&#946;-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985&#8211;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">28575679</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada C., Lima D., Nakaya H.  R Package Version 1.12.0; 2022. MetaVolcanoR: Gene Expression Meta-analysis Visualization Tool.https://www.bioconductor.org/packages/release/bioc/html/MetaVolcanoR.html</Citation></Reference><Reference><Citation>Prasad C.P., Manchanda M., Mohapatra P., Andersson T. WNT5A as a therapeutic target in breast cancer. Cancer Metastasis Rev. 2018;37(4):767&#8211;778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510844</ArticleId><ArticleId IdType="pubmed">30171384</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Z., Oleinick N.L., Zhang J. ATR/CHK1 inhibitors and cancer therapy. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2018;126(3):450&#8211;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856582</ArticleId><ArticleId IdType="pubmed">29054375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafatpanah H., Hedayati-Moghaddam M.R., Fathimoghadam F., Bidkhori H.R., Shamsian S.K., Ahmadi S., et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J. Clin. Virol. 2011;52(3):172&#8211;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840754</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmatallah Y., Emmert-Streib F., Glazko G. Gene sets net correlations analysis (GSNCA): a multivariate differential coexpression test for gene sets. Bioinformatics. 2014;30(3):360&#8211;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023302</ArticleId><ArticleId IdType="pubmed">24292935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakihama S., Karube K. Genetic alterations in adult T-cell leukemia/lymphoma: novel discoveries with clinical and biological significance. Cancers (Basel) 2022;14(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9139356</ArticleId><ArticleId IdType="pubmed">35625999</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeler K., Jakic B., Heppke J., Soratroi C., Aufschnaiter A., Hermann-Kleiter N., et al. CHK1 dosage in germinal center B cells controls humoral immunity. Cell Death Differ. 2019;26(12):2551&#8211;2567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224292</ArticleId><ArticleId IdType="pubmed">30894677</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C., Wang W., Li M., Liu Y., Zheng D. Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. IUBMB Life. 2009;61(6):685&#8211;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">19472191</ArticleId></ArticleIdList></Reference><Reference><Citation>Su G., Kuchinsky A., Morris J.H., States D.J., Meng F. GLay: community structure analysis of biological networks. Bioinformatics. 2010;26(24):3135&#8211;3137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995124</ArticleId><ArticleId IdType="pubmed">21123224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagaya Y., Gallo R.C. The exceptional oncogenicity of HTLV-1. Front. Microbiol. 2017;8:1425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539117</ArticleId><ArticleId IdType="pubmed">28824561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B.J., Sugata K., Reda O., Matsuo M., Uchiyama K., Miyazato P., et al. HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma. J. Clin. Invest. 2021;131(24)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670839</ArticleId><ArticleId IdType="pubmed">34907908</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda K., Matsuoka M. Functional and pathogenic roles of retroviral antisense transcripts. Front. Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9100821</ArticleId><ArticleId IdType="pubmed">35572593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Shen M., Kitamura N., Sennari Y., Morita K., Tsukada J., et al. Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells. Invest. New Drugs. 2021;39(1):122&#8211;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">32914311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M., Suzuki Y., Watanabe T., Uchimaru K. Clonal selection and evolution of HTLV-1-infected cells driven by genetic and epigenetic alteration. Viruses. 2022;14(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950914</ArticleId><ArticleId IdType="pubmed">35336993</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16276549</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1059-910X</ISSN><JournalIssue CitedMedium="Print"><Volume>68</Volume><Issue>3-4</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Microscopy research and technique</Title><ISOAbbreviation>Microsc Res Tech</ISOAbbreviation></Journal><ArticleTitle>The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM).</ArticleTitle><Pagination><StartPage>176</StartPage><EndPage>196</EndPage><MedlinePgn>176-96</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus to be identified in the early 1980s. The isolation and identification of a related virus, HTLV-2, and the distantly related human immunodeficiency virus (HIV) immediately followed. Of the three retroviruses, two are associated definitively with specific diseases, HIV, with acquired immune deficiency syndrome (AIDS) and HTLV-1, with adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). While an estimated 10-20 million people worldwide are infected with HTLV-I, infection is endemic in the Caribbean, parts of Africa, southwestern Japan, and Italy. Approximately 4% of HTLV-I infected individuals develop ATLL, a disease with a poor prognosis. The clinical manifestations of infection and the current biology of HTLV viruses with emphasis on HTLV-1 are discussed in detail. The implications for improvements in diagnosis, treatment, intervention, and vaccination are included, as well as a discussion of the emergence of HTLV-1 and -2 as copathogens among HIV-1-infected individuals.</AbstractText><CopyrightInformation>2005 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shuh</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Loyola University New Orleans, New Orleans, Louisiana 70118, USA. mshuh@loyno.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beilke</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5 M01-RR-05096-10</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AI-79744-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R15-CA101903-01</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microsc Res Tech</MedlineTA><NlmUniqueID>9203012</NlmUniqueID><ISSNLinking>1059-910X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006800">Deltaretrovirus Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016399">Lymphoma, T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015493">Paraparesis, Tropical Spastic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>189</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16276549</ArticleId><ArticleId IdType="doi">10.1002/jemt.20231</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34248128</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>5</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Treatment approach for relapse of adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation].</ArticleTitle><Pagination><StartPage>505</StartPage><EndPage>511</EndPage><MedlinePgn>505-511</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.62.505</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell lymphoma with a dismal prognosis. Its most effective treatment is allogeneic hematopoietic stem cell transplantation (allo-HSCT), which provides a chance of long-term remission through a graft-versus-ATLL (GvATLL) effect. However, the incidence of relapse after allo-HSCT remains high at approximately 40%, and treatment options for patients with ATLL who have relapsed disease after allo-HSCT are limited. Accumulating evidence shows that mogamulizumab or lenalidomide use for relapsed disease even after allo-HSCT might have advantages with effects similar to that of GvATLL. Recent genomic and transcriptomic studies have shown that ATLL cells evade immune surveillance. Further investigations of incorporating immune-based approaches with new molecular target drugs as therapeutic options of patients with ATLL after transplantation are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology &amp; Cardiovascular medicine, Kyushu University Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006086">Graft vs Host Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Graft-versus-ATLL effect</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>12</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34248128</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.62.505</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">23287623</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>GVL for ATL?</ArticleTitle><Pagination><StartPage>6</StartPage><EndPage>7</EndPage><MedlinePgn>6-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2012-11-464628</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nirali N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>National Cancer Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldmann</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Blood. 2013 Jan 3;121(1):219-25</RefSource><PMID Version="1">23100309</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D020544">Graft vs Leukemia Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017710">Lymphocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016879">Salvage Therapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23287623</ArticleId><ArticleId IdType="doi">10.1182/blood-2012-11-464628</ArticleId><ArticleId IdType="pii">S0006-4971(20)47316-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28329538</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1087-2108</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Dermatology online journal</Title><ISOAbbreviation>Dermatol Online J</ISOAbbreviation></Journal><ArticleTitle>Primary cutaneous smoldering adult T-cell leukemia/ lymphoma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">13030/qt14d1b851</ELocationID><Abstract><AbstractText>HTLV-1 is a virus that is endemic in southwesternJapan and the Caribbean and has been implicatedin the development of ATLL. ATLL, which is anuncommon malignant condition of peripheralT-lymphocytes, is characterized by four clinicalsubtypes, which include acute, lymphomatous,chronic, and smoldering types, that are based onLDH levels, calcium levels, and extent of organinvolvement. We present a 52-year- old woman withpruritic patches with scale on the buttocks and withtender, hyperpigmented macules and papules oftwo-years duration. Histopathologic examinationwas suggestive of mycosis fungoides, laboratoryresults showed HTLV-I and II, and the patient wasdiagnosed with primary cutaneous ATLL. We reviewthe literature on HTLV-1 and ATLL and specifically theprognosis of cutaneous ATLL. The literature suggeststhat a diagnosis of ATLL should be considered amongpatients of Caribbean origin or other endemicareas with skin lesions that suggest a cutaneousT-cell lymphoma, with clinicopathologic features ofmycosis fungoides. Differentiation between ATLLand cutaneous T-cell lymphoma is imperative as theyhave different prognoses and treatment approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gittler</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ronald O. Perelman Department of Dermatology, NYU School of Medicine, NYU Langone Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martires</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Terushkin</LastName><ForeName>Vitaly</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Brinster</LastName><ForeName>Nooshin</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ramsay</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dermatol Online J</MedlineTA><NlmUniqueID>9610776</NlmUniqueID><ISSNLinking>1087-2108</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015481">HTLV-I Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015482">HTLV-II Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000754">Anemia, Refractory, with Excess of Blasts</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015481">HTLV-I Antibodies</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015482">HTLV-II Antibodies</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015367">Human T-lymphotropic virus 2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28329538</ArticleId><ArticleId IdType="pii">13030/qt14d1b851</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9446631</PMID><DateCompleted><Year>1998</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-4971</ISSN><JournalIssue CitedMedium="Print"><Volume>91</Volume><Issue>3</Issue><PubDate><Year>1998</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.</ArticleTitle><Pagination><StartPage>735</StartPage><EndPage>746</EndPage><MedlinePgn>735-46</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uckun</LastName><ForeName>F M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Children's Cancer Group ALL Biology Reference Laboratory, St Paul, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sensel</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Steinherz</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Trigg</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Heerema</LastName><ForeName>N A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Sather</LastName><ForeName>H N</ForeName><Initials>HN</Initials></Author><Author ValidYN="Y"><LastName>Reaman</LastName><ForeName>G H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Gaynon</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>CA-13539</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA-42633</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA-51425</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014178">Translocation, Genetic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>169</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>2</Month><Day>3</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>2</Month><Day>3</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9446631</ArticleId><ArticleId IdType="pii">S0006-4971(20)55327-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36513602</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1069</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Hematological oncology</Title><ISOAbbreviation>Hematol Oncol</ISOAbbreviation></Journal><ArticleTitle>Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>395</EndPage><MedlinePgn>389-395</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hon.3115</ELocationID><Abstract><AbstractText>Patients with recurrent adult T-cell leukemia/lymphoma (ATL) after allogeneic hematopoietic cell transplantation (allo-HCT) have a dismal prognosis. We retrospectively evaluated the safety and efficacy of lenalidomide (LEN)&#160;in 11 consecutive patients with recurrent ATL after allo-HCT. The median time from allo-HCT to ATL recurrence was 111&#160;days (range, 20-1476), and that from allo-HCT to the initiation of LEN was 162&#160;days (range, 43-1560). The median initial daily dose of LEN was 10&#160;mg (range, 5-25), and the median duration of LEN treatment was 37&#160;days (range, 3-1078). Three patients (27%) achieved complete response and two (18%) achieved partial response (PR). The rates of complete or PR according to the involved site were 57% for skin and 50% for nodal or extranodal lesions. With a median follow-up of 1033&#160;days (range, 601-1465) among survivors, the 1-year probability of overall survival (OS) after ATL recurrence was 55%. Grade &#8805;3 toxicities included cytopenia (n&#160;=&#160;4), superficial vein thrombosis (n&#160;=&#160;1), and deep vein thrombosis (n&#160;=&#160;1). Graft-versus-host disease (GVHD) newly developed in five patients (45%) and worsened in four patients (36%). The median duration from the initiation of LEN to GVHD onset or worsening was 5&#160;days (range, 1-9). GVHD was manageable in all patients. Seven patients received mogamulizumab (MOG) for recurrent ATL before LEN treatment. The overall response rates to LEN were 57% in patients who had previously received MOG and 25% in those who had not. The 1-year probabilities of OS after recurrent ATL were 71% in patients who had previously received MOG and 25% in those who had not. Although cytopenia and GVHD are common among patients with recurrent ATL after allo-HCT, LEN may improve survival. Administering MOG before LEN may augment treatment efficacy in the allo-HCT population.</AbstractText><CopyrightInformation>&#169; 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inamoto</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4881-0427</Identifier><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Ayumu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Mizuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Wataru</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020-A-15</GrantID><Agency>National Cancer Center Research and Development Fund</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hematol Oncol</MedlineTA><NlmUniqueID>8307268</NlmUniqueID><ISSNLinking>0278-0232</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="D000077269">Lenalidomide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077269">Lenalidomide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">lenalidomide</Keyword><Keyword MajorTopicYN="N">mogamulizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>22</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36513602</ArticleId><ArticleId IdType="doi">10.1002/hon.3115</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492. https://doi.org/10.1182/blood.v50.3.481.481</Citation></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et&#160;al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol official J Am Soc Clin Oncol. 2019;37(8):677-687.</Citation></Reference><Reference><Citation>Utsunomiya A. Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma. Front Microbiol. 2019;10:2235. https://doi.org/10.3389/fmicb.2019.02235</Citation></Reference><Reference><Citation>Kato K, Uike N, Wake A, et&#160;al. The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019;37(1):54-61. https://doi.org/10.1002/hon.2558</Citation></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et&#160;al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol official J Am Soc Clin Oncol. 2012;30(8):837-842. https://doi.org/10.1200/jco.2011.37.3472</Citation></Reference><Reference><Citation>Inoue Y, Endo S, Matsuno N, et&#160;al. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54(2):338-342. https://doi.org/10.1038/s41409-018-0291-5</Citation></Reference><Reference><Citation>Sakamoto H, Itonaga H, Sawayama Y, et&#160;al. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162-170. https://doi.org/10.1002/hon.2712</Citation></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, et&#160;al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol official J Am Soc Clin Oncol. 2016;34(34):4086-4093. https://doi.org/10.1200/jco.2016.67.7732</Citation></Reference><Reference><Citation>Morishige S, Nishi M, Saruta H, et&#160;al. Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation. Int J Hematol. 2019;110(4):506-511. https://doi.org/10.1007/s12185-019-02675-1</Citation></Reference><Reference><Citation>Tamai H, Tajika K, Nakayama K, Arai A. Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide. Bone Marrow Transplant. 2021;56(11):2862-2863. https://doi.org/10.1038/s41409-021-01432-5</Citation></Reference><Reference><Citation>Shimoyama M, Lymphoma Study Group (1984-87). Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428-437. https://doi.org/10.1111/j.1365-2141.1991.tb08051.x</Citation></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et&#160;al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol official J Am Soc Clin Oncol. 2009;27(3):453-459. https://doi.org/10.1200/jco.2008.18.2428</Citation></Reference><Reference><Citation>Przepiorka D, Weisdorf D, Martin P, et&#160;al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.</Citation></Reference><Reference><Citation>Jagasia MH, Greinix HT, Arora M, et&#160;al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21(3):389-401. https://doi.org/10.1016/j.bbmt.2014.12.001</Citation></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458. https://doi.org/10.1038/bmt.2012.244</Citation></Reference><Reference><Citation>Sockel K, Bornhaeuser M, Mischak-Weissinger E, et&#160;al. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. 2012;97(9):e34-e35. https://doi.org/10.3324/haematol.2012.067629</Citation></Reference><Reference><Citation>Kneppers E, van der Holt B, Kersten MJ, et&#160;al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413-2419. https://doi.org/10.1182/blood-2011-04-348292</Citation></Reference><Reference><Citation>Alsina M, Becker PS, Zhong X, et&#160;al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20(8):1183-1189. https://doi.org/10.1016/j.bbmt.2014.04.014</Citation></Reference><Reference><Citation>Ando T, Kojima K, Sano H, et&#160;al. Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. Leukemia lymphoma. 2018;59(10):1-4. https://doi.org/10.1080/10428194.2018.1427859</Citation></Reference><Reference><Citation>Zhang L, Qian Z, Cai Z, et&#160;al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.&#160;Am J Hematol. 2009;84(9):553-559. https://doi.org/10.1002/ajh.21468</Citation></Reference><Reference><Citation>Sugiyama D, Nishikawa H, Maeda Y, et&#160;al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110(44):17945-17950. https://doi.org/10.1073/pnas.1316796110</Citation></Reference><Reference><Citation>Ureshino H, Shindo T, Nishikawa H, et&#160;al. Effector regulatory T cells&#160;reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016;4(8):644-649. https://doi.org/10.1158/2326-6066.cir-15-0303</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">29411267</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies.</ArticleTitle><Pagination><StartPage>135</StartPage><EndPage>152</EndPage><MedlinePgn>135-152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-018-0658-4</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Hematology, Universit&#233; Sorbonne Paris Cit&#233;, H&#244;pital Necker, Paris, France. ohermine@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobinai</LastName><ForeName>Kensei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia&#8211;lymphoma</Keyword><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Human T-cell lymphotropic virus type 1</Keyword><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">Relapsed/refractory disease</Keyword><Keyword MajorTopicYN="N">Targeted agents</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29411267</ArticleId><ArticleId IdType="pmc">PMC5818559</ArticleId><ArticleId IdType="doi">10.1007/s12325-018-0658-4</ArticleId><ArticleId IdType="pii">10.1007/s12325-018-0658-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature. 1981;294:268&#8211;271. doi: 10.1038/294268a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/294268a0</ArticleId><ArticleId IdType="pubmed">6272125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031&#8211;2035. doi: 10.1073/pnas.79.6.2031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.79.6.2031</ArticleId><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Watanabe T, Tobinai K, et al. Adult T-cell leukemia&#8211;lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, et al., editors. Abeloff&#8217;s clinical oncology. 5. Philadelphia: Elsevier Saunders; 2013. pp. 2076&#8211;2092.</Citation></Reference><Reference><Citation>Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124&#8211;4130. doi: 10.1200/JCO.2008.16.4558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.16.4558</ArticleId><ArticleId IdType="pubmed">18626005</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcais A, Suarez F, Sibon D, Frenzel L, Hermine O, Bazarbachi A. Therapeutic options for adult T-cell leukemia/lymphoma. Curr Oncol Rep. 2013;15:457&#8211;464. doi: 10.1007/s11912-013-0332-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-013-0332-6</ArticleId><ArticleId IdType="pubmed">23943384</ArticleId></ArticleIdList></Reference><Reference><Citation>Markham PD, Salahuddin SZ, Kalyanaraman VS, Popovic M, Sarin P, Gallo RC. Infection and transformation of fresh human umbilical cord blood cells by multiple sources of human T-cell leukemia&#8211;lymphoma virus (HTLV) Int J Cancer. 1983;31:413&#8211;420. doi: 10.1002/ijc.2910310404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.2910310404</ArticleId><ArticleId IdType="pubmed">6601065</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K. Human T-cell lymphotropic virus type I-associated adult T-cell leukemia&#8211;lymphoma: new directions in clinical research. Clin Cancer Res. 2014;20:5217&#8211;5225. doi: 10.1158/1078-0432.CCR-14-0572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0572</ArticleId><ArticleId IdType="pubmed">25320371</ArticleId></ArticleIdList></Reference><Reference><Citation>Qayyum S, Choi JK. Adult T-cell leukemia/lymphoma. Arch Pathol Lab Med. 2014;138:282&#8211;286. doi: 10.5858/arpa.2012-0379-RS.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2012-0379-RS</ArticleId><ArticleId IdType="pubmed">24476526</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. doi: 10.3389/fmicb.2012.00388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00388</ArticleId><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322. doi: 10.3389/fmicb.2012.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00322</ArticleId><ArticleId IdType="pmc">PMC3437524</ArticleId><ArticleId IdType="pubmed">22973265</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058&#8211;6068. doi: 10.1038/sj.onc.1208968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208968</ArticleId><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia&#8211;lymphoma. Lancet Oncol. 2014;15:e517&#8211;e526. doi: 10.1016/S1470-2045(14)70202-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis. 1999;180:1487&#8211;1493. doi: 10.1086/315088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315088</ArticleId><ArticleId IdType="pubmed">10515807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson A, Laydon DJ, Bain BJ, Fields PA, Taylor GP. Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma. Haematologica. 2013;98:385&#8211;388. doi: 10.3324/haematol.2012.069476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2012.069476</ArticleId><ArticleId IdType="pmc">PMC3659941</ArticleId><ArticleId IdType="pubmed">22875625</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood. 2012;120:4795&#8211;4801. doi: 10.1182/blood-2012-07-440073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-07-440073</ArticleId><ArticleId IdType="pubmed">23086753</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23:577&#8211;589. doi: 10.1128/CMR.00063-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00063-09</ArticleId><ArticleId IdType="pmc">PMC2901658</ArticleId><ArticleId IdType="pubmed">20610824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118:1736&#8211;1745. doi: 10.1182/blood-2011-03-345702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-345702</ArticleId><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan JE, Khabbaz RF. The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol. 1993;3:137&#8211;148. doi: 10.1002/rmv.1980030304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1980030304</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116:3438&#8211;3446. doi: 10.1002/cncr.25147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.25147</ArticleId><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisada M, Stuver SO, Okayama A, et al. Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis. 2004;190:1605&#8211;1609. doi: 10.1086/424598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/424598</ArticleId><ArticleId IdType="pubmed">15478065</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine PH, Dosik H, Joseph EM, et al. A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn. Int J Cancer. 1999;80:662&#8211;666. doi: 10.1002/(SICI)1097-0215(19990301)80:5&lt;662::AID-IJC5&gt;3.0.CO;2-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0215(19990301)80:5&lt;662::AID-IJC5&gt;3.0.CO;2-I</ArticleId><ArticleId IdType="pubmed">10048963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia&#8211;lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453&#8211;459. doi: 10.1200/JCO.2008.18.2428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.18.2428</ArticleId><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasanu CA. Newer developments in adult T-cell leukemia/lymphoma therapeutics. Expert Opin Pharmacother. 2011;12:1709&#8211;1717. doi: 10.1517/14656566.2011.571207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2011.571207</ArticleId><ArticleId IdType="pubmed">21486117</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;1987) Br J Haematol. 1991;79:428&#8211;437. doi: 10.1111/j.1365-2141.1991.tb08051.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL diagnosed in the 2000s: a report from the ATL-PI project performed in Japan. Blood. 2015;126:2570&#8211;2577. doi: 10.1182/blood-2015-03-632489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Pombo De Oliveira MS, Loureiro P, Bittencourt A, et al. Geographic diversity of adult t-cell leukemia/lymphoma in Brazil. Int J Cancer. 1999;83:291&#8211;298. doi: 10.1002/(SICI)1097-0215(19991029)83:3&lt;291::AID-IJC1&gt;3.0.CO;2-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0215(19991029)83:3&lt;291::AID-IJC1&gt;3.0.CO;2-P</ArticleId><ArticleId IdType="pubmed">10495418</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzumiya J, Ohshima K, Tamura K, et al. The international prognostic index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the international peripheral T-cell lymphoma project. Ann Oncol. 2009;20:715&#8211;721. doi: 10.1093/annonc/mdn696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdn696</ArticleId><ArticleId IdType="pubmed">19150954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986&#8211;1995. J Acquir Immun Defic Syndr Hum Retrovirol. 1996;13(suppl 1):S20&#8211;S25. doi: 10.1097/00042560-199600001-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042560-199600001-00005</ArticleId><ArticleId IdType="pubmed">8797699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos RJ, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177&#8211;4183. doi: 10.1200/JCO.2010.28.0669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tobinai K. HTLV-1-associated T-cell diseases. In: Francine F, editor. T-cell lymphomas. New York: Humana; 2013. pp. 113&#8211;135.</Citation></Reference><Reference><Citation>Zell MI, Assal A, Konda B, et al. Analysis of large cohort shows that Caribbean adult T cell leukemia/lymphoma is a chemotherapy refractory disease with very poor prognosis that behaves distinctly from Japanese subtypes. Blood. 2014;124:1685.</Citation></Reference><Reference><Citation>A predictive model for aggressive non-Hodgkin&#8217;s lymphoma The international non-Hodgkin&#8217;s lymphoma prognostic factors project. N Engl J Med. 1993;329:987&#8211;994. doi: 10.1056/NEJM199309303291402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199309303291402</ArticleId><ArticleId IdType="pubmed">8141877</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Nomura S, Shimoyama M, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A) Br J Haematol. 2014;166:739&#8211;748. doi: 10.1111/bjh.12962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12962</ArticleId><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#174;): non-Hodgkin&#8217;s lymphomas. Version 2.2015, 2015.</Citation></Reference><Reference><Citation>Ratner L, Rauch D, Abel H, et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6:e408. doi: 10.1038/bcj.2016.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bcj.2016.21</ArticleId><ArticleId IdType="pmc">PMC4817103</ArticleId><ArticleId IdType="pubmed">27015285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia&#8211;lymphoma. PLoS One. 2009;4:e4420. doi: 10.1371/journal.pone.0004420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004420</ArticleId><ArticleId IdType="pmc">PMC2636875</ArticleId><ArticleId IdType="pubmed">19204798</ArticleId></ArticleIdList></Reference><Reference><Citation>British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). http://www.guideline.gov/content.aspx?id=47071. Accessed October 30, 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">21480860</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia&#8211;lymphoma. Blood. 2010;115:4337&#8211;4343. doi: 10.1182/blood-2009-09-242347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-09-242347</ArticleId><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia&#8211;lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458&#8211;5464. doi: 10.1200/JCO.2007.11.9958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23:87&#8211;89. doi: 10.1038/sj.bmt.1701533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1701533</ArticleId><ArticleId IdType="pubmed">10037056</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips EH, Hodson A, Hermine O, Bazarbachi A, Cwynarski K. Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant? Bone Marrow Transplant. 2016;51:1549&#8211;1555. doi: 10.1038/bmt.2016.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2016.154</ArticleId><ArticleId IdType="pubmed">27618683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369&#8211;1376. doi: 10.1182/blood-2009-10-247510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-10-247510</ArticleId><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia&#8211;lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734&#8211;1741. doi: 10.1182/blood-2012-03-414490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-414490</ArticleId><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia&#8211;lymphoma. Int J Hematol. 2003;77:512&#8211;517. doi: 10.1007/BF02986621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02986621</ArticleId><ArticleId IdType="pubmed">12841391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5:130&#8211;134. doi: 10.1038/sj.thj.6200374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.thj.6200374</ArticleId><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia&#8211;lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591&#8211;1598. doi: 10.1200/JCO.2009.25.3575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia&#8211;lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837&#8211;842. doi: 10.1200/JCO.2011.37.3472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips A, Fields P, Hermine O, et al. A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab versus investigator&#8217;s choice in the treatment of patients with relapsed/refractory adult T-cell leukemia&#8211;lymphoma: overall response rate, progression-free survival, and overall survival. Blood. 2016;128:4159.</Citation></Reference><Reference><Citation>Berkowitz JL, Janik JE, Stewart DM, et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol. 2014;155:176&#8211;187. doi: 10.1016/j.clim.2014.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2014.09.012</ArticleId><ArticleId IdType="pmc">PMC4306230</ArticleId><ArticleId IdType="pubmed">25267440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Janik J, O&#8217;Mahony D, et al. Phase II study of alemtuzumab (CAMPATH-1&#174;) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Clin Cancer Res. 2017;23:35&#8211;42. doi: 10.1158/1078-0432.CCR-16-1022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1022</ArticleId><ArticleId IdType="pmc">PMC5215752</ArticleId><ArticleId IdType="pubmed">27486175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. Cancer Sci. 2015;106:1219&#8211;1223. doi: 10.1111/cas.12735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12735</ArticleId><ArticleId IdType="pmc">PMC4582992</ArticleId><ArticleId IdType="pubmed">26179770</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr PM, Li H, Spier C, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33:2399&#8211;2404. doi: 10.1200/JCO.2014.60.6327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.60.6327</ArticleId><ArticleId IdType="pmc">PMC4500834</ArticleId><ArticleId IdType="pubmed">26077240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:1219&#8211;1223. doi: 10.1200/JCO.2016.67.7732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.7732</ArticleId><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Giddings J, Lee SM, Horwitz SM. Lenalidomide in patients with relapsed or refractory HTLV-1 related adult T cell leukemia/lymphoma (ATLL) Int J Blood Res Disorders. 2015;2:1&#8211;3. doi: 10.23937/2469-5696/1410010.</Citation><ArticleIdList><ArticleId IdType="doi">10.23937/2469-5696/1410010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura M, Imaizumi Y, Uike N, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3:e107&#8211;e118. doi: 10.1016/S2352-3026(15)00284-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(15)00284-7</ArticleId><ArticleId IdType="pubmed">26947199</ArticleId></ArticleIdList></Reference><Reference><Citation>Suehiro Y, Hasegawa A, Iino T, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169:356&#8211;367. doi: 10.1111/bjh.13302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13302</ArticleId><ArticleId IdType="pubmed">25612920</ArticleId></ArticleIdList></Reference><Reference><Citation>Theravectys. Theravectys obtains orphan drug designation from the European Medicines Agency for its lentiviral vector-based therapeutic vaccine against adult T-cell leukemia and lymphoma [press release]. http://www.theravectys.com/wp-content/uploads/PDF/14_Theravectys_obtains_Orphan_Drug_Designation_from_EMA.pdf. Accessed October 30, 2017.</Citation></Reference><Reference><Citation>Kreitman RJ, Stetler-Stevenson M, Jaffe ES, et al. Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. Clin Cancer Res. 2016;22:310&#8211;318. doi: 10.1158/1078-0432.CCR-15-1412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1412</ArticleId><ArticleId IdType="pmc">PMC6314476</ArticleId><ArticleId IdType="pubmed">26350263</ArticleId></ArticleIdList></Reference><Reference><Citation>Leustatin&#174; (cladribine) injection [prescribing information]. Raritan, NJ: Centocor Ortho Biotech Products, L.P.; July, 2012.</Citation></Reference><Reference><Citation>Litak&#174; 2&#160;mg/ml solution for injection [summary of product characteristics]. Weil/Rhein, Germany: Lipomed GmbH; August, 2013.</Citation></Reference><Reference><Citation>Clolar&#174; (clofarabine) injection, for intravenous use [prescribing information]. Cambridge, MA: Genzyme Corporation; October, 2016.</Citation></Reference><Reference><Citation>Corey SJ. New agents in the treatment of childhood leukemias and myelodysplastic syndromes. Curr Oncol Rep. 2005;7:399&#8211;405. doi: 10.1007/s11912-005-0003-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-005-0003-3</ArticleId><ArticleId IdType="pubmed">16221375</ArticleId></ArticleIdList></Reference><Reference><Citation>Evoltra&#174; 1&#160;mg/ml concentrate for solution for infusion [summary of product characteristics]. The Netherlands: Genzyme Europe B.V. October, 2016.</Citation></Reference><Reference><Citation>Folotyn&#174; (pralatrexate injection) [prescribing information]. Westminster, CO: Allos Therapeutics, Inc.; May, 2012.</Citation></Reference><Reference><Citation>O&#8217;Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182&#8211;1189. doi: 10.1200/JCO.2010.29.9024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.29.9024</ArticleId><ArticleId IdType="pmc">PMC3083873</ArticleId><ArticleId IdType="pubmed">21245435</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72:1293&#8211;1298. doi: 10.2165/11631090-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11631090-000000000-00000</ArticleId><ArticleId IdType="pubmed">22686619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006;97:1139&#8211;1146. doi: 10.1111/j.1349-7006.2006.00307.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2006.00307.x</ArticleId><ArticleId IdType="pubmed">16952304</ArticleId></ArticleIdList></Reference><Reference><Citation>Approval for additional indication for PTCL and CTCL of mogamulizumab. http://www.kyowa-kirin.com/news_releases/2014/e20140317_01.html. Accessed October 30, 2017.</Citation></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672&#8211;682. doi: 10.1111/bjh.13338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520&#8211;1531. doi: 10.1158/1078-0432.CCR-09-2697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-09-2697</ArticleId><ArticleId IdType="pubmed">20160057</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466&#8211;3473. doi: 10.1074/jbc.M210665200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210665200</ArticleId><ArticleId IdType="pubmed">12427744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945&#8211;17950. doi: 10.1073/pnas.1316796110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1316796110</ArticleId><ArticleId IdType="pmc">PMC3816454</ArticleId><ArticleId IdType="pubmed">24127572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and S&#233;zary syndrome. Clin Cancer Res. 2015;21:274&#8211;285. doi: 10.1158/1078-0432.CCR-14-0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0830</ArticleId><ArticleId IdType="pubmed">25376389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurose K, Ohue Y, Wada H, et al. Phase Ia study of FoxP3&#160;+&#160;CD4 treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21:4327&#8211;4336. doi: 10.1158/1078-0432.CCR-15-0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0357</ArticleId><ArticleId IdType="pubmed">26429981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426&#8211;3433. doi: 10.1200/JCO.2016.67.8250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId><ArticleId IdType="pubmed">27507878</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugio T, Kato K, Aoki T, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1608&#8211;1614. doi: 10.1016/j.bbmt.2016.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2016.05.017</ArticleId><ArticleId IdType="pubmed">27220263</ArticleId></ArticleIdList></Reference><Reference><Citation>Adcetris&#174; (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics, Inc.; November, 2017.</Citation></Reference><Reference><Citation>Adcetris&#174; 50&#160;mg powder for concentrate for solution for infusion [summary of product characteristics]. Taastrup, Denmark: Takeda Pharma A/S; May, 2015.</Citation></Reference><Reference><Citation>Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+&#160;peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137&#8211;3143. doi: 10.1200/JCO.2013.54.2456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.54.2456</ArticleId><ArticleId IdType="pmc">PMC4171358</ArticleId><ArticleId IdType="pubmed">25135998</ArticleId></ArticleIdList></Reference><Reference><Citation>Campath&#174; (alemtuzumab) [prescribing information]. Cambridge, MA: Genzyme Corporation; September, 2014.</Citation></Reference><Reference><Citation>Ravandi F, O&#8217;Brien S. Alemtuzumab. Expert Rev Anticancer Ther. 2005;5:39&#8211;51. doi: 10.1586/14737140.5.1.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737140.5.1.39</ArticleId><ArticleId IdType="pubmed">15757437</ArticleId></ArticleIdList></Reference><Reference><Citation>Velcade&#174; (bortezomib) for injection [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; June, 2008.</Citation></Reference><Reference><Citation>Velcade&#174; 1&#160;mg powder for solution for injection [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV; March, 2015.</Citation></Reference><Reference><Citation>Revlimid&#174; (lenalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; 2007.</Citation></Reference><Reference><Citation>Revlimid&#174; 2.5&#160;mg hard capsules [summary of product characteristics]. Uxbridge, United Kingdom: Celgene Europe Limited; March, 2015.</Citation></Reference><Reference><Citation>Revaud D, Bejanariu A, Loussaief L, et al. Development of an anti-HTLV-1 vaccine for the treatment of adult T-cell leukemia/lymphoma. Presented at: 57th Annual Meeting and Exposition of the American Society of Hematology, December 5&#8211;8, 2015, Orlando, FL.</Citation></Reference><Reference><Citation>Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL) Blood. 2009;113:6528&#8211;6532. doi: 10.1182/blood-2009-03-211821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-03-211821</ArticleId><ArticleId IdType="pubmed">19411628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kchour G, Rezaee R, Farid R, et al. The combination of arsenic, interferon-alpha, and zidovudine restores an &#8220;immunocompetent-like&#8221; cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology. 2013;10:91. doi: 10.1186/1742-4690-10-91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-10-91</ArticleId><ArticleId IdType="pmc">PMC3751834</ArticleId><ArticleId IdType="pubmed">23962110</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485&#8211;4491. doi: 10.1200/JCO.2010.28.9066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.9066</ArticleId><ArticleId IdType="pubmed">20697094</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109&#8211;3115. doi: 10.1200/JCO.2006.10.2434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.10.2434</ArticleId><ArticleId IdType="pubmed">17577020</ArticleId></ArticleIdList></Reference><Reference><Citation>Istodax&#174; (romidepsin) for injection, for intravenous use [prescribing information]. Summit, NJ: Celgene Corporation; July, 2016.</Citation></Reference><Reference><Citation>Zolinza&#174; (vorinostat) capsules [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; December, 2015.</Citation></Reference><Reference><Citation>Ramos JC, Toomey N, Diaz L, Ruiz P, Barber G, Harrington W., Jr Targeting HTLV-I latency in adult T-cell leukemia/lymphoma [abstract] Retrovirology. 2011;8(suppl 1):16. doi: 10.1186/1742-4690-8-S1-A48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-8-S1-A48</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Toomey N, Ramos JC. The combination of belinostat with zidovudine for treatment of HTLV-I related adult T-cell leukemia&#8211;lymphoma. Presented at: 57th American Society of Hematology Annual Meeting and Exposition, December 5&#8211;8, 2015, Orlando, FL.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25172635</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2014</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6536</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title><ISOAbbreviation>Biol Blood Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey.</ArticleTitle><Pagination><StartPage>1968</StartPage><EndPage>1974</EndPage><MedlinePgn>1968-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2014.08.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1083-8791(14)00511-4</ELocationID><Abstract><AbstractText>Allogeneic bone marrow and peripheral blood stem cell transplantations are curative treatment modalities for adult T&#160;cell leukemia/lymphoma (ATLL) because of the intrinsic graft-versus-ATLL effect. However, limited information is available regarding whether cord blood transplantation (CBT) induces a curative graft-versus-ATLL effect against aggressive ATLL. To evaluate the effect of CBT against ATLL, we retrospectively analyzed data from 175 patients with ATLL who initially underwent single-unit CBT. The 2-year overall survival (OS) rate was 20.6% (95% confidence interval [CI], 13.8% to 27.4%). A multivariate analysis revealed that the development of graft-versus-host disease (GVHD) was a favorable prognostic factor for OS (hazard ratio, .10; 95% CI, .01 to .94; P&#160;=&#160;.044). Furthermore, the 2-year OS (42.7%; 95% CI, 28.1% to 56.6%) of patients with grade 1 to 2 acute GVHD was higher than that of patients without acute GVHD (24.2%; 95% CI, 11.2% to 39.8%; P&#160;=&#160;.048). However, the cumulative incidence of treatment-related mortality (TRM) was high (46.1%; 95% CI, 38.2% to 53.7%), and early death was particularly problematic. In conclusion, CBT cures patients with ATLL partly through a graft-versus-ATLL effect. However, novel interventions will be required, particularly in the early phase, to reduce TRM and optimize GVHD.</AbstractText><CopyrightInformation>Copyright &#169; 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. Electronic address: kojikato@intmed1.med.kyushu-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ilseung</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wake</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uike</LastName><ForeName>Naokuni</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriuchi</LastName><ForeName>Yukiyoshi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamae</LastName><ForeName>Hirohisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oku</LastName><ForeName>Eijirou</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kurume University Graduate School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eto</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamaki</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Ritsuro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of HSCT Data Management/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Takeharu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Blood Marrow Transplant</MedlineTA><NlmUniqueID>9600628</NlmUniqueID><ISSNLinking>1083-8791</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016026">Bone Marrow Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D036101">Cord Blood Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020544">Graft vs Leukemia Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D036102">Peripheral Blood Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T cell leukemia/lymphoma (ATTL)</Keyword><Keyword MajorTopicYN="N">Cord blood transplantation</Keyword><Keyword MajorTopicYN="N">Graft-versus-adult T&#160;cell leukemia/lymphoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25172635</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2014.08.012</ArticleId><ArticleId IdType="pii">S1083-8791(14)00511-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27925051</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1806-9282</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Revista da Associacao Medica Brasileira (1992)</Title><ISOAbbreviation>Rev Assoc Med Bras (1992)</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>691</StartPage><EndPage>700</EndPage><MedlinePgn>691-700</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/1806-9282.62.07.691</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0104-42302016000700691</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T-cells caused by human T-cell lymphotropic virus type 1 (HTLV-1). Twenty million people are believed to be infected throughout the world, mostly in Japan, Africa, the Caribbean, and South America, particularly in Brazil and Peru. ATL affects about 5% of infected individuals and is classified in the following clinical forms: acute, lymphoma, primary cutaneous tumoral, chronic (favorable and unfavorable), and smoldering (leukemic and non-leukemic). Although it is considered an aggressive disease, there are cases with a long progression. We emphasize the importance of clinical classification as an indispensable element for evaluating prognosis and appropriate therapeutic approach. Since several cases have been published in Brazil and this disease is still poorly known, we decided to make a review paper for dissemination of clinical, hematological and pathological aspects, diagnosis, and therapy. The best way to reduce the occurrence of ATL would be halting the transmission of the virus through breastfeeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Pedro Dantas</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>PhD, MD - Professor of Dermatology, Universidade Federal de Sergipe, Aracaju, SE, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farre</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PhD - Researcher, Centro de Pesquisa Gon&#231;alo Moniz - Fiocruz Bahia, Salvador, BA, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittencourt</LastName><ForeName>Achil&#233;a Lisboa</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>PhD, MD - Pathologist and Researcher, Universidade Federal da Bahia, Salvador, BA, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Assoc Med Bras (1992)</MedlineTA><NlmUniqueID>9308586</NlmUniqueID><ISSNLinking>0104-4230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27925051</ArticleId><ArticleId IdType="doi">10.1590/1806-9282.62.07.691</ArticleId><ArticleId IdType="pii">S0104-42302016000700691</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37294133</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2159-8290</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Cancer discovery</Title><ISOAbbreviation>Cancer Discov</ISOAbbreviation></Journal><ArticleTitle>Rare Lymphomas: Getting "a Bit Ahead".</ArticleTitle><Pagination><StartPage>OF4</StartPage><MedlinePgn>OF4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-ND2023-0005</ELocationID><Abstract><AbstractText>According to data from the phase III IELSG37 trial, consolidation radiotherapy is unnecessary for patients with primary mediastinal B-cell lymphoma who respond completely to standard immunochemotherapy. Two other studies of peripheral T-cell lymphomas and adult T-cell leukemia/lymphoma, respectively, point to golidocitinib, an investigational JAK1 inhibitor, and mogamulizumab, which targets CCR4, as potential new treatment options.</AbstractText><CopyrightInformation>&#169;2023 American Association for Cancer Research.</CopyrightInformation></Abstract><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016433">News</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Discov</MedlineTA><NlmUniqueID>101561693</NlmUniqueID><ISSNLinking>2159-8274</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37294133</ArticleId><ArticleId IdType="doi">10.1158/2159-8290.CD-ND2023-0005</ArticleId><ArticleId IdType="pii">727237</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19273141</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2768-6698</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Frontiers in bioscience (Landmark edition)</Title><ISOAbbreviation>Front Biosci (Landmark Ed)</ISOAbbreviation></Journal><ArticleTitle>Cell signaling modifiers for molecular targeted therapy in ATLL.</ArticleTitle><Pagination><StartPage>1479</StartPage><EndPage>1489</EndPage><MedlinePgn>1479-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2741/3319</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a malignancy of peripheral T lymphocytes caused by human T-cell leukemia virus type 1 (HTLV-1) infection. Available therapies for ATLL have minimal efficacy, with few responders and poor survival. New therapies are needed for ATLL patients. Three decades of research in this field has resulted in accumulation of a wealth of knowledge about the molecular pathways underlying the proliferation of HTLV-1-infected T cells. Inappropriate over- and under-activation of various signaling pathways can contribute to pathological processes such as neoplasia. Molecular and pharmacological interventions that target the aberrant state of activation are thus of potential therapeutic benefit. Here we review how signal transduction pathway components including nuclear factor-kappaB, activator protein-1, janus kinase-signal transducer and activator of transcription, and phosphatidylinositol 3-kinase-Akt contribute to the pathogenesis of ATLL. The targeted inhibition of such molecules to suppress the growth of HTLV-1-infected T cells both in vitro and in vivo is also discussed. The potential translation of such strategies into effective therapies for patients with ATLL may improve the poor outcome associated with this neoplasia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. n-mori@med.u-ryukyu.ac.jp</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Front Biosci (Landmark Ed)</MedlineTA><NlmUniqueID>101612996</NlmUniqueID><ISSNLinking>2768-6698</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>84</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19273141</ArticleId><ArticleId IdType="doi">10.2741/3319</ArticleId><ArticleId IdType="pii">3319</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32024820</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).</ArticleTitle><Pagination><StartPage>94</StartPage><MedlinePgn>94</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">94</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-2294-6</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a malignancy of mature T cells associated with chronic infection by human T-cell lymphotropic virus type-1 (HTLV-1). ATLL patients with aggressive subtypes have dismal outcomes. We demonstrate that ATLL cells co-opt an early checkpoint within the tumor necrosis factor receptor 1 (TNFR1) pathway, resulting in survival advantage. This early checkpoint revolves around an interaction between the deubiquitinase CYLD and its target RIPK1. The status of RIPK1 K63-ubiquitination determines cell fate by creating either a prosurvival signal (ubiquitinated RIPK1) or a death signal (deubiquitinated RIPK1). In primary ATLL samples and in cell line models, an increased baseline level of CYLD phosphorylation was observed. We therefore tested the hypothesis that this modification of CYLD, which has been reported to inhibit its deubiquitinating function, leads to increased RIPK1 ubiquitination and thus provides a prosurvival signal to ATLL cells. CYLD phosphorylation can be pharmacologically reversed by IKK inhibitors, specifically by TBK1/IKK&#949; and IKK&#946; inhibitors (MRT67307 and TPCA). Both of the IKK sub-families can phosphorylate CYLD, and the combination of MRT67307 and TPCA have a marked effect in reducing CYLD phosphorylation and triggering cell death. ATLL cells overexpressing a kinase-inactive TBK1 (TBK1-K38A) demonstrate lower CYLD phosphorylation and subsequently reduced proliferation. IKK blockade reactivates CYLD, as evidenced by the reduction in RIPK1 ubiquitination, which leads to the association of RIPK1 with the death-inducing signaling complex (DISC) to trigger cell death. In the absence of CYLD, RIPK1 ubiquitination remains elevated following IKK blockade and it does not associate with the DISC. SMAC mimetics can similarly disrupt CYLD phosphorylation and lead to ATLL cell death through reduction of RIPK1 ubiquitination, which is CYLD dependent. These results identify CYLD as a crucial regulator of ATLL survival and point to its role as a potential novel target for pharmacologic modification in this disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, Hematology &amp; Oncology Ward, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, GuangDong, 510180, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalac</LastName><ForeName>Matko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markson</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-0850-6730</Identifier><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagat</LastName><ForeName>Govind</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6250-048X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Rosalind L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legarda</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justus</LastName><ForeName>Scott J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Hematology &amp; Oncology Ward, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, GuangDong, 510180, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qingshan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, GuangDong, 510180, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Huabao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Adrian T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0003-0653-9923</Identifier><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. ting.adrian@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. ting.adrian@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic, Rochester, MN, 55905, USA. ting.adrian@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA013696</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI052417</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI126036</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053418">Death Domain Receptor Signaling Adaptor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047888">Receptors, Tumor Necrosis Factor, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506235">TNFRSF1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C506249">RIPK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.10</RegistryNumber><NameOfSubstance UI="D051550">I-kappa B Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="C409984">CYLD protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.19.12</RegistryNumber><NameOfSubstance UI="D000074749">Deubiquitinating Enzyme CYLD</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053418">Death Domain Receptor Signaling Adaptor Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074749">Deubiquitinating Enzyme CYLD</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051550">I-kappa B Kinase</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D047888">Receptors, Tumor Necrosis Factor, Type I</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054875">Ubiquitination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32024820</ArticleId><ArticleId IdType="pmc">PMC7002447</ArticleId><ArticleId IdType="doi">10.1038/s41419-020-2294-6</ArticleId><ArticleId IdType="pii">10.1038/s41419-020-2294-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anest V, et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature. 2003;423:659&#8211;663. doi: 10.1038/nature01648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01648</ArticleId><ArticleId IdType="pubmed">12789343</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer. 2007;7:270&#8211;280. doi: 10.1038/nrc2111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2111</ArticleId><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Pise-Masison CA, et al. Co-dependence of HTLV-1 p12 and p8 functions in virus persistence. PLoS Pathog. 2014;10:e1004454. doi: 10.1371/journal.ppat.1004454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004454</ArticleId><ArticleId IdType="pmc">PMC4223054</ArticleId><ArticleId IdType="pubmed">25375128</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Prooyen N, et al. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc. Natl Acad. Sci. USA. 2010;107:20738&#8211;20743. doi: 10.1073/pnas.1009635107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1009635107</ArticleId><ArticleId IdType="pmc">PMC2996430</ArticleId><ArticleId IdType="pubmed">21076035</ArticleId></ArticleIdList></Reference><Reference><Citation>Asquith B, Hanon E, Taylor GP, Bangham CR. Is human T-cell lymphotropic virus type I really silent? Philos. Trans. R. Soc. Lond. B Biol. Sci. 2000;355:1013&#8211;1019. doi: 10.1098/rstb.2000.0638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2000.0638</ArticleId><ArticleId IdType="pmc">PMC1692812</ArticleId><ArticleId IdType="pubmed">11186302</ArticleId></ArticleIdList></Reference><Reference><Citation>Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology. 2004;1:20. doi: 10.1186/1742-4690-1-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-1-20</ArticleId><ArticleId IdType="pmc">PMC514576</ArticleId><ArticleId IdType="pubmed">15310405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham CR, Ratner L. How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)? Curr. Opin. Virol. 2015;14:93&#8211;100. doi: 10.1016/j.coviro.2015.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2015.09.004</ArticleId><ArticleId IdType="pmc">PMC4772697</ArticleId><ArticleId IdType="pubmed">26414684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciminale V, et al. Unusual CD4+CD8+ phenotype in a greek patient diagnosed with adult T-cell leukemia positive for human T-cell leukemia virus type I (HTLV-I) Leuk. Res. 2000;24:353&#8211;358. doi: 10.1016/S0145-2126(99)00193-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0145-2126(99)00193-9</ArticleId><ArticleId IdType="pubmed">10713333</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiraku N, et al. Clonal expansion within CD4+ and CD8+ T cell subsets in human T lymphotropic virus type I-infected individuals. J. Immunol. 1998;161:6674&#8211;6680.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862696</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol. 1990;64:5682&#8211;5687. doi: 10.1128/JVI.64.11.5682-5687.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.64.11.5682-5687.1990</ArticleId><ArticleId IdType="pmc">PMC248630</ArticleId><ArticleId IdType="pubmed">1976827</ArticleId></ArticleIdList></Reference><Reference><Citation>Currer R, et al. HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front. Microbiol. 2012;3:406. doi: 10.3389/fmicb.2012.00406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00406</ArticleId><ArticleId IdType="pmc">PMC3510432</ArticleId><ArticleId IdType="pubmed">23226145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131:215&#8211;225. doi: 10.1182/blood-2017-01-761874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-01-761874</ArticleId><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129:1071&#8211;1081. doi: 10.1182/blood-2016-09-692574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-692574</ArticleId><ArticleId IdType="pmc">PMC5374731</ArticleId><ArticleId IdType="pubmed">28115366</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570&#8211;2577. doi: 10.1182/blood-2015-03-632489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell M, et al. Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016;7:51981&#8211;51990. doi: 10.18632/oncotarget.10223.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.10223</ArticleId><ArticleId IdType="pmc">PMC5239529</ArticleId><ArticleId IdType="pubmed">27341021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transpl. 2014;49:1266&#8211;1268. doi: 10.1038/bmt.2014.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2014.143</ArticleId><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D, et al. Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT) Blood Cancer J. 2013;3:e159. doi: 10.1038/bcj.2013.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bcj.2013.57</ArticleId><ArticleId IdType="pmc">PMC3880440</ArticleId><ArticleId IdType="pubmed">24241399</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 2009;27:453&#8211;459. doi: 10.1200/JCO.2008.18.2428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.18.2428</ArticleId><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 2010;28:4177&#8211;4183. doi: 10.1200/JCO.2010.28.0669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, et al. Long-term clinical remission maintained after cessation of zidovudine and interferon-alpha therapy in chronic adult T-cell leukemia/lymphoma. Int J. Hematol. 2018;107:378&#8211;382. doi: 10.1007/s12185-017-2361-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-017-2361-7</ArticleId><ArticleId IdType="pubmed">29090417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 2012;30:837&#8211;842. doi: 10.1200/JCO.2011.37.3472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 2010;28:1591&#8211;1598. doi: 10.1200/JCO.2009.25.3575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N. Engl. J. Med. 2018;378:1947&#8211;1948. doi: 10.1056/NEJMc1803181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1803181</ArticleId><ArticleId IdType="pubmed">29768155</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O. ATL treatment: is it time to change? Blood. 2015;126:2533&#8211;2534. doi: 10.1182/blood-2015-10-670489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-10-670489</ArticleId><ArticleId IdType="pubmed">26635405</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Donnell MA, Ting AT. RIP1 comes back to life as a cell death regulator in TNFR1 signaling. FEBS J. 2011;278:877&#8211;887. doi: 10.1111/j.1742-4658.2011.08016.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2011.08016.x</ArticleId><ArticleId IdType="pmc">PMC3051001</ArticleId><ArticleId IdType="pubmed">21232018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting AT, Bertrand MJM. More to life than NF-kappaB in TNFR1 signaling. Trends Immunol. 2016;37:535&#8211;545. doi: 10.1016/j.it.2016.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2016.06.002</ArticleId><ArticleId IdType="pmc">PMC5076853</ArticleId><ArticleId IdType="pubmed">27424290</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Donnell MA, Ting AT. Chronicles of a death foretold: dual sequential cell death checkpoints in TNF signaling. Cell Cycle. 2010;9:1065&#8211;1071. doi: 10.4161/cc.9.6.10982.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.9.6.10982</ArticleId><ArticleId IdType="pmc">PMC4114106</ArticleId><ArticleId IdType="pubmed">20237426</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol. 2007;17:418&#8211;424. doi: 10.1016/j.cub.2007.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2007.01.027</ArticleId><ArticleId IdType="pmc">PMC1868513</ArticleId><ArticleId IdType="pubmed">17306544</ArticleId></ArticleIdList></Reference><Reference><Citation>Justus SJ, Ting AT. Cloaked in ubiquitin, a killer hides in plain sight: the molecular regulation of RIPK1. Immunol. Rev. 2015;266:145&#8211;160. doi: 10.1111/imr.12304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12304</ArticleId><ArticleId IdType="pubmed">26085213</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand MJ, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell. 2008;30:689&#8211;700. doi: 10.1016/j.molcel.2008.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2008.05.014</ArticleId><ArticleId IdType="pubmed">18570872</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen SL, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007;12:445&#8211;456. doi: 10.1016/j.ccr.2007.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2007.08.029</ArticleId><ArticleId IdType="pmc">PMC3431210</ArticleId><ArticleId IdType="pubmed">17996648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693&#8211;703. doi: 10.1016/j.cell.2008.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.03.036</ArticleId><ArticleId IdType="pubmed">18485876</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppe C, et al. IkappaB kinasealpha/beta control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1. Hepatology. 2016;64:1217&#8211;1231. doi: 10.1002/hep.28723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.28723</ArticleId><ArticleId IdType="pubmed">27396433</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondelinger Y, et al. NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol. Cell. 2015;60:63&#8211;76. doi: 10.1016/j.molcel.2015.07.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.07.032</ArticleId><ArticleId IdType="pubmed">26344099</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondelinger Y, et al. Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation. Nat. Commun. 2019;10:1729. doi: 10.1038/s41467-019-09690-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09690-0</ArticleId><ArticleId IdType="pmc">PMC6465317</ArticleId><ArticleId IdType="pubmed">30988283</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell. 2018;174:1477&#8211;1491. e1419. doi: 10.1016/j.cell.2018.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.07.041</ArticleId><ArticleId IdType="pmc">PMC6128749</ArticleId><ArticleId IdType="pubmed">30146158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafont E, et al. TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1 phosphorylation. Nat. Cell Biol. 2018;20:1389&#8211;1399. doi: 10.1038/s41556-018-0229-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0229-6</ArticleId><ArticleId IdType="pmc">PMC6268100</ArticleId><ArticleId IdType="pubmed">30420664</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondelinger Y, et al. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat. Cell Biol. 2017;19:1237&#8211;1247. doi: 10.1038/ncb3608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3608</ArticleId><ArticleId IdType="pubmed">28920952</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaco I, et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell. 2017;66:698&#8211;710 e695. doi: 10.1016/j.molcel.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.05.003</ArticleId><ArticleId IdType="pmc">PMC5459754</ArticleId><ArticleId IdType="pubmed">28506461</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon MB, et al. p38(MAPK)/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. Nat. Cell Biol. 2017;19:1248&#8211;1259. doi: 10.1038/ncb3614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3614</ArticleId><ArticleId IdType="pubmed">28920954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondelinger Y, Darding M, Bertrand MJ, Walczak H. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell Mol. Life Sci. 2016;73:2165&#8211;2176. doi: 10.1007/s00018-016-2191-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2191-4</ArticleId><ArticleId IdType="pmc">PMC4887548</ArticleId><ArticleId IdType="pubmed">27066894</ArticleId></ArticleIdList></Reference><Reference><Citation>Harhaj EW, Dixit VM. Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 2012;246:107&#8211;124. doi: 10.1111/j.1600-065X.2012.01100.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2012.01100.x</ArticleId><ArticleId IdType="pmc">PMC3540820</ArticleId><ArticleId IdType="pubmed">22435550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Shao-Cong. Deubiquitylation and regulation of the immune response. Nature Reviews Immunology. 2008;8(7):501&#8211;511. doi: 10.1038/nri2337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2337</ArticleId><ArticleId IdType="pmc">PMC5763493</ArticleId><ArticleId IdType="pubmed">18535581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010;17:25&#8211;34. doi: 10.1038/cdd.2009.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2009.43</ArticleId><ArticleId IdType="pmc">PMC5848464</ArticleId><ArticleId IdType="pubmed">19373246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitomi J, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell. 2008;135:1311&#8211;1323. doi: 10.1016/j.cell.2008.10.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.10.044</ArticleId><ArticleId IdType="pmc">PMC2621059</ArticleId><ArticleId IdType="pubmed">19109899</ArticleId></ArticleIdList></Reference><Reference><Citation>Legarda D, et al. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN. Cell Rep. 2016;15:2449&#8211;2461. doi: 10.1016/j.celrep.2016.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.05.032</ArticleId><ArticleId IdType="pmc">PMC4909532</ArticleId><ArticleId IdType="pubmed">27264187</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Donnell MA, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 2011;13:1437&#8211;1442. doi: 10.1038/ncb2362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2362</ArticleId><ArticleId IdType="pmc">PMC3229661</ArticleId><ArticleId IdType="pubmed">22037414</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutti JE, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol. Cell. 2009;34:461&#8211;472. doi: 10.1016/j.molcel.2009.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2009.04.031</ArticleId><ArticleId IdType="pmc">PMC2746958</ArticleId><ArticleId IdType="pubmed">19481526</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiley W, Zhang M, Wu X, Granger E, Sun SC. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol. Cell Biol. 2005;25:3886&#8211;3895. doi: 10.1128/MCB.25.10.3886-3895.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.10.3886-3895.2005</ArticleId><ArticleId IdType="pmc">PMC1087725</ArticleId><ArticleId IdType="pubmed">15870263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Zhang M, Sun SC. Mutual regulation between deubiquitinase CYLD and retroviral oncoprotein Tax. Cell Biosci. 2011;1:27. doi: 10.1186/2045-3701-1-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-3701-1-27</ArticleId><ArticleId IdType="pmc">PMC3170579</ArticleId><ArticleId IdType="pubmed">21824392</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A, et al. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer. 2010;49:803&#8211;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">20607853</ArticleId></ArticleIdList></Reference><Reference><Citation>He KL, Ting AT. Essential role for IKKgamma/NEMO in TCR-induced IL-2 expression in Jurkat T cells. Eur. J. Immunol. 2003;33:1917&#8211;1924. doi: 10.1002/eji.200323650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200323650</ArticleId><ArticleId IdType="pubmed">12884855</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CS, et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 2008;9:930&#8211;936. doi: 10.1038/embor.2008.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2008.136</ArticleId><ArticleId IdType="pmc">PMC2529351</ArticleId><ArticleId IdType="pubmed">18636086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lork M, Kreike M, Staal J, Beyaert R. Importance of validating antibodies and small compound inhibitors using genetic knockout studies-T cell receptor-induced CYLD phosphorylation by IKKepsilon/TBK1 as a case study. Front. Cell Dev. Biol. 2018;6:40. doi: 10.3389/fcell.2018.00040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2018.00040</ArticleId><ArticleId IdType="pmc">PMC5932415</ArticleId><ArticleId IdType="pubmed">29755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene. 2005;24:5986&#8211;5995. doi: 10.1038/sj.onc.1208976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208976</ArticleId><ArticleId IdType="pubmed">16155605</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Z, Xiao G. Human T-cell lymphotropic virus: a model of NF-kappaB-associated tumorigenesis. Viruses. 2011;3:714&#8211;749. doi: 10.3390/v3060714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3060714</ArticleId><ArticleId IdType="pmc">PMC3131208</ArticleId><ArticleId IdType="pubmed">21743832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulda S. Promises and challenges of smac mimetics as cancer therapeutics. Clin. Cancer Res. 2015;21:5030&#8211;5036. doi: 10.1158/1078-0432.CCR-15-0365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0365</ArticleId><ArticleId IdType="pubmed">26567362</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulda S. Smac mimetics to therapeutically target IAP proteins in cancer. Int Rev. Cell Mol. Biol. 2017;330:157&#8211;169. doi: 10.1016/bs.ircmb.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ircmb.2016.09.004</ArticleId><ArticleId IdType="pubmed">28215531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell. 2006;22:245&#8211;257. doi: 10.1016/j.molcel.2006.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.03.026</ArticleId><ArticleId IdType="pubmed">16603398</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa L, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18:268&#8211;281. doi: 10.1016/j.ccr.2010.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2010.08.006</ArticleId><ArticleId IdType="pmc">PMC2963042</ArticleId><ArticleId IdType="pubmed">20832754</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellerbrand C, et al. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis. 2007;28:21&#8211;27. doi: 10.1093/carcin/bgl081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgl081</ArticleId><ArticleId IdType="pubmed">16774947</ArticleId></ArticleIdList></Reference><Reference><Citation>Massoumi R, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med. 2009;206:221&#8211;232. doi: 10.1084/jem.20082044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20082044</ArticleId><ArticleId IdType="pmc">PMC2626666</ArticleId><ArticleId IdType="pubmed">19124656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner MW, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110:3291&#8211;3300. doi: 10.1182/blood-2007-02-075069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-02-075069</ArticleId><ArticleId IdType="pubmed">17609426</ArticleId></ArticleIdList></Reference><Reference><Citation>Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131&#8211;144. doi: 10.1016/j.ccr.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2007.07.003</ArticleId><ArticleId IdType="pmc">PMC2083698</ArticleId><ArticleId IdType="pubmed">17692805</ArticleId></ArticleIdList></Reference><Reference><Citation>van Andel H, et al. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene. 2017;36:2105&#8211;2115. doi: 10.1038/onc.2016.368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2016.368</ArticleId><ArticleId IdType="pubmed">27775078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature. 2003;423:655&#8211;659. doi: 10.1038/nature01576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01576</ArticleId><ArticleId IdType="pubmed">12789342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, et al. Inactivation of BAD by IKK inhibits TNFalpha-induced apoptosis independently of NF-kappaB activation. Cell. 2013;152:304&#8211;315. doi: 10.1016/j.cell.2012.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.12.021</ArticleId><ArticleId IdType="pmc">PMC3586589</ArticleId><ArticleId IdType="pubmed">23332762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SC, Yamaoka S. Activation of NF-kappaB by HTLV-I and implications for cell transformation. Oncogene. 2005;24:5952&#8211;5964. doi: 10.1038/sj.onc.1208969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208969</ArticleId><ArticleId IdType="pubmed">16155602</ArticleId></ArticleIdList></Reference><Reference><Citation>Harhaj EW, Sun SC. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J. Biol. Chem. 1999;274:22911&#8211;22914. doi: 10.1074/jbc.274.33.22911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.33.22911</ArticleId><ArticleId IdType="pubmed">10438454</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu ZL, DiDonato JA, Hawiger J, Ballard DW. The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IkappaB kinases containing IKKalpha and IKKbeta. J. Biol. Chem. 1998;273:15891&#8211;15894. doi: 10.1074/jbc.273.26.15891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.26.15891</ArticleId><ArticleId IdType="pubmed">9632633</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin DY, Giordano V, Kibler KV, Nakano H, Jeang KT. Role of adapter function in oncoprotein-mediated activation of NF- kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma. J. Biol. Chem. 1999;274:17402&#8211;17405. doi: 10.1074/jbc.274.25.17402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.25.17402</ArticleId><ArticleId IdType="pubmed">10364167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung HH, et al. SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds. Cell Death Dis. 2011;2:e146. doi: 10.1038/cddis.2011.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2011.25</ArticleId><ArticleId IdType="pmc">PMC3122057</ArticleId><ArticleId IdType="pubmed">21490678</ArticleId></ArticleIdList></Reference><Reference><Citation>Darding M, et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ. 2011;18:1376&#8211;1386. doi: 10.1038/cdd.2011.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2011.10</ArticleId><ArticleId IdType="pmc">PMC3172091</ArticleId><ArticleId IdType="pubmed">21331077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosebeck S, et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science. 2011;331:468&#8211;472. doi: 10.1126/science.1198946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1198946</ArticleId><ArticleId IdType="pmc">PMC3124150</ArticleId><ArticleId IdType="pubmed">21273489</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375&#8211;2390. doi: 10.1182/blood-2016-01-643569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-01-643569</ArticleId><ArticleId IdType="pmc">PMC4874220</ArticleId><ArticleId IdType="pubmed">26980727</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 2005;175:2814&#8211;2824. doi: 10.4049/jimmunol.175.5.2814.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.5.2814</ArticleId><ArticleId IdType="pubmed">16116167</ArticleId></ArticleIdList></Reference><Reference><Citation>He KL, Ting AT. A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol. Cell Biol. 2002;22:6034&#8211;6045. doi: 10.1128/MCB.22.17.6034-6045.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.22.17.6034-6045.2002</ArticleId><ArticleId IdType="pmc">PMC133997</ArticleId><ArticleId IdType="pubmed">12167698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16595998</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>5</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Immunosuppressive treatment for mixed connective tissue disease may facilitate the development of adult T cell leukemia/lymphoma in a HTLVI carrier.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>301</EndPage><MedlinePgn>297-301</MedlinePgn></Pagination><Abstract><AbstractText>A 66-year-old woman who was positive for human T-lymphotropic virus type I (HTLV-I) antibody developed mixed connective tissue disease (MCTD) with interstitial pneumonia, and was successfully treated with corticosteroid. One year later, under maintenance treatment of prednisolone (PSL), she contracted acute type adult Tcell leukemia/lymphoma (ATLL) without flaring of MCTD. MCTD is considered to be as one of the HTL-V-I-related inflammatory diseases, however the development of ATLL during the treatment of HTL-V-I-related MCTD has not been well studied. Here, we review the literature and raise the issue of the mutual interactions between MCTD-causative anti-HTLV-I immune response and anti-ATLL immune response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fujiwara</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Hematology and Immunology, Department of Internal Medicine, Kagoshima University, Kagoshima, Sakuragaoka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kukita</LastName><ForeName>Toshimasa</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hamada</LastName><ForeName>Heiichiro</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Atsuo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Matsushita</LastName><ForeName>Kakushi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tei</LastName><ForeName>Chuwa</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.21</RegistryNumber><NameOfSubstance UI="D013937">Thymidine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001323">Autoantibodies</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015139">Blotting, Southern</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017563">Lung Diseases, Interstitial</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008775">Methylprednisolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008947">Mixed Connective Tissue Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015375">Receptors, Interleukin-2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013937">Thymidine Kinase</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>21</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16595998</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.45.1490</ArticleId><ArticleId IdType="pii">JST.JSTAGE/internalmedicine/45.1490</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20425378</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-822X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current hematologic malignancy reports</Title><ISOAbbreviation>Curr Hematol Malig Rep</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma and HTLV-1.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>264</EndPage><MedlinePgn>257-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11899-007-0035-x</ELocationID><Abstract><AbstractText>Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago. HTLV-1 infects 15 to 20 million individuals worldwide. This oncoretrovirus can be transmitted in three ways: horizontally (sexually), vertically (mother to child), and via blood transfusion. HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type. Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations. This article discusses a number of recent treatments including antiretroviral therapy, aggressive chemotherapy, and allogeneic bone-marrow transplantation, as well as new drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahieux</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit&#233; d'Epid&#233;miologie et Physiopathologie des Virus Oncog&#232;nes, CNRS URA 3015, Department of Virology, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris Cedex 15, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gessain</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Hematol Malig Rep</MedlineTA><NlmUniqueID>101262565</NlmUniqueID><ISSNLinking>1558-8211</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000912">Antibodies, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001152">Arsenicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010087">Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514970">tax protein, Human T-lymphotrophic virus 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A189DH42V</RegistryNumber><NameOfSubstance UI="D000074323">Alemtuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>CUJ2MVI71Y</RegistryNumber><NameOfSubstance UI="D000077561">Daclizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7V92P67HO</RegistryNumber><NameOfSubstance UI="D000077237">Arsenic Trioxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074323">Alemtuzumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000912">Antibodies, Neoplasm</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077237">Arsenic Trioxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001152">Arsenicals</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077561">Daclizumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019353">Endemic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016355">Genes, pX</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018445">Infectious Disease Transmission, Vertical</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010087">Oxides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015493">Paraparesis, Tropical Spastic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011251">Pregnancy Complications, Infectious</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20425378</ArticleId><ArticleId IdType="doi">10.1007/s11899-007-0035-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Oncol. 2004 Nov;5(11):664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15522654</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2006 May 15;107(10):3976-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16424388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol J. 2004;5(2):130-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 2006 Feb;18(2):269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">16361311</ArticleId></ArticleIdList></Reference><Reference><Citation>Retrovirology. 2007 Apr 14;4:27</Citation><ArticleIdList><ArticleId IdType="pubmed">17433108</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2000 Feb 15;95(4):1386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10666215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8797699</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1988 Apr 15;41(4):505-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2895748</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16407133</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 May 1;191(9):1490-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15809908</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1999 Jan 1;93(1):278-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9864171</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Clin Exp Hematol. 2003 Dec;7(4):336-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15129647</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1999 Jun;105(3):743-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10354140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jul 30;279(31):31991-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15090550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1995 Apr 1;75(7):1598-607</Citation><ArticleIdList><ArticleId IdType="pubmed">8826916</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1983 Oct;62(4):758-66</Citation><ArticleIdList><ArticleId IdType="pubmed">6224522</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1985 Feb 1;55(3):615-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2981152</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2007 May 1;120(9):2052-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17278106</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2005 Jan 13;24(3):419-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15543232</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2007 Apr;7(4):270-80</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1995 Mar 16;60(6):773-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7896443</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 May;69(5):2863-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7707509</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2001 Dec 15;98(13):3762-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11739184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol Oncol. 1986 Jan-Mar;4(1):59-65</Citation><ArticleIdList><ArticleId IdType="pubmed">3009298</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6326131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2007 Apr;7(4):266-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2006 Aug 1;108(3):1021-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 May 15;105(10):4143-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2005 May;19(5):829-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Apr 1;109(7):3060-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2007 Jan;27(1):1-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17216565</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Dec;76(24):12813-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12438606</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2000 Oct 12;19(43):4954-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11042682</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1998 Dec;103(3):721-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9858223</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Mar 1;103(5):1838-45</Citation><ArticleIdList><ArticleId IdType="pubmed">14592824</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1989 Feb 15;43(2):250-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2917802</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2005 Sep 5;24(39):6058-68</Citation><ArticleIdList><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1999 Sep 9;82(6):832-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10446450</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2000 Nov;13(5):657-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11114378</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2002 Sep 1;100(5):1828-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12176906</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2000 Oct 15;96(8):2849-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11023521</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 Oct 1;106(7):2462-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15956280</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1992 Jan 15;79(2):477-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1730092</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1999 Oct 29;83(3):291-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10495418</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2005 May;96(5):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15904464</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1994 Nov 15;59(4):491-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7960218</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Lab Haematol. 2005 Aug;27(4):235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16048490</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2006 Dec 15;108(13):3979-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16917009</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2005 Nov;46(11):1553-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16236609</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1991 Feb 15;77(4):896-905</Citation><ArticleIdList><ArticleId IdType="pubmed">1993227</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31467059</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>17</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.</ArticleTitle><Pagination><StartPage>1406</StartPage><EndPage>1414</EndPage><MedlinePgn>1406-1414</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2019002038</ELocationID><Abstract><AbstractText>Immune checkpoint inhibitors are a powerful new tool in the treatment of cancer, with prolonged responses in multiple diseases, including hematologic malignancies, such as Hodgkin lymphoma. However, in a recent report, we demonstrated that the PD-1 inhibitor nivolumab led to rapid progression in patients with adult T-cell leukemia/lymphoma (ATLL) (NCT02631746). We obtained primary cells from these patients to determine the cause of this hyperprogression. Analyses of clonality, somatic mutations, and gene expression in the malignant cells confirmed the report of rapid clonal expansion after PD-1 blockade in these patients, revealed a previously unappreciated origin of these malignant cells, identified a novel connection between ATLL cells and tumor-resident regulatory T cells (Tregs), and exposed a tumor-suppressive role for PD-1 in ATLL. Identifying the mechanisms driving this alarming outcome in nivolumab-treated ATLL may be broadly informative for the growing problem of rapid progression with immune checkpoint therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conlon</LastName><ForeName>Kevin C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janakiram</LastName><ForeName>Murali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brammer</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harding</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>B Hilda</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zang</LastName><ForeName>Xingxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Xiaoxin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Sydney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xiaogang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miljkovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundaramoorthi</LastName><ForeName>Hemalatha</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Ancy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skidmore</LastName><ForeName>Zachary L</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Obi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Malachi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldmann</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02631746</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R21 CA234640</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 CA186712</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 HG007940</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA063417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK100525</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA175495</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>31YO63LBSN</RegistryNumber><NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Blood. 2019 Oct 24;134(17):1366-1367</RefSource><PMID Version="1">31698427</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074322">Antineoplastic Agents, Immunological</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077594">Nivolumab</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061026">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict-of-interest disclosure: The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31467059</ArticleId><ArticleId IdType="pmc">PMC6839957</ArticleId><ArticleId IdType="doi">10.1182/blood.2019002038</ArticleId><ArticleId IdType="pii">S0006-4971(20)74025-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335-3337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588312</ArticleId><ArticleId IdType="pubmed">26325031</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiliana A, Nurrani NM, Wijaya A. Cancer immunotherapy: a review. Indones Biomedical Journal. 2016;8(1):1-20.</Citation></Reference><Reference><Citation>Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4858828</ArticleId><ArticleId IdType="pubmed">27151159</ArticleId></ArticleIdList></Reference><Reference><Citation>Champiat S, Ferrara R, Massard C, et al. . Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15(12):748-762.</Citation><ArticleIdList><ArticleId IdType="pubmed">30361681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentes-Antr&#225;s J, Provencio M, D&#237;az-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev. 2018;70:16-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">30053725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham CRM. Human T cell leukemia virus type 1: persistence and pathogenesis. Annu Rev Immunol. 2018;36(1):43-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29144838</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. . Revised adult T-cell leukemia/lymphoma international consensus meeting report. J Clin Oncol. 2019;37(8):677-687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494249</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Chung EY, Giricz O, et al. . North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018;132(14):1507-1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="pubmed">30104217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Waldmann TA, Janakiram M, Brammer J. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378:1947-1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">29768155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Ishii N, Ine S, et al. . Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol. 2006;18(2):269-277.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361311</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato P, Matsuoka M. Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. Int Immunol. 2014;26(8):419-425.</Citation><ArticleIdList><ArticleId IdType="pubmed">24792037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front Immunol. 2018;9:2374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199356</ArticleId><ArticleId IdType="pubmed">30386337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao JL, Savage PA. Unlocking the complexities of tumor-associated regulatory T cells. J Immunol. 2018;200(2):415-421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5763514</ArticleId><ArticleId IdType="pubmed">29311383</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simone M, Arrigoni A, Rossetti G, et al. . Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45(5):1135-1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119953</ArticleId><ArticleId IdType="pubmed">27851914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother. 2011;60(7):909-918.</Citation><ArticleIdList><ArticleId IdType="pubmed">21644034</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, et al. . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47(8):e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486549</ArticleId><ArticleId IdType="pubmed">30783653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Nakano K, Miyake A, et al. . Polycomb-mediated loss of miR-31 activates NIK-dependent NF-&#954;B pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121-135.</Citation><ArticleIdList><ArticleId IdType="pubmed">22264793</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#233;r&#232;s E, Blin J, Ricci EP, et al. . PDZ domain-binding motif of Tax sustains T-cell proliferation in HTLV-1-infected humanized mice. PLoS Pathog. 2018;14(3):e1006933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882172</ArticleId><ArticleId IdType="pubmed">29566098</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92(4):1057-1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42636</ArticleId><ArticleId IdType="pubmed">7862633</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang J, Rauch DA, Huey D, et al. . HTLV-1 viral oncogene HBZ induces lymphoproliferative and osteolytic bone disease in humanized mouse models. Paper presented at the 19th International Conference on Human Retrovirology. 26 April 2019. Lima, Peru.</Citation></Reference><Reference><Citation>Lowther DE, Goods BA, Lucca LE, et al. . PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5):e85935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864991</ArticleId><ArticleId IdType="pubmed">27182555</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrels A, Lund T, Serrels B, et al. . Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell. 2015;163(1):160-173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597190</ArticleId><ArticleId IdType="pubmed">26406376</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsheshet Y, Wildbaum G, Levy E, et al. . CCR8+FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci USA. 2017;114(23):6086-6091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5468670</ArticleId><ArticleId IdType="pubmed">28533380</ArticleId></ArticleIdList></Reference><Reference><Citation>van Maren WWC, Jacobs JFM, de Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology. 2008;124(4):445-452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2492951</ArticleId><ArticleId IdType="pubmed">18540962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamrouni A, Fogh H, Zak Z, &#216;dum N, Gniadecki R. Clonotypic diversity of the T-cell receptor corroborates the immature precursor origin of cutaneous T-cell lymphoma. Clin Cancer Res. 2019;25(10):3104-3114.</Citation><ArticleIdList><ArticleId IdType="pubmed">30808775</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta R, Yasunaga J-I, Miura M, et al. . Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo. PLoS Pathog. 2017;13(11):e1006722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724899</ArticleId><ArticleId IdType="pubmed">29186194</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Huang X, Wang S, et al. . Double negative Treg cells promote nonmyeloablative bone marrow chimerism by inducing T-cell clonal deletion and suppressing NK cell function. Eur J Immunol. 2012;42(5):1216-1225.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Yang W, Degauque N, Tian Y, Mikita A, Zheng XX. New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses. Blood. 2007;109(9):4071-4079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1874581</ArticleId><ArticleId IdType="pubmed">17197428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno T, Joseph A, Matsunaga T, et al. . Anti-PD-1 antibody suppressed the leukemic growth of HTLV-1 infected cells in humanized mouse model. Paper presented at the 19th International Conference on Human Retrovirology. 26 April 2019. Lima, Peru.</Citation></Reference><Reference><Citation>Ishitsuka K, Utsunomiya A, Ishida T. PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma. N Engl J Med. 2018;379(7):695-697.</Citation><ArticleIdList><ArticleId IdType="pubmed">30124278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada T, Togashi Y, Tay C, et al. . PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999-10008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525547</ArticleId><ArticleId IdType="pubmed">31028147</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Mathews Griner LA, Ju W, et al. . Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci USA. 2015;112(40):12480-12485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603455</ArticleId><ArticleId IdType="pubmed">26396258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada L, Nagano Y, Hasegawa A, et al. . IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13(9):e1006597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614654</ArticleId><ArticleId IdType="pubmed">28910419</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess C, Means TK, Autissier P, et al. . IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood. 2004;104(12):3463-3471.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292066</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Houtman JC. Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement. Immunol Res. 2014;59(1-3):23-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4125427</ArticleId><ArticleId IdType="pubmed">24816556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pancewicz J, Taylor JM, Datta A, et al. . Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA. 2010;107(38):16619-16624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944748</ArticleId><ArticleId IdType="pubmed">20823234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Zheng T, Wang Y, et al. . Activation of Notch1 signaling by HTLV-1 Tax promotes proliferation of adult T-cell leukemia cells. Biochem Biophys Res Commun. 2019;512(3):598-603.</Citation><ArticleIdList><ArticleId IdType="pubmed">30914196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh CH, Bellon M, Pancewicz-Wojtkiewicz J, Nicot C. Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci USA. 2016;113(24):6731-6736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4914202</ArticleId><ArticleId IdType="pubmed">27247421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wartewig T, Kurgyis Z, Keppler S, et al. . PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis [published correction appears in Nature. 2017;552(7683):121-125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5821214</ArticleId><ArticleId IdType="pubmed">29143824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wartewig T, Ruland J. PD-1 tumor suppressor signaling in T cell lymphomas. Trends Immunol. 2019;40(5):403-414.</Citation><ArticleIdList><ArticleId IdType="pubmed">30979616</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi H, Kiyasu J, Kato T, et al. . PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016;128(10):1374-1381.</Citation><ArticleIdList><ArticleId IdType="pubmed">27418641</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JW, Kim YH, Oh JW. Comparative analyses of signature genes in acute rejection and operational tolerance. Immune Netw. 2017;17(4):237-249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577301</ArticleId><ArticleId IdType="pubmed">28860953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Melamed A, Demontis MA, et al. . Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients. Retrovirology. 2016;13(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706667</ArticleId><ArticleId IdType="pubmed">26745892</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21091150</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1747-4094</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Expert review of hematology</Title><ISOAbbreviation>Expert Rev Hematol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches.</ArticleTitle><Pagination><StartPage>743</StartPage><EndPage>753</EndPage><MedlinePgn>743-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/ehm.10.73</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute- or lymphoma-type ATL still remains extremely poor. Zidovudine/IFN-&#945; therapy seems to be promising, although its efficacy has not yet been confirmed in well-designed prospective studies. High-dose chemotherapy with the support of autologous transplantation does not improve outcome. Allogeneic stem cell transplantation is promising and approximately 40% of aggressive ATL patients are expected to survive long-term, although transplantation-related mortality is as high as 40-50%. Stem cell transplantation using reduced-intensity conditioning is also effective and safer, with graft-versus-ATL and graft-versus-human T-cell lymphotropic virus type I effects observed after transplantation. Novel approaches including new agents such as purine nucleoside phosphorylase inhibitors and histone deacetylase inhibitors, or targeted immunotherapy using antichemokine receptor-4 antibody or dendritic cell/peptide vaccine are also warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanosaki</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pathology and Clinical Laboratory Medicine Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. rtanosak@ncc.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobinai</LastName><ForeName>Kensei</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Hematol</MedlineTA><NlmUniqueID>101485942</NlmUniqueID><ISSNLinking>1747-4094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D007167">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21091150</ArticleId><ArticleId IdType="doi">10.1586/ehm.10.73</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22706526</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>22</EndPage><MedlinePgn>17-22</MedlinePgn></Pagination><Abstract><AbstractText>CADM1/TSLC1 (Cell adhesion molecule 1/Tumor suppressor in lung cancer 1) is a cell adhesion molecule that was originally identified as a tumor suppressor in lung cancer. CADM1/TSLC1 expression is reduced in a variety of cancers via promoter methylation, and this reduction is associated with poor prognosis and enhanced metastatic potential. In contrast, we observed that CADM1/TSLC1 is highly and ectopically expressed in all primary adult T-cell leukemia/lymphoma (ATLL) cells and in most human T-cell leukemia virus type (HTLV)-1-infected T-cell and ATLL cell lines. No expression, however, was detected in CD4<sup>+</sup> T cells or in several other non-HTLV-1-infected leukemia cells. Moreover, we identified that high CADM1/TSLC1 expression plays an important role in enhanced cell-cell adhesion to the vascular endothelium, tumor growth and the ability of ATLL cells to infiltrate organs. We developed various antibodies as diagnostic tools to identify CADM1<sup>+</sup> ATLL cells. Using flow cytometry, we determined that CADM1/TSLC1 is present on the surface of ATLL cells. The percentage of CD4<sup>+</sup>CADM1<sup>+</sup> cells in the peripheral blood of HTLV-1 carriers and ATLL patients was highly correlated with the DNA copy number of HTLV-1 in lymphocytes. In particular, we identified the soluble form of CADM1/TSLC1 in the peripheral blood of HTLV-1 carriers and ATLL patients. Therefore, measurements of soluble CADM1/TSLC1 serum levels and the detection of CD4<sup>+</sup>CADM1<sup>+</sup> cells in the blood, when combined with standard diagnostic methods, would be useful for identifying and monitoring disease progression in HTLV-1 carriers. Such tests would provide increased accuracy and may aid in early diagnosis and in determining the effects of ATLL treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakahata</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C403514">CADM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075982">Cell Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000075982">Cell Adhesion Molecule-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007136">Immunoglobulins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22706526</ArticleId><ArticleId IdType="doi">10.3960/jslrt.52.17</ArticleId><ArticleId IdType="pii">DN/JST.JSTAGE/jslrt/52.17</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">33950540</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-4632</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of dermatology</Title><ISOAbbreviation>Int J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma showing parakeratosis variegata.</ArticleTitle><Pagination><StartPage>e59</StartPage><EndPage>e61</EndPage><MedlinePgn>e59-e61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ijd.15639</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torai</LastName><ForeName>Ryotaro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makino</LastName><ForeName>Teruhiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Tadamichi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Dermatol</MedlineTA><NlmUniqueID>0243704</NlmUniqueID><ISSNLinking>0011-9059</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010241">Parakeratosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010267">Parapsoriasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>5</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33950540</ArticleId><ArticleId IdType="doi">10.1111/ijd.15639</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79: 428-437.</Citation></Reference><Reference><Citation>Sibbald C, Pope E. Systematic review of cases of cutaneous T-cell lymphoma transformation in pityriasis lichenoides and small plaque parapsoriasis. Br J Dermatol 2016; 175: 807-809.</Citation></Reference><Reference><Citation>Kreuter A, Hoffmamm K, Almeyer P. A case of poikiloderma vasculare atrophicans, a rare variant of cutaneous T-cell lymphoma, responding to extracorporeal photopheresis. J Am Acad Drmatol 2005; 706-708.</Citation></Reference><Reference><Citation>Rogozi&#324;ski TT, Zekanowski C, Kaldan L, et&#160;al. Parakeratosis variegata: a possible role of environmental hazards? Dermatology 2000; 201: 54-57.</Citation></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et&#160;al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010; 115: 4337-4343.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21156467</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2152-2669</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical lymphoma, myeloma &amp; leukemia</Title><ISOAbbreviation>Clin Lymphoma Myeloma Leuk</ISOAbbreviation></Journal><ArticleTitle>Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>483</EndPage><MedlinePgn>480-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3816/CLML.2010.n.084</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute T-cell leukemia/lymphoma (ATLL) is a post thymic (peripheral) T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1). Historically, the chemotherapy regimen CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) has been the standard treatment of this rare malignancy. However, its prognosis is poor and median survival in the aggressive variants of ATLL is only 6-10 months. Recently, a more aggressive regimen piloted in Japan, vincristine/cyclophosphamide/doxorubicin/prednisone (VCAP)- doxorubicin/ranimustine/prednisone (AMP)- vindesine/etoposide/carboplatin/prednisone (VECP), has been reported to yield better survival results over biweekly CHOP in a phase III trial. However, the hyper- cyclophosphamide/vincristine/doxorubicin/dexamethasone (CVAD) regimen is a much more frequently used regimen for the treatment of aggressive hematologic malignancies, and has a higher intensity then CHOP. Yet, there is little reported experience with hyper-CVAD regimen in ATLL.</AbstractText><AbstractText Label="CASE REPORTS" NlmCategory="METHODS">We present 2 patients diagnosed with ATLL who were treated with hyper-CVAD chemotherapy and have achieved a durable complete remission. One of the patients has gone on to receive an allogeneic bone marrow transplantation and has been in complete remission for over 18 months. The other has been in a continuous remission for approximately 12 months. We also review the past published experience with the hyper-CVAD regimen in patients with ATLL.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A commonly used chemotherapy regimen for aggressive hematologic malignancies, hyper-CVAD, can induce durable remissions in patients with ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alduaij</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Warren Alpert Medical School at Brown University, Rhode Island Hospital, Providence, RI 02903, USA. dralduaij@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butera</LastName><ForeName>James N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Treaba</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lymphoma Myeloma Leuk</MedlineTA><NlmUniqueID>101525386</NlmUniqueID><ISSNLinking>2152-2669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003907">Dexamethasone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21156467</ArticleId><ArticleId IdType="doi">10.3816/CLML.2010.n.084</ArticleId><ArticleId IdType="pii">S2152-2650(11)70051-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37407474</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>6</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Adult T-cell leukemia/lymphoma: progress in understanding of pathogenesis and treatment].</ArticleTitle><Pagination><StartPage>497</StartPage><EndPage>503</EndPage><MedlinePgn>497-503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.64.497</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is an exceedingly refractory peripheral T-cell lymphoma. Despite the approval of a few new drugs for managing patients with newly diagnosed or relapsed/refractory ATL in recent years, the prognosis has yet to be substantially ameliorated. This study focuses on recent topics on the development of innovative therapies and the identification of prognostic indicators, considering the recent elucidation of the pathogenesisof ATL. Specifically, this study also delineates the advancements in developing novel EZH1/2 inhibitors and comprehensive genetic analysis; the molecular pathogenesis determined through comprehensive gene knockdown and knockout techniques, with its potential as a therapeutic target; the latest discoveries from the analysis of super-enhancer regions; and the prognostic factors extracted from comprehensive genetic analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016411">Lymphoma, T-Cell, Peripheral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Comprehensive genomic analysis</Keyword><Keyword MajorTopicYN="N">Valemetostat</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>22</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37407474</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.64.497</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31889601</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0740-2570</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Seminars in diagnostic pathology</Title><ISOAbbreviation>Semin Diagn Pathol</ISOAbbreviation></Journal><ArticleTitle>Updates in lymph node and skin pathology of adult T-cell leukemia/lymphoma, biomarkers, and beyond.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>10</EndPage><MedlinePgn>1-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.semdp.2019.12.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0740-2570(19)30114-5</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell lymphoproliferative disorder associated with the human T lymphotropic virus (HTLV-1) infection. ATLL predominantly affects individuals within HTLV-1 endemic areas such as Japan, areas of Africa, South America, and the Caribbean. HTLV-1 preferentially infects CD4+ T-cells, and several genetic hits must occur before ATLL develops. ATLL is classically divided into four clinical variants based on manifestations of disease: acute, chronic, lymphomatous, and smouldering. As of 2019, a new subtype has been described: lymphoma type of ATL, extranodal primary cutaneous. In this review, emphasis will be taken to describe the common clinicopathologic manifestations of the disease, advances in biomarker discovery, mutational landscape and targeted therapeutic approaches to treat this highly aggressive and frequently lethal type of T-cell lymphoma.</AbstractText><CopyrightInformation>Copyright &#169; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adkins</LastName><ForeName>Brian D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Virginia, Charlottesville, VA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Hematology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bliss-Moreau</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Virginia, Charlottesville, VA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gru</LastName><ForeName>Alejandro A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Pathology &amp; Dermatology, Hematopathology and Dermatopathology Sections, University of Virginia, Charlottesville, VA, United States. Electronic address: aag4b@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA240139</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA223232</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Diagn Pathol</MedlineTA><NlmUniqueID>8502262</NlmUniqueID><ISSNLinking>0740-2570</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008198">Lymph Nodes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest Dr. Alejandro A. Gru is a Consultant for Seattle Genetics, StemLine Therapeutics and Innate Pharma. The authors declare no competing financial interests. There is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31889601</ArticleId><ArticleId IdType="mid">NIHMS1611806</ArticleId><ArticleId IdType="pmc">PMC7668393</ArticleId><ArticleId IdType="doi">10.1053/j.semdp.2019.12.006</ArticleId><ArticleId IdType="pii">S0740-2570(19)30114-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed. Lyon, France: International Agency for Research on Cancer; 2017.</Citation></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. Revised adult T-Cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677&#8211;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494249</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashiro D, Sanches JA. Cutaneous manifestations of adult T-cell leukemia/lymphoma. Semin Diagn Pathol. 2019. pii:S0740&#8211;2570(19)30097&#8211;8.</Citation></Reference><Reference><Citation>Verdonck K, Gonz&#225;lez E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1&#8211;related atll in an area of prevalence in the united states. Blood Adv. 2018;2:607&#8211;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="pubmed">29545256</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Shah N, Qiao B, et al. Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the united states. Cancer. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31769871</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M, Watanabe T, Yamaguchi K. Adult T-Cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437524</ArticleId><ArticleId IdType="pubmed">22973265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittencourt AL. Manifesta&#231;&#245;es infanto-juvenis da infec&#231;&#227;o pelo v&#237;rus linfotr&#243;pico de c&#233;lulas t humanas (HTLV-I). J Pediatr (Rio J) 2006;82:411&#8211;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">17171202</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1-related atll in an area of prevalence in the united states. Blood Adv. 2018;2:607&#8211;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="pubmed">29545256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. CD8+ T cells are an in vivo reservoir for human T-cell lymphotropic virus type i. Blood. 2001;98:1858.</Citation><ArticleIdList><ArticleId IdType="pubmed">11535522</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer. 1989;43:250&#8211;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917802</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake M, Yamada Y, Atogami S, Yamaguchi K. The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in japan. Leuk Lymphoma. 2015;56:1806&#8211;1812.</Citation><ArticleIdList><ArticleId IdType="pubmed">25219595</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy EL. Infection with human T-lymphotropic virus types-1 and &#8722;2 (HTLV-1 and &#8722;2): implications for blood transfusion safety. Transfus Clin Biol. 2016;23:13&#8211;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042452</ArticleId><ArticleId IdType="pubmed">26778839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosadas C, Taylor GP. Mother-to-Child HTLV-1 transmission: unmet research needs. Front Microbiol 2019;10:999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517543</ArticleId><ArticleId IdType="pubmed">31134031</ArticleId></ArticleIdList></Reference><Reference><Citation>Beilke MA Retroviral coinfections: hiv and HTLV: taking stock of more than a quarter century of research. AIDS Res Hum Retroviruses. 2012;28:139&#8211;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275926</ArticleId><ArticleId IdType="pubmed">22171689</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M members of the lymphoma study G. diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2006;60:1373&#8211;1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2095573</ArticleId><ArticleId IdType="pubmed">18042693</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Suarez F, Fields P, Hermine O. How i treat adult T-cell leukemia/ lymphoma. Blood. 2011;118:1736&#8211;1745.</Citation><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Imaizumi Y, Tokura Y, et al. Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol. 2014;41:26&#8211;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24438141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurabielle C, Battistella M, Ram-Wolff C, et al. Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). single-center study on 37 patients in metropolitan france between 1996 and 2016. Ann Dermatol Venereol 2018;145:405&#8211;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">29661476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood. 2011;117:3961&#8211;3967.</Citation><ArticleIdList><ArticleId IdType="pubmed">21325600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R, Schwartz RA. Human T-lymphotrophic virus type 1-associated infective dermatitis: a comprehensive review. J Am Acad Dermatol. 2011;64:152&#8211;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hlela C, Bittencourt A. Infective dermatitis associated with HTLV-1 mimics common eczemas in children and may be a prelude to severe systemic diseases. Dermatol Clin. 2014;32:237&#8211;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">24680009</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano M, Setoyama M, Grant A, Kerdel FA. Human T-lymphotropic virus 1 (HTLV-1) infection&#8211;dermatological implications. Int J Dermatol. 2011;50:915&#8211;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">21781059</ArticleId></ArticleIdList></Reference><Reference><Citation>Blas M, Bravo F, Castillo W, et al. Norwegian scabies in peru: the impact of human t cell lymphotropic virus type i infection. Am J Trop Med Hyg. 2005;72:855&#8211;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">15964976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashima R, Kabashima K, Hino R, Shimauchi T, Tokura Y. Scabies superimposed on skin lesions of adult T-cell leukemia/lymphoma: case report and literature review. Int J Dermatol. 2008;47:1168&#8211;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">18986453</ArticleId></ArticleIdList></Reference><Reference><Citation>Qayyum S, Choi JK. Adult T-Cell leukemia/lymphoma. Arch Pathol Lab Med. 2014;138:282&#8211;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">24476526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino T, Jaffe ES. Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L, eds. Adult T-cell leukemia/lymphoma Elsevier; 2016:619&#8211;631. Hematopathology 2nd edition.</Citation></Reference><Reference><Citation>Kojima K, Hara M, Sawada T, et al. Human T-lymphotropic virus type i provirus and T-cell prolymphocytic leukemia. Leuk Lymphoma. 2000;38:381&#8211;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K Pathological features of diseases associated with human T-cell leukemia virus type i. Cancer Sci. 2007;98:772&#8211;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">17388788</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CT, Lee YH, Chow KC, et al. Adult T-cell leukaemia/lymphoma can mimic other lymphomas in a non-endemic area: dilemmas in diagnosis and treatment. Intern Med J. 2014;44:374&#8211;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">24533861</ArticleId></ArticleIdList></Reference><Reference><Citation>Siref A, Huang Q. Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma. Blood. 2018;131:940.</Citation><ArticleIdList><ArticleId IdType="pubmed">29472374</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker SJ, Ng YL, Rustin M, Levene G, McGibbon DH, Smith NP. HTLV-1-associated cutaneous disease: a clinicopathoiogical and molecular study of patients from the U. k. Br J Dermatol. 1993;128:483&#8211;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">8504037</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the united states. human T-cell leukemia/lymphoma virus-associated lymphoid malignancies. Am J Surg Pathol. 1984;8:263&#8211;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">6324600</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti MA, Pulitzer MP, Myskowski PL, et al. Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective study. J Am Acad Dermatol. 2015;72:293&#8211;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">25455841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokote T, Akioka T, Oka S, et al. Flow cytometric immunophenotyping of adult T-Cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol. 2005;124:199&#8211;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">16040289</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, Yuan CM, Xi L, et al. Minimal residual disease detection by flow cytometry in adult T-Cell leukemia/lymphoma. Am J Clin Pathol. 2010;133:592&#8211;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596844</ArticleId><ArticleId IdType="pubmed">20231613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TH, Wu HC, Hsieh YC, Tseng CE, Ichinohasama R, Chuang SS. CD4 and CD8 double-negative adult T-cell leukemia/lymphoma with monomorphic cells expressing CD99: a diagnostic challenge in a country non-endemic for human T-cell leukemia virus. Pathol Int. 2013;63:132&#8211;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">23464972</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza S, Naik S, Kancharla VP, Tafera F, Kalavar MR. Dual-Positive (CD4+/CD8+) acute adult T-Cell leukemia/lymphoma associated with complex karyotype and refractory hypercalcemia: case report and literature review. Case Rep Oncol. 2010;3:489&#8211;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100272</ArticleId><ArticleId IdType="pubmed">21611103</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer. 2007;120:2052&#8211;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Gottesman SR, Ayalew G, Braverman AS, Axiotis CA. Loss of foxp3 is associated with CD30 expression in the anaplastic large cell subtype of adult T-cell leukemia/lymphoma (ATLL) in US/Caribbean patients: potential therapeutic implications for CD30 antibody-mediated therapy. Am J Surg Pathol. 2013;37:1407&#8211;1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">23797717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima M, Yamochi T, Watanabe M, et al. CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1-Infected individuals. Clin Cancer Res. 2018;24:5445&#8211;5457.</Citation><ArticleIdList><ArticleId IdType="pubmed">30068708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625&#8211;3634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurabielle C, Leboeuf C, Ram-Wolff C, et al. KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia. Br J Dermatol. 2018;179:197&#8211;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">29315492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagdi HH, Demontis MA, Fields PA, Ramos JC, Bangham CR, Taylor GP. Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping. Cancer Med. 2017;6:298&#8211;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269699</ArticleId><ArticleId IdType="pubmed">28035765</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with atl. Blood. 2015;126:2570&#8211;2577.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Nakano K, Watanabe E, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2014;20:2851&#8211;2861.</Citation><ArticleIdList><ArticleId IdType="pubmed">24727323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Tian Y, Ohno N, et al. The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-i. PLoS One. 2013;8:e53728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551918</ArticleId><ArticleId IdType="pubmed">23349737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu TY, Chen CY, Tien HF, Lin CW. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology. 2009;54:214&#8211;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">19207946</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1&#8211;infected t cells. Blood. 2017;129:1071&#8211;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374731</ArticleId><ArticleId IdType="pubmed">28115366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K, Yoshida T, Kikuchi M, Masuda Y, Kimura N, Satoh H. Rearrangement of human t cell receptor beta and gamma chain genes in adult t cell leukemia/lymphoma. Hematol Oncol. 1990;8:111&#8211;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">2160910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of htlv-i provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997;89:948&#8211;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">9028326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K. The detection of human t cell leukemia virus proviral dna and its application for classification and diagnosis of t cell malignancy. Blood. 1984;63:1235&#8211;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">6324929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L Molecular biology of human t cell leukemia virus. Semin Diagn Pathol. 2019. pii:S0740&#8211;2570(19)30035&#8211;8.</Citation></Reference><Reference><Citation>Zhao T, Matsuoka M. HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol. 2012;3:247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391691</ArticleId><ArticleId IdType="pubmed">22787458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult t cell leukemia/lymphoma. Nat Genet. 2015;47:1304&#8211;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fochi S, Mutascio S, Bertazzoni U, Zipeto D, Romanelli MG. HTLV deregulation of the nf-&#954;b pathway: an update on tax and antisense proteins role. Front Microbiol. 2018;9:285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826390</ArticleId><ArticleId IdType="pubmed">29515558</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Schaefer BC. A new look at t cell receptor signaling to nuclear factor-&#954;B. Trends Immunol. 2013;34:269&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674144</ArticleId><ArticleId IdType="pubmed">23474202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogure Y, Kataoka K. Genetic alterations in adult T-cell leukemia/lymphoma. Cancer Sci. 2017;108:1719&#8211;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581529</ArticleId><ArticleId IdType="pubmed">28627735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Ogawa S. [Genetic landscape of adult T-cell leukemia/lymphoma]. Rinsho Ketsueki. 2016;57:417&#8211;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">27169444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K Genetic instability of adult T-cell leukemia/lymphoma by comparative genomic hybridization analysis. J Clin Immunol. 2002;22:57&#8211;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">11998893</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood. 2001;97:3875&#8211;3881.</Citation><ArticleIdList><ArticleId IdType="pubmed">11389029</ArticleId></ArticleIdList></Reference><Reference><Citation>Umino A, Nakagawa M, Utsunomiya A, et al. Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes. Blood. 2011;117:5473&#8211;5478.</Citation><ArticleIdList><ArticleId IdType="pubmed">21447829</ArticleId></ArticleIdList></Reference><Reference><Citation>Umino A, Seto M. Array cgh reveals clonal evolution of adult T-cell leukemia/lymphoma. Methods Mol Biol. 2013;973:189&#8211;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">23412791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kogure Y, Kataoka K. Genetic alterations in adult T-cell leukemia/lymphoma. Cancer Sci. 2017;108:1719&#8211;1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581529</ArticleId><ArticleId IdType="pubmed">28627735</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous t cell lymphoma. Nat Genet. 2015;47:1011&#8211;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552614</ArticleId><ArticleId IdType="pubmed">26192916</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Almeida AC, Abate F, Khiabanian H, et al. The mutational landscape of cutaneous t cell lymphoma and sezary syndrome. Nat Genet. 2015;47:1465&#8211;1470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878831</ArticleId><ArticleId IdType="pubmed">26551667</ArticleId></ArticleIdList></Reference><Reference><Citation>Elenitoba-Johnson KS, Wilcox R. A new molecular paradigm in mycosis fungoides and sezary syndrome. Semin Diagn Pathol. 2017;34:15&#8211;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">28024703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47:1056&#8211;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091217</ArticleId><ArticleId IdType="pubmed">26258847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiel MJ, Sahasrabuddhe AA, Rolland DCM, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-stat pathway in sezary syndrome. Nat Commun. 2015;6:8470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598843</ArticleId><ArticleId IdType="pubmed">26415585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata Y, Kontani K, Enami T, et al. Variegated rhoa mutations in adult T-cell leukemia/lymphoma. Blood. 2016;127:596&#8211;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5291304</ArticleId><ArticleId IdType="pubmed">26574607</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes JR, Ambesi-Impiombato A, Couronne L, et al. RHOA G17V induces t follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33:259&#8211;273 e257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811310</ArticleId><ArticleId IdType="pubmed">29398449</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102:e148&#8211;e151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395128</ArticleId><ArticleId IdType="pubmed">28082343</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilber J, Mederake M, Bonzheim I, et al. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations. Mod Pathol. 2019;32:1123&#8211;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">30952970</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to tcr signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128:1490&#8211;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">27369867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Zhang S, Chuang SS, et al. Angioimmunoblastic t cell lymphoma: novel molecular insights by mutation profiling. Oncotarget. 2017;8:17763&#8211;17770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392284</ArticleId><ArticleId IdType="pubmed">28148900</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumais N, Pare ME, Mercier S, et al. T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of human T-cell leukemia virus type 1. J Virol. 2003;77:11170&#8211;11179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC224985</ArticleId><ArticleId IdType="pubmed">14512564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Flies DB. Molecular mechanisms of t cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227&#8211;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7:270&#8211;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3&#8242;-UTR disruption in multiple cancers. Nature. 2016;534:402&#8211;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375&#8211;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">18830259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K, Miyoshi H, Yamada K. [The microenvironment and immune status of peripheral T-cell lymphoma: focusing on aitl and ATLL]. Rinsho Ketsueki. 2018;59:574&#8211;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">29877249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian MA, Olson S, Sundaramoorthi H, et al. An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem. 2018;293:6844&#8211;6858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5936815</ArticleId><ArticleId IdType="pubmed">29540473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Shaffer AL 3rd, Ceribelli M, et al. Targeting the HTLV-I-Regulated BATF3/IRF4 transcriptional network in adult t cell leukemia/lymphoma. Cancer Cell. 2018;34:286&#8211;297 e210.</Citation><ArticleIdList><ArticleId IdType="pubmed">30057145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada L, Nagano Y, Hasegawa A, et al. IL-10-mediated signals act as a switch for lymphoproliferation in human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13:e1006597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614654</ArticleId><ArticleId IdType="pubmed">28910419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilli SC, Salles TS, Saad ST. Regulation of the GATA3 promoter by human T-cell lymphotropic virus type i tax protein. J Cell Biochem. 2004;93:1178&#8211;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15486968</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugata K, Yasunaga J, Kinosada H, et al. HTLV-1 viral factor hbz induces CCR4 to promote T-cell migration and proliferation. Cancer Res. 2016;76:5068&#8211;5079.</Citation><ArticleIdList><ArticleId IdType="pubmed">27402079</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood. 2019;134:2159&#8211;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6908831</ArticleId><ArticleId IdType="pubmed">31562134</ArticleId></ArticleIdList></Reference><Reference><Citation>Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133:1664&#8211;1676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6460420</ArticleId><ArticleId IdType="pubmed">30782609</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123:2915&#8211;2923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014836</ArticleId><ArticleId IdType="pubmed">24632715</ArticleId></ArticleIdList></Reference><Reference><Citation>Araya N, Sato T, Ando H, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ t cells. J Clin Invest. 2014;124:3431&#8211;3442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109535</ArticleId><ArticleId IdType="pubmed">24960164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hieshima K, Nagakubo D, Nakayama T, Shirakawa AK, Jin Z, Yoshie O. Tax-inducible production of cc chemokine ligand 22 by human t cell leukemia virus type 1 (HTLV-1)-infected t cells promotes preferential transmission of HTLV-1 to CCR4- expressing CD4+ t cells. J Immunol. 2008;180:931&#8211;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">18178833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama T, Hieshima K, Arao T, et al. Aberrant expression of fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene. 2008;27:3221&#8211;3232.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071306</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Harewood JCK. Adult t cell leukemia-lymphoma (ATL): state of the art. Curr Hematol Malig Rep 2018;13:300&#8211;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">30047026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Fujikawa D, Watanabe T, Uchimaru K. HTLV-1-Mediated epigenetic pathway to adult T-Cell leukemia-lymphoma. Front Microbiol. 2018;9:1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066519</ArticleId><ArticleId IdType="pubmed">30087673</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Chung EY, Giricz O, et al. North american atll has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018;132:1507&#8211;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="pubmed">30104217</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira PD, Farre L, Bittencourt AL. Adult T-cell leukemia/lymphoma. Rev Assoc Med Bras (1992). 2016;62:691&#8211;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">27925051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo H, Fukushima S, Masuguchi S, Sakai K, Jinnin M, Ihn H. Cutaneous type adult T-cell leukaemia/lymphoma successfully treated with narrowband ultraviolet b phototherapy. Clin Exp Dermatol. 2012;37:183&#8211;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">22082228</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemori N, Hirai K, Onodera R, et al. Satisfactory remission achieved by puva therapy in a case of crisis-type adult T-cell leukaemia/lymphoma with generalized cutaneous leukaemic cell infiltration. Br J Dermatol. 1995;133:955&#8211;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">8547051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y, Shimauchi T, Yamaguchi T, et al. Combination of skin-directed therapy and oral etoposide for smoldering adult T-cell leukemia/lymphoma with skin involvement. Leuk Lymphoma. 2013;54:520&#8211;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">22830614</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177&#8211;4183.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Uozumi K Treatment of adult T-cell leukemia. J Clin Exp Hematop. 2010;50:9&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">20505272</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma. 2003;4:176&#8211;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715100</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly chop for adult T-cell leukemia-lymphoma: japan clinical oncology group study JCOG9801. J Clin Oncol 2007;25:5458&#8211;5464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz S, O&#8217;Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229&#8211;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436818</ArticleId><ArticleId IdType="pubmed">30522922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transpl. 2014;49:1266&#8211;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal M, Reljic T, Klocksieben F, et al. Efficacy of allogeneic hematopoietic cell transplantation in human t cell lymphotropic virus type 1-Associated adult t cell leukemia/lymphoma: results of a systematic review/meta-analysis. Biol Blood Marrow Transpl 2019;25:1695&#8211;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132453</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips EH, Hodson A, Hermine O, Bazarbachi A, Cwynarski K. Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant? Bone Marrow Transpl. 2016;51:1549&#8211;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">27618683</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma. Rinsho Ketsueki. 2016;57:2190&#8211;2198.</Citation><ArticleIdList><ArticleId IdType="pubmed">27795530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369&#8211;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. Defucosylated anti-ccr4 monoclonal antibody (KW-0761) for relapsed adult T-Cell leukemia-lymphoma: a multicenter phase ii study. J Clin Oncol. 2012;30:837&#8211;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson W, Mishra A, Binder A, Gru A, Porcu P. Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all. Haematologica. 2019;104:864&#8211;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518897</ArticleId><ArticleId IdType="pubmed">31040231</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator&#8217;s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2019;104:993&#8211;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518882</ArticleId><ArticleId IdType="pubmed">30573506</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka S, Ono K, Nohgawa M. Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy. Leuk Res Rep. 2019;11:21&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475659</ArticleId><ArticleId IdType="pubmed">31016134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-Cell leukemia&#8211;lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378:1947&#8211;1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">29768155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunning MA, Chiu A, Feldstein JT, et al. CD30 is a potential therapeutic target in patients with HTLV-1 associated adult T-Cell leukemia/lymphoma presenting outside of Japan. Blood. 2012;120:2706.</Citation></Reference><Reference><Citation>Sharma K, Janik JE, O&#8217;Mahony D, et al. Phase ii study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-Associated adult T-cell leukemia/lymphoma. Clin Cancer Res. 2017;23:35&#8211;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215752</ArticleId><ArticleId IdType="pubmed">27486175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23912346</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Science-based management of adult T-cell leukemia-lymphoma].</ArticleTitle><Pagination><StartPage>636</StartPage><EndPage>641</EndPage><MedlinePgn>636-41</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015486">HTLV-I Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055808">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015486">HTLV-I Antigens</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23912346</ArticleId><ArticleId IdType="pii">DN/JST.JSTAGE/rinketsu/54.636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26691420</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality.</ArticleTitle><Pagination><StartPage>725</StartPage><EndPage>727</EndPage><MedlinePgn>725-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/bmt.2015.315</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanosaki</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Blood Transfusion Division, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057234">Preoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26691420</ArticleId><ArticleId IdType="doi">10.1038/bmt.2015.315</ArticleId><ArticleId IdType="pii">bmt2015315</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Oncol. 2010 Mar 20;28(9):1591-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2014 Sep;166(5):739-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2002 May 15;99(10):3493-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11986199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2002 Aug 5;196(3):389-99</Citation><ArticleIdList><ArticleId IdType="pubmed">12163567</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cancer. 2007 Apr;7(4):270-80</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1995 Aug 1;155(3):1151-64</Citation><ArticleIdList><ArticleId IdType="pubmed">7636184</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Dev Immunol. 2013;2013:608951</Citation><ArticleIdList><ArticleId IdType="pubmed">23737813</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2002 Aug 5;196(3):401-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12163568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Mar 10;30(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27914673</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Update on diagnosis and treatment of adult T-cell leukaemia/lymphoma.</ArticleTitle><Pagination><StartPage>176</StartPage><EndPage>180</EndPage><MedlinePgn>176-180</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2016.10.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(16)30514-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mercadal</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unitat Funcional de Limfomes, Servei d'Hematologia, Institut Catal&#224; d'Oncologia, Hospital Duran i Reynals, Institut d'Investigaci&#243; Biom&#232;dica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Espa&#241;a. Electronic address: smercadal@iconcologia.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureda</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unitat Funcional de Limfomes, Servei d'Hematologia, Institut Catal&#224; d'Oncologia, Hospital Duran i Reynals, Institut d'Investigaci&#243; Biom&#232;dica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Espa&#241;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#225;lez-Barca</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unitat Funcional de Limfomes, Servei d'Hematologia, Institut Catal&#224; d'Oncologia, Hospital Duran i Reynals, Institut d'Investigaci&#243; Biom&#232;dica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Espa&#241;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Actualizaci&#243;n del diagn&#243;stico y el tratamiento de la leucemia/linfoma T del adulto.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27914673</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2016.10.005</ArticleId><ArticleId IdType="pii">S0025-7753(16)30514-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17875524</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0925-5710</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>125</EndPage><MedlinePgn>118-25</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) develops in elderly individuals who have been infected with human T-cell leukemia virus type 1 (HTLV-1), and the prognosis for patients with ATLL has been extremely poor. Retrospective studies of allogeneic stem cell transplantation (alloSCT) for selected populations of patients have achieved several encouraging results; however, the reported incidence of transplantation-related mortality (TRM) have been high, even though more than 80% of patients received stem cells from related donors and the patients were relatively young for ATLL. This report documents a prospective feasibility study of alloSCT with reduced-intensity conditioning (RIST) for elderly ATLL patients (&gt;50 years). Regimen-related toxicities and nonhematologic toxicities were acceptable. Fourteen of 15 evaluable patients achieved complete donor chimerism within 90 days, and 1 patient had early TRM after RIST. The HTLV-1 proviral load became undetectable in 8 of 15 patients, suggesting that RIST has potential as an antiviral treatment. The results of alloSCT are promising, and 30% to 40% of patients who achieve remission and have suitable donors can now become long-term survivors with either conventional alloSCT or RIST. It is clear that a graft-versus-ATLL effect is present after alloSCT, regardless of the conditioning regimen or the stem cell source.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan. jyokamur@nk-cc.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uike</LastName><ForeName>Naokuni</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tanosaki</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019172">Transplantation Conditioning</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>19</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17875524</ArticleId><ArticleId IdType="doi">10.1532/IJH97.07070</ArticleId><ArticleId IdType="pii">1G2807K21G0W97XU</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Hematol. 2002 Jul;76(1):91-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12138903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 1987 Dec;2(4):441-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3332192</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2005 Nov;82(4):357-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16298831</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2005 May;96(5):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15904464</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2003 Jan;120(2):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 May 15;105(10):4143-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2004 Jul;95(7):596-601</Citation><ArticleIdList><ArticleId IdType="pubmed">15245597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2006 Jan;37(1):41-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16247419</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Apr 20;354(16):1758-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16625020</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2004 Jan 1;64(1):391-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14729650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2001 Jan;27(1):15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1998 Aug;16(8):2817-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9704734</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1998 Feb 1;91(3):756-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9446633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 1999 Jan;23(1):87-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10037056</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2005 May;19(5):829-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">1528567</PMID><DateCompleted><Year>1992</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0030-2414</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>5</Issue><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Oncology</Title><ISOAbbreviation>Oncology</ISOAbbreviation></Journal><ArticleTitle>Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>335</EndPage><MedlinePgn>333-5</MedlinePgn></Pagination><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). Two patients achieved complete remission, lasting 12 months and more than 8 months, and 2 others partial remission, lasting 2 months and 6 weeks, respectively. The major toxicity was myelosuppression. Other toxicities were not severe and were well tolerable. Orally administered MST-16 is a promising agent for the treatment of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ichihashi</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Branch Hospital, Nagoya University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyoi</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fukutani</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kubo</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yamauchi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Naoe</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Oncology</MedlineTA><NlmUniqueID>0135054</NlmUniqueID><ISSNLinking>0030-2414</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>R1308VH37P</RegistryNumber><NameOfSubstance UI="C057773">sobuzoxane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004341">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1528567</ArticleId><ArticleId IdType="doi">10.1159/000227067</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24064832</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[ATL progress 2013].</ArticleTitle><Pagination><StartPage>1817</StartPage><EndPage>1827</EndPage><MedlinePgn>1817-27</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24064832</ArticleId><ArticleId IdType="pii">DN/JST.JSTAGE/rinketsu/54.1817</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15353320</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1093-4715</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2004</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Frontiers in bioscience : a journal and virtual library</Title><ISOAbbreviation>Front Biosci</ISOAbbreviation></Journal><ArticleTitle>Adult T cell leukemia lymphoma.</ArticleTitle><Pagination><StartPage>2852</StartPage><EndPage>2859</EndPage><MedlinePgn>2852-9</MedlinePgn></Pagination><Abstract><AbstractText>Adult T cell leukemia lymphoma (ATLL) is a CD4+ lymphoproliferative malignancy resulting from human T-cell leukemia virus type 1 (HTLV-1) infection. It includes differing clinical forms classified as smoldering, chronic, lymphomatous, and acute ATLL. The Tax protein of HTLV-1 has been implicated as a viral oncoprotein which enhances virus replication and alters cellular gene expression, including activation of nuclear factor kappa B (NF kB), to result in lymphoid transformation. Chemotherapy for ATLL has had limited efficacy with median survivals of about 1 yr. Antiviral therapy employing zidovudine and interferon has shown promising results, as have antibody-based therapies to the interleukin 2 (IL2) receptor. Novel approaches employ a combination of chemo/antiretroviral therapy, hematopoietic stem cell transplantation, or inhibitors of NF kB activation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Molecular Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA. jo@aol.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA063417-05</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA093062-02</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA093062</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730-01</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA063417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Front Biosci</MedlineTA><NlmUniqueID>9709506</NlmUniqueID><ISSNLinking>1093-4715</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044966">Anti-Retroviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D014408">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017690">Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006412">Hematopoietic Stem Cells</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015375">Receptors, Interleukin-2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15353320</ArticleId><ArticleId IdType="mid">NIHMS94164</ArticleId><ArticleId IdType="pmc">PMC2652732</ArticleId><ArticleId IdType="doi">10.2741/1442</ArticleId><ArticleId IdType="pii">1442</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group. British Journal of Hematology. 1991;79:426&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Broder S. NIH conference: T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Annals of Internal Medicine. 1984;100:543&#8211;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">6322632</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahmoush L. Adult T-cell leukemia/lymphoma. A cytopathologic, immunocytochemical, and flow cytometric study. Cancer. 2002;96:110&#8211;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">11954028</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene. 2003;22:5131&#8211;5140.</Citation><ArticleIdList><ArticleId IdType="pubmed">12910250</ArticleId></ArticleIdList></Reference><Reference><Citation>Morteux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia. 2003;17:26&#8211;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">12529656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita T. Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proceedings of the National Academy of Sciences, USA. 1989;86:5620&#8211;5624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC297674</ArticleId><ArticleId IdType="pubmed">2787512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annual Reviews of Immunology. 2001;19:475&#8211;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244044</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini G, Nicot C, Johnson JM. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Advances in Cancer Research. 2003;89:69&#8211;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">14587871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariner JM. Human T-cell lymphotropic virus type I Tax activates IL-15Ralpha gene expression through an NF kB site. Journal of Immunology. 2001;166:2602&#8211;2609.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160322</ArticleId></ArticleIdList></Reference><Reference><Citation>Azimi N. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: Implications for therapy with a monoclonal antibody direct to the IL-2/15R beta receptor. Journal of Immunology. 1999;163:4064&#8211;4072.</Citation><ArticleIdList><ArticleId IdType="pubmed">10491011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N. Bay 11&#8211;7082 inhibits transcription factor NF kB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100:1828&#8211;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruckes T. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood. 2001;98:1150&#8211;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamihira S. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. British Journal of Hematology. 2003;114:63&#8211;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL) Leukemia. 2002;16:1069&#8211;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040438</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto S. p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood. 2000;95:3939&#8211;3944.</Citation><ArticleIdList><ArticleId IdType="pubmed">10845931</ArticleId></ArticleIdList></Reference><Reference><Citation>Arima N, Tei C. HTLV-I Tax related dysfunction of adult T cell leukemia. Leukemia &amp; Lymphoma. 2001;40:267&#8211;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T. Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. Journal of Biological Chemistry. 2002;277:5187&#8211;5193.</Citation><ArticleIdList><ArticleId IdType="pubmed">11729202</ArticleId></ArticleIdList></Reference><Reference><Citation>Haoudi A. HTLV-1 tax oncoprotein functionally targets a subnuclear complex involved in cellular DNA damage-response. Journal of Biological Chemistry. 2003;278:37736&#8211;37744.</Citation><ArticleIdList><ArticleId IdType="pubmed">12842897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashibara T. Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion. British Journal of Hematology. 2002;116:94&#8211;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11841401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S. Enhanced tumorigenesis in HTLV-1 Tax transgenic mice deficient in interferon gamma. Submitted, 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N. Human T-cell leukemia virus tyhpe I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood. 2002;99:1341&#8211;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11830485</ArticleId></ArticleIdList></Reference><Reference><Citation>Amulf B. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-1 leukemogenesis. Blood. 2002;100:4129&#8211;4138.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393612</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients can be transactivated by HTLV-1 tax gene. Journal of Experimental Medicine. 1990;172:759&#8211;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2188541</ArticleId><ArticleId IdType="pubmed">2388034</ArticleId></ArticleIdList></Reference><Reference><Citation>Wano Y. Interleukin 1 gene expression in adult T cell leukemia. Journal of Clinical Investigation. 1987;80:911&#8211;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442321</ArticleId><ArticleId IdType="pubmed">2887587</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99:534&#8211;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">11781248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi T. Correlation of major histocompatibility complex class I downregulation with resistance of human T-cell leukemia virus type 1-infected T cells to cytotoxic T-lymphocyte killing in a rat model. Journal of Virology. 2002;76:7010&#8211;7019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136333</ArticleId><ArticleId IdType="pubmed">12072501</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman WJ. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proceedings of the National Academy of Sciences, USA. 1995;92:1057&#8211;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42636</ArticleId><ArticleId IdType="pubmed">7862633</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorstensson R, Albert J, Andersson S. Strategies for diagnosis of HTLV-I and -II. Transfusion. 2002;42:780&#8211;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12147033</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifarth W. Assessment of retroviral activity using a universal retrovirus chip. Journal of Virological Methods. 2003;112:79&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12951215</ArticleId></ArticleIdList></Reference><Reference><Citation>Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984&#8211;1987) Leukemia Research. 1991;15:81&#8211;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2016910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno N. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood. 2001;98:1160&#8211;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493465</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht B. Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. Journal of Virological Methods. 1998;75:123&#8211;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9870588</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehee A. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. Journal of Virological Methods. 2002;102:37&#8211;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano Y. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP) Blood. 2002;99:88&#8211;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756157</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclercq I. Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL) Br J Haematol. 1999;105:743&#8211;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">10354140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamihira S. Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clinical and Laboratory Haematology. 2003;25:111&#8211;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12641615</ArticleId></ArticleIdList></Reference><Reference><Citation>deLaFuente C. Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. Journal of Virology. 2000;74:7270&#8211;7283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112248</ArticleId><ArticleId IdType="pubmed">10906181</ArticleId></ArticleIdList></Reference><Reference><Citation>Harhaj EW. Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation. Oncogene. 1999;18:1341&#8211;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">10022816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng PW. Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK-3 mixed lineage kinase involvement in Taxmediated NF-kappaB activation. Oncogene. 2001;20:4484&#8211;4496.</Citation><ArticleIdList><ArticleId IdType="pubmed">11494144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno T. Identification of genes associated with the progression of adult T cell leukemia (ATL) Japanese Journal of Cancer Research. 2000;91:1103&#8211;1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5926287</ArticleId><ArticleId IdType="pubmed">11092974</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinai K. Chemotherapy of ATL. In: Sugamura K, editor. Two decades of adult T-cell leukemia and HTLV-I research. Karger Publishing Co; 2003. pp. 263&#8211;276.</Citation></Reference><Reference><Citation>Besson C. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leukemia &amp; Lymphoma. 2002;43:2275&#8211;2279.</Citation><ArticleIdList><ArticleId IdType="pubmed">12613513</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. British Journal of Hematology. 2001;113:375&#8211;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109) International Journal of Hematology. 2003;77:164&#8211;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau A. Enhanced MDR1 gene expression in human T-cell leukemia virus-I-infected patients offers new prospects for therapy. Blood. 1998;91:2467&#8211;2474.</Citation><ArticleIdList><ArticleId IdType="pubmed">9516147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744&#8211;1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Dega H. Unsuccessful association of zidovuine and interferon alpha for acute adult T-cell leukemia lymphoma. Dermatology. 1999;198:103&#8211;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematology Journal. 2002;3:276&#8211;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. British Journal of Hematology. 2001;113:779&#8211;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>White JD. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leukemia &amp; Lymphoma. 2001;40:287&#8211;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J AIDS. 1996;13(Suppl 1):S186&#8211;S190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JC. Successful treatment with AZT and IFNa in adult T-cell leukemia-lymphoma is characterized by in vivo induction of TRAIL and AP-1 activity. 11th International Conference on Human Retrovirology: HTLV and Related Viruses; San Francisco. 2003.</Citation></Reference><Reference><Citation>Feng X, VanderHeyden N, Ratner L. Interferon-alpha-inhibits HTLV-1 assembly. Journal of Virology. 2003;77:13389&#8211;13395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296084</ArticleId><ArticleId IdType="pubmed">14645593</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill SA. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. Journal of Infectious Diseases. 2003;188:424&#8211;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">12870124</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro C. Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V I) of the reverse transcriptase. Antimicrobial Agents and Chemotherapy. 2003;47:1774&#8211;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153342</ArticleId><ArticleId IdType="pubmed">12709359</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor GP. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T cell phenotype, and antiTax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol. 1999;73:10289&#8211;10295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113083</ArticleId><ArticleId IdType="pubmed">10559346</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi B, Balestrieri E, Mastino A. Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro. Journal of Antimicrobial Chemotherapy. 2003;51:1327&#8211;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">12716774</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RF. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653&#8211;4659.</Citation><ArticleIdList><ArticleId IdType="pubmed">12609827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson WH. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685&#8211;2693.</Citation><ArticleIdList><ArticleId IdType="pubmed">11929754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreitman RJ. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Journal of Clinical Oncology. 2000;18:1622&#8211;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proceedings of the National Academy of Sciences, USA. 2003;100:1891&#8211;1895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149929</ArticleId><ArticleId IdType="pubmed">12569172</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA. T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma. Annals of Oncology. 2000;111(Supplement):101&#8211;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707789</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995;86:4063&#8211;4075.</Citation><ArticleIdList><ArticleId IdType="pubmed">7492762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Medical Oncology. 2002;19(Supplement):S27&#8211;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12180489</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z. Effective therapy for a murine model of adult T-cell leukemia with the human anti-CD2 monoclonal antibody. MEDI -507. 2003;102:284&#8211;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">12649132</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsonomiya A. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplanation. Bone Marrow Transplantation. 2001;27:15&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa T. Allogeneic hematopoietic stem cell transplantation for ATL. In: Sugamura K, editor. Two decades of adult T-cell leukemia and HTLV-I research. Karger Publishing Co; 2003. pp. 253&#8211;262.</Citation></Reference><Reference><Citation>Kishi Y. Successful bone marrow transplantation for adult T-cell leukemia from a donor with oligoclonal proliferation of T-cells infected with human T-cell lymphotropic virus. Leukemia &amp; Lymphoma. 2001;42:819&#8211;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">11697515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kami M. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. British Journal of Hematology. 2003;120:304&#8211;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>Harashima N. Reactivation of strong HTLV-I-specific CTL response in ATL patients following non-myeloablative hematopoietic stem cell transplantation. 11th International Conference on Human Retrovirology: HTLV and Related Viruses; San Francisco. 2003.</Citation></Reference><Reference><Citation>Kami M. Allogeneic haematopoetic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. British Journal of Hematology. 2003;120:304&#8211;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sabban ME. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kB activation. Blood. 2000;96:2849&#8211;2855.</Citation><ArticleIdList><ArticleId IdType="pubmed">11023521</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101:4576&#8211;4582.</Citation><ArticleIdList><ArticleId IdType="pubmed">12560223</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278&#8211;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">9864171</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek MD, Ratner L. Immortalization of T-lymphocytes by human T-cell leukemia virus type 1 tax mutants with different transactivating phenotypes. J Virology. 1999;73:4856&#8211;4865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112529</ArticleId><ArticleId IdType="pubmed">10233947</ArticleId></ArticleIdList></Reference><Reference><Citation>Portis T, Harding JC, Ratner L. The contribution of NF kB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 (HTLV-1) tax-induced tumors. Blood. 2001;98:1200&#8211;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S, Harding J, Ratner L. Effects of the proteasome inhibitor, PS-341, on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Submitted (2004)</Citation><ArticleIdList><ArticleId IdType="pubmed">15090453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan MZ. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gamma c null mide: suppression by an inhibitor against NF kB. Journal of Virology. 2003;77:5286&#8211;5294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153944</ArticleId><ArticleId IdType="pubmed">12692230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Research. 2002;62:1083&#8211;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861386</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatasuki K. Adult T-cell leukemia. International Medicine. 1995;34:947&#8211;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">8563094</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16444967</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Progress of the ATLL study: an overview].</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>349</EndPage><MedlinePgn>339-49</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Yasuaki</ForeName><Initials>Y</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009607">Nitrosourea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018121">Receptors, Cytokine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6PLQ3CP4P3</RegistryNumber><NameOfSubstance UI="D005047">Etoposide</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RSA8KO39WH</RegistryNumber><NameOfSubstance UI="D014751">Vindesine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C118405">LSG15 regimen</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016190">Carboplatin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005047">Etoposide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019942">Genes, p16</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016158">Genes, p53</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017254">Leukemic Infiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009607">Nitrosourea Compounds</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018121">Receptors, Cytokine</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014751">Vindesine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>107</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16444967</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30047026</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-822X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current hematologic malignancy reports</Title><ISOAbbreviation>Curr Hematol Malig Rep</ISOAbbreviation></Journal><ArticleTitle>Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.</ArticleTitle><Pagination><StartPage>300</StartPage><EndPage>307</EndPage><MedlinePgn>300-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11899-018-0458-6</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">ATL is a rare and highly aggressive T cell malignancy caused by HTLV-1. We will review the state of the art of ATL epidemiology, pathogenesis, diagnosis, and treatment.</AbstractText><AbstractText Label="RECENT FINDINGS">Because of population migration, cases of ATL in non-HTLV-1 endemic countries including North America and Europe are increasingly recognized. ATL has diverse clinical manifestations, limited treatment options not widely available globally, and poor prognosis despite therapy. A small subset of patients may achieve prolonged survival with antiviral therapy or allogeneic stem cell transplant. Mogamulizumab, an anti-CCR4 monoclonal antibody, and lenalidomide, an immunomodulatory drug, are approved for ATL in Japan. Molecular studies have identified key alterations in T cell signaling and DNA methylation that may further guide drug development. Patients should be encouraged to enroll in prospective clinical trials when possible. Ongoing, collaborative, international research continues to elucidate disease pathogenesis and contribute to an evolving therapeutic landscape for ATL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Adrienne A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY, 10065, USA. adp9002@med.cornell.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Weill Cornell Medical College, 525 East 68th Street Starr Pavilion, 3rd Floor, New York, NY, 10065, USA. adp9002@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harewood</LastName><ForeName>Janine C K</ForeName><Initials>JCK</Initials><AffiliationInfo><Affiliation>Department of Medicine, New York Presbyterian Queens, Flushing, NY, 11355, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Hematol Malig Rep</MedlineTA><NlmUniqueID>101262565</NlmUniqueID><ISSNLinking>1558-8211</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="D000077269">Lenalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077269">Lenalidomide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATL</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Non-Hodgkin&#8217;s lymphoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30047026</ArticleId><ArticleId IdType="doi">10.1007/s11899-018-0458-6</ArticleId><ArticleId IdType="pii">10.1007/s11899-018-0458-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Oncol. 2016 Dec;34(34):4086-4093</Citation><ArticleIdList><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Mar 10;30(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2015 Oct;14:93-100</Citation><ArticleIdList><ArticleId IdType="pubmed">26414684</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2015 Jun;169(5):672-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2009 Apr;20(4):715-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19150954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 May;69(5):2863-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7707509</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2004 Jul 1;110(4):621-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15122598</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2007 May;92(5):719-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17488707</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2011 Mar 17;117(11):3113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21228324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2002 Apr 25;96(2):110-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11954028</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2009 Jan 20;27(3):453-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2011 May;153(4):451-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21480860</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2018 Feb;35(2):135-152</Citation><ArticleIdList><ArticleId IdType="pubmed">29411267</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2014 Oct;49(10):1266-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2014 Oct;15(11):e517-26</Citation><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Treat Options Oncol. 2015 Feb;16(2):7</Citation><ArticleIdList><ArticleId IdType="pubmed">25762122</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2014 Jun 19;123(25):3925-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24735963</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Adv. 2017 Jun 27;1(15):1195-1205</Citation><ArticleIdList><ArticleId IdType="pubmed">29296760</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2010 Sep 20;28(27):4177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol J. 2004;5(2):130-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1744-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2017 Jan 1;23(1):35-42</Citation><ArticleIdList><ArticleId IdType="pubmed">27486175</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Compr Canc Netw. 2010 Mar;8(3):288-334</Citation><ArticleIdList><ArticleId IdType="pubmed">20202462</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res Treatment. 2012;2012:932175</Citation><ArticleIdList><ArticleId IdType="pubmed">23213552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancers (Basel). 2015 Nov 25;7(4):2318-29</Citation><ArticleIdList><ArticleId IdType="pubmed">26610571</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2011 Jan;46(1):116-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20400987</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2012 Aug 23;120(8):1734-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2012 Nov 15;3:388</Citation><ArticleIdList><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2012 Sep 10;3:322</Citation><ArticleIdList><ArticleId IdType="pubmed">22973265</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2014 Sep;166(5):739-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2016 Sep;22(9):1608-1614</Citation><ArticleIdList><ArticleId IdType="pubmed">27220263</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2017 Jan;58(1):1-3</Citation><ArticleIdList><ArticleId IdType="pubmed">27786571</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 Jun;113(3):779-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 2010 Jul 15;116(14):3438-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2017 Jan;58(1):37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">27654808</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Cancer J. 2016 Mar 25;6:e408</Citation><ArticleIdList><ArticleId IdType="pubmed">27015285</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 May 15;105(10):4143-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jun;14(6):702-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Apr 1;109(7):3060-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2011 Dec 10;29(35):4696-701</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2013 Mar;9(3):e1003271</Citation><ArticleIdList><ArticleId IdType="pubmed">23555266</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2009 Nov 15;125(10):2375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19544530</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2002 Mar 1;99(5):1505-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11861261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2015 Dec;87(12):2130-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25982784</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2017 Mar 2;129(9):1071-1081</Citation><ArticleIdList><ArticleId IdType="pubmed">28115366</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1749-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinsho Ketsueki. 2014 Dec;55(12):2381-99</Citation><ArticleIdList><ArticleId IdType="pubmed">25744039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2015 Nov;47(11):1304-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Apr 20;354(16):1758-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16625020</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2016 Oct 1;34(28):3426-33</Citation><ArticleIdList><ArticleId IdType="pubmed">27507878</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2015 May;169(3):356-67</Citation><ArticleIdList><ArticleId IdType="pubmed">25612920</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2011 Aug 18;118(7):1736-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>Retrovirology. 2005 Mar 02;2:17</Citation><ArticleIdList><ArticleId IdType="pubmed">15743526</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20448111</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2003 Aug 11;22(33):5131-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12910250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31585620</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1924</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Best practice &amp; research. Clinical haematology</Title><ISOAbbreviation>Best Pract Res Clin Haematol</ISOAbbreviation></Journal><ArticleTitle>Genomics of LGL leukemia and select other rare leukemia/lymphomas.</ArticleTitle><Pagination><StartPage>196</StartPage><EndPage>206</EndPage><MedlinePgn>196-206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.beha.2019.06.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1521-6926(19)30042-8</ELocationID><Abstract><AbstractText>Genomic analysis of cancer offers the hope of identifying new treatments or aiding in the selection of existing treatments. Rare leukemias pose additional challenges in this regard as samples may be hard to acquire and when found the underlying pathway may not be attractive to drug development since so few individuals are affected. In this case, it can be useful to identify common mutational overlap among subsets of rare leukemias to increase the number of individuals that may benefit from a targeted therapy. This chapter examines the current mutational landscape of large granular lymphocyte (LGL) leukemia with a focus on STAT3 mutations, the most common mutation in LGL leukemia to date. We examined the linkage between these mutations and autoimmune symptoms and disorders, in cases of obvious and suspected LGL leukemia. We then summarized and compared mutations in a set of other rare leukemias that also have JAK/STAT signaling pathway activation brought about by genomic changes. These include T-cell acute lymphoblastic leukemia (T-ALL), T-cell prolymphocytic leukemia (T-PLL), cutaneous T-cell lymphoma (CTCL), select peripheral T-cell lymphoma (PTCL), and adult T-cell leukemia/lymphoma (ATLL). Though STAT3 activation is common in these leukemias, the way in which it is achieved, such as the activating cytokine pathway and/or the co-mutational background, is quite diverse.</AbstractText><CopyrightInformation>Copyright &#169; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moosic</LastName><ForeName>Katharine B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Pathology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: kbm4dd@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paila</LastName><ForeName>Umadevi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, MSB-6111A, West Complex, 1335 Lee Street, Charlottesville, VA, 22908, USA. Electronic address: udp3f@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Kristine C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: kco6a@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dziewulska</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Pathology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: khd4q@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>T Tiffany</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Microbiology, Immunology, and Cancer Biology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: ttw2ws@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Biomedical Engineering, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA. Electronic address: jeffrey@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratan</LastName><ForeName>Aakrosh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, MSB-6131F, West Complex, 1300 JPA, Charlottesville, VA, 22908, USA. Electronic address: ar7jq@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feith</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: djf2g@virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loughran</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: tl7cs@hscmail.mcc.virginia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>University of Virginia Cancer Center, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA; Department of Medicine, Division of Hematology/Oncology, 345 Crispell Dr, PO Box 801378, Charlottesville, VA, 22908, USA. Electronic address: tlo6s@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 CA225046</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA178393</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009109</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007267</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Best Pract Res Clin Haematol</MedlineTA><NlmUniqueID>101120659</NlmUniqueID><ISSNLinking>1521-6926</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D023281">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D054066">Leukemia, Large Granular Lymphocytic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D035583">Rare Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">CTCL</Keyword><Keyword MajorTopicYN="N">JAK/STAT</Keyword><Keyword MajorTopicYN="N">LGL</Keyword><Keyword MajorTopicYN="N">PTCL</Keyword><Keyword MajorTopicYN="N">STAT3</Keyword><Keyword MajorTopicYN="N">T-ALL</Keyword><Keyword MajorTopicYN="N">T-PLL</Keyword></KeywordList><CoiStatement>Conflict of Interest. Thomas P. Loughran, Jr. is on the Scientific Advisory Board and has stock options for both Keystone Nano and Bioniz Therapeutics. There are no conflicts of interest with the work presented in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31585620</ArticleId><ArticleId IdType="mid">NIHMS1531140</ArticleId><ArticleId IdType="pmc">PMC6779335</ArticleId><ArticleId IdType="doi">10.1016/j.beha.2019.06.003</ArticleId><ArticleId IdType="pii">S1521-6926(19)30042-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG, Jerez A, Thota S, et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018;59(2):416&#8211;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8694069</ArticleId><ArticleId IdType="pubmed">28633612</ArticleId></ArticleIdList></Reference><Reference><Citation>Melenhorst JJ, Eniafe R, Follmann D, Molldrem J, Kirby M, El Ouriaghli F, et al. T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. Hematol J. 2003;4(1):18&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12692516</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughran TP. Clonal diseases of large granular lymphocytes. Blood. 1993. July 1;82(1): 1&#8211;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8324214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamy T, Moignet A, Loughran TP. LGL leukemia: from pathogenesis to treatment. Blood. 2017. March 2;129(9):1082&#8211;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">28115367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamy T, Loughran TP. How I treat LGL leukemia. Blood. 2011. March 10;117(10):2764&#8211;2774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062292</ArticleId><ArticleId IdType="pubmed">21190991</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinway SN, LeBlanc F, Loughran TP. The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev. 2014. May;28(3):87&#8211;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155502</ArticleId><ArticleId IdType="pubmed">24679833</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblanc F, Zhang D, Liu X, Loughran TP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 2012. July;8(7):787&#8211;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464048</ArticleId><ArticleId IdType="pubmed">22830400</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughran TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985. February;102(2):169&#8211;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">3966754</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughran TP, Zickl L, Olson TL, Wang V, Zhang D, Rajala HLM, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015. April;29(4):886&#8211;894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4377298</ArticleId><ArticleId IdType="pubmed">25306898</ArticleId></ArticleIdList></Reference><Reference><Citation>Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014. April;1845(2):136&#8211;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">24388873</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013. January 10;368(2):161&#8211;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604876</ArticleId><ArticleId IdType="pubmed">23301733</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet. 2014. August;46(8):812&#8211;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129488</ArticleId><ArticleId IdType="pubmed">25038750</ArticleId></ArticleIdList></Reference><Reference><Citation>Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012. May 17;366(20):1905&#8211;1913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693860</ArticleId><ArticleId IdType="pubmed">22591296</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, Chen D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol. 2018;73:74&#8211;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">29288042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia. 2013. July;27(7): 1598&#8211;1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">23207521</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012. October 11;120(15):3048&#8211;3057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471515</ArticleId><ArticleId IdType="pubmed">22859607</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson EI, Rajala HLM, Eldfors S, Ellonen P, Olson T, Jerez A, et al. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013. December 6;3:e168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877422</ArticleId><ArticleId IdType="pubmed">24317090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, et al. Cytokine receptor signaling is required for the survival of ALK-anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proc Natl Acad Sci USA. 2017. April 11;114(15):3975&#8211;3980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5393253</ArticleId><ArticleId IdType="pubmed">28356514</ArticleId></ArticleIdList></Reference><Reference><Citation>Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015. April 13;27(4):516&#8211;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5898430</ArticleId><ArticleId IdType="pubmed">25873174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013. November;27(11):2244&#8211;2247.</Citation><ArticleIdList><ArticleId IdType="pubmed">23563237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014. July;99(7):e105&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077094</ArticleId><ArticleId IdType="pubmed">24837465</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta A, Yan D, Hutchison RE, Mohi G. STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice. Br J Haematol. 2018;180(6):911&#8211;915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5484756</ArticleId><ArticleId IdType="pubmed">28025836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajala HLM, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013. May 30;121(22):4541&#8211;4550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668487</ArticleId><ArticleId IdType="pubmed">23596048</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018. January 2;128(1):387&#8211;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5749501</ArticleId><ArticleId IdType="pubmed">29200404</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016. November 17;128(20):2465&#8211;2468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114490</ArticleId><ArticleId IdType="pubmed">27697773</ArticleId></ArticleIdList></Reference><Reference><Citation>Teramo A, Barila G, Calabretto G, Ercolin C, Lamy T, Moignet A, et al. STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget. 2017. September 22;8(37):61876&#8211;61889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5617471</ArticleId><ArticleId IdType="pubmed">28977911</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazitt T, Loughran TP. Chronic neutropenia in LGL leukemia and rheumatoid arthritis. Hematology Am Soc Hematol Educ Program. 2017. December 8;2017(1): 181&#8211;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142558</ArticleId><ArticleId IdType="pubmed">29222254</ArticleId></ArticleIdList></Reference><Reference><Citation>Valori M, Jansson L, Kiviharju A, Ellonen P, Rajala H, Awad SA, et al. A novel class of somatic mutations in blood detected preferentially in CD8+ cells. Clin Immunol. 2017;175:75&#8211;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341785</ArticleId><ArticleId IdType="pubmed">27932211</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajala HLM, Olson T, Clemente MJ, Lagstrom S, Ellonen P, Lundan T, et al. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica. 2015. January;100(1):91&#8211;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281318</ArticleId><ArticleId IdType="pubmed">25281507</ArticleId></ArticleIdList></Reference><Reference><Citation>Savola P, Bruck O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, et al. Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. Haematologica. 2018;103(2):304&#8211;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792275</ArticleId><ArticleId IdType="pubmed">29217783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami T, Sekiguchi N, Kobayashi J, Imi T, Matsuda K, Yamane T, et al. Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. Blood Adv. 2018. October 23 ;2(20): 2704&#8211;2712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199660</ArticleId><ArticleId IdType="pubmed">30337298</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerez A, Clemente MJ, Makishima H, Rajala H, Gomez-Segui I, Olson T, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013. October 3;122(14):2453&#8211;2459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790512</ArticleId><ArticleId IdType="pubmed">23926297</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan EA, Lee MN, DeAngelo DJ, Steensma DP, Stone RM, Kuo FC, et al. Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv. 2017. September 26;1(21):1786&#8211;1789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728102</ArticleId><ArticleId IdType="pubmed">29296824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettersperger J, Montcuquet N, Malamut G, Guegan N, Lopez-Lastra S, Gayraud S, et al. Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity. 2016. September 20;45(3):610&#8211;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">27612641</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamut G, Meresse B, Verkarre V, Kaltenbach S, Montcuquet N, Duong Van Huyen J-P, et al. Large granular lymphocytic leukemia: a treatable form of refractory celiac disease. Gastroenterology. 2012. December;143(6):1470&#8211;1472.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922421</ArticleId></ArticleIdList></Reference><Reference><Citation>Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001. February;107(3):351&#8211;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC199188</ArticleId><ArticleId IdType="pubmed">11160159</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppe A, Andersson EI, Binatti A, Gasparini VR, Bortoluzzi S, Clemente M, et al. Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. Leukemia. 2017. February 7;31(5):1243&#8211;1246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419584</ArticleId><ArticleId IdType="pubmed">28167832</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MV, Zhang R, Loughran TP. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S244&#8211;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4377229</ArticleId><ArticleId IdType="pubmed">19778848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA. 2008. October 21;105(42):16308&#8211;16313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2571012</ArticleId><ArticleId IdType="pubmed">18852469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, et al. Subclonal STAT3 mutations solidify clonal dominance. Blood Adv. 2019. March 26;3(6):917&#8211;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436009</ArticleId><ArticleId IdType="pubmed">30898763</ArticleId></ArticleIdList></Reference><Reference><Citation>Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016. July 25;16(8):494&#8211;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">27451956</ArticleId></ArticleIdList></Reference><Reference><Citation>Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015. March 12;125(11): 1759&#8211;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357583</ArticleId><ArticleId IdType="pubmed">25645356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002. February;1(1):75&#8211;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086890</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017. March 2;129(9):1113&#8211;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363819</ArticleId><ArticleId IdType="pubmed">28115373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes RD, Sarmento LM, Cante-Barrett K, Zuurbier L, Buijs-Gladdines JGCAM, Povoa V, et al. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events. Blood. 2014. July 24;124(4):567&#8211;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">24904117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay CS, Brown FC, Collett M, Saw J, Chiu SK, Sonderegger SE, et al. Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7 signalling. Leukemia. 2016. April 27;30(10): 1993&#8211;2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">27118408</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, et al. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun. 2015. January 7;6:5794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354161</ArticleId><ArticleId IdType="pubmed">25565005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, Knoops L, et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood. 2011. June 30;117(26):7090&#8211;7098.</Citation><ArticleIdList><ArticleId IdType="pubmed">21551237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014. August 28;124(9):1460&#8211;1472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4148768</ArticleId><ArticleId IdType="pubmed">24825865</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson EI, Putzer S, Yadav B, Dufva O, Khan S, He L, et al. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018;32(3):774&#8211;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">28804127</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern MH, Soulier J, Rosenzwajg M, Nakahara K, Canki-Klain N, Aurias A, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene. 1993. September;8(9):2475&#8211;2483.</Citation><ArticleIdList><ArticleId IdType="pubmed">8361760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A, et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood. 1998. July 15;92(2):368&#8211;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657733</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgilio L, Lazzeri C, Bichi R, Nibu K, Narducci MG, Russo G, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA. 1998. March 31;95(7):3885&#8211;3889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19932</ArticleId><ArticleId IdType="pubmed">9520462</ArticleId></ArticleIdList></Reference><Reference><Citation>Laribi K, Lemaire P, Sandrini J, Baugier de Materre A. Advances in the understanding and management of T-cell prolymphocytic leukemia. Oncotarget. 2017. November 28;8(61): 104664&#8211;104686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732835</ArticleId><ArticleId IdType="pubmed">29262669</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel A, Kern W, Zenger M, Perglerova K, Schnittger S, Haferlach T, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. Genes Chromosomes Cancer. 2016. January;55(1):82&#8211;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26493028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol. 2016. April;173(2):265&#8211;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">26917488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao W-Y, Lin Y-C, Liao F-H, Chan Y-C, Huang C-Y. Dual-Specificity Phosphatase 4 Regulates STAT5 Protein Stability and Helper T Cell Polarization. PLoS One. 2015. December 28;10(12):e0145880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692422</ArticleId><ArticleId IdType="pubmed">26710253</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C-Y, Lin Y-C, Hsiao W-Y, Liao F-H, Huang P-Y, Tan T-H. DUSP4 deficiency enhances CD25 expression and CD4+ T-cell proliferation without impeding T-cell development. Eur J Immunol. 2012. February;42(2):476&#8211;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517129</ArticleId><ArticleId IdType="pubmed">22101742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowska-Wojdylo M, Olek-Hrab K, Ruckemann-Dziurdzmska K. Primary cutaneous lymphomas: diagnosis and treatment. Postepy Dermatol Alergol. 2015. October 29;32(5):368&#8211;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692822</ArticleId><ArticleId IdType="pubmed">26759546</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005. May 15;105(10):3768&#8211;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15692063</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015. September;47(9):1011&#8211;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552614</ArticleId><ArticleId IdType="pubmed">26192916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofoletti C, Narducci MG, Russo G. Sezary Syndrome, recent biomarkers and new drugs. Chin Clin Oncol. 2019. February;8(1):2.</Citation><ArticleIdList><ArticleId IdType="pubmed">30525758</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doorn R, van Kester MS, Dijkman R, Vermeer MH, Mulder AA, Szuhai K, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009. January 1;113(1):127&#8211;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">18832135</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood. 2017. September 21;130(12):1430&#8211;1440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609333</ArticleId><ArticleId IdType="pubmed">28694326</ArticleId></ArticleIdList></Reference><Reference><Citation>Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13(21):3331&#8211;3335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612117</ArticleId><ArticleId IdType="pubmed">25485578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastidas Torres AN, Cats D, Mei H, Szuhai K, Willemze R, Vermeer MH, et al. Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes Cancer. 2018. October 25;57(12):653&#8211;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6282857</ArticleId><ArticleId IdType="pubmed">30144205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiel MJ, Sahasrabuddhe AA, Rolland DCM, Velusamy T, Chung F, Schaller M, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun. 2015. September 29;6:8470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598843</ArticleId><ArticleId IdType="pubmed">26415585</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaque JP, Gomez-Lopez G, Monsalvez V, Varela I, Martinez N, Perez C, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014. March 27;123(13):2034&#8211;2043.</Citation><ArticleIdList><ArticleId IdType="pubmed">24497536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopp KL, Ralfkiaer U, Gjerdrum LMR, Helvad R, Pedersen IH, Litman T, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013. June 15;12(12):1939&#8211;1947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735708</ArticleId><ArticleId IdType="pubmed">23676217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011. November 24; 118(22):5891&#8211;5900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342856</ArticleId><ArticleId IdType="pubmed">21865341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010. August 19;116(7): 1105&#8211;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938132</ArticleId><ArticleId IdType="pubmed">20448109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017. March 2;129(9):1095&#8211;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">28115369</ArticleId></ArticleIdList></Reference><Reference><Citation>Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014. February 27;123(9):1293&#8211;1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260974</ArticleId><ArticleId IdType="pubmed">24345752</ArticleId></ArticleIdList></Reference><Reference><Citation>Willemsen M, Abdul Hamid M, Winkens B, Zur Hausen A. Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. Blood Cancer J. 2018. January 17;8(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802554</ArticleId><ArticleId IdType="pubmed">29339730</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016. September 15;128(11):1490&#8211;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">27369867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mereu E, Pellegrino E, Scarfo I, Inghirami G, Piva R. The heterogeneous landscape of ALK negative ALCL. Oncotarget. 2017. March 14;8(11):18525&#8211;18536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392347</ArticleId><ArticleId IdType="pubmed">28061468</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F. The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL). Cancers (Basel). 2018. April 4;10(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923362</ArticleId><ArticleId IdType="pubmed">29617304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamant L, Giuriato S. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALKS subtypes. 2007;109(5):10.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002. February 7;21(7):1038&#8211;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850821</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007. October 1;110(7):2259&#8211;2267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1988960</ArticleId><ArticleId IdType="pubmed">17519389</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001. September 1;61(17):6517&#8211;6523.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522649</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarfo I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood. 2016. January 14;127(2):221&#8211;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">26463425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y, Feldman AL. Genetics of anaplastic large cell lymphoma. Leuk Lymphoma. 2016;57(1):21&#8211;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4732699</ArticleId><ArticleId IdType="pubmed">26104084</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, et al. Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK&#8226;/&#8226;&#8226; and ALK&#8226;/&#8226;&#8226;&#8226; Anaplastic Large Cell Lymphoma. :9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506160</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011. March 24;30(12):1379&#8211;1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413891</ArticleId><ArticleId IdType="pubmed">21119600</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente C, Cools J. The genomic landscape of adult T cell leukemia/lymphoma. Nat Genet. 2015. November;47(11): 1226&#8211;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">26506901</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Fujikawa D, Watanabe T, Uchimaru K. HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2018. July 24;9:1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066519</ArticleId><ArticleId IdType="pubmed">30087673</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006. January 17;103(3):720&#8211;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1334651</ArticleId><ArticleId IdType="pubmed">16407133</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y, Yasunaga J-I, Zhao T, Yoshida M, Miyazato P, Takai K, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011. February 10;7(2):e1001274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037353</ArticleId><ArticleId IdType="pubmed">21347344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J-I, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015. November;47(11): 1304&#8211;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellon M, Lu L, Nicot C. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. Blood. 2016. May 19;127(20):2439&#8211;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874225</ArticleId><ArticleId IdType="pubmed">26813676</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka M, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 1997. December 9;94(25):13897&#8211;13902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28404</ArticleId><ArticleId IdType="pubmed">9391124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol. 2001. February 15;166(4) :2602&#8211;2609.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160322</ArticleId></ArticleIdList></Reference><Reference><Citation>Tendler CL, Greenberg SJ, Blattner WA, Manns A, Murphy E, Fleisher T, et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci USA. 1990. July;87(13):5218&#8211;5222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54293</ArticleId><ArticleId IdType="pubmed">2367534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TT, Yang J, Zhang Y, Zhang M, Dubois S, Conlon KC, et al. IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective &#947;-chain cytokines, decreases leukemic T-cell viability. Leukemia. 2019. May;33(5):1243&#8211;1255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478569</ArticleId><ArticleId IdType="pubmed">30353031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25762122</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6277</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current treatment options in oncology</Title><ISOAbbreviation>Curr Treat Options Oncol</ISOAbbreviation></Journal><ArticleTitle>Incidence of adult T-cell leukemia/lymphoma in nonendemic areas.</ArticleTitle><Pagination><StartPage>7</StartPage><MedlinePgn>7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11864-014-0321-5</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell neoplasm with extremely poor prognosis caused by human T-cell leukemia virus type 1 (HTLV-1). The distribution of HTLV-1 and the incidence of ATLL in endemic areas have been well described, however, little is known about the incidences and the trends of the disease in nonendemic areas. Recently, studies have shown that the HTLV-1 carriers are increasing in nonendemic areas. Also, the incidence of ATLL seems to be significantly increasing in nonendemic areas suggesting that HTLV-1 carriers have emigrated from endemic areas. These epidemiologic studies indicate the necessity of edification of the disease caused by HTLV-1 and establishing appropriate preventive methods against infection in nonendemic areas.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chihara</LastName><ForeName>Dai</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Oncol</MedlineTA><NlmUniqueID>100900946</NlmUniqueID><ISSNLinking>1534-6277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015481">HTLV-I Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017677">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015481">HTLV-I Antibodies</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017678">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014171">Transients and Migrants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25762122</ArticleId><ArticleId IdType="doi">10.1007/s11864-014-0321-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 1982 Mar 20;1(8273):639-43</Citation><ArticleIdList><ArticleId IdType="pubmed">6121963</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1992 Jan 15;79(2):477-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1730092</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2000 May 20;16(8):709-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10826477</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2012 Feb;84(2):327-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22170555</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihon Rinsho. 1977;35(10):3757-67</Citation><ArticleIdList><ArticleId IdType="pubmed">415161</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20448111</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2014 Sep;30(9):856-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24924996</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Med. 2012 Dec;1(3):289-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23342278</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 1997 Apr;11 Suppl 3:60-2</Citation><ArticleIdList><ArticleId IdType="pubmed">9209298</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1999 Mar 1;80(5):662-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10048963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2000 Feb 15;60(4):1043-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10706122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Detect Prev. 1991;15(3):177-81</Citation><ArticleIdList><ArticleId IdType="pubmed">1905579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1989 Jan 1;49(1):226-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2908848</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2008 Sep 1;26(25):4124-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18626005</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2012 Sep 10;3:322</Citation><ArticleIdList><ArticleId IdType="pubmed">22973265</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Jun 3;115(22):4337-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1991 Nov 11;49(5):673-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1937953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2014 Nov 1;74(21):6129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">25320005</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2009 Jun;25(6):551-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19544594</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2012 Oct;103(10):1857-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22738276</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2009 Jan 1;15(1):30-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19118030</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Jan 22;343(8891):213-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7904671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 1999 Dec;189(4):539-45</Citation><ArticleIdList><ArticleId IdType="pubmed">10629555</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 2012 Nov;44(11):852-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22803699</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1996 Sep;94(4):665-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8826890</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1997 May;15(5):1778-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9164185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2014 Feb 26;5:3393</Citation><ArticleIdList><ArticleId IdType="pubmed">24569712</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1977 Sep;50(3):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hum Virol. 1997 Nov-Dec;1(1):37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10195229</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan. 1982 Dec;73(6):893-901</Citation><ArticleIdList><ArticleId IdType="pubmed">6984401</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 1991 May;7(5):447-51</Citation><ArticleIdList><ArticleId IdType="pubmed">1873079</ArticleId></ArticleIdList></Reference><Reference><Citation>J Emerg Med. 2000 Jan;18(1):109-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10645850</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1995 May 15;85(10):2699-704</Citation><ArticleIdList><ArticleId IdType="pubmed">7742529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Clin Exp Hematol. 2003 Dec;7(4):336-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15129647</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 1995 Apr;9(4):598-604</Citation><ArticleIdList><ArticleId IdType="pubmed">7723391</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1991 Jun 1;133(11):1114-24</Citation><ArticleIdList><ArticleId IdType="pubmed">2035515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2007 Apr;7(4):266-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1986 Nov;154(5):851-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2877031</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1985 Nov 15;36(5):557-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2997043</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2014 Feb;164(4):536-45</Citation><ArticleIdList><ArticleId IdType="pubmed">24245986</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Nov;77(11):6815-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6256763</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1989 Feb 15;43(2):250-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2917802</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 1997 Apr;11 Suppl 3:57-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9209297</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2012 Jan 17;21(1):121-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22264793</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Cancer J. 2013 Nov 15;3:e159</Citation><ArticleIdList><ArticleId IdType="pubmed">24241399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2006 Mar 28;234(2):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15896902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Cancer Res. 1989 Mar;80(3):191-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2498254</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2005 Sep 5;24(39):6058-68</Citation><ArticleIdList><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2011 Feb;102(2):295-301</Citation><ArticleIdList><ArticleId IdType="pubmed">21205073</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12040438</PMID><DateCompleted><Year>2002</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0887-6924</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).</ArticleTitle><Pagination><StartPage>1069</StartPage><EndPage>1085</EndPage><MedlinePgn>1069-85</MedlinePgn></Pagination><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATLL) is one of the peripheral T cell malignant neoplasms strongly associated with human T cell leukemia virus type-I (HTLV-I). Although the viral transactivating protein Tax has been proposed to play a critical role in leukemogeneis as shown by its transforming activity in various experimental systems, additional cellular events are required for the development of ATLL. One of the genetic events in ATLL is inactivation of tumor suppressor genes. Among many candidates for tumor suppressor genes, the main genetic events have been reported to center around the cyclin-dependent kinase inhibitors ((CDKIs) p15INK4A, p16INK4B, p18INK4C, p19INK4D, p21WAF1, p27KIP1, and p57KIP2), p53 and Rb genes; all of them play a major regulatory role during G1 to S transition in the cell cycle. Acute/lymphomatous ATLL has frequent alterations of p15 (20%) and p16 (28-67%), while chronic/smoldering ATLL has fewer abnormalities of p15 (0-13%) and p16 (5-26%). Most of these changes are deletion of the genes; fewer samples have mutations. ATLL patients with deleted p15 and/or p16 genes have significantly shorter survival than those individuals with both genes preserved. Although genetic alterations of p18, p19, p21, p27 have rarely been reported, inactivation of these genes may contribute to the development of ATLL because low expression levels of these genes seem to mark ATLL. The p53 gene is mutated in 10-50% of acute/lymphomatous ATLL. Functional impairment of the p53 protein, even if the gene has wild-type sequences, has been suggested in HTLV-I infected cells. Each of these genetic events are mainly found in acute/lymphomatous ATLL, suggesting that alterations of these genes may be associated with transformation to an aggressive phenotype. The Rb tumor suppressor gene is infrequently structurally altered, but one half of ATLL cases have lost expression of this key protein. Notably, alterations of one of the CDKIs, p53 and Rb genes appear to obviate the need for inactivation of other genes in the same pathway. A novel tumor suppressor gene on chromosome 6q may also have a critical role in the pathogenesis of ATLL. Taken together, tumor suppressor genes are frequently altered in acute/lymphomatous ATLL and their alteration is probably the driving force fueling the transition from chronic/smoldering to acute/lymphomatous ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hatta</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeffler</LastName><ForeName>H P</ForeName><Initials>HP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016213">Cyclins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016160">Retinoblastoma Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.22</RegistryNumber><NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018797">Cell Cycle Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019941">Cyclin-Dependent Kinase Inhibitor p16</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018844">Cyclin-Dependent Kinases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016213">Cyclins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016147">Genes, Tumor Suppressor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016160">Retinoblastoma Protein</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016159">Tumor Suppressor Protein p53</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2001</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2001</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>6</Month><Day>25</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12040438</ArticleId><ArticleId IdType="doi">10.1038/sj.leu.2402458</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27795537</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>10</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[HTLV-1-targeted immunotherapy].</ArticleTitle><Pagination><StartPage>2250</StartPage><EndPage>2258</EndPage><MedlinePgn>2250-2258</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a HTLV-1 induced T-cell malignancy with an extremely poor prognosis. There is a long latency period between HTLV-1 infection and the onset of ATL, which indicates the existence of multistep mechanisms of leukemogenesis in the infected cells. Tax, which is encoded by the HTLV-1 pX region, plays a crucial role in HTLV-1 leukemogenesis and is a major target of CTL. We developed an anti-ATL therapeutic vaccine consisting of autologous dendritic cells that is pulsed with Tax peptides (Tax-DC). The vaccination protocol was completed with three injections at a 2-week interval, within one month. Good quality of life and long-term treatment-free survival were observed for more than 3 years in two of the three patients enrolled in the pilot study. Furthermore, the proviral load remained mostly around the carrier level, with minor fluctuation, after vaccination. Tax-specific proliferative CTL responses were observed in all cases and sporadically augmented responses were also subsequently detected. The Tax-DC vaccine might be a well-tolerated and long-lasting maintenance therapy that is acceptable even for elderly patients. Based on the encouraging results, we are now conducting a clinical trial of Tax-DC vaccine combined with anti-CCR4 antibody to enhance the efficacy of the vaccine as next-generation immunotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suehiro</LastName><ForeName>Youko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Department of Cell Therapy, National Kyushu Cancer Center.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015696">Gene Products, tat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015696">Gene Products, tat</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016679">Genome, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D007167">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014611">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27795537</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.57.2250</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2375179</PMID><DateCompleted><Year>1990</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1052-4231</ISSN><JournalIssue CitedMedium="Print"><Volume>117</Volume><Issue>7</Issue><PubDate><Year>1990</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Virginia medical quarterly : VMQ</Title><ISOAbbreviation>Va Med Q</ISOAbbreviation></Journal><ArticleTitle>ATLL complicated by strongyloidiasis and isosporiasis: case report.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>316</EndPage><MedlinePgn>311-6</MedlinePgn></Pagination><Abstract><AbstractText>In summary, we present this as the first reported case of both isosporiasis and strongyloidiasis complicating HTLV-I-associated ATLL. Prompt diagnosis and treatment of these parasites in the immunocompromised host are necessary to prevent severe wasting and dehydration. This should also prevent the significant morbidity and mortality associated with dissemination well-described for Strongyloides, and recently seen at autopsy in a patient with isosporiasis. Recurrent infections are common with both organisms, therefore chronic suppressive therapy and prophylactic treatment prior to chemotherapy or steroid administration is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Virginia, Charlottesville 22908.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>W A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Va Med Q</MedlineTA><NlmUniqueID>9104333</NlmUniqueID><ISSNLinking>1052-4231</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003048">Coccidiosis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009894">Opportunistic Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013322">Strongyloidiasis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2375179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19064971</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.</ArticleTitle><Pagination><StartPage>453</StartPage><EndPage>459</EndPage><MedlinePgn>453-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2008.18.2428</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL) is a distinct peripheral T-lymphocytic malignancy associated with a retrovirus designated human T-cell lymphotropic virus type I (HTLV-1). The diversity in clinical features and prognosis of patients with this disease has led to its subclassification into the following four categories: acute, lymphoma, chronic, and smoldering types. The chronic and smoldering subtypes are considered indolent and are usually managed with watchful waiting until disease progression, analogous to the management of some patients with chronic lymphoid leukemia (CLL) or other indolent histology lymphomas. Patients with aggressive ATL generally have a poor prognosis because of multidrug resistance of malignant cells, a large tumor burden with multiorgan failure, hypercalcemia, and/or frequent infectious complications as a result of a profound T-cell immunodeficiency. Under the sponsorship of the 13th International Conference on Human Retrovirology: HTLV, a group of ATL researchers joined to form a consensus statement based on established data to define prognostic factors, clinical subclassifications, and treatment strategies. A set of response criteria specific for ATL reflecting a combination of those for lymphoma and CLL was proposed. Clinical subclassification is useful but is limited because of the diverse prognosis among each subtype. Molecular abnormalities within the host genome, such as tumor suppressor genes, may account for these diversities. A treatment strategy based on the clinical subclassification and prognostic factors is suggested, including watchful waiting approach, chemotherapy, antiviral therapy, allogeneic hematopoietic stem-cell transplantation (alloHSCT), and targeted therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Hematology, Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan. tsukasak@net.nagasaki-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Bazarbachi</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>William</ForeName><Initials>W</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>O'Mahony</LastName><ForeName>Deirdre</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Janik</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Bittencourt</LastName><ForeName>Achil&#233;a L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Graham P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Kazunari</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tobinai</LastName><ForeName>Kensei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19064971</ArticleId><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="doi">10.1200/JCO.2008.18.2428</ArticleId><ArticleId IdType="pii">JCO.2008.18.2428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, et al: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50:481-492, 1977</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiesz BJ, Ruscetti FW, Gazdar AF, et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77:7415-7419, 1980</Citation><ArticleIdList><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 79:2031-2035, 1982</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi M, Jaffe ES, Ralfkiaer E: Adult T-cell leukaemia/lymphoma, in Jaffe ES, Harris NL, Stein H, et al (eds): WHO Classification of Tumours; Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 200-203</Citation></Reference><Reference><Citation>Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative study&#8212;Lymphoma Study Group (1984-1987). Leuk Res 15:81-90, 1991</Citation><ArticleIdList><ArticleId IdType="pubmed">2016910</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatsuki K: Adult T-Cell Leukemia. New York, NY, Oxford University Press, 1994</Citation></Reference><Reference><Citation>International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans: Human immunodeficiency viruses and human T-cell lymphotropic viruses. International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans. http://monographs.iarc.fr/ENG/Monographs/vol67/volume67.pdf</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5366879</ArticleId><ArticleId IdType="pubmed">9190379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobinai K, Watanabe T: Adult T-cell leukemia-lymphoma, in Abeloff MD, Armitage JO, Niederhuber JE, et al (eds): Clinical Oncology (ed 3). Philadelphia, PA, Elsevier Churchill Livingstone, 2004, pp 3109-3130</Citation></Reference><Reference><Citation>Yamada Y, Hatta Y, Murata K, et al: Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 15:1778-1785, 1997</Citation><ArticleIdList><ArticleId IdType="pubmed">9164185</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Ishida T, Inagaki A, et al: Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: A blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res 31:915-920, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17123603</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Tsukasaki K, et al: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 31:751-757, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17188352</ArticleId></ArticleIdList></Reference><Reference><Citation>Inagaki A, Ishida T, Ishii T, et al: Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: High interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 118:3054-3061, 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16425276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, et al: Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9:3625-3634, 2003</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno N, Tani A, Uozumi K, et al: Expression of functional lung resistance&#8211;related protein predicts poor outcome in adult T-cell leukemia. Blood 98:1160-1165, 2001</Citation><ArticleIdList><ArticleId IdType="pubmed">11493465</ArticleId></ArticleIdList></Reference><Reference><Citation>Tawara M, Hogerzeil SJ, Yamada Y, et al: Impact of p53 aberration on the progression of adult T-cell leukemia/lymphoma. Cancer Lett 234:249-255, 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">15896902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Krebs J, Nagai K, et al: Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: Correlation with clinical course. Blood 97:3875-3881, 2001</Citation><ArticleIdList><ArticleId IdType="pubmed">11389029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Imaizumi Y, Tawara M, et al: Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immunophenotype and defective HTLV-1 genotype. Br J Haematol 105:369-375, 1999</Citation><ArticleIdList><ArticleId IdType="pubmed">10233406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittencourt AL, da Gra&#231;as Vieira M, Brites CR, et al: Adult T-cell leukemia/lymphoma in Bahia, Brazil: Analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol 128:875-882, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17951212</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al: A multicenter clinicopathologic experience of HTLV-1 ATLL: A retrospective 15 year review reveals little progress. Blood 110:1044a, 2007. (abstr 3569)</Citation></Reference><Reference><Citation>Hermine O, Panelatti G, Ramos JC, et al: A worldwide meta-analysis on the use of zidovudine and interferon-alpha for the treatment of adult T-cell leukemia/lymphoma: 13th International Conference on Human Retrovirology, Hakone, Japan, 2007. AIDS Res Hum Retroviruses 23:597-598, 2007. (abstr 106)</Citation></Reference><Reference><Citation>Bazarbachi A, Panelatti G, Ramos JC, et al: A worldwide meta-analysis on the use of zidovudine and interferon-alpha for the treatment of adult T-cell leukemia/lymphoma: American Society of Hematology, Atlanta, Georgia, USA, 2007. Blood 110:610a-611a, 2007. (abstr 2049)</Citation></Reference><Reference><Citation>Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias: French-American-British (FAB) Cooperative Group. J Clin Pathol 42:567-584, 1989</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1141984</ArticleId><ArticleId IdType="pubmed">2738163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">14645001</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Hanada S, Terada A, et al: Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer 61:824-828, 1988</Citation><ArticleIdList><ArticleId IdType="pubmed">3257406</ArticleId></ArticleIdList></Reference><Reference><Citation>Teshima T, Akashi K, Shibuya T, et al: Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 65:327-332, 1990</Citation><ArticleIdList><ArticleId IdType="pubmed">2295055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamihira S, Atogami S, Sohda H, et al: Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73:2753-2758, 1994</Citation><ArticleIdList><ArticleId IdType="pubmed">8194016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadamori N, Ikeda S, Yamaguchi K, et al: Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders. Leuk Res 15:99-103, 1991</Citation><ArticleIdList><ArticleId IdType="pubmed">2016911</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoyama T, Chaganti RS, Yamada Y, et al: Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: A study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 97:3612-3620, 2001</Citation><ArticleIdList><ArticleId IdType="pubmed">11369658</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshiro A, Tagawa H, Ohshima K, et al: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107:4500-4507, 2006</Citation><ArticleIdList><ArticleId IdType="pubmed">16484591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Tsushima H, Yamamura M, et al: Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: Frequent clonal change at crisis from indolent disease. Blood 89:948-956, 1997</Citation><ArticleIdList><ArticleId IdType="pubmed">9028326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JC, Ruiz P Jr, Ratner L, et al: IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 109:3060-3068, 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852214</ArticleId><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Ghez D, Lepelletier Y, et al: New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 5:664-672, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">15522654</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor GP, Matsuoka M: Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24:6047-6057, 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16155611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Murata K, Kamihira S, et al: Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. Cancer 67:2605-2609, 1991</Citation><ArticleIdList><ArticleId IdType="pubmed">2015561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-5464, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Ikeda S, Murata K, et al: Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leuk Res 17:157-166, 1993</Citation><ArticleIdList><ArticleId IdType="pubmed">8429692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W Jr, Kaplan MH, et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alpha and zidovudine. N Engl J Med 332:1744-1748, 1995</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, et al: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749-1751, 1995</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Hermine O: Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 13:S186-S190, 1996. (suppl 1)</Citation><ArticleIdList><ArticleId IdType="pubmed">8797722</ArticleId></ArticleIdList></Reference><Reference><Citation>White JD, Wharfe G, Stewart DM, et al: The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 40:287-294, 2001</Citation><ArticleIdList><ArticleId IdType="pubmed">11426550</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Taylor GP, Cavenagh J, et al: Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: Response and outcome in 15 patients. Br J Haematol 113:779-784, 2001</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Allard I, Levy V, et al: A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 3:276-282, 2002</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A, Bellon M, Sinha-Datta U, et al: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108:1021-1029, 2006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895862</ArticleId><ArticleId IdType="pubmed">16569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Tsukasaki K, Iwanaga M, et al: A long-term study of prognosis in indolent types of adult T-cell leukemia/lymphoma (ATLL): 13th International Conference on Human Retrovirology, Hakone, Japan, 2007. AIDS Res Hum Retroviruses 23:597-598, 2007. (abstr 208)</Citation></Reference><Reference><Citation>Fukushima T, Miyazaki Y, Honda S, et al: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 5:829-834, 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura J, Utsunomiya A, Tanosaki R, et al: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105:4143-4145, 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Matutes E, Catovsky D, et al: Strongyloides stercoralis as candidate co-factor for HTLV-I-induced leukaemogenesis. Lancet 2:94-95, 1987</Citation><ArticleIdList><ArticleId IdType="pubmed">2885585</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabet AS, Mortreux F, Talarmin A, et al: High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 19:4954-4960, 2000</Citation><ArticleIdList><ArticleId IdType="pubmed">11042682</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M, Toma H, Sugahara K, et al: Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis. Oncogene 21:2466-2475, 2002</Citation><ArticleIdList><ArticleId IdType="pubmed">11971181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin&#8217;s lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999</Citation><ArticleIdList><ArticleId IdType="pubmed">10561185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996</Citation><ArticleIdList><ArticleId IdType="pubmed">8652811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Pfistner B, Juweid ME, et al: The International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17242396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, El Sabban M, Nasr R, et al: Arsenic trioxide and interferon alpha synergize to induce cell cycle arrest and apoptosis in HTLV-I transformed cells. Blood 93:278-283, 1999</Citation><ArticleIdList><ArticleId IdType="pubmed">9864171</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sabban M, Nasr R, Dbaibo G, et al: Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with Tax downregulation and reversal of NF-kappa B activation. Blood 96:2849-2855, 2000</Citation><ArticleIdList><ArticleId IdType="pubmed">11023521</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R, Rosenwald A, El-Sabban ME, et al: Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-I infected leukemic cells. Blood 101:4576-4582, 2003</Citation><ArticleIdList><ArticleId IdType="pubmed">12560223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Dombret H, Poupon J, et al: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 5:130-134, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr R, El-Sabban M, Karam J, et al: Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 24:419-430, 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">15543232</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sabban M, Abu Merhi R, Abi Haidar H, et al: Human T-cell lymphotropic virus type I transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 99:3383-3389, 2002</Citation><ArticleIdList><ArticleId IdType="pubmed">11964307</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura IC, Lepelletier Y, Arnulf B, et al: A neutralizing monoclonal antibody (mAb A24) directed against the transferring receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103:1838-1845, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">14592824</ArticleId></ArticleIdList></Reference><Reference><Citation>Pise-Masison CA, Radonovich MA, Dohoney KA, et al: Gene expression profiling of ATL Patients: Identification of signaling pathways which contribute to ATL&#8212;13th International Conference on Human Retrovirology, Hakone, Japan, 2007. AIDS Res Hum Retroviruses 23:597-598, 2007. (abstr 307)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12057109</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1527-2729</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current treatment options in oncology</Title><ISOAbbreviation>Curr Treat Options Oncol</ISOAbbreviation></Journal><ArticleTitle>Human T-cell lymphotropic-I-associated leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>291</StartPage><EndPage>300</EndPage><MedlinePgn>291-300</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell lymphotropic virus-I (HTLV-I)-related adult T-cell leukemia/lymphoma (ATL) is a model disease for proof of viral oncogenesis. HTLV-I infection is endemic in southern Japan and the Caribbean basin, and occurs sporadically in Africa, Central and South America, the Middle East, and the southeastern United States. ATL occurs in only 2% to 4% of HTLV-I-infected people [1-3]. When it does occur, it is usually aggressive and difficult to treat; most people survive for less than 1 year [1-3]. Combination chemotherapy with cytotoxic agents has yielded complete response rates of 20% to 45%, but responses usually last only a few months [3]. Recently, novel treatments, such as monoclonal antibodies directed at the interleukin-2 receptor and the combination of interferon alfa and zidovudine, have been shown to be active in the treatment of patients with ATL. A small percentage of patients achieve long-lasting remissions [2,3].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>R S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gartenhaus</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Kuzel</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Treat Options Oncol</MedlineTA><NlmUniqueID>100900946</NlmUniqueID><ISSNLinking>1534-6277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006800">Deltaretrovirus Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004812">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011251">Pregnancy Complications, Infectious</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018714">Radiotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D065227">Transfusion Reaction</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>87</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>18</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12057109</ArticleId><ArticleId IdType="doi">10.1007/s11864-001-0022-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Endocrinology. 1993 Jun;132(6):2551-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8099324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1990 Sep 1;172(3):759-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2388034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1990 May 12;335(8698):1167-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1971905</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8797699</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1983 Aug 4;309(5):257-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6602943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 1998 Apr 15;90(8):617-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9554445</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1993 Nov 13;307(6914):1224-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8281049</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1989 Jul;74(1):388-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2752118</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 1993 May;9(5):381-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8318266</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 1999 Sep;5(9):2540-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10499631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 Feb 2;337(8736):308-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1671153</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):193-201</Citation><ArticleIdList><ArticleId IdType="pubmed">8680892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1991 May 15;67(10):2605-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2015561</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1986 Oct;146(10):1971-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2876692</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1996 Sep;94(4):713-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8826899</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Dermatol. 1999 Jan;40(1):116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9922028</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1995 Nov 15;86(10):3619-39</Citation><ArticleIdList><ArticleId IdType="pubmed">7579327</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1990 Nov 15;76(10):2065-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1978691</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1995 Dec 1;86(11):4063-75</Citation><ArticleIdList><ArticleId IdType="pubmed">7492762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8797707</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1998 Nov 15;92(10):3557-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9808547</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1744-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2000 Jul 1;96(1):275-81</Citation><ArticleIdList><ArticleId IdType="pubmed">10891462</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8797723</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1998 Mar;100(3):453-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9504625</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 1999 Jan;32(3-4):345-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10037032</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1993 Feb 15;81(4):1017-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8427983</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2541443</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dermatol. 1990 Apr;29(3):161-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2185999</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1991;15(2-3):99-103</Citation><ArticleIdList><ArticleId IdType="pubmed">2016911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8797697</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1993 Nov 13;307(6914):1235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8281054</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1993 Nov 1;82(9):2823-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7693049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1986 Jul 12;2(8498):104-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2873363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1993 Apr 1;71(7):2217-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8384067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Med Assoc. 1995 Oct;87(10):746-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7473848</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S2-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8797696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1985 Feb 15;55(4):851-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3871346</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1977 Sep;50(3):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1996 Apr 1;15(7):1607-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8612584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1992 Jan 11;339(8785):133-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1370235</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1988 Dec 3;297(6661):1456-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3147015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1994 Jun 1;73(11):2753-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8194016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1995 Apr 15;345(8955):978</Citation><ArticleIdList><ArticleId IdType="pubmed">7715303</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1993 Sep 15;82(6):1701-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8400227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8797706</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1997 Feb 1;89(3):948-56</Citation><ArticleIdList><ArticleId IdType="pubmed">9028326</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1993 Feb;17(2):157-66</Citation><ArticleIdList><ArticleId IdType="pubmed">8429692</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1985 Jul;66(1):120-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2988665</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S186-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8797722</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1986;10(8):989-93</Citation><ArticleIdList><ArticleId IdType="pubmed">3489140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1988 Jul;6(7):1088-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2899140</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 1994 Nov;79(5):1322-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7962324</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1988 Apr;148(4):921-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2895617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8797698</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2000 Aug 15;274(1):140-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10936095</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1987 Mar;106(3):361-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2880536</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1998 Dec;103(3):721-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9858223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1985 Aug 10;2(8450):337-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2862506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1989 Sep 15;111(6):484-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2549824</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1987 Mar 15;59(6):1059-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2880655</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1994 Oct;88(2):403-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7803291</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 1994 Oct;70(4):771-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7917938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8797717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1996 Dec 6;271(49):31723-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8940196</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8680890</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1995 Apr 1;85(7):1865-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7703492</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1991 Aug 15;68(4):695-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1855169</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1993 May 15;81(10):2810-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8490187</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1994 Nov 1;84(9):3080-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7949180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 Dec 21-28;338(8782-8783):1593-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1683991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1999 Jun 5;353(9168):1951-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10371587</ArticleId></ArticleIdList></Reference><Reference><Citation>Miner Electrolyte Metab. 1995;21(1-3):166-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7565442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1983 Jan 29;1(8318):240</Citation><ArticleIdList><ArticleId IdType="pubmed">6130269</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1987 Dec 1;60(11):2605-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2890428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 Oct;67(10):6087-95</Citation><ArticleIdList><ArticleId IdType="pubmed">8371355</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Hematol. 1999 Jul;27(7):1168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10390192</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1749-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">8680891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Jan 22;343(8891):213-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7904671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1993 Jan 15;268(2):1174-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8380405</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1991;15(2-3):81-90</Citation><ArticleIdList><ArticleId IdType="pubmed">2016910</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1995 Mar;89(3):690-1</Citation><ArticleIdList><ArticleId IdType="pubmed">7734388</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1992;16(5):435-41</Citation><ArticleIdList><ArticleId IdType="pubmed">1625468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30701465</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma.</ArticleTitle><Pagination><StartPage>249</StartPage><EndPage>259</EndPage><MedlinePgn>249-259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-018-02588-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Tumor, Saitama Medical University International Medical Center, 1397-1, Yamane, 350-1298, Hidaka-City, Saitama-Pref, Japan. tsukasak@saitama-med.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa, 903-0215, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017410">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30701465</ArticleId><ArticleId IdType="doi">10.1007/s12185-018-02588-5</ArticleId><ArticleId IdType="pii">10.1007/s12185-018-02588-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29394679</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0385-0684</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title><ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation></Journal><ArticleTitle>[Bowel Perforation in a Patient with Adult T-Cell Leukemia/Lymphoma].</ArticleTitle><Pagination><StartPage>1494</StartPage><EndPage>1496</EndPage><MedlinePgn>1494-1496</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma(ATLL)can infiltrate throughout various organs and frequently involves the gastrointestinal tract. However, bowel perforation in ATLL patients is rare. Herein, we present a case of ATLL with bowel perforation. A 75-year-old man presented with bowel distension. Computed tomography showed a large mass of the cecum. Edema and stenosis of the ascending colon was seen on colonoscopy, and tumor on the anal side of the stenosis was also found. After admission, the patient complained of abdominal pain with a peritoneal irritation sign. Free air was seen around a large mass of the cecum on computed tomography and an emergency operation was performed under the diagnosis of bowel perforation. Microscopic examination revealed bowel infiltration of ATLL. Gastrointestinal perforation can be caused by ATLL itself and is associated with a poor prognosis. The standard treatment for ATLL is chemotherapy but emergency surgery is necessary in case of perforation. It is important to observe the patient with ATLL carefully.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept. of Surgery, Naze Tokushukai Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunagawa</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shimabukuro</LastName><ForeName>Morikazu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Youjirou</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tanimoto</LastName><ForeName>Akihide</ForeName><Initials>A</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Gan To Kagaku Ryoho</MedlineTA><NlmUniqueID>7810034</NlmUniqueID><ISSNLinking>0385-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003110">Colonic Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007416">Intestinal Perforation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29394679</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8038496</PMID><DateCompleted><Year>1994</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0950-3536</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>1993</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bailliere's clinical haematology</Title><ISOAbbreviation>Baillieres Clin Haematol</ISOAbbreviation></Journal><ArticleTitle>Adult T cell leukaemia-lymphoma.</ArticleTitle><Pagination><StartPage>899</StartPage><EndPage>915</EndPage><MedlinePgn>899-915</MedlinePgn></Pagination><Abstract><AbstractText>Adult T cell leukaemia-lymphoma (ATL) was first discovered and reported in Japan, where it has a high incidence in the south-west region. The first human retrovirus HTLV-I (human T-cell lymphotropic virus type I) is considered to be related to its aetiology. In ATL endemic areas, HTLV-I carriers form a fairly high percentage of the population, even among healthy individuals. ATL shows diverse clinical features. It can be divided into four subtypes: acute, chronic, smouldering and lymphoma type. ATL cells originate from the CD4-positive subset of peripheral T cells; they show a characteristic notch in the nucleus and a tendency to lobulation. ATL resists chemotherapy, and patients with acute and lymphoma types have a fairly poor prognosis. A definite diagnosis of ATL is made by documenting the presence of HTLV-I proviral DNA in the DNA of tumour cells. HTLV-I infection is caused by transmission of live lymphocytes via three routes (from mother to child, from males to females, and by transfusion). Familial occurrence of ATL is frequently seen. HTLV-I infection is seen in other countries, but its incidence is highest in Japan. Infection with HTLV-I is a direct cause of ATL. Furthermore, infection with this virus can indirectly cause many other diseases via the induction of immunodeficiency, such as chronic lung disease, opportunistic lung infection, cancer of other organs, monoclonal gammopathy, chronic renal failure, strongyloidiasis, non-specific dermatomycosis, HTLV-I-associated lymphadenitis, HTLV-I uveitis and HTLV-I-associated myelopathy-tropical spastic paraparesis (HAM/TSP).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Blood Transfusion Service, Kumamoto University Medical School, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takatsuki</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Baillieres Clin Haematol</MedlineTA><NlmUniqueID>8800474</NlmUniqueID><ISSNLinking>0950-3536</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>395575MZO7</RegistryNumber><NameOfSubstance UI="D015649">Pentostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D017691">Caribbean Region</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008171">Lung Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016609">Neoplasms, Second Primary</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015649">Pentostatin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014605">Uveitis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8038496</ArticleId><ArticleId IdType="doi">10.1016/s0950-3536(05)80183-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20214446</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Osteolytic bone resorption in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>702</StartPage><EndPage>714</EndPage><MedlinePgn>702-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/10428191003646697</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is caused by human T lymphotropic virus type 1 (HTLV-1). Patients with ATLL frequently develop humoral hypercalcemia of malignancy (HHM) resulting from increased osteoclastic bone resorption. Our goal was to investigate the mechanisms of ATLL-induced osteoclastic bone resorption. Murine calvaria co-cultured with HTLV-1-infected cells directly or conditioned media from cell cultures had increased osteoclast activity that was dependent on RANKL, indicating that factors secreted from ATLL cells had a stimulatory effect on bone resorption. Factors released from resorbing bone stimulated proliferation of HTLV-1-infected T-cells. Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1alpha (MIP-1alpha), both osteoclast stimulators, were expressed in HTLV-1-infected T-cell lines. Interestingly, when HTLV-1-infected T-cells were co-cultured with pre-osteoblasts, the expression of osteoprotegerin (OPG), an osteoclast inhibitory factor, was significantly down-regulated in the pre-osteoblasts. When OPG was added into the ex vivo osteoclastogenesis assay induced by HTLV-1-infected T-cells, osteoclastogenesis was strongly inhibited. In addition, HTLV-1-infected T-cells inhibited expression of early osteoblast genes and induced late genes. These regulators will serve as future therapeutic targets for the treatments of HHM in ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Sherry T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Veterinary Biosciences, Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Chelsea K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Thudi</LastName><ForeName>Nanda K</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>Dirksen</LastName><ForeName>Wessel P</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Rosol</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA100730</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 RR007073</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730-09</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 CA130458-01</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 CA130458</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000831">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001862">Bone Resorption</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018920">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019169">Jurkat Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010014">Osteolysis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20214446</ArticleId><ArticleId IdType="mid">NIHMS270807</ArticleId><ArticleId IdType="pmc">PMC3057200</ArticleId><ArticleId IdType="doi">10.3109/10428191003646697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord. 2000;1:253&#8211;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706739</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005;24:6047&#8211;6057.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol. 2006;18(4):396&#8211;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">16763461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609&#8211;2617.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata H, Abe M, Hiura K, et al. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis. Clin Cancer Res. 2005;11:6109&#8211;6115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16144909</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood. 2004;104:802&#8211;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090453</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuer G, Zack JA, Harrington WJ, Jr, et al. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood. 1993;82:722&#8211;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">8338942</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard V, Nadella MV, Green PL, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia. 2005;19:1175&#8211;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661941</ArticleId><ArticleId IdType="pubmed">15889157</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchin A, Suchting S, Merson T, et al. Genetic and physical interactions between microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J Biol Chem. 2001;276:36703&#8211;36710.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481336</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97:3349&#8211;3353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11369623</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard V, Luchin A, Brena RM, Plass C, Rosol TJ. Quantitative evaluation of alternative promoter usage and 3&#8242; splice variants for parathyroid hormone-related protein by real-time reverse transcription-PCR. Clin Chem. 2003;49:1398&#8211;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">12881458</ArticleId></ArticleIdList></Reference><Reference><Citation>Holven KB, Damas JK, Yndestad A, et al. Chemokines in children with heterozygous familiar hypercholesterolemia: selective upregulation of RANTES. Arterioscler Thromb Vasc Biol. 2006;26:200&#8211;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254204</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res. 2004;19:1105&#8211;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15176993</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac (null) mice: suppression by an inhibitor against NF-kappaB. J Virol. 2003;77:5286&#8211;5294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153944</ArticleId><ArticleId IdType="pubmed">12692230</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin&#8211;a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 1990;87:4473&#8211;4475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54137</ArticleId><ArticleId IdType="pubmed">1693772</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99:634&#8211;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">11781248</ArticleId></ArticleIdList></Reference><Reference><Citation>Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005;5 Suppl. 2:S46&#8211;S53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15807924</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Falzon M. PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol Cell Endocrinol. 2003;199:165&#8211;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581888</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima M, Ohtsuru A, Luo WT, et al. Expression of parathyroid hormone-related peptide in human thyroid tumours. J Pathol. 1995;175:227&#8211;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">7738719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Inoue D, Okazaki R, Kikuchi T, Ogata E, Matsumoto T. Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone-related peptide overexpression in HTLV-I-infected T cells. Miner Electrolyte Metab. 1995;21:166&#8211;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">7565442</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao J, McCauley LK. Skeletal metastasis: established and emerging roles of parathyroid hormone-related protein (PTHrP) Cancer Metastasis Rev. 2006;25:559&#8211;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">17165129</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard V, Rosol TJ, Foley J. PTHrP gene expression in cancer: do all paths lead to Ets? Crit Rev Eukaryot Gene Expr. 2005;15:115&#8211;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832739</ArticleId><ArticleId IdType="pubmed">16022632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadella MV, Dirksen WP, Nadella KS, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia. 2007;21:1752&#8211;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676796</ArticleId><ArticleId IdType="pubmed">17554373</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood. 2002;100:4129&#8211;4138.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393612</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E, Anagnostopoulos A, Kastritis E, Bamias A, Tsionos K, Dimopoulos MA. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstr&#246;m macroglobulinaemia. Br J Haematol. 2006;133:301&#8211;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16643432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Chano T, Yamamoto K, Matsusue Y, Okabe H. Expression of macrophage inflammatory protein-1alpha in Schwann cell tumors. Neuropathology. 2004;24:131&#8211;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15139590</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96:671&#8211;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">10887133</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001;108:1833&#8211;1841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC209465</ArticleId><ArticleId IdType="pubmed">11748267</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003;102:311&#8211;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">12649140</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson JE, Amizuka N, Warshawsky H, et al. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol. 1995;15:4064&#8211;4075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230645</ArticleId><ArticleId IdType="pubmed">7623802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng F, Liang H, Liu R, et al. Parathyroid hormone-related protein regulates osteoclast inhibitory lectin expression via multiple signaling pathways in osteoblast-like cells. Endocrine. 2009;35:47&#8211;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18987998</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140:4382&#8211;4389.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499489</ArticleId></ArticleIdList></Reference><Reference><Citation>Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1&#8211;38 inhibition of osteoprotegerin gene expression. J Cell Biochem. 2001;84:1&#8211;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746511</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirunavukkarasu K, Miles RR, Halladay DL, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem. 2001;276:36241&#8211;36250.</Citation><ArticleIdList><ArticleId IdType="pubmed">11451955</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab. 2008;8:132&#8211;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569843</ArticleId><ArticleId IdType="pubmed">18680714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega N, Behonick D, Stickens D, Werb Z. How proteases regulate bone morphogenesis. Ann NY Acad Sci. 2003;995:109&#8211;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814943</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004;50:87&#8211;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">15157658</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkington PT, O&#8217;Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol. 2005;142:12&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1809491</ArticleId><ArticleId IdType="pubmed">16178851</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraudon P, Vernant JC, Confavreux C, Belin MF, Desgranges C. Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology. 1998;50:1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633766</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraudon P, Szymocha R, Buart S, et al. T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease. J Immunol. 2000;164:2718&#8211;2727.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679113</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N, Sato H, Hayashibara T, et al. Human T-cell leukemia virus type I Tax transactivates the matrix metallo-proteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood. 2002;99:1341&#8211;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11830485</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho NH, Hong KP, Hong SH, Kang S, Chung KY, Cho SH. MMP expression profiling in recurred stage IB lung cancer. Oncogene. 2004;23:845&#8211;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">14647437</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata Y, Iwata T, Maruta S, et al. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol. 2007;52:791&#8211;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">17207914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew R, Khanna R, Kumar R, et al. Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect Prev. 2002;26:222&#8211;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">12269770</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler G, Walter I, Helmreich M, Egerbacher M. Localization of matrix metalloproteinases (MMPs), their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth plates of children and adolescents indicates a role for MMPs in human postnatal growth and skeletal maturation. Calcif Tissue Int. 2005;76:326&#8211;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">15868281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32597011</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>16</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>Clinical and cytopathological characteristics of HTLV-1<sup>+</sup> hodgkin lymphoma.</ArticleTitle><Pagination><StartPage>5788</StartPage><EndPage>5797</EndPage><MedlinePgn>5788-5797</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.3139</ELocationID><Abstract><AbstractText Label="BACKGROUND">Human T-lymphotropic virus-1 (HTLV-1)<sup>+</sup> Hodgkin lymphoma (HL) is difficult to differentiate from adult T-cell leukemia/lymphoma (ATLL) with HL-like histology (HL-like ATLL).</AbstractText><AbstractText Label="METHODS">Cytological and immunohistological features, HTLV-1 proviral DNA integration, and rearrangements of the T-cell receptor (TCR) C&#946;1 gene were examined in 11 HTLV-1<sup>+</sup> patients with HL-like disease.</AbstractText><AbstractText Label="RESULTS">Six patients were classified as HTLV-1<sup>+</sup> HL and five as HL-like ATLL in accordance with genetic findings of HTLV-1 proviral DNA integration and rearrangements of the TCR C&#946;1 gene. Small ordinary looking lymphocytes with round nuclei were detected in the background of six patients with HTLV-1<sup>+</sup> HL, which were immunohistochemically negative for CD25 and CC chemokine receptor (CCR)4 and had a low MIB1 labeling index (mean: 28.3%). In the HL-like ATLL specimens, small- and medium-sized atypical lymphocytes with indented and irregular-shaped nuclei were found, and were diffusely positive for CD25 and CCR4, with high MIB1 labeling (mean: 76%). Both groups had scattered CD30<sup>+</sup> and CD15<sup>+</sup> Hodgkin and Reed Sternberg (RS) giant cells, with or without CD20 expression and Epstein-Barr virus infection. The 50% overall survival period was significantly longer for the HTLV-1<sup>+</sup> HL group (180&#160;months) than for the HL-like ATLL group (7.8&#160;months; P&#160;=&#160;.004).</AbstractText><AbstractText Label="CONCLUSIONS">HTLV-1<sup>+</sup> HL showed typical small lymphoid cells with a low MIB1 labeling index in a background of Hodgkin and RS cells, with some scattered CD25<sup>+</sup> and CCR4<sup>+</sup> lymphocytes. In HTLV-1 endemic areas, distinguishing HTLV-1<sup>+</sup> HL from HL-like ATLL is important because of their differing treatment strategies and prognoses.</AbstractText><CopyrightInformation>&#169; 2020 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobata</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Diagnostic Pathology, Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Shoichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihashi</LastName><ForeName>Yasuhito</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Otolaryngology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3711-272X</Identifier><AffiliationInfo><Affiliation>Departments of Hematology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nonaka</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Pathology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1566-4681</Identifier><AffiliationInfo><Affiliation>Division of Diagnostic Pathology, Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamatsu</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Hematology and Infectious Diseases, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ilseung</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawauchi</LastName><ForeName>Shigeto</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Pathology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7030-497X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeshita</LastName><ForeName>Morishige</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0267-2081</Identifier><AffiliationInfo><Affiliation>Division of Diagnostic Pathology, Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018951">Antigens, CD20</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018951">Antigens, CD20</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D048429">Cell Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020031">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015333">Gene Rearrangement, beta-Chain T-Cell Antigen Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D019674">Genes, T-Cell Receptor beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006689">Hodgkin Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016246">Lymphocytes, Tumor-Infiltrating</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016539">Reed-Sternberg Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016662">Virus Integration</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no significant relationships with, or financial interest in, any commercial activities pertaining to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32597011</ArticleId><ArticleId IdType="pmc">PMC7433818</ArticleId><ArticleId IdType="doi">10.1002/cam4.3139</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ohshima K, Jaffe ES, Yoshino T, Siebert R. Adult T&#8208;cell leukemia/lymphoma. WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn LARC Press: Lyon; 2017:pp. 363&#8208;367.</Citation></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T&#8208;cell leukaemia&#8208;lymphoma. A report from the Lymphoma Study Group (1984&#8211;87). Br J Hematol. 1991;79:428&#8208;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K, Suzumiya J, Kato A, et al. Clonal HTLV&#8208;infected CD4+ T&#8208;lymphocytes and non&#8208;clonal non&#8208;HTLV&#8208;1&#8208;infected giant cells in incipient ATLL with Hodgkin&#8208;like histologic features. Int J Cancer. 1997;72:592&#8208;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">9259396</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataraman G, Berkowitz J, Morris JC, et al. Adult T&#8208;cell leukemia/lymphoma with EBV&#8208;positive Hodgkin&#8208;like cells. Hum Pathol. 2011;42:1042&#8208;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118938</ArticleId><ArticleId IdType="pubmed">21315416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittencourt AL, Andrade AC, Requi&#227;o C, et al. Prolonged lymphocytosis as the first manifestation of Hodgkin&#8208;like adult T&#8208;cell leukemia/lymphoma. Braz J Infect Dis. 2017;21:119&#8208;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9425504</ArticleId><ArticleId IdType="pubmed">27789281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya Y, Yoshida M, Tsutsumi M, et al. Hodgkin&#8208;like adult T&#8208;cell leukemia/lymphoma that developed during the follow&#8208;up of HTLV&#8208;1 associated myelopathy/tropical spastic paraparesis. J Clin Exp Hematopathol. 2019;59:130&#8208;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798146</ArticleId><ArticleId IdType="pubmed">31391405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K, Suzumiya J, Sato K, et al. Survival of patients with HTLV&#8208;1&#8208;associated lymph node lesions. J Pathol. 1999;189:539&#8208;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">10629555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadahira Y, Nishihara H, Shimizu M, et al. Epstein&#8208;Barr virus&#8208;associated Hodgkin's disease in HTLV&#8208;1 seropositive patients: a report of two cases. Pathol Int. 1998;48:67&#8208;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9589468</ArticleId></ArticleIdList></Reference><Reference><Citation>Duggan DB, Ehlich GD, Davey FP, et al. HTLV&#8208;I&#8208;induced lymphoma mimicking Hodgkin&#8217;s disease. Diagnosis by polymerase chain reaction amplification of specific HTLV&#8208;1 sequences in tumor DNA. Blood. 1988;71:1027&#8208;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">2895676</ArticleId></ArticleIdList></Reference><Reference><Citation>Alikhan M, Song JY, Sohani AR, et al. Peripheral T&#8208;cell lymphoma of follicular helper T cell type frequently display an aberrant CD3&#8722;/dim CD4+ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod Pathol. 2016;29:1173&#8208;1182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331059</ArticleId><ArticleId IdType="pubmed">27312067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CY, Wang R&#8208;C, Chen B&#8208;J, et al. Granuloma with an underlying lymphomas: A diagnostic challenge and a wider histologic spectrum including adult T&#8208;cell leukemia/lymphoma. App Immunohistochem Mol Morphol. 2020;28:316&#8211;324. 10.1097/PAI.731</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAI.731</ArticleId><ArticleId IdType="pubmed">30653030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobata K, Mihashi Y, Nonaka S, et al. Cytological tumour cell characteristics and reactive small lymphocytes influence patient prognosis in acute and lymphoma type adult T&#8208;cell leukaemia/lymphoma. Cytopathol. 2019;30:402&#8208;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">30907476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto K, Kitamura T, Fujita K, et al. Cytologic differential diagnosis of follicular lymphoma Grades 1 and 2 from reactive follicular hyperplasia. Diag Cytopathol. 2005;34:11&#8208;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16355396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihashi Y, Mizoguchi M, Takamatsu Y, et al. C&#8208;MYC and its main ubiquitin ligase, FBXW7, influence cell proliferation and prognosis in adult T&#8208;cell leukemia/lymphoma. Am J Surg Pathol. 2017;41:1139&#8208;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">28498285</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamoto Y, Suga K, Shibata K, et al. Clinical importance of extraordinary integration patterns of human T&#8208;cell lymphotropic virus type I proviral DNA in adult T&#8208;cell leukemia/lymphoma. Blood. 1994;84:853&#8208;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043866</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T, Yamabe H, Haga H, et al. Synchronous presentation of Epstein&#8208;Barr virus&#8208;associated Hodgkin&#8217;s disease and adult T&#8208;cell leukemia/lymphoma (ATLL) in a patient from an endemic area of ATLL. Int J Hematol. 1995;61:215&#8208;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8547610</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T, Nakamura S, Kato H, et al. Epstein&#8208;Barr virus&#8208;related Hodgkin&#8217;s disease showing B cell lineage in an immunosuppressive patient seropositive for HTLV&#8208;I. Pathol Int. 1997;47:801&#8208;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413042</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakuni T, Oshiro K, Yagi N, et al. Clinicopathological analysis of Hodgkin disease. J Okinawa Med Ass. 1999;35:28&#8208;38. (in Japanese).</Citation></Reference><Reference><Citation>Takeshita M, Okamura S, Uike N, et al. Adult T&#8208;cell leukemia/lymphoma. Pathol Clin Med. 2003;21:279&#8208;283. (in Japanese).</Citation></Reference><Reference><Citation>Suefuji H, Ohshima K, Hayabuchi N, et al. HTLV&#8208;1 carriers in B&#8208;cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features. Brit J Haematol. 2003;123:606&#8208;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">14616963</ArticleId></ArticleIdList></Reference><Reference><Citation>Baues C, Semrau R, Gaipl US, et al. Checkpoint inhibitors and radiation treatment in Hodgkin&#8217;s lymphoma. Strahlenther Onkol. 2017;193:95&#8208;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">27704149</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzger ML, Mauz&#8208;Korholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non&#8208;Hodgkin and Hodgkin lymphoma. Brit J Haematol. 2019;185:1142&#8208;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">30729493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26361794</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><Issue>24</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Treatment and survival among 1594 patients with ATL.</ArticleTitle><Pagination><StartPage>2570</StartPage><EndPage>2577</EndPage><MedlinePgn>2570-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2015-03-632489</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature T lymphocytes caused by human T-lymphotropic virus type I. Intensive combination chemotherapy and allogeneic hematopoietic stem cell transplantation have been introduced since the previous Japanese nationwide survey was performed in the late 1980s. In this study, we delineated the current features and management of ATL in Japan. The clinical data were collected retrospectively from the medical records of patients diagnosed with ATL between 2000 and 2009, and a total of 1665 patients' records were submitted to the central office from 84 institutions in Japan. Seventy-one patients were excluded; 895, 355, 187, and 157 patients with acute, lymphoma, chronic, and smoldering types, respectively, remained. The median survival times were 8.3, 10.6, 31.5, and 55.0 months, and 4-year overall survival (OS) rates were 11%, 16%, 36%, and 52%, respectively, for acute, lymphoma, chronic, and smoldering types. The number of patients with allogeneic hematopoietic stem cell transplantation was 227, and their median survival time and OS at 4 years after allogeneic hematopoietic stem cell transplantation was 5.9 months and 26%, respectively. This study revealed that the prognoses of the patients with acute and lymphoma types were still unsatisfactory, despite the recent progress in treatment modalities, but an improvement of 4-year OS was observed in comparison with the previous survey. Of note, one-quarter of patients who could undergo transplantation experienced long survival. It is also noted that the prognosis of the smoldering type was worse than expected.</AbstractText><CopyrightInformation>&#169; 2015 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsuya</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanada</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eto</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriuchi</LastName><ForeName>Yukiyoshi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Sasebo, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saburi</LastName><ForeName>Yoshio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oita Prefectural Hospital, Oita, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sueoka</LastName><ForeName>Eisaburo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uike</LastName><ForeName>Naokuni</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzushima</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>Yuju</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Koga General Hospital, Miyazaki, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amano</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Miyazaki University, Miyazaki, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hino</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimokawa</LastName><ForeName>Mototsugu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzumiya</LastName><ForeName>Junji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Center, Shimane University Hospital, Izumo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ATL-Prognostic Index Project</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Blood. 2015 Dec 10;126(24):2533-4</RefSource><PMID Version="1">26635405</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019468">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007239">Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009026">Mortality</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Okamura</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogata</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murayama</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iida</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagoshi</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teshima</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Take</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nosaka</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuda</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harada</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uoshima</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsukada</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yakushijin</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abe</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamura</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kubuki</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamano</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kakimoto</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamimura</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koike</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adachi</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hodohara</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murase</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohbayashi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawano</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyata</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyake</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tamaki</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabata</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwahashi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Izutsu</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shinohara</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Motomura</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maeda</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ito</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitamura</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morioka</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shimomura</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayashi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsubara</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takeichi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horikoshi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wakita</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urase</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirase</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masaki</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakai</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakura</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsukaguchi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanabe</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Itoh</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaneko</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iino</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimura</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsuda</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ifuku</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sato</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pii">S0006-4971(20)30684-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36108787</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0038</ISSN><JournalIssue CitedMedium="Internet"><Volume>847</Volume><PubDate><Year>2022</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Gene</Title><ISOAbbreviation>Gene</ISOAbbreviation></Journal><ArticleTitle>Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region.</ArticleTitle><Pagination><StartPage>146885</StartPage><MedlinePgn>146885</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gene.2022.146885</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-1119(22)00705-3</ELocationID><Abstract><AbstractText>The outcome of successful infection, including human T-cell leukemia virus type 1 (HTLV-1), is determined by the interactions between the host and the infectious agent. Ten years of work on HTLV-1-associated diseases in an endemic region of Iran have been critically compared in the present study. The outstanding findings of RNA-seq, system biology analysis, and gene expression measurements on adult T-cell leukemia/lymphoma (ATLL) and enzootic bovine leukosis(EBL) in our lab encouraged us to investigate the significant role of oncogenes in the ATLL malignancy. Most studies assessed such interactions by the proviral load (PVL), Tax, and HBZ regulatory proteins in HTLV-1 and the host's immunological and cell cycle factors. The current study is a comprehensive comparing view of our previously published and unpublished results investigating the HTLV-1-host interactions leading to the transformation of the infected cell. The main focus has been on the essential proteins implicated in the virus dissemination, cell survival, and proliferation of infected cells toward leukemia development and progression. Similar to its homolog BLV-AS-1-2 in EBL, the HTLV-1-HBZ is a pivotal factor in the maintenance and progression of the ATLL. In addition, the inappropriate activities of the PI3K/Akt pathway, BRCAs, and RAD51 in the DNA repair system, which are orchestrating many other immortalization pathways, might be the central factors in the manifestation of ATLL. HTLV-1-HBZ and the host PI3K/Akt pathway, BCAs, and RAD51 could be suggested as influential targets for the prognosis and proper therapy of ATLL.</AbstractText><CopyrightInformation>Copyright &#169; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashrafi</LastName><ForeName>Fereshteh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahimzada</LastName><ForeName>Masooma</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parandi</LastName><ForeName>Mahsa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirhosseini</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mashkani</LastName><ForeName>Baratali</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: MashkaniBA@mums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi Ghezeldasht</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Blood Borne Infections Research Center, Academic Center for Education, Culture, and, Research (ACECR), Razavi Khorasan, Mashhad, Iran. Electronic address: AhmadiS971@mums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltani</LastName><ForeName>Ararsh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: SoltaniA931@mums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafatpanah</LastName><ForeName>Houshang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran; HTLV-1 Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: RafatPanahH@mums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosavat</LastName><ForeName>Arman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Blood Borne Infections Research Center, Academic Center for Education, Culture, and, Research (ACECR), Razavi Khorasan, Mashhad, Iran. Electronic address: Mosavat@acecr.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdolrahim Rezaee</LastName><ForeName>Seyed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran; HTLV-1 Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: RezaeeR@mums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gene</MedlineTA><NlmUniqueID>7706761</NlmUniqueID><ISSNLinking>0378-1119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002417">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma (ATLL)</Keyword><Keyword MajorTopicYN="N">Gene expression</Keyword><Keyword MajorTopicYN="N">Human T-cell leukemia virus type 1 (HTLV-1)</Keyword><Keyword MajorTopicYN="N">Proviral load (PVL)</Keyword><Keyword MajorTopicYN="N">RT-qPCR</Keyword><Keyword MajorTopicYN="N">Virus-host molecular interactions</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36108787</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2022.146885</ArticleId><ArticleId IdType="pii">S0378-1119(22)00705-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15904464</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1347-9032</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>Cancer science</Title><ISOAbbreviation>Cancer Sci</ISOAbbreviation></Journal><ArticleTitle>Tumor immunity against adult T-cell leukemia.</ArticleTitle><Pagination><StartPage>249</StartPage><EndPage>255</EndPage><MedlinePgn>249-55</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell leukemia virus type-I (HTLV-I) causes adult T-cell leukemia (ATL) in a small population of infected individuals after a long incubation period. Although the process of clonal evolution of ATL cells may involve multiple steps, ATL cells from half of the ATL cases still retain the ability to express HTLV-I Tax, a key molecule of HTLV-I leukemogenesis. A recent finding of reactivation of Tax-specific cytotoxic T lymphocytes (CTL) in ATL patients after hematopoietic stem cell transplantation suggests the presence of Tax expression in vivo and potential contribution of the CTL to antitumor immunity. This is consistent with the results of a series of animal experiments indicating that Tax-specific CTL limit the growth of HTLV-I-infected cells in vivo, although the animal model mimics only an early phase of HTLV-I infection and leukemogenesis. Establishment of an insufficient HTLV-I-specific T-cell response and an increased viral load in orally HTLV-I-infected rats suggests that host HTLV-I-specific T-cell response at a primary HTLV-I infection can be a critical determinant of persistent HTLV-I levels thereafter. These findings indicate that Tax-targeted vaccines may be effective for prophylaxis of ATL in a high-risk group, and also for therapy of ATL in at least half the cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kannagi</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunotherapeutics, Tokyo Medical and Dental University, Medical Research Division, Bunkyo-ku, Tokyo 113-8519, Japan. kann.impt@tmd.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harashima</LastName><ForeName>Nanae</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kurihara</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ohashi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tanosaki</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Masato</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tomonaga</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Sci</MedlineTA><NlmUniqueID>101168776</NlmUniqueID><ISSNLinking>1347-9032</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000956">Antigens, Viral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15904464</ArticleId><ArticleId IdType="doi">10.1111/j.1349-7006.2005.00050.x</ArticleId><ArticleId IdType="pii">CAS050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29279551</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>3</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>Unilateral conjunctival infiltration of Adult T-cell leukemia/lymphoma. Case report and literature review.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>146</EndPage><MedlinePgn>143-146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3960/jslrt.17027</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia virus type 1 infection. Although conjunctival lymphoma is commonly reported with B-cell lymphoma, it rarely occurs in cases of ATLL. A 73-year-old Japanese female patient was admitted to our institution with evidence of abnormal lymphocytes, lymphadenopathy, and lung nodular lesions. Acute type ATLL was diagnosed, and therapy following the mLSG15 protocol was initiated. At the end of the second course, new bone lesions were detected. A modified treatment regimen was scheduled, but was postponed due to the appearance of gastrointestinal symptoms. Close observation resulted in a diagnosis of cytomegalovirus enteritis. One month after the diagnosis, the patient developed pain and discomfort in her left eye, which was determined to be due to a bulbar conjunctival tumor. Pathological findings revealed conjunctival infiltration of ATLL. Mogamulizumab treatment was initiated and was successful in eradicating the conjunctival lesions after the first course. However, at the end of the third course of therapy, pancytopenia was noted. Therefore, mogamulizumab therapy was discontinued, and the patient was on follow-up observation. Although there was no relapse of the conjunctival lesions, the patient died 1 year after the initial diagnosis, following therapy resistance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shimono</LastName><ForeName>Joji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaino</LastName><ForeName>Shigeki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshimi</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyagishima</LastName><ForeName>Takuto</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kushiro Rosai Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teshima</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hokkaido University Faculty of Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003228">Conjunctiva</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003230">Conjunctival Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000556">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Conjunctival lymphoma</Keyword><Keyword MajorTopicYN="N">Ocular adnexal lymphoma</Keyword></KeywordList><CoiStatement><b>CONFLICTS OF INTEREST:</b> The authors declare no conflicts of interest in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29279551</ArticleId><ArticleId IdType="pmc">PMC6144186</ArticleId><ArticleId IdType="doi">10.3960/jslrt.17027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia &#8211;lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991. 10.1111/j.1365-2141.1991.tb08051.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, et al. : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2005. 10.1200/JCO.2007.11.9958</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, et al. : Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30: 837-842, 2012. 10.1200/JCO.2011.37.3472</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi R, Schymura MJ, Nayak S, Coles FB: Ocular adnexal non-Hodgkin&#8217;s lymphoma: a review of epidemiology and risk factors. Expert Rev Ophthalmol 6: 181-193, 2011. 10.1586/eop.11.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eop.11.15</ArticleId><ArticleId IdType="pmc">PMC3749740</ArticleId><ArticleId IdType="pubmed">23976898</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman C, Berg JW, Cutler SJ: Occurrence and prognosis of extranodal lymphoma. Cancer 29: 252-260, 1972. 10.1002/1097-0142(197201)29:1&lt;252::AID-CNCR2820290138&gt;3.0.CO;2-#</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(197201)29:1&lt;252::AID-CNCR2820290138&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">5007387</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles DM, Jakobiec FA, McNally L, Burke JS: Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol 21: 959-973, 1990. 10.1016/0046-8177(90)90181-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0046-8177(90)90181-4</ArticleId><ArticleId IdType="pubmed">2394438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferry JA, Fung CY, Zukerberg L, Lucarelli MJ, Hasserjian RP, et al. : Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol 31: 170-184, 2007. 10.1097/01.pas.0000213350.49767.46</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.pas.0000213350.49767.46</ArticleId><ArticleId IdType="pubmed">17255761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer SA, Fischer J, Jones J, Gartner S, Dutcher J, et al. : Orbital T- cell lymphoma in human T-cell leukemia virus-1 infection. Ophthalmol 95: 110-115, 1988. 10.1016/S0161-6420(88)33231-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(88)33231-8</ArticleId><ArticleId IdType="pubmed">2893999</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Sakuma T, Onoe S, Akasaka T, Tazawa Y: Adult T-cell leukemia with leukemic cell infiltration in the conjunctiva. A case-report. Doc Ophthalmol 83: 255-260, 1993. 10.1007/BF01204326</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01204326</ArticleId><ArticleId IdType="pubmed">8223094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno T, Uchida H, Inomata H, Fukushima S, Takeshita M, et al. : Ocular manifestations of adult T-cell leukemia/lymphoma. A clinicopathological study. Ophthalmol 100: 1794-1799, 1993. 10.1016/S0161-6420(13)31398-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(13)31398-0</ArticleId><ArticleId IdType="pubmed">8259276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa T, Ogata N, Takahashi K, Mori S, Uemura Y, et al. : Bilateral orbital tumor as initial presenting sign in human T-cell leukemia virus-1 associated adult T-cell leukemia/lymphoma. Am J Ophthalmol 140: 327-329, 2005. 10.1016/j.ajo.2005.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2005.01.049</ArticleId><ArticleId IdType="pubmed">16086963</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggage RR, Smith JA, Shen D, Chan CC: Conjunctival T-cell lymphoma caused by human T-cell lymphotrophic virus infection. Am J Ophthalmol 131: 381-383, 2011. 10.1016/S0002-9394(00)00865-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9394(00)00865-5</ArticleId><ArticleId IdType="pubmed">11239876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohba N, Matsumoto M, Sameshima M, Kabayama Y, Nakano K, et al. : Ocular manifestations in patients infected with human T-lymphotropic virus type1. Jpn J Ophthalmol 33: 1-12, 1989</Citation><ArticleIdList><ArticleId IdType="pubmed">2733251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamoi K, Nagata Y, Mochizuki M, Kobayashi D, Ohno N, et al. : Formation of Segmental Rounded Nodules During Infiltration of Adult T-Cell Leukemia Cells Into the Ocular Mucous Membrane. Cornea 35: 137-139, 2016. 10.1097/ICO.0000000000000689</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICO.0000000000000689</ArticleId><ArticleId IdType="pubmed">26555589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar SR, Gill PS, Wagner DG, Dugel PU, Moudgil T, et al. : Human T-cell lymphotropic virus type 1-associated retinal lymphoma. A clinicopathologic report. Arch Ophthalmol 112: 954-959, 1994. 10.1001/archopht.1994.01090190102028</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1994.01090190102028</ArticleId><ArticleId IdType="pubmed">8031276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori A, Deguchi HE, Mishima K, Kitaoka T, Amemiya T: A case of uveal, palpebral, and orbital invasions in adult T-cell leukemia. Jpn J Ophthalmol 47: 599-602, 2003. 10.1016/j.jjo.2003.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjo.2003.08.008</ArticleId><ArticleId IdType="pubmed">14636852</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata K, Shimamoto Y, Nishimura T, Okinami S, Yamada H, et al. : Ocular manifestations in adult T-cell leukemia/lymphoma. Ann Hematol 74: 163-168, 1997. 10.1007/s002770050276</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002770050276</ArticleId><ArticleId IdType="pubmed">9174543</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Clarke GA, Buggage RR, Shen D, Vaughn LO, Chen CC, et al. : Human T-cell lymphotropic virus type-1-associated t-cell leukemia/lymphoma masquerading as necrotizing retinal vasculitis. Ophthalmol 109: 1717-1722, 2002. 10.1016/S0161-6420(02)01132-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(02)01132-6</ArticleId><ArticleId IdType="pubmed">12208722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki M, Tajima K, Watanabe T, Yamaguchi K: Human T lymphotropic virus type 1 uveitis. Br J Ophthalmol 78: 149-154, 1994. 10.1136/bjo.78.2.149</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.78.2.149</ArticleId><ArticleId IdType="pmc">PMC504720</ArticleId><ArticleId IdType="pubmed">8123625</ArticleId></ArticleIdList></Reference><Reference><Citation>Middle S, Coupland SE, Taktak A, Kidgell V, Slupsky JR, et al. : Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol 4: 10, 2015. 10.1186/s40164-015-0004-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-015-0004-3</ArticleId><ArticleId IdType="pmc">PMC4416323</ArticleId><ArticleId IdType="pubmed">25938000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields CL, Chien JL, Surakiatchanukul T, Sioufi K, Lally SE, et al. : Conjunctival Tumors: Review of Clinical Features, Risks, Biomarkers, and Outcomes&#8212;The 2017 J.Donald M. Gass Lecture. Asia Pac J Ophthalmol (Phila) 6: 109-120, 2017. 10.22608/APO.201710</Citation><ArticleIdList><ArticleId IdType="doi">10.22608/APO.201710</ArticleId><ArticleId IdType="pubmed">28399347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobiec FA: Ocular adnexal lymphoid tumors: progress in need of clarification. Am J Ophthalmol 145: 941-950, 2008. 10.1016/j.ajo.2008.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2008.03.013</ArticleId><ArticleId IdType="pubmed">18405875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">34334531</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>Establishment of an ATLL cell line (YG-PLL) dependent on IL-2 and IL-4, which are replaced by OX40-ligand<sup>+</sup> HK with poly-L-histidine and dermatan sulfate.</ArticleTitle><Pagination><StartPage>145</StartPage><EndPage>151</EndPage><MedlinePgn>145-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3960/jslrt.20058</ELocationID><Abstract><AbstractText>We established an IL-2 and IL-4 (IL2/4) - dependent adult T-cell leukemia/lymphoma (ATLL) cell line (YG-PLL) by adding poly-L-lysine (PLL) to the culture medium. YG-PLL originates from lymphoma cells and contains a defective HTLV-I proviral genome. Although YG-PLL cannot survive without IL-2/4, the follicular dendritic cell (FDC)-like cell line HK expressing OX40-ligand gene (OX40L<sup>+</sup>HK) inhibited their death in the presence of soluble neutral polymers. After the prevention of cell death, YG-PLL proliferated on OX40L<sup>+</sup>HK without IL2/4 in the presence of two kinds of positively or negatively charged polymers. In particular, dermatan sulfate and poly-L-histidine supported growth for more than 4 months. Therefore, the original lymphoma cells proliferated transiently in the presence of IL2/4, and their growth arrest was inhibited by the addition of PLL. Furthermore, YG-PLL lost IL2/4 dependency by the following 3-step procedure: preculture with IL2/4 and neutral polymers, 3-day culture with neutral polymer on OX40L<sup>+</sup>HK to inhibit cell death, and co-culture with OX40L<sup>+</sup>HK in the presence of the positively and negatively charged polymers. The extracellular environment made by soluble polymers plays a role in the growth of ATLL in vitro.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kagami</LastName><ForeName>Yoshitoyo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Toyota Kosei Hospital, Toyota, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Harumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Yasutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratories, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seto</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Kazuhito</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053278">OX40 Ligand</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089251">TNFSF4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>24967-94-0</RegistryNumber><NameOfSubstance UI="D003871">Dermatan Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>26062-48-6</RegistryNumber><NameOfSubstance UI="C033223">polyhistidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QD397987E</RegistryNumber><NameOfSubstance UI="D006639">Histidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020566">Dendritic Cells, Follicular</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003871">Dermatan Sulfate</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006639">Histidine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007376">Interleukin-2</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015847">Interleukin-4</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053278">OX40 Ligand</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Follicular dendritic cell</Keyword><Keyword MajorTopicYN="N">Interleukin</Keyword><Keyword MajorTopicYN="N">OX-40 ligand</Keyword><Keyword MajorTopicYN="N">Soluble high-molecular-weight polymer</Keyword></KeywordList><CoiStatement>CONFLICT OF INTEREST. None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34334531</ArticleId><ArticleId IdType="pmc">PMC8519244</ArticleId><ArticleId IdType="doi">10.3960/jslrt.20058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977; 50: 481-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982; 79: 2031-2035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47: 1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori T, Uchiyama T, Toibana T, Takatsuki K, Uchino H. Surface phenotype of Japanese adult T-cell leukemia cells characterized by monoclonal antibodies. Blood. 1981; 58: 645-647.</Citation><ArticleIdList><ArticleId IdType="pubmed">6455129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuda H, Huang RW, Takatsuki K. Interleukin-2 prevents programmed cell death in adult T-cell leukemia cells. Jpn J Cancer Res. 1993; 84: 431-437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919303</ArticleId><ArticleId IdType="pubmed">8514610</ArticleId></ArticleIdList></Reference><Reference><Citation>Arima N, Daitoku Y, Ohgaki S, et al. Autocrine growth of interleukin 2-producing leukemic cells in a patient with adult T cell leukemia. Blood. 1986; 68: 779-782.</Citation><ArticleIdList><ArticleId IdType="pubmed">2874849</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama T, Kamio M, Kodaka T, et al. Leukemic cells from some adult T-cell leukemia patients proliferate in response to interleukin-4. Blood. 1988; 72: 1182-1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">3262383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagami Y, Sivasundaram K, Nakagawa A, et al. Establishment of an Adult T-Cell Leukemia Cell Line (HU-ATTAK) Dependent for Proliferation on Human Umbilical Cord Vein Endothelial Cells. The Open leukemia Journal. 2011; 4 : 1-8.</Citation></Reference><Reference><Citation>Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009; 229: 173-191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729757</ArticleId><ArticleId IdType="pubmed">19426222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunitomi A, Hori T, Maeda M, Uchiyama T. OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis. Int J Hematol. 2002; 76: 260-266.</Citation><ArticleIdList><ArticleId IdType="pubmed">12416737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara D, Kagami Y, Kato H, et al. IL2/IL-4, OX40L and FDC-like cell line support the in vitro tumor cell growth of adult T-cell leukemia/lymphoma. Leuk Res. 2014; 38: 608-612.</Citation><ArticleIdList><ArticleId IdType="pubmed">24679586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagami Y, Uchiyama S, Kato H, et al. Establishment of cell lines from adult T-cell leukemia cells dependent on negatively charged polymers. J Clin Exp Hematop. 2017; 57: 9-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6144268</ArticleId><ArticleId IdType="pubmed">28420813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HS, Zhang X, Klyushnenkova E, Choi YS. Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK. J Immunol. 1995; 155: 1101-1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543513</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga K, Ohno S, Yugawa T, et al. Efficient immortalization of primary human cells by p16 INK4a -specific short hairpin RNA or Bmi-1, combined with introduction of hTERT. Cancer Sci. 2007; 98: 147-154.</Citation><ArticleIdList><ArticleId IdType="pubmed">17233832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneba M, Bolz I, Linke B, et al. Characterization of clone-specific rearrangement T-cell receptor gamma- chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing. Blood. 1994; 84: 574-581.</Citation><ArticleIdList><ArticleId IdType="pubmed">8025283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagami Y, Jung J, Choi YS, et al. Establishment of a follicular lymphoma cell line (FLK-1) dependent on follicular dendritic cell-like cell line HK. Leukemia. 2001; 15: 148-156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11243383</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Yoon SO, Fu DD, Zhang X, Choi YS. Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055. Blood. 2004; 104: 815-821.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090445</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37345860</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8081</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>BioFactors (Oxford, England)</Title><ISOAbbreviation>Biofactors</ISOAbbreviation></Journal><ArticleTitle>Rigosertib is more potent than wortmannin and rapamycin against adult T-cell leukemia-lymphoma.</ArticleTitle><Pagination><StartPage>1174</StartPage><EndPage>1188</EndPage><MedlinePgn>1174-1188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/biof.1985</ELocationID><Abstract><AbstractText>Human T lymphotropic virus type 1 (HTLV-1) infection can cause adult T-cell lymphoblastic leukemia (ATLL), an incurable, chemotherapy-resistant malignancy. In a quest for new therapeutic targets, our study sought to determine the levels of AKT, mTOR, and PI3K in ATLL MT-2 cells, HTLV-1 infected NIH/3T3 cells (Inf-3T3), and HTLV-1 infected patients (Carrier, HAM/TSP, and ATLL). Furthermore, the effects of rigosertib, wortmannin, and rapamycin on the PI3K/Akt/mTOR pathway to inhibit the proliferation of ATLL cells were examined. The results showed that mRNA expression of Akt/PI3K/mTOR was down-regulated in carrier, HAM/TSP, and ATLL patients, as well as MT-2, and Inf-3T3 cells, compared to the healthy individuals and untreated MT-2 and Inf-3T3 as controls. However, western blotting revealed an increase in the phosphorylated and activated forms of AKT and mTOR. Treating the cells with rapamycin, wortmannin, and rigosertib decreased the phosphorylated forms of Akt and mTOR and restored their mRNA expression levels. Using these inhibitors also significantly boosted the expression of the pro-apoptotic genes, Bax/Bcl-2 ratio as well as the expression of the tumor suppressor gene p53 in the MT-2 and Inf-3T3cells. Rigosertib was more potent than wortmannin and rapamycin in inducing sub-G1 and G2-M cell cycle arrest, as well as late apoptosis in the Inf-3T3 and MT-2 cells. It also synergized the cytotoxic effects of vincristine. These findings demonstrate that HTLV-1 downregulation of the mRNA level may occur as a negative feedback response to increased PI3K-Akt-mTOR phosphorylation by HTLV-1. Therefore, using rigosertib alone or in combination with common chemotherapy drugs may be beneficial in ATLL patients.</AbstractText><CopyrightInformation>&#169; 2023 International Union of Biochemistry and Molecular Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghorbanzadeh Neghab</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Immunology, Philipps-University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalili-Nik</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1259-4593</Identifier><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltani</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>Amir R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassanian</LastName><ForeName>Seyed Mahdi</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-5247-4043</Identifier><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafatpanah</LastName><ForeName>Houshang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaee</LastName><ForeName>Seyed Abdolrahim</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Medical Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghnia</LastName><ForeName>Hamid R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ataei Azimi</LastName><ForeName>Sajad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mashkani</LastName><ForeName>Baratali</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7606-5455</Identifier><AffiliationInfo><Affiliation>Bioinformatics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>992226</GrantID><Agency>Mashhad University of Medical Sciences</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Biofactors</MedlineTA><NlmUniqueID>8807441</NlmUniqueID><ISSNLinking>0951-6433</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>XVA4O219QW</RegistryNumber><NameOfSubstance UI="D000077191">Wortmannin</NameOfSubstance></Chemical><Chemical><RegistryNumber>67DOW7F9GL</RegistryNumber><NameOfSubstance UI="C507134">ON 01910</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077191">Wortmannin</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">rapamycin</Keyword><Keyword MajorTopicYN="N">rigosertib</Keyword><Keyword MajorTopicYN="N">wortmannin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37345860</ArticleId><ArticleId IdType="doi">10.1002/biof.1985</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Forlani G, Shallak M, Accolla RS, Romanelli MG. HTLV-1 infection and pathogenesis: new insights from cellular and animal models. Int J Mol Sci. 2021;22:8001.</Citation></Reference><Reference><Citation>Giam CZ. HTLV-1 replication and adult T cell leukemia development. Recent Results Cancer Res. 2021;217:209-43.</Citation></Reference><Reference><Citation>Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H, Hashemy SI. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell leukemia/lymphoma. Int Immunopharmacol. 2021;98:107870.</Citation></Reference><Reference><Citation>Goncalves DU, Guedes AC, Carneiro-Proietti AB, Pinheiro SR, Catalan-Soares B, Proietti FA, et al. Simultaneous occurrence of HTLV-I associated myelopathy, uveitis and smouldering adult T cell leukaemia. GIPH (Interdisciplinary HTLV-I/II Research Group). Int J STD AIDS. 1999;10:336-7.</Citation></Reference><Reference><Citation>Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006;3:1-9.</Citation></Reference><Reference><Citation>Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology. 2006;3:63.</Citation></Reference><Reference><Citation>Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005;24:6047-57.</Citation></Reference><Reference><Citation>Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121:2517-28.</Citation></Reference><Reference><Citation>Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The physiopathology of T-cell acute lymphoblastic leukemia: focus on molecular aspects. Front Oncol. 2020;10:273.</Citation></Reference><Reference><Citation>Percher F, Curis C, Peres E, Artesi M, Rosewick N, Jeannin P, et al. HTLV-1-induced leukotriene B4 secretion by T cells promotes T cell recruitment and virus propagation. Nat Commun. 2017;8:15890.</Citation></Reference><Reference><Citation>Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.</Citation></Reference><Reference><Citation>Lin H-C, Hickey M, Hsu L, Medina D, Rabson AB. Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression. Virology. 2005;339:1-11.</Citation></Reference><Reference><Citation>Mukai R, Ohshima T. HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm. Oncogene. 2014;33:2317-28.</Citation></Reference><Reference><Citation>Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007;3:682-93.</Citation></Reference><Reference><Citation>Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008;8:393-412.</Citation></Reference><Reference><Citation>Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142:164-75.</Citation></Reference><Reference><Citation>Gyori D, Chessa T, Hawkins PT, Stephens LR. Class (I) phosphoinositide 3-kinases in the tumor microenvironment. Cancers. 2017;9:24.</Citation></Reference><Reference><Citation>Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, et al. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: an update. J Cell Physiol. 2018;233:6440-54.</Citation></Reference><Reference><Citation>Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci. 2019;20:755.</Citation></Reference><Reference><Citation>Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007;110:278-86.</Citation></Reference><Reference><Citation>Wu KN, Zhao YM, He Y, Wang BS, Du KL, Fu S, et al. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. Leuk Lymphoma. 2014;55:668-76.</Citation></Reference><Reference><Citation>Zhu J, Hou T, Mao X. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. Drug Discov Today. 2015;20:988-94.</Citation></Reference><Reference><Citation>Gumireddy K, Reddy MR, Cosenza SC, Nathan RB, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005;7:275-86.</Citation></Reference><Reference><Citation>Reddy MR, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2&#8242;, 4&#8242;, 6&#8242;-trimethoxystyrylsulfonyl) methyl] phenylamino} acetate (ON 01910. Na): synthesis, structure-activity relationship, and biological activity. J Med Chem. 2011;54:6254-76.</Citation></Reference><Reference><Citation>Hyoda T, Tsujioka T, Nakahara T, Suemori S, Okamoto S, Kataoka M, et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015;106:287-93.</Citation></Reference><Reference><Citation>Renshaw MA, Olds BP, Jerde CL, McVeigh MM, Lodge DM. The room temperature preservation of filtered environmental DNA samples and assimilation into a phenol-chloroform-isoamyl alcohol DNA extraction. Mol Ecol Resour. 2015;15:168-76.</Citation></Reference><Reference><Citation>T. Riss, R. Moravec, A. Niles, H. Benink, T. Worzella, L. Minor. Cell viability assays. In: Assay Guidance Manual. Eli Lilly &amp; Company and the National center for Advancing Translational Sciences, Bethesda, MD; 2013.</Citation></Reference><Reference><Citation>Itabashi K, Miyazawa T, Sekizawa A, Tokita A, Saito S, Moriuchi H, et al. A nationwide antenatal human T-cell leukemia virus type-1 antibody screening in Japan. Front Microbiol. 2020;11:595.</Citation></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-8.</Citation></Reference><Reference><Citation>Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15:1607-14.</Citation></Reference><Reference><Citation>Selvy PE, Lavieri RR, Lindsley CW, Brown HA. Phospholipase D: enzymology, functionality, and chemical modulation. Chem Rev. 2011;111:6064-119.</Citation></Reference><Reference><Citation>Kawata T, Tada K, Kobayashi M, Sakamoto T, Takiuchi Y, Iwai F, et al. Dual inhibition of the mTORC 1 and mTORC 2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2018;109:103-11.</Citation></Reference><Reference><Citation>Stoppa G, Rumiato E, Saggioro D. Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells. Apoptosis. 2012;17:219-28.</Citation></Reference><Reference><Citation>Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19:373-9.</Citation></Reference><Reference><Citation>Magaway C, Kim E, Jacinto E. Targeting mTOR and metabolism in cancer: lessons and innovations. Cell. 2019;8:1584.</Citation></Reference><Reference><Citation>Zhao YM, Zhou Q, Xu Y, Lai XY, Huang H. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin. 2008;29:481-8.</Citation></Reference><Reference><Citation>Hirase C, Maeda Y, Yamaguchi T, Miyatake J, Kanamaru A. mTOR inhibition and adult T-cell leukemia. Leuk Lymphoma. 2009;50:645-7.</Citation></Reference><Reference><Citation>Teranishi F, Takahashi N, Gao N, Akamo Y, Takeyama H, Manabe T, et al. Phosphoinositide 3-kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo. Cancer Sci. 2009;100:770-7.</Citation></Reference><Reference><Citation>Dai S, Yang S, Hu X, Sun W, Tawa G, Zhu W, et al. 17-Hydroxy wortmannin restores TRAIL's response by ameliorating increased beclin 1 level and autophagy function in TRAIL-resistant colon cancer cells. Mol Cancer Ther. 2019;18:1265-77.</Citation></Reference><Reference><Citation>Boehle AS, Kurdow R, Boenicke L, Schniewind B, Faendrich F, Dohrmann P, et al. Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo. Langenbecks Arch Surg. 2002;387:234-9.</Citation></Reference><Reference><Citation>O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-8.</Citation></Reference><Reference><Citation>Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-68.</Citation></Reference><Reference><Citation>Dang CV. MYC on the path to cancer. Cell. 2012;149:22-35.</Citation></Reference><Reference><Citation>Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol. 2013;162:517-24.</Citation></Reference><Reference><Citation>Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015;33:57-66.</Citation></Reference><Reference><Citation>Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496-508.</Citation></Reference><Reference><Citation>Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, et al. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014;20:1656-65.</Citation></Reference><Reference><Citation>Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K. Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015;6:20231-40.</Citation></Reference><Reference><Citation>Prasad A, Khudaynazar N, Tantravahi RV, Gillum AM, Hoffman BS. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines. Oncotarget. 2016;7:79388-400.</Citation></Reference><Reference><Citation>Raza A, Ali AM, Reddy MVR, Hoffman BS, Petrone ME, Maniar M, et al. Rigosertib in myelodysplastic syndromes (MDS). Expert Opin Orphan Drugs. 2016;4:981-8.</Citation></Reference><Reference><Citation>Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell. 2016;165:643-55.</Citation></Reference><Reference><Citation>Ritt DA, Abreu-Blanco MT, Bindu L, Durrant DE, Zhou M, Specht SI, et al. Inhibition of Ras/Raf/MEK/ERK pathway signaling by a stress-induced phospho-regulatory circuit. Mol Cell. 2016;64:875-87.</Citation></Reference><Reference><Citation>Baker SJ, Cosenza SC, Athuluri-Divakar S, Reddy MR, Vasquez-Del Carpio R, Jain R, et al. A contaminant impurity, not rigosertib, is a tubulin binding agent. Mol Cell. 2020;79:180-190.e4.</Citation></Reference><Reference><Citation>Xu F, He Q, Li X, Chang CK, Wu LY, Zhang Z, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014;4:7310.</Citation></Reference><Reference><Citation>Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009;69:3520-8.</Citation></Reference><Reference><Citation>Skubnik J, Pavlickova VS, Ruml T, Rimpelova S. Vincristine in combination therapy of cancer: emerging trends in clinics. Biology. 2021;10:849.</Citation></Reference><Reference><Citation>Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, et al. Combined CRISPRi/a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent. Mol Cell. 2017;68:210-223.e6.</Citation></Reference><Reference><Citation>H.-f Z, Wang J, Shao W, Wu C-p, Chen Z-p, To S-s T, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16:100.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34385616</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.</ArticleTitle><Pagination><StartPage>2862</StartPage><EndPage>2863</EndPage><MedlinePgn>2862-2863</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41409-021-01432-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamai</LastName><ForeName>Hayato</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9652-4559</Identifier><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan. hayato.tamai@marianna-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tajika</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Yokohama Minami Kyousai Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Kazutaka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Yokohama Minami Kyousai Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="D000077269">Lenalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Bone Marrow Transplant. 2019 Feb;54(2):338-342</RefSource><PMID Version="1">30116017</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077269">Lenalidomide</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>7</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34385616</ArticleId><ArticleId IdType="doi">10.1038/s41409-021-01432-5</ArticleId><ArticleId IdType="pii">10.1038/s41409-021-01432-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177&#8211;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2010.28.0669</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2:607&#8211;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2017011106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141&#8211;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-07-368233</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Fuji S, Tanosaki R, Inamoto Y, Tanaka T, Ito A, et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant. 2018;53:1105&#8211;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0139-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, et al. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54:338&#8211;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0291-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945&#8211;50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1316796110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjiaggelidou C, Mandala E, Terpos E, Yiannaki E, Markala D, Triantafyllou T, et al. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Ann Hematol. 2019;98:1457&#8211;66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-019-03657-3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">32641657</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>21</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell Leukemia-lymphoma with Primary Breast Involvement: A Case Report and Literature Review.</ArticleTitle><Pagination><StartPage>2757</StartPage><EndPage>2761</EndPage><MedlinePgn>2757-2761</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.5077-20</ELocationID><Abstract><AbstractText>Breast involvement of Adult T-cell leukemia-lymphoma (ATLL) is extremely rare, and the data on the characteristics are limited. We herein describe a 49-year-old woman who presented with skin involvement of ATLL. Positron emission tomography/computed tomography showed bilateral breast lesions. Although the patient once achieved a complete metabolic response, a relapse of her ATLL occurred. The patient received subsequent allogeneic hematopoietic stem cell transplantation (HSCT). To our knowledge, only four cases of ATLL with breast involvement have previously been reported, and the prognoses have generally been poor. Breast lesions of ATLL have aggressive features, and intensive systemic chemotherapy and HSCT are required to improve survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asada</LastName><ForeName>Noboru</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igawa</LastName><ForeName>Takuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Masaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meguri</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ennishi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimori</LastName><ForeName>Hisakazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Nobuharu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Ken-Ichi</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshino</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Yoshinobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult T-cell leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">breast involvement</Keyword><Keyword MajorTopicYN="N">positron emission tomography/computed tomography</Keyword></KeywordList><CoiStatement><b>The authors state that they have no Conflict of Interest (COI).</b></CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32641657</ArticleId><ArticleId IdType="pmc">PMC7691018</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.5077-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K. Adult T-cell leukemia-lymphoma. Hematology 17 (Suppl): S32-S35, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22507774</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Yamanaka T, Ishitsuka K, et al. . Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 30: 1635-1640, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Nomura S, Shimoyama M, et al. . Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol 166: 739-748, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. . VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Endo S, Matsuno N, et al. . Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 54: 338-342, 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30116017</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo HY, Zhao XM, Li J, Hu XC. Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience. Int J Hematol 87: 491-497, 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma. Cancer Treat Rev 40: 900-908, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24953564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualco G, Chioato L, Harrington WJ Jr, Weiss LM, Bacchi CE. Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases. Appl Immunohistochem Mol Morphol 17: 301-306, 2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739299</ArticleId><ArticleId IdType="pubmed">19318917</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera NS, Tavassoli FA, Chu WS, Abbondanzo SL. T-cell lymphoma presenting in the breast: a histologic, immunophenotypic and molecular genetic study of four cases. Mod Pathol 13: 599-605, 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">10874662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka M, Tsuchihashi N, Takishita M, et al. . Primary adult T-cell lymphoma of the breast. Acta Haematol 87: 202-205, 1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">1519436</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakoda Y, Kohno N, Nakata S, Ishikawa Y, Sashikata T. A case of T cell malignant lymphoma of the breast. J Jpn Surg Assoc 58: 85-89, 1997(in Japanese, Abstarct in English).</Citation></Reference><Reference><Citation>Morozumi K, Miyazaki H, Narai S, Kodaira K, Sugiura J. Malignant T-cell lymphoma of the breast -report of a case-. J Jpn Surg Assoc 60: 2320-2325, 1999(in Japanese, Abstarct in English).</Citation></Reference><Reference><Citation>Fujita Y, Kageyama N. A case of adult T-cell lymphoma of the breast. J Jpn Surg 65: 328-332, 2004(in Japanese, in Abstarct English).</Citation></Reference><Reference><Citation>Surov A, Holzhausen HJ, Wienke A, et al. . Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. Br J Radiol 85: e195-e205, 2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474114</ArticleId><ArticleId IdType="pubmed">22665932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Fisher RI, Barrington SF, et al. . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3068, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979083</ArticleId><ArticleId IdType="pubmed">25113753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. . Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 37: 677-687, 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494249</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakachi S, Okada M, Morishima S, et al. . Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia. Hematology 22: 536-543, 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28397608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, et al. . Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116: 1369-1376, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, et al. . Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 120: 1734-1741, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, et al. . Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant 49: 1266-1268, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshioka R, Yamaguchi K, Yoshinaga T, Takatsuki K. Pulmonary complications in patients with adult T-cell leukemia. Cancer 55: 2491-2494, 1985.</Citation><ArticleIdList><ArticleId IdType="pubmed">3872708</ArticleId></ArticleIdList></Reference><Reference><Citation>Itai Y, Kamizikkoku S, Yul LS, Tomino S, Yamaguchi K, Takatsuki K. Interstitial pneumonitis and smoldering adult T-cell leukemia. Study of anti ATLA antibody in patients with chronic pulmonary diseases in ATL endemic area. Rinsho Ketsueki (Jpn J Clin Hematol) 26: 499-503, 1985(in Japanese, Abstarct in English).</Citation><ArticleIdList><ArticleId IdType="pubmed">2995699</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata-Takata T, Takata T, Yamanouchi S, Sato Y, Harada M, Oka T. Detection of T-cell receptor gamma gene rearrangement in paraffin-embedded T or natural killer/T-cell lymphoma samples using the BIOMED-2 protocol. Leuk Lymphoma 55: 2161-2164, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24308432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25320371</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-3265</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>20</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research.</ArticleTitle><Pagination><StartPage>5217</StartPage><EndPage>5225</EndPage><MedlinePgn>5217-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-14-0572</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL) is a distinct malignancy of regulatory T cell (Treg)/TH2 cells caused by human T-cell lymphotropic virus type I (HTLV-1), with a high frequency of expression of CD3/CD4/CD25/CCR4 and FoxP3 in about half of the cells. However, in primary ATL cells, although expression of the virus, including the Tax oncoprotein, appears just after an in vitro culture, integration sites of the provirus into the host genome are random, and chromosomal/genetic abnormalities are complex. ATL is thus a single disease entity that is caused by HTLV-1 and possesses diverse molecular features. The clinical features and prognosis of ATL vary, and this has led to subtypes classified into four categories: acute, lymphomatous, chronic, and smoldering types, based on lactate dehydrogenase and calcium values and organ involvement. Approximately 15 to 20 million individuals are infected with HTLV-1 worldwide, 1.1 million of whom reside in Japan, and the annual incidence of ATL has been estimated to be approximately 1,000. HTLV-1 infection early in life, mainly from breast feeding, is crucial for the development of ATL. The age-specific occurrence of ATL and complex genome abnormalities that accumulate with disease progression suggest a multistep carcinogenesis model following HTLV-1 infection. Various treatment options are available for ATL and consist of watchful waiting for indolent ATL, intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation for aggressive ATL, and a combination of IFN&#945; and zidovudine for ATL with leukemic manifestation. Several promising new agents, including an anti-CCR4 antibody, are currently undergoing clinical trials associated with translational research. See all articles in this CCR Focus section, "Paradigm Shifts in Lymphoma."</AbstractText><CopyrightInformation>&#169;2014 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobinai</LastName><ForeName>Kensei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan. ktobinai@ncc.go.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D035843">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D057170">Translational Research, Biomedical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25320371</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0572</ArticleId><ArticleId IdType="pii">20/20/5217</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28680001</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Progress in the management of ATL].</ArticleTitle><Pagination><StartPage>676</StartPage><EndPage>682</EndPage><MedlinePgn>676-682</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.58.676</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type I (HTLV-1), and its prognosis remains poor. Three to five percent of HTLV-1 carriers, infected mainly by breast feeding, develop ATL after a latency period as long as 70 years. The standard of care for aggressive ATL and indolent ATL comprises intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation, if applicable, and watchful waiting, respectively. Outside Japan, a combination of interferon-&#945; and zidovudine has also been used as a therapeutic option for acute, chronic, and smoldering-type ATLs. A Japanese nationwide retrospective study revealed the outcome of patients diagnosed between 2000 and 2009. The median survival times were 8.3, 10.6, 31.5, and 55.0 months and the 4-year overall survival rates were 11%, 16%, 36%, and 52% for acute, lymphoma, chronic, and smoldering-type ATLs, respectively. Recently, the development of several novel agents has been attempted by targeting surface antigens on ATL cells such as CCR4 and CD30 with monoclonal antibodies, targeting molecular abnormalities in ATL cells with EZH1/2 inhibitor, and modulating the immune environment via immunomodulatory drugs (IMiDs) or immune checkpoint inhibitors. Among them, a CCR4 monoclonal antibody mogamulizumab, and an IMiD, lenalidomide, have been introduced for clinical use in Japan.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kagoshima University Hospital, Department of Hematology and Immunology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000941">Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000941">Antigens</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATL</Keyword><Keyword MajorTopicYN="N">Management</Keyword><Keyword MajorTopicYN="N">Novel therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28680001</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.58.676</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11908716</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1042-8194</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma: a rare case in the USA and review of the literature.</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>132</EndPage><MedlinePgn>127-32</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL), in its acute stage, is a uniformly fatal disease. ATLL is caused by the human T-cell lymphotropic virus I (HTLV-1), a retrovirus endemic in numerous areas throughout the world including Japan, the Caribbean, Central and South America and certain areas of the United States. Although the progression from HTLV-1 carrier status to ATLL occurs only rarely, ATLL is incurable and thus prevention of HTLV-1 transmission should be a primary goal. With the development of new anti-retroviral and monoclonal therapies, there exist potential cures or at least prolonged remissions for patients diagnosed with ATLL. We present a case of ATLL that, to our knowledge, is only the third reported case in Georgia. In addition, we present a brief review of the literature, including potential new treatment regimens that appear to have promise in the treatment of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brick</LastName><ForeName>W G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Section of Hematology/Oncology, Medical College of Georgia, Augusta 30912, USA. wbrick@mail.mcg.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalamolu</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Jillella</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Kallab</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016516">CD4-CD8 Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004813">Epidemiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005192">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005845">Georgia</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018454">Spouses</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>39</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>23</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11908716</ArticleId><ArticleId IdType="doi">10.1080/10428190210175</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">35675522</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-9537</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Blood advances</Title><ISOAbbreviation>Blood Adv</ISOAbbreviation></Journal><ArticleTitle>ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.</ArticleTitle><Pagination><StartPage>5613</StartPage><EndPage>5624</EndPage><MedlinePgn>5613-5624</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2022007725</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell lymphoma associated with the human T-cell lymphotropic virus type 1 virus endemic in regions including Japan, the Caribbean islands, and Latin America. Although progress has been made to understand the disease, survival outcomes with current standard therapy remain extremely poor particularly in acute ATLL, underlying the need for better understanding of its biology and identification of novel therapeutic targets. Recently, it was demonstrated that ATLL of North American-descendent patients (NA-ATLL) is both clinically and molecularly distinct from Japanese-descendent (J-ATLL), with inferior prognosis and higher incidence of epigenetic-targeting mutations compared with J-ATLL. In this study, combined chromatin accessibility and transcriptomic profiling were used to further understand the key transcriptional regulators of NA-ATLL compared with J-ATLL. The ETS1 motif was found to be enriched in chromatin regions that were differentially open in NA-ATLL, whereas the AP1/IRF4 motifs were enriched in chromatin regions more open in J-ATLL. ETS1 expression was markedly elevated in NA-ATLL in both cell line and primary tumor samples, and knockdown of ETS1 in NA-ATLL cells resulted in inhibition of cell growth. CCR4, a previously identified oncogenic factor in ATLL, was found to be a direct ETS1 transcriptional target in NA-ATLL. As such, ETS1 provides an alternate mechanism to enhance CCR4 expression/activity in NA-ATLL, even in the absence of activating CCR4 mutations (CCR4 mutations were identified in 4 of 9 NA-ATLL cases). Taken together, this study identifies ETS1 as a novel dominant oncogenic transcriptional regulator in NA-ATLL.</AbstractText><CopyrightInformation>&#169; 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luchtel</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-7523-5010</Identifier><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yongmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Ritesh K</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-5693-1758</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Kith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health (Biostatistics), Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maqbool</LastName><ForeName>Shahina B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Genetics, Albert Einstein College of Medicine, Bronx, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Adv</MedlineTA><NlmUniqueID>101698425</NlmUniqueID><ISSNLinking>2473-9529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494041">ETS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050784">Proto-Oncogene Protein c-ets-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002843">Chromatin</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016399">Lymphoma, T-Cell</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009656">North America</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050784">Proto-Oncogene Protein c-ets-1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict-of-interest disclosure:</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35675522</ArticleId><ArticleId IdType="pmc">PMC9647780</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2022007725</ArticleId><ArticleId IdType="pii">485487</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sandell RF, Boddicker RL, Feldman AL. Genetic landscape and classification of peripheral T cell lymphomas. Curr Oncol Rep. 2017;19(4):28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517131</ArticleId><ArticleId IdType="pubmed">28303495</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76(suppl 2):240&#8211;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">12430931</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake M, Yamada Y, Atogami S, Yamaguchi K. The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Japan. Leuk Lymphoma. 2015;56(6):1806&#8211;1812.</Citation><ArticleIdList><ArticleId IdType="pubmed">25219595</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Shah N, Qiao B, et al. Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States. Cancer. 2019;126(3):567&#8211;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978489</ArticleId><ArticleId IdType="pubmed">31769871</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al. A&#160;critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116(14):3438&#8211;3446.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell M, Assal A, Derman O, et al. Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016;7(32):51981&#8211;51990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239529</ArticleId><ArticleId IdType="pubmed">27341021</ArticleId></ArticleIdList></Reference><Reference><Citation>Licata MJ, Janakiram M, Tan S, et al. Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal. Leuk Lymphoma. 2018;59(5):1188&#8211;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">29504866</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Chung EY, Giricz O, et al. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018;132(14):1507&#8211;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="pubmed">30104217</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607&#8211;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="pubmed">29545256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99(5):1505&#8211;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Ishii N, Ine S, et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol. 2006;18(2):269&#8211;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361311</ArticleId></ArticleIdList></Reference><Reference><Citation>Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126(1):81&#8211;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15198736</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129(9):1071&#8211;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374731</ArticleId><ArticleId IdType="pubmed">28115366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L. Molecular biology of human T cell leukemia virus. Semin Diagn Pathol. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6801043</ArticleId><ArticleId IdType="pubmed">31103249</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasiri A, Abboud Guerr J, Hall WW, Sheehy N. Novel interactions between the human T-cell leukemia virus type 1 antisense protein HBZ and the SWI/SNF chromatin remodeling family: implications for viral life cycle. J&#160;Virol. 2019;93(16):e00412&#8211;e00419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675893</ArticleId><ArticleId IdType="pubmed">31142665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemasson I, Polakowski NJ, Laybourn PJ, Nyborg JK. Transcription factor binding and histone modifications on the integrated proviral promoter in human T-cell leukemia virus-I-infected T-cells. J&#160;Biol Chem. 2002;277(51):49459&#8211;49465.</Citation><ArticleIdList><ArticleId IdType="pubmed">12386157</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Shaffer AL, III, Ceribelli M, et al. Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma. Cancer Cell. 2018;34(2):286&#8211;297. e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078141</ArticleId><ArticleId IdType="pubmed">30057145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung EY, Mai Y, Shah UA, et al. PAK kinase inhibition has therapeutic activity in novel preclinical models of adult T-cell leukemia/lymphoma. Clin Cancer Res. 2019;25(12):3589&#8211;3601.</Citation><ArticleIdList><ArticleId IdType="pubmed">30862694</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda M, Tanabe-Shibuya J, Miyazato P, et al. IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia. Front Microbiol. 2020;11:356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067701</ArticleId><ArticleId IdType="pubmed">32210945</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR, Trevino AE, Hamilton EG, et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. 2017;14(10):959&#8211;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623106</ArticleId><ArticleId IdType="pubmed">28846090</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon D, Nguyen MLT, Mezger A, et al. Landscape of stimulation-responsive chromatin across diverse human immune cells. Nat Genet. 2019;51(10):1494&#8211;1505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858557</ArticleId><ArticleId IdType="pubmed">31570894</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357&#8211;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Handsaker B, Wysoker A, et al. 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078&#8211;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9(9):R137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark R, Brown GD. DiffBind: differential binding analysis of ChIP-seq peak data. http://bioconductor.org/packages/release/bioc/html/DiffBind.html Bioconductor.</Citation></Reference><Reference><Citation>Bailey TL, Boden M, Buske FA, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009;37(Web Server issue):W202&#8211;W208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703892</ArticleId><ArticleId IdType="pubmed">19458158</ArticleId></ArticleIdList></Reference><Reference><Citation>Machanick P, Bailey TL. MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics. 2011;27(12):1696&#8211;1697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106185</ArticleId><ArticleId IdType="pubmed">21486936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Stamatoyannopoulos JA, Bailey TL, Noble WS. Quantifying similarity between motifs. Genome Biol. 2007;8(2):R24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852410</ArticleId><ArticleId IdType="pubmed">17324271</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikawa D, Nakagawa S, Hori M, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790&#8211;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">26773042</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M, Nakano K, Miyake A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-&#954;B pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121&#8211;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">22264793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Dasari S, Nowakowski GS, et al. Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget. 2017;8(16):26245&#8211;26255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5432253</ArticleId><ArticleId IdType="pubmed">28412739</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545&#8211;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouillard AD, Gundersen GW, Fernandez NF, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford) 2016;2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930834</ArticleId><ArticleId IdType="pubmed">27374120</ArticleId></ArticleIdList></Reference><Reference><Citation>Matys V, Fricke E, Geffers R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31(1):374&#8211;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165555</ArticleId><ArticleId IdType="pubmed">12520026</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarter AC, Della Gatta G, Melnick A, et al. Combinatorial ETS1-dependent control of oncogenic NOTCH1 enhancers in T-cell leukemia. Blood Cancer Discov. 2020;1(2):178&#8211;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482717</ArticleId><ArticleId IdType="pubmed">32924017</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidl C, Hansmann L, Lassmann T, et al. FANTOM consortium. The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood. 2014;123(17):e68&#8211;e78.</Citation><ArticleIdList><ArticleId IdType="pubmed">24671953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, Graves BJ. DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet. 2009;5(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787013</ArticleId><ArticleId IdType="pubmed">20019798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Dai X, Berry LD, Cogan JD, Liu Q, Shyr Y. HACER: an atlas of human active enhancers to interpret regulatory variants. Nucleic Acids Res. 2019;47(D1):D106&#8211;D112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323890</ArticleId><ArticleId IdType="pubmed">30247654</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson R, Gebhard C, Miguel-Escalada I, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507(7493):455&#8211;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215096</ArticleId><ArticleId IdType="pubmed">24670763</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Xie Y, Ma J, et al. IBS: an illustrator for the presentation and visualization of biological sequences. Bioinformatics. 2015;31(20):3359&#8211;3361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595897</ArticleId><ArticleId IdType="pubmed">26069263</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddicker RL, Kip NS, Xing X, et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-&#954;B positive feedback loop in peripheral T-cell lymphoma. Blood. 2015;125(20):3118&#8211;3127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432006</ArticleId><ArticleId IdType="pubmed">25833963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao HW, Tai TS, Tseng W, et al. Ets-1 facilitates nuclear entry of NFAT proteins and their recruitment to the IL-2 promoter. Proc Natl Acad Sci USA. 2013;110(39):15776&#8211;15781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785780</ArticleId><ArticleId IdType="pubmed">24019486</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian VS, Sabui S, Moradi H, Marchant JS, Said HM. Inhibition of intestinal ascorbic acid uptake by lipopolysaccharide is mediated via transcriptional mechanisms. Biochim Biophys Acta Biomembr. 2018;1860(2):556&#8211;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732882</ArticleId><ArticleId IdType="pubmed">29030247</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu TL, Goetz TL, Graves BJ, Speck NA. Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1) Mol Cell Biol. 2000;20(1):91&#8211;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85059</ArticleId><ArticleId IdType="pubmed">10594012</ArticleId></ArticleIdList></Reference><Reference><Citation>Testoni M, Chung EY, Priebe V, Bertoni F. The transcription factor ETS1 in lymphomas: friend or foe? Leuk Lymphoma. 2015;56(7):1975&#8211;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">25363344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T, Fujita Y, Nakane K, et al. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Biochem Biophys Res Commun. 2012;417(3):966&#8211;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">22206665</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, Mahalingam K, Chakrabarti D, Periyasamy G. Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cell Mol Biol Lett. 2011;16(1):101&#8211;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6276009</ArticleId><ArticleId IdType="pubmed">21225469</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugata K, Yasunaga J, Kinosada H, et al. HTLV-1 viral factor HBZ induces CCR4 to promote T-cell migration and proliferation. Cancer Res. 2016;76(17):5068&#8211;5079.</Citation><ArticleIdList><ArticleId IdType="pubmed">27402079</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Schmitz R, Xiao W, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J&#160;Exp Med. 2014;211(13):2497&#8211;2505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267233</ArticleId><ArticleId IdType="pubmed">25488980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304&#8211;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouly E, Chemin K, Nguyen HV, et al. The Ets-1 transcription factor controls the development and function of natural regulatory T cells. J&#160;Exp Med. 2010;207(10):2113&#8211;2125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947068</ArticleId><ArticleId IdType="pubmed">20855499</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer. 2003;2(1):29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC194255</ArticleId><ArticleId IdType="pubmed">12971829</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Itoh K, Togano T, et al. Ets-1 activates overexpression of JunB and CD30 in Hodgkin&#8217;s lymphoma and anaplastic large-cell lymphoma. Am J Pathol. 2012;180(2):831&#8211;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429177</ArticleId><ArticleId IdType="pubmed">22107829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren YL, Nong L, Zhang S, Zhao J, Zhang XM, Li T. Analysis of 142 Northern Chinese patients with peripheral T/NK-Cell lymphomas: subtype distribution, clinicopathologic features, and prognosis. Am J Clin Pathol. 2012;138(3):435&#8211;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">22912362</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxus M, Twizere JC, Legros S, Dewulf JF, Kettmann R, Willems L. The HTLV-1 Tax interactome. Retrovirology. 2008;5(1):76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533353</ArticleId><ArticleId IdType="pubmed">18702816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittmer J, Pise-Masison CA, Clemens KE, Choi KS, Brady JN. Interaction of human T-cell lymphotropic virus type I Tax, Ets1, and Sp1 in transactivation of the PTHrP P2 promoter. J&#160;Biol Chem. 1997;272(8):4953&#8211;4958.</Citation><ArticleIdList><ArticleId IdType="pubmed">9030555</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittmer J, Gitlin SD, Reid RL, Brady JN. Transactivation of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus type I Tax1: evidence for the involvement of transcription factor Ets1. J&#160;Virol. 1993;67(10):6087&#8211;6095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC238030</ArticleId><ArticleId IdType="pubmed">8371355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosselut R, Duvall JF, G&#233;gonne A, et al. The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1. EMBO J. 1990;9(10):3137&#8211;3144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552042</ArticleId><ArticleId IdType="pubmed">2209540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin SD, Dittmer J, Shin RC, Brady JN. Transcriptional activation of the human T-lymphotropic virus type I long terminal repeat by functional interaction of Tax1 and Ets1. J&#160;Virol. 1993;67(12):7307&#8211;7316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC238194</ArticleId><ArticleId IdType="pubmed">8230454</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625&#8211;3634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hieshima K, Nagakubo D, Nakayama T, Shirakawa AK, Jin Z, Yoshie O. Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. J&#160;Immunol. 2008;180(2):931&#8211;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">18178833</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood. 2019;134(24):2159&#8211;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6908831</ArticleId><ArticleId IdType="pubmed">31562134</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal SG, Aichele G, Wirth T, Czernilofsky AP, Nordheim A, Dittmer J. Regulation of the human interleukin-5 promoter by Ets transcription factors. Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax1. J&#160;Biol Chem. 1999;274(18):12910&#8211;12916.</Citation><ArticleIdList><ArticleId IdType="pubmed">10212281</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Enriquez DJ, Castro DA, et al. Real-world data on adult t-cell leukemia/lymphoma in Latin America: a study from the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021;7(7):1151&#8211;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8457808</ArticleId><ArticleId IdType="pubmed">34270330</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonso PV, Cassar O, Gessain A. Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes. Retrovirology. 2019;16(1):39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6916231</ArticleId><ArticleId IdType="pubmed">31842895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24316494</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-3650</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Seminars in cancer biology</Title><ISOAbbreviation>Semin Cancer Biol</ISOAbbreviation></Journal><ArticleTitle>HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>98</EndPage><MedlinePgn>89-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semcancer.2013.11.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1044-579X(13)00124-7</ELocationID><Abstract><AbstractText>Human T lymphotropic virus type 1 (HTLV-1) causes a range of chronic inflammatory diseases and an aggressive malignancy of T lymphocytes known as adult T-cell leukaemia/lymphoma (ATLL). A cardinal feature of HTLV-1 infection is the presence of expanded clones of HTLV-1-infected T cells, which may persist for decades. A high viral burden (proviral load) is associated with both the inflammatory and malignant diseases caused by HTLV-1, and it has been believed that the oligoclonal expansion of infected cells predisposes to these diseases. However, it is not understood what regulates the clonality of HTLV-1 in vivo, that is, the number and abundance of HTLV-1-infected T cell clones. We review recent advances in the understanding of HTLV-1 infection and disease that have come from high-throughput quantification and analysis of HTLV-1 clonality in natural infection.</AbstractText><CopyrightInformation>Copyright &#169; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bangham</LastName><ForeName>Charles R M</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Section of Immunology, Imperial College, London W2 1PG, UK. Electronic address: c.bangham@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Lucy B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Section of Immunology, Imperial College, London W2 1PG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melamed</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Immunology, Imperial College, London W2 1PG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>100291</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K019090/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Semin Cancer Biol</MedlineTA><NlmUniqueID>9010218</NlmUniqueID><ISSNLinking>1044-579X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003602">Cytotoxicity, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011533">Proviruses</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056189">Viral Tropism</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016662">Virus Integration</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clonality</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">High-throughput sequencing</Keyword><Keyword MajorTopicYN="N">Integration</Keyword><Keyword MajorTopicYN="N">Leukaemia</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">Persistent infection</Keyword><Keyword MajorTopicYN="N">Retrovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24316494</ArticleId><ArticleId IdType="pmc">PMC4062949</ArticleId><ArticleId IdType="doi">10.1016/j.semcancer.2013.11.003</ArticleId><ArticleId IdType="pii">S1044-579X(13)00124-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gessain A., Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahieux R., Gessain A. HTLV-3/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects. Viruses. 2011;3:1074&#8211;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185789</ArticleId><ArticleId IdType="pubmed">21994771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M., Izumo S., Ijichi S., Kubota H., Arimura K., Kawabata M. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol. 1995;1:50&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9222342</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481&#8211;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo R.C. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene. 2005;24:5926&#8211;5930.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene. 2005;24:5931&#8211;5937.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155600</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058&#8211;6068.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonck K., Gonzalez E., Van Dooren S., Vandamme A.M., Vanham G., Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60:1373&#8211;1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2095573</ArticleId><ArticleId IdType="pubmed">18042693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamihira S., Sohda H., Atogami S., Toriya K., Yamada Y., Tsukazaki K. Phenotypic diversity and prognosis of adult T-cell leukemia. Leuk Res. 1992;16:435&#8211;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">1625468</ArticleId></ArticleIdList></Reference><Reference><Citation>Toulza F., Nosaka K., Takiguchi M., Pagliuca T., Mitsuya H., Tanaka Y. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer. 2009;125:2375&#8211;2382.</Citation><ArticleIdList><ArticleId IdType="pubmed">19544530</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;87) Br J Haematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Tobinai K., Shimoyama M., Kozuru M., Uike N., Yamada Y. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109) Int J Hematol. 2003;77:164&#8211;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Utsunomiya A., Fukuda H., Shibata T., Fukushima T., Takatsuka Y. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458&#8211;5464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375&#8211;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y., Iwanaga M., Imaizumi Y., Tawara M., Joh T., Kohno T. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010;115:4337&#8211;4343.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A., Plumelle Y., Carlos Ramos J., Tortevoye P., Otrock Z., Taylor G. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177&#8211;4183.</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodson A., Crichton S., Montoto S., Mir N., Matutes E., Cwynarski K. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol. 2011;29:4696&#8211;4701.</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashanchi F., Brady J.N. Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene. 2005;24:5938&#8211;5951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155601</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M., Jeang K.T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30:1379&#8211;1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413891</ArticleId><ArticleId IdType="pubmed">21119600</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M., Jeang K.T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7:270&#8211;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxus M., Willems L. Mechanisms of HTLV-1 persistence and transformation. Br J Cancer. 2009;101:1497&#8211;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778510</ArticleId><ArticleId IdType="pubmed">19861996</ArticleId></ArticleIdList></Reference><Reference><Citation>Asquith B., Zhang Y., Mosley A.J., de Lara C.M., Wallace D.L., Worth A. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci USA. 2007;104:8035&#8211;8040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861853</ArticleId><ArticleId IdType="pubmed">17483473</ArticleId></ArticleIdList></Reference><Reference><Citation>Igakura T., Stinchcombe J.C., Goon P.K., Taylor G.P., Weber J.N., Griffiths G.M. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003;299:1713&#8211;1716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12589003</ArticleId></ArticleIdList></Reference><Reference><Citation>Nejmeddine M., Bangham C.R. The HTLV-1 virological synapse. Viruses. 2010;2:1427&#8211;1447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185711</ArticleId><ArticleId IdType="pubmed">21994688</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman W.J., Kimata J.T., Wong F.H., Zutter M., Ley T.J., Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92:1057&#8211;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42636</ArticleId><ArticleId IdType="pubmed">7862633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa A., Ohashi T., Hanabuchi S., Kato H., Takemura F., Masuda T. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J Virol. 2003;77:2956&#8211;2963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149753</ArticleId><ArticleId IdType="pubmed">12584320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsugi T., Kumasaka T., Okada S., Urano T. The Tax protein of HTLV-1 promotes oncogenesis in not only immature T cells but also mature T cells. Nat Med. 2007;13:527&#8211;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17479090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464&#8211;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham C.R. CTL quality and the control of human retroviral infections. Eur J Immunol. 2009;39:1700&#8211;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">19582737</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudray G., Gachon F., Basbous J., Biard-Piechaczyk M., Devaux C., Mesnard J.M. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002;76:12813&#8211;12822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136662</ArticleId><ArticleId IdType="pubmed">12438606</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y., Yasunaga J., Yoshida M., Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006;103:720&#8211;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1334651</ArticleId><ArticleId IdType="pubmed">16407133</ArticleId></ArticleIdList></Reference><Reference><Citation>Basbous J., Arpin C., Gaudray G., Piechaczyk M., Devaux C., Mesnard J.M. factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem. 2003;278:43620&#8211;43627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12937177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Yasunaga J., Satou Y., Nakao M., Takahashi M., Fujii M. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood. 2009;113:2755&#8211;2764.</Citation><ArticleIdList><ArticleId IdType="pubmed">19064727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilburn S., Rowan A., Demontis M.A., MacNamara A., Asquith B., Bangham C.R. In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis. 2011;203:529&#8211;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071236</ArticleId><ArticleId IdType="pubmed">21208912</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNamara A., Rowan A., Hilburn S., Kadolsky U., Fujiwara H., Suemori K. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog. 2010;6:e1001117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944806</ArticleId><ArticleId IdType="pubmed">20886101</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold J., Yamamoto B., Li M., Phipps A.J., Younis I., Lairmore M.D. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood. 2006;107:3976&#8211;3982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895283</ArticleId><ArticleId IdType="pubmed">16424388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann A.S., Villaudy J., Gazzolo L., Castellazzi M., Mesnard J.M., Duc Dodon M. HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT) Retrovirol. 2007;4:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235888</ArticleId><ArticleId IdType="pubmed">18078517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerfelt M.A., Williams B.P., Clapham P.R., Solomon E., Goodfellow P.N., Weiss R.A. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science. 1988;242:1557&#8211;1559.</Citation><ArticleIdList><ArticleId IdType="pubmed">3201246</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson J.H., Edwards A.J., Cruickshank J.K., Rudge P., Dalgleish A.G. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol. 1990;64:5682&#8211;5687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC248630</ArticleId><ArticleId IdType="pubmed">1976827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones K.S., Petrow-Sadowski C., Huang Y.K., Bertolette D.C., Ruscetti F.W. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med. 2008;14:429&#8211;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">18376405</ArticleId></ArticleIdList></Reference><Reference><Citation>Macatonia S.E., Cruickshank J.K., Rudge P., Knight S.C. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. ARHR. 1992;8:1699&#8211;1706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1457215</ArticleId></ArticleIdList></Reference><Reference><Citation>Daenke S., Nightingale S., Cruickshank J.K., Bangham C.R. Sequence variants of human T-cell lymphotropic virus type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates. J Virol. 1990;64:1278&#8211;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249244</ArticleId><ArticleId IdType="pubmed">2304144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita T., Tsujimoto A., Shimotohno K. Sequence variations in LTR and env regions of HTLV-I do not discriminate between the virus from patients with HTLV-I-associated myelopathy and adult T-cell leukemia. Int J Cancer. 1991;47:491&#8211;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">1995478</ArticleId></ArticleIdList></Reference><Reference><Citation>Komurian F., Pelloquin F., de The G. In vivo genomic variability of human T-cell leukemia virus type I depends more upon geography than upon pathologies. J Virol. 1991;65:3770&#8211;3778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241407</ArticleId><ArticleId IdType="pubmed">2041093</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Yamashita M., Usuku K., Izumo S., Nakagawa M., Osame M. Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their association with different risks for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2000;182:1343&#8211;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11010842</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Brennan M.B., Sakai J.A., Mora C.A., Jacobson S. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood. 2001;98:1858&#8211;1861.</Citation><ArticleIdList><ArticleId IdType="pubmed">11535522</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayama A., Stuver S., Matsuoka M., Ishizaki J., Tanaka G., Kubuki Y. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer. 2004;110:621&#8211;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">15122598</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki T., Nakagawa M., Nagai M., Usuku K., Higuchi I., Arimura K. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol. 2001;7:228&#8211;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11517397</ArticleId></ArticleIdList></Reference><Reference><Citation>Overbaugh J., Bangham C.R. Selection forces and constraints on retroviral sequence variation. Science. 2001;292:1106&#8211;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavrois M., Gessain A., Wain-Hobson S., Wattel E. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene. 1996;12:2419&#8211;2423.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattel E., Cavrois M., Gessain A., Wain-Hobson S. Clonal expansion of infected cells: a way of life for HTLV-I. J AIDS Hum Retrovirol. 1996;13(Suppl. 1):S92&#8211;S99.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattel E., Vartanian J.P., Pannetier C., Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69:2863&#8211;2868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188982</ArticleId><ArticleId IdType="pubmed">7707509</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Fujisawa J., Osame M., Toita M., Sonoda S., Kubota R. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP) Blood. 1992;80:1012&#8211;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">1498321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavrois M., Leclercq I., Gout O., Gessain A., Wain-Hobson S., Wattel E. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene. 1998;17:77&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9671316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ina Y., Gojobori T. Molecular evolution of human T-cell leukemia virus. J Mol Evol. 1990;31:493&#8211;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">2176698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota R., Hanada K., Furukawa Y., Arimura K., Osame M., Gojobori T. Genetic stability of human T lymphotropic virus type I despite antiviral pressures by CTLs. J Immunol. 2007;178:5966&#8211;5972.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansky L.M. In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy. J Virol. 2000;74:9525&#8211;9531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112382</ArticleId><ArticleId IdType="pubmed">11000222</ArticleId></ArticleIdList></Reference><Reference><Citation>Asquith B., Bangham C.R. Quantifying HTLV-I dynamics. Immunol Cell Biol. 2007;85:280&#8211;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka G., Okayama A., Watanabe T., Aizawa S., Stuver S., Mueller N. The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J Infect Dis. 2005;191:1140&#8211;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747250</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Hermine O., Bazarbachi A., Ratner L., Ramos J.C., Harrington W., Jr. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453&#8211;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham C.R.M. In: Genetic susceptibility to infectious diseases. Kaslow R.A., McNicholl J.M., Hill A.V.S., editors. Oxford University Press; Oxford, UK: 2008. Human T-lymphotropic virus type 1 (HTLV-1)-associated diseases; pp. 303&#8211;317.</Citation></Reference><Reference><Citation>Jeffery K.J., Siddiqui A.A., Bunce M., Lloyd A.L., Vine A.M., Witkover A.D. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol. 2000;165:7278&#8211;7284.</Citation><ArticleIdList><ArticleId IdType="pubmed">11120862</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery K.J., Usuku K., Hall S.E., Matsumoto W., Taylor G.P., Procter J. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA. 1999;96:3848&#8211;3853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22383</ArticleId><ArticleId IdType="pubmed">10097126</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewiesk S., Daenke S., Parker C.E., Taylor G., Weber J., Nightingale S. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis. J Virol. 1994;68:6778&#8211;6781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237103</ArticleId><ArticleId IdType="pubmed">8084014</ArticleId></ArticleIdList></Reference><Reference><Citation>Vine A.M., Heaps A.G., Kaftantzi L., Mosley A., Asquith B., Witkover A. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol. 2004;173:5121&#8211;5129.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470056</ArticleId></ArticleIdList></Reference><Reference><Citation>Asquith B., Mosley A.J., Barfield A., Marshall S.E., Heaps A., Goon P. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol. 2005;86:1515&#8211;1523.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kattan T., MacNamara A., Rowan A.G., Nose H., Mosley A.J., Tanaka Y. The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol. 2009;182:5723&#8211;5729.</Citation><ArticleIdList><ArticleId IdType="pubmed">19380819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak M.A., Bangham C.R. Population dynamics of immune responses to persistent viruses. Science. 1996;272:74&#8211;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M., Harada S., Maruyama I., Inoko H., Igarashi H., Kuwashima G. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol. 1991;3:761&#8211;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">1911545</ArticleId></ArticleIdList></Reference><Reference><Citation>Goon P.K., Biancardi A., Fast N., Igakura T., Hanon E., Mosley A.J. Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J Infect Dis. 2004;189:2294&#8211;2298.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillet N.A., Malani N., Melamed A., Gormley N., Carter R., Bentley D. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T cell clones. Blood. 2011;117:3113&#8211;3122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062313</ArticleId><ArticleId IdType="pubmed">21228324</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry C.C., Gillet N.A., Melamed A., Gormley N., Bangham C.R., Bushman F.D. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics. 2012;28:755&#8211;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307109</ArticleId><ArticleId IdType="pubmed">22238265</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook L.B., Rowan A.G., Melamed A., Taylor G.P., Bangham C.R. HTLV-1-infected T cells contain a single integrated provirus in natural infection. Blood. 2012;120:3488&#8211;3490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482858</ArticleId><ArticleId IdType="pubmed">22955925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamihira S., Sugahara K., Tsuruda K., Minami S., Uemura A., Akamatsu N. Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol. 2005;27:235&#8211;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16048490</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamiya S., Matsuoka M., Etoh K., Watanabe T., Kamihira S., Yamaguchi K. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996;88:3065&#8211;3073.</Citation><ArticleIdList><ArticleId IdType="pubmed">8874205</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K., Tsushima H., Yamamura M., Hata T., Murata K., Maeda T. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 1997;89:948&#8211;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">9028326</ArticleId></ArticleIdList></Reference><Reference><Citation>Josefsson L., King M.S., Makitalo B., Brannstrom J., Shao W., Maldarelli F. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci USA. 2011;108:11199&#8211;11204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131354</ArticleId><ArticleId IdType="pubmed">21690402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nethe M., Berkhout B., van der Kuyl A.C. Retroviral superinfection resistance. Retrovirology. 2005;2:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224871</ArticleId><ArticleId IdType="pubmed">16107223</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed A., Laydon D.J., Gillet N.A., Tanaka Y., Taylor G.P., Bangham C.R. Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog. 2013;9:e1003271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605240</ArticleId><ArticleId IdType="pubmed">23555266</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryciak P.M., Varmus H.E. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. Cell. 1992;69:769&#8211;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">1317268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushman F., Lewinski M., Ciuffi A., Barr S., Leipzig J., Hannenhalli S. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol. 2005;3:848&#8211;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">16175173</ArticleId></ArticleIdList></Reference><Reference><Citation>Derse D., Crise B., Li Y., Princler G., Lum N., Stewart C. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol. 2007;81:6731&#8211;6741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900082</ArticleId><ArticleId IdType="pubmed">17409138</ArticleId></ArticleIdList></Reference><Reference><Citation>Meekings K.N., Leipzig J., Bushman F.D., Taylor G.P., Bangham C.R. HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog. 2008;4:e1000027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265437</ArticleId><ArticleId IdType="pubmed">18369476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010;464:232&#8211;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837123</ArticleId><ArticleId IdType="pubmed">20118915</ArticleId></ArticleIdList></Reference><Reference><Citation>Maertens G.N., Hare S., Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature. 2010;468:326&#8211;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2999894</ArticleId><ArticleId IdType="pubmed">21068843</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelman A., Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008;4:e1000046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2275779</ArticleId><ArticleId IdType="pubmed">18369482</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers R., De Rijck J., Demeulemeester J., Adachi N., Vets S., Ronen K. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog. 2012;8:e1002558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291655</ArticleId><ArticleId IdType="pubmed">22396646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocwieja K.E., Brady T.L., Ronen K., Huegel A., Roth S.L., Schaller T. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog. 2011;7:e1001313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053352</ArticleId><ArticleId IdType="pubmed">21423673</ArticleId></ArticleIdList></Reference><Reference><Citation>Inayoshi Y., Okino Y., Miyake K., Mizutani A., Yamamoto-Kishikawa J., Kinoshita Y. Transcription factor YY1 interacts with retroviral integrases and facilitates integration of moloney murine leukemia virus cDNA into the host chromosomes. J Virol. 2010;84:8250&#8211;8261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916549</ArticleId><ArticleId IdType="pubmed">20519390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanon E., Hall S., Taylor G.P., Saito M., Davis R., Tanaka Y. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood. 2000;95:1386&#8211;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">10666215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan L., Yang H.C., Rabi S.A., Bravo H.C., Shroff N.S., Irizarry R.A. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011;85:5384&#8211;5393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094997</ArticleId><ArticleId IdType="pubmed">21430059</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Jr., Kinzler K.W. Cancer genome landscapes. Science. 2013;339:1546&#8211;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749880</ArticleId><ArticleId IdType="pubmed">23539594</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8:1&#8211;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2007940</ArticleId><ArticleId IdType="pubmed">13172380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rende F., Cavallari I., Corradin A., Silic-Benussi M., Toulza F., Toffolo G.M. Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs. Blood. 2011;117:4855&#8211;4859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292588</ArticleId><ArticleId IdType="pubmed">21398577</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18164760</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0145-2126</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Leukemia research</Title><ISOAbbreviation>Leuk Res</ISOAbbreviation></Journal><ArticleTitle>Hexamethylene bisacetamide as a treatment for T-cell leukemia (T-ALL).</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>690</EndPage><MedlinePgn>689-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2007.11.018</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buonamici</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aifantis</LastName><ForeName>Iannis</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56AI070310</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI070310-01A1</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA149655</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA105129</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA105129-03</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA10519</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI070310</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leuk Res</MedlineTA><NlmUniqueID>7706787</NlmUniqueID><ISSNLinking>0145-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>LA133J59VU</RegistryNumber><NameOfSubstance UI="C014026">hexamethylene bisacetamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Leuk Res. 2008 May;32(5):791-7</RefSource><PMID Version="1">17964649</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000081">Acetamides</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18164760</ArticleId><ArticleId IdType="mid">NIHMS43195</ArticleId><ArticleId IdType="pmc">PMC2593865</ArticleId><ArticleId IdType="doi">10.1016/j.leukres.2007.11.018</ArticleId><ArticleId IdType="pii">S0145-2126(07)00461-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17964649</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks PA, Richon VM, Rifkind RA. Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Int J Hematol. 1996;63(1):1&#8211;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8713572</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks PA, et al. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc Natl Acad Sci U S A. 1994;91(22):10251&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44997</ArticleId><ArticleId IdType="pubmed">7937935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelly LL, Fuchs C, Miele L. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem. 1999;73(2):164&#8211;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227380</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6(5):347&#8211;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">16612405</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269&#8211;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15472075</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BJ, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007;204(8):1825&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118676</ArticleId><ArticleId IdType="pubmed">17646408</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Neil J, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813&#8211;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118656</ArticleId><ArticleId IdType="pubmed">17646409</ArticleId></ArticleIdList></Reference><Reference><Citation>Young CW, et al. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res. 1988;48(24 Pt 1):7304&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3191501</ArticleId></ArticleIdList></Reference><Reference><Citation>Conley BA, et al. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580) Cancer Res. 1989;49(12):3436&#8211;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">2720696</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Manero G, et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17962510</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvic M, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood. 2007;109(1):31&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1785068</ArticleId><ArticleId IdType="pubmed">16960145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24008301</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0080-0015</ISSN><JournalIssue CitedMedium="Print"><Volume>193</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer</Title><ISOAbbreviation>Recent Results Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Prevention of human T-cell lymphotropic virus type 1 infection and adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>225</EndPage><MedlinePgn>211-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-642-38965-8_12</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive peripheral T-cell malignancy that develops after long-term chronic infection with human T-cell lymphotropic virus type-1 (HTLV-1). Despite the recent advances in chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHSCT), and supportive care, the prognosis for patients with ATL is one of the poorest among hematological malignancies; overall survival (OS) at 3 years is only 24 % in the more aggressive subtypes of ATLL. HTLV-1 is a human retrovirus infecting approximately 10-20 million people worldwide, particularly in southern and southeastern Japan, the Caribbean, highlands of South America, Melanesia, and Equatorial Africa. Despite this high frequency of human infection, only 2-5 % of HTLV-1-infected individuals develop ATLL. Three major routes of viral transmission have been established: (1) mother-to-child transmission through breast-feeding; (2) sexual transmission, predominantly from men to women; and (3) cellular blood components. Multiple factors (e.g., virus, host cell, and immune factors) have been implicated in the development of ATLL, although the underlying mechanisms of leukemogenesis have not been fully elucidated. No preventive vaccine against HTLV-1 is currently available, and interrupting the well-recognized primary modes of HTLV-1 transmission is the mainstay of ATLL prevention. Prevention of mother-to-child transmission through the replacement of breast-feeding has been shown to have the most significant impact on the incidence of HTLV-1 infection, and public health policies should consider the risk of malnutrition, especially in developing countries where malnutrition is the significant cause of infant mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan, myoshimi@m.kufm.kagoshima-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Yohann</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Naomichi</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Recent Results Cancer Res</MedlineTA><NlmUniqueID>0044671</NlmUniqueID><ISSNLinking>0080-0015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24008301</ArticleId><ArticleId IdType="doi">10.1007/978-3-642-38965-8_12</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25281470</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.</ArticleTitle><Pagination><StartPage>e517</StartPage><EndPage>e526</EndPage><MedlinePgn>e517-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(14)70202-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(14)70202-5</ELocationID><Abstract><AbstractText>Adult T-cell leukaemia-lymphoma (ATL) is a malignancy of peripheral T lymphocytes caused by human T-lymphotropic virus type I (HTLV-1), and its prognosis is poor. There are an estimated 5 million to 20 million HTLV-1 infected individuals worldwide; their lifetime risk of developing ATL is 3-5%, and high HTLV-1 proviral loads have been shown to be an independent risk factor. Recent advances in the treatment of ATL are the introduction of treatment targeted against CC chemokine receptor 4 (CCR4), which is abundantly expressed on most ATL cells, and allogeneic haemopoietic stem-cell transplantation for aggressive ATL. Promising outcomes are also reported with early intervention for indolent ATL with interferon &#945; and zidovudine. Clinical trials should incorporate a validated prognostic index to assess the results, because of the difficulties associated with undertaking large-scale trials and significant diversity of clinical features with ATL, even in the same clinical subtypes (acute, lymphoma, chronic, and smoldering).</AbstractText><CopyrightInformation>Copyright &#169; 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan. Electronic address: kenjiishitsuka@fukuoka-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009361">Neoplasm Invasiveness</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId><ArticleId IdType="pii">S1470-2045(14)70202-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27507878</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>28</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.</ArticleTitle><Pagination><StartPage>3426</StartPage><EndPage>3433</EndPage><MedlinePgn>3426-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2016.67.8250</ELocationID><Abstract><AbstractText Label="PURPOSE">Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one important treatment option for patients with aggressive adult T-cell leukemia/lymphoma (ATLL). Mogamulizumab (anti-CCR4 monoclonal antibody; Mog) was recently approved as a treatment for ATLL in Japan. Major concerns exist about the possible adverse effects of pretransplantation Mog because Mog depletes regulatory T cells for several months. We assessed the impact of pretransplantation Mog on clinical outcomes after allo-HSCT.</AbstractText><AbstractText Label="PATIENTS AND METHODS">We included 996 allo-HSCT recipients age 70 years or younger with aggressive ATLL who were given the diagnosis between 2000 and 2013 and who received intensive chemotherapy by multiple chemotherapeutic drugs as first-line therapy. Before allo-HSCT, 82 patients received Mog with a median interval of 45 days from the last Mog to allo-HSCT.</AbstractText><AbstractText Label="RESULTS">Pretransplantation Mog was associated with an increased risk of grade 3 to 4 acute graft-versus-host disease (GVHD; relative risk, 1.80; P &lt; .01) and refractoriness to systemic corticosteroid for acute GVHD (relative risk, 2.09; P &lt; .01). One-year cumulative incidence of nonrelapse mortality was significantly higher in patients with pretransplantation Mog compared with those without (43.7% v 25.1%; P &lt; .01). The probability of 1-year overall survival was also significantly inferior in patients with pretransplantation Mog compared with those without (32.3% v 49.4%; P &lt; .01). In particular, use of Mog with intervals &lt; 50 days to allo-HSCT was associated with a dismal clinical outcome.</AbstractText><AbstractText Label="CONCLUSION">Pretransplantation Mog was significantly associated with an increased risk of GVHD-related mortality, which supports the relevance of CCR4-expressing Tregs after allo-HSCT in humans. In clinical practice, Mog should be cautiously used for patients with ATLL who are eligible for allo-HSCT.</AbstractText><CopyrightInformation>&#169; 2016 by American Society of Clinical Oncology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan. sfuji@ncc.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriuchi</LastName><ForeName>Yukiyoshi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchimaru</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ilseung</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henzan</LastName><ForeName>Hideho</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomoyose</LastName><ForeName>Takeaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosawa</LastName><ForeName>Saiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Ken-Ichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Takuhiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shigeo Fuji, Yoshitaka Inoue, Saiko Kurosawa, and Takahiro Fukuda, National Cancer Center Hospital; Kaoru Uchimaru, The University of Tokyo; Hisashi Yamamoto, Toranomon Hospital, Tokyo; Yoshitaka Inoue, Kumamoto University Hospital, Kumamoto; Atae Utsunomiya, Imamura Bun-in Hospital, Kagoshima; Yukiyoshi Moriuchi, Sasebo City General Hospital, Sasebo; Ilseung Choi, National Hospital Organization Kyushu Cancer Center; Hideho Henzan, Hamanomachi Hospital; Koji Kato, Kyushu University Graduate School of Medical Sciences, Fukuoka; Eiichi Otsuka, Oita Prefectural Hospital, Oita; Takeaki Tomoyose, University of the Ryukyus, Okinawa; Ken-ichi Matsuoka, Okayama University, Okayama; and Takuhiro Yamaguchi, Tohoku University Graduate School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000305">Adrenal Cortex Hormones</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016208">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27507878</ArticleId><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId><ArticleId IdType="pii">JCO.2016.67.8250</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21486117</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Newer developments in adult T-cell leukemia/lymphoma therapeutics.</ArticleTitle><Pagination><StartPage>1709</StartPage><EndPage>1717</EndPage><MedlinePgn>1709-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656566.2011.571207</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Adult T-cell leukemia/lymphoma (ATL) is a rare disease with a unique geographic distribution. Conducting controlled randomized trials to assess the effective therapeutic strategies has therefore been a significant challenge to date.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">This review explores the natural history and diagnostic evaluation of ATL, followed by a focused review of existing studies on the most potent individual pharmaceutical agents and combinations used in the therapy of this malignancy. Readers will acquire considerable insights about the clinical subsets, diagnosis and the most effective therapies used in various ATL types.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">International, multicenter, randomized clinical trials are essential to design optimal therapeutic strategies for various ATL subsets. It appears that patients with acute ATL type benefit considerably from the first-line combined antiviral therapy with zidovudine and interferon alpha, whereas patients with ATL of the lymphoma type may experience a better outcome with intensive chemotherapy. The role of therapy in smoldering and chronic disease types remains to be clarified. In addition, the results of allogeneic stem-cell transplantation in ATL appear promising, as up to 40% of patients who achieve remission and have suitable donors can now become long-term survivors. Prospective evaluation of novel effective agents and their incorporation into various therapeutic algorithms is stringently needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dasanu</LastName><ForeName>Constantin A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>St Francis Hospital and Medical Center, Department of Hematology-Oncology, Hartford, CT, USA. c_dasanu@yahoo.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000465">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21486117</ArticleId><ArticleId IdType="doi">10.1517/14656566.2011.571207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27618683</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?</ArticleTitle><Pagination><StartPage>1549</StartPage><EndPage>1555</EndPage><MedlinePgn>1549-1555</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/bmt.2016.154</ELocationID><Abstract><AbstractText>Adult T-cell leukaemia/lymphoma (ATL) is an aggressive HTLV-1-related malignancy, rare outside of regions where the retrovirus is endemic. Although the use of antiviral therapy has improved outcomes, particularly for indolent forms of ATL, response to combination chemotherapy is poor and outcomes for aggressive subtypes remains dismal. Consolidation with allogeneic stem cell transplant (alloSCT) has an increasing role in the management of ATL in eligible patients, offering favourable long-term remission rates. However, relatively high-transplant-related mortality and issues with donor recruitment for certain ethnicities remain problematic. In this review, we discuss the rationale for and issues surrounding alloSCT in ATL in the context of conventional and emerging therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>E H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Haematology, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodson</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Haematology, Ipswich Hospital, Ipswich, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imagine Institute, Assistance Publique H&#244;pitaux de Paris, Paris Descartes University, Necker Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazarbachi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, American University of Beirut, Medical Center, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cwynarski</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Haematology, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27618683</ArticleId><ArticleId IdType="doi">10.1038/bmt.2016.154</ArticleId><ArticleId IdType="pii">bmt2016154</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blood. 2013 Jun 13;121(24):4894-901</Citation><ArticleIdList><ArticleId IdType="pubmed">23641014</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8797699</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2013 Dec;19(12):1731-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24090597</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2002 Jul;76(1):91-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12138903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Aug;79(15):10088-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16014972</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1992 Jan 15;79(2):477-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1730092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2013 Apr 15;190(8):4382-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23475215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2016 Feb;51(2):205-11</Citation><ArticleIdList><ArticleId IdType="pubmed">26524263</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1749-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2015 Apr;21(4):696-700</Citation><ArticleIdList><ArticleId IdType="pubmed">25542158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2011 Apr;46(4):485-501</Citation><ArticleIdList><ArticleId IdType="pubmed">21358689</ArticleId></ArticleIdList></Reference><Reference><Citation>Haematologica. 2014 Feb;99(2):370-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23935024</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1994 Oct;88(2):403-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7803291</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2013 Apr;97(4):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23483425</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2005 Jan 13;24(3):419-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15543232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2014 Oct;49(10):1266-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 1998 Oct;31(3-4):295-304</Citation><ArticleIdList><ArticleId IdType="pubmed">9869193</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jun;14(6):702-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Haematol. 2002;107(4):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12053149</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2009 Jun 25;113(26):6528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19411628</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2013 Apr 1;31(10):1310-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23423745</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2006 Aug 1;108(3):1021-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2007 Aug;86(2):118-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17875524</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2014 Jun 19;123(25):3925-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24735963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2016 Mar;51(3):432-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26524267</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jul;14(7):817-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18541202</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Lett. 2014 Mar-Apr;158(1-2):120-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24389072</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 May 15;105(10):4143-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2002 Nov;30(10):699-701</Citation><ArticleIdList><ArticleId IdType="pubmed">12420209</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1990 Feb 15;45(2):237-43</Citation><ArticleIdList><ArticleId IdType="pubmed">2303290</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 1991;15(2-3):81-90</Citation><ArticleIdList><ArticleId IdType="pubmed">2016910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2013 Jul;48(7):998-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23292237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2008 Sep 1;26(25):4124-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18626005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Haematol. 2016 Mar;3(3):e107-18</Citation><ArticleIdList><ArticleId IdType="pubmed">26947199</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1990 Nov 15;76(10 ):2065-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1978691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 1995 Feb;15(2):235-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7773212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 1998 Jul;9(7):717-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9739436</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2006 Aug;47(8):1691-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16966289</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Transplant. 2014 Oct;14(10):2417-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25138148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2004 Nov;34(10):897-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15361902</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2015 Jun;169(5):672-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2006 Jan;37(1):41-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16247419</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2013 Jan 3;121(1):219-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23100309</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2014 Feb 1;192(3):940-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24363428</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Apr 20;354(16):1758-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16625020</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2015 Dec 10;126(24):2570-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Mar 26;377(9771):1124</Citation><ArticleIdList><ArticleId IdType="pubmed">21440808</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2011 Mar 17;117(11):3113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21228324</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2009 Jun;50(6):1039-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19373596</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2000 Apr;71(3):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10846838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2016 May;51(5):725-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26691420</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2012 Jun;95(6):725-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22481502</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2011 Aug 18;118(7):1736-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2010 Dec 20;207(13):2785-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21135137</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2015 Aug 27;126(9):1095-105</Citation><ArticleIdList><ArticleId IdType="pubmed">26063164</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2004 Jan 1;64(1):391-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14729650</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1997 May;15(5):1778-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9164185</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2015 Mar;29(3):556-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25118879</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2014 Dec;155(2):176-87</Citation><ArticleIdList><ArticleId IdType="pubmed">25267440</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2007 Apr;48(4):841-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17454652</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2013 Mar 14;121(11):2029-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23321252</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2012 Dec;32(6):1340-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22763862</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2005 Dec;46(12):1843-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16263592</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1997 Mar;96(4):715-23</Citation><ArticleIdList><ArticleId IdType="pubmed">9074411</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1995 Jun 29;332(26):1744-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hematol. 2007 Dec;82(12):1113-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17696205</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2011 Jan;46(1):116-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20400987</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2010 Sep 20;28(27):4177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2011 Dec 10;29(35):4696-701</Citation><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId></ArticleIdList></Reference><Reference><Citation>Retrovirology. 2013 Aug 20;10:91</Citation><ArticleIdList><ArticleId IdType="pubmed">23962110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Cancer Res. 1990 Sep;81(9):884-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2121689</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2001 Aug 15;98(4):1160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11493465</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 Nov 15;106(10):3380-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16076875</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Mar 1;103(5):1955-60</Citation><ArticleIdList><ArticleId IdType="pubmed">14604976</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2016 Feb;30(2):447-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26293645</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 Jun;113(3):779-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2014 Jun;20(6):801-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24565990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2015 Oct 1;33(28):3152-61</Citation><ArticleIdList><ArticleId IdType="pubmed">26261255</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2006 Mar 28;234(2):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15896902</ArticleId></ArticleIdList></Reference><Reference><Citation>Springerplus. 2014 Oct 04;3:581</Citation><ArticleIdList><ArticleId IdType="pubmed">25332881</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Sci. 2015 Sep;106(9):1219-23</Citation><ArticleIdList><ArticleId IdType="pubmed">26179770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2008 Jun;41(12):1029-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18332910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol J. 2004;5(2):130-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2013 Jul 1;191(1):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23733874</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Mar 10;30(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2012 Aug 23;120(8):1734-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2013 Apr;19(4):607-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23333533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 1999 Jan;23(1):87-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10037056</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 2012 Jul;36(7):857-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22209076</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37844559</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2296-5262</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>11</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Oncology research and treatment</Title><ISOAbbreviation>Oncol Res Treat</ISOAbbreviation></Journal><ArticleTitle>Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>465</EndPage><MedlinePgn>459-465</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000534040</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Adult T-cell leukemia lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection. Despite its poor prognosis, there is no standard therapy for ATLL due to its low incidence and the disease affecting only endemic geographical clusters.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective evaluation of patients with the diagnosis of ATLL at Moffitt Cancer Center and Memorial Healthcare System was done to identify patients and disease characteristics along with the progression-free survival (PFS) and overall survival (OS) for the different therapies used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 61 patients analyzed showed a median age of 58 with 82.5% of them being of African American descent. The acute variant contributed to the majority of cases (43.9%), followed by 36.8% presenting as a lymphoma variant. There was no statistical difference in the PFS (6.4 m, 3.1 m, 2.1 m; p = 0.23) or OS (14 m, 8.9 m, 18.5 m; p = 0.14) between cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), intensive chemotherapy regimens, and other modalities, respectively. However, the patients who had complete or partial remission with first-line therapy had better OS (15.9 m vs. 7.2 m; p = 0.004).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study highlighted the poor outcome of the current regimens and the lack of a unifying protocol for this vicious disease. The acute variants were treated with more intensive regimens, but there was no difference in the OS between the three major options of CHOP, intensified chemotherapy, and others. This underscores the need for more clinical trials to develop better outcomes.</AbstractText><CopyrightInformation>&#169; 2023 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Hayder</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandoval-Sus</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memorial Healthcare System, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo-Tokumori</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullukkara</LastName><ForeName>Jerrin Joy</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boisclair</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Zuckerberg Cancer Center, Northwell Health Cancer Institute, New Hyde Park, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brahim</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memorial Healthcare System, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Damaal</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Memorial Healthcare System, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bridgellal</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memorial Healthcare System, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokol</LastName><ForeName>Lubomir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Moffitt Cancer Center, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Oncol Res Treat</MedlineTA><NlmUniqueID>101627692</NlmUniqueID><ISSNLinking>2296-5270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHOP</Keyword><Keyword MajorTopicYN="N">Caribbean</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Intensive chemotherapy</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">T cell</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>17</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37844559</ArticleId><ArticleId IdType="doi">10.1159/000534040</ArticleId><ArticleId IdType="pii">000534040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23801427</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.</ArticleTitle><Pagination><StartPage>258</StartPage><EndPage>260</EndPage><MedlinePgn>258-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-013-1387-8</ELocationID><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATLL) is an aggressive peripheral T cell neoplasm caused by human T cell lymphotropic/leukemia virus type-1 and has a poor prognosis. A new anti-CC chemokine receptor 4 monoclonal antibody (mogamulizumab) has been shown to be effective for ATLL. Although mogamulizumab is now available in Japan for patients with ATLL, the influence on allogeneic hematopoietic stem cell transplantation (HSCT) remains unclear. Here we report a woman with ATLL resistant to combination chemotherapy, who achieved complete remission following treatment with mogamulizumab and subsequently received allogeneic HSCT. The patient has remained in complete remission with controlled graft-versus-host disease. To our knowledge, this is the first report of an ATLL patient who received mogamulizumab treatment followed by allogeneic HSCT. We suggest that administration of mogamulizumab to chemotherapy-resistant patients with ATLL may improve their disease status before allogeneic HSCT and result in better survival.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Motohashi</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Yokohama City University Medical Center, 4-57, Urafunecho, Minami-ku, Yokohama 232-0024, Japan. motohash@yokohama-cu.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Taisei</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>Kumiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Numata</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tachibana</LastName><ForeName>Takayoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Rika</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kuwabara</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Masatsugu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>Naoto</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ishigatsubo</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fujisawa</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23801427</ArticleId><ArticleId IdType="doi">10.1007/s12185-013-1387-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Mar 10;30(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jan;14(1):75-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18158964</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jun;14(6):702-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 1974 Oct;18(4):295-304</Citation><ArticleIdList><ArticleId IdType="pubmed">4153799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2013 Jul;48(7):998-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23292237</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2011 Nov;94(5):443-52</Citation><ArticleIdList><ArticleId IdType="pubmed">21993874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2002 Sep;13(9):1347-55</Citation><ArticleIdList><ArticleId IdType="pubmed">12196359</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2003 Feb;77(2):164-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12627852</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15160945</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1042-8194</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma (ATLL): report of two fully documented Hellenic patients.</ArticleTitle><Pagination><StartPage>715</StartPage><EndPage>721</EndPage><MedlinePgn>715-21</MedlinePgn></Pagination><Abstract><AbstractText>ATLL is etiologically associated with HTLV-I retrovirus. A population of 10 to 20 million worldwide is estimated to be infected by the virus, but only 1-4% develop ATLL during a 70-year lifespan. The latency period is more than 30 years. The aim of this study was to report two cases of ATLL in Greek patients with the concomitant study of their family members. A 55-year-old woman and a 59-year-old man presented with leucocytosis and lymphocytosis. Both were asymptomatic and physical examination was unremarkable except for minimal lymphadenopathy in the second patient. In both patients blood smears showed small-to-medium-sized, multilobulated lymphocytes, with different degrees of nuclear irregularity. Immunophenotypic study was as follows: CD2 + (97%), CD3 + (95%), CD5 + (95%), CD3/CD4 + (93%), CD3/CD25 + (84%), CD7 -/CD4 + (89%) CD2 + /HLA-DR + (53%), TCRabeta + (96%) and CD7-(7%). Bone marrow biopsy revealed a normal cellularity with dyserythropoiesis and scattered small lymphocytes (CD4 + on immunostaining) Serum HTLV I and II antibodies were positive. T-cell receptor gamma-chain rearrangement was positive in blood lymphocytes by PCR. Cytogenetic analysis showed complex karyotypic abnormalities. DNA analysis by PCR demonstrated the integration of the HTLV-I DNA in the DNA of the neoplastic T cells. Both patients rapidly developed acute type ATLL. In the first patient multiple subcutaneous nodules on the palmar surface of both hands were also observed. She received deoxycoformycin, which was stopped because of autoimmune hemolytic anemia. Corticosteroid treatment was initiated, with gradual improvement. She suffered from recurrent opportunistic infections. She is currently under interferon and zidovudine therapy with stable blood parameters. Chemotherapy was administered to the other patient with &gt; 50% initial response. Both patients' families were tested for serum anti HTLV-I antibodies and their mates were found to be positive; they also had detectable viral DNA by PCR analysis while asymptomatic, with no abnormal clinical findings and normal white blood cell count and morphology. In conclusion, the two aforementioned patients are the first fully documented ATLL patients described in Greece. Investigation for HTLV-I antibodies should be mandatory in all patients with T-cell lymphoproliferative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kokoris</LastName><ForeName>Styliani I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Haematology Section, 1st Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laikon General Hospital of Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siakantaris</LastName><ForeName>Marina P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Kontopidou</LastName><ForeName>Flora N</ForeName><Initials>FN</Initials></Author><Author ValidYN="Y"><LastName>Kyrtsonis</LastName><ForeName>Marie-Christine</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Tsakris</LastName><ForeName>Athanassios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Spanakis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Anargyrou</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vassilakopoulos</LastName><ForeName>Theodoros P</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Viniou</LastName><ForeName>Nora-Athina</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Korkolopoulou</LastName><ForeName>Penelope</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dimitrakopoulou</LastName><ForeName>Aglaia D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Legakis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Pangalis</LastName><ForeName>Gerassimos A</ForeName><Initials>GA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Leuk Lymphoma. 2004 Oct;45(10):2173-4</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005192">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D006115">Greece</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015367">Human T-lymphotropic virus 2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012698">Serologic Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15160945</ArticleId><ArticleId IdType="doi">10.1080/1042819032000140960</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16155611</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0950-9232</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>39</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Oncogene</Title><ISOAbbreviation>Oncogene</ISOAbbreviation></Journal><ArticleTitle>Natural history of adult T-cell leukemia/lymphoma and approaches to therapy.</ArticleTitle><Pagination><StartPage>6047</StartPage><EndPage>6057</EndPage><MedlinePgn>6047-57</MedlinePgn></Pagination><Abstract><AbstractText>After cell-to-cell transmission, HTLV-I increases its viral genome by de novo infection and proliferation of infected cells. Proliferation of infected cells is clonal and persistent in vivo. During the carrier state, infected cells are selected in vivo by the host's immune system, the genetic and epigenetic environment of proviral integration sites, and other factors. In leukemic cells, tax gene expression is frequently impaired by genetic and epigenetic mechanisms. Such loss of Tax expression enables ATL cells to escape the host immune system. On the other hand, ATL cells acquire the ability to proliferate without Tax by intracellular genetic and epigenetic changes. Despite advances in support and the development of novel treatment agents, the prognosis for ATLL remains poor. A number of therapies, however, do appear to improve prognosis compared to CHOP (VEPA). These include interferon-alpha plus zidovudine (probably after 1-2 cycles of CHOP), intensive chemotherapy as in LSG-15 with G-CSF support and Allo-SCT (which includes the potential for cure). Emerging novel approaches include HDAC inhibitors, monoclonal antibodies, and proteasome inhibitors. Comparison between different therapeutic approaches is complicated by the range of natural history of ATLL, different recruitments of na&#239;ve-to-therapy, refractory or relapsed patients, and variations in the reporting of outcome that frequently excludes difficult-to-evaluate patients. Moreover, results from relatively small proof-of-principle studies have not been extended with randomized, controlled trials. As a result, currently, there is no clear evidence to support the value of any particular treatment approach over others. To avoid further unnecessary patient suffering and to identify optimal therapy as rapidly as possible, large randomized, controlled trials encompassing multicenter, international collaborations will be necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Graham P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of GU Medicine &amp; Communicable Diseases, Faculty of Medicine, Imperial College, Norfolk Place, London W2 1PG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oncogene</MedlineTA><NlmUniqueID>8711562</NlmUniqueID><ISSNLinking>0950-9232</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016355">Genes, pX</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016679">Genome, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014779">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>103</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16155611</ArticleId><ArticleId IdType="doi">10.1038/sj.onc.1208979</ArticleId><ArticleId IdType="pii">1208979</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">33906721</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8686</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Seminars in hematology</Title><ISOAbbreviation>Semin Hematol</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and management of adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>122</EndPage><MedlinePgn>114-122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.seminhematol.2021.02.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0037-1963(21)00015-9</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1). Between 3% and 5% of HTLV-1-infected individuals develop ATL after a long latency. Confirmation of seropositivity of anti-HTLV-1 antibody, and clonal proliferation of CD4 and CD25 positive lymphocytes with nuclear pleomorphism in patients suspicious of malignant lymphoma or chronic lymphocytic leukemia is crucial for the diagnosis of ATL. The clinical course of ATL is very heterogeneous, and divided into acute, lymphoma, chronic, and smoldering types. The chronic type is further subclassified into the favorable and unfavorable subtypes. Acute, lymphoma, and unfavorable chronic type ATL, and favorable chronic and smoldering type ATL are defined as aggressive and indolent ATL, respectively. Recently identified prognostic indices based on clinical parameters and/or genetic predictors of outcomes need to be confirmed and incorporated for more stratified therapeutic interventions. The standard of care for aggressive ATL is multiagent chemotherapy followed by allogeneic hematopoietic stem cell transplantation if possible, while that for indolent ATL is watchful waiting until progression to aggressive ATL. The combination of interferon-&#945; and zidovudine is also standard for leukemic type ATL. In addition, mogamulizumab, lenalidomide, and brentuximab vedotin have been incorporated into clinical practices in Japan. Furthermore, several novel drugs are currently undergoing clinical trials.</AbstractText><CopyrightInformation>Copyright &#169; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan. Electronic address: kenji-i@m.kufm.kagoshima-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Hematol</MedlineTA><NlmUniqueID>0404514</NlmUniqueID><ISSNLinking>0037-1963</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATL</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Prognostic index</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Declaration of competing interest Dr. Ishitsuka reports personal fees from Celgene, grants and personal fees from Kyowa Kirin, personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Takeda Pharmaceutical, personal fees from mundiharma, grants and personal fees from Taiho Pharmaceutical, personal fees from Janssen Pharmaceutical, personal fees from Novartis, personal fees from Pfizer, grants and personal fees from Astellas Pharma, personal fees from Genzyme, grants and personal fees from Sumitomo Dainippon Pharma, grants and personal fees from Eisai, grants and personal fees from Mochida, personal fees from Shire, personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants from Teijin Pharma, grants from MSD, grants from Asahi kasei, grants from Eli Lilly, personal fees from Daiichi Sankyo, personal fees from Huya Japan, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33906721</ArticleId><ArticleId IdType="doi">10.1053/j.seminhematol.2021.02.005</ArticleId><ArticleId IdType="pii">S0037-1963(21)00015-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28251608</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-4632</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of dermatology</Title><ISOAbbreviation>Int J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma in a Peruvian hospital in human T-lymphotropic virus type 1 (HTLV-1) positive patients.</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>509</EndPage><MedlinePgn>503-509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ijd.13567</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adult T-cell leukemia/lymphoma (ATLL) is an aggressive neoplasm of T-lymphocytes associated with human T-lymphotropic virus type I (HTLV-1) infection. As HTLV-1 is endemic in native ethnics in South America, and its infection leads to several chronic diseases as ATLL with poor prognosis, we aimed to present three ATLL cases and to review current literature.</AbstractText><AbstractText Label="CASE REPORTS" NlmCategory="METHODS">Two cases were from the mountains of Peru, while one was from an endemic harbor of the country. An acute ATLL patient presented with multipapular infiltration of the skin and died 2 weeks after admission because of septic shock. The two chronic ATLL patients presented with erythematous plaques and erythroderma. They had swollen lymph nodes, lymphocytosis, and atypical lymphocytes on blood smear, with normal biochemical results. They both passed away a few months after diagnosis.</AbstractText><AbstractText Label="COMMENTS" NlmCategory="CONCLUSIONS">ATLL is developed after years of HTLV-1 carrier status; therefore, physicians should know the principal clinical and laboratory findings in order to make prompt diagnosis. Prognosis is still poor in aggressive and indolent variants, with survival rates from months to a few years. Treatment based on chemotherapy, antiretroviral, and allogeneic stem cell transplantation are improving survival rates but with limited results.</AbstractText><CopyrightInformation>&#169; 2017 The International Society of Dermatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#237;guez-Z&#250;&#241;iga</LastName><ForeName>Milton Jos&#233; Max</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-9413-2439</Identifier><AffiliationInfo><Affiliation>Dermatology Department, Hospital Nacional Daniel Alcides Carrion, Callao, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Nacional Mayor de San Marcos, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortez-Franco</LastName><ForeName>Florencio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dermatology Department, Hospital Nacional Daniel Alcides Carrion, Callao, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qujiano-Gomero</LastName><ForeName>Eberth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dermatology Department, Hospital Nacional Daniel Alcides Carrion, Callao, Peru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Dermatol</MedlineTA><NlmUniqueID>0243704</NlmUniqueID><ISSNLinking>0011-9059</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000914">Antibodies, Viral</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006761">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010568">Peru</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28251608</ArticleId><ArticleId IdType="doi">10.1111/ijd.13567</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27552830</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1476</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Auris, nasus, larynx</Title><ISOAbbreviation>Auris Nasus Larynx</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>198</EndPage><MedlinePgn>195-198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.anl.2016.05.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0385-8146(16)30151-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">One in 1000-3000 carriers of human T-cell leukemia virus type 1 (HTLV-1) develops adult T-cell leukemia/lymphoma (ATLL) per year; however, the pathogenic mechanism is not completely clear. We have observed that some patients with squamous cell carcinoma (SCC) develop ATLL during treatment at our hospital. The aim of this study was to examine treatment factors associated with onset of ATLL through an evaluation of the therapeutic background of these patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The impact of radiotherapy, chemotherapy and surgery on occurrence of ATLL was evaluated in 146 patients with head and neck SCC who were treated at our hospital between April 2010 and December 2013.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 146 patients, 17 were HTLV-1 positive and 6 developed ATLL. There was a significant relationship between ATLL development and administration of S-1 chemotherapy (p=0.0003), but not with use of radiotherapy, surgery or other drugs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The involvement of S-1 chemotherapy in ATLL development suggests that a test for HTLV-1 antibody should be performed before treatment and that S-1 should not be administered in HTLV-1 positive patients with head and neck carcinoma.</AbstractText><CopyrightInformation>Copyright &#169; 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Japan. Electronic address: nagano@m.kufm.kagoshima-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurono</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology and Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matushita</LastName><ForeName>Kakushi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology and Immunology, Kagoshima University Graduate School of Medical and Dental Sciences, Japan; Palliative Care Center, Kagoshima University Hospital, Kagoshima University Graduate School of Medical and Dental Sciences, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Auris Nasus Larynx</MedlineTA><NlmUniqueID>7708170</NlmUniqueID><ISSNLinking>0385-8146</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>150863-82-4</RegistryNumber><NameOfSubstance UI="C079198">S 1 (combination)</NameOfSubstance></Chemical><Chemical><RegistryNumber>1548R74NSZ</RegistryNumber><NameOfSubstance UI="D005641">Tegafur</NameOfSubstance></Chemical><Chemical><RegistryNumber>5VT6420TIG</RegistryNumber><NameOfSubstance UI="D010094">Oxonic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C482176">TPF protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016609">Neoplasms, Second Primary</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013517">Otorhinolaryngologic Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010094">Oxonic Acid</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011878">Radiotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077195">Squamous Cell Carcinoma of Head and Neck</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D043823">Taxoids</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005641">Tegafur</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Head and neck cancer</Keyword><Keyword MajorTopicYN="N">S-1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27552830</ArticleId><ArticleId IdType="doi">10.1016/j.anl.2016.05.002</ArticleId><ArticleId IdType="pii">S0385-8146(16)30151-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29502313</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>427</EndPage><MedlinePgn>420-427</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-018-2430-6</ELocationID><Abstract><AbstractText>The morbidity and mortality of disease vary according to the region and may also change over time. The morbidity and mortality of malignant lymphoma are also affected by differences in ethnicity, lifestyle habits, geographical area, and time period. Increasing research on malignant lymphoma has focused on its pathophysiology, diagnosis, and therapeutic treatment. Recent improvements in the accuracy of clinical study, technologies such as next-generation sequencing, and the development of targeted molecular agents have also resulted in a number of excellent studies. This review summarizes the epidemiology of malignant lymphoma and highlights novel studies on adult T-cell leukemia/lymphoma recently published in Japan.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2356-3725</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, Japan. miyoshi_hiroaki@med.kurume-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007564">Japan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009017">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009026">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012106">Research</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Japan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29502313</ArticleId><ArticleId IdType="doi">10.1007/s12185-018-2430-6</ArticleId><ArticleId IdType="pii">10.1007/s12185-018-2430-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blood. 2017 Jul 6;130(1):39-47</Citation><ArticleIdList><ArticleId IdType="pubmed">28515095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2016 Dec;34(34):4086-4093</Citation><ArticleIdList><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Histopathology. 2018 Jan 3;:null</Citation><ArticleIdList><ArticleId IdType="pubmed">29297942</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2016 Feb 4;127(5):596-604</Citation><ArticleIdList><ArticleId IdType="pubmed">26574607</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2015 Nov 5;126(19):2193-201</Citation><ArticleIdList><ArticleId IdType="pubmed">26239088</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2015 Sep 1;137(5):1217-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25694231</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hematol. 2010 Oct;85(10):760-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20806229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathol Int. 2008 Mar;58(3):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18251781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2014 Feb;46(2):171-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24413737</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2016 Sep 8;128(10 ):1374-81</Citation><ArticleIdList><ArticleId IdType="pubmed">27418641</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2015 Dec 10;126(24):2570-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathol Int. 2000 Sep;50(9):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">11012982</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2016 Sep 15;22(18):4727-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27166394</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Pathol. 2012 Sep;138(3):429-34</Citation><ArticleIdList><ArticleId IdType="pubmed">22912361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 2016 Apr;101(4):1361-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26794891</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2017 Aug 31;130(9):1114-1124</Citation><ArticleIdList><ArticleId IdType="pubmed">28646117</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2018 Jan 11;131(2):215-225</Citation><ArticleIdList><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22481502</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation.</ArticleTitle><Pagination><StartPage>725</StartPage><EndPage>730</EndPage><MedlinePgn>725-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-012-1056-3</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive hematologic neoplasm that has an extremely poor prognosis; however, this has improved following recent progress in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Several clinical studies have shown that discontinuation of immunosuppressant therapy induces durable remission in a significant number of post-transplant relapsed patients, suggesting that ATLL may be susceptible to a graft-versus-leukemia effect. Here, we report two cases with ATLL who received donor lymphocyte infusions (DLIs) for relapse after allo-HSCT; one patient achieved complete remission (CR) after a single DLI, and the other suffered repeated relapses and was treated with chemotherapy and radiotherapy combined with a total of five rounds of DLIs. Both patients presented with exacerbation of the graft-versus-host disease after the DLIs, and remained in CR for 9 and 8 years, respectively. These data support the use of DLIs as an effective therapy to induce durable CR in the treatment of relapsed ATLL. In this study, we review previous reports and discuss the role of DLIs in the treatment of post-transplant relapsed ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamimura</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Numata</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Yoshikiyo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nagafuji</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Teshima</LastName><ForeName>Takanori</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017710">Lymphocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22481502</ArticleId><ArticleId IdType="doi">10.1007/s12185-012-1056-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bone Marrow Transplant. 2011 Aug;46(8):1039-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21358685</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2002 Nov 1;100(9):3108-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12384406</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Haematol. 2008 Mar;80(3):185-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18081707</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6326131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8680890</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1993 Oct 15;82(8):2310-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8400284</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2011 Apr;11(4):473-87</Citation><ArticleIdList><ArticleId IdType="pubmed">21269237</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jul;14(7):817-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18541202</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Feb 1;103(3):767-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12958064</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2004 Jan 1;64(1):391-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14729650</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2003 Jan;120(2):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12542491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2011 Jan;46(1):116-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20400987</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1977 Sep;50(3):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1995 Jul;13(7):1800-16</Citation><ArticleIdList><ArticleId IdType="pubmed">7602369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1976 Oct;38(4):1484-93</Citation><ArticleIdList><ArticleId IdType="pubmed">791473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2003 Oct;32(8):835-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14520431</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2009 Dec;147(5):614-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19735262</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jun;14(6):702-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1988 Jul;6(7):1088-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2899140</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2005 May;19(5):829-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Nov 1;25(31):4938-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17909197</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Aug;79(15):10088-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16014972</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2008 Jun;41(12):1029-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18332910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22289924</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>1238</StartPage><EndPage>1246</EndPage><MedlinePgn>1238-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2011.379</ELocationID><Abstract><AbstractText>Cell adhesion molecule 1 (CADM1/TSLC1) was recently identified as a novel cell surface marker for adult T-cell leukemia/lymphoma (ATLL). In this study, we developed various antibodies as diagnostic tools to identify CADM1-positive ATLL leukemia cells. In flow cytometric analysis, the percentages of CD4(+)CADM1(+) double-positive cells correlated well with both the percentages of CD4(+)CD25(+) cells and with abnormal lymphocytes in the peripheral blood of patients with various types of ATLL. Moreover, the degree of CD4(+)CADM1(+) cells over 1% significantly correlated with the copy number of the human T-lymphotropic virus type 1 (HTLV-1) provirus in the peripheral blood of HTLV-1 carriers and ATLL patients. We also identified a soluble form of CADM1 in the peripheral blood of ATLL patients, and the expression levels of this form were correlated with the levels of soluble interleukin 2 receptor alpha. Moreover, lymphomas derived from ATLL were strongly and specifically stained with a CADM1 antibody. Thus, detection of CD4(+)CADM1(+) cells in the peripheral blood, measurement of serum levels of soluble CADM1 and immunohistochemical detection of CADM1 in lymphomas would be a useful set of markers for disease progression in ATLL and may aid in both the early diagnosis and measurement of treatment efficacy for ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakahata</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Marutsuka</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hatakeyama</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shiraga</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Takamatsu</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Asada</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Okayama</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kubuki</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ukai</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kurosawa</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C403514">CADM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075982">Cell Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000075982">Cell Adhesion Molecule-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007124">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007136">Immunoglobulins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011533">Proviruses</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22289924</ArticleId><ArticleId IdType="doi">10.1038/leu.2011.379</ArticleId><ArticleId IdType="pii">leu2011379</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">35417939</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Haematologica</Title><ISOAbbreviation>Haematologica</ISOAbbreviation></Journal><ArticleTitle>Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>2418</StartPage><EndPage>2431</EndPage><MedlinePgn>2418-2431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2021.280352</ELocationID><Abstract><AbstractText>In order to identify genomic biomarkers for the outcome of mogamulizumab-containing treatment, an integrated molecular analysis of adult T-cell leukemia/lymphoma (ATL) was conducted on 64 mogamulizumab-na&#239;ve patients. Among driver genes, CCR4 and CCR7 alterations were observed in 22% and 11% of the patients, respectively, both consisting of single nucleotide variants (SNV)/insertion-deletions (indels) in the C-terminus. Patients with CCR4 alterations or without CCR7 alterations exhibited a more favorable clinical response (complete response [CR] rate 93%, 13/14; P=0.024, and CR rate 71%, 40/56; P=0.036, respectively). Additionally, TP53, CD28, and CD274 alterations were identified in 35%, 16%, and 10% of the patients, respectively. TP53 alterations included SNV/indels or copy number variations (CNV) such as homozygous deletion; CD28 alterations included SNV, CNV such as amplification, or fusion; CD274 alterations included CNV such as amplification, or structural variants. Univariate analysis revealed that TP53, CD28 or CD274 alterations were associated with worse overall survival (OS) (hazard ratio [HR]: 2.330, 95% confidence interval [CI]: 1.183-4.589; HR: 3.191, 95% CI: 1.287- 7.911; HR: 3.301, 95% CI: 1.130-9.641, respectively) but that CCR4 alterations were associated with better OS (HR: 0.286, 95% CI: 0.087-0.933). Multivariate analysis indicated that in addition to performance status, TP53, CCR4 or CD274 alterations (HR: 2.467, 95% CI: 1.197-5.085; HR: 0.155, 95% CI: 0.031-0.778; HR: 14.393, 95% CI: 2.437-85.005, respectively) were independently and significantly associated with OS. The present study contributes to the establishment of precision medicine using mogamulizumab in ATL patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research. seiichi.mori@jfcr.or.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyotani</LastName><ForeName>Kazuma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotoh</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusumoto</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Nobuaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suehiro</LastName><ForeName>Youko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kyushu Cancer Centre; Department of Cell Therapy National Hospital Organization Kyushu Cancer Centre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Asahi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ilseung</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kyushu Cancer Centre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtsuka</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oita Prefectural Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Michihiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kumamoto Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Kisato</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Nagasaki University Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Tetsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Institute, Japanese Foundation for Cancer Research.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishikawa</LastName><ForeName>Hiroyoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Nagoya University Graduate School of Medicine; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Ryuzo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Immunology, Nagoya University Graduate School of Medicine; Department of Tumor Immunology, Aichi Medical University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences; Department of Immunology, Nagoya University Graduate School of Medicine. itakashi@med.nagoya-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Haematologica</MedlineTA><NlmUniqueID>0417435</NlmUniqueID><ISSNLinking>0390-6078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018106">CD28 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054400">Receptors, CCR7</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018106">CD28 Antigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056915">DNA Copy Number Variations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006720">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009711">Nucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054400">Receptors, CCR7</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017384">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>3</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35417939</ArticleId><ArticleId IdType="pmc">PMC9521232</ArticleId><ArticleId IdType="doi">10.3324/haematol.2021.280352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984&#8211;1987). Br J Haematol. 1991;79(3):428-437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. . Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37(8):677-687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494249</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A. Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma. Front Microbiol. 2019;10:2235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797831</ArticleId><ArticleId IdType="pubmed">31681185</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Iwanaga M, Imaizumi Y, et al. . Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. Cancer Sci. 2017;108(12):2478-2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715256</ArticleId><ArticleId IdType="pubmed">28905463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, et al. . Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10Pt1):3625-3634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Iida S, Akatsuka Y, et al. . The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res. 2004;10(22):7529-7539.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Ishida T, Utsunomiya A, et al. . Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520-1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. . Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837-842.</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. . Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672-682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Inoue Y, Utsunomiya A, et al. . Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426-3433.</Citation><ArticleIdList><ArticleId IdType="pubmed">27507878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Kusumoto S, Choi I, et al. . Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study. Blood Adv. 2020;4(20):5133-5145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594399</ArticleId><ArticleId IdType="pubmed">33091125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47(11):1304-1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et al. . Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453-459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Koboldt DC, Zhang Q, Larson DE, et al. . VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290792</ArticleId><ArticleId IdType="pubmed">22300766</ArticleId></ArticleIdList></Reference><Reference><Citation>Cibulskis K, Lawrence MS, Carter SL, et al. . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833702</ArticleId><ArticleId IdType="pubmed">23396013</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, et al. . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Patch AM, Christie EL, Etemadmoghadam D, et al. . Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489&#8211;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">26017449</ArticleId></ArticleIdList></Reference><Reference><Citation>Magi A, Tattini L, Cifola I, et al. . EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol. 2013;14(19):R120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053953</ArticleId><ArticleId IdType="pubmed">24172663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218867</ArticleId><ArticleId IdType="pubmed">21527027</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson A, Hormozdiari F, Zayed A, et al. . deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 2011;7(5):e1001138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098195</ArticleId><ArticleId IdType="pubmed">21625565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 2011;12(8):R72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245612</ArticleId><ArticleId IdType="pubmed">21835007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, et al. . Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature. 2016;534(7607):402-406.</Citation><ArticleIdList><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference><Reference><Citation>Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310-3316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441069</ArticleId><ArticleId IdType="pubmed">25143287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, Yamaguchi R, Mizuno S, et al. . ALPHLARD: a Bayesian method for analyzing HLA genes from whole genome sequence data. BMC Genomics. 2018;19(1):790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211482</ArticleId><ArticleId IdType="pubmed">30384854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachet AS, Rooney MS, Rajasagi M, et al. . Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152-1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747795</ArticleId><ArticleId IdType="pubmed">26372948</ArticleId></ArticleIdList></Reference><Reference><Citation>McGranahan N, Rosenthal R, Hiley CT, et al. . Allele-specific HLA loss and immune scape in lung cancer evolution. Cell. 2017;171(6):1259-1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5720478</ArticleId><ArticleId IdType="pubmed">29107330</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning. 2003;52:91-118.</Citation></Reference><Reference><Citation>Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572-1573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881355</ArticleId><ArticleId IdType="pubmed">20427518</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. . VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458-5464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. . Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma. Br J Haematol. 2021;192(2):281-291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894310</ArticleId><ArticleId IdType="pubmed">33205842</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza CJ, Boudreau JE, Zheng J, et al. . KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol. 2016;34(21):2443-2451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962735</ArticleId><ArticleId IdType="pubmed">27069083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Ni X, Covington KR, et al. . Genomic profiling of S&#233;zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015;47(12):1426-1434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829974</ArticleId><ArticleId IdType="pubmed">26551670</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Yamanaka T, Ishitsuka K, et al. . Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30(14):1635-1640.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Iwanaga M, Yasunaga J, et al. . Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131(2):215-225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. . Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma. Br J Haematol. 2021;195(4):571-584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9291095</ArticleId><ArticleId IdType="pubmed">34405395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Schmitz R, Xiao W, et al. . Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med. 2014;211(13):2497-2505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267233</ArticleId><ArticleId IdType="pubmed">25488980</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. . CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758-761.</Citation><ArticleIdList><ArticleId IdType="pubmed">29930010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesilkanal AE, Johnson GL, Ramos AF, Rosner MR. New strategies for targeting kinase networks in cancer. J Biol Chem. 2021;297(4):101128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449055</ArticleId><ArticleId IdType="pubmed">34461089</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaki A, Ishida T, Suzuki S, et al. . Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals. Cancer Sci. 2018;109(8):2383-2390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113433</ArticleId><ArticleId IdType="pubmed">29845702</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaki A, Ishida T, Maeda Y, et al. . Prognostic significance of tryptophan catabolism in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2015;21(12):2830-2839.</Citation><ArticleIdList><ArticleId IdType="pubmed">25788494</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Kusumoto S, Nakano N, et al. . Clinical significance of the IgG heavy chain repertoire in PBMC of ATL patients receiving mogamulizumab. Br J Haematol. 2022;196(3):629-638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9292985</ArticleId><ArticleId IdType="pubmed">34632569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947-1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">29768155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano H, Ishida T, Inagaki A, et al. . Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer. 2007;120(9):2052-2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102(1):44-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">21044233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada T, Togashi Y, Tay C, et al. . PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999-10008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525547</ArticleId><ArticleId IdType="pubmed">31028147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagai S, Togashi Y, Kamada T, et al. . The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346-1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">32868929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatjiharissi E, Xu L, Santos DD, et al. . Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007;110(7):2561-2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1988936</ArticleId><ArticleId IdType="pubmed">17475906</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa R, Hatanaka S, Shoji-Hosaka E, et al. . Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of Fc&#947;RIIIa functional polymorphism. Clin Cancer Res. 2004;10(18Pt1):6248-6255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25488980</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>211</Volume><Issue>13</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>2497</StartPage><EndPage>2505</EndPage><MedlinePgn>2497-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20140987</ELocationID><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATLL) is an aggressive malignancy caused by human T cell lymphotropic virus type-I (HTLV-I) without curative treatment at present. To illuminate the pathogenesis of ATLL we performed whole transcriptome sequencing of purified ATLL patient samples and discovered recurrent somatic mutations in CCR4, encoding CC chemokine receptor 4. CCR4 mutations were detected in 14/53 ATLL samples (26%) and consisted exclusively of nonsense or frameshift mutations that truncated the coding region at C329, Q330, or Y331 in the carboxy terminus. Functionally, the CCR4-Q330 nonsense isoform was gain-of-function because it increased cell migration toward the CCR4 ligands CCL17 and CCL22, in part by impairing receptor internalization. This mutant enhanced PI(3) kinase/AKT activation after receptor engagement by CCL22 in ATLL cells and conferred a growth advantage in long-term in vitro cultures. These findings implicate somatic gain-of-function CCR4 mutations in the pathogenesis of ATLL and suggest that inhibition of CCR4 signaling might have therapeutic potential in this refractory malignancy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Wenming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Carolyn K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Weihong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yandan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldmann</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staudt</LastName><ForeName>Louis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 lstaudt@mail.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515482">CCL22 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054422">Chemokine CCL22</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Exp Med. 2014 Dec 15;211(13):2485</RefSource><PMID Version="1">25512583</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000595">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054422">Chemokine CCL22</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002633">Chemotaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004705">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050505">Mutant Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020033">Protein Isoforms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25488980</ArticleId><ArticleId IdType="pmc">PMC4267233</ArticleId><ArticleId IdType="doi">10.1084/jem.20140987</ArticleId><ArticleId IdType="pii">jem.20140987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arisawa K., Soda M., Endo S., Kurokawa K., Katamine S., Shimokawa I., Koba T., Takahashi T., Saito H., Doi H., and Shirahama S.. 2000. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int. J. Cancer. 85:319&#8211;324 10.1002/(SICI)1097-0215(20000201)85:3&lt;319::AID-IJC4&gt;3.0.CO;2-B</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0215(20000201)85:3&lt;319::AID-IJC4&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">10652420</ArticleId></ArticleIdList></Reference><Reference><Citation>Balabanian K., Lagane B., Pablos J.L., Laurent L., Planchenault T., Verola O., Lebbe C., Kerob D., Dupuy A., Hermine O., et al. . 2005. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 105:2449&#8211;2457 10.1182/blood-2004-06-2289</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-06-2289</ArticleId><ArticleId IdType="pubmed">15536153</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell J.J., Haraldsen G., Pan J., Rottman J., Qin S., Ponath P., Andrew D.P., Warnke R., Ruffing N., Kassam N., et al. . 1999. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 400:776&#8211;780 10.1038/23495</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/23495</ArticleId><ArticleId IdType="pubmed">10466728</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., and Jaffe E.S.. 2011. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 117:5019&#8211;5032 10.1182/blood-2011-01-293050</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-293050</ArticleId><ArticleId IdType="pmc">PMC3109529</ArticleId><ArticleId IdType="pubmed">21300984</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Hunter Z.R., Liu X., Xu L., Yang G., Chen J., Patterson C.J., Tsakmaklis N., Kanan S., Rodig S., et al. . 2014. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom&#8217;s Macroglobulinemia. Leukemia. In press. 10.1038/leu.2014.187</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2014.187</ArticleId><ArticleId IdType="pubmed">24912431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Petrus M., Bryant B.R., Nguyen V.P., Goldman C.K., Bamford R., Morris J.C., Janik J.E., and Waldmann T.A.. 2010. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 116:5948&#8211;5956 10.1182/blood-2010-04-277418</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-04-277418</ArticleId><ArticleId IdType="pmc">PMC3031384</ArticleId><ArticleId IdType="pubmed">20858854</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong B.F., Murphy J.E., Kupper T.S., and Fuhlbrigge R.C.. 2004. E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J. Immunol. 172:1575&#8211;1581 10.4049/jimmunol.172.3.1575</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.3.1575</ArticleId><ArticleId IdType="pubmed">14734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronshaw D.G., Owen C., Brown Z., and Ward S.G.. 2004. Activation of phosphoinositide 3-kinases by the CCR4 ligand macrophage-derived chemokine is a dispensable signal for T lymphocyte chemotaxis. J. Immunol. 172:7761&#8211;7770 10.4049/jimmunol.172.12.7761</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.12.7761</ArticleId><ArticleId IdType="pubmed">15187160</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#8217;Ambrosio D., Albanesi C., Lang R., Girolomoni G., Sinigaglia F., and Laudanna C.. 2002. Quantitative differences in chemokine receptor engagement generate diversity in integrin-dependent lymphocyte adhesion. J. Immunol. 169:2303&#8211;2312 10.4049/jimmunol.169.5.2303</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.169.5.2303</ArticleId><ArticleId IdType="pubmed">12193695</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz G.A.2005. CXCR4 mutations in WHIM syndrome: a misguided immune system? Immunol. Rev. 203:235&#8211;243 10.1111/j.0105-2896.2005.00226.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2005.00226.x</ArticleId><ArticleId IdType="pubmed">15661033</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott N.E., Cleveland S.M., Grann V., Janik J., Waldmann T.A., and Dav&#233; U.P.. 2011. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood. 118:3911&#8211;3921 10.1182/blood-2010-12-319467</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-12-319467</ArticleId><ArticleId IdType="pmc">PMC3193267</ArticleId><ArticleId IdType="pubmed">21821710</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T., Baba M., Nishimura M., Kakizaki M., Takagi S., and Yoshie O.. 1997. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J. Biol. Chem. 272:15036&#8211;15042 10.1074/jbc.272.23.15036</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.23.15036</ArticleId><ArticleId IdType="pubmed">9169480</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T., Chantry D., Raport C.J., Wood C.L., Nishimura M., Godiska R., Yoshie O., and Gray P.W.. 1998. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J. Biol. Chem. 273:1764&#8211;1768 10.1074/jbc.273.3.1764</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.3.1764</ArticleId><ArticleId IdType="pubmed">9430724</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal J., Weisenburger D.D., Greiner T.C., Vose J.M., McKeithan T., Kucuk C., Geng H., Deffenbacher K., Smith L., Dybkaer K., et al. . International Peripheral T-Cell Lymphoma Project. 2010. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 115:1026&#8211;1036 10.1182/blood-2009-06-227579</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-06-227579</ArticleId><ArticleId IdType="pmc">PMC2817630</ArticleId><ArticleId IdType="pubmed">19965671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Utsunomiya A., Iida S., Inagaki H., Takatsuka Y., Kusumoto S., Takeuchi G., Shimizu S., Ito M., Komatsu H., et al. . 2003. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. 9:3625&#8211;3634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., Inagaki H., and Ueda R.. 2006. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66:5716&#8211;5722 10.1158/0008-5472.CAN-06-0261</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-0261</ArticleId><ArticleId IdType="pubmed">16740709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., Joh T., Uike N., Yamamoto K., Utsunomiya A., Yoshida S., Saburi Y., Miyamoto T., Takemoto S., Suzushima H., et al. . 2012. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 30:837&#8211;842 10.1200/JCO.2011.37.3472</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Choi U., Whiting-Theobald N.L., Linton G.F., Brenner S., Sechler J.M., Murphy P.M., and Malech H.L.. 2005. Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp. Hematol. 33:460&#8211;468 10.1016/j.exphem.2005.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exphem.2005.01.001</ArticleId><ArticleId IdType="pubmed">15781337</ArticleId></ArticleIdList></Reference><Reference><Citation>Komohara Y., Niino D., Saito Y., Ohnishi K., Horlad H., Ohshima K., and Takeya M.. 2013. Clinical significance of CD163+ tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 104:945&#8211;951 10.1111/cas.12167</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12167</ArticleId><ArticleId IdType="pmc">PMC7657152</ArticleId><ArticleId IdType="pubmed">23557330</ArticleId></ArticleIdList></Reference><Reference><Citation>Luttrell L.M., and Lefkowitz R.J.. 2002. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115:455&#8211;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861753</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M., and Jeang K.T.. 2007. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer. 7:270&#8211;280 10.1038/nrc2111</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2111</ArticleId><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Pease J.E., and Horuk R.. 2014. Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. Expert Opin Drug Discov. 9:467&#8211;483 10.1517/17460441.2014.897324</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2014.897324</ArticleId><ArticleId IdType="pubmed">24641500</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccaro A.M., Sacco A., Jimenez C., Maiso P., Moschetta M., Mishima Y., Aljawai Y., Sahin I., Kuhne M., Cardarelli P., et al. . 2014. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 123:4120&#8211;4131 10.1182/blood-2014-03-564583</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-564583</ArticleId><ArticleId IdType="pubmed">24711662</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., et al. . 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 490:116&#8211;120 10.1038/nature11378</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11378</ArticleId><ArticleId IdType="pmc">PMC3609867</ArticleId><ArticleId IdType="pubmed">22885699</ArticleId></ArticleIdList></Reference><Reference><Citation>Treon S.P., Cao Y., Xu L., Yang G., Liu X., and Hunter Z.R.. 2014. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 123:2791&#8211;2796 10.1182/blood-2014-01-550905</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-01-550905</ArticleId><ArticleId IdType="pubmed">24553177</ArticleId></ArticleIdList></Reference><Reference><Citation>Vissers J.L., Hartgers F.C., Lindhout E., Teunissen M.B., Figdor C.G., and Adema G.J.. 2001. Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. J. Leukoc. Biol. 69:785&#8211;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">11358988</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulcano M., Albanesi C., Stoppacciaro A., Bagnati R., D&#8217;Amico G., Struyf S., Transidico P., Bonecchi R., Del Prete A., Allavena P., et al. . 2001. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol. 31:812&#8211;822 10.1002/1521-4141(200103)31:3&lt;812::AID-IMMU812&gt;3.0.CO;2-L</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200103)31:3&lt;812::AID-IMMU812&gt;3.0.CO;2-L</ArticleId><ArticleId IdType="pubmed">11241286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M., and Watanabe T.. 2012. Molecular hallmarks of adult T cell leukemia. Front Microbiol. 3:334 10.3389/fmicb.2012.00334</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00334</ArticleId><ArticleId IdType="pmc">PMC3444139</ArticleId><ArticleId IdType="pubmed">23060864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K., Utsunomiya A., Tobinai K., Tsukasaki K., Uike N., Uozumi K., Yamaguchi K., Yamada Y., Hanada S., Tamura K., et al. . 2010. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28:1591&#8211;1598 10.1200/JCO.2009.25.3575</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.3575</ArticleId><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O.2005. Expression of CCR4 in adult T-cell leukemia. Leuk. Lymphoma. 46:185&#8211;190 10.1080/10428190400007607</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428190400007607</ArticleId><ArticleId IdType="pubmed">15621800</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O., Fujisawa R., Nakayama T., Harasawa H., Tago H., Izawa D., Hieshima K., Tatsumi Y., Matsushima K., Hasegawa H., et al. . 2002. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 99:1505&#8211;1511 10.1182/blood.V99.5.1505</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.5.1505</ArticleId><ArticleId IdType="pubmed">11861261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36567046</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1336</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><PubDate><Year>2023</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology</Title><ISOAbbreviation>Cardiovasc Pathol</ISOAbbreviation></Journal><ArticleTitle>Isolated cardiac valve involvement in smoldering adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>107513</StartPage><MedlinePgn>107513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.carpath.2022.107513</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1054-8807(22)00106-5</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by infection with the Human T-cell Lymphotropic Virus Type 1 (HTLV-1). Cardiac involvement in patients with ATLL is infrequent, and when it happens it is usually seen in aggressive ATLL subtypes. However, ATLL presenting as isolated cardiac valve involvement is extremely rare. To date, only three histologically proven cases of ATLL with isolated cardiac valve involvement have been reported. Herein, we describe a 61-year-old Peruvian man who presented heart failure symptoms secondary to progressive cardiac valve infiltration. The patient underwent mitral valve replacement with a mechanical prosthesis. Histopathological evaluation of the resected valve revealed leaflet thickening with a nodular appearance due to fibrous tissue containing atypical T-lymphocytes with Foxp3 expression, infiltrating all layers of the resected valve. Interestingly, tumor cells were distributed around an incidental venous malformation (i.e., cavernous hemangioma). Postoperative evaluation demonstrated positive serology for HTLV-1, and a diagnosis of ATLL was established. Postoperative positron emission tomography/computed tomography did not show lesions outside the heart and cell blood counts were within normal range with low level of circulating CD4+ CD25+ lymphoma cell counts (7%); therefore, patient's disease was considered as smoldering ATLL and a "watch and wait" strategy was pursued. Currently, the patient is alive with no progression of disease after 18 months from diagnosis. Isolated cardiac valve involvement by ATLL should be considered in the differential diagnosis of HTLV-1 carriers with progressive heart failure, even when systemic lymphoma involvement is absent or not apparent.</AbstractText><CopyrightInformation>Copyright &#169; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratorio de Patolog&#237;a, Instituto Nacional Cardiovascular, Lima, Peru. Electronic address: cristian.aguilarc@essalud.gob.pe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>Brady E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Departamento de Oncolog&#237;a, Hospital Edgardo Rebagliati Martins, Lima, Peru; Centro de Medicina de Precision, Universidad de San Martin de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Domingo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; Departamento de Patolog&#237;a, Hospital Nacional Hipolito Unanue, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#233;rrez-Garibay</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#237;a, Instituto Nacional Cardiovascular, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villela</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital General "Dr. Fernando Ocaranza" - Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Hermosillo, Sonora, M&#233;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques-Piubelli</LastName><ForeName>Mario L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vega</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Roberto N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malpica</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Pathol</MedlineTA><NlmUniqueID>9212060</NlmUniqueID><ISSNLinking>1054-8807</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006351">Heart Valves</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">cardiac valve</Keyword><Keyword MajorTopicYN="N">mitral valve</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>25</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36567046</ArticleId><ArticleId IdType="doi">10.1016/j.carpath.2022.107513</ArticleId><ArticleId IdType="pii">S1054-8807(22)00106-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15103932</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Mar</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Treatment of adult T-cell leukemia/lymphoma: progresses in the chemotherapy and stem cell transplantation].</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>201</EndPage><MedlinePgn>195-201</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>29</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15103932</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28189691</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>485</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>144</StartPage><EndPage>151</EndPage><MedlinePgn>144-151</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2017.02.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-291X(17)30307-8</ELocationID><Abstract><AbstractText>Iron is an essential nutrient for normal cell growth, and reprogramming of iron metabolism is essential to tumor cell survival and progression. HTLV-1-associated adult T-cell leukemia/lymphoma (ATLL) has no effective therapy and high levels of cell surface transferrin receptor 1 (TFR1) expression have been reported in ATLL by us and other groups. In this study, to develop a novel molecular-targeted therapy against TFR1 to modulate iron metabolism, we initially determined the expression pattern of several iron-related genes along with TFR1 and found that ATLL cells presented characteristic of an iron-deficiency state such as high expression of iron-regulatory protein 2 (IRP2) and low expression of its E3 ubiquitin-ligase, FBXL5. Therefore, we developed human IgG monoclonal antibodies to human TFR1 using a phage display method (ICOS method) to block the incorporation of the transferrin (TF)-iron complex into ATLL cells for inhibiting cell growth. One of the mAbs, JST-TFR09, presented its greater affinity to TFR1 on ATLL cells in flow cytometry (FCM) analysis than those of commercially available anti-TFR1 antibodies and identified high expression of TFR1 in most of the acute-type ATLL cells. Moreover, JST-TFR09 could interfere with binding between TFR1 and TF, which resulted in effective blockade of TFR1 internalization and induction of cell apoptosis by the treatment of ATLL cells with JST-TFR09. JST-TFR09 showed dual activities through direct cell cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC), and the treatment of JST-TFR09 significantly suppressed cell growth of ATLL cells with induction of apoptosis in in&#160;vitro and in&#160;vivo experiments. Thus, JST-TFR09 described here may become a promising therapeutic antibody for the treatment of ATLL.</AbstractText><CopyrightInformation>Copyright &#169; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shimosaki</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Science, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakahata</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Science, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Tomonaga</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Science, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitanaka</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kameda</LastName><ForeName>Takuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubuki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosawa</LastName><ForeName>Gene</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lilin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Perseus Proteomics, Inc., Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudo</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Perseus Proteomics, Inc., Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Science, Faculty of Medicine, University of Miyazaki, Japan. Electronic address: kmorishi@med.miyazaki-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C068126">CD71 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Biochem Biophys Res Commun. 2020 Sep 17;530(2):486</RefSource><PMID Version="1">32553628</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011990">Receptors, Transferrin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADCC</Keyword><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Anti-transferrin receptor 1 antibody</Keyword><Keyword MajorTopicYN="N">Direct cytotoxicity</Keyword><Keyword MajorTopicYN="N">Phage display</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28189691</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2017.02.039</ArticleId><ArticleId IdType="pii">S0006-291X(17)30307-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17233468</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].</ArticleTitle><Pagination><StartPage>1502</StartPage><EndPage>1513</EndPage><MedlinePgn>1502-13</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Utsunomya</LastName><ForeName>Atae</ForeName><Initials>A</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001897">Boronic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003512">Cyclohexanones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C464444">dehydroxymethylepoxyquinomicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>69G8BD63PP</RegistryNumber><NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001897">Boronic Acids</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000069286">Bortezomib</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002353">Carrier State</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003512">Cyclohexanones</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017320">HIV Protease Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018445">Infectious Disease Transmission, Vertical</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011480">Protease Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011719">Pyrazines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019438">Ritonavir</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>91</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17233468</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">34738707</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Cancer science</Title><ISOAbbreviation>Cancer Sci</ISOAbbreviation></Journal><ArticleTitle>Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>349</StartPage><EndPage>361</EndPage><MedlinePgn>349-361</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.15191</ELocationID><Abstract><AbstractText>CD28, one of the costimulatory molecules, has a pivotal role in T-cell activation, and its expression is strictly regulated in normal T cells. Gain-of-function genetic alterations involving CD28 have been frequently observed in adult T-cell leukemia/lymphoma (ATLL). These abnormalities, such as CD28 fusions and copy number variations, may not only confer continuous, prolonged, and enhanced CD28 signaling to downstream pathways but also induce overexpression of the CD28 protein. In this study, 120 ATLL cases were examined by immunohistochemistry for CD28 and its ligands CD80 and CD86, and their expression on tumor cells was semiquantitatively evaluated. CD28 was overexpressed in 55 (46%) cases, and CD80 or CD86 (CD80/CD86) was infrequently overexpressed in 12 (11%). Compared with non-overexpressers, CD28 overexpressers showed a higher frequency of CD28 genetic alterations and had an increased number of CD80/CD86-positive non-neoplastic cells infiltrating tumor microenvironment. In the entire ATLL patient cohort, CD28 overexpressers showed a significantly poorer overall survival (OS) compared with non-overexpressers (P&#160;=&#160;.001). The same was true for a subgroup who were treated with multidrug regimens with or without mogamulizumab. CD28 overexpression had no prognostic impact in the group who received allogeneic hematopoietic stem cell transplantation. In the multivariate analysis for OS, CD28 overexpression was selected as an independent risk factor. These results suggest ATLL patients with CD28 overexpression have more aggressive clinical course and are more refractory to treatment with multidrug chemotherapy. CD28 overexpression appears to be a novel unfavorable prognostic marker in ATLL patients, and further prospective studies are warranted to establish its prognostic significance.</AbstractText><CopyrightInformation>&#169; 2021 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Yuma</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9916-4862</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1060-0777</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masaki</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeshita</LastName><ForeName>Morishige</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yonekura</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Imamura General Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Yukie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Imamura General Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Asahi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusumoto</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4951-960X</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Ryuzo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Tumor Immunology, School of Medicine, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6157-636X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20K16177</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><Agency>Aichi Cancer Research Foundation</Agency><Country /></Grant><Grant><Agency>Nitto Foundation</Agency><Country /></Grant><Grant><GrantID>19cm0106301h0004</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant><Grant><GrantID>20cm0106301h0005</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant><Grant><GrantID>29-A-3</GrantID><Agency>National Cancer Research and Development Fund</Agency><Country /></Grant><Grant><GrantID>2020-J-3</GrantID><Agency>National Cancer Research and Development Fund</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Sci</MedlineTA><NlmUniqueID>101168776</NlmUniqueID><ISSNLinking>1347-9032</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018122">B7-1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051940">B7-2 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018106">CD28 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000634465">CD80 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497964">CD86 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018122">B7-1 Antigen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051940">B7-2 Antigen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018106">CD28 Antigens</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056915">DNA Copy Number Variations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059016">Tumor Microenvironment</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015854">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD28</Keyword><Keyword MajorTopicYN="N">CD80 (B7-1)</Keyword><Keyword MajorTopicYN="N">CD86 (B7-2)</Keyword><Keyword MajorTopicYN="N">adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">costimulatory molecule</Keyword><Keyword MajorTopicYN="N">genetic alterations</Keyword><Keyword MajorTopicYN="N">immunohistochemistry</Keyword><Keyword MajorTopicYN="N">overexpression</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>H. Iwasaki received research funding from Kyowa Kirin Co., Ltd. K. Yonekura received honoraria from AbbVie, Celgene, Daiichi Sankyo Co., Ltd., Eisai, Eli Lilly Japan, Janssen Pharmaceuticals, Kaken Pharmaceutical, Kyowa Kirin Co., Ltd., Maruho, Minophagen Pharmaceutical, Novartis, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. S. Kusumoto received research funding from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and honoraria from Chugai Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. S. Iida received research funding from Sanofi, Chugai Pharmaceutical Co., Ltd., Ono, Takeda, Kyowa Kirin Co., Ltd., Celgene, Janssen, Bristol&#8208;Myers Squibb, Abbvie, and Glaxo&#8208;Smithklein, and honoraria from Janssen, Celgene, Ono, Takeda, Sanofi, and Daiichi Sankyo Co., Ltd. A. Utsunomiya received honoraria from Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Bristol&#8208;Myers, and Celgene, and consulting fees from HUYA Japan, JIMRO, Meiji Seika Pharma Co., Ltd., and Otsuka Medical Devices Co., Ltd. R. Ueda received research funding from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. No other authors have any conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>5</Day><Hour>8</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34738707</ArticleId><ArticleId IdType="pmc">PMC8748252</ArticleId><ArticleId IdType="doi">10.1111/cas.15191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudd CE, Taylor A, Schneider H. CD28 and CTLA&#8208;4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12&#8211;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4186963</ArticleId><ArticleId IdType="pubmed">19426212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Flies DB. Molecular mechanisms of T cell co&#8208;stimulation and co&#8208;inhibition. Nat Rev Immunol. 2013;13:227&#8211;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">25838373</ArticleId></ArticleIdList></Reference><Reference><Citation>Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: From mechanism to therapy. Immunity. 2016;44:973&#8211;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932896</ArticleId><ArticleId IdType="pubmed">27192564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood AJJ, Darbyshire J. Injury to research volunteers&#8211;&#8211;the clinical&#8208;research nightmare. N Engl J Med. 2006;354:1869&#8211;1871.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672696</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti&#8208;CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018&#8211;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908486</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47:1304&#8211;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohr J, Guo S, Huo J, et al. Recurrent activating mutations of CD28 in peripheral T&#8208;cell lymphomas. Leukemia. 2016;30:1062&#8211;1070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688878</ArticleId><ArticleId IdType="pubmed">26719098</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallois D, Dupuy A, Lemonnier F, et al. RNA fusions involving CD28 are rare in peripheral T&#8208;cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica. 2018;103:e360&#8211;e363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068042</ArticleId><ArticleId IdType="pubmed">29545337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and S&#233;zary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47:1056&#8211;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091217</ArticleId><ArticleId IdType="pubmed">26258847</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47:1011&#8211;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552614</ArticleId><ArticleId IdType="pubmed">26192916</ArticleId></ArticleIdList></Reference><Reference><Citation>Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral T&#8208;cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33:2867&#8211;2883.</Citation><ArticleIdList><ArticleId IdType="pubmed">31092896</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallois D, Dobay MPD, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T&#8208;cell&#8208;derived lymphomas. Blood. 2016;128:1490&#8211;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">27369867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Ni X, Covington KR, et al. Genomic profiling of S&#233;zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015;47:1426&#8211;1434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829974</ArticleId><ArticleId IdType="pubmed">26551670</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T&#8208;cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481&#8211;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T&#8208;cell leukaemia&#8208;lymphoma. A report from the Lymphoma Study Group (1984&#8208;87). Br J Haematol. 1991;79:428&#8208;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M, Jeang KT. Human T&#8208;cell leukaemia virus type 1 (HTLV&#8208;1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7:270&#8211;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T&#8208;cell leukaemia virus type I and adult T&#8208;cell leukaemia&#8208;lymphoma. Lancet Oncol. 2014;15:e517&#8211;e526.</Citation><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. Clinical significance of CD28 gene&#8208;related activating alterations in adult T&#8208;cell leukemia/lymphoma. Br J Haematol. 2021;192:281&#8211;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894310</ArticleId><ArticleId IdType="pubmed">33205842</ArticleId></ArticleIdList></Reference><Reference><Citation>Gmyrek GB, Pingel J, Choi J, Green JM. Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma. Cell Immunol. 2017;319:28&#8211;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667648</ArticleId><ArticleId IdType="pubmed">28711152</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo HY, Kim P, Kim WS, et al. Frequent CTLA4&#8208;CD28 gene fusion in diverse types of T&#8208;cell lymphoma. Haematologica. 2016;101:757&#8211;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013939</ArticleId><ArticleId IdType="pubmed">26819049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N, Shigemori K, Donaldson N, et al. Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. Blood. 2020;135:1467&#8211;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180081</ArticleId><ArticleId IdType="pubmed">31961925</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi M, Miyoshi H, Nakashima K, et al. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma. Ann Hematol. 2020;99:1093&#8211;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H, et al. A new G&#8208;CSF&#8208;supported combination chemotherapy, LSG15, for adult T&#8208;cell leukaemia&#8208;lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375&#8211;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP&#8208;AMP&#8208;VECP compared with biweekly CHOP for adult T&#8208;cell leukemia&#8208;lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458&#8211;5464.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T&#8208;cell leukemia&#8208;lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734&#8211;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, et al. Impact of graft&#8208;versus&#8208;host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia&#8208;lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant. 2013;19:1731&#8211;1739.</Citation><ArticleIdList><ArticleId IdType="pubmed">24090597</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A. Progress in allogeneic hematopoietic cell transplantation in adult T&#8208;Cell leukemia&#8208;lymphoma. Front Microbiol. 2019;10:2235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797831</ArticleId><ArticleId IdType="pubmed">31681185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti&#8208;CCR4 monoclonal antibody KW&#8208;0761 as a novel immunotherapeutic agent for adult T&#8208;cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520&#8211;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. Defucosylated anti&#8208;CCR4 monoclonal antibody (KW&#8208;0761) for relapsed adult T&#8208;cell leukemia&#8208;lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837&#8211;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, et al. Dose&#8208;intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T&#8208;cell leukaemia&#8208;lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672&#8211;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T&#8208;Cell leukemia/lymphoma: ATLL&#8208;002. J Clin Oncol. 2016;34:4086&#8211;4093.</Citation><ArticleIdList><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Sakamoto Y, Masaki A, et al. Immunohistochemistry for CCR4 C terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T cell leukemia/lymphoma. J Pathol Clin Res. 2021;7:52&#8211;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737778</ArticleId><ArticleId IdType="pubmed">33022137</ArticleId></ArticleIdList></Reference><Reference><Citation>Inagaki H, Okabe M, Seto M, Nakamura S, Ueda R, Eimoto T. API2&#8208;MALT1 fusion transcripts involved in mucosa&#8208;associated lymphoid tissue lymphoma: multiplex RT&#8208;PCR detection using formalin&#8208;fixed paraffin&#8208;embedded specimens. Am J Pathol. 2001;158:699&#8211;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850327</ArticleId><ArticleId IdType="pubmed">11159207</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Takino H, Eimoto T, et al. Prognostic significance of NPM&#8208;ALK fusion transcript overexpression in ALK&#8208;positive anaplastic large&#8208;cell lymphoma. Mod Pathol. 2007;20:648&#8211;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">17464320</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, et al. CCR4 mutations associated with superior outcome of adult T&#8208;cell leukemia/lymphoma. Blood. 2018;132:758&#8211;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">29930010</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida J, Orfao A, Ocqueteau M, et al. High&#8208;sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121&#8211;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005;11:3661&#8211;3667.</Citation><ArticleIdList><ArticleId IdType="pubmed">15897562</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiva B, Vidriales MB, Cerver&#243; J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017&#8211;4023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581991</ArticleId><ArticleId IdType="pubmed">18669875</ArticleId></ArticleIdList></Reference><Reference><Citation>Robillard N, Jego G, Pellat&#8208;Deceunynck C, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res. 1998;4:1521&#8211;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">9626472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahlis NJ, King AM, Kolonias D, et al. CD28&#8208;mediated regulation of multiple myeloma cell proliferation and survival. Blood. 2007;109:5002&#8211;5010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885531</ArticleId><ArticleId IdType="pubmed">17311991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair JR, Carlson LM, Koorella C, et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol. 2011;187:1243&#8211;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152989</ArticleId><ArticleId IdType="pubmed">21715687</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Gavile CM, Nair JR, et al. CD28&#8208;mediated pro&#8208;survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 2014;123:3770&#8211;3779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055924</ArticleId><ArticleId IdType="pubmed">24782505</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long&#8208;term study of indolent adult T&#8208;cell leukemia&#8208;lymphoma. Blood. 2010;115:4337&#8211;4343.</Citation><ArticleIdList><ArticleId IdType="pubmed">20348391</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25209605</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience.</ArticleTitle><Pagination><StartPage>464</StartPage><EndPage>472</EndPage><MedlinePgn>464-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-014-1665-0</ELocationID><Abstract><AbstractText>VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone)-AMP (doxorubicin, ranimustine, and prednisone)-VECP (vindesine, etoposide, carboplatin, and prednisone) is a standard regimen for aggressive adult T cell leukemia-lymphoma (ATL). However, the efficacy of this regimen has not been fully elucidated for patients aged 70 years or older. Here, we retrospectively analyzed elderly patients with aggressive ATL at Nagasaki University Hospital between 1994 and 2010 to assess treatment outcomes. Of 148 evaluable patients, 54 were aged 70 years or older at diagnosis. The median survival time (MST) and overall survival (OS) at 2 years in elderly patients were 10.6 months and 22.1%, respectively. Thirty-four patients received VCAP-AMP-VECP as the initial treatment, although the doses were reduced for most patients. In these patients, MST and OS at 2 years were 13.4 months and 26.6%, respectively. Eleven of 34 patients (32%) received maintenance oral chemotherapy after two or three cycles of VCAP-AMP-VECP, and MST and OS at 2 years were 16.7 months and 32.7%, respectively. Our results suggest that the VCAP-AMP-VECP regimen may be effective and that maintenance oral chemotherapy may be considered as a therapeutic option for elderly patients with aggressive ATL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Makiyama</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tsushima</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Moriwaki</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sawayama</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Imanishi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hata</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060828">Induction Chemotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060046">Maintenance Chemotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25209605</ArticleId><ArticleId IdType="doi">10.1007/s12185-014-1665-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2010 Sep 20;28(27):4177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 Mar 10;30(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1977 Sep;50(3):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2013 Apr;97(4):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23483425</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2005 May;19(5):829-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinsho Ketsueki. 2011 Nov;52(11):1765-71</Citation><ArticleIdList><ArticleId IdType="pubmed">22185799</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7031654</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2009 Jan 20;27(3):453-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 May 10;30(14):1635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19030219</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1007-9327</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>42</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis.</ArticleTitle><Pagination><StartPage>6584</StartPage><EndPage>6588</EndPage><MedlinePgn>6584-8</MedlinePgn></Pagination><Abstract><AbstractText>Multiple lymphomatous polyposis (MLP) is an unusual form of non-Hodgkin's lymphoma characterized by polyps throughout the gastrointestinal tract. It has been reported that most MLP are observed in cases with mantle cell lymphoma of B-cell type. We herein present a case of a 66-year-old man with adult T-cell leukemia/lymphoma (ATLL). Colonoscopy revealed MLP throughout the colon and histopathological findings of ATLL cell infiltration. The patient died despite combination of chemotherapy. The literature of manifestations of colonic involvement of ATLL is reviewed and the importance of endoscopic evaluation to differentiate ATLL intestinal lesions from opportunistic infectious enterocolitis is discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hokama</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics (First Department of Internal Medicine), Control and Prevention of Infectious Disease, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. hokama-a@med.u-ryukyu.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomoyose</LastName><ForeName>Takeaki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Takako</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hirata</LastName><ForeName>Tetsuo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kinjo</LastName><ForeName>Fukunori</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Seiya</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Uezato</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Takasu</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Jiro</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003111">Colonic Polyps</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003113">Colonoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044483">Intestinal Polyposis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017211">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19030219</ArticleId><ArticleId IdType="pmc">PMC2773353</ArticleId><ArticleId IdType="doi">10.3748/wjg.14.6584</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60:1373&#8211;1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2095573</ArticleId><ArticleId IdType="pubmed">18042693</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 2007;98:772&#8211;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">17388788</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzumiya J, Marutsuka K, Nabeshima K, Nawa Y, Koono M, Tamura K, Kimura N, Hisano S, Tachibana N, Inoue S. Autopsy findings in 47 cases of adult T-cell leukemia/lymphoma in Miyazaki prefecture, Japan. Leuk Lymphoma. 1993;11:281&#8211;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">8260899</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Hanada S, Terada A, Kodama M, Uematsu T, Tsukasa S, Hashimoto S, Tokunaga M. Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer. 1988;61:824&#8211;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">3257406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87) Br J Haematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Hori T, Maeda M, Uchiyama T. Identification of an adhesion molecule expressed on adult T cell leukemia cells derived from a patient with gastrointestinal involvement: implication for a possible role of integrin beta 7 in leukemic cell infiltration into intestinal mucosa. J Clin Immunol. 1999;19:186&#8211;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">10404404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga O, Watanabe T, Shimamoto Y, Tokudome S. Primary T-cell lymphoma of the gastrointestinal tract associated with human T-cell lymphotropic virus type I. An analysis using in situ hybridization and polymerase chain reaction. Cancer. 1993;71:708&#8211;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431850</ArticleId></ArticleIdList></Reference><Reference><Citation>Itsuno M, Makiyama K, Muta K, Furukawa K, Hara K, Tabata S, Soda H, Ikeda S, Takashima H, Fukuda Y. Adult T-cell leukemia with multiple lymphomatous polyposis of the gastrointestinal tract. Endoscopy. 1995;27:700&#8211;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">8903987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gakiya I, Kugai Y, Hayashi S, Nimura S, Zaha O, Kouchi A, Oshiro J, Sakugawa H, Kitukawa K, Kinjou F, et al. Varioliform mucosal polypoid lesions in intestinal tract in a patient with adult T-cell leukemia. J Gastroenterol. 1997;32:553&#8211;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">9250907</ArticleId></ArticleIdList></Reference><Reference><Citation>Isomoto H, Ohnita K, Mizuta Y, Maeda T, Onizuka Y, Miyazaki M, Omagari K, Takeshima F, Murase K, Haraguchi M, et al. Clinical and endoscopic features of adult T-cell leukemia/lymphoma with duodenal involvement. J Clin Gastroenterol. 2001;33:241&#8211;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">11500618</ArticleId></ArticleIdList></Reference><Reference><Citation>Isomoto H, Furusu H, Onizuka Y, Kawaguchi Y, Mizuta Y, Maeda T, Kohno S. Colonic involvement by adult T-cell leukemia/lymphoma mimicking ulcerative colitis. Gastrointest Endosc. 2003;58:805&#8211;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">14997894</ArticleId></ArticleIdList></Reference><Reference><Citation>Isomoto H, Maeda T, Ohnita K, Nakayama T, Kohno S. Colonic lymphomatous polyposis. Gastrointest Endosc. 2004;59:261.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745401</ArticleId></ArticleIdList></Reference><Reference><Citation>Asada Y, Isomoto H, Shikuwa S, Ito M, Momita S, Matsumura N, Ohba K, Ohnita K, Nakamura T, Mizuta Y, et al. Adult T-cell leukemia with colorectal involvement. Gastrointest Endosc. 2004;60:983&#8211;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15605016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidaka H, Hotokezaka M, Iwamura T, Moriguchi S, Marutsuka K, Toyama T, Chijiiwa K. Primary, solitary, adult T-cell leukemia/lymphoma of the descending colon. J Gastroenterol. 2004;39:788&#8211;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">15338374</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi T, Tamura S, Onishi S. A case of adult T-cell leukemia with colon involvement. Gastrointest Endosc. 2007;65:712&#8211;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">17383471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornes JS. Multiple lymphomatous polyposis of the gastrointestinal tract. Cancer. 1961;14:249&#8211;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">13695582</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacson PG, MacLennan KA, Subbuswamy SG. Multiple lymphomatous polyposis of the gastrointestinal tract. Histopathology. 1984;8:641&#8211;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">6479906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavergne A, Brouland JP, Launay E, Nemeth J, Ruskone-Fourmestraux A, Galian A. Multiple lymphomatous polyposis of the gastrointestinal tract. An extensive histopathologic and immunohistochemical study of 12 cases. Cancer. 1994;74:3042&#8211;3050.</Citation><ArticleIdList><ArticleId IdType="pubmed">7954267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokama A, Kishimoto K, Tomiyama R, Hirata T, Kinjo F, Fujita J, Masuda M. An unusual cause of polyposis. Gut. 2006;55:1574, 1591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1860138</ArticleId><ArticleId IdType="pubmed">17047108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama T, Ohshima K, Nomura K, Taniwaki M, Nakamura N, Nakamura S, Kohno S, Yamamoto J, Karube K, Yamasita Y, et al. Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology. 2005;47:467&#8211;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">16241994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata T, Uchima N, Kishimoto K, Zaha O, Kinjo N, Hokama A, Sakugawa H, Kinjo F, Fujita J. Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg. 2006;74:246&#8211;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto K, Hokama A, Hirata T, Ihama Y, Nakamoto M, Kinjo N, Kinjo F, Fujita J. Endoscopic and histopathological study on the duodenum of Strongyloides stercoralis hyperinfection. World J Gastroenterol. 2008;14:1768&#8211;1773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695917</ArticleId><ArticleId IdType="pubmed">18350608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata H, Fujimoto K, Iwakiri R, Mizuguchi M, Koyama T, Sakai T, Inoue E, Tokunaga O, Shimamoto Y. Gastric lesions in 76 patients with adult T-cell leukemia/lymphoma. Endoscopic evaluation. Cancer. 1996;78:396&#8211;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">8697382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17138822</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-4971</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>3060</StartPage><EndPage>3068</EndPage><MedlinePgn>3060-8</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a generally fatal malignancy. Most ATLL patients fare poorly with conventional chemotherapy; however, antiviral therapy with zidovudine (AZT) and interferon alpha (IFN-alpha) has produced long-term clinical remissions. We studied primary ATLL tumors and identified molecular features linked to sensitivity and resistance to antiviral therapy. Enhanced expression of the proto-oncogene c-Rel was noted in 9 of 27 tumors. Resistant tumors exhibited c-Rel (6 of 10; 60%) more often than did sensitive variants (1 of 9; 11%). This finding was independent of the disease form. Elevated expression of the putative c-Rel target, interferon regulatory factor-4 (IRF-4), was observed in 10 (91%) of 11 nonresponders and in all tested patients with c-Rel+ tumors and occurred in the absence of the HTLV-1 oncoprotein Tax. In contrast, tumors in complete responders did not express c-Rel or IRF-4. Gene rearrangement studies demonstrated the persistence of circulating T-cell clones in long-term survivors maintained on antiviral therapy. The expression of nuclear c-Rel and IRF-4 occurs in the absence of Tax in primary ATLL and is associated with antiviral resistance. These molecular features may help guide treatment. AZT and IFN-alpha is a suppressive rather than a curative regimen, and patients in clinical remission should remain on maintenance therapy indefinitely.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Isildinha M</ForeName><Initials>IM</Initials></Author><Author ValidYN="Y"><LastName>Brites</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Gerald E</ForeName><Initials>GE</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Toomey</LastName><ForeName>Ngoc L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Andela</LastName><ForeName>Valentine</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Harhaj</LastName><ForeName>Edward W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Lossos</LastName><ForeName>Izidore S</ForeName><Initials>IS</Initials></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 CA070058</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA-10521</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA082274</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA-082274</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-CA-070058</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000715470">MAS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090063">Proto-Oncogene Mas</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020569">Proto-Oncogene Proteins c-rel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C068059">REL protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094531">interferon regulatory factor-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D024882">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D020573">Genes, rel</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050835">Interferon Regulatory Factors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007370">Interferon Type I</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000090063">Proto-Oncogene Mas</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020569">Proto-Oncogene Proteins c-rel</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17138822</ArticleId><ArticleId IdType="pmc">PMC1852214</ArticleId><ArticleId IdType="doi">10.1182/blood-2006-07-036368</ArticleId><ArticleId IdType="pii">S0006-4971(20)41813-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gallo RC, Poiesz BJ, Ruscetti FW. Regulation of human T-cell proliferation: T-cell growth factor and isolation of a new class of type-C retroviruses from human T-cells. Haematol Blood Transfus. 1981;26:502&#8211;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">6274766</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5:664&#8211;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522654</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375&#8211;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:182&#8211;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8680890</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15&#8211;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakase K, Hara M, Kozuka T, Tanimoto K, Nawa Y. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. Bone Marrow Transplant. 2006;37:41&#8211;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247419</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti&#8211;Tac. Blood. 1995;86:4063&#8211;4075.</Citation><ArticleIdList><ArticleId IdType="pubmed">7492762</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmann TA. The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-1-associated disorders. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:S179&#8211;S185.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W, Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744&#8211;1748.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Bouscary D, Gessain A, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749&#8211;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">7760891</ArticleId></ArticleIdList></Reference><Reference><Citation>Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113:779&#8211;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Allard I, Levy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276&#8211;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522449</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108:1021&#8211;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895862</ArticleId><ArticleId IdType="pubmed">16569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21:1251&#8211;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850845</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34&#8211;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer. 2000;85:720&#8211;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10699955</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Grander D, Sangfelt O, Einhorn S. Primary leukemia cells resistant to alpha-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3. Blood. 1994;84:1942&#8211;1949.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun WH, Pabon C, Alsayed Y, et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 1998;91:570&#8211;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427711</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajima K, Cartier L. Epidemiological features of HTLV-1 and adult T cell leukemia. Intervirology. 1995;38:238&#8211;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">8682622</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda M, Shimizu A, Ikuta K, et al. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia: analysis of T cell receptor gene rearrangement. J Exp Med. 1985;162:2169&#8211;2174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2187984</ArticleId><ArticleId IdType="pubmed">2866223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475&#8211;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-&#954;B in primary adult T-cell leukemia cells. Blood. 1999;93:2360&#8211;2368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090947</ArticleId></ArticleIdList></Reference><Reference><Citation>Arima N, Matsushita K, Obata H, et al. NF-&#954;B involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hematol. 1999;27:1168&#8211;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">10390192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A. 2000;97:6055&#8211;6060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18557</ArticleId><ArticleId IdType="pubmed">10811897</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-&#954;B induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96:2537&#8211;2542.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001908</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor &#954;B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861&#8211;1874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193582</ArticleId><ArticleId IdType="pubmed">11748286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N, Yamada Y, Ikeda S, et al. Bay 11-7082 inhibits transcription factor NF-&#954;B and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100:1828&#8211;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176906</ArticleId></ArticleIdList></Reference><Reference><Citation>Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia. 2004;18:1357&#8211;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsugi T, Horie R, Kumasaka T, et al. In vivo antitumor activity of the NF-&#954;B inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis. 2005;26:1382&#8211;1388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene. 2005;24:6005&#8211;6015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652704</ArticleId><ArticleId IdType="pubmed">16155607</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JE, Wilson SS, Jaye DL, Kronenberg M. An automated semiquantitative B and T cell clonality assay. Mol Diagn. 1999;4:101&#8211;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">10462626</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98&#8211;3936. Leukemia. 2003;17:2257&#8211;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">14671650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurokawa M, Ghosh SK, Ramos JC, et al. Zidovudine inhibits NF-&#954;B and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106:235&#8211;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895122</ArticleId><ArticleId IdType="pubmed">15790788</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi C, Toi M. Nuclear factor-&#954;B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297&#8211;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrdlickova R, Nehyba J, Bose HR., Jr Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts. Mol Cell Biol. 2001;21:6369&#8211;6386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC99785</ArticleId><ArticleId IdType="pubmed">11533227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540&#8211;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">8999800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohoff M, Mittrucker HW, Brustle A, et al. Enhanced TCR-induced apoptosis in interferon regulatory factor 4-deficient CD4(+) Th cells. J Exp Med. 2004;200:247&#8211;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212018</ArticleId><ArticleId IdType="pubmed">15249594</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17:226&#8211;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326949</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97:744&#8211;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;1030:275&#8211;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504078</ArticleId></ArticleIdList></Reference><Reference><Citation>Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714&#8211;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16400625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M, Iida S, Inagaki H, et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res. 2002;93:685&#8211;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927045</ArticleId><ArticleId IdType="pubmed">12079517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol. 2005;32:227&#8211;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701085</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi Y, Kohno T, Yamada Y, et al. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 2001;92:1284&#8211;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5926682</ArticleId><ArticleId IdType="pubmed">11749693</ArticleId></ArticleIdList></Reference><Reference><Citation>Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor &#954;B. J Exp Med. 2000;191:1281&#8211;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193138</ArticleId><ArticleId IdType="pubmed">10770796</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagata T, Nishida J, Tanaka S, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol. 1996;16:1283&#8211;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231112</ArticleId><ArticleId IdType="pubmed">8657101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Mamane Y, Grandvaux N, et al. Activation and regulation of interferon regulatory factor 4 in HTLV type 1-infected T lymphocytes. AIDS Res Hum Retroviruses. 2000;16:1613&#8211;1622.</Citation><ArticleIdList><ArticleId IdType="pubmed">11080800</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamane Y, Grandvaux N, Hernandez E, et al. Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene. 2002;21:6751&#8211;6765.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Grandvaux N, Mamane Y, et al. Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J Immunol. 2002;169:3120&#8211;3130.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood. 1998;92:3557&#8211;3561.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5:130&#8211;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia. 2002;16:1069&#8211;1085.52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma. 2002;43:2249&#8211;2255.</Citation><ArticleIdList><ArticleId IdType="pubmed">12613509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114:63&#8211;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa H, Yamada Y, Harasawa H, et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol. 2005;128:253&#8211;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15638862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima K, Haraoka S, Sugihara M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett. 2000;160:89&#8211;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">11098089</ArticleId></ArticleIdList></Reference><Reference><Citation>Weih F, Carrasco D, Bravo R. Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen. Oncogene. 1994;9:3289&#8211;3297.</Citation><ArticleIdList><ArticleId IdType="pubmed">7936653</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco D, Rizzo CA, Dorfman K, et al. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J. 1996;15:3640&#8211;3650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC451988</ArticleId><ArticleId IdType="pubmed">8670867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan ME. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene. 2001;20:7098&#8211;7103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S41&#8211;S47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15202524</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101:3681&#8211;3686.</Citation><ArticleIdList><ArticleId IdType="pubmed">12511414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pileri SA, Zinzani PL, Gaidano G, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl):S21&#8211;S26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15202521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontgen F, Grumont RJ, Strasser A, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995;9:1965&#8211;1977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7649478</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda M, Arima N, Daitoku Y, et al. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood. 1987;70:1407&#8211;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">2889484</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/&#947;c(null) mice: suppression by an inhibitor against NF-&#954;B. J Virol. 2003;77:5286&#8211;5294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC153944</ArticleId><ArticleId IdType="pubmed">12692230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa H, Sawa H, Lewis MJ, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12:466&#8211;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">16550188</ArticleId></ArticleIdList></Reference><Reference><Citation>Marecki S, Atchison ML, Fenton MJ. Differential expression and distinct functions of IFN regulatory factor 4 and IFN consensus sequence binding protein in macrophages. J Immunol. 1999;163:2713&#8211;2722.</Citation><ArticleIdList><ArticleId IdType="pubmed">10453013</ArticleId></ArticleIdList></Reference><Reference><Citation>Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084&#8211;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">10706878</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernis AB. The role of IRF-4 in B and T cell activation and differentiation. J Interferon Cytokine Res. 2002;22:111&#8211;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846982</ArticleId></ArticleIdList></Reference><Reference><Citation>Negishi H, Ohba Y, Yanai H, et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A. 2005;102:15989&#8211;15994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257749</ArticleId><ArticleId IdType="pubmed">16236719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-&#954;B that blocks TNF&#945;-induced apoptosis. Genes Dev. 1999;13:382&#8211;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316475</ArticleId><ArticleId IdType="pubmed">10049353</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclercq I, Mortreux F, Morschhauser F, et al. Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL). Br J Haematol. 1999;105:743&#8211;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">10354140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31132453</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6536</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title><ISOAbbreviation>Biol Blood Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis.</ArticleTitle><Pagination><StartPage>1695</StartPage><EndPage>1700</EndPage><MedlinePgn>1695-1700</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2019.05.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1083-8791(19)30338-6</ELocationID><Abstract><AbstractText>Human T cell lymphotropic virus type 1 (HTLV1)-associated adult T cell leukemia/lymphoma (ATLL) is an aggressive malignant disorder. Intensive conventional chemotherapy regimens and autologous hematopoietic cell transplantation (HCT) have failed to improve outcomes in ATLL. Allogeneic HCT (allo-HCT) is commonly offered as front-line consolidation despite lack of randomized controlled trials. We performed a comprehensive search of the medical literature using PubMed/Medline, EMBASE, and Cochrane reviews on September 10, 2018. We extracted data on clinical outcomes related to benefits (complete response [CR], overall survival [OS], and progression-free survival [PFS]) and harms (relapse and nonrelapse mortality [NRM]), independently by 2 authors. Our search strategy identified a total of 801 references. Nineteen studies (n&#8239;=&#8239;2446 patients) were included in the systematic review; however, only 18 studies (n&#8239;=&#8239;1767 patients) were included in the meta-analysis. Reduced intensity conditioning regimens were more commonly prescribed (52%). Bone marrow (50%) and peripheral blood (40%) were more frequently used as stem cell source. The pooled post-allografting CR, OS, and PFS rates were 73% (95% confidence interval [CI], 57% to 87%), 40% (95% CI, 33% to 46%), and 37% (95% CI, 27% to 48%), respectively. Pooled relapse and NRM rates were 36% (95% CI, 28% to 43%) and 29% (95% CI, 21% to 37%), respectively. The heterogeneity among the included studies was generally high. These results support the use of allo-HCT as an effective treatment for patients with ATLL, yielding pooled OS rates of 40%, but relapse still occurs in over one-third of cases. Future studies should evaluate strategies to help reduce relapse in patients with ATLL undergoing allo-HCT.</AbstractText><CopyrightInformation>Copyright &#169; 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Madiha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reljic</LastName><ForeName>Tea</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klocksieben</LastName><ForeName>Farina</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sher</LastName><ForeName>Taimur</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayala</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murthy</LastName><ForeName>Hemant</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Blood and Marrow Transplantation and Malignant Hematology Program, University of Florida Health Cancer Center, Gainesville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazarbachi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Hematology-Oncology, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ambuj</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kharfan-Dabaja</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida. Electronic address: KharfanDabaja.Mohamed@Mayo.Edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Blood Marrow Transplant</MedlineTA><NlmUniqueID>9600628</NlmUniqueID><ISSNLinking>1083-8791</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Biol Blood Marrow Transplant. 2020 Jan;26(1):209-212</RefSource><PMID Version="1">31610149</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D019172">Transplantation Conditioning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allogeneic hematopoietic cell transplantation</Keyword><Keyword MajorTopicYN="N">HTLV-1&#8211;associated adult T cell leukemia/lymphoma (ATLL)</Keyword><Keyword MajorTopicYN="N">Human T cell lymphotropic virus type 1 (HTLV-1)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31132453</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2019.05.027</ArticleId><ArticleId IdType="pii">S1083-8791(19)30338-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36083572</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>148</EndPage><MedlinePgn>143-148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-022-03447-0</ELocationID><Abstract><AbstractText>Mogamulizumab (MOG), a humanized monoclonal anti-CCR4 antibody, exerts strong antibody-dependent cellular cytotoxic effects on CCR4-positive adult T-cell leukemia/lymphoma (ATLL) cells. As CCR4 is highly expressed on regulatory T cells as well as ATLL cells, pre-transplant MOG induces severe graft-versus-host disease (GvHD). However, limited data are available on post-transplant use of MOG for relapsed ATLL. Here we describe the case of a patient with ATLL who experienced post-transplant relapse with involvement of peripheral blood, skin, lungs, and lymph nodes. Neither tacrolimus dose reduction nor cytotoxic chemotherapy was effective, but a single dose of MOG (1&#160;mg/kg) induced complete remission. After treatment with MOG, leukemic cells in the peripheral blood rapidly disappeared, and the skin, lymph node, and lung lesions gradually regressed. Most notably, the long-term remission was accompanied by recurrence of moderate acute GvHD (grade II, skin stage 2, gut stage 1, liver stage 0). Our findings indicate that MOG can augment allogeneic immune-mediated anti-tumor reactions through graft-versus-ATLL (GvATLL) even during post-transplant relapse involving the lymph nodes and lungs, along with inducing GvHD.</AbstractText><CopyrightInformation>&#169; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirosawa</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Midori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oku</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akao</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitamura</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Tsukasa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niino</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashi</LastName><ForeName>Takehiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukada</LastName><ForeName>Junichi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1905-0668</Identifier><AffiliationInfo><Affiliation>Department of Hematology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan. jtsukada@med.uoeh-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">GvATLL</Keyword><Keyword MajorTopicYN="N">GvHD</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36083572</ArticleId><ArticleId IdType="pmc">PMC9813186</ArticleId><ArticleId IdType="doi">10.1007/s12185-022-03447-0</ArticleId><ArticleId IdType="pii">10.1007/s12185-022-03447-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270&#8211;280. doi: 10.1038/nrc2111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2111</ArticleId><ArticleId IdType="pubmed">17384582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15(11):e517&#8211;e526. doi: 10.1016/S1470-2045(14)70202-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570&#8211;2577. doi: 10.1182/blood-2015-03-632489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(1):15&#8211;20. doi: 10.1038/sj.bmt.1702731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1702731</ArticleId><ArticleId IdType="pubmed">11244433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005;19(5):829&#8211;834. doi: 10.1038/sj.leu.2403682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.leu.2403682</ArticleId><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116(8):1369&#8211;1376. doi: 10.1182/blood-2009-10-247510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-10-247510</ArticleId><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Uike N, Wake A, Yoshimitsu M, Tobai T, Sawayama Y, et al. The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019;37(1):54&#8211;61. doi: 10.1002/hon.2558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2558</ArticleId><ArticleId IdType="pubmed">30171618</ArticleId></ArticleIdList></Reference><Reference><Citation>Itonaga H, Tsushima H, Taguchi J, Fukushima T, Taniguchi H, Sato S, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience. Blood. 2013;121(1):219&#8211;225. doi: 10.1182/blood-2012-07-444372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-07-444372</ArticleId><ArticleId IdType="pubmed">23100309</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, et al. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant. 2008;14(7):817&#8211;823. doi: 10.1016/j.bbmt.2008.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2008.04.014</ArticleId><ArticleId IdType="pubmed">18541202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Utsunomiya A, Takatsuka Y, Takeuchi S, Tashiro Y, Kanzaki T, et al. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(12):1029&#8211;1035. doi: 10.1038/bmt.2008.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2008.39</ArticleId><ArticleId IdType="pubmed">18332910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120(8):1734&#8211;1741. doi: 10.1182/blood-2012-03-414490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-03-414490</ArticleId><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119(9):2141&#8211;2148. doi: 10.1182/blood-2011-07-368233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-07-368233</ArticleId><ArticleId IdType="pubmed">22234682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837&#8211;842. doi: 10.1200/JCO.2011.37.3472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672&#8211;682. doi: 10.1111/bjh.13338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Crawford B, Yi J, Kuan W, Matsumoto T, Takahashi T. Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2022;108(3):212&#8211;222. doi: 10.1111/ejh.13728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13728</ArticleId><ArticleId IdType="pmc">PMC9299810</ArticleId><ArticleId IdType="pubmed">34862665</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation Anti-CCR4 antibody mogamulizumab against adult T-Cell Leukemia/Lymphoma Is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016 doi: 10.1200/JCO.2016.67.8250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId><ArticleId IdType="pubmed">27507878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan clinical oncology group study 9303. Br J Haematol. 2001;113(2):375&#8211;382. doi: 10.1046/j.1365-2141.2001.02737.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2001.02737.x</ArticleId><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Sakamoto Y, Masaki A, Murase T, Tashiro Y, Yonekura K, et al. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma. J Pathol Clin Res. 2021;7(1):52&#8211;60. doi: 10.1002/cjp2.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjp2.180</ArticleId><ArticleId IdType="pmc">PMC7737778</ArticleId><ArticleId IdType="pubmed">33022137</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto H, Itonaga H, Sawayama Y, Furumoto T, Fujioka M, Chiwata M, et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162&#8211;170. doi: 10.1002/hon.2712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2712</ArticleId><ArticleId IdType="pubmed">31922287</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Endo S, Matsuno N, Kikukawa Y, Shichijo T, Koga K, et al. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54(2):338&#8211;342. doi: 10.1038/s41409-018-0291-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0291-5</ArticleId><ArticleId IdType="pubmed">30116017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413&#8211;2419. doi: 10.1182/blood-2011-04-348292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-04-348292</ArticleId><ArticleId IdType="pubmed">21690556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroger N, Zabelina T, Klyuchnikov E, Kropff M, Pfluger KH, Burchert A, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 2013;48(3):403&#8211;407. doi: 10.1038/bmt.2012.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.142</ArticleId><ArticleId IdType="pubmed">22863722</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1183&#8211;1189. doi: 10.1016/j.bbmt.2014.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2014.04.014</ArticleId><ArticleId IdType="pmc">PMC5036168</ArticleId><ArticleId IdType="pubmed">24769014</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamai H, Tajika K, Nakayama K, Arai A. Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide. Bone Marrow Transplant. 2021;56(11):2862&#8211;2863. doi: 10.1038/s41409-021-01432-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-021-01432-5</ArticleId><ArticleId IdType="pubmed">34385616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant. 2008;14(6):702&#8211;708. doi: 10.1016/j.bbmt.2008.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2008.03.010</ArticleId><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, et al. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant. 2013;19(12):1731&#8211;1739. doi: 10.1016/j.bbmt.2013.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2013.09.014</ArticleId><ArticleId IdType="pubmed">24090597</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med. 2014;211(13):2497&#8211;2505. doi: 10.1084/jem.20140987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20140987</ArticleId><ArticleId IdType="pmc">PMC4267233</ArticleId><ArticleId IdType="pubmed">25488980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N, Miyoshi H, Kato T, Sakata-Yanagimoto M, Niino D, Taniguchi H, et al. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis. J Pathol. 2016;238(5):621&#8211;626. doi: 10.1002/path.4699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4699</ArticleId><ArticleId IdType="pubmed">26847489</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758&#8211;761. doi: 10.1182/blood-2018-02-835991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-02-835991</ArticleId><ArticleId IdType="pubmed">29930010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano N, Yoshida N, Kawano S, Arakawa F, Miyoshi H, Yamada K, et al. Clinical features, pathological features, and treatment outcomes of 22 patients with aggressive adult T-cell Leukemia-lymphoma treated with a humanized CCR4 antibody (Mogamulizumab) at a single institution during a 6-year period (2012&#8211;2018) Intern Med. 2019;58(15):2159&#8211;2166. doi: 10.2169/internalmedicine.2513-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.2513-18</ArticleId><ArticleId IdType="pmc">PMC6709313</ArticleId><ArticleId IdType="pubmed">30996180</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano N, Utsunomiya A, Matsuo K, Yoshida N, Seto M, Ohshima K, et al. Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT. Blood Adv. 2021;5(2):475&#8211;486. doi: 10.1182/bloodadvances.2020003639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003639</ArticleId><ArticleId IdType="pmc">PMC7839361</ArticleId><ArticleId IdType="pubmed">33496743</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamimura T, Miyamoto T, Kawano N, Numata A, Ito Y, Chong Y, et al. Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95(6):725&#8211;730. doi: 10.1007/s12185-012-1056-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-012-1056-3</ArticleId><ArticleId IdType="pubmed">22481502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31934889</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5741</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Anti-cancer drugs</Title><ISOAbbreviation>Anticancer Drugs</ISOAbbreviation></Journal><ArticleTitle>Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.</ArticleTitle><Pagination><StartPage>536</StartPage><EndPage>539</EndPage><MedlinePgn>536-539</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CAD.0000000000000895</ELocationID><Abstract><AbstractText>Although treatments for adult T-cell leukemia/lymphoma in the past two decades have advanced, the current standard treatment for aggressive adult T-cell leukemia/lymphoma, particularly in patients who are not eligible for stem cell transplantation, remains inadequate; therefore, treatments to prolong the duration of remission and provide relevant benefits in terms of survival and quality of life are needed. Adult T-cell leukemia/lymphoma tumor cells express CD30 in some cases and the increased expression of CD30 is considered to be one of the causes of constitutive NF-&#954;B activation in adult T-cell leukemia/lymphoma cells. Brentuximab vedotin represents a major breakthrough in the treatment of CD30-positive lymphomas. Elderly patients treated with chemotherapy generally have higher rates of grade 3 or 4 adverse events; however a retrospective analysis demonstrated the safety and efficacy of brentuximab vedotin in adults &#8805;60 years with relapsed and refractory CD30-positive lymphomas. We herein report the clinical effects of brentuximab vedotin and the significance of CD30 expression in an elderly refractory/relapse adult T-cell leukemia/lymphoma patient. CD30 expression is associated with disease progression in adult T-cell leukemia/lymphoma patients and brentuximab vedotin may be a new and promising treatment option for these patients. Further investigations on the use of brentuximab vedotin for adult T-cell leukemia/lymphoma are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oka</LastName><ForeName>Satoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nohgawa</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anticancer Drugs</MedlineTA><NlmUniqueID>9100823</NlmUniqueID><ISSNLinking>0959-4973</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>7XL5ISS668</RegistryNumber><NameOfSubstance UI="D000079963">Brentuximab Vedotin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074322">Antineoplastic Agents, Immunological</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000079963">Brentuximab Vedotin</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016879">Salvage Therapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31934889</ArticleId><ArticleId IdType="doi">10.1097/CAD.0000000000000895</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20887496</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1743-7563</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Asia-Pacific journal of clinical oncology</Title><ISOAbbreviation>Asia Pac J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma in Taiwan: an analysis of 17 patients and review of the literature.</ArticleTitle><Pagination><StartPage>161</StartPage><EndPage>164</EndPage><MedlinePgn>161-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1743-7563.2010.01320.x</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We reviewed our experience with adult T-cell leukemia (ATL), describing the clinical manifestations and outcome in order to facilitate case recognition in the future.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively reviewed the charts of 17 patients with ATL diagnosed from January 1996 to September 2009 at Mackay Memorial Hospital, Taipei, Taiwan.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall survival of the whole study group was 138 days. The medial survival of the 10 patients who received chemotherapy is 204 days. The other six patients who did not receive any chemotherapy had a median survival of 28 days. The co-infection rate with HTLV-1 and HBV or HCV is 47% and 35% respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ATL in Taiwan is a rare malignant T-cell lymphoma with a very poor prognosis. Our series raised the interesting possibility of an association with chronic hepatitis B or C.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chun-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan. aps624@yahoo.com.tw</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ming-Chih</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yi-Fang</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Ruey-Kuen</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Johnson</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kung-Shen</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Asia Pac J Clin Oncol</MedlineTA><NlmUniqueID>101241430</NlmUniqueID><ISSNLinking>1743-7555</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006509">Hepatitis B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006526">Hepatitis C</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013624">Taiwan</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20887496</ArticleId><ArticleId IdType="doi">10.1111/j.1743-7563.2010.01320.x</ArticleId><ArticleId IdType="pii">AJCO1320</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12613513</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1042-8194</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>12</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide.</ArticleTitle><Pagination><StartPage>2275</StartPage><EndPage>2279</EndPage><MedlinePgn>2275-9</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Adult T-cell leukemia-lymphoma (ATLL) has a very bad prognosis and remains resistant to conventional therapy. Promising results have been reported with the combination of zidovudine (AZT) and alpha-interferon (IFN).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A combination with IFN and antinucleoside [AZT or zalcitabine (ddC)] was applied since 1995 in Martinique (French West Indies). An initial treatment with two cycles of CHOP was added to reduce initial tumoral burden, followed by antiretroviral (ARV) therapy associated with etoposide. We report the characteristics and outcomes of 29 patients diagnosed with an ATLL between 1990 and 1999. The overall median survival was 8 months. A striking improvement of survival was observed when comparing the periods between 1990-1994 and 1995-1999 (17 months versus 3 months, p = 0.004). During the second period, seven patients received a therapy with oral etoposide, antinucleoside and IFN, among which, six patients received an initial induction CHOP chemotherapy. No major toxicity was observed with this strategy. In conclusion, the progression of survival since 1995 suggests that a therapeutic approach combining initial polychemotherapy with CHOP followed by ARV drugs, IFN and oral etoposide is an interesting option in treating patients with ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Besson</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de M&#233;d&#233;cine Interne, CHU Pierre Zobda-Quitman, BP 632, 97261 Fort de France, Martinique, French West Indies, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panelatti</LastName><ForeName>Gerard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Delaunay</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gonin</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Brebion</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Plumelle</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6L3XT8CB3I</RegistryNumber><NameOfSubstance UI="D016047">Zalcitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6PLQ3CP4P3</RegistryNumber><NameOfSubstance UI="D005047">Etoposide</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005047">Etoposide</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016047">Zalcitabine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>10</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12613513</ArticleId><ArticleId IdType="doi">10.1080/1042819021000039983</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">33559154</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-4632</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of dermatology</Title><ISOAbbreviation>Int J Dermatol</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma with pagetoid reticulosis-like skin lesions.</ArticleTitle><Pagination><StartPage>e342</StartPage><EndPage>e344</EndPage><MedlinePgn>e342-e344</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ijd.15446</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishikawa</LastName><ForeName>Yotaro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-4796-9711</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanemaru</LastName><ForeName>Shiho</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Aina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Manami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochida</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amano</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Dermatol</MedlineTA><NlmUniqueID>0243704</NlmUniqueID><ISSNLinking>0011-9059</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D056267">Pagetoid Reticulosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D012871">Skin Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33559154</ArticleId><ArticleId IdType="doi">10.1111/ijd.15446</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Amano M, Setoyama M, Grant A, et&#160;al. Human T-lymphotropic Virus 1 (HTLV-1) infection - dermatological implications. Int J Dermatol 2011; 50: 915-920.</Citation></Reference><Reference><Citation>Willemze R, Jaffe ES, Burg G, et&#160;al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.</Citation></Reference><Reference><Citation>Grubb B, Henderson DB, Pandya AG. Adult T-cell lymphoma/leukemia presenting as pagetoid reticulosis of the palms and soles. J Am Acad Dermatol 2011; 65: 1063-1064.</Citation></Reference><Reference><Citation>Cho-Vega JH, Tschen JA, Duvic M, et&#160;al. Early-stage mycosis fungoides variants: case-based review. Ann Diagn Pathol 2010; 14: 369-385.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20359583</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-8686</ISSN><JournalIssue CitedMedium="Internet"><Volume>47 Suppl 1</Volume><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Seminars in hematology</Title><ISOAbbreviation>Semin Hematol</ISOAbbreviation></Journal><ArticleTitle>Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.</ArticleTitle><Pagination><StartPage>S5</StartPage><EndPage>S7</EndPage><MedlinePgn>S5-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.seminhematol.2010.01.015</ELocationID><Abstract><AbstractText>The most common subtype of T-/natural killer (NK) cell lymphoma in Japan is adult T-cell leukemia-lymphoma (ATL), which is associated with the human T-cell lymphotropic virus type I (HTLV-1). The investigators in Japan have conducted several clinical trials on multi-agent chemotherapy and stem cell transplantation for patients with ATL. They have also initiated several new clinical trials with a number of agents: an anti-CCR4 antibody, KW-0761; forodesine, a purine nucleoside phosphorylase inhibitor; and lenalidomide, an immunomodulatory agent. Clinical trials with pralatrexate, a folate analog, and denileukin diftitox, an immunoconjugate, are under discussion for patients with ATL and peripheral T-cell lymphoma (PTCL).</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tobinai</LastName><ForeName>Kensei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Cancer Center Hospital, Tokyo, Japan. ktobinai@ncc.go.jp</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Hematol</MedlineTA><NlmUniqueID>0404514</NlmUniqueID><ISSNLinking>0037-1963</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011684">Purine Nucleosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>426X066ELK</RegistryNumber><NameOfSubstance UI="C113101">forodesine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4Z8R6ORS6L</RegistryNumber><NameOfSubstance UI="D013792">Thalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="D000077269">Lenalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015507">Drugs, Investigational</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007564">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077269">Lenalidomide</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015337">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011684">Purine Nucleosides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011744">Pyrimidinones</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013792">Thalidomide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>9</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20359583</ArticleId><ArticleId IdType="doi">10.1053/j.seminhematol.2010.01.015</ArticleId><ArticleId IdType="pii">S0037-1963(10)00016-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28152225</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0609</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of haematology</Title><ISOAbbreviation>Eur J Haematol</ISOAbbreviation></Journal><ArticleTitle>Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.</ArticleTitle><Pagination><StartPage>501</StartPage><EndPage>507</EndPage><MedlinePgn>501-507</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejh.12863</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Relapsed/refractory ATLL patients with a median age of 70&#160;years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0&#160;months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5&#160;months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12&#160;months, longer than the 5.8&#160;months in a historical cohort without mogamulizumab.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.</AbstractText><CopyrightInformation>&#169; 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sekine</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5481-3451</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubuki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kameda</LastName><ForeName>Takuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Koga General Hospital, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toyama</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Miyazaki Prefectural Nobeoka Hospital, Nobeoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Kouichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Miyakonojo Medical Center, Miyakonojo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fujimoto Genral Hospital, Miyakonojo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishizaki</LastName><ForeName>Junzo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Miyazaki Aisenkai Nichinan hospital, Nichinan, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Koga General Hospital, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamiunten</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akizuki</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahira</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>Haruko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shide</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitanaka</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Koga General Hospital, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Haematol</MedlineTA><NlmUniqueID>8703985</NlmUniqueID><ISSNLinking>0902-4441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000074322">Antineoplastic Agents, Immunological</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019008">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019233">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CC chemokine receptor 4</Keyword><Keyword MajorTopicYN="N">adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">antibody therapy</Keyword><Keyword MajorTopicYN="N">mogamulizumab</Keyword><Keyword MajorTopicYN="N">retrospective</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28152225</ArticleId><ArticleId IdType="doi">10.1111/ejh.12863</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16106073</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0257-277X</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1-3</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Immunologic research</Title><ISOAbbreviation>Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Pathogenesis and treatment of human T-cell leukemia virus infection.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>223</EndPage><MedlinePgn>217-23</MedlinePgn></Pagination><Abstract><AbstractText>The pathogenesis of human T-cell leukemia virus (HTLV)-induced adult T-cell leukemia-lymphoma (ATLL) was explored using an infectious molecular viral clone and a transgenic mouse model. Activation of nuclear factor-kappaB by the HTLV transcriptional transactivator protein Tax was found to be important for lymphocyte immortalization and tumorigenesis. Interferon-gamma regulates tumor development owing primarily to angiostatic effects. Translational clinical studies of chemotherapy, interferon-alpha, and nucleoside reverse transcriptase inhibitors have also assisted in identifying the pathogenic features of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Molecular Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. lratner@im.wustl.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA063417-05</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA093062-02</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA093062</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730-069003</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730-02</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA063417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunol Res</MedlineTA><NlmUniqueID>8611087</NlmUniqueID><ISSNLinking>0257-277X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044966">Anti-Retroviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016355">Genes, pX</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16106073</ArticleId><ArticleId IdType="mid">NIHMS94163</ArticleId><ArticleId IdType="pmc">PMC2652731</ArticleId><ArticleId IdType="doi">10.1385/IR:32:1-3:217</ArticleId><ArticleId IdType="pii">IR:32:1-3:217</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Franchini G, Nicot C, Johnson JM. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res. 2003;89:69&#8211;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">14587871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L. Adult T cell leukemia lymphoma. Front Biosci. 2004;9:2852&#8211;2859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652732</ArticleId><ArticleId IdType="pubmed">15353320</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Osame M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol. 2003;9:228&#8211;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707853</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene. 2003;22:5131&#8211;5140.</Citation><ArticleIdList><ArticleId IdType="pubmed">12910250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Multiple viral strategies of HTLV-1 for dys-regulation of cell growth control. Annu Rev Immunol. 2001;19:475&#8211;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimata JT, Wong F-H, Wang JJ, VanderHeyden N, Ratner L. Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology. 1994;204:656&#8211;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">7941334</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins ND, Newbound GC, Ratner L. In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotropic virus type 1 (HTLV-1) J Virol. 1996;70:7241&#8211;7246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190781</ArticleId><ArticleId IdType="pubmed">8794375</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek MD, Ratner L. Immortalization of T-lymphocytes by human T-cell leukemia virus type 1 tax mutants with different trans-activating phenotypes. J Virol. 1999;73:4856&#8211;4865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112529</ArticleId><ArticleId IdType="pubmed">10233947</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek M, Ratner L. Role of Tax-CBP interaction in HTLV-1 immortalization. J Virol. 2000;74:11,988&#8211;11,992.</Citation></Reference><Reference><Citation>Jeang K-T. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-B. Cytokine Growth Factor Rev. 2001;12:207&#8211;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325603</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JP, D&#8217;Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature. 1990;343:762&#8211;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">2154701</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe AJ, McGlade J, Pawson T, Hayman MJ. Phosphorylation of the SHC proteins on tyrosine correlates with the transformation of fibroblasts and erythroblasts by the v-sea tyrosine kinase. Oncogene. 1994;9:537&#8211;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">8290264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavala G, Pretto C, Chow YH, et al. Relevance of Akt phosphorylation in cell transformation induced by Jaagsiekte sheep retrovirus. Virology. 2003;312:95&#8211;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890624</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara T, Ratner L. Characterizataion of envelope glycoprotein mutants for HTLV-1 infectivity and immortalization. J Virol. 2001;75:9553&#8211;9559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114525</ArticleId><ArticleId IdType="pubmed">11533220</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht B, Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev. 2002;66:396&#8211;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC120794</ArticleId><ArticleId IdType="pubmed">12208996</ArticleId></ArticleIdList></Reference><Reference><Citation>Robek M, Wong F-H, Ratner L. The human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes. J Virol. 1998;72:4458&#8211;4462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109681</ArticleId><ArticleId IdType="pubmed">9557741</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins ND, D&#8217;Souza C, Albrecht B, et al. Proliferation response to interleukin-2 and Jak/Stat activation of T cells immortalized by human T-cell lymphotropic virus type 1 is independent of open reading frame I expression. J Virol. 1999;73:9642&#8211;9649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113003</ArticleId><ArticleId IdType="pubmed">10516077</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins ND, Newbound GC, Ratner L, Lairmore MD. Selective ablation of human T-cell lymphotropic virus type 1 p12-I reduces viral infectivity in vivo. Blood. 1999;91:4701&#8211;4707.</Citation><ArticleIdList><ArticleId IdType="pubmed">9616168</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht B, D&#8217;Souza CD, Ding W, Tridanapani S, Coggeshall KM, Lairmore MD. Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I) J Virol. 2002;76:3493&#8211;3501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136046</ArticleId><ArticleId IdType="pubmed">11884573</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht B, Collins ND, Burniston MT, et al. Human T-lymphotropic virus type 1 (HTLV-1) ORF I p12-I is required for efficient viral infectivity in primary lymphocytes. J Virol. 2001;74:9828&#8211;9835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102019</ArticleId><ArticleId IdType="pubmed">11024109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W, Nair SJ, Michael B, et al. Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation. J Virol. 2003;77:11,027&#8211;11,039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC225008</ArticleId><ArticleId IdType="pubmed">14512551</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuskahara T, Ratner L. Substitution of HIV-1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses. 2004;20:938&#8211;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652723</ArticleId><ArticleId IdType="pubmed">15585081</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman LR, Phipps AJ, Montgomery A, Ratner L, Lairmore MD. Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol. 2004;78:3837&#8211;3845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374265</ArticleId><ArticleId IdType="pubmed">15047799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoe JT, Albrecht B, Collins ND, et al. Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol. 2000;74:1094&#8211;1100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111443</ArticleId><ArticleId IdType="pubmed">10627519</ArticleId></ArticleIdList></Reference><Reference><Citation>Thebault S, Basbous J, Hivin P, Devaux C, Mesnard J-M. HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett. 2004;562:165&#8211;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044019</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman W, Ratner L. Transgenic mouse models for HTLV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(Suppl 1):S162&#8211;S169.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797719</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman WJ, Kimata JT, Wong F-H, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92:1057&#8211;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42636</ArticleId><ArticleId IdType="pubmed">7862633</ArticleId></ArticleIdList></Reference><Reference><Citation>Portis T, Harding JC, Ratner L. The contribution of NF kB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 (HTLV-1) tax-induced tumors. Blood. 2001;98:1200&#8211;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S, Harding J, Hess J, Ratner L. Effects of the proteasome inhibitor, PS-341, on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood. 2004;104:802&#8211;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090453</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman W, Ratner L. Cytokine expression in human T-cell leukemia virus tax transgenic leukemia. Blood. 1997;90:783&#8211;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">9226179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 Tax transgenic mice deficient in interferon gamma. Blood. 2004;104:3305&#8211;3311.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292059</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Dole K, Stanley JR, et al. Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. Leukemia Res. 2002;26:561&#8211;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007504</ArticleId></ArticleIdList></Reference><Reference><Citation>Delebecque F, Pramberger K, Prevost MC, Brahic M, Tangy F. A chimeric human T-cell lymphotropic virus type 1 with the envelope glycoprotein of Moloney murine leukemia virus is infectious for murine cells. J Virol. 2002;76:7883&#8211;7889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136376</ArticleId><ArticleId IdType="pubmed">12097602</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerrose TE, Herrbich P, Hess DA, Nolta JA. Immune-deficient mouse models for analysis of human stem cells. Bio Techniques. 2003;35:1262&#8211;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">14682062</ArticleId></ArticleIdList></Reference><Reference><Citation>Trejo S, Ratner L. The HTLV receptor is widely expressed. Virology. 2000;268:41&#8211;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683325</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, VanderHeyden N, Ratner L. Interferon-alpha-inhibits HTLV-1 assembly. J Virol. 2003;77:13,389&#8211;13,395.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">34407152</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-&#954;B signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.</ArticleTitle><Pagination><StartPage>e0256320</StartPage><MedlinePgn>e0256320</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0256320</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0256320</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) originates from human T-cell leukemia virus type 1 (HTLV-1) infection due to the activation of the nuclear factor-&#954;B (NF-&#954;B) signaling pathway to maintain proliferation and survival. An important mechanism of the activated NF-&#954;B signaling pathway in ATLL is the activation of the macroautophagy (herafter referred to as autophagy in the remainder of this manuscript)-lysosomal degradation of p47 (NSFL1C), a negative regulator of the NF-&#954;B pathway. Therefore, we considered the use of chloroquine (CQ) or hydroxychloroquine (HCQ) (CQ/HCQ) as an autophagy inhibitor to treat ATLL; these drugs were originally approved by the FDA as antimalarial drugs and have recently been used to treat autoimmune diseases, such as systemic lupus erythematosus (SLE). In this paper, we determined the therapeutic efficacy of CQ/HCQ, as NF-&#954;B inhibitors, in ATLL mediated by blockade of p47 degradation. Administration of CQ/HCQ to ATLL cell lines and primary ATLL cells induced cell growth inhibition in a dose-dependent manner, and the majority of cells underwent apoptosis after CQ administration. As to the molecular mechanism, autophagy was inhibited in CQ-treated ATLL cells, and activation of the NF-&#954;B pathway was suppressed with the restoration of the p47 level. When the antitumor effect of CQ/HCQ was examined using immunodeficient mice transplanted with ATLL cell lines, CQ/HCQ significantly suppressed tumor growth and improved the survival rate in the ATLL xenograft mouse model. Importantly, HCQ selectively induced ATLL cell death in the ATLL xenograft mouse model at the dose used to treat SLE. Taken together, our results suggest that the inhibition of autophagy by CQ/HCQ may become a novel and effective strategy for the treatment of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fauzi</LastName><ForeName>Yanuar Rahmat</ForeName><Initials>YR</Initials><Identifier Source="ORCID">0000-0002-4605-2266</Identifier><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakahata</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4944-5807</Identifier><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chilmi</LastName><ForeName>Syahrul</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0821-9117</Identifier><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Tomonaga</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nueangphuet</LastName><ForeName>Phawut</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Ryoji</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8409-8505</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tatsufumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Social Work, Faculty of Human and Social Studies, Nagasaki International University, Sasebo City, Nagasaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki City, Miyazaki Prefecture, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498751">Nsfl1c protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052067">Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002738">Chloroquine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006886">Hydroxychloroquine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061251">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D052067">Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>17</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34407152</ArticleId><ArticleId IdType="pmc">PMC8372904</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0256320</ArticleId><ArticleId IdType="pii">PONE-D-21-15148</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77: 7415&#8211;7419. doi: 10.1073/pnas.77.12.7415</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.77.12.7415</ArticleId><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross C, Thoma-Kress AK. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8: 1&#8211;22. doi: 10.3390/v8030074</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8030074</ArticleId><ArticleId IdType="pmc">PMC4810264</ArticleId><ArticleId IdType="pubmed">27005656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#231;alves DU, Proietti FA, Ribas JGR, Ara&#250;jo MG, Pinheiro SR, Guedes AC, et al.. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23: 577&#8211;589. doi: 10.1128/CMR.00063-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00063-09</ArticleId><ArticleId IdType="pmc">PMC2901658</ArticleId><ArticleId IdType="pubmed">20610824</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan: An Update. Front Microbiol. 2020;11: 1&#8211;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273189</ArticleId><ArticleId IdType="pubmed">32547527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham Charles R M, Miura Michi, Kulkarni Anurag M M. Regulation of Latency in the Human T Cell Leukemia Virus, HTLV-1. Annu Rev Virol. 2019;6: 365&#8211;385. doi: 10.1146/annurev-virology-092818-015501</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092818-015501</ArticleId><ArticleId IdType="pubmed">31283437</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene. 2003;22: 5131&#8211;5140. doi: 10.1038/sj.onc.1206551</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1206551</ArticleId><ArticleId IdType="pubmed">12910250</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A. Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2019;10: 1&#8211;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797831</ArticleId><ArticleId IdType="pubmed">31681185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Mar&#231;ais A, Nasr R, Kato K, Fukuda T, Hermine O, et al.. Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. Front Microbiol. 2020;11: 1&#8211;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7317092</ArticleId><ArticleId IdType="pubmed">32636814</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie O, Matsushima K. CCR4 and its ligands: From bench to bedside. Int Immunol. 2015;27: 11&#8211;20. doi: 10.1093/intimm/dxu079</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu079</ArticleId><ArticleId IdType="pubmed">25087232</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, et al.. Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia. Nature Publishing Group; 2012;26: 1238&#8211;1246. doi: 10.1038/leu.2011.379</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2011.379</ArticleId><ArticleId IdType="pubmed">22289924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan MZ, Takamatsu N, Hidaka T, Hatakeyama K, Nakahata S, Fujisawa J, et al.. Critical Role for TSLC1 Expression in the Growth and Organ Infiltration of Adult T-Cell Leukemia Cells In Vivo. J Virol. 2008;82: 11958&#8211;11963. doi: 10.1128/JVI.01149-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01149-08</ArticleId><ArticleId IdType="pmc">PMC2583669</ArticleId><ArticleId IdType="pubmed">18922876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki H, Nishikata I, Shiraga T, Akamatsu E, Fukami T, Hidaka T, et al.. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood. American Society of Hematology; 2005;105: 1204&#8211;1213. doi: 10.1182/blood-2004-03-1222</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-03-1222</ArticleId><ArticleId IdType="pubmed">15471956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar B, Nishikata I, Nakahata S, Ichikawa T, Shiraga T, Saha HR, et al.. Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-&#954;B. Sci Rep. 2019;9: 1&#8211;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6400899</ArticleId><ArticleId IdType="pubmed">30837480</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhang L, Joo D, Sun SC. NF-&#954;B signaling in inflammation. Signal Transduct Target Ther. 2017;2. doi: 10.1038/sigtrans.2017.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sigtrans.2017.23</ArticleId><ArticleId IdType="pmc">PMC5661633</ArticleId><ArticleId IdType="pubmed">29158945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SC, Yamaoka S. Activation of NF-&#954;B by HTLV-I and implications for cell transformation. Oncogene. 2005;24: 5952&#8211;5964. doi: 10.1038/sj.onc.1208969</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208969</ArticleId><ArticleId IdType="pubmed">16155602</ArticleId></ArticleIdList></Reference><Reference><Citation>Fochi S, Mutascio S, Bertazzoni U, Zipeto D, Romanelli MG. HTLV deregulation of the NF-&#954;B pathway: An update on tax and antisense proteins role. Front Microbiol. 2018;9: 1&#8211;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5826390</ArticleId><ArticleId IdType="pubmed">29515558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata Y, Oyama M, Kozuka-Hata H, Han X, Tanaka Y, Gohda J, et al.. P47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. Nat Commun. Nature Publishing Group; 2012;3. doi: 10.1038/ncomms2068</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2068</ArticleId><ArticleId IdType="pubmed">22990857</ArticleId></ArticleIdList></Reference><Reference><Citation>Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G, et al.. Life, death, and autophagy in cancer: NF-&#954;B turns up everywhere. Cell Death Dis. Springer US; 2020;11. doi: 10.1038/s41419-020-2399-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2399-y</ArticleId><ArticleId IdType="pmc">PMC7105474</ArticleId><ArticleId IdType="pubmed">32231206</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA / CDER. Plaquenil &#174; Hydroxychloroquine Sulfate Tablets, USP Description. Fda. 2017;</Citation></Reference><Reference><Citation>Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al.. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. Taylor &amp; Francis; 2018;14: 1435&#8211;1455. doi: 10.1080/15548627.2018.1474314</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1474314</ArticleId><ArticleId IdType="pmc">PMC6103682</ArticleId><ArticleId IdType="pubmed">29940786</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Tatsufumi; Tsujihata Mitsuhiro; Shirabe Susumu; Matsuo Hidenori; Ueki Yukitaka; Nagataki S. Characterization of HTLV-I in a T-Cell Line Established From a Patient With Myelopathy. Arch Neurol. 1989;46: 35&#8211;37. doi: 10.1001/archneur.1989.00520370037015</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520370037015</ArticleId><ArticleId IdType="pubmed">2642698</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima Naomi; Nakamura Tatsufumi; Nishiura Yoshihiro; Ida Hiroaki; Aramaki Toshiyuki; Eguchi K. HTLV-I Production Based on Activation of Integrin/Ligand Signaling in HTLV-I-Infected T Cell Lines Derived from HAM/TSP Patients. Intervirology. 2008;51: 123&#8211;129. doi: 10.1159/000139130</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000139130</ArticleId><ArticleId IdType="pubmed">18552504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimosaki S, Nakahata S, Ichikawa T, Kitanaka A, Kameda T, Hidaka T, et al.. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochem Biophys Res Commun. Elsevier Ltd; 2017;485: 144&#8211;151. doi: 10.1016/j.bbrc.2017.02.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.02.039</ArticleId><ArticleId IdType="pubmed">28189691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakhter AJ, Sahu RP, Sun Y, Kaufmann WK, Androphy EJ, Travers JB, et al.. Chloroquine promotes apoptosis in melanoma cells by inhibiting BH3 domain-mediated PUMA degradation. J Invest Dermatol. Elsevier Masson SAS; 2013;133: 2247&#8211;2254. doi: 10.1038/jid.2013.56</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jid.2013.56</ArticleId><ArticleId IdType="pmc">PMC3675185</ArticleId><ArticleId IdType="pubmed">23370537</ArticleId></ArticleIdList></Reference><Reference><Citation>Molejon MI, Swayden M, Fanale D, Bintz J, Gayet O, Soubeyran P, et al.. Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma. Oncotarget. 2018;9: 30837&#8211;30846. doi: 10.18632/oncotarget.25745</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25745</ArticleId><ArticleId IdType="pmc">PMC6089401</ArticleId><ArticleId IdType="pubmed">30112111</ArticleId></ArticleIdList></Reference><Reference><Citation>Masud Alam M, Kariya R, Kawaguchi A, Matsuda K, Kudo E, Okada S. Inhibition of autophagy by chloroquine induces apoptosis in primary effusion lymphoma in vitro and in vivo through induction of endoplasmic reticulum stress. Apoptosis. Springer US; 2016;21: 1191&#8211;1201. doi: 10.1007/s10495-016-1277-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-016-1277-7</ArticleId><ArticleId IdType="pubmed">27484211</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffer PJ, et al.. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Cell Death Dis. Nature Publishing Group; 2017;8: e2927. doi: 10.1038/cddis.2017.317</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.317</ArticleId><ArticleId IdType="pmc">PMC5550863</ArticleId><ArticleId IdType="pubmed">28703806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, et al.. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine. Autophagy. Taylor &amp; Francis; 2017;13: 955&#8211;966. doi: 10.1080/15548627.2017.1287652</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2017.1287652</ArticleId><ArticleId IdType="pmc">PMC5446057</ArticleId><ArticleId IdType="pubmed">28282266</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandia Rekha, Dadar Maryam, Munjal Ashok, Dhama Kuldeep, Karthik Kumaragurubaran Tiwari Ruchi, Yatoo Mohd. Iqbal, et al.. Various Roles in Infectious, Non-Infectious, and Lifestyle Diseases: Current Knowledge and Prospects for Disease Prevention, Novel Drug. Cells. 2019. p. 674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6678135</ArticleId><ArticleId IdType="pubmed">31277291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahedi S, Fitzwalter BE, Morin A, Grob S, Desmarais M, Nellan A, et al.. Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. Cell Death and Disease. 2019. doi: 10.1038/s41419-019-1880-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1880-y</ArticleId><ArticleId IdType="pmc">PMC6742667</ArticleId><ArticleId IdType="pubmed">31515514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy prevents bortezomib-induced NF-&#954;B activation by reducing I-&#954;B&#945; degradation in lymphoma cells. PLoS ONE. 2012. doi: 10.1371/journal.pone.0032584</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032584</ArticleId><ArticleId IdType="pmc">PMC3290566</ArticleId><ArticleId IdType="pubmed">22393418</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez Gricelis P., Zabaleta Mercedes E., Di Giulio Camilo C JE and M MR. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Curr Pharm Des. 2020;26: 4467&#8211;4485. doi: 10.2174/1381612826666200707132920</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612826666200707132920</ArticleId><ArticleId IdType="pubmed">32634079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokura Yoshiki, Sawada Yu S T. Skin manifestations of adult T-cell leukemia/lymphoma: Clinical, cytological and immunological features. Journal of Dermatology; 2014. pp. 19&#8211;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">24438140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Yu, Shimauchi Takatoshi, Yamaguchi Takashi, Okura Risa, Hama-Yamamoto Kayo, Fueki-Yoshioka Haruna, et al.. Combination of skin directed therapy and oral etoposide for smoldering adult T cell leukemia lymphoma with skin involvement.pdf. Leukemia &amp; Lymphoma; 2013. pp. 520&#8211;527. doi: 10.3109/10428194.2012.715351</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2012.715351</ArticleId><ArticleId IdType="pubmed">22830614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30171618</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1069</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Hematological oncology</Title><ISOAbbreviation>Hematol Oncol</ISOAbbreviation></Journal><ArticleTitle>The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>61</EndPage><MedlinePgn>54-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hon.2558</ELocationID><Abstract><AbstractText>Treatment options for patients with adult T cell leukemia/lymphoma (ATLL) who have relapsed disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. To clarify which patients with ATLL are likely to benefit from these treatment options and to define patient populations for novel treatments, we performed a nationwide retrospective analysis of 252 Japanese patients who had relapsed ATLL after allo-HSCT. Some long-term survivors remained after tapering and withdrawal of immunosuppressive agents. Thirty-six patients who received donor lymphocyte infusion had a better overall survival (OS) in comparison to those who did not [hazard ratio (HR), 0.63; 95% confidence interval (CI), 0.43-0.93; P&#160;=&#160;.02], suggesting the efficacy of a graft-versus-ATLL (GvATLL) effect even after relapse. Multivariate analysis demonstrated that skin lesions at initial relapse of ATLL were independently associated with higher OS (HR, 0.41; 95% CI, 0.22-0.74; P&#160;=&#160;.003), indicating that the skin is a susceptible target organ of GvATLL. This study suggested that enhancement of a GvATLL effect is a potential therapeutic option for relapsed disease after allo-HSCT. Further investigations of incorporation of immune-based approaches with new molecular target drugs into the therapeutic options of patients with ATLL before and after transplantation are warranted.</AbstractText><CopyrightInformation>&#169; 2018 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5815-4585</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uike</LastName><ForeName>Naokuni</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wake</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobai</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawayama</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takatsuka</LastName><ForeName>Yoshifusa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eto</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Tadakazu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Kyoto University Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamae</LastName><ForeName>Hirohisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichinohe</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Ritsuro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of HSCT Data Management/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>15Ack0106136h0002</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hematol Oncol</MedlineTA><NlmUniqueID>8307268</NlmUniqueID><ISSNLinking>0278-0232</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019172">Transplantation Conditioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">DLI</Keyword><Keyword MajorTopicYN="N">allo-HSCT</Keyword><Keyword MajorTopicYN="N">graft-versus-ATLL</Keyword><Keyword MajorTopicYN="N">relapse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30171618</ArticleId><ArticleId IdType="doi">10.1002/hon.2558</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23947237</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-5384</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine</Title><ISOAbbreviation>Nihon Naika Gakkai Zasshi</ISOAbbreviation></Journal><ArticleTitle>[Leukemia: recent progress in diagnosis and treatment. Topics: IV. Recent topics; 1. Novel antibody therapy targeting CCR4 for adult T-cell leukemia/lymphoma].</ArticleTitle><Pagination><StartPage>1744</StartPage><EndPage>1750</EndPage><MedlinePgn>1744-50</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology &amp; Immunology, Nagoya City University Graduate School of Medical Sciences, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Naika Gakkai Zasshi</MedlineTA><NlmUniqueID>19130210R</NlmUniqueID><ISSNLinking>0021-5384</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23947237</ArticleId><ArticleId IdType="doi">10.2169/naika.102.1744</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32656636</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>496</StartPage><EndPage>503</EndPage><MedlinePgn>496-503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-020-02939-1</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a highly invasive and refractory T-cell malignancy, with poor prognosis. We previously identified that cell adhesion molecule 1 (CADM1) is overexpressed consistently in ATLL cells, and that CADM1 expression increases the adhesion capacity of ATLL cells to endothelial cells and promotes the organ invasion of ATLL cells in a xenograft mouse model. In this study, we first show that newly developed several anti-human CADM1 antibodies, which were complete human IgG antibodies generated by phage display method, specifically recognize CADM1 on ATLL cells. Although most of the CADM1 antibodies did not have a direct cytotoxic effect against CADM1-positive ATLL cells, clone 089-084 exhibited weak but significant antibody-dependent cell-mediated cytotoxic activity. Moreover, clone 103-189 effectively inhibits the interaction between endothelial cells and CADM1-positive ATLL cells. Furthermore, in mice bearing intra-splenic transplantation of EL4 mouse lymphoma cells expressing CADM1, the treatment of 103-189 significantly suppressed the organ invasion of CADM1-positive EL4 cells, resulting in improved survival time of mice. Therefore, since the anti-CADM1 antibody may be useful for the suppression of organ invasion in ATLL patients, combination use of the anti-CADM1 antibody with chemotherapy drugs could be beneficial for the efficient elimination of ATLL cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chilmi</LastName><ForeName>Syahrul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakahata</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauzi</LastName><ForeName>Yanuar Rahmat</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Tomonaga</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Chikako</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwanruengsri</LastName><ForeName>Mathurot</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen-kibanadai-nishi-1-1, Miyazaki, 889-2192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Ryoji</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Gakuen-kibanadai-nishi-1-1, Miyazaki, 889-2192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Tadashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Perseus Proteomics Inc., 4-7-6, Komaba Meguro-ku, Tokyo, 153-0041, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosawa</LastName><ForeName>Gene</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Innovation Center for Advanced Medicine, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. kmorishi@med.miyazaki-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>25293081</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><GrantID>17H03581</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><GrantID>18fk0108027h0003</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C403514">CADM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075982">Cell Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000920">Antibody-Dependent Cell Cytotoxicity</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000075982">Cell Adhesion Molecule-1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061505">Cell Surface Display Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000076722">Drug Development</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061307">Human Umbilical Vein Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Anti-cell adhesion molecule 1 antibody</Keyword><Keyword MajorTopicYN="N">Invasion</Keyword><Keyword MajorTopicYN="N">Phage display</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32656636</ArticleId><ArticleId IdType="doi">10.1007/s12185-020-02939-1</ArticleId><ArticleId IdType="pii">10.1007/s12185-020-02939-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32157421</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0584</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of hematology</Title><ISOAbbreviation>Ann Hematol</ISOAbbreviation></Journal><ArticleTitle>Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>1093</StartPage><EndPage>1098</EndPage><MedlinePgn>1093-1098</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00277-020-03967-x</ELocationID><Abstract><AbstractText>Acute or lymphomatous type adult T cell leukemia/lymphoma (ATLL) is an aggressive hematopoietic malignancy with poor prognosis. We previously reported that programmed cell death ligand 1 (PD-L1) expression could predict ATLL outcomes. However, the roles of other immune checkpoint molecules remain largely unknown in ATLL. Our aim in this study was to explore the clinicopathological impacts of immune checkpoint molecules in ATLL. Immunohistochemistry was performed in 69 ATLL patients with antibodies against the following: PD-L1, programmed cell death ligand 2 (PD-L2), OX40, OX40 ligand (OX40L), CD137, CD137 ligand (CD137L), Galectin-9, T cell immunoglobulin mucin-3 (Tim-3), cytotoxic T lymphocyte associated protein-4 (CTLA-4), lymphocyte activating-3 (LAG-3), CD80, CD86, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), GITR ligand (GITRL), and programmed death-1 (PD-1). Immune checkpoint molecules were variably expressed on neoplastic and/or microenvironmental cells. Expression of PD-1, OX40L, Galectin-9, and PD-L1 was nearly mutually exclusive on neoplastic cells, suggesting that immune checkpoint pathways differ in patients. Microenvironmental expression of PD-L1, OX40L, and Tim-3 was significantly associated with better overall survival (log-rank test; P&#8201;=0.0004, 0.0394, and 0.0279, respectively). Univariate and multivariate analyses with clinical prognostic factors identified microenvironmental expression of PD-L1 and OX40L, and age (&gt;&#8201;70&#160;years) as significant prognostic factors. This is the first comprehensive analysis of ATLL immune checkpoint molecules. Our results may provide information on new therapeutic strategies in ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2356-3725</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan. miyoshi_hiroaki@med.kurume-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Kazutaka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamoto</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, 951-8520, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kyohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanagida</LastName><ForeName>Eriko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muta</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritsubo</LastName><ForeName>Mayuko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umeno</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Takaharu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, 951-8520, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seto</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Asahimachi 67, Kurume, Fukuoka, 830-0011, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP26460446</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><GrantID>JP17K17894</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><GrantID>15ck0106015h0002</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Hematol</MedlineTA><NlmUniqueID>9107334</NlmUniqueID><ISSNLinking>0939-5555</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T cell</Keyword><Keyword MajorTopicYN="N">Immune evasion</Keyword><Keyword MajorTopicYN="N">Immunohistochemistry</Keyword><Keyword MajorTopicYN="N">Leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">OX40 ligand</Keyword><Keyword MajorTopicYN="N">Programmed cell death 1 receptor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32157421</ArticleId><ArticleId IdType="doi">10.1007/s00277-020-03967-x</ArticleId><ArticleId IdType="pii">10.1007/s00277-020-03967-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ohshima K, Jaffe E, Yoshino T, Siebert R (2017) Adult T-cell leukemia/lymphoma. In: Swerdlow SH, campo CE, Harris NL, et al., editors. World Health Organization classification of tumours. Revised 4th edn. IARC press, Lyon, pp 363&#8211;367</Citation></Reference><Reference><Citation>Shimoyama M (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia&#8211;lymphoma. A report from the lymphoma study group (1984&#8211;87). Br J Haematol 79:428&#8211;437. https://doi.org/10.1111/j.1365-2141.1991.tb08051.x</Citation></Reference><Reference><Citation>Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, Kato K, Imaizumi Y, Seto M, Ohshima K (2016) PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 128:1374&#8211;1381. https://doi.org/10.1182/blood-2016-02-698936</Citation></Reference><Reference><Citation>Hodi FS, O&#8217;Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711&#8211;723. https://doi.org/10.1056/NEJMoa1003466</Citation></Reference><Reference><Citation>Pennnock GK, Chow LQM (2015) The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 20:812&#8211;822. https://doi.org/10.1634/theoncologist.2014-0422</Citation></Reference><Reference><Citation>Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A (2016) Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 52:50&#8211;66. https://doi.org/10.1016/j.ejca.2015.08.021</Citation></Reference><Reference><Citation>Croft M, So T, Soroosh P (2009) The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 229:173&#8211;191. https://doi.org/10.1111/j.1600-065x.2009.00766.x</Citation></Reference><Reference><Citation>Liu K, Ye H, Zhou J et al (2018) OX40 regulates the conversion and suppressive function of double-negative regulatory T-cells. Int Immunopharmacol 65:16&#8211;22. https://doi.org/10.1016/j.intimp.2018.09.035</Citation></Reference><Reference><Citation>Omar HA, Tolba MF (2019) Tackling molecular targets beyond PD-1/PD-L1: novel approaches to boost patient&#8217;s response to cancer immunotherapy. Crit Rev Oncol Hematol 135:21&#8211;29. https://doi.org/10.1016/j.critrevonc.2019.01.009</Citation></Reference><Reference><Citation>Chou FC, Chen HY, Kuo CC et al (2018) Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci 19:E430. https://doi.org/10.3390/ijms19020430</Citation></Reference><Reference><Citation>Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 44:989&#8211;1004. https://doi.org/10.1016/j.immuni.2016.05.001</Citation></Reference><Reference><Citation>Anderson AC (2012) Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 24:213&#8211;216. https://doi.org/10.1016/j.coi.2011.12.005</Citation></Reference><Reference><Citation>Das M, Zhu C, Kuchroo VK (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 276:97&#8211;111. https://doi.org/10.1111/imr.12520</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16247419</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0268-3369</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2006</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.</ArticleTitle><Pagination><StartPage>41</StartPage><EndPage>44</EndPage><MedlinePgn>41-4</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukaemia/lymphoma (ATLL) is a highly aggressive haematological malignancy. More than 40 cases of ATLL treated by allogeneic bone marrow transplantation (BMT) from sibling donors have been reported, while there have been only a few cases of unrelated BMT for treatment of this disease. We began performing allogeneic BMT from unrelated donors in 1999 to improve the outcome of ATLL patients with no suitable sibling donors. Eight ATLL patients underwent unrelated BMT; five received the conventional conditioning regimen consisting of cyclophosphamide and total body irradiation, while three received a reduced-intensity preparative regimen. Two patients died due to encephalopathy of unknown aetiology on days 10 and 35, and one patient died due to progression of ATLL 25 months after BMT. Five patients are currently alive and disease-free at a median of 20 months after BMT. Proviral human T-lymphotropic virus type-I (HTLV-I) DNA load in peripheral blood mononuclear cells (PBMCs) was assessed in four cases before and after BMT. HTLV-I proviral DNA load was reduced significantly after transplantation. Unrelated BMT is feasible for treatment of ATLL. Further studies in a larger number of cases are required to determine the optimal conditioning regimen and stem cell source.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakase</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama City, Ehime, Japan. nakase.koichi@nifty.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kozuka</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tanimoto</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nawa</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019653">Myeloablative Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016026">Bone Marrow Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006650">Histocompatibility Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D019520">Living Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019653">Myeloablative Agonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D019172">Transplantation Conditioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014916">Whole-Body Irradiation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16247419</ArticleId><ArticleId IdType="doi">10.1038/sj.bmt.1705197</ArticleId><ArticleId IdType="pii">1705197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11500618</PMID><DateCompleted><Year>2001</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0192-0790</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of clinical gastroenterology</Title><ISOAbbreviation>J Clin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Clinical and endoscopic features of adult T-cell leukemia/lymphoma with duodenal involvement.</ArticleTitle><Pagination><StartPage>241</StartPage><EndPage>246</EndPage><MedlinePgn>241-6</MedlinePgn></Pagination><Abstract><AbstractText>We describe three cases of adult T-cell leukemia/lymphoma (ATLL) with duodenal involvement and provide a review of the literature. The first case, a 74-year-old woman with acute subtype of ATLL, had multiple polypoid lesions from the bulbus extending into the descending portion of the duodenum. The second case, a 70-year-old man with lymphoma subtype of ATLL, had a polypoid tumor in the descending portion of the duodenum and multiple protruded lesions in the small and large intestines. The third case, a 67-year-old man with lymphoma subtype of ATLL, had a flat-elevated lesion in the descending portion of the duodenum, as well as a gastric ulcerated lesion. Biopsies from these lesions showed mucosal invasion of ATLL cells in each case. All patients received combination chemotherapy, which was successful in the first and third cases, accompanied by the disappearance of gastroduodenal lesions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Isomoto</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Second Department of Internal Medicine, Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan. hhisomot@net.nagasaki-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohnita</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mizuta</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Onizuka</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Omagari</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Takeshima</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Murase</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Haraguchi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kohno</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Gastroenterol</MedlineTA><NlmUniqueID>7910017</NlmUniqueID><ISSNLinking>0192-0790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004379">Duodenal Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016099">Endoscopy, Gastrointestinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007414">Intestinal Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>9</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11500618</ArticleId><ArticleId IdType="doi">10.1097/00004836-200109000-00017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18027201</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0883-0185</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>5-6</Issue><PubDate><Year>2007</Year><Season>Sep-Dec</Season></PubDate></JournalIssue><Title>International reviews of immunology</Title><ISOAbbreviation>Int Rev Immunol</ISOAbbreviation></Journal><ArticleTitle>NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>269</StartPage><EndPage>281</EndPage><MedlinePgn>269-81</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) induces aberrant nuclear factor-kappaB (NF-kappaB) activation. Although Tax is thought to play major roles in NF-kappaB activation, cells expressing Tax become a target of cytotoxic T cells. Accordingly, HTLV-1-infected cells lose Tax expression and acquire Tax-independent NF-kappaB activation. Blocking NF-kappaB not only induces apoptosis in adult T-cell leukemia/lymphoma (ATL) cells but also reduces the number of HTLV-1-infected cells in virus carriers. Therefore, because constitutively activated NF-kappaB appears to be the common biological basis shared between HTLV-1-infected untransformed cells and ATL cells, blocking NF-kappaB might be a potential strategy for treating and preventing ATL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horie</LastName><ForeName>Ryouichi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology, School of Medicine, Kitasato University, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. rhorie@med.kitasato-u.ac.jp</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Rev Immunol</MedlineTA><NlmUniqueID>8712260</NlmUniqueID><ISSNLinking>0883-0185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18027201</ArticleId><ArticleId IdType="doi">10.1080/08830180701703364</ArticleId><ArticleId IdType="pii">785374287</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30541986</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1880-9952</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>4</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Journal of clinical and experimental hematopathology : JCEH</Title><ISOAbbreviation>J Clin Exp Hematop</ISOAbbreviation></Journal><ArticleTitle>Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>160</EndPage><MedlinePgn>152-160</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3960/jslrt.18034</ELocationID><Abstract><AbstractText>The c-fms proto-oncogene is also known as macrophage colony stimulating factor receptor (M-CSFR) or colony-stimulating factor-1 receptor (CSF-1R), and is expressed on several types of malignant tumor cells and myeloid cells. In the present study, we found that overexpression of M-CSFR was present in adult T-cell leukemia/lymphoma (ATLL) cases. M-CSFR signaling was associated with lymphoma cell proliferation, and M-CSFR inhibition induced apoptosis in lymphoma cells. The ATLL cell line ATL-T expressed M-CSF/CSF-1 and interleukin (IL)-34, which are both M-CSFR ligands. M-CSF and IL-34 expression was seen in ATLL cases, and co-expression of these ligands was detected in 11 of 13 ATLL cases. M-CSFR inhibition suppressed programmed death-1 and -2 ligand in ATL-T cells and macrophages stimulated with conditioned medium from ATL-T cells. Thus, an M-CSFR inhibitor may be useful as additional therapy against ATLL due to direct and indirect mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Komohara</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Noyori</LastName><ForeName>Osamu</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Takeya</LastName><ForeName>Hiroto</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Baghdadi</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kitagawa</LastName><ForeName>Fumihito</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hama</LastName><ForeName>Naoki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Kozo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Okuno</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Kisato</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Seino</LastName><ForeName>Ken-Ichiro</ForeName><Initials>KI</Initials></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suzu</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Clin Exp Hematop</MedlineTA><NlmUniqueID>101141257</NlmUniqueID><ISSNLinking>1346-4280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000715470">MAS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090063">Proto-Oncogene Mas</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D016186">Receptor, Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060890">B7-H1 Antigen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000090063">Proto-Oncogene Mas</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016186">Receptor, Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">CSF-1R</Keyword><Keyword MajorTopicYN="N">M-CSFR</Keyword><Keyword MajorTopicYN="N">PD-L1</Keyword><Keyword MajorTopicYN="N">macrophage</Keyword></KeywordList><CoiStatement><b>CONFLICT OF INTEREST:</b> None of the authors have any conflicts of interest in association with this
manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30541986</ArticleId><ArticleId IdType="pmc">PMC6407477</ArticleId><ArticleId IdType="doi">10.3960/jslrt.18034</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol. 1991; 79: 428-437. 10.1111/j.1365-2141.1991.tb08051.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. ATL-Prognostic Index Project . Treatment and survival among 1594 patients with ATL. Blood. 2015; 126: 2570-2577. 10.1182/blood-2015-03-632489</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata K, Yamada Y. The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL. Int Rev Immunol. 2007; 26: 249-268. 10.1080/08830180701709817</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830180701709817</ArticleId><ArticleId IdType="pubmed">18027200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012; 119: 1810-1820. 10.1182/blood-2011-09-379214</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-09-379214</ArticleId><ArticleId IdType="pubmed">22186992</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghdadi M, Umeyama Y, Hama N, et al. Interleukin-34, a comprehensive review. J Leukoc Biol. 2018; 104: 931-951. 10.1002/JLB.MR1117-457R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.MR1117-457R</ArticleId><ArticleId IdType="pubmed">30066957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008; 320: 807-811. 10.1126/science.1154370</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154370</ArticleId><ArticleId IdType="pubmed">18467591</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Petitbarat M, Dubanchet S, et al. Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. J Reprod Immunol. 2015; 109: 1-6. 10.1016/j.jri.2015.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2015.01.005</ArticleId><ArticleId IdType="pubmed">25721620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kascinski B. Expression of CSF-1 and its receptor CSF-1R in non-hematopoietic neoplasms. Cancer Treat Res. 2002; 107: 285-292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11775455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries CH, Hoves S, Cannarile MA, R&#252;ttinger D. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol. 2015; 23: 45-51. 10.1016/j.coph.2015.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2015.05.008</ArticleId><ArticleId IdType="pubmed">26051995</ArticleId></ArticleIdList></Reference><Reference><Citation>Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol. 2014; 5: 489. 10.3389/fimmu.2014.00489</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00489</ArticleId><ArticleId IdType="pmc">PMC4188035</ArticleId><ArticleId IdType="pubmed">25339957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills K. Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Front Biosci. 2008; Volume: 4605-4616. 10.2741/3026</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3026</ArticleId><ArticleId IdType="pubmed">18508532</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruss HJ, Brach MA, Drexler HG, et al. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 1992; 52: 3353-3360.</Citation><ArticleIdList><ArticleId IdType="pubmed">1596893</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappa B ligand on adult T-cell leukemia cells. Blood. 2002; 99: 634-640. 10.1182/blood.V99.2.634</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.2.634</ArticleId><ArticleId IdType="pubmed">11781248</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Gamal MI, Anbar HS, Yoo KH, Oh CH. FMS Kinase Inhibitors: Current Status and Future Prospects. Med Res Rev. 2013; 33: 599-636. 10.1002/med.21258</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21258</ArticleId><ArticleId IdType="pubmed">22434539</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CJ, Wilks AF. c-FMS inhibitors: a patent review. Expert Opin Ther Pat. 2011;21:147-165.</Citation><ArticleIdList><ArticleId IdType="pubmed">21204725</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowski N, Colman H, De Groot JF, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncol. 2016; 18: 557-564. 10.1093/neuonc/nov245</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nov245</ArticleId><ArticleId IdType="pmc">PMC4799682</ArticleId><ArticleId IdType="pubmed">26449250</ArticleId></ArticleIdList></Reference><Reference><Citation>DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1: 54-67. 10.1158/2159-8274.CD-10-0028</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8274.CD-10-0028</ArticleId><ArticleId IdType="pmc">PMC3203524</ArticleId><ArticleId IdType="pubmed">22039576</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammeijer F, Lievense LA, Kaijen-Lambers ME, et al. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunol Res. 2017; 5: 535-546. 10.1158/2326-6066.CIR-16-0309</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0309</ArticleId><ArticleId IdType="pubmed">28536100</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafford JH, Hirai T, Deng L, et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro-oncol. 2016; 18: 797-806. 10.1093/neuonc/nov272</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nov272</ArticleId><ArticleId IdType="pmc">PMC4864255</ArticleId><ArticleId IdType="pubmed">26538619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T, Ohnishi K, Kosaki Y, et al. Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop. 2017; 57: 31-36. 10.3960/jslrt.17017</Citation><ArticleIdList><ArticleId IdType="doi">10.3960/jslrt.17017</ArticleId><ArticleId IdType="pmc">PMC6144271</ArticleId><ArticleId IdType="pubmed">28679964</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghdadi M, Endo H, Takano A, et al. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep. 2018; 8: 418. 10.1038/s41598-017-18796-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-18796-8</ArticleId><ArticleId IdType="pmc">PMC5765132</ArticleId><ArticleId IdType="pubmed">29323162</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005; 24: 6047-6057. 10.1038/sj.onc.1208979</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208979</ArticleId><ArticleId IdType="pubmed">16155611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chihara T, Suzu S, Hassan R, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010; 17: 1917-1927. 10.1038/cdd.2010.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2010.60</ArticleId><ArticleId IdType="pubmed">20489731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hide T, Komohara Y, Miyasato Y, et al. Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. EBioMedicine. 2018; 30: 94-104. 10.1016/j.ebiom.2018.02.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.02.024</ArticleId><ArticleId IdType="pmc">PMC5952226</ArticleId><ArticleId IdType="pubmed">29559295</ArticleId></ArticleIdList></Reference><Reference><Citation>Takaishi K, Komohara Y, Tashiro H, et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010; 101: 2128-2136. 10.1111/j.1349-7006.2010.01652.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2010.01652.x</ArticleId><ArticleId IdType="pubmed">20860602</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci. 2011; 102: 206-211. 10.1111/j.1349-7006.2010.01772.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2010.01772.x</ArticleId><ArticleId IdType="pubmed">21073634</ArticleId></ArticleIdList></Reference><Reference><Citation>Horlad H, Ma C, Yano H, et al. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci. 2016; 107: 1696-1704. 10.1111/cas.13065</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13065</ArticleId><ArticleId IdType="pmc">PMC5132271</ArticleId><ArticleId IdType="pubmed">27564404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J, Cheung J, Navarro A, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017; 8: 14572. 10.1038/ncomms14572</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14572</ArticleId><ArticleId IdType="pmc">PMC5321797</ArticleId><ArticleId IdType="pubmed">28220772</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K. Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. J Clin Exp Hematop. 2017; 57: 87-97. 10.3960/jslrt.17008</Citation><ArticleIdList><ArticleId IdType="doi">10.3960/jslrt.17008</ArticleId><ArticleId IdType="pmc">PMC6144188</ArticleId><ArticleId IdType="pubmed">28592744</ArticleId></ArticleIdList></Reference><Reference><Citation>Komohara Y, Niino D, Saito Y, et al. Clinical significance of CD163 + tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 2013; 104: 945-951. 10.1111/cas.12167</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12167</ArticleId><ArticleId IdType="pmc">PMC7657152</ArticleId><ArticleId IdType="pubmed">23557330</ArticleId></ArticleIdList></Reference><Reference><Citation>Horlad H, Ohnishi K, Ma C, et al. TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma. Oncol Lett. 2016; 12: 1519-1524. 10.3892/ol.2016.4774</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2016.4774</ArticleId><ArticleId IdType="pmc">PMC4950894</ArticleId><ArticleId IdType="pubmed">27446463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008; 320: 807-811. 10.1126/science.1154370</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154370</ArticleId><ArticleId IdType="pubmed">18467591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou RP, Wu XS, Xie YY, et al. Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology. 2016; 149: 362-373. 10.1111/imm.12660</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12660</ArticleId><ArticleId IdType="pmc">PMC5095491</ArticleId><ArticleId IdType="pubmed">27550090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, Gokhan &#350;, Nandi S, Mehler MF, Stanley ER. Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System. Trends Neurosci. 2016; 39: 378-393. 10.1016/j.tins.2016.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.03.005</ArticleId><ArticleId IdType="pmc">PMC4884457</ArticleId><ArticleId IdType="pubmed">27083478</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang EJ, Lee SK, Song YS, et al. IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab. 2014; 99: E1263-E1271. 10.1210/jc.2013-4409</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2013-4409</ArticleId><ArticleId IdType="pubmed">24712570</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#233;galiny AI, Mohamadi A, Dizier B, et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015; 137: 73-85. 10.1002/ijc.29376</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29376</ArticleId><ArticleId IdType="pubmed">25471534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zins K, Heller G, Mayerhofer M, Schreiber M, Abraham D. Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes. Oncotarget. 2018; 9: 23126-23148. 10.18632/oncotarget.25226</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25226</ArticleId><ArticleId IdType="pmc">PMC5955405</ArticleId><ArticleId IdType="pubmed">29796177</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz&#232; E, Dinallo V, Rizzo A, et al. Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue. Oncotarget. 2017; 9: 3432-3445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790474</ArticleId><ArticleId IdType="pubmed">29423057</ArticleId></ArticleIdList></Reference><Reference><Citation>Giricz O, Mo Y, Dahlman KB, et al. The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight. 2018; 3: e120422; Epub ahead of print. 10.1172/jci.insight.120422</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.120422</ArticleId><ArticleId IdType="pmc">PMC6124424</ArticleId><ArticleId IdType="pubmed">30046005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#8217;s lymphoma. N Engl J Med. 2015; 372: 311-319. 10.1056/NEJMoa1411087</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1411087</ArticleId><ArticleId IdType="pmc">PMC4348009</ArticleId><ArticleId IdType="pubmed">25482239</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016; 128: 1374-1381. 10.1182/blood-2016-02-698936</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-02-698936</ArticleId><ArticleId IdType="pubmed">27418641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Horlad H, Pan C, et al. Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. J Clin Exp Hematop. 2017; 57: 21-25. 10.3960/jslrt.17006</Citation><ArticleIdList><ArticleId IdType="doi">10.3960/jslrt.17006</ArticleId><ArticleId IdType="pmc">PMC6144272</ArticleId><ArticleId IdType="pubmed">28496056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3&#8242;-UTR disruption in multiple cancers. Nature. 2016; 534: 402-406. 10.1038/nature18294</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18294</ArticleId><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12481881</PMID><DateCompleted><Year>2003</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-2977</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Netherlands journal of medicine</Title><ISOAbbreviation>Neth J Med</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukaemia and lymphoma: report of two cases and a brief review of the literature.</ArticleTitle><Pagination><StartPage>330</StartPage><EndPage>333</EndPage><MedlinePgn>330-3</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell lymphotropic virus type 1 (HTLV-1) can cause adult T-cell leukaemia/lymphoma (ATLL). Two patients originating from the Caribbean area with ATLL are described. The first patient developed respiratory insufficiency due to acute T-cell leukaemia. The diagnosis was suspected because of characteristics of abnormal lymphocytes in the blood smear. The second patient had lymphadenopathy and developed severe hypercalcaemia. Both patients were typical cases of ATLL. The pathogenesis, clinical manifestations, pitfalls and treatment of this intriguing disease are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Zaanen</LastName><ForeName>H C T</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Sint Franciscus Gasthuis, Kleiweg 500, 3045 PM Rotterdam, The Netherlands. h_van_zaanen@franciscus.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegels</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Neth J Med</MedlineTA><NlmUniqueID>0356133</NlmUniqueID><ISSNLinking>0300-2977</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>17</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>12</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>1</Month><Day>11</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>12</Month><Day>17</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12481881</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32859220</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1742-4690</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Retrovirology</Title><ISOAbbreviation>Retrovirology</ISOAbbreviation></Journal><ArticleTitle>Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.</ArticleTitle><Pagination><StartPage>27</StartPage><MedlinePgn>27</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">27</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12977-020-00535-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adult T-cell leukemia lymphoma (ATLL) is a chemotherapy-resistant malignancy with a median survival of less than one year that will afflict between one hundred thousand and one million individuals worldwide who are currently infected with human T-cell leukemia virus type 1. Recurrent somatic mutations in host genes have exposed the T-cell receptor pathway through nuclear factor &#954;B to interferon regulatory factor 4 (IRF4) as an essential driver for this malignancy. We sought to determine if IRF4 represents a therapeutic target for ATLL and to identify downstream effectors and biomarkers of IRF4 signaling in vivo.</AbstractText><AbstractText Label="RESULTS">ATLL cell lines, particularly Tax viral oncoprotein-negative cell lines, that most closely resemble ATLL in humans, were sensitive to dose- and time-dependent inhibition by a next-generation class of IRF4 antisense oligonucleotides (ASOs) that employ constrained ethyl residues that mediate RNase H-dependent RNA degradation. ATLL cell lines were also sensitive to lenalidomide, which repressed IRF4 expression. Both ASOs and lenalidomide inhibited ATLL proliferation in vitro and in vivo. To identify biomarkers of IRF4-mediated CD4&#8201;+&#8201;T-cell expansion in vivo, transcriptomic analysis identified several genes that encode key regulators of ATLL, including interleukin 2 receptor subunits &#945; and &#946;, KIT ligand, cytotoxic T-lymphocyte-associated protein 4, and thymocyte selection-associated high mobility group protein TOX 2.</AbstractText><AbstractText Label="CONCLUSIONS">These data support the pursuit of IRF4 as a therapeutic target in ATLL with the use of either ASOs or lenalidomide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rauch</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8069, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Sydney L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8069, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harding</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8069, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundaramoorthi</LastName><ForeName>Hemalatha</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8069, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Youngsoo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Tianyuan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLeod</LastName><ForeName>A Robert</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Challen</LastName><ForeName>Grant</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8069, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Lee</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2744-7294</Identifier><AffiliationInfo><Affiliation>Division of Oncology, Department of Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8069, St Louis, MO, 63110, USA. lratner@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA063417</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 CA171963</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA026652</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA100730</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA234640</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Retrovirology</MedlineTA><NlmUniqueID>101216893</NlmUniqueID><ISSNLinking>1742-4690</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013873">Thionucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094531">interferon regulatory factor-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="D000077269">Lenalidomide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050835">Interferon Regulatory Factors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077269">Lenalidomide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016376">Oligonucleotides, Antisense</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013873">Thionucleotides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASO</Keyword><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">IRF4</Keyword><Keyword MajorTopicYN="N">Lenalidomide</Keyword></KeywordList><CoiStatement>Drs Kim, Zhou, and MacLeod are employed by Ionis Pharmaceuticals who have manufactured the IRF4 ASOs and have ongoing clinical trials with these reagents. Other authors have no funding, honoraria, and stock interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32859220</ArticleId><ArticleId IdType="pmc">PMC7456374</ArticleId><ArticleId IdType="doi">10.1186/s12977-020-00535-z</ArticleId><ArticleId IdType="pii">10.1186/s12977-020-00535-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YB, Kaidarova Z, Hindes D, Bravo M, Kiely N, Kamel H, Dubay D, Hoose B, Murphy EL. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors - United States, 2000&#8211;2009. J Infect Dis. 2014;209:523&#8211;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903373</ArticleId><ArticleId IdType="pubmed">24068702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, et al. Effector regulatory T-cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016;4:644&#8211;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">27215229</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group. Br J Hematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Ike N, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570&#8211;2577.</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang XX, Ren X, Olson S, Cheng X, et al. Rapid progression of adult T-cell leukemia/lymphhoma as tumor infiltrating Treg cells after PD-1 blockade. Blood. 2019;134:1406&#8211;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839957</ArticleId><ArticleId IdType="pubmed">31467059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, et al. Integrated molecular analysis of adult T-cell leukemia/lymphoma. Nat Genet. 2015;47:1304&#8211;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Currer R, VanDuyne R, Jaworski E, Guendel I, Sampey G, Das R, Narayanan A, Kashanchi F. HTLV Tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front Microbiol. 2012;3:406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510432</ArticleId><ArticleId IdType="pubmed">23226145</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxus M, Twizere J-C, Legros S, Dewulf J-F, Kettmann R, Willems L. The HTLV-I Tax interactome. Retrovirology. 2008;5:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533353</ArticleId><ArticleId IdType="pubmed">18702816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: a hope for disease-preventive therapy. Cancer Sci. 2019;110:849&#8211;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398881</ArticleId><ArticleId IdType="pubmed">30666755</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan A, Dillon R, Witkover A, Melamed A, Demontis M-A, Gillet N, Mun LJ, Bangham C, Cook L, Fields P, Taylor G. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis. Blood. 2020;135:2023&#8211;2032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381760</ArticleId><ArticleId IdType="pubmed">32160278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RWJ, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, et al. Feed-forward regulatory loop driven by IRF4 and NF-kB in adult T-cell luekmeia/lymphoma. Blood. 2020;135:934&#8211;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">31972002</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi Y, Kohno T, Yamada Y, Ikeda S, Tanaka Y, Tomonaga M, Matsuyama T. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 2001;92:1284&#8211;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5926682</ArticleId><ArticleId IdType="pubmed">11749693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada L, Nagano Y, Hasegawa A, Kanai H, Nogami K, Ito S, Sato T, Yamano Y, Tanaka Y, Masuda T, Kannagi M. IL-10-mediated signals act as a switch for lymphoproliferation in human T-cell leukmeia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13:e1006597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614654</ArticleId><ArticleId IdType="pubmed">28910419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JC, Ruiz P, Ratner L, Reis IM, Brites C, Pedroso C, Byrne GE, Toomey NL, Andela V, Harhaj EW, et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood. 2007;109:3060&#8211;3068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852214</ArticleId><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Shaffer AL, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petgrus MN, Yang Y, et al. Targeting the HTLV-1-regulated BATF3/IRF4 transcriptional network in adult T-cell leukemia/lymphoma. Cancer Cell. 2018;34:286&#8211;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">30057145</ArticleId></ArticleIdList></Reference><Reference><Citation>Refaat A, Zhou Y, Suzuki S, Takasaki I, Koizumi K, Yamaoka S, Tabuchi Y, Saiki I, Sakurai H. Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J Biol Chem. 2011;2866:21092&#8211;21099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122170</ArticleId><ArticleId IdType="pubmed">21498517</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian MA, Olson S, Sundaramoorthi H, Cates K, Cheng X, Harding J, Martens A, Challen GA, Tyagi M, Ratner L, Rauch D. An activating mutation of IRF4 unique to adult T-cell leukemia. J Biol Chem. 2018;293:6844&#8211;6858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5936815</ArticleId><ArticleId IdType="pubmed">29540473</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer AL, Embre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226&#8211;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2542904</ArticleId><ArticleId IdType="pubmed">18568025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125:2471&#8211;2476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4467884</ArticleId><ArticleId IdType="pubmed">25736312</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016;7:209&#8211;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959641</ArticleId><ArticleId IdType="pubmed">27493711</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstein SA, Suman VJ, McCarthy PL. Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol. 2018;9:175&#8211;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041862</ArticleId><ArticleId IdType="pubmed">30013765</ArticleId></ArticleIdList></Reference><Reference><Citation>Talati C, Sallman D, List A. Lenalidomide: myelodysplastic syndromes with del(51) and beyond. Semin Hematol. 2017;54:159&#8211;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">28958290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu YX, Kortuem KM, Stewart AK. Molecular mechaism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multple myeloma. Leukemia Lymphoma. 2013;54:683&#8211;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931443</ArticleId><ArticleId IdType="pubmed">22966948</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdan E, Leblond V, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Woolridge JE, Moreau PA. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. Leukemia Lymphoma. 2014;55:2013&#8211;2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">24180331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronke J, Udeshi ND, Narta A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Corner E, Li X, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301&#8211;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077049</ArticleId><ArticleId IdType="pubmed">24292625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305&#8211;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4070318</ArticleId><ArticleId IdType="pubmed">24292623</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DA, Shrestha P, Aisabor AI, Stream A, Galli V, Pise-Masison CA, Tagawa T, Ziegelbauer JM, Franchini G, Yarchoan R. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. Oncoimmunology. 2018;8:e1546544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343774</ArticleId><ArticleId IdType="pubmed">30713808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Kim Y, MacLeod AR, et al. Targeting long noncoding RNA with antisense oligonucleotide technology as cancer therapeutics. In: Zhang YF, et al., editors. Methods in molecular biology, volume 1402. New York: Spring; 2016. pp. 199&#8211;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">26721493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatenangelo M, Wang M, Ren Y, Cuoto S, Breider M, et al. Rate of CRL4 (CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635186</ArticleId><ArticleId IdType="pubmed">26430725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307&#8211;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">30691367</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, et al. Nusinersen versus sham control in infantile-onset spinal muscular atropy. ENDEAR Study Group. N Engl J Med. 2017;377:1723&#8211;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al. AZD9150, a next-generation antisense-oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;18:314ra185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5279222</ArticleId><ArticleId IdType="pubmed">26582900</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, et al. STAT3 antisense oligonucloeotide AZD9150 in a subset of patients with heavily pretreated lymphoma, results of a phase 1b trial. J Immunother Cancer. 2018;16:119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240242</ArticleId><ArticleId IdType="pubmed">30446007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086&#8211;4093.</Citation><ArticleIdList><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamoorthy V, Kannaganat S, Maienschein-Cline M, Cook SL, Chen J, Bahroos N, Sievert E, Corse E, Chong A, Sciammas R. The IRF4 gene regulatory module functions as a read-write integrator to dynamically coordinate T helper cell fate. Immunity. 2017;47:481&#8211;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5661949</ArticleId><ArticleId IdType="pubmed">28930660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99:634&#8211;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">11781248</ArticleId></ArticleIdList></Reference><Reference><Citation>Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann TA, Hermine O, Nicot C. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci USA. 2010;107:16619&#8211;16624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944748</ArticleId><ArticleId IdType="pubmed">20823234</ArticleId></ArticleIdList></Reference><Reference><Citation>Trejo SR, Fahl WE, Ratner L. The tax protein of human T-cell leukemia virus type 1 mediates the transactivation of the c-sis/platelet-derived growth factor-B promoter through interactions with zinc finger transcription factors Sp1 and NGFI-A/Egr-1. J Biol Chem. 1997;272:27411&#8211;27421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratner L, Rauch D, Abel H, Caruso B, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6:3408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4817103</ArticleId><ArticleId IdType="pubmed">27015285</ArticleId></ArticleIdList></Reference><Reference><Citation>Man K, Miasari M, Shi W, Xin A, Henstridge DC, Preston S, Pellegrini M, Belz GT, Smyth GK, Febbraio MA, et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T-cells. Nat Immunol. 2014;14:1155&#8211;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">24056747</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">26635405</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><Issue>24</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>ATL treatment: is it time to change?</ArticleTitle><Pagination><StartPage>2533</StartPage><EndPage>2534</EndPage><MedlinePgn>2533-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2015-10-670489</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>NECKER HOSPITAL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Blood. 2015 Dec 10;126(24):2570-7</RefSource><PMID Version="1">26361794</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000706">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26635405</ArticleId><ArticleId IdType="doi">10.1182/blood-2015-10-670489</ArticleId><ArticleId IdType="pii">S0006-4971(20)30677-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">32393644</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>21</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis.</ArticleTitle><Pagination><StartPage>11685</StartPage><EndPage>11691</EndPage><MedlinePgn>11685-11691</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1920346117</ELocationID><Abstract><AbstractText>Human T cell leukemia virus 1 (HTLV-1) causes the functionally debilitating disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) as well as adult T cell leukemia lymphoma (ATLL). Although there were concerns that the mortality of HAM/TSP could be affected by the development of ATLL, prospective evidence was lacking in this area. In this 5-y prospective cohort study, we determined the mortality, prevalence, and incidence of ATLL in 527 HAM/TSP patients. The standard mortality ratio of HAM/TSP patients was 2.25, and ATLL was one of the major causes of death (5/33 deaths). ATLL prevalence and incidence in these patients were 3.0% and 3.81 per 1,000 person-y, respectively. To identify patients at a high risk of developing ATLL, flow cytometry, Southern blotting, and targeted sequencing data were analyzed in a separate cohort of 218 HAM/TSP patients. In 17% of the HAM/TSP patients, we identified an increase in T cells positive for cell adhesion molecule 1 (CADM1), a marker for ATLL and HTLV-1-infected cells. Genomic analysis revealed that somatic mutations of HTLV-1-infected cells were seen in 90% of these cases and 11% of them had dominant clone and developed ATLL in the longitudinal observation. In this study, we were able to demonstrate the increased mortality in patients with HAM/TSP and a significant effect of ATLL on their prognosis. Having dominant clonal expansion of HTLV-1-infected cells with ATLL-associated somatic mutations may be important characteristics of patients with HAM/TSP who are at an increased risk of developing ATLL.</AbstractText><CopyrightInformation>Copyright &#169; 2020 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagasaka</LastName><ForeName>Misako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamagishi</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagishita</LastName><ForeName>Naoko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araya</LastName><ForeName>Natsumi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Seiichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makiyama</LastName><ForeName>Junya</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0883-2920</Identifier><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubokawa</LastName><ForeName>Miyuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamauchi</LastName><ForeName>Junji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0292-1594</Identifier><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coler-Reilly</LastName><ForeName>Ariella L G</ForeName><Initials>ALG</Initials><Identifier Source="ORCID">0000-0001-8549-6559</Identifier><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsutsumi</LastName><ForeName>Shuntaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uemura</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takata</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Eisuke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3200-376X</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Practical Management of Medical Information, St. Marianna University Graduate School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8561, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchimaru</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Tomoo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamano</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7527-0345</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan; yyamano@marianna-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8512, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015493">Paraparesis, Tropical Spastic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HAM/TSP</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">SMR</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>Competing interest statement: M.N. reports personal fees from AstraZeneca and grants from Tempus, outside the submitted work. E.I. reports personal fees from Merck Bio Pharma Japan, outside the submitted work. Y.Y. reports grants from Japan Agency for Medical Research and Development, grants from Ministry of Health, Labour and Welfare, and Japan Society for the Promotion of Science KAKENHI during the conduct of the study; grants from Daiichi Sankyo Co., Ltd.; grants from ONO Pharmaceutical Co., Ltd.; and grants from Kyowa Hakko Kirin, Japan, outside the submitted work; In addition, Y.Y. and N.A. have a patent &#8220;Medicine for Treating or Preventing HTLV-I-Related Myelopathy, and Method for Forecasting the Effect of Antibody Therapy for Patient of HTLV-I-Related Myelopathy&#8221; (Japan Patent 5552630 licensed to St. Marianna University School of Medicine). Y.Y. has a patent &#8220;Therapeutic Method and Medicament for HTLV-1-Associated Myelopathy (HAM)&#8221; (Japan Patent 6310845, US9,642,910, AUS2013285970 licensed to St. Marianna University School of Medicine, Kyowa Hakko Kirin, Japan); and a patent &#8220;Preventive or Therapeutic Agent for HTLV-1-Associated Myelopathy Using Low-Dose Anti-CCR4 Antibody&#8221; (Japan Patent 6430082 licensed to St. Marianna University School of Medicine, Kyowa Hakko Kirin, Japan). All other authors have no competing interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32393644</ArticleId><ArticleId IdType="pmc">PMC7260950</ArticleId><ArticleId IdType="doi">10.1073/pnas.1920346117</ArticleId><ArticleId IdType="pii">1920346117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poiesz B. J., et al. , Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 77, 7415&#8211;7419 (1980).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A., Cassar O., Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 3, 388 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Osame M., et al. , HTLV-I associated myelopathy, a new clinical entity. Lancet 1, 1031&#8211;1032 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">2871307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A., et al. , Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2, 407&#8211;410 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">2863442</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H., Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50, 481&#8211;492 (1977).</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagaya Y., Matsuoka M., Gallo R., 40 years of the human T-cell leukemia virus: Past, present and future. F1000Res. 8, F1000 Faculty Rev 228 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396841</ArticleId><ArticleId IdType="pubmed">30854194</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin F., Tagaya Y., Gallo R., Time to eradicate HTLV-1: An open letter to WHO. Lancet 391, 1893&#8211;1894 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29781438</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow S. H., et al. , WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC, Lyon, France, 2008).</Citation></Reference><Reference><Citation>Katsuya H., et al. ; ATL-Prognostic Index Project , Treatment and survival among 1594 patients with ATL. Blood 126, 2570&#8211;2577 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham C. R., Araujo A., Yamano Y., Taylor G. P., HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat. Rev. Dis. Primers 1, 15012 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">27188208</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington W. J., Jr, et al. , Clinical spectrum of HTLV-I in south Florida. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 466&#8211;473 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7697443</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin F., Fedina A., Youshya S., Taylor G. P., A 15-year prospective longitudinal study of disease progression in patients with HTLV-1 associated myelopathy in the UK. J. Neurol. Neurosurg. Psychiatry 81, 1336&#8211;1340 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20660921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#231;alves D. U., et al. , Simultaneous occurrence of HTLV-I associated myelopathy, uveitis and smouldering adult T cell leukaemia. GIPH (Interdisciplinary HTLV-I/II Research Group). Int. J. STD AIDS 10, 336&#8211;337 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10361926</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwanaga M., et al. ; Joint Study on Predisposing Factors of ATL Development Investigators , Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan. Blood 116, 1211&#8211;1219 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20448111</ArticleId></ArticleIdList></Reference><Reference><Citation>Firouzi S., et al. , Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia. Blood Adv. 1, 1195&#8211;1205 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728319</ArticleId><ArticleId IdType="pubmed">29296760</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., et al. , Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J. Neurovirol. 4, 586&#8211;593 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">10065900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K., et al. , Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47, 1304&#8211;1315 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Coler-Reilly A. L. G., et al. , Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet J. Rare Dis. 11, 69 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881005</ArticleId><ArticleId IdType="pubmed">27225443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano Y., et al. , Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8+ T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 99, 88&#8211;94 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11756157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuramitsu M., et al. , Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan. Microbiol. Immunol. 62, 673&#8211;676 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30125970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., et al. , Mogamulizumab (Anti-CCR4) in HTLV-1-associated myelopathy. N. Engl. J. Med. 378, 529&#8211;538 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29414279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., et al. , Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci. 106, 598&#8211;603 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452161</ArticleId><ArticleId IdType="pubmed">25703103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., et al. , CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin. Cancer Res. 20, 2851&#8211;2861 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24727323</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M., Osame M., Usuku K., Matsumoto M., Igata A., Viruses detected in HTLV-I-associated myelopathy and adult T-cell leukaemia are identical on DNA blotting. Lancet 1, 1085&#8211;1086 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">2883415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondka Z., et al. , The COSMIC cancer gene census: Describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696&#8211;705 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450507</ArticleId><ArticleId IdType="pubmed">30293088</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M., et al. , Polycomb-mediated loss of miR-31 activates NIK-dependent NF-&#954;B pathway in adult T cell leukemia and other cancers. Cancer Cell 21, 121&#8211;135 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22264793</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., et al. ; 1000 Genome Project Data Processing Subgroup , The sequence alignment/map (SAM) format and SAMtools. Bioinformatics 25, 2078&#8211;2079 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Cibulskis K., et al. , Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213&#8211;219 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833702</ArticleId><ArticleId IdType="pubmed">23396013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Li M., Hakonarson H., ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Manouchehrinia A., Tanasescu R., Tench C. R., Constantinescu C. S., Mortality in multiple sclerosis: Meta-analysis of standardised mortality ratios. J. Neurol. Neurosurg. Psychiatry 87, 324&#8211;331 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25935887</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcusso R. M. N., et al. , Dichotomy in fatal outcomes in a large cohort of people living with HTLV-1 in S&#227;o Paulo, Brazil. Pathogens 9, E25 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7168659</ArticleId><ArticleId IdType="pubmed">31888093</ArticleId></ArticleIdList></Reference><Reference><Citation>Arisawa K., et al. , Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int. J. Cancer 85, 319&#8211;324 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10652420</ArticleId></ArticleIdList></Reference><Reference><Citation>Makiyama J., et al. , CD4+ CADM1+ cell percentage predicts disease progression in HTLV-1 carriers and indolent adult T-cell leukemia/lymphoma. Cancer Sci. 110, 3746&#8211;3753 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6890436</ArticleId><ArticleId IdType="pubmed">31642546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K., et al. , Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood 131, 215&#8211;225 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T., et al. , The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin. Cancer Res. 10, 7529&#8211;7539 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15569983</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">34755979</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1087-2108</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Dermatology online journal</Title><ISOAbbreviation>Dermatol Online J</ISOAbbreviation></Journal><ArticleTitle>Assessing smoldering adult T cell leukemia/lymphoma: a case report.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.5070/D327955137</ELocationID><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATLL) is a rare, extremely aggressive malignancy with four different clinical variants, all of which are associated with human T cell lymphotropic virus type 1. Antiretrovirals have been recognized as an effective therapy after study in clinical trials around the world. However, oncologists traditionally wait for asymptomatic patients with ATLL to reach a more severe stage of disease before treatment is initiated. We describe a patient with Fitzpatrick Skin Type V who presented with asymptomatic dyschromia of her neck, breast, and jaw. Her clinical, laboratory, and histological findings were consistent with smoldering type-ATLL. We teamed up with her oncologist to successfully treat her cutaneous symptoms with interferon-alpha/zidovudine. This report demonstrates efficacy with the employment of antiretroviral therapy immediately following a diagnosis of smoldering type ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olayinka</LastName><ForeName>J T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Dermatology, SUNY Downstate Health Sciences University, Brooklyn, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heilman</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vatanchi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dermatol Online J</MedlineTA><NlmUniqueID>9610776</NlmUniqueID><ISSNLinking>1087-2108</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044966">Anti-Retroviral Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017495">Hyperpigmentation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34755979</ArticleId><ArticleId IdType="doi">10.5070/D327955137</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24772829</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-6178</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Connecticut medicine</Title><ISOAbbreviation>Conn Med</ISOAbbreviation></Journal><ArticleTitle>Respiratory failure due to lung involvement with adult T-cell leukemia/lymphoma: case report and review of literature.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>142</EndPage><MedlinePgn>139-42</MedlinePgn></Pagination><Abstract><AbstractText>Acute adult T-cellleukemia/lymphoma (ATLL) is a hematologic malignancy that usually entails a poor prognosis; median survival is only six months. Significant immunosuppression is commonly seen in these patients. Lung involvement in ATLL is usually documented either radiographically or as an autopsy finding. Few proven cases of ante mortem extensive lung infiltration have been described in the scientific literature. We present a fatal case of acute respiratory failure as a result of histologically proven lung infiltration by malignant lymphocytes in a patientwith acuteATLL. Although the most common cause of death i n patients with ATLL is respiratory failure in the setting of an infectious process, it should be kept in mind that patients with ATLL with acute respiratory failure may have malignant lung infiltration as a potential cause.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mutneja</LastName><ForeName>Rahul</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Mamta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vyas</LastName><ForeName>Dhwanil</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vyas</LastName><ForeName>Anuja</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Dasanu</LastName><ForeName>Constantin A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Conn Med</MedlineTA><NlmUniqueID>0372745</NlmUniqueID><ISSNLinking>0010-6178</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003643">Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012131">Respiratory Insufficiency</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24772829</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31930552</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of medical primatology</Title><ISOAbbreviation>J Med Primatol</ISOAbbreviation></Journal><ArticleTitle>A pilot study to establish human T-cell leukemia virus type 1 (HTLV-1) carrier model using common marmoset (Callithrix jacchus).</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>94</EndPage><MedlinePgn>86-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jmp.12454</ELocationID><Abstract><AbstractText Label="BACKGROUND">For the diagnosis and treatment of adult T-cell leukemia/lymphoma (ATLL) caused by human T-lymphotropic virus type 1 (HTLV-1) are required therapeutic modalities urgently. Non-human primate models for ATLL would provide a valuable information for clinical studies. We did a pilot study to establish an ATLL non-human primate model using common marmosets (Callithrix jacchus).</AbstractText><AbstractText Label="METHODS">We inoculated HTLV-1-producing MT-2 cells into 9-month-old marmosets, either intraperitoneally or intravenously. We next administrated MT-2 cells into 13-month-old marmosets under cyclosporine A (CsA) treatment to promote infection. HTLV-1 infection was determined by measuring HTLV-1 antibody titer in the common marmosets.</AbstractText><AbstractText Label="RESULTS">The HTLV-1 antibody titer increased in the intraperitoneally inoculated marmoset with or without CsA treatment, and it kept over five 5&#160;years though proviral copy number (proviral load, PVL) remained low throughout the study.</AbstractText><AbstractText Label="CONCLUSION">We obtained HTLV-1 asymptomatic carriers of common marmosets by inoculating MT-2 cells.</AbstractText><CopyrightInformation>&#169; 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirose</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiramoto</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yamin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohara</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Seiichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Etsuko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denda</LastName><ForeName>Tamami</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yukihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiyuan</LastName><ForeName>Liao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Shohei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miura</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hijikata</LastName><ForeName>Yasuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soda</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Institute for Experimental Animals, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okahara</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Central Institute for Experimental Animals, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itoh</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Institute for Experimental Animals, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Central Institute for Experimental Animals, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tojo</LastName><ForeName>Arinobu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchimaru</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Computational Biology and Medical Science, The Tokyo University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Kenzaburo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3335-6188</Identifier><AffiliationInfo><Affiliation>Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>J Med Primatol</MedlineTA><NlmUniqueID>0320626</NlmUniqueID><ISSNLinking>0047-2565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D002144">Callithrix</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">MT-2 cells</Keyword><Keyword MajorTopicYN="N">common marmoset</Keyword><Keyword MajorTopicYN="N">cyclosporine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31930552</ArticleId><ArticleId IdType="doi">10.1111/jmp.12454</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79(6):2031-2035.</Citation></Reference><Reference><Citation>Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci. 1980;77(12):7415-7419.</Citation></Reference><Reference><Citation>Watanabe T. HTLV-1-associated diseases. Int J Hematol. 1997;66(3):257-278.</Citation></Reference><Reference><Citation>Arisawa K, Soda M, Endo S, et al. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer. 2000;85(3):319-324.</Citation></Reference><Reference><Citation>Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211-1219.</Citation></Reference><Reference><Citation>Martins ML, Guimar&#227;es JC, Ribas JG, Romanelli LCF, de Freitas Carneiro-Proietti AB. Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease? J Neurovirol. 2017;23(1):125-133.</Citation></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol. 1991;79(3):428-437.</Citation></Reference><Reference><Citation>Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60(12):1373-1377.</Citation></Reference><Reference><Citation>Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki. Proc Japan Acad Ser B. 2011;87(4):152-166.</Citation></Reference><Reference><Citation>Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. Int J Cancer. 1990;45(2):237-243.</Citation></Reference><Reference><Citation>Hino S. Primary prevention of adult T cell leukemia (ATL) in Nagasaki, Japan by refraining from breast-feeding. Gann Monogr Cancer Res. 2003;50:241-251.</Citation></Reference><Reference><Citation>Doi K, Wu X, Taniguchi Y, et al. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood. 2005;106(3):1048-1053.</Citation></Reference><Reference><Citation>Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene. 2005;24(39):6005-6015.</Citation></Reference><Reference><Citation>Panfil AR, Al-saleem JJ, Green PL. Animal models utilized in HTLV-1 research. Virology: Research and Treatment, 2013; 4: 49-59.</Citation></Reference><Reference><Citation>Koya Y, Ohashi T, Kato H, et al. Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1- immortalized T-cell line preferentially expressing tax. J Virol. 1999;73(8):6436-6443.</Citation></Reference><Reference><Citation>Ohashi T, Hanabuchi S, Kato H, et al. Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells. J Virol. 1999;73(7):6031-6040.</Citation></Reference><Reference><Citation>Kushida S, Maeda N, Fang J, Uchida K, Miwa M. Establishment of HTLV-1 carrier mice by injection with HTLV-1-producing T cells. Leukemia. 1997;11(suppl 3):260-262.</Citation></Reference><Reference><Citation>Tanaka M, Sun B, Fang J, et al. Human T-cell leukemia virus type 1 (HTLV-1) infection of mice: proliferation of cell clones with integrated HTLV-1 provirus in lymphoid organs. Society. 2001;75(9):4420-4423.</Citation></Reference><Reference><Citation>Miyoshi I, Yoshimoto S, Taguchi H, et al. Transformation of rabbit lymphocytes with T-cell leukemia virus. Gan. 1983;74(1):1-4.</Citation></Reference><Reference><Citation>Collins ND, Newbound GC, Ratner L, Lairmore MD. In vitro CD4+ lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotropic virus type 1. J Virol. 1996;70:7241-7246.</Citation></Reference><Reference><Citation>Haynes RAH, Ware E, Premanandan C, et al. Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model. Blood. 2010;115(4):815-823.</Citation></Reference><Reference><Citation>Miyoshi I, Yoshimoto S, Fujishita M, Kubonishi I, Taguchi H, Ohtsuki Y. Infectious transmission of human T-cell leukemia virus to animals. Princess Takamatsu Symp. 1984;15:121-127.</Citation></Reference><Reference><Citation>Kazanji M, Ureta-Vidal A, Ozden S, et al. Lymphoid organs as a major reservoir for human T-cell leukemia virus type 1 in experimentally infected squirrel monkeys (Saimiri sciureus): provirus expression, persistence, and humoral and cellular immune responses. J Virol. 2000;74(10):4860-4867.</Citation></Reference><Reference><Citation>Nakamura H, Tanaka Y, Komuro-Tsujimoto A, et al. Experimental inoculation of monkeys with autologous lymphoid cell lines immortalized by and producing human T-cell leukemia virus type-I. Int J Cancer. 1986;38(6):867-875.</Citation></Reference><Reference><Citation>McGinn TM, Wei Q, Stallworth J, Fultz PN. Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques. AIDS Res Hum Retroviruses. 2004;20(4):443-456.</Citation></Reference><Reference><Citation>McGinn TM, Wei Q, Stallworth J, Fultz PN. Immune responses to HTLV-I(ACH) during acute infection of pig-tailed macaques. AIDS Res Hum Retroviruses. 2004;20(4):443-456.</Citation></Reference><Reference><Citation>Miyoshi I, Kubonishi I, Yoshimoto S, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature. 1981;294(5843):770-771.</Citation></Reference><Reference><Citation>Kobayashi S, Tian Y, Ohno N, et al. The CD3 versus CD7 Plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I. PLoS ONE. 2013;8(1):e53728.</Citation></Reference><Reference><Citation>Sasaki E, Suemizu H, Shimada A, et al. Generation of transgenic non-human primates with germline transmission. Nature. 2009;459(7246):523-527.</Citation></Reference><Reference><Citation>Mansfield K. Marmoset models commonly used in biomedical research. Comp Med. 2003;53(4):383-392.</Citation></Reference><Reference><Citation>Sato K, Oiwa R, Kumita W, et al. Generation of a nonhuman primate model of severe combined immunodeficiency using highly efficient genome editing. Cell Stem Cell. 2016;19(1):127-138.</Citation></Reference><Reference><Citation>Megumi M, Jun-ichirou Y, Ayaka W, et al. Efficient horizontal transmission without viral super-spreaders may cause the high prevalence of STLV-1 infection in Japanese macaques. bioRxiv. 2019:1-44.</Citation></Reference><Reference><Citation>Hasegawa A, Ohashi T, Hanabuchi S, et al. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J Virol. 2003;77(5):2956-2963.</Citation></Reference><Reference><Citation>Inoue Y, Morita M, Goto N, et al. Analysis of the antibodies for Htlv-1 structural proteins and proviral load in peripheral blood from Htlv-1-infected individuals. Japanese J Transfus Cell Ther. 2014;60(6):592-599.</Citation></Reference><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492.</Citation></Reference><Reference><Citation>Kametani Y, Suzuki D, Kohu K, et al. Development of monoclonal antibodies for analyzing immune and hematopoietic systems of common marmoset. Exp Hematol. 2009;37(11):1318-1329.</Citation></Reference><Reference><Citation>Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16098064</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1048</ISSN><JournalIssue CitedMedium="Print"><Volume>130</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br J Haematol</ISOAbbreviation></Journal><ArticleTitle>Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia.</ArticleTitle><Pagination><StartPage>511</StartPage><EndPage>515</EndPage><MedlinePgn>511-5</MedlinePgn></Pagination><Abstract><AbstractText>Central nervous system (CNS) presentation of adult T-cell lymphoma/leukaemia is rare, and almost invariably associated with systemic disease. We report an unusual manifestation of adult T-cell lymphoma/leukaemia, with isolated CNS involvement and unusual imaging findings. We also describe objective response to antiviral therapy. To our knowledge, this is the first report of such presentation and response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dungerwalla</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Haemato-Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osuji</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Waldman</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Al Jehani</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tailor</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wotherspoon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cogill</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Matutes</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Br J Haematol. 2005 Nov;131(4):557</RefSource><Note>Taylor, R [corrected to Tailor, R]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005625">Frontal Lobe</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007372">Interferons</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>22</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16098064</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2141.2005.05629.x</ArticleId><ArticleId IdType="pii">BJH5629</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">35815408</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-8576</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Cancer biology &amp; therapy</Title><ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation></Journal><ArticleTitle>Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3&#946;) inhibitor, in refractory adult T-Cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>417</StartPage><EndPage>423</EndPage><MedlinePgn>417-423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2088984</ELocationID><Abstract><AbstractText>GSK-3&#946; is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3&#946; blockade downregulates the NF-&#954;B pathway, modulates immune cell PD-1 and tumor cell PD-L1 expression, and increases CD8&#160;+&#160;T cell and NK cell function. We report a case of adult T-cell leukemia/lymphoma (ATLL) treated with 9-ING-41, a selective GSK-3&#946; inhibitor in clinical development, who achieved a durable response. A 43-year-old male developed diffuse lymphadenopathy, and biopsy of axillary lymph node showed acute-type ATLL. Peripheral blood flow cytometry revealed a circulating clonal T cell population, and CSF was positive for ATLL involvement. After disease progression on the 3<sup>rd</sup> line of treatment, he started treatment with 9-ING-41 monotherapy in a clinical trial (NCT03678883). CT imaging after seven months showed a partial response. Sustained reduction of peripheral blood ATLL cells lasted 15&#160;months. Treatment of patient-derived CD8&#160;+&#160;T cells with 9-ING-41 increased the secretion of IFN-&#947;, granzyme B, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In conclusion, treatment of a patient with refractory ATLL with the GSK-3&#946; inhibitor 9-ING-41 resulted in a prolonged response. Ongoing experiments are investigating the hypothesis that 9-ING-41-induced T cell activation and immunomodulation contributes to its clinical activity. Further clinical investigation of 9-ING-41 for treatment of ATLL is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Brown University and the Lifespan Cancer Institute, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huntington</LastName><ForeName>Kelsey E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Souza</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Brown University and the Lifespan Cancer Institute, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lanlan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olszewski</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Brown University and the Lifespan Cancer Institute, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makwana</LastName><ForeName>Nirav P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Radiology, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treaba</LastName><ForeName>Diana O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalcante</LastName><ForeName>Ludimila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Actuate Therapeutics, Fort Worth, Tx, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>Francis J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Actuate Therapeutics, Fort Worth, Tx, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safran</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Brown University and the Lifespan Cancer Institute, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Deiry</LastName><ForeName>Wafik S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Brown University and the Lifespan Cancer Institute, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carneiro</LastName><ForeName>Benedito A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-5468-1126</Identifier><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Brown University and the Lifespan Cancer Institute, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03678883</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Biol Ther</MedlineTA><NlmUniqueID>101137842</NlmUniqueID><ISSNLinking>1538-4047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000071679">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">9-ING-41</Keyword><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">GSK-3</Keyword><Keyword MajorTopicYN="N">GSK-3b</Keyword><Keyword MajorTopicYN="N">glycogen synthase kinase 3</Keyword></KeywordList><CoiStatement>LC and FJG are consultants to Actuate Therapeutics. BAC has received institutional support from Actuate Therapeutics related to ongoing clinical trial with 9-ING-41. All other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>11</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35815408</ArticleId><ArticleId IdType="pmc">PMC9272832</ArticleId><ArticleId IdType="doi">10.1080/15384047.2022.2088984</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL.. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058&#8211;6068. doi:10.1038/sj.onc.1208968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208968</ArticleId><ArticleId IdType="pubmed">16155612</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570&#8211;2577. doi:10.1182/blood-2015-03-632489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984-87). Br J Haematol. 1991;79:428&#8211;437. doi:10.1111/j.1365-2141.1991.tb08051.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K, Harada K, Nakamoto K, Shiroma M, Miyakuni T. Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers. Clin Exp Immunol. 2000;119:259&#8211;263. doi:10.1046/j.1365-2249.2000.01136.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2000.01136.x</ArticleId><ArticleId IdType="pmc">PMC1905500</ArticleId><ArticleId IdType="pubmed">10632660</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375&#8211;2390. doi:10.1182/blood-2016-01-643569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-01-643569</ArticleId><ArticleId IdType="pmc">PMC4874220</ArticleId><ArticleId IdType="pubmed">26980727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69:2863&#8211;2868. doi:10.1128/jvi.69.5.2863-2868.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.5.2863-2868.1995</ArticleId><ArticleId IdType="pmc">PMC188982</ArticleId><ArticleId IdType="pubmed">7707509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475&#8211;496. doi:10.1146/annurev.immunol.19.1.475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.19.1.475</ArticleId><ArticleId IdType="pubmed">11244044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury Y, Nasr R, Hermine O, de Th&#233; H, Bazarbachi A. Proapoptotic regimes for HTLV-I-transformed cells: targeting tax and the NF-kappaB pathway. Cell Death Differ. 2005;12(Suppl 1):871&#8211;877. doi:10.1038/sj.cdd.4401624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401624</ArticleId><ArticleId IdType="pubmed">15846376</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N, Fujii M, Cheng G, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, Yamamoto N. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways. Virus Genes. 2001;22:279&#8211;287. doi:10.1023/A:1011158021749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011158021749</ArticleId><ArticleId IdType="pubmed">11450946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, and Koeffler, H.P. Mutations of the p53 gene in adult T-cell leukemia. Blood. 1992;79:477&#8211;480. doi:10.1182/blood.V79.2.477.477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V79.2.477.477</ArticleId><ArticleId IdType="pubmed">1730092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, et al. Aberrant PD-L1 expression through 3&#8217;-UTR disruption in multiple cancers. Nature. 2016;534:402&#8211;406. doi:10.1038/nature18294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18294</ArticleId><ArticleId IdType="pubmed">27281199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimauchi T, Kabashima K, Nakashima D, Sugita K, Yamada Y, Hino R, and Tokura, Y. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int J Cancer. 2007;121:2585&#8211;2590. doi:10.1002/ijc.23042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.23042</ArticleId><ArticleId IdType="pubmed">17721918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375&#8211;382. doi:10.1038/leu.2008.272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2008.272</ArticleId><ArticleId IdType="pubmed">18830259</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol. 2007;178:2714&#8211;2720. doi:10.4049/jimmunol.178.5.2714.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.5.2714</ArticleId><ArticleId IdType="pubmed">17312113</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill PS, Harrington W Jr., Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744&#8211;1748. doi:10.1056/NEJM199506293322603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199506293322603</ArticleId><ArticleId IdType="pubmed">7760890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672&#8211;682. doi:10.1111/bjh.13338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13338</ArticleId><ArticleId IdType="pmc">PMC5024033</ArticleId><ArticleId IdType="pubmed">25733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult t-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086&#8211;4093. doi:10.1200/JCO.2016.67.7732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.7732</ArticleId><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116:1175&#8211;1186. doi:10.1242/jcs.00384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00384</ArticleId><ArticleId IdType="pmc">PMC3006448</ArticleId><ArticleId IdType="pubmed">12615961</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin I, Eturi A, De Souza A, Pamarthy S, Tavora F, Giles FJ, and Carneiro, B.A. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther. 2019;20:1047&#8211;1056. doi:10.1080/15384047.2019.1595283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2019.1595283</ArticleId><ArticleId IdType="pmc">PMC6606036</ArticleId><ArticleId IdType="pubmed">30975030</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger J, Rudd CE, Taylor A. Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. Semin Immunol. 2019;42:101295. doi:10.1016/j.smim.2019.101295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2019.101295</ArticleId><ArticleId IdType="pubmed">31604533</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI, and Rudd CE. Glycogen synthase kinase 3 inactivation drives t-bet-mediated downregulation of co-receptor PD-1 to Enhance CD8(+) Cytolytic T cell responses. Immunity. 2016;44:274&#8211;286. doi:10.1016/j.immuni.2016.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.01.018</ArticleId><ArticleId IdType="pmc">PMC4760122</ArticleId><ArticleId IdType="pubmed">26885856</ArticleId></ArticleIdList></Reference><Reference><Citation>C-W L, Lim S-O, Xia W, Lee -H-H, Chan L-C, Kuo C-W, Khoo K-H, Chang -S-S, Cha J-H, Kim T, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632. doi:10.1038/ncomms12632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12632</ArticleId><ArticleId IdType="pmc">PMC5013604</ArticleId><ArticleId IdType="pubmed">27572267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005;334:1365&#8211;1373. doi:10.1016/j.bbrc.2005.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2005.07.041</ArticleId><ArticleId IdType="pubmed">16043125</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O&#8217;Halloran TV, Giles FJ, Billadeau DD, Mazar AP. Molecular pathways: revisiting glycogen synthase kinase-3&#946; as a target for the treatment of cancer. Clin Cancer Res. 2017;23:1891&#8211;1897. doi:10.1158/1078-0432.CCR-15-2240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2240</ArticleId><ArticleId IdType="pmc">PMC5392367</ArticleId><ArticleId IdType="pubmed">28053024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86&#8211;90. doi:10.1038/35017574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017574</ArticleId><ArticleId IdType="pubmed">10894547</ArticleId></ArticleIdList></Reference><Reference><Citation>Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O&#8217;Connor O, Hoffmann A, Elenitoba-Johnson KS, Pagano M. Fbxw7&#945;- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol. 2012;14:375&#8211;385. doi:10.1038/ncb2463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2463</ArticleId><ArticleId IdType="pmc">PMC3339029</ArticleId><ArticleId IdType="pubmed">22388891</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro BA, Cavalcante L, Bastos BR, Powell SF, Ma WW, Sahebjam S, Harvey D, De Souza AL, Dhawan MS, Safran H, et al. Phase I study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3&#946;) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. J Clin Oncol. 2020;38:3507. suppl; abstr 3507 doi:10.1200/JCO.2020.38.15_suppl.3507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2020.38.15_suppl.3507</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor A, Rothstein D, Rudd CE. Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy. Cancer Res. 2018;78:706&#8211;717. doi:10.1158/0008-5472.CAN-17-0491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0491</ArticleId><ArticleId IdType="pubmed">29055015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd CE, Chanthong K, Taylor A. Small molecule inhibition of GSK-3 specifically inhibits the transcription of inhibitory co-receptor LAG-3 for enhanced anti-tumor immunity. Cell Rep. 2020;30:2075&#8211;82.e4. doi:10.1016/j.celrep.2020.01.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.01.076</ArticleId><ArticleId IdType="pubmed">32075731</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington KE, Zhang S, Carneiro BA, El-Deiry WS. GSK3&#946; inhibition by small molecule 9-ING-41 decreases VEGF and other cytokines, and boosts NK and T cell-mediated killing of colorectal tumor cells. Cancer Res. 2021;81:2676. doi:10.1158/1538-7445.AM2021-2676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2021-2676</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington KE, Louie A, Zhou L, El-Deiry WS. A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs. Oncotarget. 2021;12:1980&#8211;1991. doi:10.18632/oncotarget.28079.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.28079</ArticleId><ArticleId IdType="pmc">PMC8487726</ArticleId><ArticleId IdType="pubmed">34611474</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro F, Cardoso AP, Gon&#231;alves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. doi:10.3389/fimmu.2018.00847.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00847</ArticleId><ArticleId IdType="pmc">PMC5945880</ArticleId><ArticleId IdType="pubmed">29780381</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol. 1989;143:1210&#8211;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">2501391</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395&#8211;417. doi:10.1038/s41571-020-0341-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-020-0341-y</ArticleId><ArticleId IdType="pmc">PMC8211386</ArticleId><ArticleId IdType="pubmed">32203277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JS, Herreros-Villanueva M, Koenig A, Deng Z, de Narvajas AA, Gomez TS, Meng X, Bujanda L, Ellenrieder V, Li XK, et al. Differential activity of GSK-3 isoforms regulates NF-&#954;B and TRAIL- or TNF&#945; induced apoptosis in pancreatic cancer cells. Cell Death Dis. 2014;5:e1142. doi:10.1038/cddis.2014.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.102</ArticleId><ArticleId IdType="pmc">PMC4067531</ArticleId><ArticleId IdType="pubmed">24675460</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164:2200&#8211;2206. doi:10.4049/jimmunol.164.4.2200.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.4.2200</ArticleId><ArticleId IdType="pubmed">10657675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini C, Celeghini C, Monasta L, Zauli G. NF-&#954;B pathways in hematological malignancies. Cell Mol Life Sci. 2014;71:2083&#8211;2102. doi:10.1007/s00018-013-1545-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1545-4</ArticleId><ArticleId IdType="pubmed">24419302</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, and Giles, F.J. GSK-3&#946; inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017;8:114924&#8211;114934. doi:10.18632/oncotarget.22414.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.22414</ArticleId><ArticleId IdType="pmc">PMC5777742</ArticleId><ArticleId IdType="pubmed">29383130</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd-Ellah A, Voogdt C, Krappmann D, M&#246;ller P, Marienfeld RB. GSK3&#946; modulates NF-&#954;B activation and RelB degradation through site-specific phosphorylation of BCL10. Sci Rep. 2018;8:1352. doi:10.1038/s41598-018-19822-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19822-z</ArticleId><ArticleId IdType="pmc">PMC5777991</ArticleId><ArticleId IdType="pubmed">29358699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30862694</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3265</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin Cancer Res</ISOAbbreviation></Journal><ArticleTitle>PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.</ArticleTitle><Pagination><StartPage>3589</StartPage><EndPage>3601</EndPage><MedlinePgn>3589-3601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-18-3033</ELocationID><Abstract><AbstractText Label="PURPOSE">To evaluate therapeutic activity of PAK inhibition in ATLL and to characterize the role of PAK isoforms in cell proliferation, survival, and adhesion of ATLL cells in preclinical models.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN">Frequency and prognostic impact of <i>PAK2</i> amplification were evaluated in an ATLL cohort of 370 cases. Novel long-term cultures and <i>in vivo</i> xenograft models were developed using primary ATLL cells from North American patients. Two PAK inhibitors were used to block PAK kinase activity pharmacologically. siRNA-based gene silencing approach was used to genetically knockdown (KD) PAK1 and PAK2 in ATLL cell lines.</AbstractText><AbstractText Label="RESULTS">PAK1/2/4 are the three most abundantly expressed PAK family members in ATLL. <i>PAK2</i> amplifications are seen in 24% of ATLLs and are associated with worse prognosis in a large patient cohort. The pan-PAK inhibitor PF-3758309 (PF) has strong <i>in vitro</i> and <i>in vivo</i> activity in a variety of ATLL preclinical models. These activities of PF are likely attributed to its ability to target several PAK isoforms simultaneously because genetic silencing of either PAK1 or PAK2 produced more modest effects. PAK2 plays a major role in CADM1-mediated stromal interaction, which is an important step in systemic dissemination of the disease. This finding is consistent with the observation that <i>PAK2</i> amplification is more frequent in aggressive ATLLs and correlates with inferior outcome.</AbstractText><AbstractText Label="CONCLUSIONS">PAK2, a gene frequently amplified in ATLL, facilitates CADM1-mediated stromal interaction and promotes survival of ATLL cells. Taken together, PAK inhibition may hold significant promise as a targeted therapy for aggressive ATLLs.</AbstractText><CopyrightInformation>&#169;2019 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Elaine Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Urvi A</ForeName><Initials>UA</Initials><Identifier Source="ORCID">0000-0001-8419-1091</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yongqiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Xiaoxin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Kith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartholdy</LastName><ForeName>Boris</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7401-8591</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Yiyu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinghang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Seishi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steidl</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zang</LastName><ForeName>Xingxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, Albert Einstein College of Medicine, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janakiram</LastName><ForeName>Murali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, Montefiore Medical Center, Bronx, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>B Hilda</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York. hilda.ye@einstein.yu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA013330</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 CA121947</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C403514">CADM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075982">Cell Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C550923">PF 3758309</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515907">PAK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054462">p21-Activated Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002448">Cell Adhesion</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000075982">Cell Adhesion Molecule-1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005784">Gene Amplification</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061251">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011758">Pyrroles</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054462">p21-Activated Kinases</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30862694</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3033</ArticleId><ArticleId IdType="pii">1078-0432.CCR-18-3033</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10435685</PMID><DateCompleted><Year>1999</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1120-009X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of chemotherapy (Florence, Italy)</Title><ISOAbbreviation>J Chemother</ISOAbbreviation></Journal><ArticleTitle>Successful treatment of cytomegalovirus colitis with ganciclovir in a patient with adult T cell leukemia lymphoma: case report.</ArticleTitle><Pagination><StartPage>215</StartPage><EndPage>219</EndPage><MedlinePgn>215-9</MedlinePgn></Pagination><Abstract><AbstractText>An 84-year-old patient with adult T cell leukemia lymphoma (ATLL) developed diarrhea on day 5 of chemotherapy and was diagnosed with cytomegalovirus (CMV) colitis. Sigmoidoscopy revealed multiple superficial erosions surrounded by a flare. Computed tomography (CT) and ultrasonogram of the abdomen revealed marked thickening of the colonic mucosa. There were 186 CMV antigen-positive leukocytes per 31,000 white blood cells (WBC). A colonic biopsy specimen showed typical CMV nuclear inclusions. Immunohistological study of the specimen was positive for CMV antigen. Administration of ganciclovir (DHPG) 500 mg/day for 14 days improved the diarrhea and other symptoms. On day 30 of the chemotherapy, the patient developed diarrhea again but was diagnosed with pseudomembranous colitis instead of CMV colitis. At that time, CMV antigenemia and a histologic study for CMV were negative. The stool was positive for Clostridium difficile toxin antigen. ATLL patients are believed to be immunocompromised hosts and often develop opportunistic infections such as CMV infection. Most suffer from CMV pneumonia at the end of their course of therapy. Few gastrointestinal (GI) CMV infections are seen in ATLL patients and details of CMV colitis have never been reported. When an ATLL patient develops diarrhea that barely responds to conventional therapy, CMV colitis and pseudomembranous colitis should be listed in the differential diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oshima</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Takagi Hospital, Ohkawa-city, Fukuoka, Japan. oshima@i.kyushu-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kawazoye</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Higashijima</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yanaga</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Chemother</MedlineTA><NlmUniqueID>8907348</NlmUniqueID><ISSNLinking>1120-009X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P9G3CKZ4P5</RegistryNumber><NameOfSubstance UI="D015774">Ganciclovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003092">Colitis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003586">Cytomegalovirus Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015774">Ganciclovir</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016867">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10435685</ArticleId><ArticleId IdType="doi">10.1179/joc.1999.11.3.215</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23100309</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience.</ArticleTitle><Pagination><StartPage>219</StartPage><EndPage>225</EndPage><MedlinePgn>219-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2012-07-444372</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) relapse is a serious therapeutic challenge after allogeneic hematopoietic stem cell transplantation (allo-SCT). In the present study, we retrospectively analyzed 35 patients who experienced progression of or relapsed persistent ATL after a first allo-SCT at 3 institutions in Nagasaki prefecture (Japan) between 1997 and 2010. Twenty-nine patients were treated by the withdrawal of immune suppressants as the initial intervention, which resulted in complete remission (CR) in 2 patients. As the second intervention, 9 patients went on to receive a combination of donor lymphocyte infusion and cytoreductive therapy and CR was achieved in 4 patients. Of 6 patients who had already had their immune suppressants discontinued before the relapse, 3 patients with local recurrence received local cytoreductive therapy as the initial treatment, which resulted in CR for more than 19 months. Donor lymphocyte infusion-induced remissions of ATL were durable, with 3 cases of long-term remission of more than 3 years and, interestingly, the emergence or progression of chronic GVHD was observed in all of these cases. For all 35 patients, overall survival after relapse was 19.3% at 3 years. The results of the present study suggest that induction of a graft-versus-ATL effect may be crucial to obtaining durable remission for ATL patients with relapse or progression after allo-SCT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itonaga</LastName><ForeName>Hidehiro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsushima</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Takuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shinya</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sawayama</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Matsuo</LastName><ForeName>Emi</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Yamasaki</LastName><ForeName>Reishi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Onimaru</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Imanishi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hata</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Moriuchi</LastName><ForeName>Yukiyoshi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Uike</LastName><ForeName>Naokuni</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Blood. 2013 Jan 3;121(1):6-7</RefSource><PMID Version="1">23287623</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D020544">Graft vs Leukemia Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017254">Leukemic Infiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017710">Lymphocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015337">Multicenter Studies as Topic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000706">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016879">Salvage Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23100309</ArticleId><ArticleId IdType="doi">10.1182/blood-2012-07-444372</ArticleId><ArticleId IdType="pii">S0006-4971(20)47341-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34862665</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0609</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of haematology</Title><ISOAbbreviation>Eur J Haematol</ISOAbbreviation></Journal><ArticleTitle>Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>222</EndPage><MedlinePgn>212-222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejh.13728</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Adult T-cell leukemia-lymphoma (ATL) is a mature T-cell lymphoproliferative neoplasm caused by human T-cell leukemia virus type-1 infection. There is no standard treatment for relapsed or refractory (r/r) ATL, and clinical outcomes are poor. This systematic review examined the survival outcomes for r/r ATL treated with various systemic therapies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">EMBASE and PubMed were searched for studies on r/r ATL, published between January 2010 and January 2020. The main outcome of interest was overall survival (OS). Median OS and an exploratory 30% OS time were assessed based on published data and Kaplan-Meier curves.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 21 unique treatment subgroups (from 14&#160;studies), that met the eligibility criteria. Nine subgroups were mogamulizumab treatment, two were mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo-HSCT), five were allo-HSCT, and five were other chemotherapy. Respectively, the median OS and 30% OS varied considerably in range for mogamulizumab treatment (2.2-17.6&#160;months and 8.7-27.1&#160;months), allo-HSCT (3.8-6.2&#160;months and 7.5-19.8&#160;months), and other chemotherapy arms (4.1-20.3&#160;months and 7.1-17.0&#160;months).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Mogamulizumab was the most frequently studied treatment regimen and can potentially provide longer survival compared with chemotherapy alone. Future comparisons with synthetic or historical control arms may enable clearer insights into treatment efficacy.</AbstractText><CopyrightInformation>&#169; 2021 Kyowa Kirin Co., Ltd. European Journal of Haematology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Kisato</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cancer Center, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crawford</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Syneos Health, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Jingbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Syneos Health, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuan</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Syneos Health, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Syneos Health, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Kyowa Kirin Co., Ltd.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Haematol</MedlineTA><NlmUniqueID>8703985</NlmUniqueID><ISSNLinking>0902-4441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult T-cell leukemia-lymphoma</Keyword><Keyword MajorTopicYN="N">drug therapy</Keyword><Keyword MajorTopicYN="N">hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">recurrence</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList><CoiStatement>KN has received honoraria from Kyowa Kirin, Chugai Pharma, Novartis, Celgene, Eisai, Merck Sharp &amp; Dohme, and Bristol&#8208;Myers Squibb and consultant fees from Kyowa Kirin; TT is a full&#8208;time employee of Kyowa Kirin Co., Ltd; BC, JY, WK, and TM were employees of Syneos Health at the time of this study and have no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34862665</ArticleId><ArticleId IdType="pmc">PMC9299810</ArticleId><ArticleId IdType="doi">10.1111/ejh.13728</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T&#8208;cell leukemia and its implication in the disease. Proc Natl Acad Sci. 1982;79(6):2031&#8208;2035. 10.1073/pnas.79.6.2031</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.79.6.2031</ArticleId><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T&#8208;cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):7415&#8208;7419. 10.1073/pnas.77.12.7415</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.77.12.7415</ArticleId><ArticleId IdType="pmc">PMC350514</ArticleId><ArticleId IdType="pubmed">6261256</ArticleId></ArticleIdList></Reference><Reference><Citation>Takatsuki K, Uchiyama J, Sagawa K, Yodoi J. Adult T&#8208;cell leukemia in Japan. In: Seno S, Takaku F, Irino S, editors. Topics in Hematology. Exerpta Medica; 1977. pp. 73&#8208;77.</Citation></Reference><Reference><Citation>Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T&#8208;cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481&#8208;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka K, Iwanaga M, Imaizumi Y, et al. Epidemiological and clinical features of adult T&#8208;cell leukemia&#8211;lymphoma in Japan, 2010&#8211;2011: A nationwide survey. Cancer Sci. 2017;108(12):2478&#8208;2486. 10.1111/cas.13398</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13398</ArticleId><ArticleId IdType="pmc">PMC5715256</ArticleId><ArticleId IdType="pubmed">28905463</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Ramos JC, Tobinai K. A review of new findings in adult t&#8208;cell leukemia&#8208;lymphoma: a focus on current and emerging treatment strategies. Adv Ther. 2018;35(2):135&#8208;152. 10.1007/s12325-018-0658-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-018-0658-4</ArticleId><ArticleId IdType="pmc">PMC5818559</ArticleId><ArticleId IdType="pubmed">29411267</ArticleId></ArticleIdList></Reference><Reference><Citation>The T&#8208; and B&#8208;Cell Malignancy Study Group . Statistical analyses of clinico&#8208;pathological, virological and epidemiological data on lymphoid malignancies with special reference to adult T&#8208;cell leukemia/lymphoma: a report of the second nationwide study of Japan. Jpn J Clin Oncol. 1985;15(3):517&#8208;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">2997510</ArticleId></ArticleIdList></Reference><Reference><Citation>Vose J, Armitage J, Weisenburger D. International T&#8208;Cell Lymphoma Project. International peripheral T&#8208;cell and natural killer/T&#8208;cell lymphoma study: pathology findings and clinical outcomes. Journal of clinical oncology : official journal of the American Society of. Clin Oncol (R Coll Radiol). 2008;26(25):4124&#8208;4130. 10.1200/JCO.2008.16.4558</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.16.4558</ArticleId><ArticleId IdType="pubmed">18626005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP&#8208;AMP&#8208;VECP compared with biweekly CHOP for adult T&#8208;cell leukemia&#8208;lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458&#8208;5464. 10.1200/JCO.2007.11.9958</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.11.9958</ArticleId><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T&#8208;cell leukaemia&#8208;lymphoma. A report from the Lymphoma Study Group (1984&#8208;87). Br J Haematol. 1991;79(3):428&#8208;437. 10.1111/j.1365-2141.1991.tb08051.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1991.tb08051.x</ArticleId><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi Y, Iwanaga M, Nosaka K, et al. Prognosis of patients with adult T&#8208;cell leukemia/lymphoma in Japan: A nationwide hospital&#8208;based study. Cancer Sci. 2020;111(12):4567&#8208;4580. 10.1111/cas.14658</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.14658</ArticleId><ArticleId IdType="pmc">PMC7734015</ArticleId><ArticleId IdType="pubmed">32976684</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570&#8208;2577. 10.1182/blood-2015-03-632489</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632489</ArticleId><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Tamura K. Human T&#8208;cell leukaemia virus type I and adult T&#8208;cell leukaemia&#8208;lymphoma. Lancet Oncol. 2014;15(11):e517&#8208;e526. 10.1016/S1470-2045(14)70202-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70202-5</ArticleId><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in the treatment of adult T&#8208;cell leukemia&#8208;lymphomas. Cancer Sci. 2015;106(4):344&#8208;345. 10.1111/cas.12617</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12617</ArticleId><ArticleId IdType="pmc">PMC4409876</ArticleId><ArticleId IdType="pubmed">25613789</ArticleId></ArticleIdList></Reference><Reference><Citation>Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T&#8208;cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood. 2013;121(1):219&#8208;225. 10.1182/blood-2012-07-444372</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-07-444372</ArticleId><ArticleId IdType="pubmed">23100309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Phillips AA. How I treat adult T&#8208;cell leukemia/lymphoma. Blood. 2021;137(4):459&#8208;470. 10.1182/blood.2019004045</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019004045</ArticleId><ArticleId IdType="pubmed">33075812</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi H, Imaizumi Y, Makiyama J, et al. Outcome of patients with relapsed/refractory adult T&#8208;cell leukemia&#8208;lymphoma after salvage therapy. Rinsho Ketsueki. 2013;54(12):2159&#8208;2166.</Citation><ArticleIdList><ArticleId IdType="pubmed">24452146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine M, Kameda T, Shide K, et al. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T&#8208;cell leukemia/lymphoma. Eur J Haematol. 2021;106(3):398&#8208;407. 10.1111/ejh.13565</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13565</ArticleId><ArticleId IdType="pubmed">33301622</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz SM, Ansell S, Ai WZ, et al. NCCN Guidelines Insights: T&#8208;Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020;18(11):1460&#8208;1467. 10.6004/jnccn.2020.0053</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2020.0053</ArticleId><ArticleId IdType="pubmed">33152703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T&#8208;cell lymphoma. Onco Targets Ther. 2019;12:1085&#8208;1094. 10.2147/OTT.S165615</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S165615</ArticleId><ArticleId IdType="pmc">PMC6369856</ArticleId><ArticleId IdType="pubmed">30799938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshie OFR, Nakayama T, Harasawa H, et al. Frequent expression of CCR4 in adult T&#8208;cell leukemia and human T&#8208;cell leukemia virus type 1&#8208;transformed T cells. Blood. 2002;99(5):1505&#8208;1511. 10.1182/blood.v99.5.1505</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v99.5.1505</ArticleId><ArticleId IdType="pubmed">11861261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T&#8208;cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10):3625&#8208;3634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Joh T, Uike N, et al. Defucosylated anti&#8208;CCR4 monoclonal antibody (KW&#8208;0761) for relapsed adult T&#8208;cell leukemia&#8208;lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837&#8208;842. 10.1200/JCO.2011.37.3472</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.37.3472</ArticleId><ArticleId IdType="pubmed">22312108</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake A, Konishi A, Azuma Y, et al. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T&#8208;cell leukemia/lymphoma: A retrospective analysis. Eur J Haematol. 2020;105(6):704&#8208;711. 10.1111/ejh.1347</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.1347</ArticleId><ArticleId IdType="pubmed">32564395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T&#8208;cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713&#8208;4720. 10.1182/blood-2009-04-217687</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-04-217687</ArticleId><ArticleId IdType="pmc">PMC2780306</ArticleId><ArticleId IdType="pubmed">19786615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T&#8208;cell leukemia/lymphoma: ATLL&#8208;002. J Clin Oncol. 2016;34(34):4086&#8208;4093. 10.1200/JCO.2016.67.7732</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.7732</ArticleId><ArticleId IdType="pubmed">27621400</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta&#8208;analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. 10.1371/journal.pmed.1000097</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta&#8208;analyses of the published literature for survival endpoints. Stat Med. 1998;23(11):1817. 10.1002/(sici)1097-0258(19981230)17:24&lt;2815:aid-sim110&gt;3.0.co;2-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0258(19981230)17:24&lt;2815:aid-sim110&gt;3.0.co;2-8</ArticleId><ArticleId IdType="pubmed">9921604</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan&#8208;Meier survival curves. BMC Med Res Methodol. 2012;12:9. 10.1186/1471-2288-12-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-12-9</ArticleId><ArticleId IdType="pmc">PMC3313891</ArticleId><ArticleId IdType="pubmed">22297116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka K, Yurimoto S, Tsuji Y, Iwabuchi M, Takahashi T, Tobinai K. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T&#8208;cell leukemia&#8208;lymphoma. Eur J Haematol. 2019;102(5):407&#8208;415. 10.1111/ejh.13220</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13220</ArticleId><ArticleId IdType="pmc">PMC6850465</ArticleId><ArticleId IdType="pubmed">30740787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Utsunomiya A, Inoue Y, et al. Outcomes of patients with relapsed aggressive adult T&#8208;cell leukemia&#8208;lymphoma: clinical effectiveness of anti&#8208;CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Haematologica. 2018;103(5):e211&#8208;e214. 10.3324/haematol.2017.184564</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.184564</ArticleId><ArticleId IdType="pmc">PMC5927966</ArticleId><ArticleId IdType="pubmed">29371324</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Fuji S, Tanosaki R, et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant. 2018;53(9):1105&#8208;1115. 10.1038/s41409-018-0139-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0139-z</ArticleId><ArticleId IdType="pmc">PMC7102069</ArticleId><ArticleId IdType="pubmed">29523883</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Fuji S, Wake A, et al. Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T&#8208;cell leukemia/lymphoma, a Japanese nation&#8208;wide study. Bone Marrow Transplant. 2017;52(3):484&#8208;488. 10.1038/bmt.2016.313</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2016.313</ArticleId><ArticleId IdType="pubmed">28067877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K, Uike N, Wake A, et al. The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019;37(1):54&#8208;61. 10.1002/hon.2558</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2558</ArticleId><ArticleId IdType="pubmed">30171618</ArticleId></ArticleIdList></Reference><Reference><Citation>Toriyama E, Imaizumi Y, Taniguchi H, et al. EPOCH regimen as salvage therapy for adult T&#8208;cell leukemia&#8208;lymphoma. Int J Hematol. 2018;108(2):167&#8208;175. 10.1007/s12185-018-2455-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-018-2455-x</ArticleId><ArticleId IdType="pubmed">29651666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T&#8208;cell leukemia&#8208;lymphoma: Updated follow&#8208;up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022&#8208;2029. 10.1111/cas.13343</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13343</ArticleId><ArticleId IdType="pmc">PMC5623751</ArticleId><ArticleId IdType="pubmed">28776876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga M, Yonekura K, Nakamura D, et al. Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T&#8208;cell leukaemia&#8208;lymphoma. Br J Haematologica. 2018;181(4):539&#8208;542. 10.1111/bjh.14634</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14634</ArticleId><ArticleId IdType="pubmed">28369823</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T&#8208;cell leukemia/lymphoma. Haematologica. 2019;104(5):993&#8208;1003. 10.3324/haematol.2018.205096</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.205096</ArticleId><ArticleId IdType="pmc">PMC6518882</ArticleId><ArticleId IdType="pubmed">30573506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima J, Imaizumi Y, Taniguchi H, et al. Clinical factors to predict outcome following mogamulizumab in adult T&#8208;cell leukemia&#8208;lymphoma. Int J Hematol Oncol. 2018;108(5):516&#8208;523. 10.1007/s12185-018-2509-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-018-2509-0</ArticleId><ArticleId IdType="pubmed">30032392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine M, Kubuki Y, Kameda T, et al. Effects of mogamulizumab in adult T&#8208;cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017;98(5):501&#8208;507. 10.1111/ejh.12863</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.12863</ArticleId><ArticleId IdType="pubmed">28152225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto H, Itonaga H, Sawayama Y, et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T&#8208;cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience. Hematol Oncol. 2020;38(2):162&#8208;170. 10.1002/hon.2712</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2712</ArticleId><ArticleId IdType="pubmed">31922287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti&#8208;CCR4 antibody mogamulizumab against adult T&#8208;cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid&#8208;refractory graft&#8208;versus&#8208;host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426&#8208;3433. 10.1200/JCO.2016.67.8250</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.67.8250</ArticleId><ArticleId IdType="pubmed">27507878</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Kanzaki T, Gunshin K, et al. Effect of anti&#8208;CCR4 monoclonal antibody (mogamulizumab) on adult T&#8208;cell leukemia&#8208;lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41(3):239&#8208;244. 10.1111/1346-8138.12419</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.12419</ArticleId><ArticleId IdType="pubmed">24628073</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura K, Kusumoto S, Choi I, et al. Mogamulizumab for adult T&#8208;cell leukemia&#8208;lymphoma: a multicenter prospective observational study. Blood Adv. 2020;4(20):5133&#8208;5145. 10.1182/bloodadvances.2020003053</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003053</ArticleId><ArticleId IdType="pmc">PMC7594399</ArticleId><ArticleId IdType="pubmed">33091125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW&#8208;0761, a defucosylated humanized anti&#8208;CCR4 antibody, in relapsed patients with adult T&#8208;cell leukemia&#8208;lymphoma and peripheral T&#8208;cell lymphoma. J Clin Oncol. 2010;28(9):1591&#8208;1598. 10.1200/jco.2009.25.3575</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2009.25.3575</ArticleId><ArticleId IdType="pubmed">20177026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano N, Kuriyama T, Sonoda KH, et al. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T&#8208;cell Leukemia&#8208;lymphoma Treated at a Single Institution During a Three&#8208;year Period (2012&#8211;2014). Intern Med. 2016;55(11):1439&#8208;1445. 10.2169/internalmedicine.55.6312</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.55.6312</ArticleId><ArticleId IdType="pubmed">27250049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">27374686</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>13</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>1793</StartPage><EndPage>1796</EndPage><MedlinePgn>1793-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.55.5987</ELocationID><Abstract><AbstractText>A 74-year-old woman with refractory adult T-cell leukemia/lymphoma (ATLL) received three courses of mogamulizumab. Despite obtaining complete remission, she thereafter presented with progressive ascites. An analysis of the ascites and laboratory tests revealed no evidence of ATLL invasion, infectious disease, or liver cirrhosis. The mogamulizumab concentrations were maintained in the ascites at approximately 10-15% of that in the plasma. Mogamulizumab was considered to be a plausible pathogenesis of her ascites. To the best of our knowledge, this is the first report suggesting mogamulizumab-induced ascites.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shima</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamezaki</LastName><ForeName>Kenjiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Higashioka</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Shuichiro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yoshimoto</LastName><ForeName>Goichi</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Muta</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Takenaka</LastName><ForeName>Katsuto</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Hiromi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Akashi</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001201">Ascites</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27374686</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.55.5987</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23797717</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0979</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of surgical pathology</Title><ISOAbbreviation>Am J Surg Pathol</ISOAbbreviation></Journal><ArticleTitle>Loss of Foxp3 is associated with CD30 expression in the anaplastic large cell subtype of adult T-cell leukemia/lymphoma (ATLL) in US/Caribbean patients: potential therapeutic implications for CD30 antibody-mediated therapy.</ArticleTitle><Pagination><StartPage>1407</StartPage><EndPage>1412</EndPage><MedlinePgn>1407-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PAS.0b013e31828f2322</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is caused by the HTLV-1 virus, endemic to Japan and the Caribbean, and is likely derived from cells with the T-regulatory phenotype. The malignant cells express IL2 receptor &#945; (CD25), and the majority express transcription factor Forkhead box P3 (Foxp3), in addition to T-cell markers. Occasional cases express CD30. Whereas Japanese cases are predominantly of the acute and chronic leukemic types, the less well-studied Caribbean cases are more often lymphomatous. We performed immunohistochemical analysis for CD25, Foxp3, and CD30 on samples from 42 US/Caribbean ATLL patients and correlated these markers with morphologic subtype and clinical characteristics. In the 16/42 patients who had successive biopsies, we determined the expression stability of these markers. Foxp3 was expressed in 26 of the 42 (62%) initial biopsies, and its intensity correlated with CD25 expression. It was more frequent in pleomorphic small-sized and medium-sized cell types than in large cell tumors but did not correlate with patients' clinical attributes. Foxp3 expression and morphology were unchanged in successive biopsies in 13 of 16 patients. Four initial biopsies had features of anaplastic large cell T lymphomas, all of which were Foxp3. Successive biopsies from 2 patients with pleomorphic medium cell variant showed diminishing expression of originally weak Foxp3 expression and de novo CD30 expression, whereas they showed morphologic progression to the anaplastic cell variant. A third patient's second biopsy revealed progression from pleomorphic medium to anaplastic large cell morphology with loss of Foxp3, but it remained CD30. Foxp3 expression correlates with pleomorphic small and medium cell types and may be lost with large cell transformation. The evolution of the latter type can be associated with the gain of CD30 expression; such ATLL tumors might respond to anti-CD30 monoclonal antibody therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Jinjuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of *Pathology &#8225;Hematology/Oncology, SUNY Downstate Medical Center Departments of &#8224;Pathology &#167;Hematology/Oncology, Kings County Hospital Center, Brooklyn, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Susan R S</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Ayalew</LastName><ForeName>Getinet</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Braverman</LastName><ForeName>Albert S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Axiotis</LastName><ForeName>Constantine A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Surg Pathol</MedlineTA><NlmUniqueID>7707904</NlmUniqueID><ISSNLinking>0147-5185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C418974">FOXP3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508017">IL2RA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053645">Interleukin-2 Receptor alpha Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017730">Ki-1 Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000906">Antibodies</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017691">Caribbean Region</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051858">Forkhead Transcription Factors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053645">Interleukin-2 Receptor alpha Subunit</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017730">Ki-1 Antigen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D058990">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014481">United States</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23797717</ArticleId><ArticleId IdType="doi">10.1097/PAS.0b013e31828f2322</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26524263</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>205</StartPage><EndPage>211</EndPage><MedlinePgn>205-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/bmt.2015.265</ELocationID><Abstract><AbstractText>Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, &lt;100 days, n=72; late transplant group, &#10878;100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujiwara</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, Ehime University Hospital, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wake</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9653-6170</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidaka</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriuchi</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uike</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taguchi</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eto</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomoyose</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Second Department of Internal Medicine, Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, University Hospital, University of the Ryukyus, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Kyoto University Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanoha</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Haematology, Heart-Life Hospital, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichinohe</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atsuta</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012042">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26524263</ArticleId><ArticleId IdType="doi">10.1038/bmt.2015.265</ArticleId><ArticleId IdType="pii">bmt2015265</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Haematol. 2001 May;113(2):375-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11380402</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2013 Apr;97(4):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23483425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2013 Jun 1;31(16):1970-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23610113</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2013 Oct;27(10):2068-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23648670</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2013 Apr 1;31(10):1310-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23423745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2014 Oct;15(11):e517-26</Citation><ArticleIdList><ArticleId IdType="pubmed">25281470</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2012 May 10;30(14):1635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22473153</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2007 Oct;86(3):269-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17988995</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2014 Sep;166(5):739-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24931507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 1995 Jun;15(6):825-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7581076</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2014 Dec;20(12):1968-74</Citation><ArticleIdList><ArticleId IdType="pubmed">25172635</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Aug 26;116(8):1369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20479287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2013 Mar;48(3):452-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2012 Nov;96(5):657-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22976114</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2012 Mar 1;119(9):2141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22234682</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jun;14 (6):641-50</Citation><ArticleIdList><ArticleId IdType="pubmed">18489989</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2008 Apr;87(3):319-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18288565</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2009 Jan 20;27(3):453-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2012 Aug 23;120(8):1734-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22689862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17488707</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Haematologica</Title><ISOAbbreviation>Haematologica</ISOAbbreviation></Journal><ArticleTitle>Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>719</StartPage><EndPage>720</EndPage><MedlinePgn>719-20</MedlinePgn></Pagination><Abstract><AbstractText>Arsenic trioxide (As2O3) with or without interferon-a (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). Treatment with As2O3 and IFN showed an encouraging response in two moderately-aggressive ATLL patients, while As2O3 alone was ineffective in two patients with very aggressive and rapidly progressing ATLL. Further studies are needed to clarify the role of As2O3 and its usefulness when combined with IFN for the treatment of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Suzumiya</LastName><ForeName>Junji</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Mikiko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ogata</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Shuuji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Haematologica</MedlineTA><NlmUniqueID>0417435</NlmUniqueID><ISSNLinking>0390-6078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001152">Arsenicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010087">Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7V92P67HO</RegistryNumber><NameOfSubstance UI="D000077237">Arsenic Trioxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077237">Arsenic Trioxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001152">Arsenicals</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010087">Oxides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016879">Salvage Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013921">Thrombocytopenia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17488707</ArticleId><ArticleId IdType="doi">10.3324/haematol.10703</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17373678</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0361-8609</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>American journal of hematology</Title><ISOAbbreviation>Am J Hematol</ISOAbbreviation></Journal><ArticleTitle>Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature.</ArticleTitle><Pagination><StartPage>748</StartPage><EndPage>752</EndPage><MedlinePgn>748-52</MedlinePgn></Pagination><Abstract><AbstractText>Primary adrenal lymphoma (PAL) is very rare; the majority of cases reported previously were of B-cell origin. We report a rare case of primary adrenal adult T-cell leukemia/lymphoma (primary adrenal ATLL). ATLL is a highly aggressive T-cell type non-Hodgkin's lymphoma and etiologically associated with human T-cell lymphotropic virus 1 (HTLV-1). Most ATLL patients present with leukemia and widespread lymphadenopathy. A 37-year-old Japanese woman presented with back pain in January 2004. Examination showed no peripheral lymphadenopathy, circulating lymphoma cells, hepatosplenomegaly, and skin lesions. Imaging studies demonstrated large adrenal masses bilaterally. Subsequently, she underwent open adrenal biopsy and pathological diagnosis was confirmed as T-cell lymphoma. The serum antibody to HTLV-1 was positive. Southern blot analysis detected monoclonal integration of proviral DNA of HTLV-1 into host genome in the biopsy specimen. The diagnosis of ATLL arising in adrenal glands was established. Despite repeated systemic chemotherapy, the patient died of progressive disease in December 2004. ATLL could primarily involve the adrenal gland and this disease entity should be included in the differential diagnosis of adrenal mass lesions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomoyose</LastName><ForeName>Takeaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Internal Medicine, University of the Ryukyus School of Medicine, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagasaki</LastName><ForeName>Akitoshi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Uchihara</LastName><ForeName>Jun-Nosuke</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Kinjo</LastName><ForeName>Shigeko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sugaya</LastName><ForeName>Kimio</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Onaga</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Kouichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Masato</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takasu</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hematol</MedlineTA><NlmUniqueID>7610369</NlmUniqueID><ISSNLinking>0361-8609</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000310">Adrenal Gland Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015898">Tomography Scanners, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17373678</ArticleId><ArticleId IdType="doi">10.1002/ajh.20856</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22042945</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>35</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>4696</StartPage><EndPage>4701</EndPage><MedlinePgn>4696-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2011.35.5578</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Adult T-cell leukemia/lymphoma (ATLL) is a mature (post-thymic) T-cell lymphoma associated with human T-lymphotropic virus type 1 infection. Survival in aggressive subtypes remains poor, and treatment resistance is frequent. Use of zidovudine (ZDV) and interferon alfa (IFN-&#945;) has been associated with improved response rates in small studies and prolonged overall survival in leukemic ATLL subtypes in a recent meta-analysis.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We report the clinicopathologic characteristics, treatment, and outcome of 73 patients with aggressive ATLL (acute ATLL, 29; lymphoma ATLL, 44) diagnosed and treated in England between 1999 and 2009. The impact of ZDV/IFN-&#945; on treatment response and survival was assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-&#945;). Median overall survival (OS) was 9 months: 7.5 months for acute ATLL and 10 months for lymphoma ATLL. Use of ZDV/IFN-&#945; at any time prolonged survival in acute (P &lt; .001) and lymphoma ATLL (P &lt; .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL (hazard ratio, 0.23; 95% CI, 0.09 to 0.60; P = .002). Combined first-line therapy prolonged median OS in acute (P = .0081) and lymphoma ATLL (P = .001) compared with chemotherapy alone.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data support the use of low-dose ZDV/IFN-&#945; with chemotherapy in first-line treatment of acute and lymphoma ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hodson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Centre for Human Retrovirology, St Mary&#8217;s Hospital, Imperial College Healthcare National Health Service Trust, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crichton</LastName><ForeName>Siobhan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Montoto</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>Naheed</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Matutes</LastName><ForeName>Estella</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cwynarski</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kumaran</LastName><ForeName>Thurai</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ardeshna</LastName><ForeName>Kirit M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Pagliuca</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Graham P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>4B9XT59T7S</RegistryNumber><NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22042945</ArticleId><ArticleId IdType="doi">10.1200/JCO.2011.35.5578</ArticleId><ArticleId IdType="pii">JCO.2011.35.5578</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22323448</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>13</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>3097</StartPage><EndPage>3104</EndPage><MedlinePgn>3097-104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2011-09-379982</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an intractable hematologic malignancy caused by human T-lymphotropic virus type 1 (HTLV-1), which infects approximately 20 million people worldwide. Here, we have explored the possible expression of cancer/testis (CT) antigens by ATLL cells, as CT antigens are widely recognized as ideal targets of cancer immunotherapy against solid tumors. A high percentage (87.7%) of ATLL cases (n = 57) expressed CT antigens at the mRNA level: NY-ESO-1 (61.4%), MAGE-A3 (31.6%), and MAGE-A4 (61.4%). CT antigen expression was confirmed by immunohistochemistry. This contrasts with other types of lymphoma or leukemia, which scarcely express these CT antigens. Humoral immune responses, particularly against NY-ESO-1, were detected in 11.6% (5 of 43) and NY-ESO-1-specific CD8(+) T-cell responses were observed in 55.6% (5 of 9) of ATLL patients. NY-ESO-1-specific CD8(+) T cells recognized autologous ATLL cells and produced effector cytokines. Thus, ATLL cells characteristically express CT antigens and therefore vaccination with CT antigens can be an effective immunotherapy of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nishikawa</LastName><ForeName>Hiroyoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gnjatic</LastName><ForeName>Sacha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Eiichi</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Fumiko</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Asahi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fukumori</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Old</LastName><ForeName>Lloyd J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Ryuzo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sakaguchi</LastName><ForeName>Shimon</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000941">Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C104948">CTAG1B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C072013">MAGEA3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C095204">MAGEA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000941">Antigens</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000951">Antigens, Neoplasm</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015973">Gene Expression Regulation, Leukemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056724">Immunity, Humoral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013737">Testis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22323448</ArticleId><ArticleId IdType="doi">10.1182/blood-2011-09-379982</ArticleId><ArticleId IdType="pii">S0006-4971(20)49178-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17938020</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-6787</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>5 Suppl</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Dermatology</Title><ISOAbbreviation>J Am Acad Dermatol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous-type adult T-cell leukemia/lymphoma presenting as a solitary large skin nodule: a review of the literature.</ArticleTitle><Pagination><StartPage>S115</StartPage><EndPage>S117</EndPage><MedlinePgn>S115-7</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) often involves the skin. Cases with skin lesions without either leukemic nor lymph node involvement have been categorized into a cutaneous type. While the clinical manifestations of the cutaneous-type ATLL are variable, including multiple papules, nodules, plaques, or erythroderma, a solitary skin nodule alone is rare, and only 2 cases have been reported in the literature. We present a 58-year-old Japanese patient with cutaneous-type ATLL that presented as a large, solitary skin nodule as the sole clinical feature. The skin tumor was completely resolved after treatment with x-ray and electron beam irradiation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Satoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Sapporo City General Hospital, Sapporo, Japan. satoko.shimizu@nifty.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Chikako</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Hikaru</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tsuchiya</LastName><ForeName>Kikuo</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Dermatol</MedlineTA><NlmUniqueID>7907132</NlmUniqueID><ISSNLinking>0190-9622</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014964">X-Ray Therapy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>10</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17938020</ArticleId><ArticleId IdType="doi">10.1016/j.jaad.2006.12.031</ArticleId><ArticleId IdType="pii">S0190-9622(07)00023-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">33327284</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>50</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>11</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Cutaneous plaque in adult T cell leukemia/lymphoma: A case report.</ArticleTitle><Pagination><StartPage>e23491</StartPage><MedlinePgn>e23491</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e23491</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000023491</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">The rarity of adult T cell leukemia/lymphoma (ATLL) in China, coupled with its clinicopathologic mimicry of primary skin disease, poses a diagnostic challenge. The method of diagnosis and mechanism of immune regulation in ATLL are discussed in the present report.</AbstractText><AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">A 51-year-old Chinese man was admitted to the hospital with 2-years history of systemic plaque lesions and 1-year history of left ankle joint pain.</AbstractText><AbstractText Label="DIAGNOSES" NlmCategory="METHODS">The patient was diagnosed with ATLL based on the results of flow cytometry immunophenotype and human T-cell lymphotropic virus type 1 (HTLV-1) serology.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The patient received 3 cycles of cyclophosphamide, epirubicin/ vinorelbine, and dexamethasone (CHOP) chemotherapy. However, he relapsed and did not respond to epirubicin, vindesine, etoposide, dexamethasone (EPOCH) chemotherapy.</AbstractText><AbstractText Label="OUTCOMES" NlmCategory="RESULTS">His family discontinued the treatment and opted for hospice care.</AbstractText><AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">Patch and plaque ATLL types exhibits a better survival rate, but atypical skin patches delays the diagnosis of ATLL and negatively affects the patient survival. Based on the present findings, we suggest that patients with petal-like nuclear lymphocytes in blood smears, a high CD4: CD8 ratio, and strong CD25 expression should undergo HTLV-1 serology testing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Chen Shuang</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Zhejiang Chinese Medical University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>College of Medical Technology, Zhejiang Chinese Medical University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Qinhua</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Liannv</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6PLQ3CP4P3</RegistryNumber><NameOfSubstance UI="D005047">Etoposide</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C079446">EPOCH protocol</SupplMeshName><SupplMeshName Type="Protocol" UI="C036337">VAP-cyclo protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005047">Etoposide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012871">Skin Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33327284</ArticleId><ArticleId IdType="pmc">PMC7738110</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000023491</ArticleId><ArticleId IdType="pii">00005792-202012110-00065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martino G, Zanelli M, Marra A, et al. Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. Tumori 2019;105: NP38&#8211;NP42.</Citation><ArticleIdList><ArticleId IdType="pubmed">31041884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Xu L, Huang X, et al. Arsenic induced complete remission in a refractory T-ALL patient with a distinct T-cell clonal evolution without molecular complete remission: a case report. Oncol Lett 2016;11:4123&#8211;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888266</ArticleId><ArticleId IdType="pubmed">27313752</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanlari M, Ramos JC, Sanchez SP, et al. Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. Modern Pathology An Official Journal of the United States &amp; Canadian Academy of Pathology Inc 2018;31:1046&#8211;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6931282</ArticleId><ArticleId IdType="pubmed">29449683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol 2019;37:677&#8211;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494249</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira CR, Zhao S, Sahoo MK, et al. FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype. Hum Pathol 2018;80:138&#8211;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">29898383</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Chikuma S, Hori S, et al. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. Proc Natl Acad Sci U S A 2016;113:8490&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968716</ArticleId><ArticleId IdType="pubmed">27410049</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolova M, Lelievre JD, Carriere M, et al. Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets. Blood 2009;113:4556&#8211;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811717</ArticleId><ArticleId IdType="pubmed">19246340</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899&#8211;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">19464196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263&#8211;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930702</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science (New York, NY) 2008;322:271&#8211;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18845758</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016;44:989&#8211;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942846</ArticleId><ArticleId IdType="pubmed">27192565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagihara T, Ikematsu Y, Kato K, et al. Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma. Ann Hematol 2018;97:359&#8211;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28967040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni N, Meitei HT, Sonar SA, et al. CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation. J Autoimmun 2018;88:121&#8211;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29126851</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulissen SM, van Hamburg JP, Dankers W, et al. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 2015;74:43&#8211;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25828206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Deng X, Guan X, et al. Herpes simplex virus type 2 infection-induced expression of CXCR3 ligands promotes CD4 (+) T cell migration and is regulated by the viral immediate-early protein ICP4. Frontiers immunol 2018;9:2932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305738</ArticleId><ArticleId IdType="pubmed">30619292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling CC, Ng KT, Shao Y, et al. Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol 2014;60:103&#8211;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23994383</ArticleId></ArticleIdList></Reference><Reference><Citation>Legler DF, Loetscher M, Roos RS, et al. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655&#8211;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212150</ArticleId><ArticleId IdType="pubmed">9463416</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas S, Sengupta S, Roy Chowdhury S, et al. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat 2014;143:265&#8211;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">24337540</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster R, Mattis AE, Kremmer E, et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996;87:1037&#8211;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramezani G, Pourgheysari B, Shirzad H, et al. Pterostilbene increases Fas expression in T-lymphoblastic leukemia cell lines. Res Pharm Sci 2019;14:55&#8211;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407337</ArticleId><ArticleId IdType="pubmed">30936933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009;23:375&#8211;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18830259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011;117:3961&#8211;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21325600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">37544729</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>7</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Tax-targeted dendritic cell vaccine therapy for long-term remission of adult T-cell leukemia-lymphoma].</ArticleTitle><Pagination><StartPage>670</StartPage><EndPage>677</EndPage><MedlinePgn>670-677</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.64.670</ELocationID><Abstract><AbstractText>Adult T-cell leukemia-lymphoma (ATL) is a highly aggressive peripheral T-cell neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1) infection occurring in approximately 5% of patients after prolonged latent period. ATL relapses within a short period despite its transient response to multiagent chemotherapy and the prognosis is extremely poor due to anticancer drug resistance and immunodeficiency. Although novel agents with different mechanisms, such as molecular targeted agents, have improved the prognosis, the number of cured patients remains limited. Hematopoietic stem cell transplantation resulted in long-term remission, whereas its indication is limited due to treatment-related mortality. As most ATL patients are of advanced age, development of a lesser toxic treatment is necessary. Therefore, we developed a novel therapeutic dendritic cell vaccine targeting the HTLV-1 Tax antigen. The safety profile has been confirmed in a pilot and phase I clinical studies, and a promising long-term clinical efficacy has also been obtained. This novel vaccine is a noninvasive, long-lasting therapy for ATL and can potentially be extended to different applications for low-grade ATL and high-risk HTLV-1 carriers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suehiro</LastName><ForeName>Youko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013602">T-Lymphocytes, Cytotoxic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016233">Immunotherapy, Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATL</Keyword><Keyword MajorTopicYN="N">DC vaccine</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Tax</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>6</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37544729</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.64.670</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">28586006</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-2423</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of oncology</Title><ISOAbbreviation>Int J Oncol</ISOAbbreviation></Journal><ArticleTitle>Butein inhibits NF-&#954;B, AP-1 and Akt activation in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>633</StartPage><EndPage>643</EndPage><MedlinePgn>633-643</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2017.4026</ELocationID><Abstract><AbstractText>Human T-cell leukemia virus type 1&#160;(HTLV-1) is the causative agent of adult T-cell leukemia/lymphoma&#160;(ATLL) but there is no effective treatment for HTLV-1-associated diseases. Herein, we determined the effect of butein, a bioactive plant polyphenol, on cell growth, apoptosis and signaling pathways in HTLV-1-infected T-cell lines and on tumor growth in SCID mice. Treatment with butein caused a decrease in viability of HTLV-1-infected T-cell lines. T&#160;cells cultured with butein showed obvious apoptosis morphology, and cleavage of poly(ADP-ribose) polymerase with activation of caspase-3, -8 and -9. Pretreatment of cells with caspase inhibitor partially blocked butein-induced inhibition of cell viability. Butein also resulted in cell cycle arrest at G1&#160;phase. Butein markedly downregulated the protein expression levels of CDK4, CDK6, cyclin D1, cyclin D2, cyclin E, survivin, XIAP, c-IAP2 and phospho-pRb. Butein also inhibited i) total and phospho-protein levels of I&#954;B kinase (IKK)&#945; and IKK&#946;, ii) degradation and phosphorylation of I&#954;B&#945;, iii) JunB and JunD, iv) total and phospho-protein levels of Akt, v) phosphorylation of RelA, vi)&#160;heat shock protein&#160;90, and vii) DNA-binding activity of NF-&#954;B and AP-1. In mice harboring ATLL xenograft tumors, butein caused a significant inhibition of tumor growth and reduced serum levels of soluble interleukin-2 receptor&#160;&#945; chain and soluble cluster of differentiation&#160;30. Considered together, the results indicated that butein has antiproliferative and proapoptotic properties through the suppression of NF-&#954;B, AP-1 and Akt signaling in HTLV-1-infected T&#160;cells, both in&#160;vitro and in&#160;vivo, suggesting its therapeutic potential against HTLV-1-associated diseases including ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Chie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senba</LastName><ForeName>Masachika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Int J Oncol</MedlineTA><NlmUniqueID>9306042</NlmUniqueID><ISSNLinking>1019-6439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047188">Chalcones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>4WVS5M0LGF</RegistryNumber><NameOfSubstance UI="C040918">butein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059447">Cell Cycle Checkpoints</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D047188">Chalcones</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016328">NF-kappa B</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013601">T-Lymphocytes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018808">Transcription Factor AP-1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D023041">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28586006</ArticleId><ArticleId IdType="doi">10.3892/ijo.2017.4026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20120839</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-9091</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>14</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Oncology (Williston Park, N.Y.)</Title><ISOAbbreviation>Oncology (Williston Park)</ISOAbbreviation></Journal><ArticleTitle>Adult T-cell leukemia/lymphoma: complexities in diagnosis and novel treatment strategies.</ArticleTitle><Pagination><StartPage>1267</StartPage><EndPage>1270</EndPage><MedlinePgn>1267, 1270</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Center for Lymphoma, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abramson</LastName><ForeName>Jeremy S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncology (Williston Park)</MedlineTA><NlmUniqueID>8712059</NlmUniqueID><ISSNLinking>0890-9091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015480">Deltaretrovirus Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Oncology (Williston Park). 2009 Dec;23(14):1250-6</RefSource><PMID Version="1">20120837</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015480">Deltaretrovirus Antibodies</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054242">Emigrants and Immigrants</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20120839</ArticleId><ArticleId IdType="pii">166405</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">33779474</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.</ArticleTitle><Pagination><StartPage>2177</StartPage><EndPage>2183</EndPage><MedlinePgn>2177-2183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10428194.2021.1897806</ELocationID><Abstract><AbstractText>Few publications exist concerning allogeneic hematopoietic cell transplant (alloHCT) outcomes in non-Japanese patients with HTLV-1-associated ATLL. We detail the patient and disease characteristics, transplant approach, and clinical outcomes in 17 patients with ATLL at our institution who underwent alloHCT. We report favorable outcomes, with 8/17 in ongoing remission, 2/17 with prolonged (&gt;6&#8201;years) disease-free survival, and a low incidence of transplant-related mortality (2/17). These results validate the feasibility and efficacy of alloHCT in non-Japanese patients with ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Epstein-Peterson</LastName><ForeName>Zachary D</ForeName><Initials>ZD</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesan</LastName><ForeName>Nivetha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Juliet N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drullinsky</LastName><ForeName>Pamela R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghione</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakubowski</LastName><ForeName>Ann A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskowitz</LastName><ForeName>Alison J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noy</LastName><ForeName>Ariela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perales</LastName><ForeName>Miguel-Angel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponce</LastName><ForeName>Doris M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoder</LastName><ForeName>Heiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>James W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giralt</LastName><ForeName>Sergio A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horwitz</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauter</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahi</LastName><ForeName>Parastoo B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Adult BMT Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia lymphoma</Keyword><Keyword MajorTopicYN="N">allogeneic stem cell transplantation</Keyword></KeywordList><CoiStatement>Declaration of interests: A.K. receives research funding from Abbvie, Adaptive Biotechnologies, Celgene, Pharmacyclics, and Seattle Genetics; member of the advisory board for Celgene, Kite Pharma, AstraZeneca and the Summit Advisory Committee; has served on the steering committee for the MCL Registry with AstraZeneca. D.M.P. serves as a consultant on scientific advisory board for Generon Corporation, paid consultant on scientific advisory boards of Kadmon Corporation, Ceramedix; paid consultant and received honorarium from CareDx; she has received research funds for clinical trial from Takeda Pharmaceutical. C.S.S. has served as a paid consultant on advisory boards for: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene, Gamida Cell and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene, Precision Biosciences and Sanofi-Genzyme. M.-A.P. has received honoraria from AbbVie, Bellicum, BMS, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; serves on data safety and monitoring boards for Servier and Medigene and on scientific advisory boards of MolMed and NexImmune; and has received research support for clinical trials from Incyte, Kite Pharma/Gilead, Miltenyi Biotec, and Novartis. P.B.D. serves on the advisory board for Kite/a Gilead Company. A.N. serves on the advisory board for Janssen and Morphosys, has received honoraria from Medscape, has received research funding and honoraria from Pharmacyclics, and has received research funding from Rafael Pharma. S.A.G. received research funding from Actinnum, Celgene, Bristol-Myers Squibb, Sanofi, Amgen, Pfizer, and Jensenn; and serves on the advisory board for Actinnum, Celgene, Bristol-Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, Jazz, and Jensenn. A.J.M has received research support from Miragen, Seattle Genetics, Merck, Bristol-Myers Squibb, and Incyte; and honoraria from Imbrium Therapeutics L.P., Purdue Pharma L.C., Merck, and Seattle Genetics. S.H. has consulted, received honorarium from, or participated in advisory boards for; ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Verastem, and Vividion Therapeutics and has received research support for clinical trials from ADC Therapeutics, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium/Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem. All other authors declare no commercial affiliations, consultancies, stock or equity interests, or patent-licensing arrangements that could be considered to pose a conflict of interest regarding the submitted article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>29</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33779474</ArticleId><ArticleId IdType="mid">NIHMS1830145</ArticleId><ArticleId IdType="pmc">PMC9531547</ArticleId><ArticleId IdType="doi">10.1080/10428194.2021.1897806</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimoyama M, Group LS. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984&#8211;87). British journal of haematology 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Frontiers in microbiology 2012;3:388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA, Shapira I, Willim RD, et al.. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: A multicenter clinicopathologic experience and new prognostic score. Cancer 2010;116:3438&#8211;3446.</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Iwanaga M, Yasunaga J-i, et al.. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood 2018;131:215&#8211;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757690</ArticleId><ArticleId IdType="pubmed">29084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, The Journal of the American Society of Hematology 2016;127:2391&#8211;2405.</Citation><ArticleIdList><ArticleId IdType="pubmed">27069254</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal M, Reljic T, Klocksieben F, et al.. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1&#8211;Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. Biology of Blood and Marrow Transplantation 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A, Cwynarski K, Boumendil A, et al.. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone marrow transplantation 2014;49:1266&#8211;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029232</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA, Chung EY, Giricz O, et al.. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies 2018;132:1507&#8211;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="pubmed">30104217</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipp M A predictive model for aggressive non-Hodgkin&#8217;s lymphoma. The international non-Hodgkin&#8217;s lymphoma prognostic factors project. N Engl j Med 1993;329:987&#8211;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8141877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallamini A, Stelitano C, Calvi R, et al.. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474&#8211;2479.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Fisher RI, Barrington SF, et al.. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology 2014;32:3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979083</ArticleId><ArticleId IdType="pubmed">25113753</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipovich AH, Weisdorf D, Pavletic S, et al.. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation 2005;11:945&#8211;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorror ML, Maris MB, Storb R, et al.. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT 2005;106:2912&#8211;2919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895304</ArticleId><ArticleId IdType="pubmed">15994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahoud OB, Moskowitz AJ, Horwitz SM, Giralt SA, Dahi PBJBmt. Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma 2018;53:654&#8211;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">29358601</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragert L, Eapen M, Williams E, et al.. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. New England Journal of Medicine 2014;371:339&#8211;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965695</ArticleId><ArticleId IdType="pubmed">25054717</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L, Pimentel A, Reis IM, et al.. Epidemiology, clinical features, and outcome of HTLV-1&#8211;related ATLL in an area of prevalence in the United States. Blood advances 2018;2:607&#8211;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="pubmed">29545256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et al.. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. Journal of Clinical Oncology 2009;27:453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">29743403</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma].</ArticleTitle><Pagination><StartPage>426</StartPage><EndPage>431</EndPage><MedlinePgn>426-431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.59.426</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell lymphoma caused by the human T-cell lymphotropic virus type I. Patients with aggressive ATL show dismal prognoses, even with intensive dose-dense chemotherapy. Such patients often show chemo-refractoriness. Mogamulizumab (Moga) is a potent treatment option for patients with relapsed or refractory ATL. However, use of Moga before allo-HSCT could theoretically increase the risk of post-transplant complications like graft-versus-host disease (GVHD) as Moga depletes regulatory T-cells (Tregs). We retrospectively assessed the impact of Moga on post-transplant outcomes using data from a nationwide survey. Pre-transplant administration of Moga was associated with an increased risk of grade 3 to 4 acute GVHD and refractoriness to systemic corticosteroid for acute GVHD. The one-year cumulative incidence of non-relapse mortality was significantly higher in patients who were treated with Moga pre-transplant compared with those who were not (43.7% vs. 25.1%, P&lt;0.01). The probability of one-year overall survival was also significantly lower in patients with pre-transplant Moga use compared to those without (32.3% vs. 49.4%, P&lt;0.01). In summary, pre-transplant Moga was significantly associated with an increased risk of GVHD-related mortality, which supports the relevance of CCR4-expressing Tregs after allo-HSCT in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Osaka International Cancer Institute.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Mogamulizumab</Keyword><Keyword MajorTopicYN="N">Regulatory T-cell</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29743403</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.59.426</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21440808</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>377</Volume><Issue>9771</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Donor-derived adult T-cell leukaemia.</ArticleTitle><Pagination><StartPage>1124</StartPage><MedlinePgn>1124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(11)60315-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamizo</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Maidashi, Fukuoka, Japan. nakamizo@ns.med</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akagi</LastName><ForeName>Yojiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Amano</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Satoshi O</ForeName><Initials>SO</Initials></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Rie</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Yasunobu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yoshimoto</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Iwaki</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Tomio</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001037">Aphasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D002353">Carrier State</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015490">HTLV-I Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007121">Immunocompetence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D036102">Peripheral Blood Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21440808</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(11)60315-2</ArticleId><ArticleId IdType="pii">S0140-6736(11)60315-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19705056</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation.</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>401</EndPage><MedlinePgn>397-401</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-009-0406-2</ELocationID><Abstract><AbstractText>Only some carriers of human T cell lymphotropic virus type I (HTLV-1) develop adult T cell leukemia/lymphoma (ATLL) after a long latency period, and an association has been reported between chronic refractory eczema, known as infective dermatitis, and young-onset ATLL. A 25-year-old female developed ATLL and underwent allogeneic hematopoietic stem cell transplantation (HSCT) in non-remission. She had chronic refractory eczema and corneal injury at the onset of ATLL. Remission of ATLL was achieved, and the HTLV-1 proviral load decreased after HSCT. In addition, her pre-existing eczema and corneal injuries almost disappeared. More than a year has passed since the transplantation was performed, and she has had no recurrence of either ATLL or lesions in the skin and eye. Her clinical course suggests a possible association between skin and eye lesions and HTLV-1 infection. Changes in the immunological condition after HSCT might play a key role. Special attention is needed when HTLV-1 carriers develop eye or skin lesions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyamura</LastName><ForeName>Fumiya</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kako</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamagami</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Miki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terasako</LastName><ForeName>Kiriko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Shun-Ichi</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakasone</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Satoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuda</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshima</LastName><ForeName>Kumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshinaga</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>Takakazu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>Junji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demitsu</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakehashi</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanda</LastName><ForeName>Yoshinobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama, Saitama, 330-8503, Japan. ycanda-tky@umin.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003316">Corneal Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004485">Eczema</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19705056</ArticleId><ArticleId IdType="doi">10.1007/s12185-009-0406-2</ArticleId><ArticleId IdType="pii">10.1007/s12185-009-0406-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Haematol. 1991 Nov;79(3):428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1986 May 3;1(8488):1031-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2871307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jpn J Ophthalmol. 1989;33(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2733251</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2005 Jun 1;40(11):e90-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15889351</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 2000 Feb 1;85(3):319-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10652420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1990 Dec 1;336(8727):1345-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1978165</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jul;14(7):817-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18541202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone Marrow Transplant. 2005 Jun;35(12):1223-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15880131</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Dermatol. 2005 Jan-Feb;15(1):26-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15701589</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2007 Dec 1;25(34):5458-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17968021</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1977 Sep;50(3):481-92</Citation><ArticleIdList><ArticleId IdType="pubmed">301762</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Hematol. 2007 Aug;86(2):118-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17875524</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Ophthalmol. 2003 Dec;14(6):420-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14615649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1985 Aug 24;2(8452):407-10</Citation><ArticleIdList><ArticleId IdType="pubmed">2863442</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Dermatol. 2006 Jan-Feb;16(1):62-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16436345</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 2001 Mar;131(3):305-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11239861</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 2006 Nov;142(5):811-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16989761</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermatology. 1999;199(4):356-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10640850</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 May 15;105(10):4143-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15665110</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2008 Jun;14(6):702-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18489996</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2005 May;19(5):829-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15744352</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 2001 Dec;132(6):950-1</Citation><ArticleIdList><ArticleId IdType="pubmed">11730678</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2005 Aug 15;41(4):535-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16028164</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17222757</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cancer. 1994 Apr 15;57(2):293</Citation><ArticleIdList><ArticleId IdType="pubmed">8157367</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dermatol. 1998 Apr;134(4):439-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9554295</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ophthalmol. 2001 Mar;131(3):309-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11239862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1991 Dec 21-28;338(8782-8783):1593-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1683991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Allergy Asthma Immunol. 1997 May;78(5):513-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9164366</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29382244</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.</ArticleTitle><Pagination><StartPage>2474</StartPage><EndPage>2477</EndPage><MedlinePgn>2474-2477</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10428194.2018.1427859</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Kensuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kidoguchi</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusaba</LastName><ForeName>Kana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimura</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoo</LastName><ForeName>Masako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubota</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>b Department of Transfusion Medicine , Saga University Hospital , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takase</LastName><ForeName>Yukari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>c Department of Pathology and Microbiology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aishima</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>c Department of Pathology and Microbiology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine , Saga University , Saga , Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="D000077269">Lenalidomide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D036101">Cord Blood Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077269">Lenalidomide</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29382244</ArticleId><ArticleId IdType="doi">10.1080/10428194.2018.1427859</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15129647</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1127-0020</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Reviews in clinical and experimental hematology</Title><ISOAbbreviation>Rev Clin Exp Hematol</ISOAbbreviation></Journal><ArticleTitle>HTLV-1 and associated adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>336</StartPage><EndPage>361</EndPage><MedlinePgn>336-61</MedlinePgn></Pagination><Abstract><AbstractText>Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) infects 15-20 millions individuals worldwide. This oncoretrovirus can be transmitted through 3 ways: horizontally, vertically (mother to child) and via blood transfusion. HTLV-1 causes 2 major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy. Tax is a 40-kDa phosphoprotein that is encoded by the pX region of the virus. Several lines of evidence have demonstrated a central role for this protein in the immortalization or transformation of the HTLV-1 infected cells. Apart from its ability to drive transcription from the viral promoter, it also deregulates the cell cycle, inhibits apoptosis, has an effect on the maintenance of the genomic stability and induces the production of several cytokines. In addition, several arguments strongly suggest the existence of host genetic factors, that could be involved in the HTLV-1 infection as well as in the development of ATLL among HTLV-1 infected individuals. ATLL can be classified into 4 major subtypes: a smoldering type, a chronic type, a lymphoma type and a leukemic type. The demonstration by Southern blot analysis of the clonal integration of an HTLV-1 provirus in the tumoral cells represents the gold-standard to define biologically ATLL. The survival rate of ATLL patients, especially those who develop the acute leukemic or lymphomas forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahieux</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit&#233; d'Epid&#233;miologie et Physiopathologie des Virus Oncog&#232;nes, Institut Pasteur, 28 rue du Dr Roux, 75724, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gessain</LastName><ForeName>Antoine</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Rev Clin Exp Hematol</MedlineTA><NlmUniqueID>9815344</NlmUniqueID><ISSNLinking>1127-0020</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016356">Gene Products, tax</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Rev Clin Exp Hematol. 2003 Dec;7(4):327-8</RefSource><PMID Version="1">15129645</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016356">Gene Products, tax</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015491">HTLV-II Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015367">Human T-lymphotropic virus 2</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000472">pathogenicity</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016410">Lymphoma, T-Cell, Cutaneous</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008232">Lymphoproliferative Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009894">Opportunistic Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011251">Pregnancy Complications, Infectious</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>138</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15129647</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31738645</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1651-226X</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta oncologica (Stockholm, Sweden)</Title><ISOAbbreviation>Acta Oncol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous adult T-cell leukemia/lymphoma presenting as sweet syndrome.</ArticleTitle><Pagination><StartPage>334</StartPage><EndPage>335</EndPage><MedlinePgn>334-335</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/0284186X.2019.1691259</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Alana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLellan</LastName><ForeName>Beth N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Oncol</MedlineTA><NlmUniqueID>8709065</NlmUniqueID><ISSNLinking>0284-186X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D033581">Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016463">Sweet Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31738645</ArticleId><ArticleId IdType="doi">10.1080/0284186X.2019.1691259</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20644608</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1609-722X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru</Title><ISOAbbreviation>Rev Gastroenterol Peru</ISOAbbreviation></Journal><ArticleTitle>[Gastric adult T cell leukemia/lymphoma: report of four cases and review of literature].</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>157</EndPage><MedlinePgn>153-7</MedlinePgn></Pagination><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease associated with human T-cell lymphotropic virus type-I (HTLV-I) with heterogeneous clinical presentation and outcomes. We report four cases with gastric involvement. We describe clinical and endoscopic findings of cases and review literature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beltr&#225;n</LastName><ForeName>Brady</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Onc&#243;logo m&#233;dico del Departamento Oncolog&#237;a-Radioterapia del Hospital Edgardo Rebagliati Martins, Lima, Per&#250;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palomino</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Qui&#241;ones</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Domingo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cotrina</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Leucemia/linfoma T del adulto g&#225;strico: reporte de cuatro casos y revisi&#243;n de la literatura.</VernacularTitle></Article><MedlineJournalInfo><Country>Peru</Country><MedlineTA>Rev Gastroenterol Peru</MedlineTA><NlmUniqueID>9108294</NlmUniqueID><ISSNLinking>1022-5129</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6PLQ3CP4P3</RegistryNumber><NameOfSubstance UI="D005047">Etoposide</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C071945">CHOEP protocol</SupplMeshName><SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005047">Etoposide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013274">Stomach Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013276">Stomach Ulcer</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20644608</ArticleId><ArticleId IdType="pii">08</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26981740</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-0311</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>The American Journal of dermatopathology</Title><ISOAbbreviation>Am J Dermatopathol</ISOAbbreviation></Journal><ArticleTitle>An Unusual Association of Adult T-Cell Leukemia/Lymphoma With Hyalohyphomycosis.</ArticleTitle><Pagination><StartPage>370</StartPage><EndPage>373</EndPage><MedlinePgn>370-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DAD.0000000000000533</ELocationID><Abstract><AbstractText>Infection by human T-cell lymphotropic virus (HTLV-1) causes deregulation of the immune system, which makes the infected individuals more susceptible to infectious diseases. Immune deregulation is even more pronounced in HTLV-1 carriers with adult T-cell leukemia/lymphoma (ATLL), which results in frequent opportunistic infections. Hyalohyphomycosis is a rare subcutaneous mycosis which is more commonly associated with immunocompromised patients. We report a case of a HTLV-1-infected man with skin tumors, inguinal lymphadenomegaly, and lymphocytosis. Histopathological examination of skin biopsies revealed a T-cell lymphoma intermingled with a granulomatous process with abscesses and hyaline-septated hyphae. The lymph node showed only a T-cell lymphoma. The patient was diagnosed with acute ATLL and hyalohyphomycosis. He was treated with itraconazole for the subcutaneous mycosis and with chemotherapy for ATLL. A few months later, despite the treatment, he died because of progression of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Pedro Dantas</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>*Dermatology, and &#8224;Hematology Service, and &#8225;Laboratory of Pathology of the Complexo Hospitalar Universit&#225;rio Prof. Edgard Santos, Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvino</LastName><ForeName>Marco Aur&#233;lio</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Herbert Henrique de Melo</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Bittencourt</LastName><ForeName>Achil&#233;a Lisboa</ForeName><Initials>AL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Dermatopathol</MedlineTA><NlmUniqueID>7911005</NlmUniqueID><ISSNLinking>0193-1091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000935">Antifungal Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003881">Dermatomycoses</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060605">Hyalohyphomycosis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016867">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26981740</ArticleId><ArticleId IdType="doi">10.1097/DAD.0000000000000533</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="&quot;Automated&quot;" Owner="NLM" Status="MEDLINE"><PMID Version="1">35868352</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>319</Volume><PubDate><Year>2022</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment.</ArticleTitle><Pagination><StartPage>198875</StartPage><MedlinePgn>198875</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2022.198875</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(22)00203-9</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a human T-cell leukemia virus (HTLV) type 1-associated disease of TCD4<sup>+</sup>&#160;cell transformation. Despite extensive studies on ATLL development and progression, the fundamental processes of HTLV-1 oncogenicity are yet to be understood. This study aimed to integrate high-throughput microarray datasets to find novel genes involved in the mechanism of ATLL progression. For this purpose, five microarray datasets were downloaded from the Gene Expression Omnibus database and then profoundly analyzed. Differentially expressed genes and miRNAs were determined using the MetaDE package in the R software and the GEO2R web tool. The STRING database was utilized to construct the protein-protein interaction network and explore hub genes. Gene ontology and pathway enrichment analysis were carried out by employing the EnrichR web tool. Furthermore, flow cytometry was employed to assess the CD4/CD8 ratio, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to confirm the high-throughput data analysis results. Four miRNAs, including hsa-mir-146, hsa-mir-451, hsa-mir-31, and hsa-mir-125, were among the statistically significant differentially expressed miRNAs between healthy individuals and ATLL patients. Moreover, 924 differentially expressed genes were identified between normal and ATLL samples. Further network analysis highlighted 59 hub genes mainly regulating pathways implicated in viral interferences, immunological processes, cancer, and apoptosis pathways. Among the identified hub genes, RhoA and PRKACB were most considerable in the high-throughput analysis and were further validated by qRT-PCR. The RhoA and PRKACB expression were significantly down-regulated in ATLL patients compared to asymptomatic carriers (p&lt;0.0001 and p=0.004) and healthy subjects (p=0.043 and p=0.002). Therefore, these corresponding miRNAs and proteins could be targeted for diagnosis purposes and designing effective treatments.</AbstractText><CopyrightInformation>Copyright &#169; 2022. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mozhgani</LastName><ForeName>Sayed-Hamidreza</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran; Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarei Ghobadi</LastName><ForeName>Mohadeseh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norouzi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahimi</LastName><ForeName>Hossein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hematology and Oncology Ward, Internal Medicine Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valizadeh</LastName><ForeName>Narges</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teymoori-Rad</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarokhian</LastName><ForeName>Hanieh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostadali</LastName><ForeName>Mohammadreza</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farajifard</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pediatric cell and gene therapy research center, Tehran university of medical sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaee</LastName><ForeName>Seyed Abdolrahim</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: RezaeeR@mums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D063990">Gene Ontology</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053263">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D035683">MicroRNAs</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Network analysis</Keyword><Keyword MajorTopicYN="N">PRKACB</Keyword><Keyword MajorTopicYN="N">RhoA</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35868352</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2022.198875</ArticleId><ArticleId IdType="pii">S0168-1702(22)00203-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20160057</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3265</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>1520</StartPage><EndPage>1531</EndPage><MedlinePgn>1520-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-09-2697</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Adult T-cell leukemia/lymphoma (ATLL) has a very poor prognosis. We have developed the humanized defucosylated anti-CC chemokine receptor 4 (CCR4) monoclonal antibody KW-0761 as a next generation immunotherapeutic agent. The first aim of the present study was to evaluate whether the antitumor activity of KW-0761 would likely be sufficient for therapeutic clinical application against ATLL. The second aim was to fully elucidate the mechanism of antibody-dependent cellular cytotoxicity (ADCC) mediated by this defucosylated monoclonal antibody.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">The antitumor activity of KW-0761 against ATLL cell lines was evaluated in vitro using human cells and in mice in vivo. Primary ATLL cells from 23 patients were evaluated for susceptibility to autologous ADCC with KW-0761 by two independent methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">KW-0761 showed potent antitumor activity against ATLL cell lines both in vitro and in the ATLL mouse model in vivo. In addition, KW-0761 showed potent antitumor activity mediated by highly enhanced ADCC against primary ATLL cells both in vitro and ex vivo in an autologous setting. The degree of KW-0761 ADCC against primary ATLL cells in an autologous setting was mainly determined by the amount of effector natural killer cells present, but not the amount of the target molecule CCR4 on the ATLL cell surface.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">KW-0761 should be sufficiently active for therapeutic clinical application for ATLL. In addition, combination treatment strategies that augment natural killer cell activity should be promising for amplifying the effect of KW-0761. In the near future, the actual efficacy of KW-0761 will be established in pivotal clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yano</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Komatsu</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Imada</LastName><ForeName>Kazunori</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Akinaga</LastName><ForeName>Shiro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shitara</LastName><ForeName>Kenya</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Ryuzo</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000920">Antibody-Dependent Cell Cytotoxicity</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015374">Biosensing Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002469">Cell Separation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007167">Immunotherapy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20160057</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-09-2697</ArticleId><ArticleId IdType="pii">1078-0432.CCR-09-2697</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30116017</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.</ArticleTitle><Pagination><StartPage>338</StartPage><EndPage>342</EndPage><MedlinePgn>338-342</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41409-018-0291-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan. yinoue1110@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan. yinoue1110@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Naofumi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikukawa</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1111-4666</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shichijo</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1272-3738</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takaki</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwanaga</LastName><ForeName>Kouta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Nao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nosaka</LastName><ForeName>Kisato</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6682-2451</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI437801BE</RegistryNumber><NameOfSubstance UI="C549035">mogamulizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bone Marrow Transplant. 2021 Nov;56(11):2862-2863</RefSource><PMID Version="1">34385616</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061067">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050378">T-Lymphocytes, Regulatory</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30116017</ArticleId><ArticleId IdType="doi">10.1038/s41409-018-0291-5</ArticleId><ArticleId IdType="pii">10.1038/s41409-018-0291-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">29297942</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2559</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Histopathology</Title><ISOAbbreviation>Histopathology</ISOAbbreviation></Journal><ArticleTitle>Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.</ArticleTitle><Pagination><StartPage>945</StartPage><EndPage>954</EndPage><MedlinePgn>945-954</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/his.13461</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Adult T cell leukaemia/lymphoma (ATLL) is an aggressive malignancy with a poor prognosis. Human leucocyte antigen (HLA) and &#946;2 microglobulin (&#946;2M) serve as key molecules in tumour immunity, and their expression is reduced frequently in tumour cells. Programmed cell death (PD)-1/PD-ligand1 (PD-L1) interactions play a role in escape of tumour cells from T cell immunity. Therefore, this study aimed to determine the clinicopathological relevance of HLA and &#946;2M expressions in ATLL cells and PD-L1 expression in lymphoma or stromal cells and predict the overall survival of patients with ATLL.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We analysed a total of 123 biopsy samples from patients newly diagnosed with ATLL by using immunohistochemical analysis. Of the patients enrolled, 91 (74%) were positive for HLA (in cell membrane, 60 patients), 89 (72%) were positive for &#946;2M (in cell membrane, 54 patients) and 48 (39%) were positive for both HLA and &#946;2M in the cell membrane (HLA<sup>m+</sup> &#946;2M<sup>m+</sup> ). No significant clinical differences other than prognosis were found between the HLA<sup>m+</sup> &#946;2M<sup>m+</sup> group and the other groups. Immunophenotypical evaluation revealed significantly higher rates of CD30-positive lymphoma cells (P = 0.003) and PD-L1-positive stromal cells in microenvironments (miPD-L1<sup>high</sup> ) (P = 0.011) of the HLA<sup>m+</sup> &#946;2M<sup>m+</sup> group than in the other groups. The HLA<sup>m+</sup> &#946;2M<sup>m+</sup> group had a significantly better prognosis that the other groups (P = 0.0096), and patients showing HLA<sup>m+</sup> &#946;2M<sup>m+</sup> with miPD-L1<sup>high</sup> had the most favourable prognosis among all groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The membranous expression of HLA and &#946;2M is likely to reflect the immune response and would be useful to predict prognosis before starting ATLL therapy.</AbstractText><CopyrightInformation>&#169; 2018 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asano</LastName><ForeName>Naoko</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7536-6179</Identifier><AffiliationInfo><Affiliation>Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2356-3725</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takeharu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimono</LastName><ForeName>Joji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7001-0106</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurita</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamoto</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seto</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Histopathology</MedlineTA><NlmUniqueID>7704136</NlmUniqueID><ISSNLinking>0309-0167</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001613">beta 2-Microglobulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060890">B7-H1 Antigen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006680">HLA Antigens</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016016">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001613">beta 2-Microglobulin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PD-L1</Keyword><Keyword MajorTopicYN="N">adult T cell leukaemia/lymphoma</Keyword><Keyword MajorTopicYN="N">immunophenotype</Keyword><Keyword MajorTopicYN="N">immunosurveillance</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29297942</ArticleId><ArticleId IdType="doi">10.1111/his.13461</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">31645398</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>HTLV-positive adult T-cell leukaemia/lymphoma with Epstein-Barr virus and hepatitis B coinfection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e231086</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2019-231086</ELocationID><Abstract><AbstractText>Human T-cell lymphotropic virus (HTLV) is a human oncoretrovirus known to cause adult T-cell leukaemia/lymphoma (ATLL). Coinfection of human T-lymphotropic virus type 1 with Epstein-Barr virus (EBV) results in enhanced expression of the HTLV virus and leads to aggressive organ involvement from T-cell malignancy. It has also been observed that the prevalence of hepatitis B infection has been higher in patients with HTLV ATLL as compared with the general population in certain countries. We describe a case of a 34-year-old man who initially presented with leucocytosis, fatigue and conjunctival erythema. His radiological images revealed significant generalised adenopathy, and his flow cytometry analysis came back positive for CD4-positive T-cell lymphoma. He was subsequently diagnosed with HTLV-positive ATLL. Ultimately the patient was also diagnosed with acute hepatitis B and EBV. We describe a unique case of ATLL with coinfection with two other viruses, the association of which can be of potential prognostic value in guiding the treatment strategies for ATLL.</AbstractText><CopyrightInformation>&#169; BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munir</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine, Albany Medical Center Hospital, Albany, New York, USA ayeshamnr6@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raval</LastName><ForeName>Mihir</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology/Oncology, New York Oncology Hematology PC, Albany, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Chunlai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Albany Medical Center Hospital, Albany, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subik</LastName><ForeName>M Kristina</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Albany Medical Center Hospital, Albany, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060085">Coinfection</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020031">Epstein-Barr Virus Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006509">Hepatitis B</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006515">Hepatitis B virus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004854">Herpesvirus 4, Human</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Haematology (incl blood transfusion)</Keyword><Keyword MajorTopicYN="N">Malignant and Benign haematology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31645398</ArticleId><ArticleId IdType="pmc">PMC6827748</ArticleId><ArticleId IdType="doi">10.1136/bcr-2019-231086</ArticleId><ArticleId IdType="pii">12/10/e231086</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marr I, Davies J, Baird RW. Hepatitis B virus and human T-cell lymphotropic virus type 1 co-infection in the Northern Territory, Australia. Int J Infect Dis 2017;58:90&#8211;5. 10.1016/j.ijid.2017.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2017.03.010</ArticleId><ArticleId IdType="pubmed">28315754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda S, Maeda Y, Yamaguchi T, et al. . Influence of Epstein-Barr virus infection in adult T-cell leukemia. Hematology 2008;13:154&#8211;62. 10.1179/102453308X316130</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/102453308X316130</ArticleId><ArticleId IdType="pubmed">18702873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifuku H, Kusumoto S, Tanaka Y, et al. . Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res 2015;45:1363&#8211;7. 10.1111/hepr.12513</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hepr.12513</ArticleId><ArticleId IdType="pubmed">25753008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada Y, Nitta Y, Ikeya T, et al. . [A case of smoldering ATLL in high risk family and familial double infection of HTLV-1 and HBV]. Nihon Hifuka Gakkai Zasshi 1991;101:843&#8211;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">1942589</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile G, Mele A, Monarco B, et al. . And C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case-control study. The Italian leukemia Study Group. Cancer Epidemiology and Prevention Biomarkers 1996;5:227&#8211;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8833624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012;3:388 10.3389/fmicb.2012.00388</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00388</ArticleId><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>LEE CW, Chang MC, Chang YF, et al. . Adult T&#8208;cell leukemia/lymphoma in Taiwan: an analysis of 17 patients and review of the literature. Asia&#8208;Pacific Journal of Clinical Oncology 2010;6:161&#8211;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20887496</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZJ, Zheng XY, Yang XZ, et al. . [Clinical characteristics and prognosis in 12 patients with adult T cell leukemia/lymphoma confirmed by HTLV-1 provirus gene detection]. Zhonghua Xue Ye Xue Za Zhi 2016;37:1027&#8211;32. 10.3760/cma.j.issn.0253-2727.2016.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0253-2727.2016.12.003</ArticleId><ArticleId IdType="pmc">PMC7348501</ArticleId><ArticleId IdType="pubmed">28088963</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SC, Ashraf I, Mir F, et al. . Dual infection with hepatitis B and Epstein-Barr virus presenting with severe jaundice, coagulopathy, and hepatitis B virus chronicity outcome. Am J Case Rep 2017;18:170&#8211;2. 10.12659/AJCR.901688</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.901688</ArticleId><ArticleId IdType="pmc">PMC5322865</ArticleId><ArticleId IdType="pubmed">28202897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24418858</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0979</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of surgical pathology</Title><ISOAbbreviation>Am J Surg Pathol</ISOAbbreviation></Journal><ArticleTitle>Clinicopathologic features of adult T-cell leukemias/lymphomas at a North American tertiary care medical center: infrequent involvement of the central nervous system.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>256</EndPage><MedlinePgn>245-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PAS.0000000000000109</ELocationID><Abstract><AbstractText>Human T-cell lymphotropic virus type 1 is associated with adult T-cell leukemia/lymphoma (ATLL). Published series of ATLLs seen at a United States medical institution are rare. We present the features of 4 ATLLs diagnosed at our North American tertiary care medical center from 1990 to 2012. Despite the absence of a history of origin from an endemic region, all our ATLLs demonstrated evidence of human T-cell lymphotropic virus type 1 infection. Central nervous system (CNS) involvement by ATLL was uncommon in our series, and represented only 1.6% (1/64) of all CNS B-cell or T-cell lymphomas diagnosed over a 20+ year period at our institution. Review of the medical literature reveals that the majority of CNS-involved ATLLs present with the lymphoma or acute subtype, and complete remission is difficult to achieve in these cases. CNS involvement frequently occurs with a systemic disease, which carries an aggressive clinical course with poor prognosis. In addition, CNS involvement by ATLL can be the initial presentation or seen with relapsed disease, can be the only site or be associated with other tissue sites of involvement, and may manifest with variable clinical signs/symptoms. Our retrospective study reveals that ATLLs are rare mature T-cell lymphomas in a native North American population, but the clinical and histopathologic features of ATLLs from this nonendemic region are similar to those seen from other endemic regions. Early recognition of these rare ATLLs involving uncommon sites, such as the CNS, will help optimize treatment for these infrequent mature T-cell lymphomas.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsi</LastName><ForeName>Andy C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Immunology, Division of Anatomic Pathology, Washington University, St Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreisel</LastName><ForeName>Friederike H</ForeName><Initials>FH</Initials></Author><Author ValidYN="Y"><LastName>Frater</LastName><ForeName>John L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>TuDung T</ForeName><Initials>TT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Surg Pathol</MedlineTA><NlmUniqueID>7707904</NlmUniqueID><ISSNLinking>0147-5185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016543">Central Nervous System Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055088">Early Detection of Cancer</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015321">Gene Rearrangement</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019675">Genes, T-Cell Receptor gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D008923">Missouri</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D062606">Tertiary Care Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24418858</ArticleId><ArticleId IdType="doi">10.1097/PAS.0000000000000109</ArticleId><ArticleId IdType="pii">00000478-201402000-00013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30999833</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-1052</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of STD &amp; AIDS</Title><ISOAbbreviation>Int J STD AIDS</ISOAbbreviation></Journal><ArticleTitle>Bowenoid papulosis unveiling a rare cause of immunosuppression.</ArticleTitle><Pagination><StartPage>522</StartPage><EndPage>525</EndPage><MedlinePgn>522-525</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0956462418813057</ELocationID><Abstract><AbstractText>Bowenoid papulosis (BP) is a premalignant condition usually caused by oncogenic types of human papillomavirus (HPV) presenting clinically as warty genital papules. Adult T-cell leukaemia-lymphoma (ATLL) is a peripheral T-cell leukaemia-lymphoma caused by the retrovirus, human T-cell lymphotropic virus 1 (HTLV-1). We report a case of BP initially mistaken as genital warts; on detailed evaluation the patient had features of chronic immunosuppression. The presence of leukaemic cells in the peripheral blood, bone marrow and skin along with a positive HTLV-1 serology confirmed the diagnosis of ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ambooken</LastName><ForeName>Betsy</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4124-0900</Identifier><AffiliationInfo><Affiliation>Department of Dermatology &amp; Venereology, Govt. Medical College, Thrissur, Kerala.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asokan</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Dermatology &amp; Venereology, Govt. Medical College, Thrissur, Kerala.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philip</LastName><ForeName>Prizey</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Dermatology &amp; Venereology, Govt. Medical College, Thrissur, Kerala.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jisha</LastName><ForeName>K T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Dermatology &amp; Venereology, Govt. Medical College, Thrissur, Kerala.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J STD AIDS</MedlineTA><NlmUniqueID>9007917</NlmUniqueID><ISSNLinking>0956-4624</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003218">Condylomata Acuminata</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007165">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011230">Precancerous Conditions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bowenoid papulosis</Keyword><Keyword MajorTopicYN="N">adult T-cell leukaemia&#8211;lymphoma</Keyword><Keyword MajorTopicYN="N">human T-cell lymphotropic virus 1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30999833</ArticleId><ArticleId IdType="doi">10.1177/0956462418813057</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20231613</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1943-7722</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>American journal of clinical pathology</Title><ISOAbbreviation>Am J Clin Pathol</ISOAbbreviation></Journal><ArticleTitle>Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>592</StartPage><EndPage>601</EndPage><MedlinePgn>592-601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1309/AJCPS1K0OHLJYWWV</ELocationID><Abstract><AbstractText>Little information exists regarding the detection of minimal residual disease (MRD) in adult T-cell leukemia/lymphoma (ATLL). We evaluated 75 peripheral blood samples from 17 ATLL cases using flow cytometry (FC); 50 of the samples were concurrently evaluated by polymerase chain reaction (PCR) for clonal T-cell receptor gamma chain (TRG) gene rearrangement and the presence of human T-cell lymphotropic virus-1 proviral sequences. Residual ATLL cells were identified using a multiparametric approach to identify aberrant T-cell immunophenotypes. Malignant T cells were CD4+, CD3 dim+, CD26-, CD25 bright, CD7+, and CD27+, with occasional dim expression of CD2 or CD5. FC exhibited a high sensitivity, detecting as few as 0.29% ATLL cells/WBC (4.9 cells/microL) in the peripheral blood. PCR for TRG gene rearrangement was slightly more sensitive, and FC and PCR complemented each other in detecting MRD. In 2 patients, there was complete remission; 4 patients had disease refractory to therapy, and 3 died; 11 others had persistent disease with variable numbers of ATLL cells in the peripheral blood. Higher levels of ATLL cells appeared to correlate with disease severity. FC detection of aberrant T cells permits sensitive and quantitative monitoring of MRD in ATLL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Haipeng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Constance M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Liqiang</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Raffeld</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Janik</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Stetler-Stevenson</LastName><ForeName>Maryalice</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 BC011104</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Clin Pathol</MedlineTA><NlmUniqueID>0370470</NlmUniqueID><ISSNLinking>0002-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015703">Antigens, CD</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D005434">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018365">Neoplasm, Residual</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20231613</ArticleId><ArticleId IdType="mid">NIHMS1635052</ArticleId><ArticleId IdType="pmc">PMC7596844</ArticleId><ArticleId IdType="doi">10.1309/AJCPS1K0OHLJYWWV</ArticleId><ArticleId IdType="pii">133/4/592</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet. 1999;353:1951&#8211;1958.</Citation><ArticleIdList><ArticleId IdType="pubmed">10371587</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangham CR. HTLV-1 infections. J Clin Pathol. 2000;53:581&#8211;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762938</ArticleId><ArticleId IdType="pubmed">11002759</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I&#8211;leukemia/lymphoma. Curr Treat Options Oncol. 2001;2:291&#8211;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057109</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy EL, Hanchard B, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer. 1989;43:250&#8211;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917802</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi K Human T-lymphotropic virus type I in Japan. Lancet. 1994;343:213&#8211;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">7904671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States: human T-cell leukemia/lymphoma virus-associated lymphoid malignancies. Am J Surg Pathol. 1984;8:263&#8211;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">6324600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med. 1983;309:257&#8211;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">6602943</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoyama M Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428&#8211;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawson R, Mufti GJ, Pagliuca A. Management of adult T-cell leukaemia/lymphoma. Br J Haematol. 1998;100:453&#8211;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">9504625</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453&#8211;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:281&#8211;284.</Citation></Reference><Reference><Citation>Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol. 2009;131:16&#8211;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19095561</ArticleId></ArticleIdList></Reference><Reference><Citation>Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995;85:1416&#8211;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888664</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 1999;13:1221&#8211;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">10450750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokote T, Akioka T, Oka S, et al. Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol. 2005;124:199&#8211;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">16040289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginaldi L, Farahat N, Matutes E, et al. Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry. J Clin Pathol. 1996;49:539&#8211;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC500565</ArticleId><ArticleId IdType="pubmed">8813949</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhold U, Abken H, Kukel S, et al. CD7&#8211; T cells represent a subset of normal human blood lymphocytes. J Immunol. 1993;150:2081&#8211;2089.</Citation><ArticleIdList><ArticleId IdType="pubmed">7679701</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55&#8211;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9553764</ArticleId></ArticleIdList></Reference><Reference><Citation>Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol. 2004;19:1345&#8211;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">15375776</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones D, Dang NH, Duvic M, et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885&#8211;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">11392886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelemen K, Guitart J, Kuzel TM, et al. The usefulness of CD26 in flow cytometric analysis of peripheral blood in S&#233;zary syndrome. Am J Clin Pathol. 2008;129:146&#8211;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">18089499</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji T, Sugahara K, Tsuruda K, et al. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells. Int J Hematol. 2004;80:254&#8211;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">15540901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo S, Kotani T, Tamura K, et al. Expression of CD26/dipeptidyl peptidase IV in adult T cell leukemia/lymphoma (ATLL). Leuk Res. 1996;20:357&#8211;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">8642848</ArticleId></ArticleIdList></Reference><Reference><Citation>Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia: comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol. 2003;119:213&#8211;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">12579991</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy KP, Sloane JP, Kabarowski JH, et al. A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol. 1992;1:173&#8211;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">1342963</ArticleId></ArticleIdList></Reference><Reference><Citation>Segurado AA, Domingues RB, Muniz MR, et al. Molecular detection and isolation of human T-cell lymphotropic virus type I (HTLV-I) from patients with HAM/TSP in Sao Paulo, Brazil. Clin Diagn Virol. 1998;9:17&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562854</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht B, Collins ND, Newbound GC, et al. Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J Virol Methods. 1998;75:123&#8211;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9870588</ArticleId></ArticleIdList></Reference><Reference><Citation>Digiuseppe JA. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy. Clin Lab Med. 2007;27:533&#8211;549, vi.</Citation><ArticleIdList><ArticleId IdType="pubmed">17658406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29&#8211;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11418459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol. 2000;71:290&#8211;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mone A, Puhalla S, Whitman S, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-&#945;&#8211;refractory adult T-cell leukemia. Blood. 2005;106:3380&#8211;3382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895052</ArticleId><ArticleId IdType="pubmed">16076875</ArticleId></ArticleIdList></Reference><Reference><Citation>Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol. 2004;16:89&#8211;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036232</ArticleId></ArticleIdList></Reference><Reference><Citation>Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp. 2003;252:67&#8211;91, 106-114.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginaldi L, Matutes E, Farahat N, et al. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol. 1996;93:921&#8211;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz P, Zacharievich N, Shenkin M. Multicolor cytoenzymatic evaluation of dipeptidyl peptidase IV (CD26) function in normal and neoplastic human T-lymphocyte populations. Clin Diagn Lab Immunol. 1998;5:362&#8211;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104525</ArticleId><ArticleId IdType="pubmed">9605992</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis. 1999;180:1487&#8211;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515807</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki R, Miyazaki Y, Moriuchi Y, et al. Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma. Leukemia. 2007;21:1212&#8211;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">17410191</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21673346</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0020</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Blood</Title><ISOAbbreviation>Blood</ISOAbbreviation></Journal><ArticleTitle>How I treat adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>1736</StartPage><EndPage>1745</EndPage><MedlinePgn>1736-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2011-03-345702</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I. ATL carries a bad prognosis because of intrinsic chemoresistance and severe immunosuppression. In acute ATL, Japanese trials demonstrated that although combinations of chemotherapy improved response rate, they failed to achieve a significant impact on survival. Patients with chronic and smoldering ATL have a better prognosis, but long-term survival is poor when these patients are managed with a watchful-waiting policy or with chemotherapy. Recently, a worldwide meta-analysis revealed that the combination of zidovudine and IFN-&#945; is highly effective in the leukemic subtypes of ATL and should be considered as standard first-line therapy in that setting. This combination has changed the natural history of the disease through achievement of significantly improved long-term survival in patients with smoldering and chronic ATL as well as a subset of patients with acute ATL. ATL lymphoma patients still benefit from chemotherapy induction with concurrent or sequential antiretroviral therapy with zidovudine/IFN. To prevent relapse, clinical trials assessing consolidative targeted therapies such as arsenic/IFN combination or novel monoclonal antibodies are needed. Finally, allogeneic BM transplantation should be considered in suitable patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bazarbachi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. bazarbac@aub.edu.lb</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suarez</LastName><ForeName>Felipe</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Hermine</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood</MedlineTA><NlmUniqueID>7603509</NlmUniqueID><ISSNLinking>0006-4971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001152">Arsenicals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010087">Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7V92P67HO</RegistryNumber><NameOfSubstance UI="D000077237">Arsenic Trioxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D044966">Anti-Retroviral Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000077237">Arsenic Trioxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001152">Arsenicals</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015490">HTLV-I Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010087">Oxides</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21673346</ArticleId><ArticleId IdType="doi">10.1182/blood-2011-03-345702</ArticleId><ArticleId IdType="pii">S0006-4971(20)41086-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12691167</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1042-8194</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>A patient with congenital ichthyosis hystrix (disseminated congenital naevus) and acute lymphoblastic leukaemia.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>212</EndPage><MedlinePgn>209-12</MedlinePgn></Pagination><Abstract><AbstractText>Congenital ichthyosis is an uncommon spectrum of hereditary and sporadic hyperkeratotic epidermolytic disorders that may occur in isolation or in association with other clinical syndromes. The pattern of distribution of the hyperkeratotic lesions and family history form the basis of diagnosis. Ichthyosis may be a marker for immune deficiency and cancer prone conditions. We report a 16-year old Chinese patient with a diagnosis of ichthyosis hystrix hystrix (disseminated congenital naevus) since birth who presented with T cell acute lymphoblastic leukaemia with tetraploid clones. There are four reports of acute leukaemia complicating ichthyosis, all involving paediatric acute lymphoblastic leukaemia. The possible mechanisms involved are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Au</LastName><ForeName>W Y</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Queen Mary Hospital, University of Hong Kong, 4/F, Professorial Block, Pokfulam Road, Hong Kong, People's Republic of China. auwing@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>S Y</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>C K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Trendell-Smith</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002999">Clone Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017488">Hyperkeratosis, Epidermolytic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007057">Ichthyosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009506">Nevus</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000151">congenital</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011123">Polyploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000151">congenital</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>21</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>10</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12691167</ArticleId><ArticleId IdType="doi">10.1080/1042819021000054724</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">30613940</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2141</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br J Haematol</ISOAbbreviation></Journal><ArticleTitle>Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.</ArticleTitle><Pagination><StartPage>205</StartPage><MedlinePgn>205</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.15744</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bataller</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6085-2745</Identifier><AffiliationInfo><Affiliation>Department of Haematology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combalia</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Herrera</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrach</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matutes</LastName><ForeName>Estella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Haematology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C036337">VAP-cyclo protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30613940</ArticleId><ArticleId IdType="doi">10.1111/bjh.15744</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9504625</PMID><DateCompleted><Year>1998</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1048</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>3</Issue><PubDate><Year>1998</Year><Month>Mar</Month></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br J Haematol</ISOAbbreviation></Journal><ArticleTitle>Management of adult T-cell leukaemia/lymphoma.</ArticleTitle><Pagination><StartPage>453</StartPage><EndPage>458</EndPage><MedlinePgn>453-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pawson</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Haematology, Royal Free Hospital, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mufti</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Pagliuca</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016026">Bone Marrow Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>61</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9504625</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2141.1998.00582.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">27521318</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2152-2669</ISSN><JournalIssue CitedMedium="Internet"><Volume>16 Suppl</Volume><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical lymphoma, myeloma &amp; leukemia</Title><ISOAbbreviation>Clin Lymphoma Myeloma Leuk</ISOAbbreviation></Journal><ArticleTitle>Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.</ArticleTitle><Pagination><StartPage>S191</StartPage><EndPage>S194</EndPage><MedlinePgn>S191-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clml.2016.02.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2152-2650(16)00065-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adult T-cell leukemia/lymphoma (ATLL) is aggressive mature T-cell lymphoproliferative disorder with a poor outcome.</AbstractText><AbstractText Label="METHODS">We present 10 patients with acute and lymphomatous subtypes of ATLL treated with distinct induction regimens, including CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine [Oncovin], prednisone or prednisolone), interferon/zidovudine, and VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone; doxorubicin, ranimustine, prednisone; vindesine, etoposide, carboplatin, prednisone).</AbstractText><AbstractText Label="RESULTS">The overall response rate was 50%, with 10% complete remission (CR). Two patients achieved CR with the second-line regimen. Three patients underwent consolidation with allogeneic stem cell transplantation (ASCT) in the first CR. The median overall survival was 51&#160;months for the entire group and 84 months for the patients who had undergone ASCT versus 34 months for the non-ASCT patients.</AbstractText><CopyrightInformation>Copyright &#169; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Christa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: Christa.Roe@moffitt.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komrokji</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokol</LastName><ForeName>Lubomir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lymphoma Myeloma Leuk</MedlineTA><NlmUniqueID>101525386</NlmUniqueID><ISSNLinking>2152-2669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001773">Blood Cells</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014184">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014481">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">Human T-lymphotrophic virus 1</Keyword><Keyword MajorTopicYN="N">Non-Hodgkin lymphoma</Keyword><Keyword MajorTopicYN="N">Peripheral T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">Retrovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27521318</ArticleId><ArticleId IdType="doi">10.1016/j.clml.2016.02.010</ArticleId><ArticleId IdType="pii">S2152-2650(16)00065-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">26847489</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2016</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9896</ISSN><JournalIssue CitedMedium="Internet"><Volume>238</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of pathology</Title><ISOAbbreviation>J Pathol</ISOAbbreviation></Journal><ArticleTitle>CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis.</ArticleTitle><Pagination><StartPage>621</StartPage><EndPage>626</EndPage><MedlinePgn>621-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/path.4699</ELocationID><Abstract><AbstractText>Adult T cell leukaemia/lymphoma (ATLL) is an intractable T cell neoplasm caused by human T cell leukaemia virus type 1. Next-generation sequencing-based comprehensive mutation studies have revealed recurrent somatic CCR4 mutations in ATLL, although clinicopathological findings associated with CCR4 mutations remain to be delineated. In the current study, 184 cases of peripheral T cell lymphoma, including 113 cases of ATLL, were subjected to CCR4 mutation analysis. This sequence analysis identified mutations in 27% (30/113) of cases of ATLL and 9% (4/44) of cases of peripheral T cell lymphoma not otherwise specified. Identified mutations included nonsense (NS) and frameshift (FS) mutations. No significant differences in clinicopathological findings were observed between ATLL cases stratified by presence of CCR4 mutation. All ATLL cases with CCR4 mutations exhibited cell-surface CCR4 positivity. Semi-quantitative CCR4 protein analysis of immunohistochemical sections revealed higher CCR4 expression in cases with NS mutations of CCR4 than in cases with wild-type (WT) CCR4. Furthermore, among ATLL cases, FS mutation was significantly associated with a poor prognosis, compared with NS mutation and WT CCR4. These results suggest that CCR4 mutation is an important determinant of the clinical course in ATLL cases, and that NS and FS mutations of CCR4 behave differently with respect to ATLL pathophysiology.</AbstractText><CopyrightInformation>Copyright &#169; 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7001-0106</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyoshi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takeharu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakata-Yanagimoto</LastName><ForeName>Mamiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Haematology, Faculty of Medicine, University of Tsukuba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niino</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Haematology, Sasebo City General Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriuchi</LastName><ForeName>Yukiyoshi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Haematology, Sasebo City General Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Karatsu Red Cross Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurita</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimono</LastName><ForeName>Joji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamoto</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsunomiya</LastName><ForeName>Atae</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Haematology, Imamura Bun-in Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seto</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohshima</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Kurume University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pathol</MedlineTA><NlmUniqueID>0204634</NlmUniqueID><ISSNLinking>0022-3417</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515354">CCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054398">Receptors, CCR4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014408">Biomarkers, Tumor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004252">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016368">Frameshift Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053208">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054398">Receptors, CCR4</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCR4 mutation</Keyword><Keyword MajorTopicYN="N">adult T cell leukaemia/lymphoma</Keyword><Keyword MajorTopicYN="N">clinicopathological analyses</Keyword><Keyword MajorTopicYN="N">prognostic impact</Keyword><Keyword MajorTopicYN="N">tissue array</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26847489</ArticleId><ArticleId IdType="doi">10.1002/path.4699</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2601035</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>8</Issue><PubDate><Year>1989</Year><Month>Aug</Month></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[ATL (adult T-cell leukemia/lymphoma)].</ArticleTitle><Pagination><StartPage>1208</StartPage><EndPage>1211</EndPage><MedlinePgn>1208-11</MedlinePgn></Pagination><Abstract><AbstractText>128 cases of ATL (adult T-cell leukemia/lymphoma) were divided into 3 subgroups, 70 cases of acute type, 19 cases of chronic type and 39 cases of lymphoma type, and their prognosis were evaluated. Median survival time from the onset of acute type using Kaplan-Meier method was 8 months, that of lymphoma type was 14 months and that of chronic type was 50 months. Median survival time from the start of treatment of acute type was 5 months, that of lymphoma type was 11 months and that of chronic type was 22 months. Relatively short median survival time of chronic type may be due to they had some duration with observation only at first. No significant elongation of survival time could be obtained when acute type was divided into 2 stages, before and after 1982. Twelve patients with non-Hodgkins' lymphoma unresponsive to the first line combination chemotherapy were treated with combination therapy with cis-dichlorodiammineplatinum (CDDP). Ten patients were evaluable for response (4 cases of CR, 6 cases of PR). To stop the HTLV-1 carrier mothers milk for giving their children seems to be effective method to decrease the occurrence of ATL in future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ichimaru</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tsukazaki</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2601035</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34585997</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.</ArticleTitle><Pagination><StartPage>315</StartPage><EndPage>325</EndPage><MedlinePgn>315-325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10428194.2021.1984455</ELocationID><Abstract><AbstractText>Adult T-cell leukemia/lymphoma (ATLL) is a largely incurable disease. Cutaneous involvement is common and could be first symptom of the disease. We analyzed 169 patients with ATLL of whom 63 had cutaneous involvement. Cutaneous involvement was found in 48, 27, 17, and 60% of acute, lymphomatous, chronic and smoldering ATLL cases, respectively. Eight cases had primary cutaneous tumoral variant. Erythroderma (24%) and plaques (22%) were the most frequent skin lesions. The presence of cutaneous involvement was associated with better overall survival compared to non-cutaneous involvement (aHR 0.55 [95% CI: 0.37-0.82], <i>p</i>&#8201;&lt;&#8201;0.01; 1-year OS 53 vs. 27%, respectively, <i>p</i>&#8201;=&#8201;0.012). Combination zidovudine and interferon-alpha (AZT-IFN) yielded high response rates (overall response, OR = 100%, <i>n</i>&#8201;=&#8201;8; complete response 62.5%) compared to chemotherapy (OR = 33.3%, <i>n</i>&#8201;=&#8201;12/36). In conclusion, cutaneous involvement was associated with better survival in Latin American patients with ATLL. AZT-IFN demonstrated encouraging responses in ATLL patients with cutaneous involvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malpica</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7082-1846</Identifier><AffiliationInfo><Affiliation>Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Denisse</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departamento de Oncolog&#237;a y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#243;n de Medicina de Precisi&#243;n, Universidad de San Martin de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enriquez</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-0855-8936</Identifier><AffiliationInfo><Affiliation>Departamento de Oncologia Medica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oviedo-Pecho</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Servicio de Dermatolog&#237;a, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#241;a</LastName><ForeName>Camila</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hematology Section, Hospital Del Salvador, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idrobo</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hospital Universitario del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiad</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hematolog&#237;a, Hospital Italiano de La Plata, La Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prates</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematolog&#237;a, Hospital Italiano de La Plata, La Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valcarcel</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Servicio de Dermatolog&#237;a, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#225;nchez</LastName><ForeName>Gadwyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Servicio de Dermatolog&#237;a, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mois&#233;s</LastName><ForeName>Celia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Servicio de Dermatolog&#237;a, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-9490-7532</Identifier><AffiliationInfo><Affiliation>Bing Center for Waldenstr&#246;m Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villela</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Fernando Ocaranza del ISSSTE, Universidad Del Valle de Mexico, Campus Hermosillo, Sonora, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biglione</LastName><ForeName>Mirna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#233;dicas en Retrovirus y SIDA (INBIRS) UBA - CONICET, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>Brady E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-4469-3817</Identifier><AffiliationInfo><Affiliation>Departamento de Oncolog&#237;a y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#243;n de Medicina de Precisi&#243;n, Universidad de San Martin de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA223232</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATLL</Keyword><Keyword MajorTopicYN="N">Adult-T cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Latin America</Keyword><Keyword MajorTopicYN="N">interferon alpha</Keyword><Keyword MajorTopicYN="N">skin lymphoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34585997</ArticleId><ArticleId IdType="doi">10.1080/10428194.2021.1984455</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">34270330</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos.</ArticleTitle><Pagination><StartPage>1151</StartPage><EndPage>1166</EndPage><MedlinePgn>1151-1166</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">GO.21.00084</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO.21.00084</ELocationID><Abstract><AbstractText Label="PURPOSE">Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by the human T-cell leukemia virus type 1. Real-world data of ATLL in Latin America are lacking.</AbstractText><AbstractText Label="PATIENTS AND METHODS">We analyzed patients with ATLL (acute, lymphomatous, chronic, and smoldering) encountered in 11 Latin American countries between 1995 and 2019. Treatment response was assessed according to the 2009 consensus report. Survival curves were estimated using the Kaplan-Meier method and log-rank test.</AbstractText><AbstractText Label="RESULTS">We identified 253 patients; 226 (lymphomatous: n = 122, acute: n = 73, chronic: n = 26, and smoldering: n = 5) had sufficient data for analysis (median age 57 years). Most patients with ATLL were from Peru (63%), Chile (17%), Argentina (8%), and Colombia (7%). Hypercalcemia was positively associated with acute type (57% <i>v</i> lymphomatous 27%, <i>P</i> = .014). The median survival times (months) were 4.3, 7.9, 21.1, and not reached for acute, lymphomatous, chronic, and smoldering forms, with 4-year survival rates of 8%, 22%, 40%, and 80%, respectively. First-line zidovudine (AZT)-interferon alfa (IFN) resulted in an overall response rate of 63% (complete response [CR] 24%) for acute. First-line chemotherapy yielded an overall response rate of 41% (CR 29%) for lymphomatous. CR rate was 42% for etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone versus 12% for cyclophosphamide, vincristine, doxorubicin, and prednisone-like regimen (<i>P</i> &lt; .001). Progression-free survival at 1 year for acute type patients treated with AZT-IFN was 67%, whereas 2-year progression-free survival in lymphomatous type patients who achieved CR after chemotherapy was 77%.</AbstractText><AbstractText Label="CONCLUSION">This study confirms Latin American ATLL presents at a younger age and has a high incidence of lymphomatous type, low incidence of indolent subtypes, and worse survival rates as compared with Japanese patients. In aggressive ATLL, chemotherapy remains the preferred choice for lymphomatous favoring etoposide-based regimen (etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone), whereas AZT-IFN remains a good first-line option for acute subtype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malpica</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7082-1846</Identifier><AffiliationInfo><Affiliation>Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enriquez</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-0855-8936</Identifier><AffiliationInfo><Affiliation>Departamento de Oncologia Medica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Denisse A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-5330-9309</Identifier><AffiliationInfo><Affiliation>Departamento de Oncolog&#237;a y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#243;n de Medicina de Precisi&#243;n, Universidad de San Martin de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#241;a</LastName><ForeName>Camila</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8076-2077</Identifier><AffiliationInfo><Affiliation>Hematology Section, Hospital Del Salvador, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idrobo</LastName><ForeName>Henry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7686-5874</Identifier><AffiliationInfo><Affiliation>Hospital Universitario del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiad</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hematolog&#237;a, Hospital Italiano de La Plata, La Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prates</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematolog&#237;a, Hospital Italiano de La Plata, La Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otero</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Secci&#243;n Hematolog&#237;a, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biglione</LastName><ForeName>Mirna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#233;dicas en Retrovirus y SIDA (INBIRS) UBA-CONICET, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altamirano</LastName><ForeName>Milagros</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Guillermo Almenara, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandival-Ampuero</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4759-2328</Identifier><AffiliationInfo><Affiliation>Departamento de Oncologia Medica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aviles-Perez</LastName><ForeName>Ursula</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-8394-8152</Identifier><AffiliationInfo><Affiliation>Universidad Nacional Federico Villareal, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meza</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1777-2360</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre-Martinez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7423-0824</Identifier><AffiliationInfo><Affiliation>Facultad de Salud, Universidad del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristaldo</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Secci&#243;n Hematolog&#237;a, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maradei</LastName><ForeName>Juan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Servicio de Hematologia, Hospital Municipal Emilio Ferreyra, Necochea, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guanchiale</LastName><ForeName>Luciana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Privado Universitario de C&#243;rdoba, Cordoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4312-4519</Identifier><AffiliationInfo><Affiliation>Hematology Section, Hospital de Puerto Montt, Puerto Montt, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vi&#241;uela</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hematology Section, Hospital S&#243;tero de Rio, Santiago de Chile, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrera</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-9059-3871</Identifier><AffiliationInfo><Affiliation>Hematology Section, Hospital Del Salvador, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Sally Rose</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Departamento de Oncolog&#237;a y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#243;n de Medicina de Precisi&#243;n, Universidad de San Martin de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Eloisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>C&#225;tedra de Hematolog&#237;a, Hospital de Cl&#237;nicas, Facultad de Medicina, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Stefano</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6749-6261</Identifier><AffiliationInfo><Affiliation>Hospital Solca Quito, Hospital de los Valles, Universidad San Francisco de Quito, Quito, Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noboa</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Hematologia, Instituto Oncol&#243;gico Nacional Dr. Juan Tanca Marengo, Guayaquil, Ecuador.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choque</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-1994-4234</Identifier><AffiliationInfo><Affiliation>Hospital de Especialidades Materno Infantil-Caja Nacional de Salud, La Paz, Bolivia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candelaria</LastName><ForeName>Myrna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5478-714X</Identifier><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Cancerolog&#237;a, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Von Glasenapp</LastName><ForeName>Alana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1805-5830</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Instituto de Prevision Social, Asuncion, Paraguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valvert</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0687-2419</Identifier><AffiliationInfo><Affiliation>Liga Nacional Contra el Cancer, Instituto de Cancerolog&#237;a-INCAN, Ciudad de Guatemala, Guatemala.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Viera</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-6188-8494</Identifier><AffiliationInfo><Affiliation>Universidad Central de Venezuela, Caracas, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-9490-7532</Identifier><AffiliationInfo><Affiliation>Bing Center for Waldenstr&#246;m Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-6282-4406</Identifier><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villela</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Universidad Del Valle de Mexico, Campus Hermosillo, Hospital Fernando Ocaranza del ISSSTE, Sonora, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>Brady E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-4469-3817</Identifier><AffiliationInfo><Affiliation>Departamento de Oncolog&#237;a y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#243;n de Medicina de Precisi&#243;n, Universidad de San Martin de Porres, Lima, Peru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA223232</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001118">Argentina</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002677">Chile</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D003105">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007843">Latin America</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008223">Lymphoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D010568">Peru</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Denisse A. Castro</b><b>Consulting or Advisory Role:</b> Johnson &amp; Johnson del Per&#250; S.A. <b>Camila Pe&#241;a</b><b>Honoraria:</b> Janssen, Bristol Myers Squibb/Medarex<b>Consulting or Advisory Role:</b> Janssen<b>Travel, Accommodations, Expenses:</b> Tecnofarma <b>Victoria Otero</b><b>Employment:</b> AstraZeneca <b>Eloisa Riva</b><b>Honoraria:</b> Sanofi<b>Travel, Accommodations, Expenses:</b> Roemmers <b>Maria A. Torres-Viera</b><b>Speakers' Bureau:</b> Takeda <b>Jorge J. Castillo</b><b>Consulting or Advisory Role:</b> Janssen, Roche/Genentech, Beigene, AbbVie/Pharmacyclics<b>Research Funding:</b> Pharmacyclics, AbbVie, Janssen, BeiGene, TG Therapeutics <b>Juan Carlos Ramos</b><b>Research Funding:</b> miRagen <b>Luis Villela</b><b>Consulting or Advisory Role:</b> Jazz Pharmaceuticals, Roche-Syntex, AstraZeneca LATAM<b>Speakers' Bureau:</b> Amgen Mexico, AbbVieNo other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34270330</ArticleId><ArticleId IdType="pmc">PMC8457808</ArticleId><ArticleId IdType="doi">10.1200/GO.21.00084</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79:2031-2035, 1982</Citation><ArticleIdList><ArticleId IdType="pmc">PMC346116</ArticleId><ArticleId IdType="pubmed">6979048</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiesz BJ Ruscetti FW Reitz MS, et al. : Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S&#233;zary T-cell leukaemia. Nature 294:268-271, 1981</Citation><ArticleIdList><ArticleId IdType="pubmed">6272125</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonck K, Gonz&#225;lez E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E: Human T-lymphotropic virus 1: Recent knowledge about an ancient infection. Lancet Infect Dis 7:266-281, 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessain A, Cassar O: Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3:388, 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498738</ArticleId><ArticleId IdType="pubmed">23162541</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica L Pimentel A Reis IM, et al. : Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv 2:607-620, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873228</ArticleId><ArticleId IdType="pubmed">29545256</ArticleId></ArticleIdList></Reference><Reference><Citation>Azran I, Schavinsky-Khrapunsky Y, Aboud M: Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 1(1):20, 2004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC514576</ArticleId><ArticleId IdType="pubmed">15310405</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya H Ishitsuka K Utsunomiya A, et al. : Treatment and survival among 1594 patients with ATL. Blood 126:2570-2577, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26361794</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake M Yamada Y Atogami S, et al. : The incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type 1 carriers in Japan. Leuk Lymphoma 56:1806-1812, 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">25219595</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpica Castillo LE Pe&#241;a C Rojas C, et al. : Identifying a simple clinical prognostic model for aggressive adult T-cell leukemia/lymphoma in Latin American population and its validation: A large International Study of the Latin America Working Group for Lymphomas (GELL). Blood 134, 2019. (suppl 1; abstr 4045)</Citation></Reference><Reference><Citation>Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br J Haematol 79:428-437, 1991</Citation><ArticleIdList><ArticleId IdType="pubmed">1751370</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo LM, Dittus C: Adult T-cell leukemia/lymphoma, in Novel Therapeutics for Rare Lymphomas. Springer Nature Switzerland AG, Springer International Publishing, 2019, pp 137-164</Citation></Reference><Reference><Citation>Vose J, Armitage J, Weisenburger D: International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18626005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallamini A Stelitano C Calvi R, et al. : Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">14645001</ArticleId></ArticleIdList></Reference><Reference><Citation>International Non-Hodgkin's Lymphoma Prognostic Factors Project : A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993</Citation><ArticleIdList><ArticleId IdType="pubmed">8141877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos JC Ruiz P Ratner L, et al. : IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 109:3060-3068, 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852214</ArticleId><ArticleId IdType="pubmed">17138822</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukasaki K Hermine O Bazarbachi A, et al. : Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 27:453-459, 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737379</ArticleId><ArticleId IdType="pubmed">19064971</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor OA Pro B Illidge T, et al. : Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL). J Clin Oncol 32, 2014. (abstr TPS8612)</Citation></Reference><Reference><Citation>Oliveira PD, de Carvalho RF, Bittencourt AL: Adult T-cell leukemia/lymphoma in South and Central America and the Caribbean: Systematic search and review. Int J STD AIDS 28:217-228, 2017</Citation><ArticleIdList><ArticleId IdType="pubmed">28178905</ArticleId></ArticleIdList></Reference><Reference><Citation>Enriquez DJ Haro JC Rioja P, et al. : New prognostic classification for adult T cell lymphoma/leukemia based on hypercalcemia and neutrophil-to-lymphocyte ratio. Blood 130, 2017. (suppl 1; abstr 4164)</Citation></Reference><Reference><Citation>Beltran BE, Cotacallapa E, Castillo JJ: Adult T-cell leukemia/lymphoma in Peru: A report of 120 cases. Blood 120, 2012(abstr 5110)</Citation></Reference><Reference><Citation>Zell M Assal A Derman O, et al. : Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget 7:51981-51990, 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239529</ArticleId><ArticleId IdType="pubmed">27341021</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AA Shapira I Willim RD, et al. : A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. Cancer 116:3438-3446, 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20564100</ArticleId></ArticleIdList></Reference><Reference><Citation>Balduin B Priore C Acosta C, et al. : Infecci&#243;n por virus linfotr&#243;pico de c&#233;lulas T humanas (HTLV) en Uruguay: identificaci&#243;n de problemas. Anales de la Facultad de Medicina Universidad de la Rep&#250;blica Uruguay 4:41-51, 2017. http://www.anfamed.edu.uy/index.php/rev/article/view/286</Citation></Reference><Reference><Citation>Mosquera-Herrera CE Aspiazu-Miranda EP de Waard JH, et al. : A high prevalence of human T-lymphotropic virus (HTLV 1/2) infection among Afro-descendants, Esmeraldas province, Ecuador&#8212;Need for the implementation of surveys and control programs. Infect Drug Resist 12:1969-1974, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625744</ArticleId><ArticleId IdType="pubmed">31360069</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma P Barrientos JM Posadas MA, et al. : Prevalencia del virus linfotr&#243;pico de c&#233;lulas T humanas (HTLV) I/II en donantes de sangre. Cienc Tecnol Salud 4:15-50, 2017</Citation></Reference><Reference><Citation>Eusebio-Ponce E, Candel FJ, Anguita E: Human T-cell lymphotropic virus type 1 and associated diseases in Latin America. Trop Med Int Heal 24:934-953, 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31183938</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiva A, Casseb J: Origin and prevalence of human T-lymphotropic virus type 1 (HTLV-1) and type 2 (HTLV-2) among indigenous populations in the Americas. Rev Inst Med Trop Sao Paulo 57:1-13, 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4325517</ArticleId><ArticleId IdType="pubmed">25651320</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathaniel Berger D Bulanin N Garc&#237;a-Alix L, et al. : 2 IWGIA-the indigenous world-2020. www.NickPurserDesign.com</Citation></Reference><Reference><Citation>Congressional Research Service : Indigenous Peoples in Latin America: Statistical Information. Bethesda, MD, 2020. https://fas.org/sgp/crs/row/R46225.pdf</Citation></Reference><Reference><Citation>Cruz-Saco MA: Indigenous Communities and Social Inclusion in Latin America&#8212;United Nations. Connecticut, 2018. https://www.un.org/development/desa/family/wp-content/uploads/sites/23/2018/05/2-1.pdf</Citation></Reference><Reference><Citation>Organizaci&#243;n Panamericana de la Salud : Suministro de sangre para transfusiones en los pa&#237;ses de Am&#233;rica Latina y el Caribe 2016-2017. 2020. https://iris.paho.org/handle/10665.2/52150</Citation></Reference><Reference><Citation>Ishak R, De Oliveira Guimar&#227;es Ishak M, Vallinoto ACR: The challenge of describing the epidemiology of HTLV in the Amazon region of Brazil. Retrovirology 17:4, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7023703</ArticleId><ArticleId IdType="pubmed">32059740</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosadas C Puccioni&#8208;Sohler M Oliveira ACP, et al. : Adult T&#8208;cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed? Br J Haematol 188:e46-e49, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">31743423</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira FM de Almeida MdCC Santos FLN, et al. : Evidence of new endemic clusters of human T-cell leukemia virus (HTLV) infection in Bahia, Brazil. Front Microbiol 10:1002, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6528468</ArticleId><ArticleId IdType="pubmed">31156570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pombo De Oliveira MS Loureiro P Bittencourt A, et al. : Geographic diversity of adult T-cell leukemia/lymphoma in Brazil. Int J Cancer 83:291-298, 1999</Citation><ArticleIdList><ArticleId IdType="pubmed">10495418</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltran B Qui&#241;ones P Morales D, et al. : Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. Leuk Res 35:334-339, 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">20828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah UA Chung EY Giricz O, et al. : North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood 132:1507-1518, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410908</ArticleId><ArticleId IdType="pubmed">30104217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarbachi A Plumelle Y Carlos Ramos J, et al. : Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28:4177-4183, 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20585095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9452266</PMID><DateCompleted><Year>1998</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-543X</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>3</Issue><PubDate><Year>1998</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Possible association between adult T-cell leukemia/lymphoma and acute myeloid leukemia.</ArticleTitle><Pagination><StartPage>488</StartPage><EndPage>494</EndPage><MedlinePgn>488-94</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To the authors' knowledge, an association between adult T-cell leukemia/lymphoma (ATL) and acute myeloid leukemia (AML) has been reported only in four patients. The authors identified five additional patients with both neoplasms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A review of the clinical records of patients with AML, ATL, or lymphoid neoplasms other than ATL diagnosed between 1986 and 1995 was performed. Cytokine levels were assayed in selected patients. The authors searched for reports from other institutions using MEDLINE and the proceedings of two Japanese hematology societies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ATL was diagnosed in 134 patients, whereas 180 had AML. Five patients with both neoplasms were identified (3.7% of ATL patients and 2.8% of AML patients). In seven of the nine patients (including four patients in the literature) with ATL and AML, the ATL was diagnosed prior to the AML, whereas in the remaining two patients both neoplasms were diagnosed simultaneously. Six of the nine cases were therapy-related (t)-AML, which developed after chemotherapy for ATL. Monoclonal integration of proviral human T-lymphotropic virus type 1 was detected in ATL cells but not in AML cells in the six patients examined. The plasma levels of macrophage colony-stimulating factor (M-CSF), granulocyte-colony stimulating factor, and granulocyte-macrophage-colony stimulating factor (GM-CSF) were elevated in 3, 1, and 1, respectively, of the 4 patients examined at AML onset who had active ATL. In one case, the levels of several cytokines, including GM-CSF and M-CSF, in the supernatant fluid of short term cultured ATL cells were elevated. Three patients with de novo ATL and AML received remission induction therapy, and two achieved a complete remission (CR) of both diseases. Among the four patients who received chemotherapy for t-AML, two achieved CR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ATL patients also can develop AML, irrespective of treatment with chemotherapy for ATL. This association does not indicate exclusive chemoresistance of both neoplasms. Cytokines produced by ATL cells may support the growth of AML cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukasaki</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koba</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Iwanaga</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Atogami</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kamihira</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tomonaga</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>81627-83-0</RegistryNumber><NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>83869-56-1</RegistryNumber><NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007951">Leukemia, Myeloid</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016173">Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009378">Neoplasms, Multiple Primary</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9452266</ArticleId><ArticleId IdType="doi">10.1002/(sici)1097-0142(19980201)82:3&lt;488::aid-cncr10&gt;3.0.co;2-y</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1097-0142(19980201)82:3&lt;488::AID-CNCR10&gt;3.0.CO;2-Y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25542158</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6536</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title><ISOAbbreviation>Biol Blood Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.</ArticleTitle><Pagination><StartPage>696</StartPage><EndPage>700</EndPage><MedlinePgn>696-700</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2014.12.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1083-8791(14)01439-6</ELocationID><Abstract><AbstractText>Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral T cell neoplasm with very poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been reported as a curative treatment modality for ATL. However, there are no reports comparing chemotherapy alone with allo-HSCT in ATL. In this report, we retrospectively analyzed data for patients treated with (n = 29, median age 55 years) or without allo-HSCT (n = 37, median age 58 years) for ATL in Kagoshima University Hospital, located in one of the most endemic areas of human T cell lymphotropic leukemia virus type 1 infection. Forty patients (61%) started coordination for allo-HSCT. Ten patients (34.4%) received allo-HSCT while in complete remission (CR), whereas the others were not in CR. Twenty-five patients (86.2%) received reduced-intensity conditioning, and the others received myeloablative conditioning. With a median follow-up period for survivors of 41 months (range, 5 to 125 months), the 3-year overall survival (OS) rate from first chemotherapy for all patients (with or without allo-HSCT) was 35.2%. The 3-year OS from first chemotherapy for patients who received allo-HSCT or only chemotherapy was 44.9% and 27.7%, respectively. Univariate analyses revealed that high serum soluble IL-2 receptor (sIL-2R) levels (&#8805; 2000 U/mL) just before the conditioning regimen and progressive disease (PD) status at HSCT (according to Japan Clinical Oncology Group Study 0907 criteria) were significant risk factors for OS in the allo-HSCT group. Multivariate analyses revealed that PD status was a significant risk factor for OS in the allo-HSCT group. In the chemotherapy-only group, the 3-year OS rate was 61.5% (95% CI, 30.8% to 81.8%) in patients with serum sIL-2R levels &lt; 2000 U/mL for &gt; 3 months. In contrast, the 3-year OS rate was 5.7% (95% CI, .4% to 22.4%) in patients who did not achieve serum sIL-2R levels &lt; 2000 U/mL for &gt;3 months. Our single-center cohort experience indicates that chemosensitivity is the most important prognostic factor for OS in ATL patients and the use of allo-HSCT is limited in chemorefractory patients with aggressive ATL disease. In the chemosensitive patients, allo-HSCT demonstrated a tendency toward better OS. Further clinical studies are warranted to determine optimal treatments for patients who are less sensitive to conventional chemotherapy.</AbstractText><CopyrightInformation>Copyright &#169; 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawada</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. Electronic address: myoshimi@m.kufm.kagoshima-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashida</LastName><ForeName>Maiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamada</LastName><ForeName>Yuhei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maekawa</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujino</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Mamiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Naosuke</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabuchi</LastName><ForeName>Tomohisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Hirosaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamda</LastName><ForeName>Heiichiro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushita</LastName><ForeName>Kakushi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arima</LastName><ForeName>Naomichi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Blood Marrow Transplant</MedlineTA><NlmUniqueID>9600628</NlmUniqueID><ISSNLinking>1083-8791</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D064591">Allografts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018572">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015368">Human T-lymphotropic virus 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult T cell leukemia/lymphoma</Keyword><Keyword MajorTopicYN="N">Allogeneic stem cell transplantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25542158</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2014.12.020</ArticleId><ArticleId IdType="pii">S1083-8791(14)01439-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8384067</PMID><DateCompleted><Year>1993</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-543X</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>7</Issue><PubDate><Year>1993</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group.</ArticleTitle><Pagination><StartPage>2217</StartPage><EndPage>2221</EndPage><MedlinePgn>2217-21</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MST-16, a new orally administered bis(2,6-dioxopiperazine) analogue and an inhibitor of topoisomerase II, was given to 24 patients with adult T-cell leukemia-lymphoma (ATLL) in a Phase I-II multi-institutional cooperative study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MST-16 was administered orally daily for 7 days, with courses repeated at intervals of 2-3 weeks in 24 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two complete remissions (CR) and eight partial remissions (PR) were obtained in 23 evaluable patients who received 1200-2800 mg/day of MST-16. Among 13 acute-type ATLL, one CR and five PR were obtained. Among eight lymphoma-type ATLL, two PR were detected. Among two chronic-type ATLL, one CR and one PR occurred. Remissions were obtained at 7-232 days (median, 23 days) and lasted 43-374 days (median, 68 days). The major toxic effects were leukopenia (68%), anemia (52%), thrombocytopenia (35%), and gastrointestinal disorders (22%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MST-16 was shown to be effective in ATLL, which has no standard therapy. This drug deserves further clinical trials because it shows little cross resistance to currently available antitumor drugs.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Ohno</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Nagoya University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masaoka</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shirakawa</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hirano</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hanada</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Yasunaga</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yokomaku</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mitomo</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059005">Topoisomerase II Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>R1308VH37P</RegistryNumber><NameOfSubstance UI="C057773">sobuzoxane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002415">Cats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D059005">Topoisomerase II Inhibitors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8384067</ArticleId><ArticleId IdType="doi">10.1002/1097-0142(19930401)71:7&lt;2217::aid-cncr2820710709&gt;3.0.co;2-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE"><PMID Version="1">36966214</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation></Journal><ArticleTitle>The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy.</ArticleTitle><Pagination><StartPage>729</StartPage><EndPage>731</EndPage><MedlinePgn>729-731</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41409-023-01969-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5118-7950</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Osaka International Cancer Institute, Osaka, Japan. fujishige1231@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3967-7356</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makiyama</LastName><ForeName>Junya</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0883-2920</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Nobuaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Imamura General Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Ayumu</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5681-6357</Identifier><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakita</LastName><ForeName>Toshiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eto</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suehiro</LastName><ForeName>Youko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itonaga</LastName><ForeName>Hidehiro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawayama</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6425-1720</Identifier><AffiliationInfo><Affiliation>Hematology, Oncology &amp; Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5952-5926</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishima</LastName><ForeName>Satoko</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7391-4271</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes and Metabolism, Hematology, University of the Ryukyus Hospital, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onizuka</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3864-0823</Identifier><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishitsuka</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7030-497X</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atsuta</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4404-2870</Identifier><AffiliationInfo><Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimitsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5935-0385</Identifier><AffiliationInfo><Affiliation>Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D006086">Graft vs Host Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36966214</ArticleId><ArticleId IdType="doi">10.1038/s41409-023-01969-7</ArticleId><ArticleId IdType="pii">10.1038/s41409-023-01969-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37:677&#8211;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.18.00501</ArticleId><ArticleId IdType="pubmed">30657736</ArticleId><ArticleId IdType="pmc">6494249</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#8217;Neill AT, Chakraverty R. Graft Versus Leukemia: Current Status and Future Perspectives. J Clin Oncol. 2021;39:361&#8211;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.01801</ArticleId><ArticleId IdType="pubmed">33434054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141&#8211;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-07-368233</ArticleId><ArticleId IdType="pubmed">22234682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology Am Soc Hematol Educ Program. 2021;2021:254&#8211;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/hematology.2021000257</ArticleId><ArticleId IdType="pubmed">34889392</ArticleId><ArticleId IdType="pmc">8791130</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Hakoda A, Kanda J, Murata M, Terakura S, Inamoto Y, et al. Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021;56:2990&#8211;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-021-01443-2</ArticleId><ArticleId IdType="pubmed">34480119</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtan SG, MacMillan ML. A risk-adapted approach to acute GVHD treatment: are we there yet? Bone Marrow Transplant. 2016;51:172&#8211;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2015.261</ArticleId><ArticleId IdType="pubmed">26551780</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology &amp; guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53:1401&#8211;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0204-7</ArticleId><ArticleId IdType="pubmed">29872128</ArticleId><ArticleId IdType="pmc">6786777</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4&#8211;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2015.09.001</ArticleId><ArticleId IdType="pubmed">26386318</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JE, Hogan WJ, Harris AC, Litzow MR, Efebera YA, Devine SM, et al. Improved accuracy of acute graft-versus-host disease staging among multiple centers. Best Pract Res Clin Haematol. 2014;27:283&#8211;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2014.10.011</ArticleId><ArticleId IdType="pubmed">25455279</ArticleId><ArticleId IdType="pmc">4381784</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512&#8211;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1083-8791(03)00162-9</ArticleId><ArticleId IdType="pubmed">12931120</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji S, Kurosawa S, Inamoto Y, Nakano N, Miyazaki Y, Miyashita K, et al. Does an increased probability of graft-vs-host disease improve the survival of patients with adult T-cell leukemia-lymphoma? A simulation analysis using a Markov model. Advances in Cell and Gene Therapy 2019;2:e56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acg2.56</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE"><PMID Version="1">26073237</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>12</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).</ArticleTitle><Pagination><StartPage>1489</StartPage><EndPage>1498</EndPage><MedlinePgn>1489-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.54.1953</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Despite the remarkable advances in chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), adult T-cell leukemia-lymphoma (ATL) is still associated with a high mortality rate. It is therefore essential to elucidate the current features of ATL.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed 81 patients with aggressive type ATL at our institution over a 7-year period based on Shimoyama's diagnostic criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-one patients with a median age of 67.5 years were classified as having acute (n=47), lymphoma (n=32), or chronic type (n=2) ATL. They were initially treated by either palliative therapy (n=25) or systemic chemotherapy [n=56; cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy (n=25)/vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)-doxorubicin, ranimustine, and prednisone (AMP)-vindesine, etoposide, carboplatin, and prednisone (VECP) therapy (VCAP-AMP-VECP) or CHOP-VMMV therapy (n=31)], and showed median survival durations of 16 and 277 days, respectively. Subsequent to the initial treatment, HSCT (n=6) was performed for certain patients, thus revealing that two-thirds (n=4) relapsed, and one-third (n=2) survived for 131 days and 203 days, respectively. The relapsed ATL patients were treated with conventional salvage therapy (n=29) or anti-CC chemokine receptor 4 antibody (mogamulizumab) (n=3). The patients treated with mogamulizumab demonstrated complete response (2) and partical response (1) with short duration periods of 82 days, 83 days, and 192 days, respectively. Among the five long-term survivors (&gt;5 years) who received chemotherapy, most showed a low and intermediate risk according to the ATL prognostic index.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In our study, the overall survival of ATL remains poor due to the advanced age of the patients at diagnosis, a high proportion of patients receiving palliative therapy, and a small proportion of long-term survivors receiving chemotherapy and undergoing HSCT. This study illustrates the current clinical features, treatment strategies, and outcomes in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Noriaki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shuro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kuriyama</LastName><ForeName>Takuro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tahara</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nagahiro</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kawano</LastName><ForeName>Jiro</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Koketsu</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Toyofuku</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Manabe</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Beppu</LastName><ForeName>Kiichiro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ono</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Himeji</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yokota-Ikeda</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Sanshiro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ochiai</LastName><ForeName>Hidenobu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sonoda</LastName><ForeName>Koh-Hei</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Shimoda</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Fumihiko</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018380">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26073237</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.54.1953</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16810767</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1007-9327</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>25</Issue><PubDate><Year>2006</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literature.</ArticleTitle><Pagination><StartPage>4089</StartPage><EndPage>4092</EndPage><MedlinePgn>4089-92</MedlinePgn></Pagination><Abstract><AbstractText>Acute liver failure (ALF) is a medical emergency requiring immediate evaluation for liver transplantation. We describe an unusual case of a patient who presented with ascites, jaundice, and encephalopathy and was found to have ALF due to natural killer (NK)-like T cell leukemia/lymphoma. The key immunophenotype was CD2+, CD3+, CD7+, CD56+. This diagnosis, which was based on findings in the peripheral blood and ascitic fluid, was confirmed with liver biopsy, and was a contraindication to liver transplantation. A review of the literature shows that hematologic malignancies are an uncommon cause of fulminant hepatic failure, and that NK-like T-cell leukemia/lymphoma is a relatively recently recognized entity which is characteristically CD3+ and CD56+. This case demonstrates that liver biopsy is essential in diagnosing unusual causes of acute liver failure, and that infiltration of the liver with NK-like T-cell lymphoma/leukemia can cause acute liver failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dellon</LastName><ForeName>Evan S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>University of North Carolina School of Medicine, Division of Gastroenterology and Hepatology, CB#7080, Bioinformatics Bldg, Rm 1140, 130 Mason Farm Rd, Chapel Hill, NC 27599-7080, United States. edellon@unch.unc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Shannon R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Wozhan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Dunphy</LastName><ForeName>Cherie H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000075202">Contraindications</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017114">Liver Failure, Acute</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016031">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16810767</ArticleId><ArticleId IdType="pmc">PMC4087729</ArticleId><ArticleId IdType="doi">10.3748/wjg.v12.i25.4089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179&#8211;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15841455</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407&#8211;1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15880505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WM. Acute liver failure. N Engl J Med. 1993;329:1862&#8211;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">8305063</ArticleId></ArticleIdList></Reference><Reference><Citation>Myszor MF, Record CO. Primary and secondary malignant disease of the liver and fulminant hepatic failure. J Clin Gastroenterol. 1990;12:441&#8211;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">2204655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowbotham D, Wendon J, Williams R. Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut. 1998;42:576&#8211;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1727084</ArticleId><ArticleId IdType="pubmed">9616324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima H, Shimizu S, Yoshida C, Katsura Y, Suzukawa K, Mukai HY, Hasgawa Y, Imagawa S, Mori N, Nagasawa T. Rapidly progressive Lennert's lymphoma terminating in fulminant hepatic failure. Leuk Lymphoma. 2003;44:1409&#8211;1412.</Citation><ArticleIdList><ArticleId IdType="pubmed">12952236</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos ES, Raez LE, Salvatierra J, Morgensztern D, Shanmugan N, Neff GW. Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature. Am J Gastroenterol. 2003;98:2789&#8211;2793.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lettieri CJ, Berg BW. Clinical features of non-Hodgkins lymphoma presenting with acute liver failure: a report of five cases and review of published experience. Am J Gastroenterol. 2003;98:1641&#8211;1646.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873593</ArticleId></ArticleIdList></Reference><Reference><Citation>Morali GA, Rozenmann E, Ashkenazi J, Munter G, Braverman DZ. Acute liver failure as the sole manifestation of relapsing non-Hodgkin's lymphoma. Eur J Gastroenterol Hepatol. 2001;13:1241&#8211;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11711783</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson DR, Faust TW, Stone MJ, Polter DE. Hepatic failure as the presenting manifestation of malignant lymphoma. Clin Lymphoma. 2001;2:123&#8211;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">11707855</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeshurun M, Isnard F, Garderet L, Rambeloarisoa J, Prevot S, Carbonell N, Najman A. Acute liver failure as initial manifestation of low-grade non-Hodgkin's lymphoma transformation into large-cell lymphoma. Leuk Lymphoma. 2001;42:555&#8211;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">11699425</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson SH, Richardson P, Wendon J, Pagliuca A, Portmann B. Acute liver failure as the initial manifestation of acute leukaemia. Liver. 2001;21:287&#8211;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11454193</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart KS, Gordon MC. Non-Hodgkin lymphoma in pregnancy presenting as acute liver failure. Obstet Gynecol. 1999;94:847.</Citation><ArticleIdList><ArticleId IdType="pubmed">10546758</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa M, Yamane Y, Yoneda S, Iwasawa S, Nishimura K, Kawamoto H, Nakano H, Fukui H, Nakamine H. Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus. J Gastroenterol. 1998;33:880&#8211;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">9853565</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Tsuji H, Nakamura S, Asabe H, Sueishi K, Fujishima M. An autopsy case of Ki-1 lymphoma associated with hepatic failure. Am J Gastroenterol. 1998;93:115&#8211;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">9448189</ArticleId></ArticleIdList></Reference><Reference><Citation>Souto P, Rom&#227;ozinho JM, Figueiredo P, Ferreira M, Sousa I, Camacho E, Donato A, Freitas D. Severe acute liver failure as the initial manifestation of haematological malignancy. Eur J Gastroenterol Hepatol. 1997;9:1113&#8211;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9431904</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehab TM, Kaminski MS, Lok AS. Acute liver failure due to hepatic involvement by hematologic malignancy. Dig Dis Sci. 1997;42:1400&#8211;1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">9246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolf GM, Petrovic LM, Rojter SE, Villamil FG, Makowka L, Podesta LG, Sher LS, Memsic L, Vierling JM. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig Dis Sci. 1994;39:1351&#8211;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">8200270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafrani ES, Gaulard P. Primary lymphoma of the liver. Liver. 1993;13:57&#8211;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8510487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sal&#243; J, Nomdedeu B, Bruguera M, Ordi J, Gin&#232;s P, Castells A, Vilella A, Rod&#233;s J. Acute liver failure due to non-Hodgkin's lymphoma. Am J Gastroenterol. 1993;88:774&#8211;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">8480749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathiapalan RK, Hainau B, Al-Mane K, Belgaumi AF. Favorable response to treatment of a child with T-cell-rich large B-cell lymphoma presenting with liver failure. J Pediatr Hematol Oncol. 2003;25:809&#8211;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">14528106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega L&#243;pez Juan J, L&#243;pez Espinosa J, Roqueta Mas J, Sabado Alvarez C, Ruiz Marcellan C, Iglesias Berengu&#233; J. [Acute liver failure due to T cell lymphoma without hepatic infiltration] An Pediatr (Barc) 2003;58:59&#8211;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628121</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen-Benz C, Hoffmann N, Beckurts T, Goeser T, Steffen HM, Dries V. Fulminant liver failure induced by hepatosplenic alphabeta T-cell lymphoma. Z Gastroenterol. 2003;41:1083&#8211;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">14648377</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo-Dom&#232;nech J, Fern&#225;ndez J, L&#243;pez-Guillermo A, Miquel R. [Fulminant hepatic failure as form of presentation of a peripheral T cell lymphoma] Med Clin (Barc) 2002;119:715&#8211;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459111</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakolmer K, Gaulard P, Mannhalter C, Swerdlow S, Fassati LR, Rossi G, Maggi U, Conte D, Demetris AJ. Unusual peripheral T cell lymphoma presenting as acute liver failure and reappearing in the liver allograft. Transplantation. 2000;70:1802&#8211;1805.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152113</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz RA, Rezuke WN, Cartun RW, Hasson J. Case report: an autopsy study of a rare T-cell lymphoma clinically misdiagnosed as fulminant hepatic disease. Conn Med. 1998;62:643&#8211;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hino T, Sata M, Arima N, Nouno R, Kumashiro R, Koga Y, Uchimura Y, Yoshitake M, Sakisaka S, Kojiro M, et al. A case of malignant lymphoma with hemophagocytic syndrome presenting as hepatic failure. Kurume Med J. 1997;44:53&#8211;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154762</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer JP, Cousar JB, Miller RF, Vogler LB, Goodin JC, Graber SE, Collins RD. T4+ (helper phenotype) chronic lymphocytic leukemia: case report with liver failure and literature review. Med Pediatr Oncol. 1988;16:356&#8211;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">2972899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafrani ES, Leclercq B, Vernant JP, Pinaudeau Y, Chomette G, Dhumeaux D. Massive blastic infiltration of the liver: a cause of fulminant hepatic failure. Hepatology. 1983;3:428&#8211;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">6573294</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist. 2004;9:247&#8211;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169980</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Program. 2001:259&#8211;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11722988</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshimi K. Leukemia and lymphoma of natural killer lineage cells. Int J Hematol. 2003;78:18&#8211;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12894846</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002;17:539&#8211;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">11962758</ArticleId></ArticleIdList></Reference><Reference><Citation>Porcu P, Baiocchi RA, Magro C. Recent developments in the biology and therapy of T-cell and natural killer-cell lymphomas. Curr Opin Oncol. 2003;15:353&#8211;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun T, Brody J, Susin M, Marino J, Teichberg S, Koduru P, Hall WW, Urmacher C, Hajdu SI. Aggressive natural killer cell lymphoma/leukemia. A recently recognized clinicopathologic entity. Am J Surg Pathol. 1993;17:1289&#8211;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">8238737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40:221&#8211;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">12876671</ArticleId></ArticleIdList></Reference><Reference><Citation>Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol. 2003;40:124&#8211;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">12704589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501&#8211;4513.</Citation><ArticleIdList><ArticleId IdType="pubmed">9192774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnuma K, Toyoda Y, Nishihira H, Iguchi A, Honda K, Nagao T, Kigasawa H, Tanaka Y, Kikuta H. Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the literature. Leuk Lymphoma. 1997;25:387&#8211;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168449</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura N, Kusunoki Y, Kawa-Ha K, Yumura K, Hara J, Oda K, Abe K, Dohy H, Inada T, Kajihara H. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49&#8211;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375924</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock J, Jaffe ES, Wilson WH, McManus DT, Alexander HD, Morris TC. Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature. Leuk Lymphoma. 2004;45:1269&#8211;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15360011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile TC, Uner AH, Hutchison RE, Wright J, Ben-Ezra J, Russell EC, Loughran TP Jr. CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood. 1994;84:2315&#8211;2321.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522625</ArticleId></ArticleIdList></Reference><Reference><Citation>Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JB. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood. 1996;87:1474&#8211;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">8608238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimura K, Kagami Y, Suzuki R, Kojima M, Yoshino T, Ohshima K, Koike K, Kondo E, Taji H, Ogura M, et al. Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites. Pathol Int. 2003;53:333&#8211;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787307</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>